<SEC-DOCUMENT>0000950170-24-018766.txt : 20240222
<SEC-HEADER>0000950170-24-018766.hdr.sgml : 20240222
<ACCEPTANCE-DATETIME>20240222161048
ACCESSION NUMBER:		0000950170-24-018766
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240222
DATE AS OF CHANGE:		20240222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		24664824

	BUSINESS ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dvax-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:dvax="http://www.dynavax.com/20231231" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_a3342d5e-59ac-45d1-9d04-2069f075ab1c" name="us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend" contextRef="C_cbf226fd-6dcc-47b4-b352-348770773ff2">false</ix:nonNumeric><ix:nonNumeric id="F_8a51f06c-f78d-454c-a591-a149eb677053" name="us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend" contextRef="C_eab3cba9-923b-419c-bdef-b0654a1ab2b1">false</ix:nonNumeric><ix:nonNumeric id="F_49781d38-8281-4017-b0c0-310f8c7fa3af" name="dei:AmendmentFlag" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_9b89cf33-a247-457c-a842-47ee488137e6" name="dei:CurrentFiscalYearEndDate" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a">--12-31</ix:nonNumeric><ix:nonNumeric id="F_1a94fa36-f1e2-4e14-9333-16743c2d50d4" name="dei:EntityCentralIndexKey" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a">0001029142</ix:nonNumeric><ix:nonNumeric id="F_628f4796-66d9-4e33-90c9-c2fdc02facf2" name="dei:DocumentFiscalPeriodFocus" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a">FY</ix:nonNumeric><ix:nonFraction id="F_3031d482-7693-42b9-bd85-bcbc62b2bbaa" name="us-gaap:CommitmentsAndContingencies" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_f9326331-0510-474c-8729-f02e4262a88e" name="us-gaap:CommitmentsAndContingencies" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_f58b1a95-4b8b-4052-956a-3314f3bd58e1" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_92c8237b-9eec-4d96-8dc1-a494a9120777" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_6d4caeb9-dd64-4460-a26d-4c0009adec9d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_8cba3a01-4eef-41de-8eac-974320f6f0aa" format="ixt-sec:duryear">7</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="dvax-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_92e5b8ce-fc26-44df-be6c-b93ab6266391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7cd9712-92a6-43fa-a3e4-620df529380f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99635370-1a22-4b6f-b761-e726efa96bc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bad25b6b-347d-48e5-9b97-3f8c19355518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa260df4-3e48-4fdf-8ab8-54f380fb7620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCollaborationPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bdc419f-cd33-4f84-9be9-6a7a197b6800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">dvax:RevenueReserveAccrualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3f4c696-246e-4a9c-a510-583ee8c9731e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99afab35-99e9-4d2e-bfac-d15173962934"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70bb3c92-fdce-4bba-8d13-f7445805823e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbf226fd-6dcc-47b4-b352-348770773ff2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="dvax:NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis">dvax:PowellStreetSubleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a78eb8f1-5744-4979-8db7-230dc51613bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9c3ac11-c1b5-431c-85fe-3a4cce93994b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38284c71-50a1-429d-8131-ac0563038784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dvax:DebtInstrumentConversionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc8ddedc-d903-4ea8-884d-cff004170dad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_527a5bef-aec8-4da7-8ad2-8c92c7570a64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:SymphonyDynamoHoldingsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7697cec1-5a5c-4cda-96a7-3a7c51da9ed4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0c51341-46c1-468f-b8a4-d22a9e93bea9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d26b0e54-e633-48c7-b851-f555aaf0ac91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0b842a8-48c1-4246-8a13-5bc899141fe0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9bb4111-0938-4d2d-bd83-eeb18b9ba154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9680928-634a-4740-b0dc-8e7ca6e0523a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">dvax:RevenueReserveAccrualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bd10d4c-3dad-4350-b83d-0c72c2905fea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d904b5d-a1ff-4762-bd22-3e30cec979bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2119199-7038-4bb0-8c9c-d8181ef231e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b066d0df-653b-4391-8933-b31cdb392277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CRGServicingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b272903-9c51-40dd-8f58-0e6dd1d903ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_751580b2-fbfe-41c1-b881-e6d093f5c273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9822878d-e9c6-42eb-aba9-e6d1be0c6c26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f5207a1-1b60-4990-be95-58289e708128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dvax:DebtInstrumentConversionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bc4c639-7c83-4569-b3d6-4d528d1abaf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1ba67ff-228c-4a77-8fbc-f341080d81e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">dvax:DeutscheBankSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b86641c3-95a4-4d1b-8c32-20129a34a510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e8bbc07-0e01-4b4f-8236-8ea97338e319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b4b7402-722d-4537-a94a-f71d88ccd9c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06216486-f415-476b-92e9-c173c38795fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25c9967d-9381-4ce1-aec3-a06102b373ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc46d573-296e-4a0d-aa85-c245577e3d2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:SupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46ea9e3a-6a19-4c11-a0b8-d28df71f9995"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7463f82-87b8-4f1d-9935-b4868bc5cd26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52588853-8260-401a-beed-26f3945ae871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_087bb460-7784-4ea1-8991-e6e00539b1cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a2ff8b8-7c89-4242-a4e1-a77b739e4b68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8aafc35f-0931-49c4-99f3-ba14874dc415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4c83557-99eb-4dae-a4b6-8f5fe7a1fff4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58b0bb3f-bb8e-49d1-a9e2-0615cfa1a595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39e6c092-46ac-445b-8f0b-7dcdd766c1ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25a5468a-bacc-477f-bef1-e85543a6913f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90d829ca-90bc-4f0f-997f-b75da4b1cbeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98bd1202-de67-46fa-812a-b3388651d485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55e18a2b-9266-46ed-bd0b-26af19bac2fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60a06249-5799-4cae-8123-c33c744ecedc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3b6b8e9-b6aa-434a-b512-84475ede426d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1aaf5950-6ea9-46e6-a2da-ed62c66484da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9ce0868-3fca-4734-adae-586106f4f8d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e83edc5d-57bf-4f45-8c00-a78bad8a160f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d3137c5-4a24-4ea8-bd54-b337cfe3189f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_501845fd-14fc-4143-a5da-15378a311c6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebe94c6f-4531-439d-ab70-697744f5951a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01f47823-0ce7-49df-83a3-cd706589f4dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:TwentySeventeenAtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3753588-e357-4568-8f96-aac287465012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6788e286-c14c-450b-b13d-2eea895a38ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c45b2a41-c8d9-409b-9f76-329e71219be7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79c0f9eb-0184-4dba-a43c-01f7640ee145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b671bf2b-5135-415b-beb9-c44190ad1450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48680940-6818-40d2-9606-4f38488cee91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CoalitionForEpidemicPreparednessInnovationsPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a35251a8-36c2-46bd-be47-03e6fe5c7a03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">dvax:DeutscheBankSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef72dbdf-e573-4481-9cf4-b43c84730269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">dvax:CpG1018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a02082a3-bcf6-4470-924c-b963a2bcd1c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7cdc223-9b33-484b-b064-ffbb1dd743fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef0e8934-759f-4093-bac5-8fa40486ee52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8317906-5e1f-4330-9194-db9aef7be671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cff3f8b-5d8e-4085-91dc-8a1a4395f4c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4818259-befe-457e-b5e4-83ccf0a85a8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2ca19d3-f268-4784-a5f2-05a124a3d30c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16e235b1-3b2d-4e5d-8443-14ad46e6d0bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64302cd3-066f-4f94-90bb-67102762e43f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dvax:StockOptionsAndShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bc231fb-46e7-4fb0-a5fd-dde6eed5fb39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d65d29d7-24ac-4d7b-bfef-53e5f9ec99ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd1be51a-97e7-41a8-8c3a-1b53c43091c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c265dbab-c590-4635-805d-fcfcffc40237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10ed8dc0-a4c7-4909-9310-8008b51e41a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cd05fc1-4367-467f-b1f4-b88105492b67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a210ba4e-63a8-4224-b689-4b3fcc4782cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_344d9e72-8b1f-4434-9db5-252aa7e877e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1f0d8d2-631d-4ed4-8031-fd5a057c56bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_887ba154-ef1b-44c1-92ad-b5335653b28b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3679aead-0bf6-46ad-8149-c7043f490baf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_518ea503-766c-4a37-b80d-037d29359c1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c385cf83-1634-4094-87c8-c188ad78b7ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc9620c9-1c43-40ea-a14b-d5100d03b2e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1074222-76a7-46bd-9644-2e3690082980"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56114482-df3d-4e07-a8de-d386532d7a4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_876b9f96-bdb9-42b7-883d-e9aed3b08eb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98f50ec3-eed0-482b-abdc-e3f4d764dcdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ca8debb-5a5e-47ec-ac9b-67db2519efb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8cf97a7-7cc0-4345-ac03-211d0a8e0250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cebee1a-3aa7-4377-b9dc-63b5df400e74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01905c0f-bf3b-4a9e-aa83-f267ccc52200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dvax:LaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44be1a55-42bb-4223-9a35-d53aa56a00cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_960f69a5-6c26-4021-b7c8-8789aedcdc97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ba29514-78ad-4553-a6f6-379d75c85d9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c882f98c-09ae-4335-9956-04f9b0df4820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef4a36fd-eaf7-46db-ac29-52ed918668e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00cf7693-c589-4da2-bf41-f883d3c76f3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_affe35a2-f489-4bea-a377-a5366608b680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90d340bb-3e21-4b45-b920-340abe04b8ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e381175a-06e1-46c3-b77b-df4ad235482a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61dba5ad-822d-4501-bae4-9a20bd0eed27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd4dc0db-3b94-4730-9f10-12f7f1a154c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0af7c37-af17-4bba-9ae6-7bbd452527b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:CappedCallsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d5090c3-cf85-4395-8b36-a4feb0cf89ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2def0eb-ee73-4354-805a-b882be4a3888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10125268-dcf7-417c-8e67-6935f116fdcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7b73016-1aa5-4068-89fc-abd4a56ae044"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b40fc463-936b-4ff9-a706-0dc8d375ef2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a1e5c04-44fa-417c-a4e7-018c2ad6e933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1a8ccc2-b5c3-4443-91b6-3ade9ce8f4e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8004c05b-80cb-4d34-b5be-e0a034b69331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7951b5b5-dd53-4f52-b40f-bfff22a01db5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5431114c-d857-438b-8f6d-8010eba4cc30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_448dc083-473d-475c-ad68-1d927557d2eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_709c2910-32d1-45cb-9204-ef2070cb1241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29f44f8e-0fe5-45f6-8bba-6cd65b85e586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4daec9bd-18e0-4c0a-8754-6c97e388d5ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21d5cf56-92b9-4489-b44b-c533985be50f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c81fc228-69ab-44c3-95b9-aea5499fe2bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23872491-571b-4186-b6ac-a7b968b913ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3aa89f6-f4c8-4a9f-8753-f6b4ba518016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdc045d5-f884-4bd3-ac9d-65b497b60faf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1eda147-6a7d-43bb-8a22-8d62411d3073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3727f25c-7b34-4d8b-ad87-5a284d913f8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cecce06-d788-4a18-b30c-961790a113af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a407ebc3-a04a-4922-9be0-f544bb630be4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">dvax:DeutscheBankSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35f1c43c-dc20-4692-ac8b-37df12d565ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_187a89d5-4a78-4080-82d7-8eeffa21fc7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbe06c3d-ec16-449f-bdd3-62e26d98ec74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28ee40ae-f91d-4b89-9194-6b624b4ce391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa7ac349-6ef6-4d33-8b91-dc174a56618b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dvax:StockOptionsAndShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2e2ad27-c3c5-4b53-9737-1774805c2105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CRGServicingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-19</xbrli:startDate><xbrli:endDate>2018-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be62f7fb-690c-4474-bca0-b70c2e4a2fe2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e638b00f-55b0-4873-beaa-4bf842f5fdd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cce5446-2af2-4a9a-b1c4-38be430937ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcd78d0a-af33-44bf-8d8a-2f5c1a9a376f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dvax:DebtInstrumentConversionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a1fceba-ab37-4367-a47b-ccd8390d5afa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4bb7def-af41-4d15-8eda-59023addc137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b9b2b3e-0d8a-43a5-b40a-ddc5b8ced167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54064a80-7e76-458d-93d5-b4613985ec73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-05-27</xbrli:startDate><xbrli:endDate>2014-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4349a3de-f389-4fe9-a46d-67b78b2213f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e101de03-ed18-4895-96b6-d6251ed99d3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fc345ed-b272-49ff-b9eb-c47bc4c9266b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a49cd4e9-42d6-4cad-96d6-a2965e333846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb0aaad0-c346-40c7-80b3-5c0e4926bc06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7c94b74-9da6-4908-b131-d871909fbeb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9ba0f50-bcbf-42ff-bb4d-52d504f7633c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e7a4e28-ee23-4846-846a-acac7d54f31f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d98acd8-10b6-453e-b7a4-a290b0056620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86657944-51ae-463d-89b1-ae4a4ccfa124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ef86bfc-0585-40df-9bd1-4bd0b18b364e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">dvax:CaliforniaAndOtherStatesTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e94f899-6711-4da9-bcee-5a61cdbdcf61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4720dcda-852f-4e2a-bec3-37de58fa755d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec73c440-29fa-41e8-b4b7-62558e948364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e30bc85-1e80-4230-b3a9-6904f8577805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dadabb88-1dfa-43da-9394-44029f60ca3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96ad4e0b-9a01-4e43-b0c5-c677a5fe8543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TimeBasedVestingScheduleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f6d8975-50fd-4d21-a136-be743356b082"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ff495d2-c2ab-4702-a574-69eda60e3e44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdaf1c5c-c380-46df-bd25-46af0336eb49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-06</xbrli:startDate><xbrli:endDate>2020-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cade9713-0ce0-4b8f-b617-650718d89561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_120e58b6-236e-4e1b-bac7-eb5813c1cb61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93b7b614-27fa-4eae-80c5-0b38da148a6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4811b6ec-afc2-4141-bee4-2808586bc8f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e889c2ed-7138-45fb-adce-a5dc91946a89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6d1d749-5eda-4173-857c-d2e9ec42eec9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_739cf94c-d0c3-431e-93da-9d8dc48a3718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b3ae74c-64c3-410c-a990-9b1b3a879aef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08fff746-9f3a-44ee-9a05-fcd200656170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc5b84ae-0185-4375-b0d0-b39df828ca23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3fabb2f0-37ad-4f85-8819-9ad5b0716fdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:CappedCallsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_452bdfa1-ad45-4a00-a35b-9cb73b9e9295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab1c6ec8-3564-4d41-9ebc-32087bc08f68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TimeBasedVestingScheduleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3e9b8ea-11ad-4a81-b1a0-52ecab46df50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_721a703d-dac9-4278-b357-e4756d07b6a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ccde060-5732-4dbe-854e-2ad06dd8b47e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7128fc7b-020c-499d-ae72-19db57703cc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48cfc4ff-27e8-4913-84be-fd420b811781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41d532a7-2bee-4d4a-a774-19c130efe064"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_011b6204-96fe-4257-8305-4c2c24467a75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">dvax:RevenueReserveAccrualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c75ba6c-c9fa-4cf1-982e-13bb8407020d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_618e0bb6-70e6-4ad8-a103-f5bc6b7f8d80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad16fd8d-2d92-4d26-8d96-bf058a356d05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a3dbbd9-f7d4-4560-b0a0-3f291802b72e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5413023b-1fa8-4b55-b7bd-90b2b2bbf2cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">dvax:CaliforniaStateTaxAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83ebfedc-dcd6-474a-b76f-5c72dd085aac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a1fce12-44dc-4910-9727-fa459734732a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:CappedCallsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6507c936-b545-4e7c-859a-811146d183ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b162a2fb-1421-4817-89b7-7fd0107432f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbd430d0-723d-4b78-8014-3bf90a7f958f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ca507f0-264d-4d6b-a1d7-6b4736681fa7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f81a00fa-c973-4197-b3a1-e0cc4a36b149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a835f5a8-e3de-4348-8afc-9aa8d3f5191d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fdc1062-7a2e-42a6-a0ee-956964678351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4dc5908b-5edd-428d-affa-04a86844ffaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6050d5e9-4d2a-42f3-8f76-80e6c68a8a88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:SymphonyDynamoHoldingsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2009-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29ad1ccd-24bd-4275-9420-8e03c7809a91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c82b1535-2190-4e2c-8859-50ce0d536831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e9700d5-220a-480f-9422-65d949c449a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdb2bd2a-2c3d-42e8-ad0d-04fb4a9ce3fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_497a4353-898d-4ae9-9975-8c32c4ebb9d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TimeBasedVestingScheduleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cd9059e-33d1-45f0-85b0-9bedacb0a4f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfe1bbb8-9cb8-4010-b417-57ad46abca6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_931a84ee-4853-4900-bad8-f584f37e2aaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa937874-39fc-49fc-b659-927ec58d6789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6423ea24-b03e-48e6-addc-0d0d41661afc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d63e3291-43c4-4ac8-b139-8fea8704f1a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dvax:LaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef39c4dd-1299-4749-a67d-a06698c37b4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4272aeb3-6074-4246-8638-d6db1157f771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5445db9b-2a99-4cf2-a2cd-3f86b5ae5b30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForNotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d83504a-3b1b-47be-be67-be586b5c04f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f301073-2f8b-4fb6-92dd-c36e81bb7b9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dvax:StockOptionsAndShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_413555f4-1d4a-4bf8-8c72-64ae359a9907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d274567-d036-45ef-8bff-f4dc34904726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e3ef292-a629-4f6e-9ba6-f332258de6b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc1b7051-c0ab-49af-aabf-551b7383e779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b92550c8-3f5d-45cc-9390-8d5d61858315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a814d382-f3ad-4c19-84d6-7b9bde2b4316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCollaborationPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d1752d7-1a8f-47fe-a52e-e23618ff2973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30de9d80-f061-4903-9ccb-6711842fb3d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d0c6594-c70c-45dd-b459-b3da8ed9a07a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c5e6277-2512-4769-b1e2-9247324bb9ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82eb336f-5756-41e1-8639-c454abdcbaaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7000fe3e-8aa0-4198-8de5-4640128d667d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f971b14-535c-4dd6-9f52-1e81c12d5af5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3712e127-94e3-4474-a4e8-4efc91f83f9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cba3a01-4eef-41de-8eac-974320f6f0aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93236fd5-e3be-44e0-a948-b795ea15d021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCollaborationPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d661040-605b-43cf-b60b-b20b979ad675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8c27e53-0ae1-4e32-8d68-96f7ec110ec2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cda2680-5634-444f-82ba-0702b3f55696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93f06617-1210-471c-aa60-542728a9d90e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9821d0e8-ecc7-4666-9acc-0bbaa41571ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e60f6c41-5373-4982-bda4-495d22ef947a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce1c0cc3-d217-4341-a89c-76cd4302ac34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7acdd60a-63f0-4280-9662-6e8d7e0e625f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7da260d2-2100-4998-858a-d9177d745e45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10088c6a-e568-4bb6-8203-26ba3572c356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">dvax:RevenueReserveAccrualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6081d343-1a70-4d79-938f-b5c367c4a904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1790227d-10fa-4cab-abdb-eb0e7d848a20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_065dab0d-65d8-4bc3-b27e-bda7f559f545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32dacd1a-2cf4-4e7d-a9cb-0223b786f81e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">dvax:RevenueReserveAccrualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5e1933f-3515-412a-9687-dae5c9a6b824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5d40eed-ddd7-4243-9e53-3cfc906ba5a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eab3cba9-923b-419c-bdef-b0654a1ab2b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97e9955d-8f3c-4e73-96cc-3ff1b69da22b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cccd4a85-7cd2-47b0-8792-edf0ca811695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCollaborationPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6451506c-a0f7-4a87-ac9f-42b2634d9a77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_970dc7a0-06ce-4b4c-a6b1-53363f517586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72dff176-fdce-41b0-bd7a-2057a380f269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53c34584-541c-4321-ab58-9d0fe2f1fd0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26a1416a-c87f-4567-b7f7-4e8b77e534c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:TwentySeventeenAtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a048ebc-c8de-4126-86ee-1592940450b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68391399-2908-490f-99f6-ed291d638344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fcb751e6-cdea-4a40-9300-946017e2ec1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:PerformanceBasedVestingScheduleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_304335a0-4bda-469c-809d-39c049a6dfae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccc907f7-07b3-4485-bad7-b638c7661924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_743ce050-0aa0-47d1-90ac-18e05e613453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6adf0287-276d-4c38-aa2a-2587117e5871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4324081c-f2df-428f-82a0-7b99f17493ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17561271-4a7b-4b2f-bb36-76707b8268dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:USDepartmentOfDefenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_faa950c0-0245-4bdf-aa7b-50e9c38ec395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5287e9ff-4a22-4227-b33c-aef9575adc2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dvax:DebtInstrumentConversionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02645021-8828-4251-8736-7889f9068d7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad54aada-ef84-4b1b-b532-5c907b0a02c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f400d9db-46ac-46b2-b217-0a803cda715f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0d39007-043c-4130-9d47-4b28ecc8e767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCollaborationPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_260c0775-ec5e-4e9a-83f8-a1b4aa2f06c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_529c356f-70af-41f9-a631-87c29cdb73e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bbfa976-1e7d-4da7-bc09-d8fb7b04dbd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-05-27</xbrli:startDate><xbrli:endDate>2014-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb7a44e4-c892-49a3-b202-b907c029e24f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CoalitionForEpidemicPreparednessInnovationsPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23485235-7712-4e50-8b13-23e29659179c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CRGServicingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d7cb580-217f-495d-9dc8-c7a31af8234f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61e4fae6-429a-477a-9549-6b5ff699fbf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfd94056-2ea8-4584-9e10-0cb5bec164e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f26b2cd-7c84-4953-85e9-83acbeb93d90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:USDepartmentOfDefenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58733421-ee84-4c5d-9a12-53149c7e8b38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0797703a-9cf9-4f2a-a2ab-e188c2fa6d75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b70264d-6f06-4292-a106-b2ff81f59d36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e53f99f-a072-4fb9-b577-17596226d68f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a801bf1-6b19-4a7c-8dc9-d56926556425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a778631e-7026-4533-acd7-c0e2a158a18d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c48f9ef2-11f3-4b36-9b5a-e093eb35a836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af9c3a6e-6e11-44bc-ad28-b459d2203fed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d33fabd0-98d3-439e-b8a4-3bba01fe695a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10486a1b-be2f-40a5-b01f-0bcd65255d81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07eaa0a5-29dc-4366-a233-4616595cc0e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:USDepartmentOfDefenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c8b18ed-3d15-4464-921d-cd75ad104a77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_712b1a93-fff4-4b0c-8c9b-e29381d7d61f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d9fa1a4-607b-4714-b950-2d3ee7d6606a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c9ae35d-bbf7-49a3-ab55-60aabc35c7b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_333f7989-91c9-45d9-a30d-059fd745363e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87f096fc-5022-4951-928c-a55c0c09d734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCollaborationPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d3d0244-f5ac-41e6-b1e4-39944e862722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdafacc4-ce23-4518-be33-853c6f2b2e35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de1bbf7b-39e6-455e-a6ad-d72e13ff09c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf03e8de-4dfe-4921-8f60-87f1256383af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25b31f57-0a7e-4cd3-b3c8-ac133125ecf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19035b31-a18b-4349-93e6-45dccd60c49e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9059078-1d7f-42cf-9ac7-53b904e61b2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d50c3d18-220b-403a-97e4-cf6868d818cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CRGServicingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3226f406-b30a-4fe8-b77d-6acd3bc687cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9937706-ff8e-4688-b5fb-817ee1b77e6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22fa84c0-ee5b-418a-bab8-0db6e2ecbd21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13bbb079-e389-44b2-b0fe-129eed17bc18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7e1bd25-a160-4d2a-9aa1-1570a122f4cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa18ccc3-e6a3-4fc5-84a7-11116a04094b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:SupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74aa1aa7-40d9-43b4-9261-d413646b1f6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a546293-5326-4ca1-b866-7d58c5fc2258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ac1d460-1347-453f-a512-bbc25081089d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5136ab72-32fb-4b8a-a285-f65c7aae72f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b2ac57c-b971-472c-8ad3-2eb87f03dd71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ae2c12d-5812-46ba-bc06-5eb199a307cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8132c0b8-7437-4b80-a8db-085c7a1df0da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecd4b79e-9828-475d-9c9f-5c628dfa3993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df4c54ad-6b4c-4547-9c0b-6d82cd6c4cde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4dc6828d-94e8-4ca1-9e05-1d3d58d0dc47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-26</xbrli:startDate><xbrli:endDate>2023-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72b2baa2-131f-4929-818e-a53fbd5d4d42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ef049fa-5c44-4e24-81ac-16efb8ddcea8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">dvax:CaliforniaAndOtherStatesTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38abd918-f40c-4d00-8c67-0b1cee772c9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21f845e6-44c3-401e-bfcd-a9d88abc20b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88dea699-9bab-4426-88ed-ff1960599278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">dvax:CaliforniaAndOtherStatesTaxAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51decfbd-05ba-43b9-a300-132adf0402d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6a1605d-0ed8-4293-af91-e392daff1469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e844c02-fd3f-4039-9675-b2ca051071e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ace65c5a-30fc-4278-a936-73964385612f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CRGServicingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47db32ab-ff21-4bf4-92e5-39d73f0bf345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80741f76-5a9d-474f-ac4c-18ba54f8364e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0bdb5c9-6635-4822-a0d4-b057bdc6bf7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_600e9b74-60a6-45e3-9267-97174756699a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d17521b7-e208-42c4-b34d-99bc5b411173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c1e3d78-dd4b-4d59-b5e6-4fe90c415647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3eff1578-c6f0-49d6-9432-a944eed0709e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Days"><xbrli:measure>dvax:Days</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>dvax:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_4b6758f3-5084-45ca-8640-344a9ad1524b" fromRefs="F_3e2c2b77-11ae-45d6-a4ff-5efa14a8a961 F_030a5d8c-7c33-4a59-ba90-6103938eb1ce F_cb64a042-6b38-4867-8734-d0eb22b365cc"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997" fromRefs="F_5edd96ac-e2e3-4eab-ba59-1dce17251a9e F_b2c509cf-4658-4d4b-b728-8d4a0640a162 F_d6145b6a-d040-4dd6-9cb7-4c98c35a46d0 F_1008207a-8c71-49e0-993d-4989f909b1a5 F_f3da79f1-24c7-4632-b740-8b131a9d2be9 F_55b39750-cebc-4736-b3f2-9395cfe6ff03 F_2db33005-69a9-4d8f-82a2-0a0b43266bb2 F_bf5112d8-1c04-421c-a1d7-be09e25b39c7 F_55014c25-30ae-4571-8d55-fc4908e71a29 F_56283b7b-0bf3-4c03-a372-2a21083d9543"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2" fromRefs="F_af7984ca-1c6a-4061-9b34-3096cb7c7363 F_50131afd-0f80-49d3-83f5-48f0a9a291ba F_f05c35cd-44b9-4458-bbd6-5b766235a786 F_573be19d-8823-4dbc-8931-9152157e5823 F_8668cc6b-7fde-4c88-a624-d220fba70b18 F_1fd1191c-48bf-416e-9986-9e4ecc313c72 F_e4271787-7be9-41a9-9ec1-ae5a48e736d9 F_66c01725-80e8-4499-8bed-8476bf3e4e03 F_f54dd4fc-9a50-4c74-866f-36bf8b38e7ae F_6af692da-77b0-4aed-aaed-263dbd1e56db"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_cb54f36d-15f9-4a6b-ae57-6ba45a3be2fe" fromRefs="F_f29e6226-f7ac-44ea-9124-1bc9c7d80f69 F_2187e669-a5cb-494d-ae16-0757a0fc46b6"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_c5bf0a05-18a8-4de7-a66b-18eb61ca0e15" fromRefs="F_e6c2e3e9-7ea7-45bb-acd3-c2f99efa17be F_2187e669-a5cb-494d-ae16-0757a0fc46b6 F_2cd4b012-2bd4-43b0-a40d-b6cfbe828de6 F_b2703284-0338-4fab-9adc-c678bfd78578 F_f3c36f18-2b1d-4b81-b1c8-7e990a1b8f82"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_f71fd845-812c-43cf-97f6-a213c94f92fc" fromRefs="F_70c93f68-26e0-4dc6-9761-1747a7bdeee6 F_2020b3e4-1f4a-4785-a846-ac2f166dc9d8"></ix:relationship></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">Form </span><span style="font-size:15pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1ce2261-86b5-4702-a828-fa42bc8b89bd" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_79bd63e4-5340-4727-a1a8-d54dfe6e3000" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c4ea41a-ee19-456e-bad2-be365d85d680" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_050edb6f-8be3-4c8f-b6bc-39c8477a6fc2" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_3fff9108-4dd2-4197-b46d-c75372f6c42a" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from                        to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">                        </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commission file number: </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63ea247d-4f20-464b-bfe0-a2342c182a84" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">001-34207</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_641d0dab-2bd1-420f-b5a9-9f2d380351c3" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">Dynavax Technologies Corp</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">oration</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"/>
    <td style="width:2%;"/>
    <td style="width:49%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_13d7fbae-3863-466b-be28-0c0c73c5a35d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_2cb5fb24-62e0-416b-9514-af332f9344c7" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">33-0728374</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_edc5d1fe-2ecb-4d10-8687-c257a35222a3" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2100 Powell Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cea424ba-fbc8-47a3-816d-1396fb26228b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Suite 720</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2126771-0e76-49ea-891c-398afc130916" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Emeryville</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73b35706-9056-458b-9e7d-b4df9a851ec2" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f9f370e-bee5-4e78-989b-e91b75b8ae71" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">94608</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9f4bf92-927c-4eb1-82e5-465bb6b50adb" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">510</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6dda5e74-202e-47a4-815f-f07f1912266a" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">848-5100</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(Address, including Zip Code, and telephone number, including area code, of the registrant&#8217;s principal executive offices)</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.814%;"/>
    <td style="width:23.075%;"/>
    <td style="width:47.111%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading symbol(s):</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered:</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_9b8c38a8-4e6f-489b-a73d-aabbaa2f6f39" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_565314b4-090c-4505-b1e3-799bba90b2c9" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">DVAX</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_228400fb-4252-4ea7-80fd-18006ecae4bc" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities Registered Pursuant to Section 12(g) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62acd4b9-1f8e-4179-8563-543a9a66b9aa" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  &#9744;    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1db291cd-5900-481e-8c9d-d6fd46b64bef" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12218843-c603-476b-abde-311784a66041" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;   No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit such files).    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7b964f8-1d32-4dff-88af-f7c824168698" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27.846%;"/>
    <td style="width:1.34%;"/>
    <td style="width:18.104%;"/>
    <td style="width:1.34%;"/>
    <td style="width:22.184%;"/>
    <td style="width:1.34%;"/>
    <td style="width:27.846%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_02475e4f-48d1-4a52-82c3-b754301621e5" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer &#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer &#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Smaller reporting company </span><span style="font-size:8pt;"><ix:nonNumeric id="F_f13b9f9b-ca50-42c1-a961-2c0c151e9d5a" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Emerging growth company </span><span style="font-size:8pt;"><ix:nonNumeric id="F_db0d0094-bff9-4fee-8788-97a775ab5920" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73e0818e-f40d-48b5-9bd9-5d81b42d604e" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_59de8064-775e-481a-8660-f7ddc36eaa69" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b).  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  &#9744;    No  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d2beddc-bdc5-487c-8530-cd76f1da8365" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the voting and non-voting stock held by non-affiliates of the registrant, based upon the closing sale price of the common stock on June 30, 2023 as reported on the Nasdaq Global Select Market, was approximat</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ely $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c24ffdc-14aa-4ba4-be98-5e2da3c6ee82" contextRef="C_1b272903-9c51-40dd-8f58-0e6dd1d903ad" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> billion. </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Shares of common stock held by each officer and director and by each person known to the Company who owns 5% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of February 20, 2024, the registrant had outstanding</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e1c148b-7477-4fcf-9730-00ef12a4e7a5" contextRef="C_55e18a2b-9266-46ed-bd0b-26af19bac2fd" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">130,614,772</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> sh</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_b303d141-6b7c-4455-8019-6e6e6820c0ab" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Definitive Proxy Statement for the registrant&#8217;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III, Items 10-14 of this Form 10-K. The Definitive Proxy Statement will be filed no later than 120 days after the close of the registrant&#8217;s fiscal year ended December 31, 2023.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.258%;"/>
    <td style="width:16.657%;"/>
    <td style="width:12.198%;"/>
    <td style="width:19.996%;"/>
    <td style="width:13.337%;"/>
    <td style="width:25.555%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Firm Id:</span></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_c7a8b951-26d7-46ad-a456-3549f1dd9eb1" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Name:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_6febfd91-7891-422b-a722-b619ec01c6bb" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Location:</span></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_815973ca-4209-4a64-9fda-189e7024c65f" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">San Francisco, California</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DYNAVAX TECHNOLOGIES CORPORATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.18%;"/>
    <td style="width:1%;"/>
    <td style="width:81.92%;"/>
    <td style="width:1.12%;"/>
    <td style="width:7.78%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page No.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="5" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">BUSINESS</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">RISK FACTORS</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">UNRESOLVED STAFF COMMENTS</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CYBERSECURITY</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PROPERTIES</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">LEGAL PROCEEDINGS</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">MINE SAFETY DISCLOSURE</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="5" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[RESERVED]</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><a href="#item_7"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><a href="#item_9"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CONTROLS AND PROCEDURES</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="5" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><a href="#item_10"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">EXECUTIVE COMPENSATION</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><a href="#item_12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="5" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">EXHIBIT AND FINANCIAL STATEMENT SCHEDULES</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">FORM 10-K SUMMARY</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements, including statements about sales of HEPLISAV-B&#174;, our ability to successfully commercialize HEPLISAV-B, CpG 1018 adjuvant or any future product, our anticipated market opportunity and level of sales of HEPLISAV-B and CpG 1018 adjuvant, our ability to manufacture sufficient supply of HEPLISAV-B to meet future demand, our business, collaboration and regulatory strategy, our ability to successfully support the development, manufacture and commercialization of other vaccines containing our CpG 1018 adjuvant, including any current or potential vaccine or vaccine candidate that stems from any of our collaborations, our ability to manufacture sufficient supply of CpG 1018 adjuvant to meet potential future demand in connection with new vaccines, our ability to advance our other product candidates, such as our shingles, Tdap and plague programs, and to otherwise develop and expand our clinical research pipeline, meet regulatory requirements, including post-marketing obligations and commitments, uncertainty regarding our capital needs and future operating results and profitability, anticipated sources of funds, liquidity and cash needs (including our ability to collect on accounts receivables), anticipated future revenue, as well as our plans, objectives, strategies, expectations and intentions for our business. These statements appear throughout this Annual Report on Form 10-K and can be identified by the use of forward-looking language such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;future,&#8221; or &#8220;intend,&#8221; or the negative of these terms or other variations or comparable terminology. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Actual results may vary materially from those in our forward-looking statements as a result of various factors that are identified in &#8220;Item 1A&#8212;Risk Factors&#8221; and &#8220;Item 7&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report on Form 10-K. No assurance can be given that the risk factors described in this Annual Report on Form 10-K are all of the factors that could cause actual results to vary materially from the forward-looking statements. All forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Readers should not place undue reliance on these forward-looking statements and are cautioned that any such forward-looking statements are not guarantees of future performance. We assume no obligation to update any forward-looking statements after the date they are made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This Annual Report on Form 10-K includes trademarks and registered trademarks of Dynavax Technologies Corporation. Products or service names of other companies mentioned in this Annual Report on Form 10-K may be trademarks or registered trademarks of their respective owners. References herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Dynavax&#8221; or the &#8220;Company&#8221; refer to Dynavax Technologies Corporation and its subsidiaries.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISK FACTOR SUMMARY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found in the more detailed discussion that follows this summary, and the below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should carefully consider the risks and uncertainties described herein as part of your evaluation of an investment in our securities:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B has been approved in the United States, the European Union and Great Britain and launched in the United States and Germany, and there is significant competition in these marketplaces.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since this is our first marketed product, the timing of uptake and distribution efforts are unpredictable and there is a risk that we may not achieve and sustain commercial success for HEPLISAV-B.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial results may vary significantly from quarter to quarter or may fall below the expectations of investors or securities analysts, each of which may adversely affect our stock price.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred annual net losses in most years since our inception and could continue to incur significant losses if we do not successfully commercialize HEPLISAV-B, launch new products and/or significant sales of our CpG 1018 adjuvant do not resume. Until we are able to generate significant revenues or achieve profitability </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">through product sales on a consistent basis, we may require substantial additional capital to finance our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors have greater financial resources and expertise than we do. If we are unable to successfully compete with existing or potential competitors as a result of these disadvantages, we may be unable to generate sufficient, or any, revenues and our business will be harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on our facility in D&#252;sseldorf, Germany and third parties to supply materials or perform processes necessary to manufacture our products and our product candidates. We rely on a limited number of suppliers to produce the oligonucleotides we require for development and commercialization. Additionally, we have limited experience in manufacturing our products or product candidates in commercial quantities. With respect to HEPLISAV-B, we use a pre-filled syringe presentation of the vaccine and our ability to meet future demand will depend on our ability to manufacture or have manufactured sufficient supply in this presentation.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we continue to focus on the commercialization of our HEPLISAV-B vaccine and our CpG 1018 adjuvant, we may encounter difficulties in managing our commercial growth and expanding our operations successfully.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we continue to grow as a commercial organization and enter into supply agreements with customers, those supply agreements will have obligations to deliver product that we are reliant upon third parties to manufacture on our behalf. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face uncertainty regarding coverage, pricing and reimbursement and the practices of third-party payors, which may make it difficult or impossible to sell certain of our products or product candidates on commercially reasonable terms.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to ongoing United States Food and Drug Administration (&#8220;FDA&#8221;), EU and comparable foreign post-marketing obligations concerning HEPLISAV-B, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated regulatory issues with HEPLISAV-B. If HEPLISAV-B or any products we develop are not accepted by the market or if regulatory authorities limit our labeling indications, require labeling content that diminishes market uptake of HEPLISAV-B or any other products we develop, or limit our marketing claims, we may be unable to generate significant future revenues, if any.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B and all of our clinical programs rely on oligonucleotide toll-like receptor (&#8220;TLR&#8221;) agonists. In the event of serious adverse events relating to TLR agonists, we may be required to reduce the scope of, or discontinue, our operations, or reevaluate the viability of strategic alternatives.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B is subject to regulatory obligations and continued regulatory review, and if we receive regulatory approval for our other product candidates, we will be subject to ongoing FDA and foreign regulatory obligations and continued regulatory review for such products.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities may require more clinical trials for our product candidates than we currently expect or are conducting before granting regulatory approval, if regulatory approval is granted at all. Our clinical trials may be extended which may lead to substantial delays in the regulatory approval process for our product candidates and may impair our ability to generate revenues.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials for our commercial product and product candidates are expensive and time consuming, may take longer than we expect or may not be completed at all, and have uncertain outcomes.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A key part of our business strategy for products in development is to establish collaborative relationships to help fund or manage development and commercialization of our product candidates and research programs. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to continue to develop and commercialize those products and programs, if at all. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we plan for the broader commercialization of our HEPLISAV-B vaccine and for the requisite capacity to manufacture our CpG 1018 adjuvant, our financial commitments for manufacturing and supply capacity might outpace actual demand for our products.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may develop, seek regulatory approval for and market HEPLISAV-B or any other product candidates outside of the U.S., the European Union and Great Britain, requiring a significant additional commitment of resources. Failure to successfully manage our international operations could result in significant unanticipated costs and delays in regulatory approval or commercialization of our products or product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on clinical research organizations (&#8220;CROs&#8221;) and clinical sites and investigators for our clinical trials. If these third parties do not fulfill their contractual obligations or meet expected deadlines, our planned clinical </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trials may be delayed and we may fail to obtain the regulatory approvals necessary to commercialize our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a biopharmaceutical company, we engage CROs to conduct clinical studies, and failure by us or our CROs to conduct a clinical study in accordance with good clinical practices (&#8220;GCP&#8221;) standards and other applicable regulatory requirements could result in disqualification of the applicable clinical trial from consideration in support of approval of a potential product.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If third parties assert that we have infringed their patents or other proprietary rights or challenge our patents or other proprietary rights, we may become involved in disputes and litigation that would be costly, time consuming and have a negative impact on the commercialization of our current products and delay or prevent development or commercialization of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock price is subject to volatility, and your investment may suffer a decline in value. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future sales of our common stock or the perception that such sales may occur in the public market could cause our stock price to fall.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt. Conversion of the Convertible Notes (defined below) may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The loss of key personnel could delay or prevent achieving our objectives. In addition, our continued growth to support commercialization may result in difficulties in managing our growth and expanding our operations successfully.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our information technology systems or those of third parties upon which we rely, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RT I</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. BUSINESS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OUR COMPANY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a commercial stage biopharmaceutical company dedicated to developing and commercializing innovative vaccines in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in vaccines and our proven, proprietary vaccine adjuvant technology. We are currently focused on our efforts to drive long-term shareholder value by maximizing utilization of our HEPLISAV-B&#174; hepatitis B vaccine, expanding our own portfolio of innovative vaccine candidates leveraging our proven adjuvant technology, and leveraging our CpG 1018&#174; adjuvant supply strategy through both commercial and research collaborations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our first marketed product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States, the European Union and Great Britain for prevention of infection caused by all known subtypes of hepatitis B virus ("HBV") in adults aged 18 years and older. HEPLISAV-B is the only two-dose hepatitis B vaccine for adults approved in the United States, the European Union and Great Britain. In Phase 3 trials, HEPLISAV-B demonstrated faster and higher rates of protection with two doses in one month compared to other currently approved hepatitis B vaccines, which require three doses over six months, with similar safety profiles. We received marketing authorization approval of HEPLISAV-B in February 2021 from the European Commission for prevention of infection caused by all known subtypes of HBV in adults aged 18 years and older. In May 2021, we entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV-B in Germany, and in May 2022, we commenced commercial shipments of HEPLISAV-B in Germany. In March 2023, we received marketing authorization in Great Britain for HEPLISAV-B for the active immunization against hepatitis B virus infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pipeline Programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing a pipeline of differentiated product candidates that leverage our CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. These programs include vaccine candidates under development for shingles, Tdap and plague.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shingles vaccine program: Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tdap vaccine program: Tdap-1018 is an investigational vaccine candidate intended for active booster immunization against tetanus, diphtheria, and pertussis ("Tdap").</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Plague vaccine program: We are developing a plague (rF1V) vaccine candidate adjuvanted with CpG 1018, currently in a Phase 2 clinical trial in collaboration with, and fully funded by, the U.S. Department of Defense ("DoD").</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we manufacture and have supplied in the past CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B, through both commercial supply agreements and preclinical and clinical research collaborations with third-party organizations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adjuvant Technology Overview: Toll-like Receptor Immune Modulation Platform</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Toll-like receptors (TLRs) are a family of transmembrane proteins that play a vital role in innate immunity and subsequent adaptive immunity. Signaling through these receptors is triggered by the binding of a variety of pathogen-associated molecules and is essential to generation of innate immunity. The innate immune response is the first line of defense against viruses, bacteria and other potential pathogens. Importantly, the innate response initiates and regulates the generation of an adaptive immune response composed of highly specific antibodies and T cells. Compounds used in vaccine products that stimulate enhanced immune responses are generally referred to as adjuvants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our work in this area has been focused primarily on stimulation of a subset of TLRs that recognize bacterial and viral nucleic acids. This work resulted in the identification of proprietary unmethylated synthetic oligonucleotides (short segments of deoxyribonucleic acid (DNA)), that mimic the activity of microbial DNA, and selectively activate one of these important receptors, TLR9. These TLR9 agonists are called CpG oligonucleotides &#8211; or &#8220;CpGs&#8221; for short &#8211; referring to the presence of specific nucleotide sequences containing the CG base pair.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our vaccine research to date has focused on the use of TLR9 agonists as novel vaccine adjuvants. B-Class TLR9 agonists, such as our CpG 1018 adjuvant, stimulate release of cytokines necessary for T cell activation establishing long-term immunity. TLR9 stimulation particularly helps generate Th1 immune responses that are important to control pathogens such as viruses and bacteria. As a result, TLR9 adjuvanted vaccines induce a specific Th1 immune response and more durable levels of protective antibodies relative to non-adjuvanted vaccines. Our CpG 1018 adjuvant has an established tolerability profile demonstrated in a wide range of clinical trials and real-world, commercial use, and has consistently demonstrated its ability to enhance the immune response without excessive reactogenicity as shown in multiple clinical trials in our HEPLISAV-B and COVID-19 vaccine collaboration programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key 2023 Business and Financial Highlights</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drive Growth of HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HEPLISAV-B vaccine is the first and only adult hepatitis B vaccine approved in the U.S. and EU that enables series completion with only two doses in one month. Hepatitis B vaccination is universally recommended for adults aged 19-59 in the U.S.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized $213.3 million of HEPLISAV-B product revenue in the U.S. during the year ended December 31, 2023, representing a 69% increase compared to the year ended December 31, 2022. This increase was primarily driven by an increase in HEPLISAV-B demand and market share gains in the U.S. in 2023, compared to 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B estimated total market share in the U.S. increased to approximately 42%, compared to approximately 35% at the end of 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B estimated market share in the retail pharmacy segment increased to approximately 58%, compared to approximately 42% at the end of 2022. HEPLISAV-B estimated market share in the Integrated Delivery Networks ("IDNs") and Large Clinics segment increased to approximately 56%, compared to approximately 47% at the end of 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A supplemental Biologic License Application ("sBLA") for HEPLISAV-B vaccination of adults on hemodialysis is currently under priority review by the FDA with a Prescription Drug User Fee Act action date planned for May 13, 2024.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actively leveraging on the CDC's Advisory Committee on Immunization Practices ("ACIP") recommendation for hepatitis B vaccination in adults, which was published in April 2022, advising that all adults aged 19-59 should be vaccinated against hepatitis B. We believe this will help enable a significantly expanded total annual market opportunity of approximately $800 million in the U.S. by 2027, with HEPLISAV-B well positioned to achieve a majority market share.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advance Clinical Pipeline Leveraging our Proven Adjuvant Technology</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are advancing a pipeline of product candidates that leverage our CpG 1018 adjuvant, which has demonstrated its ability to enhance the immune response with a favorable tolerability profile in a wide range of clinical trials and real-world commercial use.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shingles vaccine program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recently received Type B meeting feedback from the FDA on the Z-1018 clinical development plan and submitted an Investigational New Drug Application ("IND") to the FDA to support the initiation of a Phase 1/2 trial of Z-1018, upon IND clearance, in the first half of 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tdap vaccine program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recently received Type B meeting feedback from the FDA on the Tdap-1018 clinical development plan. We plan to submit an IND to the FDA to support the initiation of the Phase 2 human challenge study of Tdap-1018 in the second half of 2024, upon completion of the independent study being conducted by the Canadian Center for Vaccinology to establish the human challenge dose, which we will utilize in our Phase 2 study.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></div></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plague vaccine candidate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate top line data for the randomized, active-controlled Phase 2 clinical trial evaluating immunogenicity, safety, and tolerability of the plague vaccine candidate in 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Corporate and Financial Highlights</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized $213.3 million of HEPLISAV-B vaccine net product revenue during the year ended December 31, 2023, representing 69% growth compared to 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We generated $100.6 million in cash from operating activities during the year ended December 31, 2023 and ended the year with $742.3 million in cash and cash equivalents, and marketable securities.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We reported a net loss of $6.4 million during the year ended December 31, 2023.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not recognize CpG 1018 adjuvant net product revenue during the year ended December 31, 2023, as we completed all obligations and product delivery under our CpG 1018 adjuvant collaboration agreements as of December 31, 2022.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our vision is to continue building a leading vaccines company dedicated to developing and commercializing innovative vaccines in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in vaccines and our proven, proprietary vaccine adjuvant technology. Our strategy is focused on our core priorities: drive growth in our HEPLISAV-B commercial vaccine, advance a differentiated vaccine pipeline, and identify strategic opportunities to accelerate growth. Key elements of our strategy include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Increase our HEPLISAV-B vaccine market share to become the market leader in the future;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maximize total addressable HEPLISAV-B vaccine market based on the ACIP Universal Recommendation;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leverage HEPLISAV-B vaccine as a foundational commercial asset to support company growth and pipeline development;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deliver on our innovative and diversified pipeline leveraging CpG 1018 adjuvant with proven antigens;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Build an adult vaccine portfolio of best-in-class products;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advance innovative pre-clinical and discovery efforts leveraging collaborations;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Continue disciplined allocation of capital aligned with corporate strategy to deliver long-term value through internal and external innovation; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursue external opportunities to further leverage our U.S. commercial vaccine capabilities, prioritizing first or best-in-class assets.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HEPLISAV-B [Hepatitis B Vaccine, (Recombinant), Adjuvanted]</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our first commercial product, HEPLISAV-B [Hepatitis B Vaccine, (Recombinant), Adjuvanted], is approved by the FDA, the European Commission and the UK Medicines and Healthcare products Regulatory Agency for prevention of infection caused by all known subtypes of HBV in adults aged 18 years and older. HEPLISAV-B combines CpG 1018 adjuvant, our proprietary TLR9 agonist adjuvant, and recombinant hepatitis B surface antigen (&#8220;rHBsAg&#8221; or &#8220;HBsAg&#8221;) that is manufactured by Dynavax GmbH, our wholly owned subsidiary, in D&#252;sseldorf, Germany. HEPLISAV-B and each of the vaccines it directly competes against use rHBsAg to elicit an immune response to the virus.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">About Hepatitis B</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is a major global health problem. It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer. The World Health Organization (&#8220;WHO&#8221;) and the CDC have set a goal to eliminate all viral hepatitis infections, including hepatitis B, globally by 2030, and are calling for a continued commitment to increase services to eliminate hepatitis. The WHO estimates that worldwide, approximately 296 million people were living with chronic hepatitis B in 2019, and that in the same year hepatitis B resulted in and estimated 820,000 deaths primarily from liver cancer. In addition, the CDC estimated that in 2020 approximately 580,000 to 1.2 million people in the U.S. were living with HBV infection. There was a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">total of 2,157 new cases of acute hepatitis B reported to the CDC in 2020. However, after adjusting for under-ascertainment and under reporting, the CDC estimated that 14,000 acute hepatitis B cases occurred in the U.S. in 2020.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recommendations for Adult Vaccination to Prevent Hepatitis B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The CDC&#8217;s ACIP unanimously voted at its November 2021 meeting to recommend that all adults 19 to 59 years of age should receive a hepatitis B vaccination, and such recommendation was published in April 2022. This universal recommendation greatly simplifies the identification of patients who need a hepatitis B vaccine compared to the previous risk-based recommendation, and significantly expands the number of adults in the United States who should be vaccinated against hepatitis B under the CDC recommendation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This recommendation is a significant milestone for hepatitis B prevention, making hepatitis B the fifth vaccine routinely recommended for adult immunization along with influenza, shingles, Tdap and pneumococcal. Based on this opportunity, we launched a series of innovative marketing campaigns targeting consumers and healthcare providers to increase the awareness of HEPLISAV-B as the only two-dose hepatitis B vaccine option, with broad protection across most patient types. Such efforts have driven an increase in HEPLISAV-B demand and market share in the U.S. in 2023 compared to 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Protection Against Hepatitis B by HEPLISAV-B</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The approval of HEPLISAV-B by the FDA was based on data from three Phase 3 non-inferiority trials involving nearly 10,000 adult participants who received HEPLISAV-B. These pivotal studies compared HEPLISAV-B administered in two doses over one month to Engerix-B&#174; administered in three doses over a six-month schedule. Results from HBV-23, the largest Phase 3 trial, which included 6,665 participants, showed that HEPLISAV-B demonstrated a statistically significantly higher rate of protection of 95% compared with 81% for Engerix-B. Across the three clinical trials, the most common local reaction was injection site pain (23% to 39%). The most common systemic reactions were fatigue (11% to 17%) and headache (8% to 17%).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have worldwide commercial rights to HEPLISAV-B. In addition to HEPLISAV-B, there are four other vaccines approved for the prevention of hepatitis B in the U.S.: Engerix-B and Twinrix&#174; from GlaxoSmithKline plc (GSK), Recombivax-HB&#174; from Merck &amp; Co. (&#8220;Merck&#8221;) and PreHevbrio&#153; from VBI Vaccines Inc. HEPLISAV-B is currently approved in the U.S., the EU and Great Britain for the prevention of hepatitis B in adults. We are also considering additional territories where it would be commercially feasible to market HEPLISAV-B.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The largest segments of the market are concentrated in independent hospitals and clinics, integrated delivery networks, dialysis centers, public health clinics and prisons, the Departments of Defense and Veterans Affairs and retail pharmacies. Our promotional activity is focused on the largest accounts in each segment. Our field sales force of approximately 117 people are targeting customers that we believe</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have the highest impact on adult hepatitis B vaccine utilization in the U.S. We deploy our sales force to the physician or pharmacist level, as well as at the procurement level within respective healthcare segments where vaccines are utilized. Our primary objectives are to both increase market share, as well as increase market size over time.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to explore ways to enhance the clinical profile of HEPLISAV-B. We completed an open-label, single-arm study of a 4-dose regimen of HEPLISAV-B in adults with end-stage renal disease who are initiating or undergoing hemodialysis. Final immunogenicity results included a seroprotection rate of 89.3% with high levels of anti-HBs antibodies. Safety data showed HEPLISAV-B was well tolerated and no safety concerns were observed. The safety and effectiveness of HEPLISAV-B in adults on hemodialysis have not yet been established. This study alone, regardless of results, may not be sufficient to support a label change to include dialysis patients. If we do receive approval of this dosing schedule, we expect to add dialysis centers to our personal promotion efforts. An sBLA for HEPLISAV-B vaccination of adults on hemodialysis is currently under priority review by the FDA with a Prescription Drug User Fee Act action date planned for May 13, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CpG 1018 Vaccine Adjuvant</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe the favorable immunogenicity and safety results achieved with HEPLISAV-B utilizing our CpG 1018 adjuvant support our efforts to develop it as a broadly useful vaccine adjuvant platform. CpG 1018 adjuvant has an established profile for the potential development of safe and effective vaccines. It has a well-defined mechanism of action, targeting select immune system cells, with well-characterized effects on the immune response that mimic the immune response to naturally occurring TLR9 agonists in pathogens. This results in potent adjuvant activity for antibody responses. In HEPLISAV-B, our CpG 1018 adjuvant is believed to drive faster and consistently higher rates of seroprotection than</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Engerix-B, even in the elderly and populations known to be less responsive to other vaccines. CpG 1018 adjuvant differentially elicits a preferred T Helper 1 (Th1) cell polarized response and drives protective antibody production. CpG 1018 adjuvant has a large safety database that indicates a favorable reactogenicity profile with lower reactogenicity compared to other adjuvants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established several clinical and preclinical collaborations with vaccine developers to evaluate CpG 1018 adjuvanted vaccine product candidates against influenza, other infectious diseases, and particularly COVID-19 across a variety of vaccine platforms. Data from studies in non-human primates demonstrate our CpG 1018 adjuvant can elicit a robust immune response to COVID-19 and protect animals from disease in challenge studies. Results from Phase 2 and 3 human clinical studies demonstrated vaccines utilizing CpG 1018 adjuvant had a favorable safety and tolerability profile, induced strong immune responses, including neutralizing antibodies and Th1-biased cell-mediated immunity, and resulted in a high efficacy against COVID-19 disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Vaccine Research and Development Pipeline</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are building an innovative pipeline of investigational vaccine product candidates, leveraging our proven, proprietary vaccine adjuvant technology. A summary of our pipeline programs follows:</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shingles Vaccine Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shingles is an extremely painful consequence of the reactivation of a latent varicella-zoster virus (&#8220;VZV&#8221;) infection, with attacks leading to potential complications including chronic pain. The current shingles vaccine market is approximately $4 billion and expected to grow over time. Our CpG 1018 adjuvant has demonstrated its ability to enhance the immune response without excessive reactogenicity in both HEPLISAV-B and multiple COVID-19 clinical trials. Importantly, CpG 1018 adjuvant has shown the ability to generate high levels of CD4+-cells which have been demonstrated to be key cell types in controlling latent VZV infection to avoid reactivation leading to shingles, with potentially lower reactogenicity compared to the current standard of care.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2022, we initiated a Phase 1 clinical trial of our shingles vaccine candidate, utilizing our CpG 1018 adjuvant. The global Phase 1 study was designed to evaluate safety, tolerability and immunogenicity of the vaccine candidate which is comprised of glycoprotein E (gE) plus CpG 1018 adjuvant.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we announced the completion of a randomized Phase 1 clinical trial of our shingles vaccine program evaluating the safety, tolerability, and immunogenicity in adults. At four weeks following the 2-dose regimen, the investigational shingles vaccine Z-1018 demonstrated high antibody and CD4 positive T-cell vaccine response rates in all arms, which were similar to the licensed comparator. Robust increases in CD4 positive T-cells were observed in all Z-1018 arms, although lower than the comparator. Total frequency of solicited systemic adverse events and local post-injection reactions and moderate and severe reactions were similar across the Z-1018 arms and lower than the comparator.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we presented results from a Phase 1 randomized, active-controlled, dose escalation, multicenter trial to evaluate the safety, tolerability, and immunogenicity of Z-1018, at the National Foundation for Infectious Diseases&#8217; 2023 Annual Conference on Vaccinology Research. These results demonstrate the opportunity to develop a shingles vaccine with improved vaccine tolerability and comparable efficacy to Shingrix and support the continued development of our shingles vaccine candidate. We received Type B meeting feedback from the FDA on the Z-1018 clinical development plan and submitted an IND to the FDA to support the initiation of a Phase 1/2 trial of Z-1018, upon IND clearance, in the first half of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tdap Vaccine Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pertussis (whooping cough) is a serious illness in people of all ages and can be life-threatening, especially in infants. Whooping cough is caused by the highly contagious respiratory bacterium, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bordetella pertussis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. People with pertussis usually spread the disease to others by coughing, sneezing or spending time in the same breathing environment. According to the CDC, there are an estimated 24.1 million cases of pertussis and about 160,700 deaths per year globally. The resurgence of B. pertussis in multiple countries has been attributed to the Tdap vaccine&#8217;s limited duration of protection. Our Tdap booster vaccine candidate adjuvanted with CpG 1018 is anticipated to improve the durability of protection against pertussis by redirecting T cell responses and enhancing protective antibody responses in a booster vaccine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2017, we entered into an agreement with Serum Institute of India Pvt. Ltd. ("SIIPL") to collaborate on development and commercialization of certain potential vaccines including Tdap booster adjuvated with CpG 1018. Under the collaboration, we have exclusive worldwide rights to commercialize the vaccine, except that SIIPL has exclusive rights to distribute in India and to fulfill WHO/United Nations Children's Fund (UNICEF) tender contracts. Each party is responsible for clinical development cost in their respective territories.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2022, we presented adult and adolescent safety data from the Phase 1 clinical trial of Tdap-1018, which was well tolerated with no safety concerns observed. Additionally, immunogenicity levels in adults met our expectations and support our plan to continue advancement of this clinical program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, we</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completed a pertussis challenge study in nonhuman primates demonstrating protection from disease upon challenge and robust Type 1 T helper (Th1) cell responses in nonhuman primates vaccinated with Tdap-1018. We recently received Type B meeting feedback from the FDA on the Tdap-1018 clinical development plan. We plan to submit an IND to the FDA to support the initiation of a Phase 2 human challenge study of Tdap-1018 in the second half of 2024, upon completion of the independent study being conducted by the Canadian Center for Vaccinology to establish the human challenge dose, which we plan to utilize in our Phase 2 study.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Department of Defense (Plague Vaccine) Phase 2 Study</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, we entered into an agreement with the U.S. Department of Defense ("DoD") for the development of a recombinant plague vaccine adjuvanted with CpG 1018 for approximately $22.0 million over two and a half years. Under the agreement, we agreed to conduct a Phase 2 clinical trial combining our CpG 1018 adjuvant with the DoD's rF1V vaccine designed to show that two doses of CpG 1018 adjuvanted vaccine administrated within a period of one month is similar to three doses of the aluminum-adjuvanted vaccine administered over a period of six months.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, we commenced the Phase 2 clinical trial with the first participant dosed, evaluating the immunogenicity, safety and tolerability of the DoD&#8217;s rF1V vaccine combined with our CpG 1018 adjuvant, in adults 18 to 55 years of age.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, Part 1 of the Phase 2 clinical trial evaluating the immunogenicity, safety, and tolerability in adults of a plague (rF1V) vaccine candidate adjuvanted with CpG 1018 was successfully completed. Both CpG 1018 adjuvanted arms met the Part 1 primary endpoint and demonstrated a greater than two-fold increase in antibodies over the alum adjuvanted control arm after two doses. In 2023, we completed enrollment and dosing in Part 2 of the Phase 2 clinical trial evaluating immunogenicity, safety, and tolerability. Preliminary results are expected in 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, we executed a contract modification with the DoD to support advancement of the plague vaccine candidate into a nonhuman primate challenge study, which was initiated in August 2023, with the agreement now totaling $33.7 million through 2025.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CpG 1018 Adjuvant Supply Partnerships for COVID-19 Vaccine Development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To support the fight against COVID-19, we collaborated with five other organizations on their development of COVID-19 vaccines, by supplying them with CpG 1018 adjuvant under commercial supply agreements supported by two contract manufacturing organizations, with whom we developed and implemented plans to help scale-up activities to support pandemic-level production of our CpG 1018 adjuvant as necessary to support these and any future collaborations. As of December 31, 2023, all five of our collaborators have received emergency use authorization and/or full approval for their COVID-19 vaccines, and our delivery obligations under our related supply agreements have been fully satisfied. Under our agreement (together with subsequent amendments, the "CEPI Agreement") with Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;), through December 31, 2023, we received Advance Payments totaling approximately $175.0 million pursuant to the CEPI Agreement, of which $67.3 million have been repaid and $47.4 million have been forgiven. As of December 31, 2023, remaining Advance Payments totaling $60.3 million in CEPI accrual long-term were reflected in our consolidated balance sheets. We continue to work to identify other programs where CpG 1018 adjuvant can be utilized to enhance the immune response to a coronavirus vaccine or other vaccines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a summary of our significant CpG 1018 adjuvant collaboration agreements, see Note 9 - Collaborative Research, Development and License Agreements, in the accompanying notes to the consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INTELLECTUAL PROPERTY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our products, product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Generally, we seek patent protection in the U.S and foreign countries on a selective basis to further protect the inventions that we or our partners consider important to the development of our business. We also rely on trade secrets and contracts to protect our proprietary information, and we rely on trademarks to protect our brand, products, product candidates, and technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our intellectual property portfolio included over 25 issued U.S. patents, over 65 granted foreign patents and over 115 additional Dynavax-solely owned or co-owned pending U.S. non-provisional and foreign patent applications claiming compositions containing TLR agonists or antagonists, methods of use, and/or methods of manufacture thereof. Specifically, our portfolio includes: (i) three issued U.S. patents related to certain uses of HEPLISAV-B that expire in 2032; (ii) 23 pending U.S. and foreign patent applications related to an investigational tetanus, diphtheria, pertussis (Tdap) booster vaccine, which are co-owned with SIIPL; (iii) 17 pending U.S. and foreign patent applications related to an investigational shingles vaccine; (iv) over 55 pending U.S. non-provisional and foreign patent applications related to COVID-19 vaccines, which include patent families that are either solely-owned or co-owned with Valneva Austria GmbH, Medigen Vaccine Biologics Corporation, or Colorado State University Research Foundation; and (v) one pending U.S. patent application related to an investigational plague vaccine, which is co-owned with The Government of the United States, as Represented by the Secretary of the Army. Lastly, some of the patents and patent applications in our portfolio relate to our discontinued immuno-oncology programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, the term of a patent extends for 20 years from the filing date of the earliest U.S. non-provisional or international (PCT) application to which priority is claimed. In certain instances, a patent term may be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. Moreover, in the U.S., the term of a patent may be extended as a consequence of patent office delays during prosecution. Our patent estate, based on patents existing now and expected by us to issue based on pending applications, is projected to expire on dates ranging from 2024 to 2043.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The actual protection afforded by a patent varies on a product-by-product basis, from country-to-country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because patent applications in the U.S. and many foreign jurisdictions typically are not published until 18 months after filing and publications of discoveries in the scientific literature often lag behind actual discoveries, we cannot be certain that we were the first to file for protection of the inventions set forth in these patent applications or in our issued patents. Further, there could be post-grant proceedings such as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review (IPR), post grant review (PGR), reexamination, reissue or opposition which could result in claims in our patents being narrowed or invalidated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends significantly on our ability to operate without infringing patents and other proprietary rights of third parties. A number of pharmaceutical companies and biotechnology companies, as well as universities and research institutions, may have filed patent applications or may have been granted patents that cover inventions similar to the inventions owned by or licensed to us. We may not be able to determine with certainty whether patents or patent applications of other parties may materially affect our ability to make, use, offer to sell, or sell any products. If another party controls patents or patent applications covering our products, we may not be able to obtain the rights we need to those patents or patent applications in order to commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Litigation may be necessary to enforce patents issued or licensed to us or to determine the scope or validity of another party&#8217;s proprietary rights. The existence of third-party patent applications and patents could significantly reduce the coverage of the patents owned by or licensed to us and limit our ability to obtain meaningful patent protection. Litigation or any other proceedings could result in substantial costs to and diversion of effort by us, and an adverse outcome in a court or patent office could subject us to significant liabilities, require disputed rights to be licensed from other parties, or require us to cease using some of our technology. We may not prevail in these actions or proceedings if they arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other parties may duplicate, design around or independently develop similar or alternative technologies to ours or our licensors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may rely, in some circumstances, on trade secrets and confidentiality agreements to protect our technology. Although trade secrets are difficult to protect, wherever possible, we use confidential disclosure agreements to protect the proprietary nature of our technology. Our standard practice is to require each of our collaborators, commercial partners, employees, consultants, contractors and advisors to enter into an agreement before beginning their employment, consulting or advisory relationship with us that in general provides that the individuals must keep confidential and not disclose to other parties any of our confidential information developed or learned by the individuals during the course of their relationship with us except in limited circumstances. These agreements with employees, consultants and contractors also generally provide that we own all inventions conceived by the individuals in the course of rendering their employment or services to us. However, there can be no assurance that these agreements will not be breached, that we will have adequate remedies for any breach, or that our trade secrets and/or proprietary information will not otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants or contractors use intellectual property owned by others in their work for us, disputes may also arise as to the rights in related or resulting know-how and inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COMPETITION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Our products and development programs compete with several commercially available vaccine and adjuvant products. Many companies and institutions are making substantial investments in developing additional vaccines and adjuvants that could compete directly or indirectly with our marketed products and products under development by us and our collaborators. For example, there are multiple other shingles vaccine candidates in development including those being developed by Pfizer, BioNTech SE, Curevo Vaccine and others. The approved products from these programs will all need to compete with a single approved vaccine currently available in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also believe our CpG 1018 adjuvant, which we use in our own products and product candidates and provide to our collaborators through clinical and commercial supply agreements, is as or more effective than other available adjuvants and, being a yeast-derived product, is far more sustainable that other available products that are derived from, for example, shark squalene or tree bark. Regardless, there can be no guarantee that we can compete with other companies for sales of adjuvant, or any approved vaccine.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Competition for HEPLISAV-B</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B, a two-dose in one month adult hepatitis B vaccine, competes directly with three-dose over six months marketed vaccines Engerix-B from GSK, as well as Recombivax-HB marketed by Merck. There are also modified schedules of conventional hepatitis B vaccines for limited age ranges that are approved in the EU, Great Britain and the U.S. In addition, HEPLISAV-B competes against Twinrix, a bivalent vaccine marketed by GSK for protection against hepatitis B and hepatitis A. Additionally, PreHevbrio, a three-dose adult hepatitis B vaccine manufactured by VBI Vaccines Inc. (&#8220;VBI&#8221;) is commercially available in multiple countries including the U.S. While we believe that HEPLISAV-B competes very well with other approved vaccines available on the market, we face significant competition in our longer term goal to capture a majority of U.S. market share. While we may explore additional territories outside of the U.S., the EU and Great Britain to market HEPLISAV-B, in doing so we will likely face competition from these or other products and competitors.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Competition for our adjuvant supply supporting COVID-19 and our development pipeline including shingles, Tdap, plague and other potential pipeline indications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also in competition with companies developing vaccines, and vaccine adjuvants, generally including, among others, GSK, Pfizer, Inc., Sanofi S.A., Merck, Bavarian Nordic A/S, Emergent BioSolutions, Inc., Novavax, Inc., Medicago Inc., Valneva, AstraZeneca plc, Moderna, Inc., Johnson &amp; Johnson and VBI.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the entities developing or marketing these competing products have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative agreements with large, established companies with access to capital. These entities may also compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to or necessary for our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">REGULATORY CONSIDERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose extensive requirements upon the clinical development, pre-market approval, manufacture, labeling, marketing, promotion, pricing, import, export, storage and distribution of biopharmaceuticals. These agencies and other regulatory agencies regulate research and development activities and the testing, approval, manufacture, quality control, safety, effectiveness, labeling, storage, recordkeeping, advertising and promotion of drugs and biologics. Failure to comply with applicable FDA or foreign regulatory agency requirements may result in warning letters, fines, civil or criminal penalties, additional reporting obligations and/or agency oversight, suspension or delays in clinical development, recall or seizure of products, partial or total suspension of production or withdrawal of a product from the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act and its implementing regulations and biologics additionally under the Public Health Service Act. The process required by the FDA before biopharmaceuticals may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin and, at a minimum, must be updated annually; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of extensive pre-clinical laboratory tests and pre-clinical animal studies, all performed in accordance with the FDA&#8217;s Good Laboratory Practice (&#8220;GLP&#8221;) regulations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well controlled human clinical trials to establish the safety and efficacy of the product for each proposed indication; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of a new drug application or a biologics license application, NDA or BLA, depending on the nature of the product after completion of all pivotal clinical trials to demonstrate the safety, purity and potency of the product for the indication for use; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a determination by the FDA to accept the application for review; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities to assess compliance with the FDA&#8217;s current good manufacturing practices (&#8220;cGMP&#8221;) regulations for pharmaceuticals; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of an NDA or BLA prior to any commercial marketing or sale of the product in the United States. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates, or those of our collaborators, will be granted on a timely basis, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of pre-clinical tests (which include laboratory evaluation as well as GLP studies to evaluate toxicity in animals) for a particular product candidate, together with related manufacturing information and analytical data, are submitted as part of an IND to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the thirty-day time period, raises concerns or questions about the conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. IND submissions may not result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also be made for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">each successive clinical trial conducted during product development. Further, an independent institutional review board, or IRB, for each medical center proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that center and it must monitor the study until completed. The FDA, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive good clinical practice (&#8220;GCP&#8221;) regulations and regulations for informed consent and privacy of individually identifiable information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For purposes of an NDA or BLA submission and approval, clinical trials are typically conducted in the following sequential phases, which may overlap:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Studies are initially conducted in a limited population to test the product candidate for safety, dose tolerance, absorption, distribution, metabolism, and excretion, typically in healthy humans, but in some cases in patients. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Studies are generally conducted in a limited patient population to identify possible adverse effects and safety risks, explore the initial efficacy of the product for specific targeted indications and to determine dose range or pharmacodynamics. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. These are commonly referred to as pivotal studies. When Phase 2 evaluations demonstrate that a dose range of the product is effective and has an acceptable safety profile, Phase 3 clinical trials are undertaken in large patient populations to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial centers. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The FDA may approve an NDA or BLA for a product candidate, but require that the sponsor conduct additional clinical trials to further assess the product after approval under a post-marketing commitment or post- marketing requirement. In addition, a sponsor may decide to conduct additional clinical trials after the FDA has approved a product. Post-approval trials are typically referred to as Phase 4 clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of product development, pre-clinical studies and clinical trials are submitted to the FDA as part of an NDA or BLA. Applications also must contain extensive manufacturing and control information. Applications must be accompanied by a significant user fee. Once the submission has been accepted for filing, the FDA&#8217;s goal is to review applications within ten months of accepting the submission or, if the application relates to an unmet medical need in a serious or life-threatening indication, eight months from accepting the submission. During the review process, the FDA often has multiple requests for information or clarifications. The review process may be extended if the FDA deems that a response contains significant new information and will require additional time beyond the period originally designated to appropriately review. The FDA will typically conduct a pre-approval inspection of the manufacturer to ensure that the product can be reliably produced in compliance with cGMPs and will typically inspect certain clinical trial sites for compliance with GCP. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations. The FDA may deny approval of an application by issuing a Complete Response Letter if the applicable regulatory criteria are not satisfied. A Complete Response Letter may require additional clinical data and/or trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials, pre-clinical studies or manufacturing. Approval may occur with boxed warnings on product labeling or Risk Evaluation and Mitigation Strategies, which limit the labeling, distribution or promotion of a product. Once issued, the FDA may withdraw product approval if ongoing regulatory requirements are not met or if safety problems occur after the product reaches the market. In addition, the FDA may require testing, including Phase 4 clinical trials, and surveillance programs to monitor the safety effects of approved products which have been commercialized and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs or other information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Regulatory Requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including recordkeeping, annual product quality review, payment of program user fees and reporting requirements. Adverse event experience with the product must be reported to the FDA in a timely fashion and pharmacovigilance programs to proactively look for these adverse events are mandated by the FDA. Manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, injunctive action, additional reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements and/or oversight by the agency, import alert or possible civil or criminal penalties. The FDA may also require us to recall a product from distribution or withdraw approval for that product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA closely regulates the post-approval marketing and promotion of pharmaceuticals, including standards and regulations for direct-to-consumer advertising, dissemination of off-label information, industry-sponsored scientific and educational activities and promotional activities involving the Internet, including certain social media activities. Further, if there are any modifications to the product, including changes in indications, labeling, or manufacturing processes or facilities, we may be required to submit and obtain FDA approval of a new or supplemental application, which may require us to develop additional data or conduct additional pre-clinical studies and clinical trials. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential administrative, civil and criminal penalties, as well as damages, fines, withdrawal of regulatory approval, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs, additional reporting requirements and/or oversight by the agency, and imprisonment, any of which could adversely affect our ability to sell our products or operate our business and also adversely affect our financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Physicians may, in their independent medical judgment, prescribe legally available pharmaceuticals for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers&#8217; communications regarding off-label use. Additionally, a significant number of pharmaceutical companies have been the target of inquiries and investigations by various U.S. federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for off-label uses and other sales practices. These investigations have alleged violations of various U.S. federal and state laws and regulations, including claims asserting antitrust violations, violations of the Food, Drug and Cosmetic Act, false claims laws, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. If our promotional activities, including any promotional activities that a contracted sales force may perform on our behalf, fail to comply with these regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to issue warning letters or untitled letters, suspend or withdraw an approved product from the market, require corrective advertising or a recall or institute fines or civil fines, additional reporting requirements and/or oversight or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, the ability of our partners and us to market a product is contingent upon obtaining marketing authorization from the appropriate regulatory authorities. The requirements governing marketing authorization, pricing and reimbursement vary widely from country to country and region to region.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trials in the EU. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014 (&#8220;CTR&#8221;), which entered into application on January 31, 2022 repealing and replacing the former Clinical Trials Directive 2001/20 (&#8220;CTD&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increase transparency. Specifically, the regulation, which is directly applicable in all EU Member States, introduces a streamlined application procedure through a single-entry point, the "EU portal," the Clinical Trials Information System (&#8220;CTIS&#8221;); a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I assessment is led by the competent authorities of a reference Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State concerned. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The extent to which on-going clinical trials will be governed by the CTR will depend on the duration of the individual clinical trial. For clinical trials in relation to which an application for approval was made on the basis of the CTD before January 31, 2023, the CTD will continue to apply on a transitional basis until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In all cases, clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Medicines used in clinical trials</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">must be manufactured in accordance with the guidelines on cGMP and in a GMP licensed facility, which can be subject to GMP inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union Marketing Authorization</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain a Marketing Authorization ("MA") for a product in the EU, an applicant must submit a Marketing Authorization Application ("MAA") either under a centralized procedure administered by the European Medicines Agency ("EMA") or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure, national procedure or mutual recognition procedure). An MA may be granted only to an applicant established in the EU.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The centralized procedure provides for the grant of a single MA by the European Commission that is valid for all EU Member States. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for (i) medicinal products derived from biotechnological processes, (ii) products designated as orphan medicinal products, (iii) advanced therapy medicinal products ("ATMPs"), and (iv) products with a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use ("CHMP") is responsible for conducting the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (not including clock stops). The CHMP can, however, revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unlike the centralized authorization procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the Heads of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures &#8211; Human ("CMDh") for review. The subsequent decision of the European Commission is binding on all EU Member States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States. Like the decentralized procedure, the mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the MA of a medicinal product by the competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent authority of an EU Member State requesting that this authority recognize the MA delivered by the competent authority of another EU Member State.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In principle, an MA has an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was granted. To support the application, the MA holder must provide the EMA or the competent authority with a consolidated version of the eCTD (Common Technical Document) providing up-to-date data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period for the MA. Once subsequently</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (in case of centralized procedure) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines ("PRIME") scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. It permits increased interaction and early dialogue with companies developing promising medicinal products, to optimize their product development plans and speed up their evaluation to help the product reach patients earlier than normal. Product developers that benefit from PRIME designation are potentially eligible for accelerated assessment of their MAA although this is not guaranteed. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA will cease to be renewed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An MA may also be granted &#8220;under exceptional circumstances&#8221; where the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved to medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for authorization in exceptional circumstances is not subsequently required to provide the missing data. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to an MA, various other requirements apply to the manufacturing and placing on the EU market of medicinal products. Manufacture of medicinal products in the EU requires a manufacturing authorization, and import of medicinal products into the EU requires a manufacturing authorization allowing for import. The manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance. These requirements include compliance with EU GMP standards when manufacturing medicinal products and active pharmaceutical ingredients ("APIs"), including the manufacture of APIs outside of the EU with the intention to import the APIs into the EU. Similarly, the distribution of medicinal products within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. MA holders and/or manufacturing and import authorization ("MIA") holders and/or distribution authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in case of non-compliance with the EU or EU Member States&#8217; requirements applicable to the manufacturing of medicinal products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data and Market Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU provides opportunities for data and market exclusivity related to MAs. Upon receiving an MA, innovative medicinal products are generally entitled to receive eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall ten-year period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for MA. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, Regulation (EC) No 1901/2006 provides that all MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan ("PIP") agreed with the EMA&#8217;s Pediatric Committee ("PDCO"). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for a six-month extension to the Supplementary Protection Certificate ("SPC") if any is in effect at the time of authorization or, in the case of orphan medicinal products, a two-year extension of orphan market exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where an MA is granted in relation to a medicinal product in the EU, the holder of the MA is required to comply with a range of regulatory requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the individual EU Member States. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports ("PSURs").</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All new MAAs must include a risk management plan ("RMP") describing the risk management system that a company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, the advertising and promotion of medicinal products are subject to both EU and EU Member States&#8217; laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each Member State and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics ("SmPC") as approved by the competent authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU. Direct-to-consumer advertising of prescription medicinal products is also prohibited in the EU.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Medicinal Products in the UK and Brexit. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United Kingdom&#8217;s (&#8220;UK&#8221;) withdrawal from the EU on January 31, 2020, commonly referred to as Brexit,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">has changed the regulatory relationship between the UK and the EU. The Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), is now the UK&#8217;s standalone regulator for medicinal products and medical devices.  Great Britain (England, Scotland and Wales) is now a third country to the EU. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules for now.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The UK regulatory framework in relation to clinical trials is governed by the </span><span style="color:#040c28;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">derived from the CTD, as implemented into UK national law through secondary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">legislation. On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials, and which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The UK Government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations will align with the CTR. In October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and risk-proportionate approach to initial clinical trial applications for Phase 4 and low-risk Phase 3 clinical trial applications.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketing authorizations in the UK are governed by the </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Medicines Regulations (SI 2012/1916), as amended. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since January 1, 2021, an applicant for the EU centralized procedure marketing authorization can no longer be established in the UK. As a result, since this date, companies established in the UK cannot use the EU centralized procedure and instead must follow one of the UK national authorization procedures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or one of the remaining post-Brexit international cooperation procedures</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to obtain a marketing authorization to market products in the UK. A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ll existing EU marketing authorizations for centrally authorized products were automatically converted or grandfathered into UK marketing authorization, effective in Great Britain only, free of charge on January 1, 2021, unless the marketing authorization holder opted-out of this possibility. Northern Ireland currently remains within the scope of EU authorizations in relation to centrally authorized medicinal products. Accordingly, u</span><span style="color:#0b0c0c;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntil the Windsor Framework is implemented in Northern Ireland on January 1, 2025, products falling within the scope of the EU centralized procedure can only be authorized through UK national authorization procedures in Great Britain.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MHRA has also introduced changes to national marketing authorization procedures. This includes introduction of procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment route, a rolling review procedure and the International Recognition Procedures which entered into application on January 1, 2024. Since January 1, 2024, the MHRA may also rely on the International Recognition Procedure (&#8220;IRP&#8221;), when reviewing certain types of marketing authorization applications. This procedure is available for applicants for marketing authorization who have already received an authorization for the same product from a reference regulator. These include the FDA, the EMA, and national competent authorities of individual EEA countries. A positive opinion from the EMA and CHMP, or a positive end of procedure outcome from the mutual recognition or decentralized procedures are considered to be authorizations for the purposes of the IRP.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Fraud and Abuse Laws. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a pharmaceutical company, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights may be applicable to our business. We may be subject to various federal, state and foreign laws targeting fraud and abuse in the healthcare industry. For example, in the United States, there are federal and state anti-kickback laws that prohibit the payment or receipt of kickbacks, bribes or other remuneration intended to induce the purchase or recommendation of healthcare products and services or reward past purchases or recommendations. These laws are applicable to manufacturers of products regulated by the FDA, such as us, and pharmacies, hospitals, physicians and other potential purchasers of such products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; is defined as any remuneration, direct or indirect, overt or covert, in cash or in kind, and has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payment, ownership interests and providing anything at less than its fair market value. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute may have been violated, and enforcement will depend on the relevant facts and circumstances. The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "ACA"), among other things, amended the intent requirement of the federal Anti-Kickback Statute to state that a person or entity need not have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act (discussed below) or the civil monetary penalties statute, which imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or to have offered improper inducements to federal health care program beneficiaries to select a particular provider or supplier. The federal Anti-Kickback Statute is broad, and despite a series of narrow statutory exceptions and regulatory safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs, and do not contain identical safe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">harbors. In addition, where such activities involve foreign government officials, they may also potentially be subject to the Foreign Corrupt Practices Act. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, including our activities with physician customers, pharmacies, and patients, as well as our activities pursuant to partnerships with other companies and pursuant to contracts with contract research organizations, could be subject to challenge under one or more of such laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal criminal and civil false claims laws, including the False Claims Act, which prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, the ACA specified that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. The False Claims Act has been the basis for numerous enforcement actions and settlements by pharmaceutical and other healthcare companies in connection with various alleged financial relationships with customers. In addition, a number of pharmaceutical manufacturers have reached substantial financial settlements in connection with allegedly causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-reimbursable, uses. Certain marketing practices, including off-label promotion, may also violate false claims laws, as might violations of the federal physician self-referral laws, such as the Stark laws, which prohibit a physician from making a referral to certain designated health services with which the physician or the physician&#8217;s family member has a financial interest and prohibit submission of a claim for reimbursement pursuant to the prohibited referral. The &#8220;qui tam&#8221; provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In addition, various states have enacted similar fraud and abuse statutes or regulations, including, without limitation, false claims laws analogous to the False Claims Act that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Separately, there are a number of other fraud and abuse laws that pharmaceutical manufacturers must be mindful of, particularly after a product candidate has been approved for marketing in the United States. For example, a federal criminal law enacted as part of, the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") prohibits, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. There are also federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Privacy and Security Laws. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to, or our marketing activities may be limited by, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH") and their respective implementing regulations, which established uniform standards for certain &#8220;covered entities&#8221; (certain healthcare providers, health plans and healthcare clearinghouses) governing the conduct of certain electronic healthcare transactions and protecting the security and privacy of protected health information. Among other things, HIPAA&#8217;s privacy and security standards are directly applicable to &#8220;business associates&#8221; &#8212; independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity, as well as their covered subcontractors. In addition to possible civil and criminal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">penalties for violations, HITECH created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. State laws also govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Further, we are required to comply with international personal data protection laws and regulations, particularly as the result of our operations in D&#252;sseldorf, Germany.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Privacy and Security Laws. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to diverse laws and regulations relating to data privacy and security, including HIPAA in the United States, the European Union's General Data Protection Regulation ("EU GDPR") in the European Economic Area ("EEA"), and the United Kingdom's General Data Protection Regulation ("UK GDPR"). New privacy rules are being enacted in the United States and globally, and existing ones are being expanded, updated and strengthened.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, the EU GDPR which went into effect in May 2018 introduced strict requirements regarding the processing of personal data, which apply to non-EU entities that process, or control the processing of, the personal information of EU subjects, including clinical trial data. The EU GDPR implements more stringent operational requirements than its predecessor legislation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also, in June 2018, the State of California enacted the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), which became effective in January 2020. The CCPA establishes a privacy framework for covered businesses, including an expansive definition of personal information and data privacy rights for California residents. The CCPA includes a framework with potentially severe statutory damages and private rights of action. The CCPA requires covered companies to provide new disclosures to California consumers (as that word is broadly defined in the CCPA), provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, California voters approved a new privacy law, the California Privacy Rights Act ("CPRA") in the November 3, 2020 election. Effective starting on January 1, 2023, the CPRA will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;Sunshine&#8221; and Marketing Disclosure Laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> There are an increasing number of federal and state &#8220;sunshine&#8221; laws and equivalent foreign laws that require pharmaceutical manufacturers to make reports to states and equivalent foreign authorities on pricing and marketing information. Several states and local jurisdictions and equivalent foreign laws have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales and marketing activities, register pharmaceutical sales representatives, and prohibiting certain other sales and marketing practices. In addition, a similar federal requirement, known as the Physician Payments Sunshine Act, requires manufacturers, including pharmaceutical manufacturers, to track and report annually to the federal government certain payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals and information regarding ownership or investment interests held by such physicians and their immediate family members. The federal government discloses the reported information on a publicly available website. Certain states, such as Massachusetts, also make the reported information publicly available. Some foreign jurisdictions, including a number of EU Member States, impose equivalent requirements. In addition, there are state and local laws that require pharmaceutical representatives to be licensed and comply with codes of conduct, transparency reporting, and other obligations. These laws may adversely affect our sales, marketing, and other activities with respect to our products in the United States and on some foreign markets by imposing administrative and compliance burdens on us. If we fail to track and report as required by these laws or otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Government Price Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are required to discount such products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply. These programs require submission of pricing data and calculation of discounts pursuant to complex statutory formulas, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear. Compliance with such requirements can require significant investment in personnel, systems and resources, but failure to properly calculate our prices or offer required discounts could subject us to substantial penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Penalties. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of available statutory exception and regulatory safe harbors, it is possible that some of our business activities in the United States could be subject to challenge under one or more of such laws. Moreover, state governmental agencies may propose or enact laws and regulations that extend or contradict federal requirements. If we or our operations are found to be in violation of any of the state or federal laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in U.S. federal or state healthcare programs, additional reporting requirements and/or oversight, if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, exclusion from participation in federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could materially adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, sunshine, government price reporting, and fraud laws may prove costly.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Sales of any marketed product, in particular for HEPLISAV-B, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">plan-by-plan basis. These third-party payors are increasingly reducing coverage and reimbursement for medical products, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any marketed product or a decision by a third-party payor not to cover a market product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impact of Healthcare Reform and Recent Public Scrutiny of Specialty Drug Pricing on Coverage, Reimbursement, and Pricing. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and other potentially significant foreign markets for our products, federal and state authorities as well as third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">products and therapies, which has resulted in lower average net selling prices. Further, there is increased scrutiny of prescription drug pricing practices by federal and state lawmakers and enforcement authorities. In addition, there is an emphasis on managed healthcare in the United States, which will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and, in the US, regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in Massachusetts, the MassHealth program has requested permission from the federal government to use commercial tools, such as a closed formulary, to negotiate more favorable rebate agreements from drug manufactures. There also has been particular and increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices, particularly with respect to drugs that have been subject to relatively large price increases over relatively short time periods. Such interest has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services ("HHS") released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) into law, which among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. </span><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare &amp; Medicaid Services Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program ("SIP") proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. Additionally, in California, effective January 1, 2019, drug companies must notify insurers and government regulators of certain price increases and provide an explanation of the reasons for such increases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the United States, the pharmaceutical industry has already been significantly affected by major legislative initiatives, including, for example, the ACA. The ACA, among other things, imposes a significant annual fee on companies that manufacture or import branded prescription drug products. It also contains substantial provisions intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, and impose additional health policy reforms, any or all of which may affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There remain judicial, Congressional, and executive branch challenges to certain aspects of the ACA. Since January 2017, President Trump signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. For example, the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, there have been a number of health reform measures by the Biden administration that have impacted the ACA. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have also been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions in Medicare payments to providers of up to two percent per fiscal year, starting in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect until 2032 unless additional Congressional action is taken. In addition, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Such laws, and others that may affect our business that have been recently enacted or may in the future be enacted, may result in additional reductions in Medicare and other healthcare funding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, in the EEA some countries require the completion of additional studies that compare the cost-effectiveness of a particular medicinal product candidate to currently available therapies. This Health Technology Assessment ("HTA") process, which is currently governed by the national laws of the individual EU Member States, is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. </span><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 15, 2021, the Health Technology Regulation (&#8220;HTA Regulation&#8221;), was adopted. The HTA Regulation is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. When it enters into application in 2025, the HTA Regulation will be intended to harmonize the clinical benefit assessment of HTA across the European Union. In light of the fact that the United Kingdom has left the EU, Regulation No 2021/2282 on HTA will not apply in the United Kingdom. However, the UK Medicines and Healthcare products Regulation Agency (&#8220;MHRA&#8221;) is working with UK HTA bodies and other national organizations, such as the Scottish Medicines Consortium (&#8220;SMC&#8221;), the National Institute for Health and Care Excellence (&#8220;NICE&#8221;), and the All-Wales Medicines Strategy Group, to introduce new pathways supporting innovative approaches to the safe, timely and efficient development of medicinal products.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MANUFACTURING</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on our facility in D&#252;sseldorf, Germany and third parties to perform the multiple processes involved in manufacturing HBsAg for use in HEPLISAV-B, the combination of the oligonucleotide and the antigens, and formulation, fill and finish. As is common in our industry, in light of FDA inspection and licensing requirements for manufacturing sites, we have relied on a limited number of suppliers to produce oligonucleotides for clinical trials and conduct fill and finish operations. Historically, we relied on a single supplier to produce our CpG 1018 adjuvant for HEPLISAV-B and for our collaborators. We also have a second qualified supplier to produce CpG 1018 adjuvant for our collaboration partners, to the extent needed. Switching suppliers, or bringing on additional suppliers, could be complicated and time consuming, but we generally seek to maintain inventory to help bridge any unexpected gap in supply. In order to help us successfully manufacture and commercialize HEPLISAV-B, we have secured long-term supply agreements with the key third-party suppliers and vendors for commercial supply of our component products and finished goods. We currently manufacture the HBsAg for HEPLISAV-B at our Dynavax GmbH facility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COMMITMENT TO COMPLIANCE AND ENVIRONMENT</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are committed to conducting our business in compliance with all applicable legal and ethical standards. In addition, we are committed to helping to protect the environment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Ethics and Compliance program includes our Code of Business Conduct and Ethics (&#8220;Code&#8221;), which sets forth our expectations of all Dynavax directors, officers and employees globally that they conduct their business activities in a legal and ethical manner. The Code can be found on our website under the header &#8220;Investors&#8221; and within that under the header &#8220;Corporate Governance and Compliance.&#8221; We have a Chief Ethics and Compliance Officer, a Compliance Steering Committee and policies, procedures and training addressing specific aspects of our business, including advertising and promotion; engagements with healthcare providers; and regarding our business activities outside the United States to ensure they comply with the U.S. Foreign Corrupt Practices Act and all other applicable anti-corruption laws. We certify on an annual basis to having a comprehensive compliance program that meets the standards set forth under California law. This certification, which sets forth all of the elements of our healthcare compliance program, can be found on our website.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also care about the environment. To that end, our headquarters is in a building certified as &#8220;Gold&#8221; level on the LEED Scorecard as set forth by the United States Green Building Committee. Our transition to a largely virtual environment has further helped reduce congestion and pollution. Our relatively small headquarters space (approximately 8,000 square feet) has further reduced our carbon footprint. In addition, we participate in our buildings active recycling program. We continue to consider other ways in which we can conduct our business in an environmentally friendly manner.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have made, and will continue to make, expenditures for environmental compliance and protection. We do not expect that expenditures for compliance with environmental laws will have a material effect on our results of operations in the future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HUMAN CAPITAL MANAGEMENT</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 408 employees, comprised of 275 employees in the U.S., including 117 members of our field sales team located throughout the U.S., as well as 133 employees in our office and manufacturing facility in D&#252;sseldorf, Germany. Many of our employees hold advanced degrees, including Masters degrees and Pharm.D., Ph.D., M.D. or J.D. degrees. We consider the intellectual capital of our employees to be an essential driver of our business and key to our future prospects. None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relations with our employees to be very good.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Retention and Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our regrettable turnover rate for 2023 was 7% in the U.S. and 5% in D&#252;sseldorf. Despite these low turnover rates, as a vaccine-focused company, we face stiff competition to hire and retain our employees. The average tenure among our employees, is 3.0 years in the U.S. and 6.2 years in D&#252;sseldorf. We also believe that our remote-first working environment in the U.S. serves as a useful recruiting and retention tool.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We monitor our compensation programs closely and provide what we consider to be a very competitive mix of compensation and insurance benefits for all our employees, which includes base salary, annual cash bonus opportunity or semi-annual sales incentive bonus for our field sales team, comprehensive benefits package and equity compensation. Each of our employees participates in our equity programs. The annual cash bonus opportunity and equity compensation generally</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increase as a percentage of total compensation based on level of responsibility. Any actual cash bonus payout for our employees is based on a combination of our performance against corporate goals and individual performance, with the exception of any actual cash bonus payouts to our Chief Executive Officer and President which is based solely on our performance against corporate goals. The mix of equity compensation also shifts based on the level of responsibility; employees below the senior director level typically receive 100 percent of their equity compensation in restricted stock units, while more senior level employees typically receive a mix of stock options and restricted stock units. Annual equity awards to our senior leadership team include performance-based restricted stock units.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development and Training</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Attracting and retaining top talent is key to the achievement of our strategic goals. The development and engagement of our employees is also a top priority of the human resources team. We perform annual performance reviews of all employees, and we seek employee feedback in a variety of ways, including annual employee surveys. In 2023, 32 leaders and key contributors completed a leadership development program, in addition to the 30 who participated in the prior year. Our senior management and human resources team periodically undertake comprehensive organizational reviews. In addition, we have an extensive series of employee training programs on business ethics and compliance matters, including required annual trainings on our Code, our Anti-Corruption Compliance Policy and certain cybersecurity topics. Also, depending on employee roles and departments, we have employee training programs on medical affairs, commercial, sales and other matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, with support from our Diversity Leadership Team comprised of employees from across our company, we continued to advance our three Diversity, Equity, and Inclusion (DEI) Commitments:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fostering a culture where all employees are recognized and appreciated for the unique individuals they are and for their accomplishments in the workplace.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Providing education to our employees on the negative effects of unconscious bias.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Building and sustaining a team filled with a diversity of personal experiences, backgrounds, and perspectives.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In support of our three DEI Commitments, we again partnered with external DEI consultants to develop and deliver unconscious bias training to our newly hired employees in 2023. Further, we train all hiring managers and those who interview candidates in the talent acquisition process on unconscious bias. Our human resources team oversees our DEI commitments and initiatives periodically and regularly reports to our senior management, including with respect to workforce demographic data.  In 2023, we launched an internal DEI survey to all U.S. based employees, such that we can gather further information on our DEI initiatives and continue to work on our DEI commitments.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024 Initiative</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In furtherance of these efforts, we identified, as one of our corporate goals for 2024, further delivery on our DEI commitments by advancing key initiatives through each of our four DEI subcommittees: Recruitment, Employee Resource Groups, Community Involvement, and Development.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CORPORATE INFORMATION &amp; AVAILABLE INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal executive offices are located at 2100 Powell Street, Suite 720, Emeryville, California, 94608. Our telephone number is (510) 848-5100. We make available, free of charge on our website located at www.dynavax.com, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports, as soon as reasonably practicable after filing such reports with the Securities and Exchange Commission (&#8220;SEC&#8221;). Alternatively, you may access these reports at the SEC&#8217;s website at www.sec.gov. The contents of our websites are not incorporated by reference into this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our websites are intended to be inactive textual references only.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1A.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RISK FACTORS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An investment in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, in addition to the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes, before making an investment decision. The risks described below are not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">the only ones facing us. If any of the events described in the following risk factors occurs, our business, operating results and financial condition could be seriously harmed. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Business and Capital Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HEPLISAV-B has been approved in the United States, the European Union and Great Britain and launched in the United States and Germany, and there is significant competition in these marketplaces. Since this is our first marketed product, the timing of uptake and distribution efforts are unpredictable and there is a risk that we may not achieve and sustain commercial success for HEPLISAV-B.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established sales, marketing and distribution capabilities and commercialized HEPLISAV-B in the United States and Germany. We have also received approval in the European Union and Great Britain for HEPLISAV-B. Successful commercialization of HEPLISAV-B in these regions or elsewhere will require significant resources and time, and there can be no certainty that we will succeed in these efforts. While our personnel are experienced with respect to marketing of healthcare products, because HEPLISAV-B is our first marketed product, the potential uptake of the product through distribution, and the timing, trajectory, rate and sustainability for growth in sales is unpredictable, and we may not be successful in commercializing HEPLISAV-B in the long term. In particular, successful commercialization of HEPLISAV-B will require that we continue to negotiate and enter into contracts with wholesalers, distributors, group purchasing organizations, and other parties, and that we maintain those contractual relationships. There is a risk that we may fail to complete or maintain some or all of these important contracts on favorable terms or at all, or that in a potentially evolving reimbursement environment, our efforts may fail to overcome established competition at favorable pricing, or at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have continued to expand our field sales force. As these teams expand, it will take time for our expanded teams to generate significant sales momentum, if they do so at all. Although we have had some success growing and developing our field sales force following the launch of HEPLISAV-B, there is no guarantee that we will be able to generate sales at the same or improved rates going forward, if at all. In addition, retention of capable sales personnel may be more difficult for us compared to our competitors, as we focus on a single product offering. We must retain our sales force in order for HEPLISAV-B to maintain or expand its commercial presence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, we expect that we will need to divert resources in order to successfully market, sell and distribute HEPLISAV-B for use with dialysis patients, one of our targeted patient populations. We do not yet have approval to market the regimen for dialysis. Although the Centers for Disease Control and Prevention (&#8220;CDC&#8221;) and the CDC&#8217;s Advisory Committee on Immunization Practices (&#8220;ACIP&#8221;) recommend that all adults aged 19-59, including patients on dialysis, receive hepatitis B vaccinations, our predictions of how many of those patients actually receive HEPLISAV-B may be inaccurate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the risks with employing and maintaining our own commercial capabilities and with contracting, other factors that may inhibit our efforts to successfully commercialize HEPLISAV-B include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we are able to continue recruiting and retaining adequate numbers of effective sales and marketing personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we are able to access key health care providers to discuss HEPLISAV-B;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we can continue to compete successfully as a relatively new entrant in established distribution channels for vaccine products; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we will maintain sufficient financial resources to cover the costs and expenses associated with sustaining a capable sales and marketing organization and related commercial infrastructure.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to enter new markets ourselves, we may be required to collaborate or partner HEPLISAV-B with a third-party pharmaceutical or biotechnology company with existing products. To the extent we collaborate or partner, as we have done for HEPLISAV-B distribution in Germany, the product&#8217;s financial value will be shared with another party and we will need to establish and maintain a successful collaboration arrangement, and we may not be able to enter into these arrangements on acceptable terms or in a timely manner in order to establish HEPLISAV-B in these new markets. To the extent that we enter into co-promotion or other arrangements, any revenues we receive will depend upon the efforts of third parties, which may not be successful and are only partially in our control. In that event, our product revenues may be lower than if we marketed and sold our products directly with the highest priority, and we may be required to reduce or eliminate much of our commercial infrastructure and personnel as a result of such collaboration or partnership.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governments influence the price of medicinal products in the European Union through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Even though we have been granted a marketing authorization in the European Union for HEPLISAV-B, we have yet to obtain broad reimbursements and pricing approval in any European Union Member State and rely on our distributor to do so, who currently only markets in Germany. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other European Union Member States allow companies to fix their own prices for medicines, but monitor and control company profits. Any delay in being able to market our products in the European Union, Great Britain or elsewhere may adversely affect our business and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we, or our partners, are not successful in setting our marketing, pricing and reimbursement strategies, recruiting and maintaining effective sales and marketing personnel or building and maintaining the infrastructure to support commercial operations in the U.S., Germany and elsewhere, we will have difficulty successfully commercializing HEPLISAV-B, which would adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our financial results may vary significantly from quarter to quarter or may fall below the expectations of investors or securities analysts, each of which may adversely affect our stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous factors, many of which are outside our control, may cause or contribute to significant fluctuations in our quarterly and annual operating results. For example, during the year ended December 31, 2022, we recognized $587.7 million of CpG 1018 adjuvant revenue. However, our CpG 1018 adjuvant supply agreements expired at the end of 2022, and as a result, we did not recognize CpG 1018 adjuvant revenue for the year ended December 31, 2023. Similarly, if demand for HEPLISAV-B decreases from recent trends for any reason, that could also cause unexpected fluctuations in our quarterly and annual operating results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence and timing of any transfer of control of product sold to customers can also be difficult to predict, and the recognition of revenue can vary widely depending on timing of product deliveries and satisfaction of other obligations. As an example, any future revenue we do receive from sales of our CpG 1018 adjuvant has been and will continue to be difficult to predict, if it materializes at all. Historically, we generally required customers to place orders for CpG 1018 adjuvant with at least six months lead time and to make an advance payment toward the finished order. Where we receive such advance payments, we record such payments as deferred revenue until we have delivered the adjuvant and met all criteria to recognize revenue. In accordance with our stated revenue policy, we historically recorded revenue for these contracts upon meeting all of the criteria for revenue recognition under Accounting Standards Codification 606, which includes, among other criteria, the transfer of control for CpG 1018 adjuvant to our customer. During the year ended December 31, 2023, we did not receive any advanced payments from any of our customers to purchase CpG 1018 adjuvant. Our collaborators in many cases have purchase agreements with government agencies. If our collaborators do not receive payment from these agencies for any past or future adjuvant orders, our ability to collect our own receivables may be adversely affected. For example, as of December 31, 2023, we had recorded an allowance for doubtful accounts of $12.3 million in connection with our accounts receivable balance due from Bio E, which was determined by assessing changes in Bio E&#8217;s credit risk, contemplation of ongoing negotiations relating to an amendment to the supply agreement with Bio E, and Bio E&#8217;s dependence on cash collections from the Government of India, which have been delayed significantly by the Government of India.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have in the past, and may in the future, adjust delivery dates, allow cancellations or give concessions on outstanding receivables in certain circumstances to better enable our customers to meet their obligations, which can impact the timing or amount of our revenue recognition, cash collections and transfer of control. For example, in August and October 2022, we entered into amendments to our Supply Agreement, dated June 29, 2021, with Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited (the "Clover Supply Agreement"), which, among other things, modified the scope of the Clover Supply Agreement to reduce certain quantities of CpG 1018 adjuvant deliverable under the agreement and/or reduce amounts receivable, which we originally intended to deliver in accordance with a purchase order previously issued by Clover, and apply prepayments Clover previously made to us as payment for portions of pending outstanding purchase orders. In January 2023, we entered into another amendment to the Clover Supply Agreement to modify the price per dose of CpG 1018 adjuvant paid by Clover for adjuvant used in finished vaccine doses sold through government procurement programs relating to the booster program promoted by the China National Health Commission. In addition, in April 2023, we entered into the Bio E Amendment No. 3 and the CEPI-Bio E Assignment Agreement, pursuant to which CEPI forgave amounts outstanding relating to the Bio E CEPI Advance Payments and assumed our previous rights to collect $47.4 million of Bio E accounts receivable. Among other things, the CEPI-Bio E Assignment Agreement resulted in no accounts receivable from Bio E, the derecognition of $47.4 million CEPI accrual in connection with the Bio E CEPI Advance Payments, and certain additional future payments contingent on Bio E&#8217;s receipt of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payments from the Government of India associated with its CORBEVAX product on or before August 15, 2025, which may not materialize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, our revenue or operating expenses in one period may be disproportionately higher or lower relative to the others due to, among other factors, revenue fluctuations or increases in expenses as we invest in our pipeline. Accordingly, comparing our operating results on a period-to-period basis may not be meaningful, and investors should not rely on any particular past results as an indication of our future performance. If such fluctuations occur or if our operating results deviate from our expectations or the expectations of investors or securities analysts, our stock price may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred annual net losses in most years since our inception and could continue to incur significant losses if we do not successfully commercialize HEPLISAV-B, launch new products and/or significant sales of our CpG 1018 adjuvant do not resume.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to January 1, 2021, we had incurred losses in each year since we commenced operations in 1996. We recognized a net loss of $6.4 million for the year ended December 31, 2023. As of December 31, 2023, we had an accumulated deficit of $930.6 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With our investment in the launch and commercialization of HEPLISAV-B in the United States and Germany, we have in the past, and could in the future, incur operating losses. Our expenses have increased substantially as we maintain our HEPLISAV-B commercial infrastructure, including investments in internal infrastructure to support our field sales force and investments in manufacturing and supply chain commitments to maintain commercial supply of HEPLISAV-B. Further, we expect to increase research and development costs as we invest in our pipeline. We are already advancing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs including Phase 1 clinical trials in shingles and Tdap, and a Phase 2 clinical trial for plague in collaboration with and fully funded by the U.S. Department of Defense (&#8220;DoD&#8221;). We expect research and development costs to increase further if we add additional programs to our pipeline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of CpG 1018 adjuvant generated significant revenue during the COVID-19 pandemic, but we do not expect such revenues to continue in the long term, and </span><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we did not recognize any CpG 1018 adjuvant revenue in the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The timing for uptake of our products in the U.S. and abroad may further affect costs or losses related to commercialization. Due to the numerous risks and uncertainties associated with developing and commercializing vaccine products or other products we may choose to offer in the future, we are unable to predict the extent of any future losses or when, if ever, we will become profitable on an annual recurring basis, or, that if we are able to reach consistent profitability that it will be sustainable for any period of time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Many of our competitors have greater financial resources and expertise than we do. If we are unable to successfully compete with existing or potential competitors as a result of these disadvantages, we may be unable to generate sufficient, or any, revenues and our business will be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We compete with pharmaceutical companies, biotechnology companies, academic institutions and research organizations, in developing and marketing vaccines and adjuvants. For example, HEPLISAV-B competes in the U.S. with established hepatitis B vaccines marketed by Merck, GlaxoSmithKline plc (&#8220;GSK&#8221;) and VBI Vaccines Inc. ("VBI"), and with vaccines from those companies as well as several additional established pharmaceutical companies who market abroad. There are also modified schedules of conventional hepatitis B vaccines for limited age ranges that are approved in the United States, the European Union and Great Britain. Competition in European markets could affect our success or the success of our distributor in that market as well. In addition, HEPLISAV-B competes against Twinrix, a bivalent vaccine marketed by GSK for protection against hepatitis B and hepatitis A.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also in competition with companies developing vaccines and vaccine adjuvants, generally including, among others, GSK, Pfizer, Inc., Sanofi S.A., Merck, Bavarian Nordic A/S, Emergent BioSolutions, Inc., Novavax, Inc., Medicago Inc., Valneva, AstraZeneca plc, Moderna, Inc., Johnson &amp; Johnson, VBI, BioNTech SE and Curevo Vaccine. We will likely compete with several of these companies in the hepatitis space, shingles space, Tdap space and other spaces occupied by any other product candidates we ultimately choose to advance through our pipeline in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Products in our clinical pipeline, if approved, will also face competition from competitors who have competing clinical programs or already approved products. Existing and potential competitors or other market participants may also compete with us for qualified commercial, scientific and management personnel, as well as for technology that would otherwise be advantageous to our business. Our success in developing marketable products and achieving a competitive position will depend, in part, on our ability to attract and retain qualified personnel in the near-term, particularly with respect to HEPLISAV-B commercialization. If we do not succeed in attracting new personnel and retaining and motivating existing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">personnel, our operations may suffer and we may be unable to properly manage our business, obtain financing as needed, enter into collaborative arrangements, advance or sell our product candidates or generate revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on our facility in D&#252;sseldorf, Germany and third parties to supply materials or perform processes necessary to manufacture our products and our product candidates. We rely on a limited number of suppliers to produce the oligonucleotides we require for development and commercialization. Additionally, we have limited experience in manufacturing our products or product candidates in commercial quantities. With respect to HEPLISAV-B, we use a pre-filled syringe presentation of the vaccine and our ability to meet future demand will depend on our ability to manufacture or have manufactured sufficient supply in this presentation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on our facility in D&#252;sseldorf and third parties to perform the multiple processes involved in manufacturing hepatitis B surface antigen for use in HEPLISAV-B, the combination of the oligonucleotide and the antigens, and formulation, fill and finish. We may continue to do the same for any additional products we might add in the future through natural internal expansion of our pipeline, or in transactions with an external third-party or parties. The FDA approved our pre-filled syringe presentation of HEPLISAV-B in 2018 and we expect such presentation will be the sole presentation for HEPLISAV-B going forward. We have limited experience in manufacturing and supplying this presentation ourselves, and rely on a contract manufacturer to do so. Our contract manufacturer is the only approved provider that we have, and there can be no assurance that we or they can successfully manufacture sufficient quantities of pre-filled syringes in compliance with good manufacturing practice ("GMP") in order to meet market demand, whether because of problems with our supplier&#8217;s own operations, operations of its sub-suppliers, issues with downstream supply chains or otherwise. If our contract manufacturer is unable to source components needed to complete fill and finish of our pre-filled syringes, we may be required to identify a second source which would have associated costs and regulatory requirements. Qualifying a second source could take more than a year to accomplish. If we are unable to do all this, on a timely basis or at all, our HEPLISAV-B sales could be materially and adversely impacted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, we have also relied on a limited number of suppliers to produce oligonucleotides for clinical trials and a single supplier to produce (i) our CpG 1018 adjuvant for manufacture of HEPLISAV-B and for sale to our collaborators and (ii) our pre-filled syringe presentation. In 2021, we qualified a second supplier to manufacture CpG 1018 adjuvant for our COVID business. If we are unable to maintain our existing suppliers for CpG 1018 adjuvant, we would have to establish an alternate qualified manufacturing capability ourselves, which would result in significant additional operating costs and delays in manufacturing HEPLISAV-B, or CpG 1018 adjuvant, and developing and commercializing our, and potentially our collaborators&#8217;, product candidates. We or other third parties may not be able to produce product at a cost, quantity and quality that are available from our current third-party suppliers, or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In countries outside of the U.S., we may not be able to comply with comparable foreign regulations, and our manufacturing process may be subject to delays, disruptions or quality control/quality assurance problems. Noncompliance with these regulations or other problems with our manufacturing process may limit or disrupt the commercialization of our products or our and our collaborators&#8217; product candidates and could result in significant expense.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">As we continue to focus on the commercialization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">of our HEPLISAV-B vaccine and our CpG 1018 adjuvant, we may encounter difficulties in managing our commercial growth and expanding our operations successfully.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As our commercial operations expand, we expect that we will also need to manage additional relationships with various third parties, including sole source suppliers, distributors, collaboration partners, wholesalers and hospital customers. Future growth will impose significant added responsibilities on our organization, in particular on management. Our future financial performance and our ability to successfully commercialize our HEPLISAV-B vaccine and CpG 1018 adjuvant or any new products, and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we may not be able to manage our growth efforts effectively, and hire, train, retain and integrate additional management, administrative and sales and marketing personnel, or secure sufficient or timely supply from third party service and product providers. Any failure to accomplish any of these activities could prevent us from successfully increasing or maintaining the same level of commercial growth as we have seen in the past.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If HEPLISAV-B or any products we develop are not accepted by the market or if regulatory authorities limit our labeling indications, require labeling content that diminishes market uptake of HEPLISAV-B or any other products we develop, or limit our marketing claims, we may be unable to generate significant future revenues, if any.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain regulatory approval for our product candidates, such as our U.S., European Union and Great Britain approvals of HEPLISAV-B, and are able to commercialize them as we have with HEPLISAV-B, our products may not gain market acceptance among physicians, patients, healthcare payors and the medical community.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of market acceptance of HEPLISAV-B and any of our future approved products will depend upon a number of factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the indication for which the product is approved and its approved labeling;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the presence of other competing approved products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential advantages of the product over existing and future treatment methods;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the relative convenience and ease of administration of the product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of our sales, marketing and distribution efforts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the price and cost-effectiveness of the product; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket in the absence of sufficient reimbursement by third-party payors. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or other regulatory authorities could limit the labeling indication for which our product candidates may be marketed or could otherwise limit marketing efforts for our products. If we are unable to achieve approval or successfully market any of our products or product candidates, or marketing efforts are restricted by regulatory limits, our ability to generate revenue could be significantly impaired.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">As we continue to grow as a commercial organization and enter into supply agreements with customers, those supply agreements will have obligations to deliver product that we are reliant upon third parties to manufacture on our behalf.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As our commercial business begins to expand in connection with commercial sales of HEPLISAV-B or CpG 1018 adjuvant, as applicable, the contracts we enter into with our customers will generally carry delivery obligations that require us to deliver product in certain quantities and meet certain quality thresholds, among other things, all within specified timeframes. If, for any reason, whether due to reliance on third-party manufacturers or otherwise, we are unable to deliver timely, compliant products to our customers in quantities that meet our contractual obligations, we could be subject to lost revenue, contractual penalties, suits for damages, harm to our reputation or other problems that could materially and adversely affect our business. To the extent we add new products in the future, these risks could be exacerbated by the added complexity of managing multiple product lines.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face uncertainty regarding coverage, pricing and reimbursement and the practices of third-party payors, which may make it difficult or impossible to sell certain of our products or product candidates on commercially reasonable terms.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In both domestic and foreign markets, our ability to achieve profitability will depend in part on the negotiation of a favorable price, as well as the availability of coverage and adequate reimbursement, from third-party payors, in particular for HEPLISAV-B, where existing products are already marketed. In the U.S., pricing for hepatitis B vaccines is currently stable and reimbursement is favorable as we believe private and public payors recognize the value of prophylaxis in this setting given the high costs of potential morbidity and mortality, and we have achieved coverage with most third-party payors. However, there is a risk that some payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include HEPLISAV-B. Reimbursement or pricing in jurisdictions outside the U.S. may be less favorable. Thus, there can be no assurance that HEPLISAV-B will achieve and sustain stable pricing and favorable reimbursement. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Our ability to successfully obtain and retain market share and achieve and sustain profitability will be significantly dependent on the market&#8217;s acceptance of a price for HEPLISAV-B sufficient to achieve profitability, and future acceptance of such pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party payors are increasingly challenging the price and cost-effectiveness of medical products and services, and pricing, as well as coverage and reimbursement decisions, may not allow our future products to compete effectively with existing competitive products. Because we intend to offer products, if approved, that involve new technologies, the willingness of third-party payors to reimburse for our products is uncertain. We will have to charge a price for HEPLISAV-B or any other products we commercialize that is sufficient to enable us to recover our considerable investment in product development and our operating costs. Further, coverage policies and third&#8209;party reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. Adequate third-party payor reimbursement may not be available to enable us to maintain price levels sufficient to achieve or maintain profitability, and such unavailability could harm our future prospects and reduce our stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United Kingdom ("UK") and many EU Member States periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status. We expect that legislators, policymakers and healthcare insurance funds in European countries will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some European countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. This Health Technology Assessment ("HTA") of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, Regulation No 2021/2282 on HTA amending Directive 2011/24/EU, was adopted in the EU. This Regulation, which entered into force in January 2022 and will apply as of January 2025, is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation foresees a three-year transitional period and will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected. In light of the fact that the United Kingdom has left the EU, Regulation No 2021/2282 on HTA will not apply in the United Kingdom. However, the UK Medicines and Healthcare products Regulation Agency (&#8220;MHRA&#8221;) is working with UK HTA bodies and other national organizations, such as </span><span style="color:#040c28;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Scottish Medicines Consortium (&#8220;SMC&#8221;), </span><span style="color:#151529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the National Institute for Health and Care Excellence (&#8220;NICE&#8221;)</span><span style="color:#040c28;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and the All-Wales Medicines Strategy Group,</span><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to introduce new pathways supporting innovative approaches to the safe, timely and efficient development of medicinal products. For example, in March 2021, the UK introduced the Innovative Licensing and Access Pathways (&#8220;ILAP&#8221;) which brings together the MHRA, NICE, SMC and the All Wales Therapeutics and Toxicology Centre, to accelerate time to market for certain innovative products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legislators, policymakers and healthcare insurance funds in the EU and the United Kingdom may continue to propose and implement cost-containing measures to keep healthcare costs down, particularly due to the financial strain that COVID-19 placed on national healthcare systems of European countries. These measures could include limitations on the prices we would be able to charge for product candidates that we may successfully develop and for which we may obtain regulatory approval or the level of reimbursement available for these products from governmental authorities or third-party payors. Further, an increasing number of EU and other foreign countries use prices for medicinal products established in other countries as &#8220;reference prices&#8221; to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to ongoing FDA, EU and comparable foreign post-marketing obligations concerning HEPLISAV-B, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated regulatory issues with HEPLISAV-B.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our HEPLISAV-B regulatory approval in the United States is subject to certain post-marketing obligations and commitments to the FDA. For example, we were required to conduct an observational comparative study of HEPLISAV-B to Engerix-B to assess occurrence of acute myocardial infarction (&#8220;AMI&#8221;). This post-marketing study was initiated in August 2018 and concluded in November 2020. While the results of the study, announced in April 2021, indicated that there was no increased risk of AMI associated with vaccination with HEPLISAV-B compared to Engerix-B, we may be required to conduct further studies on HEPLISAV-B or our other product candidates in the future. Also, we received data from the autoimmune portion of our observational study, and the data indicated no association between HEPLISAV-B and any of the studied autoimmune diseases. In addition, we conducted a pregnancy registry study to provide information on outcomes following pregnancy exposure to HEPLISAV-B and submitted the information to the FDA in December 2023. Failure to complete the study to the satisfaction of the FDA could result in withdrawal of our biologics license application approval, which would have a material adverse effect on our business, results of operations, financial condition and prospects. As we advance our pipeline, similar studies may be required for other candidates. The results of post-marketing studies may also result in additional warnings or precautions for the HEPLISAV-B label or labels of any future products, if authorized, or expose additional safety concerns that may result in product liability and withdrawal of a product or products from the market, any of which would have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar post-marketing obligations and commitments exist in the European Union and Great Britain. For example, we are required to submit periodic safety update reports to the European Medicines Agency ("EMA") and the MHRA and to keep an up-to-date risk management plan that takes into account new information that may lead to a significant change in the risk/benefit profile of HEPLISAV-B. In addition, in accordance with our EU marketing authorization for HEPLISAV-B, HEPLISAV-B is subject to additional monitoring, meaning that it is monitored more intensively than other medicinal products. We may have similar obligations for future products if and when approved. Non-compliance with European Union or United Kingdom requirements regarding safety monitoring or pharmacovigilance can result in significant financial penalties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the manufacturing processes, labelling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for HEPLISAV-B are subject to extensive and ongoing regulatory requirements in the United States, the European Union and Great Britain. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practices (&#8220;cGMP&#8221;), good clinical practices (&#8220;GCP&#8221;), International Conference on Harmonization guidelines, and good laboratory practices </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;GLP&#8221;</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If we are not able to meet and maintain regulatory compliance for HEPLISAV-B or any future product, if authorized, we may lose marketing approval and be required to withdraw our product. Withdrawal of our product would have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HEPLISAV-B and all of our clinical programs rely on oligonucleotide TLR agonists. In the event of serious adverse events relating to TLR agonists, we may be required to reduce the scope of, or discontinue, our operations, or reevaluate the viability of strategic alternatives.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our programs, including HEPLISAV-B, incorporate TLR9 agonist CpG oligonucleotides. If any of our product candidates in clinical trials or similar products from competitors or collaborators result in serious adverse events, we may be required to delay, discontinue or modify our clinical trials or our clinical trial strategy, or significantly reevaluate strategic alternatives. If a safety risk based on mechanism of action or the molecular structure were identified, it may hinder our ability to develop our product candidates or enter into potential collaboration or commercial arrangements. Rare diseases and a numerical imbalance in cardiac adverse events have been observed in patients in our clinical trials. If adverse events are found to relate to our TLR agonist as a whole, we may be required to significantly reduce or discontinue our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HEPLISAV-B is subject to regulatory obligations and continued regulatory review, and if we receive regulatory approval for our other product candidates, we will be subject to ongoing FDA and foreign regulatory obligations and continued regulatory review for such products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to HEPLISAV-B and our other product candidates in development, we and our third-party manufacturers and suppliers are required to comply with applicable cGMP regulations and other international regulatory requirements. The regulations require that our products and product candidates be manufactured and records maintained in a prescribed manner</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with respect to manufacturing, testing and quality control/quality assurance activities. Manufacturers and suppliers of key components and materials must be named in a Biologics License Application (&#8220;BLA&#8221;) submitted to the FDA for any product candidate for which we are seeking FDA approval. Additionally, third-party manufacturers and suppliers and any manufacturing facility must undergo a pre-approval inspection before we can obtain marketing authorization for any of our product candidates. Even after a manufacturer has been qualified by the FDA, the manufacturer must continue to expend time, money and effort in the area of production and quality control to ensure full compliance with GMP. Manufacturers are subject to regular, periodic inspections by the FDA following initial approval. Further, to the extent that we contract with third parties for the manufacture of our products or product candidates, our ability to control third-party compliance with FDA requirements will be limited to contractual remedies and rights of inspection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If, as a result of the FDA&#8217;s inspections, it determines that the equipment, facilities, laboratories or processes do not comply with applicable FDA regulations and conditions of product approval, the FDA may not approve the product or may suspend the manufacturing operations. If the manufacturing operations of any of the suppliers for our products or product candidates are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand, which would harm our business. In addition, if delivery of material from our suppliers is interrupted for any reason, we might be unable to ship our approved product for commercial supply or to supply our products in development for clinical trials. Significant and costly delays can occur if the qualification of a new supplier is required. Similar requirements and procedures apply outside of the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with regulatory requirements could prevent or delay marketing approval or require the expenditure of money or other resources to correct. Failure to comply with applicable requirements may also result in warning letters, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, refusal of the government to renew marketing applications and criminal prosecution, any of which could be harmful to our ability to generate revenues and to our stock price.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory authorities may require more clinical trials for our product candidates than we currently expect or are conducting before granting regulatory approval, if regulatory approval is granted at all. Our clinical trials may be extended which may lead to substantial delays in the regulatory approval process for our product candidates and may impair our ability to generate revenues.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our registration and commercial timelines depend on further discussions with regulatory authorities and requirements and any requests that they may make for additional data or completion of additional clinical trials. Any such requirements or requests could:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adversely affect our ability to timely and successfully commercialize or market these product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">result in significant additional costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potentially diminish any competitive advantages for those products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potentially limit the markets for those products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adversely affect our ability to enter into collaborations or receive milestone payments or royalties from potential collaborators;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cause us to abandon the development of the affected product candidate; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit our ability to obtain additional financing on acceptable terms, if at all. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical trials for our commercial product and product candidates are expensive and time consuming, may take longer than we expect or may not be completed at all, and have uncertain outcomes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials, including post-marketing studies, to generate sufficient data to meet FDA and other regulatory authority requirements are expensive and time consuming, may take more time to complete than expected, may not be completed at all, and may not have favorable outcomes if they are completed. In addition, results from smaller, earlier stage clinical studies may not be representative of larger, controlled clinical trials that would be required in order to obtain regulatory approval of a product candidate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of our clinical trials requires the investment of substantial planning, expense and time and the timing of the commencement, continuation and completion of these clinical trials may be subject to significant delays relating to various</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">causes, including scheduling conflicts with participating clinicians and clinical institutions, difficulties in identifying and enrolling participants who meet trial eligibility criteria, failure of participants to complete the clinical trial, delay or failure to obtain Institutional Review Board (&#8220;IRB&#8221;), Ethics Committee or regulatory approval to conduct a clinical trial at a prospective site, unexpected adverse events and shortages of available vaccine or component supply. Participant enrollment is a function of many factors, including the size of the relevant population, the proximity of participants to clinical sites, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments. Failure of one or more product candidates to successfully advance through to approval and licensure could result in the loss of unrecoverable costs expended and impact our ability to generate future revenue from such products, either of which, or both of which, could have an adverse impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A key part of our business strategy for products in development is to establish collaborative relationships to help fund or manage development and commercialization of our product candidates and research programs. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to continue to develop and commercialize those products and programs, if at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have and may in the future need to establish collaborative relationships to obtain domestic and/or international sales, marketing, research, development and distribution capabilities for our products or product candidates and our discovery research programs. Failure to obtain a collaborative relationship for those products or product candidates and programs in markets outside the U.S. requiring extensive sales efforts may significantly impair the potential for those products and programs and we may be required to raise additional capital to continue them. The process of establishing and maintaining collaborative relationships is difficult and time-consuming, and even if we establish such relationships, they may involve significant uncertainty, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our perceived shortage of capital resources may impact the willingness of companies to collaborate with us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our contracts for collaborative arrangements are often terminable at will on written notice and may otherwise expire or terminate and we may not have alternative funding available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our partners may choose to pursue alternative technologies, including those of our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may have disputes with a partner that could lead to litigation or arbitration;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we have limited control over the decisions of our partners and they may change the priority of our programs in a manner that would result in termination of the agreement or add significant delay in the partnered program;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate future payments and royalties from our partners depends upon the abilities of our partners to establish the safety and efficacy of product candidates, obtain regulatory approvals and successfully manufacture and commercialize the products developed from product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may use our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our intellectual property or other proprietary rights or expose us to potential liability;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our partners may not devote sufficient capital or resources towards our product candidates; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our partners may not comply with applicable government regulatory requirements.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supporting diligence activities conducted by potential collaborators and negotiating the financial and other terms of a collaboration agreement are long and complex processes with uncertain results. Despite our efforts, we may be unable to secure collaborative arrangements. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense or find alternative sources of capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even when we are successful in entering into collaboration agreements, collaborations can involve greater uncertainty for us, as we have less control over certain aspects of our collaborative programs than we do over our solely-owned development and commercialization programs, and the financial terms upon which collaborators are willing to enter into such an arrangement cannot be certain. If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research, clinical development, manufacturing or commercialization efforts pursuant to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, we are working to develop our CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations, partnerships and supply arrangements. Current relationships and efforts are focused on adjuvanted vaccines for COVID-19, shingles, Tdap, plague and influenza. For some of these relationships, our collaborators have primary responsibility for the development, conduct of clinical trials, and for seeking and obtaining regulatory approval of potential vaccines containing our adjuvant. We have limited or no control over our collaborators&#8217; decisions, including the amount and timing of resources that any of these collaborators will dedicate to such activities. In circumstances where our collaborators do not purchase as much adjuvant as we anticipate or they delay placing orders or taking certain deliveries, there can be a negative impact on our revenue recognition. If a collaborator fails to conduct collaborative activities successfully, the development and commercialization of a vaccine could be delayed or may not occur at all. Lastly, the ability of our collaborators to deliver, sell and collect on receivables is not guaranteed and this could, in turn, impact our own ability to collect receivables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Until we are able to generate significant revenues or achieve profitability through product sales on a consistent basis, we may require substantial additional capital to finance our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had $742.3 million in cash and cash equivalents, and marketable securities. Prior to January 1, 2021, we incurred net losses in each year since our inception. We recorded a net loss of $6.4 million for the year ended December 31, 2023. As of December 31, 2023, we had an accumulated deficit of $930.6 million. We expect to continue to incur substantial expenses as we continue to invest in the commercialization and development of HEPLISAV-B and our CpG 1018 adjuvant, clinical trials for our pipeline candidates, and other development. If we cannot generate a sufficient amount of revenue from product sales, we may need to finance our operations through strategic alliance and licensing arrangements and/or future public or private debt and equity financings. Raising additional funds through the issuance of equity or debt securities could result in dilution to our existing stockholders, increased fixed payment obligations, or both. In addition, our 2.50% convertible senior notes due 2026 (&#8220;Convertible Notes&#8221;) and other securities we issue in the future may have rights senior to those of our common stock and could include covenants that restrict our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common stock, which itself is subject to a number of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us. In addition, our ability to raise additional funds may be adversely impacted by deteriorating global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide. Adequate financing may not be available to us on acceptable terms, or at all. If adequate funds are not available when needed, we may need to significantly reduce our operations while we seek strategic alternatives, which could have an adverse impact on our ability to achieve our intended business objectives and the value of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">As we plan for the broader commercialization of our HEPLISAV-B vaccine and for the requisite capacity to manufacture our CpG 1018 adjuvant, our financial commitments for manufacturing and supply capacity might outpace actual demand for our products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we manage our production capabilities for HEPLISAV-B and CpG 1018 adjuvant to support recent market share gains and other initiatives, we have been, and in the future could be, required to make significant financial commitments at our contract manufacturing organizations (&#8220;CMOs&#8221;), including minimum purchase commitments and prepayments of purchase orders to facilitate the procurement of raw materials and the incurrence of various manufacturing costs. Because of minimum or advance purchase commitments and uncertainty about the expected demand for HEPLISAV-B or CpG 1018 adjuvant, the financial commitments we make to our CMOs to support manufacturing may not be recovered in their entirety, or at all, if our customers do not ultimately purchase from us at expected volumes, or other concessions are made by us. Capacity reservation fees are generally not recoverable if we do not use the capacity we have reserved as a result of lower than expected demand, or otherwise. Similarly, prepayments of purchase orders may not be recoverable if we do not ultimately require the entire volume subject to the applicable purchase order. As a result, we could end up making financial commitments that we never recover if demand for HEPLISAV-B or CpG 1018 adjuvant does not materialize in the volumes we are expecting or at all. This may require us to record certain charges or write-offs in one or more fiscal periods, which in turn could result in significant, unexpected fluctuations in our quarterly and annual operating results, and potentially have a material adverse effect on our results of operations, and financial condition.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in August and October 2022, we entered into amendments to the Clover Supply Agreement, which, among other things, modified the scope of the Clover Supply Agreement to reduce certain quantities of CpG 1018 adjuvant that we originally intended to deliver in accordance with a purchase order previously issued by Clover. As a result of the concessions made in the amendments to the Clover Supply Agreement, prior financial commitments made to certain CMOs to manufacture quantities of CpG 1018 adjuvant to fulfill the original Clover purchase order, and reduced demand for CpG 1018 adjuvant, we recorded write-offs of $13.9 million of CpG 1018 adjuvant raw materials inventory and $20.4 million of finished goods inventory during the year ended December 31, 2022. Relating to our Bio E Supply Agreement, we entered into an amendment and an assignment agreement in April 2023, pursuant to which (i) CEPI forgave the entirety of remaining amounts outstanding relating to the Bio E CEPI Advance Payments for CpG 1018 Materials allocated to Bio E and has assumed our previous rights to collect $47.4 million of Bio E accounts receivable, (ii) we collected $14.5 million from Bio E, resulting in no accounts receivable balance as of December 31, 2023, and (iii) we derecognized a $47.4 million CEPI accrual in connection with the Bio E CEPI Advance Payments. It is possible we may have similar write-offs in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may develop, seek regulatory approval for and market HEPLISAV-B or any other product candidates outside of the U.S., the European Union and Great Britain, requiring a significant additional commitment of resources. Failure to successfully manage our international operations could result in significant unanticipated costs and delays in regulatory approval or commercialization of our products or product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek to introduce HEPLISAV-B, or any other product candidates we may develop, to various additional markets in or outside of the U.S., the European Union and Great Britain. Developing, seeking regulatory approval for and marketing our product candidates in or outside of the U.S., the European Union and Great Britain in jurisdictions where we don't currently have approval could impose substantial costs, impose burdens on our personnel, and divert management&#8217;s attention from domestic operations. International operations are subject to risk, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the difficulty of managing geographically distant operations, including recruiting and retaining qualified employees, locating adequate facilities and establishing useful business support relationships in the local community;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with varying international regulatory requirements, laws and treaties;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">securing international distribution, marketing and sales capabilities upon favorable terms;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adequate protection of our intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining regulatory and pricing approvals at a level sufficient to justify commercialization;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">legal uncertainties and potential timing delays associated with tariffs, export licenses and other trade barriers;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign tax compliance and diverse tax consequences;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fluctuation of conversion rates between foreign currencies and the U.S. dollar; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regional and geopolitical risks.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that we determine to pursue commercialization of HEPLISAV-B outside the United States, the European Union and Great Britain, our opportunity will depend upon our receiving regulatory approval, which can be costly and time consuming, and there is a risk that one or more regulatory bodies may require that we conduct additional clinical trials and/or take other measures which will take time and require that we incur significant additional expense. In addition, we may not receive approval in one or more jurisdictions, even if we undertake these efforts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of clinical trials conducted to support regulatory approval in one or more jurisdictions, and any failure or delay in obtaining regulatory approval in one or more jurisdictions, may have a negative effect on the regulatory approval process in other jurisdictions, including our existing regulatory approval in the United States, the European Union and Great Britain. If we are unable to successfully manage our international operations, we may incur significant unanticipated costs and delays in regulatory approval or commercialization of our products or product candidates, which would impair our ability to generate revenues.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on CROs and clinical sites and investigators for our clinical trials. If these third parties do not fulfill their contractual obligations or meet expected deadlines, our planned clinical trials may be delayed and we may fail to obtain the regulatory approvals necessary to commercialize our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on CROs, clinical sites and investigators for our clinical trials. If these third parties do not perform their obligations or meet expected deadlines our planned clinical trials may be extended, delayed, modified or terminated. While we maintain oversight over our clinical trials and conduct regular reviews of the data, we are dependent on the processes and quality control efforts of our third-party contractors to ensure that clinical trials are conducted properly and that detailed, quality records are maintained to support the results of the clinical trials that they are conducting on our behalf. Any extension, delay, modification or termination of our clinical trials or failure to ensure adequate documentation and the quality of the results in the clinical trials could delay or otherwise adversely affect our ability to commercialize our product candidates and could have a material adverse effect on our business and operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">As a biopharmaceutical company, we engage CROs to conduct clinical studies, and failure by us or our CROs to conduct a clinical study in accordance with GCP standards and other applicable regulatory requirements could result in disqualification of the applicable clinical trial from consideration in support of approval of a potential product.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are responsible for conducting our clinical trials consistent with GCP standards and for oversight of our vendors to ensure that they comply with such standards. We depend on medical institutions and CROs to conduct our clinical trials in compliance with GCP. To the extent that we or they fail to comply with GCP standards, fail to enroll participants for our clinical trials, or are delayed for a significant time in the execution of our trials, including achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials must be conducted in accordance with FDA or other applicable foreign government guidelines and are subject to oversight by the FDA, other foreign regulatory authorities, IRBs and the Ethics Committees at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of our product candidates produced under GMP and other requirements in foreign countries and may require large numbers of participants.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we obtain guidance from regulatory authorities on certain aspects of our clinical development activities and seek to comply with written guidelines provided by the authorities. These discussions and written guidelines are not binding obligations on the part of the regulatory authorities and the regulatory authorities may require additional patient data or studies to be conducted. Regulatory authorities may revise or retract previous guidance during the course of a clinical trial or after completion of the trial. The authorities may also disqualify a clinical trial from consideration in support of approval of a potential product if they deem the guidelines have not been met. The FDA or foreign regulatory authorities may determine our clinical trials or other data regarding safety, efficacy or consistency of manufacture or compliance with GMP regulations are insufficient for regulatory approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or other foreign regulatory authorities or we ourselves could delay, suspend or halt our clinical trials of a product candidate for numerous reasons, including with respect to our product candidates and those of our partners in combination agent studies:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">deficiencies in the trial design;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">deficiencies in the conduct of the clinical trial including failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">deficiencies in the clinical trial operations or trial sites resulting in the imposition of a clinical hold;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a product candidate may have unforeseen adverse side effects, including fatalities, or a determination may be made that a clinical trial presents unacceptable health risks;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the time required to determine whether a product candidate is effective may be longer than expected;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fatalities or other adverse events arising during a clinical trial that may not be related to clinical trial treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a product candidate or combination study may appear to be no more effective than current therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the quality or stability of a product candidate may fail to conform to acceptable standards;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to produce or obtain sufficient quantities of a product candidate to complete the trials;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to reach agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to obtain IRB or Ethics Committee approval to conduct a clinical trial at a prospective site;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to obtain regulatory approval to conduct a clinical trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of adequate funding to continue a clinical trial, including the occurrence of unforeseen costs due to enrollment delays, requirements to conduct additional trials and studies and increased expenses associated with the services of our CROs and other third parties;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to recruit and enroll individuals to participate in clinical trials for reasons including competition from other clinical trial programs for the same or similar indications; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to retain participants who have initiated a clinical trial but may withdraw due to side effects from the product, lack of efficacy or personal issues, or who are otherwise unavailable for further follow-up.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may experience significant setbacks in advanced clinical trials, even after promising results in earlier trials, such as unexpected adverse events that occur when our product candidates are given to larger patient populations, which often occur in later-stage clinical trials, or less favorable clinical outcomes. Moreover, clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Negative or inconclusive results or adverse medical events, including participant fatalities that may be attributable to our product candidates, during a clinical trial may necessitate that it be redesigned, repeated or terminated. Further, some of our clinical trials may be overseen by a Data Safety Monitoring Board (&#8220;DSMB&#8221;), and the DSMB may determine to delay or suspend one or more of these trials due to safety or futility findings based on events occurring during a clinical trial. Any such delay, suspension, termination or request to repeat or redesign a trial could increase our costs and prevent or significantly delay our ability to commercialize our product candidates. Even if we complete all such activities without issue, final results may not actually support approval of a particular product candidate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant net operating losses ("NOLs") during our history, and despite prior profitability, may not be able to achieve sustained profitability over the long term. Unused U.S. federal NOLs for taxable years beginning before January 1, 2018 may be carried forward to offset future taxable income, if any, until such unused NOLs expire. Under legislation enacted in 2017, as modified by legislation enacted in 2020, U.S. federal NOLs incurred in taxable years beginning after December 31, 2017 can be carried forward indefinitely, but the deductibility of such U.S. federal NOLs in taxable years beginning after December 31, 2020 is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the aforementioned U.S. tax law provisions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had U.S. federal and state NOL carryforwards of $376.6 million and $283.9 million, respectively. Of the $376.6 million U.S. federal NOL carryforwards, $353.5 million may be carried forward indefinitely with utilization limited to 80% of taxable income, and the remainder will begin to expire in 2024. The state NOL carryforwards will begin to expire in 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as one or more stockholders or groups of stockholders who own at least 5% of our stock increasing their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards to offset its post-change income or taxes may be limited. We have experienced ownership changes as a result of shifts in our stock ownership in the past, and in the future it is possible that we may be deemed to have experienced additional ownership changes as a result of shifts in our stock ownership, some of which may be outside of our control. This could limit the amount of NOLs that we can utilize annually to offset future taxable income or tax liabilities. Subsequent ownership changes and changes to the U.S. tax rules in respect of the utilization of NOLs may further affect the limitation in future years. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tax law changes could adversely affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation informally titled the Tax Cuts and Jobs Act of 2017, the 2020 Coronavirus Aid, Relief, and Economic Security Act, and the 2022 Inflation Reduction Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of the foregoing tax legislation could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to such legislation or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under past or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we process personal data and other sensitive information, including our proprietary and confidential business data, trade secrets, intellectual property, data we may collect about trial participants in connection with clinical trials, and other sensitive data. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). In the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;) (collectively, &#8220;CCPA&#8221;) requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Similar laws are being considered in several other states, as well as at the federal and local levels. These developments may further complicate compliance efforts and may increase legal risk and compliance costs for us and the third parties upon whom we rely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s General Data Protection Regulation (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal data. For example, under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may be unable to transfer personal data from the EEA and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Although there are various mechanisms that may be used in some cases to lawfully transfer personal data to the United States or other countries, these mechanisms are subject to legal challenges and may not be available to us. An inability or material limitation on our ability to transfer personal data to the United States or other countries could materially impact our business operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we may transfer personal data from the EEA and other jurisdictions to the United States or other countries. We may be unable to transfer personal data from Europe and other jurisdictions to the United States</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the EEA and the United Kingdom have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some regulators in the EEA have ordered certain companies to suspend or permanently cease certain transfers of data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 7, 2022, President Biden signed an Executive Order on &#8220;Enhancing Safeguards for United States Signals Intelligence Activities,&#8221; which implements into United States law the agreement in principle announced in March 2022 on a new EU-U.S. Data Privacy Framework. However, if this new transatlantic data transfer framework is not adopted and we are unable to continue to rely on standard contractual clauses or alternative mechanisms of data transfers from the EEA to the United States, this may materially and adversely affect our business, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional privacy advocates and industry groups have proposed, and may propose in the future, standards with which we are legally or contractually bound to comply.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. We may be subject to contractual obligations and policies related to data privacy and security. We may also be bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the EU GDPR and UK GDPR, require our customers to impose specific contractual restrictions on their service providers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data privacy and security laws are quickly changing, and compliance (and any perceived non-compliance) is costly. Although we endeavor to comply with all applicable data privacy and security obligations, these obligations are quickly changing in an increasingly stringent fashion, creating some uncertainty as to how to comply. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations, including our clinical trials; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with the extensive requirements applicable to biopharmaceutical manufacturers and marketers under the healthcare fraud and abuse, anticorruption, privacy, transparency and other laws of the jurisdictions in which we conduct our business, we may be subject to significant liability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our activities, and the activities of our agents, including some contracted third parties, are subject to extensive government regulation and oversight both in the U.S. and in foreign jurisdictions. Our interactions with physicians and others in a position to prescribe or purchase our products are subject to a legal regime designed to prevent healthcare fraud and abuse and off-label promotion. We also are subject to laws pertaining to transparency of transfers of value to healthcare providers; privacy and data protection; compliance with industry voluntary compliance guidelines; and prohibiting the payment of bribes. Relevant U.S. laws include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits persons from, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal health care programs, such as the Medicare and Medicaid programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal false claims laws, including the False Claims Act and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for payment to the government or its agents that are false or fraudulent;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Federal Food, Drug and Cosmetic Act and governing regulations which, among other things, prohibit off-label promotion of prescription drugs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Physician Payments Sunshine Act created under the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education and Reconciliation Act of 2010 (collectively, &#8220;ACA&#8221;) which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and ownership and investment interests held by such physicians and their immediate family members; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created, among other things, new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors relating to the privacy, security, and transmission of individually identifiable health information; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Foreign Corrupt Practices Act, which prohibits the payment of bribes to foreign government officials and requires that a company&#8217;s books and records accurately reflect our transactions; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign and state law equivalents of each of the federal laws described above, such as anti-kickback and false claims laws which may apply to items or services reimbursed by state health insurance programs or any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information on the pricing of certain drugs; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., the Office of Inspector General for the Department of Health and Human Services, the Department of Justice, states&#8217; Attorneys General and other governmental authorities actively enforce the laws and regulations discussed above. These entities also coordinate extensively with the FDA, using legal theories that connect violations of the Federal Food, Drug and Cosmetic Act (such as off-label promotion) to the eventual submission of false claims to government healthcare programs. Prosecution of such promotion cases under the False Claims Act provides the potential for private parties (qui tam relators, or &#8220;whistleblowers&#8221;) to initiate cases on behalf of the government and provides for significantly higher penalties upon conviction.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., pharmaceutical and biotechnology companies have been the target of numerous government prosecutions and investigations alleging violations of law, including claims asserting impermissible off-label promotion of pharmaceutical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">products, payments intended to influence the referral of federal or state health care business, submission of false claims for government reimbursement, or submission of incorrect pricing information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Violations of any of the laws described above or any other applicable governmental regulations and other similar foreign laws may subject us, our employees or our agents to significant criminal, civil and administrative penalties, including fines, civil monetary penalties, exclusion from participation in government health care programs (including, in the U.S., Medicare and Medicaid), disgorgement, imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the restriction or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. Additionally, whether or not we have complied with the law, an investigation into alleged unlawful conduct may cause us to incur significant expense, cause reputational damage, divert management time and attention, and otherwise adversely affect our business. While we have developed and instituted a corporate compliance program, we cannot guarantee that we, our employees, our consultants, contractors, or other agents are or will be in compliance with all applicable U.S. or foreign laws.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have applied for, and in some cases have received, grants that, if and when received, may involve pricing or other restrictions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have applied for, and in some cases have received, grants from various charitable, philanthropic and other organizations that, if and when received, may come with certain pricing requirements, global access requirements, reporting requirements or other covenants that require us to make the funded product available worldwide and on a nondiscriminatory basis. For example, we received such an initial grant from the Bill and Melinda Gates Foundation in 2020 to help fund the potential scale-up of production of our CpG 1018 adjuvant that may be required in the event the CpG 1018 adjuvant is included in any approved and commercially available vaccine, whether a COVID-19 vaccine or otherwise. Covenants in these types of grants may limit the price we can charge for any funded product and may involve a license to use technology we own that is included in the funded products if we do not comply. Such price limitations or licenses, if invoked, could serve to limit the prices we charge, or our control over the manufacturing and distribution of grant-funded products. Failure to agree to such requirements, may result in us not receiving some or all of the grant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Enacted or future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may have an adverse effect on our operations and business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect there will continue to be federal and state laws and/or regulations, proposed and implemented, that could impact our operations and business. For example, the ACA, among other things, imposes a significant annual fee on companies that manufacture or import branded prescription drug products. It also contains substantial provisions intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, and impose additional health policy reforms, any or all of which may affect our business. There have been executive, legal and political challenges to certain aspects of ACA. For example, President Trump signed several executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by ACA. Concurrently, Congress considered legislation that would repeal or repeal and replace all or part of ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January l, 2021, also eliminated the health insurer tax. The Bipartisan Budget Act of 2018 among other things, amended the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In addition, the ACA has been subject to various health reform measures. For example, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is unclear how any such challenges and additional healthcare reform measures by the Biden administration will impact the ACA and our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have also been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions in Medicare payments to providers of up to two percent per fiscal year, starting in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect until 2032 unless additional Congressional action is taken. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. In addition, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Such laws, and others that may affect our business that have been recently enacted or may in the future be enacted, may result in additional reductions in Medicare and other healthcare funding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also, there has been heightened governmental scrutiny recently in the U.S. over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (i) directs HHS to negotiate the price of certain drugs and biologics covered under Medicare, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions take effect progressively starting in 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug pricing negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare &amp; Medicaid Services ("CMS") Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, and restrictions on certain product access. In some cases, such legislation and regulations have been designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many EU Member States periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status. We expect that legislators, policymakers and healthcare insurance funds in the EU Member States will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the initiatives that may be adopted in the future or the effect any such initiatives may have on our business. However, in the future, there will likely continue to be additional proposals relating to the reform of the U.S. healthcare system, and other equivalent foreign systems, some of which could further limit coverage and reimbursement of products, including our product candidates. Any reduction in reimbursement from Medicare or other government programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In connection with our work with the U.S. Department of Defense ("DoD"), we have become a defense contractor, and are therefore subject to additional administrative burdens and control requirements in connection with the maintenance of that relationship.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, we entered into an agreement with the DoD relating to the conduct of a clinical trial and studies in connection with the development of an improved plague vaccine. In connection with this agreement, we became subject to new administrative and control requirements, including certain reporting obligations as well as a requirement to develop, implement and maintain an International Traffic in Arms Regulations compliance program, among other things. Further, if our efforts result in an improved plague vaccine and we enter into a supply agreement for finished plague vaccines with the DoD, we expect that such a supply contract would impose additional administrative, control, compliance and other obligations. We have limited experience developing and administering such programs. Development and maintenance of such programs can be burdensome and costly and there can be no guarantee that we will be able to maintain compliance with all of the terms of such an agreement. Failure to comply with these requirements could have a significant reputational or financial impact on our business and on our stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face product liability exposure, which, if not covered by insurance, could result in significant financial liability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have not experienced any product liability claims to date, the use of any of our product candidates in clinical trials and the sale of any approved products, including HEPLISAV-B, will subject us to potential product liability claims and may raise questions about a product&#8217;s safety and efficacy. As a result, we could experience a delay in our ability to commercialize one or more of our product candidates or reduced sales of any approved product candidates. In addition, a product liability claim may exceed the limits of our insurance policies and exhaust our internal resources. We have obtained limited clinical trial liability and umbrella insurance coverage for our clinical trials. This coverage may not be adequate or may not continue to be available in sufficient amounts, at an acceptable cost, or at all. While we have obtained product liability insurance coverage for HEPLISAV-B, there is a risk that this coverage may not be adequate or may not continue to be available in sufficient amounts, at an acceptable cost or at all. We also may not be able to obtain commercially reasonable product liability insurance for any product approved for marketing in the future. A product liability claim, product recalls or other claims, as well as any claims for uninsured liabilities or in excess of insured liabilities, would divert our management&#8217;s attention from our business and could result in significant financial liability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If third parties assert that we have infringed their patents or other proprietary rights or challenge our patents or other proprietary rights, we may become involved in disputes and litigation that would be costly, time consuming and have a negative impact on the commercialization of our current products and delay or prevent development or commercialization of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be exposed to future litigation or other dispute with third parties based on claims that our products, product candidates or proprietary technologies infringe their intellectual property rights, or we may be required to enter into litigation to enforce patents issued or licensed to us or to determine the ownership, scope or validity of our or another party&#8217;s proprietary rights, including a challenge as to the validity and scope of our issued and pending claims. From time to time, we have been, and in the future may become, involved in various administrative proceedings related to our intellectual property which can cause us to incur certain legal expenses. If we become involved in any litigation and/or other administrative proceedings related to our intellectual property or the intellectual property of others, we will incur substantial additional expenses and it will divert the efforts of our technical and management personnel.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our collaborators are unsuccessful in defending or prosecuting our issued and pending claims or in defending potential claims against our products, for example, as may arise in connection with the commercialization of HEPLISAV-B or any similar or other product candidate, we or our collaborators could be required to pay substantial damages or be unable to commercialize our product candidates or use our proprietary technologies without a license from such third party. A license may require the payment of substantial fees or royalties, require a grant of a cross-license to our intellectual property or technologies or may not be available on acceptable terms, if at all. Any of these outcomes could require us to change our business strategy and could materially impact our business, operations or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the combination of patents, trade secrets and contractual provisions that we rely on to protect our intellectual property is inadequate, the value of our products or product candidates may decrease, and we may be unable to realize any commercial benefit from the development of our products or product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends on our ability to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain and protect commercially valuable patents or the rights to patents both domestically and abroad;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operate without infringing upon the proprietary rights of others; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent others from successfully challenging or infringing our proprietary rights.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will be able to protect our proprietary rights from unauthorized use only to the extent that these rights are covered by valid and enforceable patents for a commercially sufficient term or are otherwise effectively maintained as trade secrets. We try to protect our proprietary rights by filing and prosecuting U.S. and foreign patent applications. However, in certain cases such protection may be limited, depending in part on existing patents held by third parties, or other disclosures which impact patentability, which may only allow us to obtain relatively narrow patent protection, if any at all. In the U.S., and worldwide, legal standards relating to the validity and scope of patent claims in the biopharmaceutical field can be highly uncertain, are still evolving and involve complex legal and factual questions for which important legal principles remain unresolved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in U.S. patent and ex-U.S. patent laws could diminish the value of patents in general, thereby impairing us and our collaborators&#8217; ability to protect our products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our HEPLISAV-B vaccine and CpG 1018 adjuvant have no composition of matter patent protection in the United States or elsewhere. We must therefore rely primarily on the protection afforded by method of use patent claims relating to HEPLISAV-B vaccine and the use of CpG 1018 adjuvant in vaccines, and trade secret protection and confidentiality and other agreements to protect our interests in proprietary know-how related to HEPLISAV-B vaccine and CpG 1018 adjuvant. We have three issued U.S. patents relating to certain uses of HEPLISAV-B that are projected to expire in 2032. We have filed patent applications claiming compositions and methods of use of CpG 1018 adjuvant for COVID-19 and other vaccines, but we cannot provide any assurances that we will receive an issued patent for any of these patent applications or that, if issued, any of these patents will provide adequate protection for any intended use of CpG 1018 adjuvant in vaccines. In addition, we are or may be subject to co-ownership of the underlying intellectual property with our collaborators and, therefore, may not be the sole owner and be in a position to diligently control patent prosecution, or enforce our rights. If we are unable to adequately obtain patent protection or enforce our other proprietary rights relating to CpG 1018 adjuvant, we may be unable to realize any recurring commercial benefit from the development of a vaccine containing CpG 1018 adjuvant, and we may not have the ability to prevent others from developing or commercializing a vaccine containing CpG 1018 adjuvant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely on trade secret protection and confidentiality and other agreements to protect our interests in proprietary know-how related to CpG 1018 adjuvant. If we or our collaborators are unable to adequately obtain, protect or enforce our proprietary rights relating to CpG 1018 adjuvant, we may be unable to realize recurring commercial benefit from the development of a vaccine containing CpG 1018 adjuvant, and we or our collaborators may not have the ability to prevent others from developing or commercializing a vaccine containing the adjuvant. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including disputes over ownership rights to intellectual property, know-how or technologies developed with our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because patent applications in the U.S. and many foreign jurisdictions typically are not published until 18 months after filing and publications of discoveries in the scientific literature lag behind actual discoveries, we cannot be certain that we were the first to file for protection of the inventions set forth in these patent applications or in our issued patents. Further, there could be post-grant proceedings such as inter partes review ("IPR"), post grant review ("PGR"), reexamination, reissue or opposition which could result in claims in our patents being narrowed or invalidated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends significantly on our ability to operate without infringing patents and other proprietary rights of third parties. A number of pharmaceutical companies and biotechnology companies, as well as universities and research institutions, may have filed patent applications or may have been granted patents that cover inventions similar to the inventions owned by or licensed to us. We may not be able to determine with certainty whether patents or patent applications of other parties may materially affect our ability to make, use, offer to sell, or sell any products. If another party controls patents or patent applications covering our products, we may not be able to obtain the rights we need to those patents or patent applications in order to commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Litigation may be necessary to enforce patents issued or licensed to us or to determine the scope or validity of another party&#8217;s proprietary rights. The existence of third-party patent applications and patents could significantly reduce the coverage of the patents owned by or licensed to us and limit our ability to obtain meaningful patent protection. Litigation or any other proceedings could result in substantial costs to and diversion of effort by us, and an adverse outcome in a court or patent office could subject us to significant liabilities, require disputed rights to be licensed from other parties, or require us to cease using some of our technology. We may not prevail in these actions or proceedings if they arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other parties may duplicate, design around or independently develop similar or alternative technologies to ours or our licensors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risks and uncertainties that we face with respect to our patents and other proprietary rights include the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not receive an issued patent for any of our patent applications or for any patent applications that we may have exclusively licensed, now or in the future;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pending patent applications we have filed or to which we have exclusive rights may take longer than we expect to result in issued patents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the claims of any patents that are issued may not provide meaningful protection or may not be valid or enforceable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we might not be able to develop additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents licensed or issued to us or our collaborators may not provide a competitive advantage;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patents issued to other parties may limit our intellectual property protection or harm our ability to do business;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other parties may independently develop similar or alternative technologies or duplicate our technologies and commercialize discoveries that we attempt to patent; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other parties may design around technologies we have licensed, patented or developed;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pending patent applications or issued patents may be challenged by third parties in litigation or other proceedings, such as inter partes reviews, pre- and post-grant oppositions, reexaminations, derivation proceedings and post-grant review, in the U.S or abroad;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be subject to claims that our employees or consultants have used or disclosed trade secrets or other proprietary information of their former employers or clients, thus putting our intellectual property at risk;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reliance on trade secret protection and confidentiality and other agreements may not be sufficient to protect our interests and proprietary know-how related to our products and processes; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it may be found that we or our collaborators have not complied with various procedural, document submission, fee payment and other requirements imposed by patent offices, and our patent protection could be reduced or eliminated.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely on trade secret protection and confidentiality agreements to protect our interests in proprietary know-how that may not be directed to what is considered to be patentable subject matter, and for processes for which patents are difficult to enforce. We cannot be certain that we will be able to protect our trade secrets or other proprietary know-how adequately. Any disclosure of confidential data in the public domain or to third parties could allow our competitors to learn our trade secrets. If we are unable to adequately obtain or enforce proprietary rights, we may be unable to commercialize or continue to commercialize our products, enter into or maintain collaborations, generate revenues or maintain any advantage we may have with respect to existing or potential competitors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have in the past, and may in the future, rely on licenses to intellectual property from third parties. Impairment of these licenses or our inability to obtain or maintain them could severely harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current or future research and development efforts may depend in part upon our license arrangements for certain intellectual property owned by or co-owned with third parties. Our dependence on these licenses could subject us to numerous risks, such as disputes regarding the use of the licensed intellectual property and the creation and ownership of new discoveries under such license agreements. In addition, these license arrangements could require us to make timely payments to maintain our licenses and typically contain diligence or milestone-based termination provisions. Our failure to meet any obligations pursuant to such agreements could allow licensors to terminate our agreements or undertake other remedies such as converting exclusive to non-exclusive licenses if we are unable to cure or obtain waivers for such failures or amend such agreements on terms acceptable to us or at all. In addition, license agreements may be terminated or may expire by their terms, and we may not be able to maintain the exclusivity of these licenses or any rights to the underlying intellectual property. If we cannot obtain and maintain licenses that are advantageous or necessary to the development or the commercialization of our products or product candidates, we may be required to expend significant time and resources to develop or license similar technology or to find other alternatives to maintaining the competitive position of our products or product candidates. If such alternatives are not available to us in a timely manner or on acceptable terms, we may be unable to develop or commercialize certain of our products or product candidates. In the absence of a current license, we may be required to redesign our technology so it does not infringe a third-party&#8217;s intellectual property (including patents), which may not be possible or could require substantial funds and time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees or consultants may have been previously employed in other biopharmaceutical companies, including our competitors or potential competitors. Some of these individuals executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment or engagements. Although no claims against us are currently pending, we may be subject to claims that these employees or consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or clients. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to develop and ultimately commercialize, or prevent us from developing and commercializing, our product candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may rely, in some circumstances, on trade secrets and confidentiality agreements to protect our technology. Although trade secrets are difficult to protect, wherever possible, we use confidential disclosure agreements to protect the proprietary nature of our technology. Our standard practice is to require each of our collaborators, commercial partners, employees, consultants, contractors and advisors to enter into an agreement before beginning their employment, consulting or advisory relationship with us that in general provides that the individuals must keep confidential and not disclose to other parties any of our confidential information developed or learned by the individuals during the course of their relationship with us except in limited circumstances. These agreements with employees, consultants and contractors also generally provide that we own all inventions conceived by the individuals in the course of rendering their employment or services to us. However, there can be no assurance that these agreements will not be breached, that we will have adequate remedies for any breach, or that our trade secrets and/or proprietary information will not otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants or contractors use intellectual property owned by others in their work for us, disputes may also arise as to the rights in related or resulting know-how and inventions, which could result in substantial costs which could severely harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications are due to be paid to the United States Patent and Trademark Office and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ reputable law firms and other professionals to help us comply, and in many cases an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdictions, and in such an event, our competitors might be able to enter the market.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biopharmaceutical patent environment outside the U.S. is also uncertain. We may be particularly affected by this uncertainty since several of our product candidates or our collaborators&#8217; vaccine candidates may initially address market opportunities outside the U.S., where we may only be able to obtain limited patent protection, if any at all. For example, while many countries such as the U.S. permit method of use patents or patent claims relating to the use of drug products, in some countries the law relating to patentability of such use claims is evolving, or may prohibit certain activities, and may be unfavorably interpreted to prevent us from successfully prosecuting some or all of our pending patent applications. There are some countries that currently do not allow such method of use patents or patent claims, or that significantly limit the types of uses, claims or subject matter that are patentable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents are of national or regional effect. Filing, prosecuting and defending patents on all of our products and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These competitor products may compete with our products and product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Geo-political actions in the U.S. and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various countries outside the U.S. have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. As a result, a patent owner may have limited remedies in certain circumstances, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the standards applied by the USPTO, foreign patent offices and other adjudicating bodies in granting and/or adjudicating patents are not always applied uniformly or predictably. As such, we do not know the degree of future protection that we will have on our products and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the U.S. or in other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In the U.S., numerous recent changes to the patent laws and proposed changes to the rules of the USPTO may have a significant impact on our ability to protect our technology and enforce our intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, the America Invents Act, involved significant changes in patent legislation. Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years, some of which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in Europe, a new unitary patent system took effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court ("UPC"). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our stock price is subject to volatility, and your investment may suffer a decline in value.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market prices for securities of biopharmaceutical companies have in the past been, and are likely to continue in the future to be, very volatile. The market price of our common stock is subject to substantial volatility depending upon many factors, many of which are beyond our control, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impact of COVID-19 or other respiratory or seasonal vaccination initiatives on our HEPLISAV-B vaccine, CpG 1018 adjuvant, or other product revenue;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">progress or results of any of our clinical trials or regulatory or manufacturing efforts, in particular any announcements regarding the progress or results of our planned trials and BLA filing and communications, from the FDA or other regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to receive timely regulatory approval for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain collaborations for the development and commercialization of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to raise additional capital to fund our operations, to the extent needed;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">technological innovations, new commercial products or drug discovery efforts and preclinical and clinical activities by us or our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in our intellectual property portfolio or developments or disputes concerning the proprietary rights of our products or product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain component materials and successfully enter into manufacturing relationships for our products or product candidates or establish manufacturing capacity on our own;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain licensing agreements for intellectual property necessary for the development of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in government regulations, general economic conditions or industry announcements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issuance of new or changed securities analysts&#8217; reports or recommendations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated fluctuations in our quarterly financial and operating results; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the volume of trading in our common stock;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investor perceptions or negative announcements by our customers, competitors or suppliers regarding their own performance; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">industry conditions and general financial, economic and political instability.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Changes in the broader macroeconomic condition, including historically high inflation, changes in interest rates, government tapering policies, impact of pandemics or endemics and instances of geopolitical instability, such as that resulting from the conflicts in the Middle East and Ukraine, can and have caused changes in market prices, notwithstanding a lack of fundamental change in the underlying business models or prospects of companies. These broad market fluctuations have adversely affected and may in the future adversely affect the market price of our common stock, regardless of our actual operating performance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One or more of these factors could cause a substantial decline in the price of our common stock. In addition, securities class action and shareholder derivative litigation have often been brought against a company following a decline in the market price of its securities. We have in the past been, and we may in the future be, the target of such litigation. Securities and shareholder derivative litigation could result in substantial costs, and divert management&#8217;s attention and resources, which could harm our business, operating results and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future sales of our common stock or the perception that such sales may occur in the public market could cause our stock price to fall.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under our universal shelf registration statement, we may sell any combination of common stock, preferred stock, debt securities and warrants in one or more offerings, including pursuant to our sales agreement with Cowen &amp; Company, LLC, under which we can offer and sell our common stock from time to time up to aggregate sales proceeds of $120.0 million. As of December 31, 2023, we had approximately $120.0 million of our common stock remaining available for future issuance under our sales agreement with Cowen &amp; Company, LLC. The sale or issuance of our securities, including those issuable upon exercise of the outstanding warrants or conversion of the preferred stock, as well as the existence of outstanding options and shares of common stock reserved for issuance under our option and equity incentive plans also may adversely affect the terms upon which we are able to obtain additional capital through the sale of equity securities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Outstanding Convertible Notes</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the $225.5 million in Convertible Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not continue to generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not have the ability to generate or raise the funds necessary to settle conversions of the Convertible Notes in cash or to repurchase the notes for cash upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Convertible Notes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of the Convertible Notes will have the right, subject to certain conditions and limited exceptions, to require us to repurchase all or a portion of their Convertible Notes upon the occurrence of a fundamental change at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. In addition, upon conversion of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Convertible Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to make cash payments in respect of the Convertible Notes being converted. Moreover, we will be required to repay the Convertible Notes in cash at their maturity unless earlier converted, redeemed or repurchased. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Convertible Notes surrendered therefore or pay cash with respect to Convertible Notes being converted. In addition, our ability to repurchase the Convertible Notes or to pay cash upon conversions of the Convertible Notes may be limited by law, by regulatory authority or by agreements governing our future indebtedness. Our failure to repurchase Convertible Notes at a time when the repurchase is required by the indenture governing the Convertible Notes or to pay any cash payable on future conversions of the Convertible Notes as required by the indenture governing the Convertible Notes would constitute a default under the indenture governing the Convertible Notes. A default under the indenture governing the Convertible Notes or the occurrence of a fundamental change itself could also lead to a default under agreements governing our future indebtedness. Moreover, the occurrence of a fundamental change under the indenture governing the Convertible Notes could constitute an event of default under any agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Convertible Notes or make cash payments upon conversions thereof.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The conditional conversion feature of the Convertible Notes may adversely affect our financial condition and operating results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From October 1 through December 31, 2023, the conditions allowing holders to convert all or any portion of their Convertible Notes were not met. In the event the conditional conversion feature of the Convertible Notes is triggered, holders of Convertible Notes will be entitled to convert their Convertible Notes at any time during specified periods at their option. If one or more holders elect to convert their Convertible Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Convertible Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Convertible Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conversion of the Convertible Notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From October 1 through December 31, 2023, the conditions allowing holders to convert all or any portion of their Convertible Notes have not been met. In the event the conditional conversion feature of the Convertible Notes is triggered, the conversion of some or all of the Convertible Notes to shares of common stock may dilute the ownership interests of our stockholders. Upon conversion of the Convertible Notes, we have the option to pay or deliver, as the case may be, cash, shares of our common stock, or a combination of cash and shares of our common stock. If we elect to settle our conversion obligation in shares of our common stock or a combination of cash and shares of our common stock, any sales in the public market of our common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Convertible Notes may encourage short selling by market participants because the conversion of the Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes into shares of our common stock could depress the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain provisions in the indenture governing the Convertible Notes may delay or prevent an otherwise beneficial takeover attempt of us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain provisions in the indenture governing the Convertible Notes may make it more difficult or expensive for a third party to acquire us. For example, the indenture governing the Convertible Notes will require us, subject to certain exceptions, to repurchase the Convertible Notes for cash upon the occurrence of a fundamental change and, in certain circumstances, to increase the conversion rate for a holder that converts its Convertible Notes in connection with a make-whole fundamental change. A takeover of us may trigger the requirement that we repurchase the Convertible Notes and/or increase the conversion rate, which could make it more costly for a potential acquirer to engage in such takeover. Such additional costs may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to investors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Capped Calls may affect the value of the Convertible Notes and our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the issuance of the Convertible Notes, we have entered into capped call transactions with the option counterparties totaling $27.2 million (the "Capped Calls"). The Capped Calls cover, subject to customary adjustments under the terms of the Capped Calls, the number of shares of common stock that initially underlie the Capped Calls. The Capped Calls are expected to offset the potential dilution to our common stock as a result of any conversion of the Convertible Notes, subject to a cap based on the cap price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with establishing their initial hedges of the Capped Calls, we have been advised that the option counterparties and/or their respective affiliates entered into various derivative transactions with respect to our common stock concurrently with or shortly after the pricing of the Convertible Notes and/or purchased shares of our common stock concurrently with or shortly after the pricing of the Convertible Notes. In addition, the option counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions following the pricing of the Convertible Notes and prior to the maturity of the Convertible Notes (and are likely to do so on each exercise date of the Capped Calls, which are expected to occur during the 30 trading day period beginning on the 31st scheduled trading day prior to the maturity date of the Convertible Notes, or following any termination of any portion of the Capped Calls in connection with any repurchase, redemption or early conversion of the Convertible Notes). This activity could also cause or avoid an increase or a decrease in the market price of our common stock or the Convertible Notes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to counterparty risk with respect to the capped call transactions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The option counterparties are financial institutions, and we will be subject to the risk that any or all of them might default under the Capped Calls. Our exposure to the credit risk of the option counterparties will not be secured by any collateral.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an option counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under the Capped Calls with such option counterparty. Our exposure will depend on many factors but, generally, an increase in our exposure will be correlated to an increase in the market price and in the volatility of our common stock. In addition, upon a default by an option counterparty, we may suffer adverse tax consequences and more dilution than we currently anticipate with respect to our common stock. We can provide no assurances as to the financial stability or viability of the option counterparties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The loss of key personnel could delay or prevent achieving our objectives. In addition, our continued growth to support commercialization may result in difficulties in managing our growth and expanding our operations successfully.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend on our senior executive officers, as well as other key scientific personnel. Our commercial and business efforts could be adversely affected by the loss of one or more key members of our commercial or management staff, including our senior executive officers. We currently have no key person insurance on any of our employees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As our operations expand, we expect that we will need to manage additional relationships with various vendors, partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management. Our future financial performance and our ability to successfully commercialize HEPLISAV-B, or other future products we may attempt to commercialize, and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to effectively manage our commercialization efforts, research efforts and clinical trials and hire, train and integrate additional regulatory, manufacturing, administrative, and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing and achieving profitability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business operations are vulnerable to interruptions by natural disasters, health epidemics and other catastrophic events beyond our control, the occurrence of which could materially harm our manufacturing, distribution, sales, business operations and financial results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business operations are subject to interruption by natural disasters and other catastrophic events beyond our control, including, but not limited to, earthquakes, hurricanes, fires, droughts, tornadoes, electrical blackouts, public health crises and pandemics, war, terrorism, bank failures and geo-political unrest and uncertainties. We have not undertaken a systematic analysis of the potential consequences to our business that might result from any such natural disaster or other catastrophic event and have limited recovery plans in place. If any of these events occur, our manufacturing and supply chain,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">distribution, sales and marketing efforts and other business operations could be subject to business shutdowns or disruptions and financial results could be adversely affected. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions resulting from these events, but if we or any of the third parties with whom we engage, including the suppliers, contract manufacturers, distributors and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and adversely affected in a number of ways, some of which are not predicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business could be adversely affected by health epidemics in regions where we have manufacturing facilities, sales activities or other business operations. For example, outbreaks of epidemic or pandemic diseases, such as COVID-19, or the fear of such events, have and could again in the future cause restrictions on supply chains, restrict access to workplaces and affect employee health and availability. Furthermore, during the peak of the COVID-19 pandemic there was a significantly reduced utilization of all adult vaccines (other than COVID-19 vaccines), including a reduced utilization of HEPLISAV-B.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain inventories of HEPLISAV-B and its components, our ability and those of our contractors and distributors to produce and distribute HEPLISAV-B could be adversely affected. A pandemic or similar health challenge could severely impact the U.S. healthcare system, which may have an adverse effect on usage and sales of HEPLISAV-B. In addition, any such event could result in widespread global health crisis that could adversely affect global economies and financial markets resulting in an economic downturn that could affect the demand for HEPLISAV-B and future revenue and operating results and our ability to raise additional capital when needed on acceptable terms, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, our corporate headquarters in Emeryville, California, is located in a seismically active region that also is subject to possible electrical shutdowns and wildfires. Because we do not carry earthquake insurance for earthquake-related losses and significant recovery time could be required to resume operations, our financial condition and operating results could be materially adversely affected in the event of a major earthquake or catastrophic event. We carry only limited business interruption insurance that would compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us in excess of insured amounts could adversely affect our business and operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our information technology systems or those of third parties upon which we rely, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including internet-based systems, to support business processes as well as internal and external communications. In addition, our dependence on information technology systems has intensified because many of our critical business activities are now being conducted remotely in our remote-first work environment. The size and complexity of our computer systems make them potentially vulnerable to breakdown, malicious intrusion and computer viruses that may result in the impairment of key business processes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our systems, along with those of our customers, suppliers, or third-party service providers which operate critical business systems to process sensitive information in a variety of contexts are potentially vulnerable to a variety of evolving threats and data security breaches&#8212;whether by employees or others&#8212;that may expose sensitive data to unauthorized persons. Such threats could include, but not be limited to social-engineering attacks (including through phishing attacks), online and offline fraud, malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, access attacks (such as credential stuffing or credential harvesting), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable flaws or bugs that could result in a breach of or disruption to our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">information technology systems (including our products or the third-party information technology systems that support us and our goods). If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The potential liability and associated consequences we could suffer as a result of any such cyber events could be catastrophic and result in irreparable harm including (a) the loss of trade secrets or other intellectual property, or (b) the public exposure of personally identifiable information (including sensitive personal information) of our employees, collaborators, clinical trial patients, and others, (c) extortion and other monetary damages due to malware or business email compromise, (d) significant interruptions in our operations, or (e) other significant damages. A data security breach or privacy violation that leads to disclosure or modification of or prevents access to patient information, including personally identifiable information or protected health information, could harm our reputation, compel us to comply with federal, state and/or international data breach notification laws, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, including, but not limited to, HIPAA, similar state data protection regulations, and the EU GDPR and UK GDPR, resulting in significant penalties; increased costs; loss of revenue; expenses of computer or forensic investigations; material fines and penalties; compensatory, special, punitive or statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services and/or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; or injunctive relief.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. and equivalent foreign authorities and international authorities warned businesses of increased cybersecurity threats from actors seeking to exploit the COVID-19 pandemic. In 2020, we experienced a cybersecurity incident known as a phishing e-mail scam, and although we do not consider its impact on us to be material, if we are unable to prevent this or other such data security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive patient data. Moreover, failure to maintain effective internal accounting controls related to data security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and could subject us to regulatory scrutiny. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures that are intended to protect our data security and information technology systems, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities including on a timely basis.  Further, we may experience delays in deploying remedial measures and patches designed to address identified vulnerabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such disruptions and breaches of security could have a material adverse effect on our business, financial condition and results of operations. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.  We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adverse developments affecting the financial services industry may have adverse consequences on our business, financial condition and stock price.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We regularly maintain cash balances at third-party financial institutions in excess of the FDIC insurance limit. Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1B. UNRE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SOLVED STAFF COMMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_1c"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1C. CYBERSECURITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Management and Strategy</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, along with personal data and other sensitive information, including our trade secrets, data we may collect about trial participants in connection with clinical trials, and other sensitive data (&#8220;Information Systems and Data&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Senior Director of IT Infrastructure &amp; Security also functions as our information security officer (&#8220;ISO&#8221;). The ISO (as part of our security function), along with our broader internal cybersecurity, IT infrastructure, and digital technology automation functions, as well as third-party service providers, all help identify, assess and manage our cybersecurity threats and risks. Our security function identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example, manual tools, automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and actors, conducting scans of the threat environment, evaluating our and our industry&#8217;s risk profile, evaluating threats reported to us, coordinating with law enforcement concerning threats, responding to proactive outreach from CISA and FBI, internal and/or external audits, conducting threat assessments for internal and external threats, third-party threat assessments, conducting vulnerability assessments to identify vulnerabilities, and use of external intelligence feeds.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to help manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: a corporate security incident response plan, a vulnerability management policy, incident detection and response processes, IT systems disaster recovery procedures, risk assessments, reasonable implementation of security controls in accordance with applicable security standards/certifications, encryption of data, network security controls, data segregation, access controls, physical security, asset management, tracking and disposal, systems monitoring, employee training, penetration testing, cybersecurity insurance, dedicated cybersecurity staff/officer. We also rely on third-party vendor backup/restore, disaster recovery and business continuity procedures as stated in the respective SOC 1 and SOC 2 reports if provided by such vendors as they pertain to certain of our managed services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our procedures for assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes. For example, (1) cybersecurity risk is evaluated as a component of our broader enterprise risk management program, identified in our risk register and monitored and managed more specifically by our Corporate Security Incident Response Team (CSIRT);  (2) the security function works with the CSIRT to help prioritize our risk management processes and help mitigate cybersecurity threats that we believe are more likely to lead to a possible material impact to our business; (3) our ISO evaluates material risks identified from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors (the "Audit Committee"), which reviews and discusses with senior management our overall risk assessment and management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use third-party managed service providers to assist us in identifying, assessing, mitigating and managing potential risks from cybersecurity threats. In addition, we engage other advisors from time to time to help identify, assess, mitigate and manage new or developing risks in a changing threat landscape. Such ongoing services and periodic services include professional services from providers such as legal counsel, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, penetration testing firms, dark web monitoring services, and forensic investigators (as needed).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use third-party service providers to perform a variety of functions throughout our business, such as application service providers, software-as-a-service providers, hosting companies, contract research organizations, contract manufacturing organizations, distributors, and other supply chain resources. We have a vendor management process to help manage cybersecurity risks associated with our use of these providers. This includes risk assessment for each vendor, review of security assessments, supplemental security questionnaires (as needed), security assessment calls with the vendor's security personnel, and imposition of certain information contractual obligations on the vendor. In addition, depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our information technology systems or those of third parties upon which we rely, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The Audit Committee is responsible for reviewing and discussing with management our cybersecurity risk assessment and management processes, including our oversight and the steps we take to monitor and help control risks from cybersecurity threats.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain of our management, including our ISO, who has over 20 years of experience in information security.  Our ISO oversees a global team of information security professionals consisting of multiple</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">full time equivalent employees in multiple countries.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ISO is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. Our ISO (in coordination with our CSIRT) is also responsible for other functions, including preparing for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our CSIRT reviews, approves and prioritizes information security and cybersecurity policies, projects and initiatives. Executive management is responsible for prioritizing initiatives and approving budgets to allocate funding for the foregoing based on feedback from the ISO, the CSIRT and the Audit Committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our ISO. The ISO works with our CSIRT to help us mitigate and remediate cybersecurity threats or incidents of which they are notified. The ISO is responsible for designing and promoting general security awareness and training, as well as defining and training relevant participants on our incident response processes. Our security and incident response processes include escalation and reporting to the CSIRT, Disclosure Committee, senior management and Audit Committee for certain information security incidents, as warranted under the circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Audit Committee receives periodic reports from the ISO concerning our significant cybersecurity threats and risk, and the processes we have implemented to address them. The Audit Committee also has access to various reports, summaries of reports or presentations related to cybersecurity threats, risk and mitigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 2. P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROPERTIES</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the following are the material properties that we occupy:</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.78%;"/>
    <td style="width:20.14%;"/>
    <td style="width:13.64%;"/>
    <td style="width:13.76%;"/>
    <td style="width:25.68%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Property Description</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Location</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Square Footage</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Owned or Leased</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Expiration Date</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate headquarters office</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emeryville, CA</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,053</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leased</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 31, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing and office space</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">D&#252;sseldorf, Germany</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,558</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leased</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 31, 2031</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory and office space</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emeryville, CA</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,662</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leased (*)</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2031</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(*) The entire 75,662 square feet have been subleased to a third party. Both our lease and sublease with the third party will continue until March 31, 2031.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our facilities are adequate to meet our requirements for the near term.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 3. LE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GAL PROCEEDINGS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time in the ordinary course of business, we receive claims or allegations regarding various matters, including employment, vendor and other similar situations in the conduct of our operations. We are not currently aware of any material legal proceedings involving our Company.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 4. MINE S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AFETY DISCLOSURE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RT II</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 5. MARKET FOR REGISTRANT&#8217;S </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information and Holders</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is traded on the Nasdaq Global Select Market under the ticker symbol &#8220;DVAX&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 20, 2024, there were approximately 39 holders of record of our common stock, one of which was Cede &amp; Co., a nominee for Depository Trust Company (&#8220;DTC&#8221;). All of the shares of our common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore considered to be held of record by Cede &amp; Co. as one stockholder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never paid any cash dividends on our common stock. We currently expect to retain future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The chart below compares total stockholder return on an investment of $100 in cash on December 31, 2018, for our common stock, the Nasdaq Stock Market (U.S. companies), and the Nasdaq Biotechnology Index. All values assume reinvestment of the full amount of all dividends.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note: Dynavax management cautions that the stock price performance shown in the graph below should not be considered indicative of potential future stock price performance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img25882306_0.jpg" alt="img25882306_0.jpg" style="width:672px;height:437px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Section is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the Securities and Exchange Commission and is not to be incorporated by reference in any filing of Dynavax Technologies Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Sales of Unregistered Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuer Purchases of Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 6. [RE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SERVED]</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 7. MANAGEMENT&#8217;S DISCUSSIO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">N AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from those indicated by forward-looking statements as a result of various factors, including but not limited to, the period for which we estimate our cash resources are sufficient, the availability of additional funds, as well as those set forth under &#8220;Risk Factors&#8221; and those that may be identified from time to time in our reports and registration statements filed with the Securities and Exchange Commission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis is intended to provide an investor with a narrative of our financial results and an evaluation of our financial condition and results of operations. The discussion should be read in conjunction with the Consolidated Financial Statements and the related notes thereto set forth in &#8220;Item 8&#8212;Financial Statements and Supplementary Data.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Our first marketed product, HEPLISAV-B&#174; [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States, the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older. In May 2022, we commenced commercial shipments of HEPLISAV-B in Germany.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, the CDC's Advisory Committee on Immunization Practices ("ACIP") published its universal recommendation for hepatitis B vaccination in adults, advising that all adults aged 19-59 should be vaccinated against hepatitis B. We believe this has helped create a significantly expanded total annual market opportunity of approximately $800 million in the U.S. by 2027, with HEPLISAV-B well positioned to achieve a majority market share. Our annual revenue has continued to grow significantly since the recommendation was made, as a result of our successful efforts to capture a greater share of an expanding market.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing a pipeline of differentiated product candidates that leverage our CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. These programs include vaccine candidates under development for shingles, Tdap and plague. Additionally, we are working to advance product candidates utilizing our CpG 1018 adjuvant through discovery efforts and preclinical and clinical collaborations with third-party research organizations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we manufacture and have supplied in the past, and could supply in the future, our CpG 1018 adjuvant to a number of global customers, including companies engaged in the development and manufacture of COVID-19 vaccines across a variety of vaccine platforms utilizing CpG 1018 adjuvant. While we did not recognize any CpG 1018 adjuvant revenue in 2023, we could see new demand in the future if our collaborators work through their inventory on hand and need additional supply, or new programs utilizing our adjuvant advance to later stages up to and including commercialization. However, long-term demand for CpG 1018 adjuvant supporting COVID-19 or other vaccines will be highly dependent on each customer&#8217;s ability to commercialize in respective territories and geographies where their respective COVID-19 or other vaccines are approved for use.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HEPLISAV-B&#174; Vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted]</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Phase 3 trials, HEPLISAV-B demonstrated faster and higher rates of protection with two doses in one month compared to another currently approved hepatitis B vaccine which requires three doses over six months, with a similar safety profile. HEPLISAV-B is the only two-dose hepatitis B vaccine for adults approved in the U.S., the European Union and Great Britain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have worldwide commercial rights to HEPLISAV-B and we market it in the United States and the European Union. There are four other vaccines approved for the prevention of hepatitis B in the U.S.: Engerix-B and Twinrix&#174; from GlaxoSmithKline plc, Recombivax-HB&#174; from Merck &amp; Co and PreHevbrio&#153; from VBI Vaccines Inc. In February 2021, we received Marketing Authorization of HEPLISAV-B from the European Commission for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older. In May 2021, we entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV-B in Germany, and in May 2022, we commenced commercial shipments of HEPLISAV-B in Germany. In March 2023, we received marketing authorization in Great Britain for HEPLISAV-B for the active immunization against hepatitis B virus infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs and retail pharmacies. All of our HEPLISAV-B sales in Germany are to one distributor. For the year ended December 31, 2023, HEPLISAV-B product revenue, net was $213.3 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CpG 1018&#174; Adjuvant Supply for COVID-19 Vaccines</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2021, we entered into an agreement (together with subsequent amendments, the "CEPI Agreement") with Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) for the manufacture and reservation of a specified quantity of CpG 1018 adjuvant. In May 2021, we entered into the first amendment to the CEPI Agreement. The CEPI Agreement enables CEPI to direct the supply of CpG 1018 adjuvant to CEPI partner(s). In exchange for reserving CpG 1018 adjuvant, CEPI has agreed to provide advance payments in the form of an interest-free, unsecured, forgivable loan (the &#8220;Advance Payments&#8221;) of up to $176.4 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through December 31, 2023, we have received Advance Payments totaling approximately $175.0 million pursuant to the CEPI Agreement, of which $67.3 million have been repaid and $47.4 million have been forgiven (as discussed below). As of December 31, 2023, remaining Advance Payments totaling $60.3 million were reflected in CEPI accrual long-term in our consolidated balance sheets, representing the outstanding balance of the Advance Payments relating to the Clover Supply Agreement (as defined and discussed below). As of December 31, 2022, we recorded Advance Payments of $107.7 million included in CEPI accrual. There were no deferred revenue balances related to the CEPI Agreement as of December 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 27, 2023, we entered into a waiver and second amendment to the CEPI Agreement by and between us and CEPI (the &#8220;CEPI-Bio E Assignment Agreement&#8221;). Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of the outstanding Advance Payments for CpG 1018 Materials allocated to and ordered by Bio E under the CEPI Agreement and has assumed our previous rights to $47.4 million of Bio E accounts receivable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, we entered into an agreement (together with subsequent amendments, the &#8220;Clover Supply Agreement&#8221;) with Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited (collectively, &#8220;Clover&#8221;) for the commercial supply of CpG 1018 adjuvant, for use with its protein-based COVID-19 vaccine candidate, SCB-2019. Under the Clover Supply Agreement, Clover committed to purchase specified quantities of CpG 1018 adjuvant, at pre-negotiated prices pursuant to the CEPI Agreement, for use in Clover&#8217;s commercialization of vaccines containing SCB-2019 and CpG 1018 adjuvant (&#8220;Clover Product&#8221;). The Clover Supply Agreement also provides terms for Clover to order additional quantities of CpG 1018 adjuvant beyond the quantities reserved by CEPI. In 2022 and 2023, we signed four amendments to the Clover Supply Agreement. The terms and conditions of the Clover Supply Agreement were operative through December 2022, and as of December 31, 2022, we had satisfied all delivery obligations thereunder.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For CpG 1018 adjuvant reserved for Clover under the CEPI Agreement, Clover is obligated to pay us the purchase price upon the earliest of (i) the true-up exercise, (ii) within a specified period after Clover delivers Clover Product to a customer, or (iii) Clover&#8217;s receipt of payment for Clover Product from a customer. When we transfer control of CpG 1018 adjuvant that is reserved under the CEPI Agreement, we recognize product revenue and a corresponding contract asset as our right to consideration is contingent on something other than the passage of time, as outlined above.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approximately $71.3 million relating to future amounts receivable representing a contract asset from Clover in connection with the CEPI Agreement are classified as other assets (long term) as of December 31, 2023. The classification as long term reflects the timing of expected utilization of CpG 1018 adjuvant for Clover Product expected to be sold under the CEPI Agreement. Corresponding Advance Payments of $60.3 million relating to Clover are recorded in CEPI accrual long-term in our consolidated balance sheets as of December 31, 2023. These Advance Payments may be repaid using cash collected from Clover or forgiven in accordance with the CEPI Agreement. We had no accounts receivable balance from Clover as of December 31, 2023. We did not recognize CpG 1018 adjuvant net product revenue from Clover for the year ended December 31, 2023. We recognized CpG 1018 adjuvant net product revenue of $288.0 million from Clover for the year ended December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, we entered into an agreement (together with subsequent amendments, the &#8220;Bio E Supply Agreement&#8221;) with Biological E. Limited (&#8220;Bio E&#8221;), for the commercial supply of CpG 1018 adjuvant, for use with Bio E&#8217;s subunit COVID-19 vaccine candidate, CORBEVAX&#153;. Under the Bio E Supply Agreement, Bio E previously committed to purchase specified quantities of CpG 1018 adjuvant at pre-negotiated prices pursuant to the CEPI Agreement, for use in Bio E&#8217;s commercialization of its CORBEVAX vaccine. The Bio E Supply Agreement also provides terms for Bio E to order</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional quantities of CpG 1018 adjuvant beyond the quantities reserved by CEPI. In June 2022 and October 2022, we entered into two amendments to the Bio E Supply Agreement (the &#8220;Bio E Amendment No. 1&#8221; and the &#8220;Bio E Amendment No. 2,&#8221; respectively, together the &#8220;Bio E Amendments&#8221;). The Bio E Amendments primarily established: (i) a new payment schedule for certain outstanding invoices related to the CEPI product to be the earlier of December 31, 2022, or receipt of certain amounts by Bio E from the Government of India in connection with their advance purchase agreement for CORBEVAX, and (ii) further modified the scope of the Bio E Supply Agreement, by reducing certain quantities of CpG 1018 adjuvant to be delivered. The terms and conditions of the Bio E Supply Agreement were operative through December 2022, and as of December 31, 2022 and we had satisfied all delivery obligations thereunder.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had no accounts receivable balance from Bio E. During the first quarter of 2023, we recorded an allowance for doubtful accounts of $12.3 million, which was determined by assessing changes in Bio E&#8217;s credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (defined below), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 26, 2023, we entered into a third amendment to the Bio E Supply Agreement (the &#8220;Bio E Amendment No. 3&#8221;), and on April 27, 2023, we entered into the CEPI-Bio E Assignment Agreement. Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of remaining amounts outstanding relating to a liability for Advance Payments of $47.4 million (the &#8220;Bio E CEPI Advance Payments&#8221;) for CpG 1018 Materials allocated to Bio E, and has assumed our previous rights to collect $47.4 million of Bio E accounts receivable. Pursuant to the Bio E Amendment No. 3, we collected $14.5 million from Bio E (including $13.5 million in April 2023 and $1.0 million in August 2023). Accordingly, as of December 31, 2023, the CEPI-Bio E Assignment Agreement resulted in: (i) no accounts receivable balance, and (ii) the derecognition of $47.4 million CEPI accrual in connection with the Bio E CEPI Advance Payments. The Bio E Amendment No. 3 provides for additional future payment of either $5.5 million in the event that Bio E receives at least $125.0 million, or $12.3 million in the event that Bio E receives at least $250.0 million in future payments from the Government of India associated with its CORBEVAX product on or before August 15, 2025. These additional amounts are not considered collectible until the achievement of these future milestones.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not recognize CpG 1018 adjuvant net product revenue from Bio E for the year ended December 31, 2023. We recognized CpG 1018 adjuvant net product revenue of $206.2 million from Bio E for the year ended December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Past performance is not a reliable indicator of future performance, however, and future revenue and associated profit or loss may therefore vary significantly. Specifically, a</span><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s our CpG 1018 adjuvant customers have purchased a significant quantity of CpG 1018 adjuvant as part of their initial COVID-19 vaccine development inventory, we currently expect minimal to no CpG 1018 adjuvant revenue in 2024 associated with these arrangements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 9 - Collaborative Research, Development and License Agreements, in the accompanying notes to the consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, we issued $225.5 million aggregate principal amount of 2.50% convertible senior notes due in 2026 (the &#8220;Convertible Notes&#8221;) in a private placement. Total proceeds from the issuance of the Convertible Notes, net of debt issuance and offering costs of $5.7 million, were $219.8 million. We used $190.2 million of the net proceeds to repay, in full, our outstanding debt and other obligations under our previous loan agreement with CRG Servicing LLC ("Loan Agreement") and $27.2 million of the net proceeds to pay the costs of capped call transactions (the "Capped Calls").</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the issuance of the Convertible Notes, we entered into the Capped Calls with one of the initial purchasers and other financial institutions, totaling $27.2 million. The Capped Calls have an initial strike price and an initial cap price of $10.47 per share and $15.80 per share, respectively, subject to certain adjustments under the terms of the Capped Calls. The Capped Calls are freestanding and are considered separately exercisable from the Convertible Notes. The Capped Calls are expected to offset the potential dilution to our common stock as a result of any conversion of the Convertible Notes, subject to a cap based on the cap price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Seasonality</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B is currently our only revenue-producing product. We believe that HEPLISAV-B product revenue is, and will likely continue to be, subject to seasonal variations. Specifically, HEPLISAV-B product revenue has generally been, and will likely continue to be, lower in the fourth quarter of our fiscal year compared to the third quarter due to holiday schedules</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and increased focus by healthcare providers on respiratory disease vaccines, including vaccines for influenza, COVID-19 and respiratory syncytial virus, during the fall and winter months.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles. In doing so, we are required to make estimates and assumptions. Our critical accounting estimates are those estimates that involve a significant level of uncertainty at the time the estimate was made, and changes in them have had or are reasonably likely to have a material effect on our financial condition or results of operations. Actual results could differ materially from our estimates. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 2 - Summary of Significant Accounting Policies, in the accompanying notes to the consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K for a summary of our significant accounting policies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Revenue, Net &#8211; HEPLISAV-B</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize revenue when we transfer control of promised goods to the customer at the net sales price, which includes estimates such as product returns, chargebacks, discounts, rebates and other fees. While each item is more fully described in Note 2 to the Consolidated Financial Statements, the following items reflect the more critical and significant estimates used in the preparation of our consolidated financial statements. Our estimates of such items are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of accounts receivable reserves or revenue reserves accrual that we report in a particular period.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Returns: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consistent with industry practice, we offer our customers a limited right of return based on the product&#8217;s expiration date for product that has been purchased from us. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We consider several factors in the estimation of potential product returns including expiration dates of the product shipped, the limited product return rights, available information about our customers&#8217; inventory and other relevant factors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chargebacks:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our customers subsequently resell our product to healthcare providers, pharmacies and others. In addition to distribution agreements with our customers, we enter into arrangements with qualified healthcare providers that provide for chargebacks and discounts with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from us. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by customers, and we issue credits for such amounts generally within a few weeks of the customer&#8217;s notification to us of the resale. Reserves for chargebacks consists of credits that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect will be sold to the qualified healthcare providers, and chargebacks for units that our customers have sold to the qualified healthcare providers, but for which credits have not been issued.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rebates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Under certain contracts, customers may obtain rebates for purchasing minimum volumes of our product. We estimate these rebates based upon the expected purchases and the contractual rebate rate and record this estimate as a reduction in revenue in the period the related revenue is recognized.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 2 &#8211; Summary of Significant Accounting Policies, in the accompanying notes to the consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K for information regarding recent accounting pronouncements that are of significance, or potential significance to us.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This section of this Form 10-K generally discusses 2023 and 2022 items and year-to-year comparisons between 2023 and 2022. Discussions of 2021 items and year-to-year comparisons between 2022 and 2021 that are not included in this Form 10-K can be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of our </span><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001029142/000095017023004130/dvax-20221231.htm"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annual Report on Form 10-K for the year ended December 31, 2022.</span></a></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenues</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues consist of amounts earned from product sales and other revenues. Product revenue, net, includes sales of HEPLISAV-B and CpG 1018 adjuvant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from HEPLISAV-B product sales is recorded at the net sales price, which includes estimates of product returns, chargebacks, discounts, rebates and other fees. We sell our CpG 1018 adjuvant to our collaboration partners for use in their development and/or potential commercialization of COVID-19 vaccines. Overall, product revenue, net, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of our revenues (in thousands, except for percentages):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.76%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.8%;"/>
    <td style="width:1%;"/>
    <td style="width:11.76%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Decrease) from</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022 to 2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Revenues:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">HEPLISAV-B</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">213,295</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,937</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,358</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CpG 1018 adjuvant</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">587,708</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(587,708</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total product revenue, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">213,295</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">713,645</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(500,350</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(70</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,989</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,038</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,951</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">232,284</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">722,683</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(490,399</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(68</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B product revenue increased by $87.4 million for the year ended December 31, 2023 compared to the year ended December 31, 2022. Approximately $76.5 million of the increase was primarily due to higher volume driven by continued improvement in market share, particularly in the integrated delivery networks and retail segments, and growth in the U.S. hepatitis-B vaccine market related to the Advisory Committee on Immunization Practices ("ACIP") universal recommendation. Approximately $10.9 million of the increase was due to higher net sales price.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was no CpG 1018 adjuvant product revenue for the year ended December 31, 2023, as we completed all obligations and product delivery under our CpG 1018 adjuvant collaboration agreements as of December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As our CpG 1018 adjuvant customers have purchased a significant quantity of CpG 1018 adjuvant as part of their initial COVID-19 vaccine development inventory, we currently expect minimal to no CpG 1018 adjuvant revenue in 2024. Long-term demand for CpG 1018 adjuvant supporting COVID-19 vaccines will be highly dependent on each customer&#8217;s ability to commercialize in respective territories and geographies where their respective COVID-19 vaccine is approved for use.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other revenue primarily includes revenue from our agreement with the DoD. During the year ended December 31, 2023, we recognized $17.6 million of revenue from our agreement with the DoD. The increase in other revenue was primarily driven by the advancement into a nonhuman primate challenge study initiated in August 2023 combined with the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognition of $1.3 million license fee revenue on the achievement of a milestone in connection with a collaboration and license agreement with SIIPL.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Sales &#8211; Product</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of sales - product, consists primarily of raw materials, certain fill, finish and overhead costs, and any inventory adjustment charges for HEPLISAV-B and inventory costs to produce CpG 1018 adjuvant for our collaboration partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of our cost of sales - product (in thousands, except for percentages):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.76%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.8%;"/>
    <td style="width:1%;"/>
    <td style="width:11.76%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Decrease) from</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022 to 2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Cost of Sales - Product:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">HEPLISAV-B</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,167</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,131</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,036</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CpG 1018 adjuvant</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">222,022</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(222,022</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cost of sales - product</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,167</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">262,153</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(211,986</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(81</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B cost of sales-product increased by $10.0 million for the year ended December 31, 2023 compared to the year ended December 31, 2022. Approximately $20.0 million of the increase was primarily due to higher sales volume driven by continued improvement in HEPLISAV-B market share, offset by a decrease of $10.0 million due to lower per-unit manufacturing costs as the result of previous process improvements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was no CpG 1018 adjuvant cost of sales-product for the year ended December 31, 2023, as we satisfied all delivery obligations under our CpG 1018 adjuvant collaboration agreements as of December 31, 2022. In addition, CpG 1018 adjuvant cost of sales-product for the year ended December 31, 2022, includes certain one-time charges totaling approximately $45.4 million, comprising an inventory write-off of $34.3 million in connection with cancelled orders and the reduction in demand associated with the Clover Supply Agreement, as amended, and $11.1 million in charges related to certain non-refundable pre-payments made to one of our CMOs regarding certain raw materials costs that are not likely to be manufactured into finished goods inventory.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses are tracked on a program-by-program basis and consist primarily of costs incurred for the continued research and development of HEPLISAV-B and CpG 1018 adjuvant, clinical product candidates and preclinical studies, which include but are not limited to, compensation and related personnel costs (which include benefits, recruitment and travel costs), expenses incurred under agreements with contract research organizations, contract manufacturing organizations and service providers that assist in conducting clinical studies and costs associated with our preclinical activities, development activities and regulatory operations. We do not allocate stock-based compensation or facility expenses to specific programs because these costs are deployed across multiple programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of our research and development expenses (in thousands, except for percentages):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.55%;"/>
    <td style="width:1%;"/>
    <td style="width:9.178%;"/>
    <td style="width:1%;"/>
    <td style="width:1.92%;"/>
    <td style="width:1%;"/>
    <td style="width:9.178%;"/>
    <td style="width:1%;"/>
    <td style="width:1.92%;"/>
    <td style="width:1%;"/>
    <td style="width:9.178%;"/>
    <td style="width:1%;"/>
    <td style="width:1.44%;"/>
    <td style="width:1%;"/>
    <td style="width:9.638%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Decrease) from</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022 to 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Program Expenses:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">HEPLISAV-B development</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,486</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,973</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(487</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CpG 1018 adjuvant development</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,140</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,379</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(239</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tetanus, diphtheria, and acellular pertussis</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,620</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,994</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,374</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(26</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shingles</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,252</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,943</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">309</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Plague </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,319</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,065</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,254</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,210</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,421</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,789</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other Research and Development Expenses:</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facility costs</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,574</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,871</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">703</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash stock-based compensation</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,285</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,954</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,331</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,886</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,600</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,286</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1)  In September 2021, we entered into an agreement with the DoD for the development of a recombinant plague vaccine adjuvanted with CpG 1018. Under the agreement, we are conducting a Phase 2 clinical trial and studies combining our CpG 1018 adjuvant with the DoD's rF1V vaccine. We are being fully reimbursed by the DoD for the costs of this study, which is recorded in other revenue in our consolidated statements of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses increased by $8.3 million for the year ended December 31, 2023 compared to the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HEPLISAV-B development costs decreased due to lower clinical costs following the completion of the HEPLISAV-B dialysis study and lower other HEPLISAV-B related development costs. This was offset by a $1.1 million expense related to an engineering run performed for product testing purposes in 2023. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CpG 1018 adjuvant development costs decreased as supply agreements were fulfilled for our collaborators utilizing CpG 1018 adjuvant in 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shingles program costs increased as we completed activities related to the Phase 1 clinical trial, including presentation of study results at a medical conference in June 2023, and due to trial start up activities, including manufacturing of clinical materials to support the expected initiation of a Phase 1/2 clinical trial in the first half of 2024. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tdap costs decreased as we completed the Phase 1 clinical trial in early 2023, offset by an increase in activities to support initiation of a human challenge study expected in the second half of 2024.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Plague program costs increased compared to the previous year following our initiation of part 2 of the Phase 2 clinical trial in early 2023 and advancement into a nonhuman primate challenge study in August 2023.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other program costs increased as we continue to invest in product candidates utilizing our CpG 1018 adjuvant through discovery efforts and through preclinical and clinical collaborations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-cash stock-based compensation expense increased primarily due to the need for increased headcount to support the advancement of our clinical vaccine programs.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we continue to progress our clinical-stage pipeline, we expect research and development expenses to continue to represent a substantial portion of our expenses and to continue to increase, both in dollar amount and proportion of total expense, in future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling, General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling, general and administrative expenses consist primarily of compensation and related costs for our commercial support personnel, medical education professionals and personnel in executive and other administrative functions, including legal, finance and information technology; costs for outside services such as sales and marketing, post-marketing studies of HEPLISAV-B, accounting, commercial development, consulting, business development, investor relations and insurance; legal costs that include corporate and patent-related expenses; allocated facility costs and non-cash stock-based compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of our selling, general and administrative expenses (in thousands, except for percentages):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.132%;"/>
    <td style="width:1.52%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.52%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.52%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.06%;"/>
    <td style="width:1%;"/>
    <td style="width:7.420999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Decrease) from</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022 to 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Selling, General and Administrative:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation and related personnel costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,937</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,865</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,072</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outside services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,374</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,049</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,325</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Legal costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,981</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,223</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,758</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facility costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,585</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,153</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,568</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(29</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,069</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,118</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,951</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total selling, general and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">152,946</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,408</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,538</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling, general and administrative expenses increased by $21.5 million for the year ended December 31, 2023 compared to the year ended December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation and related personnel costs and non-cash stock-based compensation costs increased due to continued headcount and personnel investments in our general and administrative and field sales functions to support business growth and increased travel. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside services increased due to more targeted commercial and marketing efforts to increase market share and maximize the opportunities presented by the ACIP's universal recommendation.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal costs increased due to ongoing general legal activities supporting our continued growth and intellectual property activities supporting our clinical-stage pipeline.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Facility costs decreased due to lower rent expense, as one of our leases expired in 2022, and lower depreciation expense related to furniture and fixtures fully depreciated in 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-cash stock-based compensation expense increased primarily due to increased headcount of our field sales team.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our selling, general and administrative expenses to increase in future periods to support the overall growth in our business.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gain on Sale of Assets</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2020, we sold assets related to our immuno-oncology compound, SD-101, which included intellectual property, clinical and non-clinical data, regulatory filings, clinical supply inventory and certain contracts to Surefire Medical Inc. d/b/a TriSalus Life Sciences (&#8220;TriSalus&#8221;). Pursuant to the Asset Purchase Agreement, we received $5.0 million upon closing of the transaction and $4.0 million in December 2020 as reimbursement for certain clinical trial expenses. In addition, we could receive up to an additional $250.0 million upon the achievement of certain development, regulatory, and commercial milestones and low double-digit royalties based on potential future net sales of product containing SD-101 compound.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In each of September 2023 and May 2022, we received payment of $1.0 million from TriSalus because it met a pre-commercialization milestone. In each of the third quarter of 2023 and second quarter of 2022, we recognized a gain on sale of SD-101 assets of $1.0 million in our consolidated statements of operations.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bad Debt Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recorded $12.3 million of bad debt expense during the year ended December 31, 2023 in connection with the allowance for doubtful accounts of $12.3 million recorded with respect to outstanding accounts receivable from Bio E and relating to CpG 1018 Materials delivered under the Bio E Supply Agreement and CEPI Agreement. The allowance for doubtful accounts was determined by assessing changes in Bio E&#8217;s credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3, and Bio E's dependence on cash collections from the Government of India, which have been delayed significantly by the Government of India.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income is reported net of amortization of premiums and discounts on marketable securities and includes realized gains on investments. Interest expense includes the stated interest and accretion of discount of our Convertible Notes. Sublease income is recognized in connection with our sublease of office and laboratory space. Change in fair value of warrant liability reflects the changes in fair value of warrants issued in connection with equity financing in August 2019.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of our other income (expense) (in thousands, except for percentages):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.76%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.8%;"/>
    <td style="width:1%;"/>
    <td style="width:11.76%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Decrease) from</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022 to 2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,993</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,912</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,081</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">304</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,757</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,732</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,577</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,685</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(108</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,801</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,801</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(152</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(263</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(237</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income increased due to higher yields and balances in our marketable securities portfolio.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The change in the fair value of warrant liability resulted primarily from the warrants, which expired in February 2022. There were no warrants outstanding as of December 31, 2023. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The change in other is primarily due to foreign currency transactions and related fluctuations in the value of the Euro compared to the U.S. dollar. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our income tax expense and effective income tax rate were as follows (in thousands, except for percentages):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.76%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:2.28%;"/>
    <td style="width:1%;"/>
    <td style="width:11.280000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.8%;"/>
    <td style="width:1%;"/>
    <td style="width:11.76%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Decrease) from</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022 to 2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,022</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,143</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">879</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(46.3</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense increased by $0.9 million for the year ended December 31, 2023 compared to the year ended December 31, 2022. Our income tax expense of $2.0 million and $1.1 million for the years ended December 31, 2023 and 2022 which is primarily comprised of state and foreign income tax expense. Our effective tax rate for the year ended December 31, 2023 was (46.3)%, which is primarily comprised of state and foreign income tax expense.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had $742.3 million in cash and cash equivalents, and marketable securities. Since our inception, we have relied primarily on the proceeds from public and private sales of our equity securities, borrowings, government grants and revenues from product sales and collaboration agreements to fund our operations. Our funds are currently invested in money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We currently anticipate that our cash and cash equivalents, and short-term marketable securities as of December 31, 2023, and anticipated revenues from HEPLISAV-B will be sufficient to fund our operations for at least the next 12 months from the date of this filing and in the longer term.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advanced payments received from CEPI to reserve a specified quantity of CpG 1018 adjuvant are initially accounted for as long-term deferred revenue. When we deliver CpG 1018 adjuvant to CEPI partner(s) or when we receive payment from CEPI partner(s), we reclassify the advanced payments from long-term deferred revenue to accrued liabilities. As of December 31, 2023, we had no CEPI-related net accounts receivable relating to Bio E. CEPI-related accruals and contract assets relating to Clover totaled $60.3 million and $71.3 million as of December 31, 2023, respectively. As of December 31, 2023, the CEPI-related accrual relating to Clover may be repaid using cash to be collected from Clover or forgiven in accordance with the CEPI Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 26, 2023, we entered into the Bio E Amendment No. 3, and on April 27, 2023, we entered into the CEPI-Bio E Assignment Agreement. Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of remaining amounts outstanding relating to the Bio E CEPI Advance Payments for CpG 1018 Materials allocated to Bio E and has assumed our previous rights to collect $47.4 million of Bio E accounts receivable. The CEPI-Bio E Assignment Agreement resulted in no accounts receivable balance from Bio E. Pursuant to the Bio E Amendment No. 3, we collected $13.5 million from Bio E in April 2023 and subsequently collected the remaining $1.0 million in August 2023. The Bio E Amendment No. 3 provides for additional future payment of either $5.5 million in the event that Bio E receives at least $125.0 million, or $12.3 million in the event that Bio E receives at least $250.0 million in future payments from the Government of India associated with its CORBEVAX product on or before August 15, 2025. These additional amounts are not considered collectible until the achievement of these future milestones.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the aggregate principal amount of our Convertible Notes was $225.5 million, excluding debt discount of $2.8 million. The Convertible Notes bear interest at a rate of 2.50% per year, payable semiannually in arrears on May 15 and November 15 of each year. The Convertible Notes mature on May 15, 2026, unless converted, redeemed or repurchased in accordance with their terms prior to such date. See Note 10 &#8211; Convertible Notes, in the accompanying notes to the consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We entered into an at-the-market Sales Agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;) on August 6, 2020 and an amendment to such agreement on August 3, 2023 (the sales agreement as amended, the &#8220;ATM Agreement&#8221;). Under the ATM Agreement, we may offer and sell from time to time, at our sole discretion, shares of our common stock having an aggregate offering price of up to $120.0 million through Cowen as our sales agent. We agreed to pay Cowen a commission of up to 3% of the gross sales proceeds of any common stock sold through Cowen under the ATM Agreement. As of December 31, 2023, we had approximately $120.0 million remaining under the ATM Agreement.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to January 1, 2021, we incurred net losses in each year since our inception. For the year ended December 31, 2023, we recorded a net loss of $6.4 million. For the year ended December 31, 2022, we recorded a net income of $293.2 million. We cannot be certain that sales of our products, and the revenue from our other activities will be sustainable. Further, we expect to continue to incur substantial expenses as we continue investing in commercialization of HEPLISAV-B, advancing our research and development pipeline, and investing in clinical trials and other development. If we cannot generate a sufficient amount of revenue from product sales, we will need to finance our operations through strategic alliance and licensing arrangements and/or future public or private debt and equity financings. Raising additional funds through the issuance of equity or debt securities could result in dilution to our existing stockholders, increased fixed interest payment obligations, or both. In addition, these securities may have rights senior to those of our common stock and could include covenants that would restrict our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common stock, which itself is subject to a number of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us or at all. In addition, our ability to raise additional funds may be adversely impacted by deteriorating global economic conditions and the recent or future disruptions to and volatility in the credit and financial markets in the United States and worldwide. Adequate financing may not be available to us on acceptable terms, or at all. If adequate funds are not available when needed, we may need to significantly reduce our operations while we seek strategic alternatives, which could have an adverse impact on our ability to achieve our intended business objectives.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, we generated $100.6 million of cash from our operations, which consisted of a net loss of $6.4 million, a $46.7 million of net adjustments from non-cash items, which included stock-based compensation, depreciation and amortization, amortization of right-of-use assets, non-cash interest expense, accretion of discounts on marketable securities and bad debt expense, and approximately $61.2 million net changes from operating assets and liabilities, which included a decrease of $43.3 million in accounts and other receivables, net and an increase of $19.8 million in accrued and other liabilities. By comparison, during the year ended December 31, 2022, we generated $62.7 million of cash from our operations, which consisted of our net income of $293.2 million, a $69.0 million of net adjustments from non-cash items, which included stock-based compensation, change in fair value of warrant liability, non-cash interest expense, depreciation and amortization, amortization of right-of-use assets, accretion of discount on marketable securities and inventory write-off, and approximately $298.4 million net changes from operating assets and liabilities, which included $349.9 million decrease in deferred revenue due to the fulfillment of our obligations to deliver CpG 1018 adjuvant to our collaboration partners, $24.8 million decrease in accrued liabilities and other liabilities, $159.7 million decrease in prepaid manufacturing, which converted into CpG 1018 adjuvant inventory during 2022, $32.4 million increase in inventories and $21.1 million decrease in CEPI accrual. Overall, cash provided by our operations during the year ended December 31, 2023 increased by $37.8 million compared to the same period in December 31, 2022. Net cash provided by operating activities is also impacted by changes in our operating assets and liabilities due to timing of cash receipts and expenditures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, net cash used in investing activities was $153.9 million compared to $316.0 million of cash used in investing activities for the year ended December 31, 2022. Cash used in investing activities during the year ended December 31, 2023 included $150.8 million of net purchases of marketable securities compared to $309.9 million of net purchases of marketable securities for the year ended December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, net cash provided by financing activities was $1.4 million. During the year ended December 31, 2022, net cash provided by financing activities was $19.5 million. Cash used in financing activities for the year ended December 31, 2023 included $6.5 million for the payments of taxes related to net share settlement of restricted stock units ("RSUs"), partially offset by proceeds received from the exercise of options and from share purchases under our employee stock purchase plan for $7.9 million combined. Cash provided by financing activities for the year ended December 31, 2022 included proceeds of $8.5 million from warrants exercised, and proceeds of $11.1 million from the exercise of stock options and employee stock purchase plan.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contractual Obligations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We lease our facilities in Emeryville, California and D&#252;sseldorf, Germany. We lease and sublease certain manufacturing and office space with lease terms ranging from 3 to 12 years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at our election to renew or extend the lease for two successive five-year terms. These optional periods have not been considered in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the determination of the Right-of-use (&#8220;ROU&#8221;) assets or lease liabilities associated with these leases as we did not consider the exercise of these options to be reasonably certain.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also sublease one of our leased premises to a third party. Rent is subject to scheduled annual increases and the subtenant is responsible for certain operating expenses and taxes throughout the life of the sublease. The sublease term expires on March 31, 2031, unless earlier terminated, concurrent with the term of our lease. The subtenant has no option to extend the sublease term. Sublease income was $7.6 million, $7.7 million and $7.7 million for the years ended December 31, 2023, 2022 and 2021, respectively. Sublease income is included in other income (expense) in our consolidated statements of operations. Rent received from the subtenant in excess of rent paid to the landlord is shared by paying the landlord 50% of the excess rent. The excess rent is considered a variable lease payment and the total estimated payments are being recognized as additional rent expense on a straight-line basis.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, we issued $200.0 million aggregate principal amount of 2.50% convertible senior notes due 2026 in a private placement. The purchasers also partially exercised their option to purchase additional Convertible Notes in May 2021 and we issued an additional $25.5 million of the Convertible Notes. As of December 31, 2023, the aggregate principal amount of our Convertible Notes was $225.5 million, excluding debt discount of $2.8 million. The Convertible Notes bear interest at a rate of 2.50% per year, payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2021. The Convertible Notes mature on May 15, 2026, unless converted, redeemed or repurchased in accordance with their terms prior to such date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, we repaid the principal on the term loans (the "Term Loans") under the term loan agreement (&#8220;Loan Agreement&#8221;) with CRG Servicing LLC in full. With the full repayment of the Term Loans, all security interests, covenants, liens and encumbrances under the Loan Agreement were permanently released.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into material purchase commitments with commercial manufacturers for the supply of HEPLISAV-B. In November 2013, we entered into a Commercial Manufacturing and Supply Agreement with Baxter Pharmaceutical Solutions LLC (&#8220;Baxter&#8221;) that was amended in September 2021 (as amended, the &#8220;Baxter Agreement&#8221;). Baxter provides formulation, fill and finish services and produces HEPLISAV-B for commercial use. Pursuant to the Baxter Agreement, we are obligated to purchase an annual minimum number of batches of HEPLISAV-B through December 31, 2026, and there are certain limits on the number of batches that Baxter is required to produce. As of December 31, 2023, our aggregate minimum commitment under the Baxter Agreement was $11.4 million within the next 12 months, and $24.5 million beyond the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 7, 2023 (the &#8220;Effective Date&#8221;), we entered into an agreement (the &#8220;Avecia Supply Agreement&#8221;) with Nitto Denko Avecia Inc. (&#8220;Avecia&#8221;) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the &#8220;2012 Agreement&#8221;). As of December 31, 2023, our aggregate minimum commitment for the supply of CpG 1018 adjuvant under the Avecia Supply Agreement was $7.4 million for the 12 months following December 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the non-cancelable commitments noted above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely on and have entered into agreements with research institutions, contract research organizations and clinical investigators as well as clinical material manufacturers. These agreements are typically terminable by us upon reasonable written notice. Generally, we are only obligated to pay for actual time spent and materials consumed by the organizations at any point in time during the contract through the notice period.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In conjunction with our agreement with Symphony Dynamo, Inc. and Symphony Dynamo Holdings LLC (&#8220;Holdings&#8221;) in November 2009, we agreed to make contingent cash payments to Holdings equal to 50% of the first $50 million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any third party with respect to the development and/or commercialization of cancer and hepatitis C therapies originally licensed to Symphony Dynamo, Inc., including our immune-oncology compound, SD-101. In July 2020, we sold assets related to SD-101 to Surefire Medical, Inc. d/b/a TriSalus Life Sciences (&#8220;TriSalus&#8221;). We paid $2.5 million to Holdings in August 2020. In each of September 2021, May 2022 and September 2023, we received $1.0 million from TriSalus because it met pre-commercialization milestones. We recorded the proceeds as gain on sale of assets in our consolidated statements of operations. We paid Holdings $0.5 million in each of September 2021, May 2022 and October 2023. We included the payments in selling, general and administrative expenses in our consolidated statements of operations. No liability has been recorded under this agreement as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 7A. QUANTITATIVE </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quantitative and Qualitative Disclosure about Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to interest rate risk. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The primary objective of our investment activities is to preserve principal and, secondarily, to maximize income we receive from our investments without significantly increasing risk. Some of the securities that we invest in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, we maintain our portfolio of cash equivalents and investments in highly liquid investments in money market funds, U.S. government agency securities, U.S. treasuries and corporate debt securities. We do not invest in auction rate securities or securities collateralized by home mortgages, mortgage bank debt or home equity loans. We do not have derivative financial instruments in our investment portfolio. To assess our risk, we calculate that if interest rates were to rise or fall from current levels by 100 basis points or by 125 basis points, the pro forma change in fair value of investments would be $7.0 million or $9.0 million as of December 31, 2023, compared to $4.1 million or $5.1 million as of December 31, 2022, respectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the short duration and nature of our cash equivalents and marketable securities, as well as our intention to hold the investments to maturity, we do not expect any material loss with respect to our investment portfolio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have certain investments outside the U.S. for the operations of Dynavax GmbH, Dynavax India LLP, and a branch of Dynavax registered in Italy, with exposure to foreign exchange rate fluctuations. The cumulative translation adjustment reported in the consolidated balance sheet as of December 31, 2023 and 2022 was a $3.0 million and $4.0 million loss, respectively, primarily related to the translation of Dynavax GmbH assets, liabilities and operating results from Euros to U.S. dollars. As of December 31, 2023 and 2022, the effect of our exposure to these exchange rate fluctuations has not been material, and we do not expect it to become material in the foreseeable future. We do not hedge our foreign currency exposures and have not used derivative financial instruments for speculation or trading purposes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 8. FINANCIAL STAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EMENTS AND SUPPLEMENTARY DATA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:91%;"/>
    <td style="width:1%;"/>
    <td style="width:8%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page No.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span><ix:nonNumeric id="F_a9fe1da1-fb1d-4652-b165-59a7244ac624" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Consolidated Financial Statements:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><a href="#consolidated_statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><a href="#statements_of_comprehensive_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Comprehensive (Loss) Income</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><a href="#statements_of_stockholders"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><a href="#statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><a href="#notes_to_consolidated_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="report_of_independent_registered"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Ind</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ependent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Dynavax Technologies Corporation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Dynavax Technologies Corporation (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive (loss) income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 22, 2024 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:1.204%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.097%;"/>
    <td style="width:2.719%;"/>
    <td style="width:83.183%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Reserves for returns on product revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">During the year ended December 31, 2023, the Company&#8217;s net product revenues for HEPLISAV-B were $213.3 million. As explained in Note 2 of the consolidated financial statements, revenue from product sales includes estimates of variable consideration for which reserves are established, including reserves for product returns.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditing the Company&#8217;s measurement of reserves for HEPLISAV-B product returns under its contracts with wholesalers and specialty distributors (collectively, &#8220;Customers&#8221;) was challenging because (1) the calculation involves management assumptions about inventory remaining in the distribution channel (i.e., units held by Customers) as of the balance sheet date that could be subject to return in future periods under the Company&#8217;s returns policy, and (2) the Company has limited returns history on which to base its assumptions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:1.204%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.097%;"/>
    <td style="width:2.719%;"/>
    <td style="width:83.183%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls that identified risks related to the Company&#8217;s process used to determine reserves for returns on product revenue. For example, we tested controls over management&#8217;s review of the completeness and accuracy of the data used in the process and the assumptions about Customers&#8217; units in the channel as of the balance sheet date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">To test the Company&#8217;s reserves for returns on product revenue, our audit procedures included, among other procedures, testing the accuracy and completeness of the underlying data used in the calculations and evaluating the assumptions used by management to estimate its reserves. To test management&#8217;s assumptions, we inspected agreements with significant Customers to validate the rights of return policy, obtained written representations from members of the commercial and market access functions regarding changes to the terms and conditions reported to the legal and accounting departments, examined credit memos issued during and after year end for unusual items or trends not consistent with the Company&#8217;s analysis of product returns, performed revenue cutoff testing at period end to assess whether there were unusual trends that should have been considered in the Company analysis of product returns and compared the shipment reports to Customers sell through information to assess the extent of inventory in the distribution channel. We also performed sensitivity analyses over the Company&#8217;s return rate to assess the effect of changes in assumptions.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company's auditor since 2002.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Francisco, California</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 22, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DYNAVAX TECHNOLOGIES CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ED BALANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.673%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:12.923%;"/>
    <td style="width:1%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:12.923%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db113578-e79e-4d32-945a-c537f1823e6a" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,279</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa9aec73-0234-4ed3-8a9f-aa2fcf90cc6e" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,004</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities available-for-sale</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8840f5b8-bbbb-422f-91c5-3f28bf76016e" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">592,023</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1f560a7-2481-4f3e-8e22-9de77f676a73" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">422,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivables, net of allowance for doubtful accounts of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d380b0a3-4f46-4631-8380-46b26e843b0d" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,313</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e4a26bd-ae1b-4909-963b-8344f4a5cc05" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;at December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69474df5-3821-4c48-96ed-2c0f86553899" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,607</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4ea4ad1-f214-4083-bda0-af080c1edc02" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,130</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f01176c-0c5b-4dd2-adc4-d8da2a6159f1" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,926</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a077a45-e15c-4ee9-97ad-9d221fdbfcc3" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,385</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfbff718-5a0c-4e0f-9bf4-1cc27cb4498f" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,290</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ae03704-a2fc-4e1d-9c5c-f3dd616aefbd" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,446</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb984053-f9b6-446e-8644-3d357c3f4bd0" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,995</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_738178f7-bc10-4a5d-839f-7a196b603372" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef593e6a-a5e7-4fbc-8437-8f80ee5bc9db" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">859,120</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6677ec1a-d7eb-4d85-b983-fb6787cace11" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">916,985</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_238bf37c-9f28-4209-92c4-a89aaa7e3f07" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,297</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_643a2275-b65f-49d8-a67b-3b081f27e6ad" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,596</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef6e9759-c148-4d5e-ad97-10001c7cf170" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,287</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed812de2-31a9-46a1-9c6e-02d6f3373c34" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,745</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1be834c-9184-4602-9073-6b83b789e205" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,067</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f52306a-0432-4cf8-bc44-8146bce60fe6" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,006</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets (Note 9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a1d4bee-61a8-464e-9bc3-ec272d2fd8dc" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,325</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_164a8eb9-c3f3-4034-afa7-27ccea71eafa" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,518</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90da2919-3c3e-41fb-9009-7e3cf4087150" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">997,096</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45ff681f-7933-49a4-9a21-6f325ce734de" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">985,850</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4d5dbb1-49b7-412b-8ee2-7cba8e493627" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,245</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b2db2ad-86de-4286-9b0e-9ed9cd1f2771" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03d7afcf-a032-4112-be4a-3c646e0ce110" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,982</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8eba079-2fde-4889-8a87-281b74f50042" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,775</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CEPI accrual (Note 9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fc5b422-1df1-4116-8246-79a38c10c676" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:CoalitionForEpidemicPreparednessInnovationsAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd2c8fee-d695-4d73-a176-c5c961a88aed" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:CoalitionForEpidemicPreparednessInnovationsAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,738</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities (Note 7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2198aa33-e0c7-4958-a7de-956ee2ed3c40" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,448</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_652d5904-a2ca-4265-92c7-c24fee09f9c3" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,719</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e2ee94f-8b21-4082-9fe3-af10b3d72ffe" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,520</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c47801f-8623-4067-8b1e-f86fa765b08f" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,631</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a4f2a2d-cfb4-431f-8230-8cefb3f34c5a" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,195</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8361bbe1-ee95-4990-bd31-c05aef7ba6b0" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Notes, net of debt discount of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9d38e49-a2a4-4da4-b395-76e763c1fe1b" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,802</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_520471a4-3919-44dd-88f2-3e6495a3d385" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,922</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;at December 31,<br/>&#160;&#160;&#160;2023 and December 31, 2022, respectively (Note 10)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a39dc4db-f800-4ff7-96c4-be061605bced" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ConvertibleNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,698</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f362f45b-5f1c-4c8c-8147-ef5f8236a51e" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:ConvertibleNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,578</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term portion of lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5abf1700-252b-419f-b185-d8ab27344c1f" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,720</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_050b775e-4c45-4fac-8d80-0f1d6cc2268f" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CEPI accrual long-term (Note 9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ab04638-2233-4383-b4e3-2810482102b8" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:CepiAccrualLongTerm" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,337</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adc9ad9c-fe12-4821-a978-ce6b28350905" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:CepiAccrualLongTerm" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f52f9a0c-280a-4fa7-b35f-43bec244fd60" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_959e3550-9cb4-46d8-8485-5f74793a1a3d" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d65289d-eb1e-457b-b954-a835ae95e59e" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375,024</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5bdaef5-234c-4fd0-8a53-d3c3fc0abd21" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_3031d482-7693-42b9-bd85-bcbc62b2bbaa;"><span style="-sec-ix-hidden:F_f9326331-0510-474c-8729-f02e4262a88e;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 8)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock: $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e697531-46b5-45b1-b024-0abd5f1fa986" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3ae02837-4c01-4659-8aca-c9d46ab83776" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e47e4693-2d5c-42ad-962b-1e9cac61a971" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3bac5ac5-bf96-4777-8269-837d6f259847" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized at December 31,<br/>&#160;&#160;&#160;2023, and 2022; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea8697c0-fab9-415d-b808-3fe0f53f9cba" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7381862f-f1eb-444a-8069-fd48f875fb8e" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares outstanding at December 31, 2023 and 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de58c35d-d303-4e0b-9a1a-ef38eedb686e" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed3124e9-62dc-4a2f-8d48-fd2bd75748c9" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock: $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_252820cb-61d6-4273-94bb-9a75adafb4bd" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ffb9293f-6b9c-4562-99a0-5e996923ce50" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_163250c2-9d3d-410d-91bb-81bb833accf6" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a181e8fa-a549-43a4-ae50-a38fce3ea046" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">278,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized at December 31,<br/>&#160;&#160;&#160;2023 and 2022; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94c4a4c3-196d-4bae-b656-4da791af67b8" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5b0dffdf-e292-409f-8ec5-70a6ea4caa77" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,530</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08d4118d-9640-494f-9ee0-d235eaf599b4" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ea8283c3-7037-48a0-b7b5-c8cd6180d959" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">127,604</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at<br/>&#160;&#160;&#160;December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2aab72ba-4970-4949-9194-5943eaae0630" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5cdf9a6-07e5-4336-a22f-5d4731bf1730" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_812cefbd-1c49-48f3-b5a1-6e1a91443b10" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,554,634</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d557c4d6-c69f-4c96-b444-b98541aa1623" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,510,518</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d60096f0-2770-4792-8ad2-8fdc39c53a09" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,108</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4389851a-de0b-4218-a7ac-8a91337328d4" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,438</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47232dd1-5bae-4435-9da2-0d72464a8fe5" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">930,584</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1f97a25-4c97-4eaf-bb4e-1fa40ad4e83f" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">924,195</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0c04f05-7f32-46dc-8f0a-5d961c0c9859" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">622,072</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d29a54a-458c-4915-bc5e-348029d12f52" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">581,013</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_621043b9-d1eb-44a0-9fea-43aa83c76118" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">997,096</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6670c5cd-70ce-4f04-a8e5-36c8557c9977" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">985,850</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DYNAVAX TECHNOLOGIES CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ED STATEMENTS OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Product revenue, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_380e2d8d-40f3-464a-880f-be29ce93008d" contextRef="C_e9ba0f50-bcbf-42ff-bb4d-52d504f7633c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,295</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80c6fbaa-38a3-48a1-8ff8-5b3e1dacf633" contextRef="C_dfe1bbb8-9cb8-4010-b417-57ad46abca6f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">713,645</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7503cd6c-ee92-48ce-9ab7-096fb0c5e1e8" contextRef="C_6423ea24-b03e-48e6-addc-0d0d41661afc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">437,099</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_379356a2-74e6-4c44-8aff-cf68fb24d97a" contextRef="C_ce1c0cc3-d217-4341-a89c-76cd4302ac34" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,989</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_979dba1a-62ef-4845-bd7f-ee467f5cb310" contextRef="C_600e9b74-60a6-45e3-9267-97174756699a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97f60a4b-4d0c-4aab-bb2c-d67d5ead95ff" contextRef="C_e638b00f-55b0-4873-beaa-4bf842f5fdd2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,343</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenues</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e61904c-f7a1-42cb-9d8b-e3e80fe53f4b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">232,284</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebc5a7c2-38ec-44c1-9604-9042d58b3bf9" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722,683</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2027afd0-9935-4dd0-9b7c-00b4759f316b" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,442</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales - product</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39bf8c4c-03a3-4c30-9491-a7cb181c5b6a" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,167</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b9e0622-1277-49dc-a990-dbd954b03709" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a254a02b-a5cb-4204-96d9-83bbf2c270d0" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d2aa332-fce4-43d8-bcbe-f717886e481b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,886</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7a6f405-bde1-4d5d-a6fb-7a120566e049" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,600</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00f16f20-0204-4e40-a4d4-e3d3b11039fc" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,228</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca2d88bb-8b5c-4ef5-9dfa-3eaf4af310ef" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,946</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f009e8a-36f4-4adb-99df-2b62b6a2687d" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,408</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa1cc8ba-bdfe-4ab7-bfdb-40636ca63489" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gain on sale of assets (Note 8)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1bdf656-01e3-443b-9a09-0ac069f16324" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:GainsLossesOnSalesOfAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e9a5f25-718a-4b5d-ad99-ed22d5f46cd1" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:GainsLossesOnSalesOfAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d4c56da-d8ec-473e-b2aa-b18e0c03f362" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:GainsLossesOnSalesOfAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bad debt expense (Note 9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfdad6e4-1ba7-4403-8520-451dcc7cc9be" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:BadDebtExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,313</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8abeee8-ef91-4f2b-95e6-cca7a505698d" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:BadDebtExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c4ff06c-f07a-45df-9afc-073c2f6d038e" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:BadDebtExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e3098ee-d195-4bd9-adfc-09ad1f4dc73d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269,312</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0107e57a-4f1d-4925-a00e-959aa1e8bf0f" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,161</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70cfebfc-ebd4-4855-980d-5d597ad481d7" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Loss) income from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8867a762-739c-4bb1-b777-74e9ccccb9dd" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,028</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e8734d9-e55b-4998-b053-59fe6f2fc0ba" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">283,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb2d8cf3-1bef-4218-afb2-0544701ce2a4" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,486</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other (expense) income:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0392e7c8-11a9-45b0-88f1-2f47b4d7d476" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,993</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6956b99e-3bb7-4b10-b994-389c9bb42310" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,912</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b5c1fbf-af85-444d-8abe-e4a125423cf3" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15d8df44-d3d0-4aab-86bd-0a7e90f966e6" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,757</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28c26f63-e3cc-457c-bd38-5bd7bd42f899" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,732</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b85fcf9c-ed41-4ea7-8e06-aada4abf2563" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,176</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4801a38-fd43-4612-a074-36c634e7b752" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,577</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_213fc923-cc90-46cc-9932-8b70efa111be" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,685</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e6526e0-de8d-48ca-ae07-7b30bc481d9b" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,735</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on debt extinguishment (Note 11)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_035ed737-b2e6-4d62-ab36-5fdf36426b4b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb0c7af1-52f3-48b3-8601-c6fad479de8f" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a820a77b-78d4-445e-9eb0-b1cd124bb8e5" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,232</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability (Note 14)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_483c1ea8-dca8-4cba-9438-00833d74cb73" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_567e1c02-20a5-4916-a3dc-553706e375bd" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3017db99-b49e-4491-9b19-6658f13e1f82" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,354</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40221923-6d7c-41d7-a1e7-55e8f4268ecb" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">152</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79cf62f0-a678-4be7-a090-7d2fe284fda8" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06fbbbe6-a843-4090-8701-4f0d982eff76" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">922</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb9919e6-3f14-4ef7-97e5-f54c865c89e0" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,367</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a509523-a4ef-4297-8241-0919de3a554d" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294,299</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f05afaaa-c8f0-4a5a-a492-e6a684bd6498" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,521</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9ef3492-778b-42cd-ad33-b2b32071b082" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,022</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db6f43e5-4fde-4344-be8e-e144654d3152" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,143</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57aca8a7-679f-4e79-8c86-55c05f966b82" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">808</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f1c5274-3bea-4e05-9e3f-f7d14c99247c" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a779a901-9c76-4685-9198-cfc471130949" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cc8c878-1ada-4689-a2b0-93e1a18a374a" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,713</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Undistributed earnings allocated to participating securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1026a715-b2fe-4da0-9654-462ba7469f3a" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:UndistributedEarningsAllocatedToParticipatingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d991df7d-fe32-4381-94cd-93b0a06a4bf9" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:UndistributedEarningsAllocatedToParticipatingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">283</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b503a36f-1c16-4977-a166-0378fdc753d5" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:UndistributedEarningsAllocatedToParticipatingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,569</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income allocable to common stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_953a39b9-d5b7-41d9-8a8c-601ec50e4459" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30273a2a-a901-4ad7-a642-506503d279fa" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,873</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c8152c2-9276-42ac-afce-428569c78688" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,144</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income per share allocable to common stockholders</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b05230f8-ef42-4d99-b132-1d69b3771dd2" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.05</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae3b7fd4-f33c-4ae4-93ea-bb764a683e9a" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.32</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ed45e57-67be-4a42-a486-9b0f6b3c2faf" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.62</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c6a9e67-0aab-4969-887a-e5aa3195e71e" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.05</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ba2c86d-c20f-45c1-b553-28f406e95110" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.97</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c35a32d-2249-4dc3-8ec9-e32b0667a99a" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.57</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net (loss) income per share<br/>&#160;&#160;&#160;allocable to common stockholders:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76f43863-8542-4d7c-8df3-9da12ab32924" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">128,733</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4e77704-71cc-4bb0-be44-285f02b7993a" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,398</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_529729b9-23a9-460a-bf03-e52a18e3d1d1" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fc5a8e5-0ce1-46c4-989b-d712e0f60bb6" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">128,733</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddf99fed-2c97-47a7-9275-67b2f340ffaf" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97931827-3c15-45c6-8b6d-ea64d2ddc630" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,006</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_comprehensive_income"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F COMPREHENSIVE (LOSS) INCOME</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffa0c4a3-bfb9-4097-9874-20253c08f35b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8c9a9f8-57db-4a45-b289-55d692f81b88" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e0f5dee-97a0-4e4b-bf2f-86200c326209" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,713</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income (loss), net of tax:</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in unrealized loss on marketable securities available-for-sale</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2189e9d-df45-4018-8b61-2232e0d90c40" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b3e9ad8-3852-4e99-a71a-984bb589ea95" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,407</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_185dee78-c80a-405e-9b3e-a9a0f4d8eada" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cumulative foreign currency translation adjustments</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a572116-ec24-4e62-b686-b6455d78ba71" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,079</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0d38dce-defd-4aad-85bb-5a4854842d8a" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,765</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1db3968-3cd9-4b32-ba08-9bfd750b95a5" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,509</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other comprehensive income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8603efc-4e7a-45a9-bd8d-44eaf1547995" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,330</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67270217-e213-4e69-96d2-7caf870b8c12" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c21373c7-adaf-40b8-8dcb-f72eecc46df7" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,539</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total comprehensive (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_412d9564-f1f8-44a3-bbb2-cff66ae30fbd" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77901f21-98c7-4758-927d-673d86ed9e94" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,984</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b4f6712-f7dd-41f1-b0cb-0ca6046b560c" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,174</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DYNAVAX TECHNOLOGIES CORPORATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_stockholders"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F STOCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.604%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.161%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.281%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.161%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.661%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.181%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.922%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.121%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.902%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Par Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Par Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In<br/>Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders'<br/>Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balances at December 31, 2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2339adf-5230-4911-a7a3-c7a3d8c08185" contextRef="C_60a06249-5799-4cae-8123-c33c744ecedc" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">110,190</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca0e8d9e-f1c2-41bc-b9a5-79f08d293717" contextRef="C_60a06249-5799-4cae-8123-c33c744ecedc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a28bf2b3-8575-46e2-b29a-64de51b4273c" contextRef="C_1b2ac57c-b971-472c-8ad3-2eb87f03dd71" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd1e2bd2-d4b2-47bb-971b-5eb889739799" contextRef="C_1b2ac57c-b971-472c-8ad3-2eb87f03dd71" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fa31524-c0a0-4fbf-b0e7-39601c799bfd" contextRef="C_e60f6c41-5373-4982-bda4-495d22ef947a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,352,374</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a8ecb5c-151f-41b2-93e6-8909914397a6" contextRef="C_e889c2ed-7138-45fb-adce-a5dc91946a89" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b540deb-aa61-4ebb-9cd4-deea762fda8a" contextRef="C_8c5e6277-2512-4769-b1e2-9247324bb9ea" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,294,064</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebdc760a-1cda-4d8b-b116-6a4cc35175ab" contextRef="C_d6a1605d-0ed8-4293-af91-e392daff1469" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,693</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of preferred stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64f5fba6-9cf9-44f0-80a0-164ac5a672a7" contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">4,140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bce71dcd-9edb-4a3f-a3d5-94871f58d246" contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c055d85e-6436-4022-b7b0-68d5d4584ae6" contextRef="C_22fa84c0-ee5b-418a-bab8-0db6e2ecbd21" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="3" decimals="INF" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce462c6a-7607-4f45-87bd-bff5ab5e7448" contextRef="C_22fa84c0-ee5b-418a-bab8-0db6e2ecbd21" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b55096c-3106-4235-a3d0-8be54922b231" contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30d54d71-9eda-44b4-9c54-36a05fc2217e" contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptionsShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,035</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8245ee0d-b08d-44f4-aa71-c57dd29f5297" contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b17499d2-ca68-4bb1-86cd-ce8105ac18a3" contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49dced53-1c2a-4a3f-861c-7cdb87c3cc18" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon release of restricted stock awards</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f812493-2bcf-4d17-9db3-c3ac174abf46" contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a" name="dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">525</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b60c51a-4463-4796-bcc2-f20357afed01" contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff" name="dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f253975-74c1-4260-900f-c1ab1fb17e49" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under Employee Stock Purchase Plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c95ecc5-1904-4890-8a5a-ff6ed664a220" contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_571e1718-6752-424b-9889-9bfde13e7db1" contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2cec085-2ace-4ba7-9278-002a70d50b42" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc07fcbb-1e5b-4695-a8ae-6fc8b9a1e252" contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a" name="dvax:IssuanceOfCommonStockUponExerciseOfWarrantsShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">3,959</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57edcb99-df05-4201-a94f-4296f67c7adf" contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a" name="dvax:IssuanceOfCommonStockUponExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1dafc69-4303-4138-8560-a96470df8594" contextRef="C_22fa84c0-ee5b-418a-bab8-0db6e2ecbd21" name="dvax:IssuanceOfCommonStockUponExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3692b57-763d-49de-b69c-11cd1965caf7" contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff" name="dvax:IssuanceOfCommonStockUponExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,884</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fca0ad8-9966-4fc1-82a2-73257cdba45a" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IssuanceOfCommonStockUponExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,888</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net of issuance costs, in conjunction<br/>&#160;&#160;&#160;with an At Market Sales Agreement (Note 14)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_664f165e-2092-406f-881d-94fb409a847f" contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a" name="dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">2,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a65085d-7f1d-40bd-bc56-a4453f001912" contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a" name="dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56b21f12-9418-4d52-b8ba-ce18ac531cbc" contextRef="C_22fa84c0-ee5b-418a-bab8-0db6e2ecbd21" name="dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb7b3e59-ccb1-4503-8da8-47bd1977d7a4" contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff" name="dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b98c2ad1-4af6-4df9-b3e3-a7d4b565ad2b" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of capped call options (Note 10)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c94cfa5-f192-4e29-aec7-88471059661c" contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff" name="dvax:IssuanceOfCappedCallOptionsSeeNote10" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,240</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8a7ab97-0aa1-46c9-8a1d-add7be162cfa" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IssuanceOfCappedCallOptionsSeeNote10" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,240</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81daa921-0e51-40a4-9d2d-89a29ee41bfe" contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,285</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eda36706-dd9c-41a2-aacf-895a2579aea3" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,285</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc832f2c-62e1-4ea0-8822-1ebafa21dae8" contextRef="C_6d7cb580-217f-495d-9dc8-c7a31af8234f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,539</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1342c3e2-8dbd-4373-8df0-170fe0fb7116" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,539</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a681ed6-176a-43a8-a5d0-97e23a4e28c4" contextRef="C_4dc5908b-5edd-428d-affa-04a86844ffaf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,713</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ccbd483-2379-409a-bd21-f4c7e873cbca" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,713</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balances at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdcc2eaa-b2f3-4720-8dcb-2382d439f5b3" contextRef="C_97e9955d-8f3c-4e73-96cc-3ff1b69da22b" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">122,945</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d7466c1-c789-4aa9-bc49-e1ca0163469a" contextRef="C_97e9955d-8f3c-4e73-96cc-3ff1b69da22b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6265748f-9fe2-48d6-99db-80f2ea48d67c" contextRef="C_4cda2680-5634-444f-82ba-0702b3f55696" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ac7a37b-437e-4db9-8510-00ce2cd1ac3f" contextRef="C_4cda2680-5634-444f-82ba-0702b3f55696" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63ec0575-1ee7-48ea-b330-c84f2eb378af" contextRef="C_3eff1578-c6f0-49d6-9432-a944eed0709e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,441,868</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59449e4a-1561-47ef-a222-976352a549bb" contextRef="C_10486a1b-be2f-40a5-b01f-0bcd65255d81" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,266</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c27e1c1d-0c30-4b85-9e90-2133a6ff30b5" contextRef="C_e381175a-06e1-46c3-b77b-df4ad235482a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,217,351</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35d3dba0-4a7d-41e0-86b6-63b01553e08f" contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,374</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46d1c619-48b3-48b9-878e-b23c199afc02" contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptionsShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,194</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad07cf57-b2b5-48c7-8cea-ae993b684734" contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a475d320-d1c4-43dd-8fda-83a422bdbf2e" contextRef="C_b3aa89f6-f4c8-4a9f-8753-f6b4ba518016" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53aa9f00-14a3-4986-8b83-c1418859c544" contextRef="C_48cfc4ff-27e8-4913-84be-fd420b811781" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,638</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fcf0b11-683c-4cde-a332-45315e25d1f7" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,640</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon release of restricted stock awards</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d78d1b0-7477-42eb-bb25-aea6174fb2d2" contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38" name="dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,432</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_642bd897-26db-41aa-b04f-e3f912756604" contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38" name="dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce96dbe3-ae52-474f-b242-43a6ad9e8abd" contextRef="C_48cfc4ff-27e8-4913-84be-fd420b811781" name="dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under Employee Stock Purchase Plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88baf44b-44de-4fc2-b49e-00bc5b24fdb1" contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0419457c-9d49-45a3-9e65-8a7f4fcc027d" contextRef="C_48cfc4ff-27e8-4913-84be-fd420b811781" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,430</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_008c1798-b357-4b09-b6ca-fefd125e4108" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,430</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24226978-c1da-4f94-95fb-3f9df7c06021" contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38" name="dvax:IssuanceOfCommonStockUponExerciseOfWarrantsShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd97963d-5e55-49d4-bef6-43539c737aa3" contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38" name="dvax:IssuanceOfCommonStockUponExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3c398eb-7b20-4ba9-8bef-da5f553a069d" contextRef="C_b3aa89f6-f4c8-4a9f-8753-f6b4ba518016" name="dvax:IssuanceOfCommonStockUponExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_359e7514-d28a-4998-9470-94d83cf5bd9c" contextRef="C_48cfc4ff-27e8-4913-84be-fd420b811781" name="dvax:IssuanceOfCommonStockUponExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,668</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9c31498-4ae5-43b5-bf29-868f3923edf7" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:IssuanceOfCommonStockUponExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,670</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaee08de-49bc-452f-a17d-8f0d7ada9c70" contextRef="C_48cfc4ff-27e8-4913-84be-fd420b811781" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c8460d1-527b-4665-8783-93e194be2e39" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0e126c7-5158-41ae-b3ec-c7970819d80a" contextRef="C_f2119199-7038-4bb0-8c9c-d8181ef231e3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa604e68-8b25-4b8a-94f4-98ef7eb77e50" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f3e7328-f7ad-47b9-aa47-732f1deac93c" contextRef="C_3727f25c-7b34-4d8b-ad87-5a284d913f8c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fadb692-70f3-4b9e-a0fc-84ed18bfca2b" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balances at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4acd56be-17e4-4d22-b1ea-f277ab702280" contextRef="C_9822878d-e9c6-42eb-aba9-e6d1be0c6c26" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">127,604</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a378e6a3-d82e-49b9-82b3-dc035dd6f830" contextRef="C_9822878d-e9c6-42eb-aba9-e6d1be0c6c26" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b92a0a2-99e2-46b0-b44c-6e983a45bcef" contextRef="C_4cecce06-d788-4a18-b30c-961790a113af" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18877675-88a7-4890-9fab-da56c080ef15" contextRef="C_4cecce06-d788-4a18-b30c-961790a113af" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e0ef6f0-0476-407d-ab9e-42112e13d7c4" contextRef="C_d26b0e54-e633-48c7-b851-f555aaf0ac91" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,510,518</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d34376da-e584-4204-b624-dc8002f35f90" contextRef="C_8d9fa1a4-607b-4714-b950-2d3ee7d6606a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,438</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb6056aa-1f18-4082-a966-40420a001e1d" contextRef="C_8ff495d2-c2ab-4702-a574-69eda60e3e44" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">924,195</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00b31007-e5e2-4129-9fb0-3c7256abed82" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">581,013</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9aff6e0-f476-45a3-8e79-787a8d9362a5" contextRef="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptionsShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">850</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecfb9fab-fe3c-4bb6-9aaa-3d7d04a2aee8" contextRef="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a09d9db-05c4-48d1-ae37-3ab58abd522d" contextRef="C_739cf94c-d0c3-431e-93da-9d8dc48a3718" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_313c7131-9bbe-4069-9cf1-8f2a62e90621" contextRef="C_bfd94056-2ea8-4584-9e10-0cb5bec164e1" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6f7b199-d17a-4899-b874-9e738771b782" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:IssuanceOfCommonStockUponExerciseOfStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,361</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_668ee53e-3955-4965-9ab4-34ed78b7bf04" contextRef="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9" name="dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8476a8f-4466-45ab-9c75-4a7d743180fb" contextRef="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9" name="dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05232c3a-6b3d-4870-8181-87a1ad6ca32b" contextRef="C_bfd94056-2ea8-4584-9e10-0cb5bec164e1" name="dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,371</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8edac67-cda3-42a8-9eae-2eceeea2a007" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,370</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock under Employee Stock Purchase Plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67c9beac-46de-4e5d-83b2-7b85388fdd0b" contextRef="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9f0352e-f1d6-44e2-b85a-bb7d205854e3" contextRef="C_bfd94056-2ea8-4584-9e10-0cb5bec164e1" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,535</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_418bc2f4-db6d-4e5f-ae5f-065d2c4edfa4" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,535</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ef4bdbd-9341-4a66-bda2-9cc47dbad512" contextRef="C_bfd94056-2ea8-4584-9e10-0cb5bec164e1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,592</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d953b69-4bd1-48a7-b470-ddced47d0ec4" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,592</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other comprehensive income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2425a38-f71e-45a1-b4fd-33c2417e20a1" contextRef="C_0c75ba6c-c9fa-4cf1-982e-13bb8407020d" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,330</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_697d25d3-88a9-4768-92d2-b0d026bdc8c0" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,330</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:4pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecd2040c-bda9-44a0-a9b3-68d80f886e45" contextRef="C_74aa1aa7-40d9-43b4-9261-d413646b1f6d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57969e1d-53e5-4c57-8fe4-ae552e5dd426" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f53e8f6a-a855-436e-afcb-bb094b7b98a5" contextRef="C_7fc345ed-b272-49ff-b9eb-c47bc4c9266b" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,530</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91a630b1-6cd2-49ae-9976-bd5499e25ba7" contextRef="C_7fc345ed-b272-49ff-b9eb-c47bc4c9266b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_291d9064-c6e6-4831-a6b5-33e1b8c8d4ef" contextRef="C_6451506c-a0f7-4a87-ac9f-42b2634d9a77" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14f1ae22-acc3-4d5c-b0bb-7fa7ebba47ca" contextRef="C_6451506c-a0f7-4a87-ac9f-42b2634d9a77" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc62f34d-b51e-485f-acf2-915c7cc5619b" contextRef="C_413555f4-1d4a-4bf8-8c72-64ae359a9907" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,554,634</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c1b6b1a-a809-4df6-8888-1967e58e0d73" contextRef="C_30de9d80-f061-4903-9ccb-6711842fb3d0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,108</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3017e58-642d-4dc9-b0d5-a75f13853c44" contextRef="C_a9bb4111-0938-4d2d-bd83-eeb18b9ba154" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">930,584</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea289423-b99e-427d-8cbe-4684d7a8431c" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">622,072</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DYNAVAX TECHNOLOGIES CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MENTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.151%;"/>
    <td style="width:1.34%;"/>
    <td style="width:1%;"/>
    <td style="width:10.942%;"/>
    <td style="width:1%;"/>
    <td style="width:1.34%;"/>
    <td style="width:1%;"/>
    <td style="width:10.942%;"/>
    <td style="width:1%;"/>
    <td style="width:1.34%;"/>
    <td style="width:1%;"/>
    <td style="width:10.942%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d79aedb6-fd98-4435-a6cb-9758273b2f47" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0a903b1-d495-4caf-91ff-de594ee2f538" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df798bbf-0c28-4c29-af0d-92a46ceb25cb" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,713</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1febd96d-0324-432f-92fb-ff697ad369aa" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,342</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9e5610c-63df-41b8-b6ed-7bceb14b1e3a" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,812</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b30dec5f-2854-4186-abd0-448f9f0d04ce" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,296</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c9709fd-cbbb-474b-b68f-1161381f0a21" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,934</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4b33e65-ffea-424d-a262-d20e6893f75c" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,856</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0f1ba85-d7a7-4c62-a902-761c9968eaa8" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,762</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory write-off</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d75d7be7-c599-4edb-a70e-fd9fab28d836" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_039bf0c0-41a7-49c3-8c31-d713e68be3d1" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8956c563-f7b8-4b88-9beb-6d74f5df27e1" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,588</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of premiums (accretion of discounts) on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2414f8e-a895-4407-a857-6989abbc9487" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,555</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3b6b591-2ab0-4fbb-932a-84e7268634df" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,181</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f88d0a2-6aae-416a-9525-8686457a08f2" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">470</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on debt extinguishment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a953bc3c-368f-42e6-9dd6-01e7eb670c11" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6dcf0ede-8805-43bb-a19f-4828bfd08f96" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a9376c8-5b44-417c-ba55-4e8c7908194c" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,232</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_968cceb4-8e50-4836-8a1a-b13034727523" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc3f033c-88aa-47d1-94f3-e71769bffeb3" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93e2a9ad-3569-4076-8931-738cfd42c775" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,354</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5931f42-112a-438c-b21b-3d5b1e751243" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,592</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ea51d90-e864-42f8-a33a-2ac4867004ca" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1fe343a-658a-48bf-8d14-d0cd7ed026b3" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,285</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a58682a4-86e7-4df7-aedf-77e3499898b2" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:NonCashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,120</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d256a157-d454-4fee-9cd0-45a891f4af8a" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:NonCashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,088</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5d89a18-8b5c-4a10-bb45-e231ea08ce9e" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:NonCashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,608</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gain on sale of assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c038c4cd-6425-42dd-8f64-cfdb6f70a87d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:GainsLossesOnSalesOfAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f437d391-9200-4927-bd01-b05425291d58" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:GainsLossesOnSalesOfAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7d1540d-73e1-4c84-9da3-e6313aa7f68b" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:GainsLossesOnSalesOfAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bad debt expense (Note 9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d2957e3-0a26-4436-abaf-cfda92b0d7eb" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:BadDebtExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,313</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53aad0d4-1b45-4c70-bb87-9484cfc4c9ed" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:BadDebtExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a6e2883-b6e6-4f7b-8ca6-02ba53933930" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:BadDebtExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:5pt;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts and other receivables, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e473ef2-00d8-49c4-9736-d4738f567fba" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">43,268</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efe3d2a7-05f8-416f-9092-bfe081ef8a68" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,699</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5c52643-67f6-48b2-a63f-65b86551edfc" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,155</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1ea17d0-f603-4820-afe5-b6c38e2c810d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,909</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f73a02c4-da56-46b1-a531-c8619e136226" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,399</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbe7d298-cc9d-4ef3-a766-beaa0482dfaf" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">234</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid manufacturing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43c5bfea-917e-40ab-b4a2-a204f0558dae" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:IncreaseDecreaseInPrepaidManufacturing" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8190f012-4a1d-481f-86de-daee28654876" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:IncreaseDecreaseInPrepaidManufacturing" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,655</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91184e0d-28dd-4387-93db-36b206687774" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IncreaseDecreaseInPrepaidManufacturing" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,232</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_711c5005-a6c5-4d5a-b00e-bebab2595f89" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,673</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68506c07-bf5c-4f2b-a9ae-94aed5c0c7b7" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,865</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f01c23be-18fe-4ff4-8257-3e41e7d36ddf" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,558</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2409ba3c-8a86-4cf5-8bc0-cb7f4fcce258" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">570</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e65200a8-47ee-48b0-ab99-a7daa34145d8" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51929c58-3727-4603-a688-a24568d940b9" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">175</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_316ce678-7d76-47a9-97ce-8cd5638eb961" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,952</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a205327a-ac5e-4a00-b51b-1ae548057cf8" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">691</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52f53cd9-b4be-450d-a260-0c80bf122521" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">767</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CEPI accrual (Note 9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e354b852-e386-4d58-97de-b1467be4bb83" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:IncreaseDecreaseInCepiAccrual" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21e1421c-2404-4d14-a80a-9164994e8995" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:IncreaseDecreaseInCepiAccrual" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,110</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9642b3c0-f403-4b3e-935c-8f71aafcef6b" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IncreaseDecreaseInCepiAccrual" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128,848</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4743adb-2c4c-46e0-8b12-4fe05549d680" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec59d8e5-295b-4b11-9d28-f387640f3f57" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,125</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_751d9898-c8ae-46d7-9b23-e7b5bf05e9bd" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,234</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f858004d-1058-4bf4-be86-51da8324d8c1" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49e82067-61a9-4186-9f34-ea581fc2992a" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349,864</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98e2fa73-503b-4dd2-9042-13dad0c301dd" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,652</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued and other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85f9a322-4934-4363-8a8b-fd7eae70e272" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,809</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c54787b6-7125-4827-a54b-ce078a5f9e05" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,788</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21f742f3-4c55-41c5-a72c-6e9fc56201bf" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,725</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7303085-d6f2-4400-90f3-d8d132c8dd44" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,563</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e34a8e1e-733b-4e2c-9c14-8c490202c363" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,716</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87b9edea-1cc1-40b2-be4d-4159f63638d3" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">335,528</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2188547-18e5-43ce-8c67-0cee0361bcca" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">636,921</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97965cc7-b48b-4d63-bb1b-6e23328b1b95" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">632,306</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d582069-2e76-43b5-ad55-a2ff0175eadc" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,928</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities and redemptions of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18a0fead-bdfa-46c0-983a-59692f939e08" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">486,097</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0903d6db-a77a-4a70-98a4-d3413211cc31" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">322,450</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acab4632-beb5-418c-99e1-2e799eae447d" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0885f98-c501-4154-9912-76c03f9e5f35" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a5e2f16-0ffa-4c7b-9a5e-1e596ac6830a" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,139</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f90c6fcb-e11d-484b-a255-6a03e9763d01" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,477</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sale of assets, net of transaction costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7af4ff79-8f34-41da-943b-3680220d7ce6" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09def43b-596b-4084-955b-bdf793d15c96" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1b6f0d7-d7a9-43d2-923a-209d532ec472" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a52e8579-e090-41f8-b8a6-a88745f69780" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,928</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3454253-859e-421b-950d-d3f489f43062" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">315,995</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1910244e-a7ff-4e96-a6b6-077a0bca69ec" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,225</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuances of common stock, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_626a55f2-9a8f-430d-a9de-1549d86e9b67" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b125b2e-91cc-48f1-9ec6-9c7af828be9f" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5d58a69-29e9-45aa-ade0-e43c648bf811" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of Convertible Notes, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d57a117-e043-4aa9-b255-ea0bb320c813" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ec3e12f-d554-4bb5-800a-848204466536" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d55e5e6-201a-4a19-94e8-93facec96bb9" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219,822</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of capped call options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ae70e22-4f78-46dc-b8df-afa8ae52d3b4" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:PaymentsForPurchaseOfCappedCallOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_027e7655-757a-476a-ae4c-0d1d8d383180" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:PaymentsForPurchaseOfCappedCallOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f848b6f5-fa64-4bc8-a66a-b22d8966bda1" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:PaymentsForPurchaseOfCappedCallOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,240</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repayment of long-term debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_873b25b8-de4b-47fb-83b5-f8cb6d076b18" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25a2f240-3f66-4345-ae8b-88cc37eb1dc3" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc9df6fe-c1e5-4c17-acc8-46b4d80eaed1" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190,194</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from warrants exercises</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52dfe52b-f12f-4f1f-b07a-946f3a98a001" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_579e04c0-f5f6-4db9-a521-fff393a5863e" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,455</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0de04b7-7a91-4d7c-a236-6151996814fd" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,814</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options and/or release of restricted stock awards, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d895abeb-f714-40d1-b8fb-0d1e8a9084b1" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb724bd4-2ff2-4a11-89dd-bb34dc52620b" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45e4602f-70a9-48f7-bf76-5b098bc22a31" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,577</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from Employee Stock Purchase Plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e862ac5-e30d-4849-8f34-993c27d12c7e" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,535</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1991cd14-7a09-4ad1-9bbe-2f0a08f988ce" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da0bc9e1-3ea7-42d0-843b-4a699bb95059" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments for taxes related to net share settlement of RSUs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1605957d-d4b8-4c53-8826-bafdde159348" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:PaymentsForTaxesRelatedToNetShareSettlementOfRsus" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,509</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce0b80ae-9773-4fdf-b931-1c5a865c5774" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:PaymentsForTaxesRelatedToNetShareSettlementOfRsus" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5444af80-7d72-4457-b6f0-9d73e5d9887f" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:PaymentsForTaxesRelatedToNetShareSettlementOfRsus" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa4278f1-4b49-4dc4-910e-ef2c8c50fc0b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_829c16d5-eed7-4cb0-a082-01f32b676f16" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,525</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_981822e7-62f5-419a-bc5d-751b35c6ce38" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,776</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_226fd49d-5950-490b-8595-7882e1b07908" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">324</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03fa2dd1-cc39-499a-8347-270d31400a55" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">443</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1042fbbc-7428-42f9-abe5-57d01486e1e2" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1aaa2cb1-834e-4b97-96cd-ebefb942e19c" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">51,655</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63040909-b156-44db-941c-af71bcf8b8ae" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,197</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edea9a5a-f632-4f7a-8814-014a25914e64" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404,098</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents, and restricted cash at beginning of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa37acca-36bd-49ef-b7f4-d9bbf92ddbc9" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,211</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffa6aa42-ac09-45ef-9f3e-ee3f7780d60e" contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436,408</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8379b787-28d1-4322-af7c-f1446d79bf0e" contextRef="C_d6a1605d-0ed8-4293-af91-e392daff1469" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,310</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents, and restricted cash at end of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37eb5675-0bf4-48e5-b8a4-55c290db9bd7" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,556</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5abd9abd-7ba2-495f-8c34-d7d97abfd8d4" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,211</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a232c518-ab24-49de-8faf-ef71eeb67c22" contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436,408</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental disclosure of cash flow information</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid during the year for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81f1ff16-69a7-4934-ade9-f0a134a70858" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,014</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c9e7a6c-5f0e-4140-bf71-0ec2dbed4fce" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,208</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0158da6d-2e41-49d3-807d-891a70b88953" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,312</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid during the year for interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee7be46e-41cf-49ab-8fdd-a83da9e9566f" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,638</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89c6c203-98e7-4d43-9e72-703a8b7edf29" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,638</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_379e5afa-f737-4e99-a9c3-44ec87d0f200" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,815</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of contract asset from other current assets to other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01276704-f5bc-4d90-ae0f-d4f91c934c2f" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,307</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fb99a91-cd83-4a3d-b10d-9f4694dadc6c" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14c5115e-06cf-46c7-b1ba-af20444229f7" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of CEPI accrual to CEPI accrual long-term</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_418ceca0-ed04-45e9-a31a-7de6fc1fb378" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:ReclassificationOfCepiAccrualToCepiAccrualLongTerm" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60,337</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10d53c41-797c-4dca-95bb-5db092569684" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:ReclassificationOfCepiAccrualToCepiAccrualLongTerm" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7950b6ee-b38d-4e34-bcce-883825975f26" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:ReclassificationOfCepiAccrualToCepiAccrualLongTerm" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Advance Payments forgiven per CEPI-Bio E Assignment Agreement (Note 9)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_028e9706-dc0e-4208-a1c3-d275f4475fb8" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:AdvancePaymentFromCustomer" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47,401</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac410721-a41a-49f8-919a-7ba8c535406d" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:AdvancePaymentFromCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_601f2200-80c4-49d2-ac0e-60d7919907e7" contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d" name="dvax:AdvancePaymentFromCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment, not yet paid</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_476959f0-b745-4982-b939-4da7c64843f5" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">299</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29f7a100-f9f9-4f41-b41c-8bf4229c1234" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,015</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9528520-8844-4753-a282-56517ddc30b6" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets obtained in exchange for operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3765356a-9dcc-498c-88c7-776ecce38918" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,332</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47ead126-cf4d-492a-87fa-a5def4e25d76" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,848</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05c1e17c-53dd-49df-90d9-e313a50fe7c4" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,468</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DYNAVAX TECHNOLOGIES CORPORATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED F</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ead21dd-e683-429b-a372-389444bfa309" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dynavax Technologies Corporation (&#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Dynavax&#8221; or the &#8220;Company&#8221;) is a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Our first marketed product, HEPLISAV-B&#174; [Hepatitis B Vaccine (Recombinant), Adjuvanted] is approved in the United States, the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47e3ae98-6178-45a1-8e9a-08c3ef7dfaf5" contextRef="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b" name="dvax:MinimumAgeApprovedForVaccinePreventionOfInfectionCaused" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and older. In May 2022, we commenced commercial shipments of HEPLISAV-B in Germany.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing a pipeline of differentiated product candidates that leverage our CpG 1018&#174; adjuvant, the adjuvant used in HEPLISAV-B, to develop improved vaccines in indications with unmet medical needs. These programs include vaccine candidates under development for shingles and Tdap, and a plague vaccine candidate program in collaboration with and fully funded by the U.S. Department of Defense ("DoD").</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally. we manufacture and have supplied in the past CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B, through both commercial supply agreements, and through preclinical and clinical research collaborations with third-party organizations. As of December 31, 2022, we had satisfied all delivery obligations under our commercial supply agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3638845-2ba8-4a78-9ce5-fa0502b76d92" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e785bc37-ffd5-4bfc-a17a-e18fc7f51d5b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and include our accounts and those of our wholly-owned subsidiaries, Dynavax GmbH located in D&#252;sseldorf, Germany, Dynavax India LLP in India and a branch of Dynavax in Italy. All intercompany accounts and transactions among the entities have been eliminated from the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae72bd5a-d9a8-47af-9fc9-f3540b46fa53" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management&#8217;s estimates are based on historical information available as of the date of the consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_082065dd-a252-43a8-827e-eeb05449db59" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency Translation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider the local currency to be the functional currency for our international subsidiaries, Dynavax GmbH, located in D&#252;sseldorf, Germany, Dynavax India LLP, and a branch of Dynavax registered in Italy. Accordingly, assets and liabilities denominated in this foreign currency are translated into U.S. dollars using the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the year. Currency translation adjustments arising from period to period are charged or credited to accumulated other comprehensive income (loss) in stockholders&#8217; equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of Decemb</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">er 31, 2023 and 2022, the cumulative translation adjustments balance was $</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5816ded-2e6c-491a-ace2-c51dc12f6ce9" contextRef="C_df4c54ad-6b4c-4547-9c0b-6d82cd6c4cde" name="dvax:CumulativeTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b1c1892-718b-4a34-a724-8bdd9abaf22d" contextRef="C_8004c05b-80cb-4d34-b5be-e0a034b69331" name="dvax:CumulativeTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) million, respectively, primarily related to the translation of Dynavax GmbH assets, liabilities and operating results from Euros to U.S. dollars. F</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or the years ended December 31, 2023, 2022 and 2021, we reported an unrealized foreign currency translation gain (loss) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4897a9a-ae86-4b98-afaa-f9e76fe2cc23" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bc36523-42e2-4d8b-a710-0329cc9f44d0" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) million and $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4c72ed0-b689-4248-87b0-d72ec09bdc93" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) million, respectively. Realized gains and losses resulting from currency transactions are included in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> other (expense) income in the consolidated statements of operations. For the years ended December 31, 2023, 2022 and 2021, we reported a (loss) gain of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee05be14-02b4-4dd0-932b-750705468301" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">llion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b5792bb-a2a7-441e-bdae-66fd81cd4579" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47f7d39d-33a1-474b-8188-d911e0b298b8" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, resulting from currency transactions in our consolidated statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24954831-31e8-4b69-b721-54402632b9ce" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">segment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and in assessing performance. Our Chief Executive Officer is the CODM. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, management has determined that we operate in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90d57e20-4d45-4b03-b576-5373ea1ed4ff" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment that is focused on the discovery, development, and commercialization of innovative vaccines. Net assets outside of the U.S. w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ere less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb327e6e-06af-444b-98ab-305202d381c7" contextRef="C_b4c83557-99eb-4dae-a4b6-8f5fe7a1fff4" name="dvax:PercentageOfLongLivedAssets" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_598cb243-ba03-4f9e-9dfb-7beaa447c4dc" contextRef="C_16e235b1-3b2d-4e5d-8443-14ad46e6d0bb" name="dvax:PercentageOfLongLivedAssets" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of total net assets as of December 31, 2023 and 2022.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f819a9e-88cb-4c94-90df-a2538f216c4f" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and Cash Equivalents and Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider all liquid investments purchased with an original maturity of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57702625-d3d0-4c79-a093-6defa3adb4de" contextRef="C_c4bb7def-af41-4d15-8eda-59023addc137" name="dvax:CashEquivalentsMaturityPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or less and that can be liquidated without prior notice or penalty to be cash equivalents. Management determines the appropriate classification of marketable securities at the time of purchase. In accordance with our investment policy, we invest in short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We believe these types of investments are subject to minimal credit and market risk.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive loss in stockholders&#8217; equity. Commencing with our adoption of (&#8220;ASC&#8221;) 326, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8212; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(&#8220;ASC 326")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on January 1, 2023, we determine whether a decline in the fair value of our available-for-sale ("AFS") debt securities below their amortized cost basis (i.e., an impairment) is due to credit-related factors or noncredit-related factors. Any impairment that is not credit related is recognized in other comprehensive income (loss), net of applicable taxes. Credit-related impairments (if any) are recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Both the allowance and the adjustment to net income can be reversed if conditions change. To date, there have been no declines in fair value that have been identified as a credit-related impairment.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9070f18-487e-4e0c-9455-67e04e48d0e9" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any significant losses on our cash equivalents and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts. We estimate our allowance for doubtful accounts based on</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. During the year ended December 31, 2023, we recorded an allowance for doubtful accounts of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_661f5b31-e854-41dc-b0f6-ef8d890204f4" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was determined by assessing changes in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biological E. Limited's (&#8220;Bio E&#8221;) credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (See Note 9), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8576c74-baa3-4ac3-a96b-9bc015095c4c" contextRef="C_23872491-571b-4186-b6ac-a7b968b913ea" name="us-gaap:ConcentrationRiskCustomer"><ix:nonNumeric id="F_b6f3312c-d390-4489-ab28-eb588ef4515c" contextRef="C_3712e127-94e3-4474-a4e8-4efc91f83f9a" name="us-gaap:ConcentrationRiskCustomer"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customers collectively represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80b923c3-1a94-4e8e-beae-989bb193a749" contextRef="C_5cce5446-2af2-4a9a-b1c4-38be430937ac" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">81</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61786731-da1e-47a3-ad72-c8756aa200fe" contextRef="C_b2def0eb-ee73-4354-805a-b882be4a3888" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our HEPLISAV-B trade receivable balance, respectively. As of December 31, 2023, we had no CpG 1018 adjuvant trade receivable balance. As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_363e8caf-1c6a-4fd5-b6ef-4cd3686d8698" contextRef="C_93f06617-1210-471c-aa60-542728a9d90e" name="us-gaap:ConcentrationRiskCustomer"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35025d4e-9dd5-4f54-84be-9db99e08bf71" contextRef="C_47db32ab-ff21-4bf4-92e5-39d73f0bf345" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our CpG 1018 adjuvant trade receivable balance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates will require approval from the United States Food and Drug Administration ("FDA") and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our product candidates will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process that could affect our authorizations in the future.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our long-lived assets located in the United States as of December 31, 2023 and 2022, represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79b1553a-6790-4121-a81c-3281a250207d" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:PercentageOfLongLivedAssets" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af761efc-88e7-445b-aaf9-1e054e755e97" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:PercentageOfLongLivedAssets" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our total assets, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respectively, and the remaining long-lived assets were located in Germany.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad8a0650-c436-48f9-87e8-44de1f1dec37" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HEPLISAV-B Inventories</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the years ended December 31, 2023 and 2022, there w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ere </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85a913c6-0868-4105-94cb-38f84d20f02f" contextRef="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b" name="us-gaap:InventoryWriteDown" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> invento</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ry reserves or write-offs recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to the required regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory. Instead, those are expensed as research and development costs. We begin capitalization of these inventory related costs once regulatory approval is obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CpG 1018 Adjuvant Inventories</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the year ended December 31, 2023, there was no remaining CpG 1018 adjuvant inventory balance. For the year ended December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1aa11362-c345-4a82-8c4d-5766e25659bc" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:InventoryWriteOffsRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">34.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of inventory write-off to cost of sales - product, in connection with cancelled orders and the reduction in demand for CpG 1018 adjuvant reflected in the Clover Supply Agreement, as amended (See Note 9).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad7e97a3-dc76-4701-adbf-b287c09f6ded" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized, while repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluate the carrying value of long-lived assets, whenever events or changes in business circumstances or our planned use of long-lived assets indicate, based on undiscounted future operating cash flows, that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. When an indicator of impairment exists, undiscounted future operating cash flows of long-lived assets are compared to their respective carrying value. If the carrying value is greater than the undiscounted future operating cash flows of long-lived assets, the long-lived assets are written down to their respective fair values and an impairment loss is recorded. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. There have been no material adjustments to these estimates during the years presented.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9cfd5e2f-5437-45c7-8749-275c4d352e7d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determine if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset, and whether we have the right to control the identified asset. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, other current liabilities and long-term portion of lease liabilities in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. The classification of our leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of ROU assets and lease liabilities is based on the present value of future lease payments over the lease term. The ROU asset also includes the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the implicit rate in our leases is generally unknown, we use our incremental borrowing rate based on information available at the lease commencement date in determining the present value of future lease payments. We consider our credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary, when calculating our incremental borrowing rate. The lease terms may include options to extend or terminate the lease when it is reasonably certain we will exercise any such options. Rent expense for our operating leases is recognized on a straight-line basis over the lease term. Variable lease payments are recorded as an expense in the period incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have elected not to apply the recognition requirements of Accounting Standards Codification ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases ("ASC 842")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for short-term leases. We have also elected the practical expedient to not separate lease components from non-lease components.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As lessors, we determine if an arrangement includes a lease at inception. We elected the practical expedient to not separate lease components from non-lease components. Sublease income is recognized on a straight-line basis over the expected lease term and is included in other income (expense) in our consolidated statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6cfc3206-3a92-4f90-9093-65804495faa8" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess purchase price over the fair value of tangible and intangible assets acquired and liabilities assumed. Our goodwill balance relates to our acquisition of Dynavax GmbH in 2006. Goodwill is not amortized, but instead is reviewed for impairment test at least annually, or more frequently if events occur or circumstances change that would indicate the carrying amount may be impaired. Goodwill is assigned to, and impairment testing is performed at, the reporting unit level. We determined that we have only </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e902699-e288-4acf-aa4b-20d6a7b9d9b1" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment and there are no components of that operating segment that are deemed to be separate reporting units, such that we have one reporting unit for purposes of our goodwill impairment testing. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f766ce33-050e-4f92-9d7f-82b4e7f64b1c" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment has been identified for the years presented.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35a0265e-3a5b-4c7a-98db-fbe8114d21a4" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DebtPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Convertible Notes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e699c69-5606-481d-9f77-e0f3217c5659" contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% convertible senior notes due in 2026 (&#8220;Convertible Notes&#8221;), as a long-term liability equal to the proceeds received from issuance, including the embedded conversion feature, net of the unamortized debt issuance and offering costs on the consolidated balance sheets (See Note 10). We evaluate all conversion, repurchase and redemption features contained in a debt instrument to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is not required to be accounted for separately as an embedded derivative. We amortize debt issuance and offering costs over the contractual term of the Convertible Notes, using the effective interest method, as interest expense on the consolidated statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c815413-5855-4836-9898-cac4c412b46e" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:CappedCallsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capped Calls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluate financial instruments under ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging ("ASC 815")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The capped calls purchased in connection with the Convertible Notes financing ("Capped Calls") cover the same number of shares of common stock that initially underlie the Convertible Notes (subject to anti-dilution and certain other adjustments). The Capped Calls meet the definition of derivative under ASC 815. In addition, the Capped Calls meet the conditions in ASC 815 to be classified in stockholders&#8217; equity and are not subsequently remeasured as long as the conditions for the equity classification continue to be met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a4c47d3-1ddd-4197-b72d-17310a1cc9c8" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration, which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers ("ASC 606")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we apply the following five step model:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the performance obligation(s) in the contract;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determine the transaction price;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocate the transaction price to the performance obligation(s) in the contract; and </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognize revenue when (or as) we satisfy a performance obligation. </span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Revenue, Net &#8211; HEPLISAV-B</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We sell HEPLISAV-B to a limited number of wholesalers and specialty distributors in the U.S. (collectively, our &#8220;Customers&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product upon delivery to the Customer. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Because our standard credit terms are short-term and we expect to receive payment in less than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_896ef656-0b9b-4bce-9e3d-9128f06d7d5c" contextRef="C_c4bb7def-af41-4d15-8eda-59023addc137" name="dvax:ContractWithCustomersExpectedPeriodOfPaymentToBeReceived" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there is no significant financing component on the related receivables. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. Since our performance obligation is part of a contract that has an original expected duration of one year or less, we elect not to disclose the information about our remaining performance obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overall, product revenue, net - HEPLISAV-B, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reserves for Variable Consideration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration such as product returns, chargebacks, discounts, rebates and other fees that are offered within contracts between us and our Customers, healthcare providers, pharmacies and others relating to our product sales. We estimate variable consideration using either the most likely amount method or the expected value method, depending on the type of variable consideration and what method better predicts the amount of consideration we expect to receive. We take into consideration relevant factors such as industry data, current contractual terms, available information about Customers&#8217; inventory, resale and chargeback data and forecasted customer buying and payment patterns, in estimating each variable consideration. The variable consideration is recorded at the time product sales is recognized, resulting in a reduction in product revenue and a reduction in accounts receivable (if the Customer offsets the amount against its accounts receivable) or as an accrued liability (if we pay the amount through our accounts payable process). Variable consideration requires significant estimates, judgment and information obtained from external sources. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. If we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of revenue that we report in a particular period. We evaluate our estimates of variable considerations including, but not limited to, product returns, chargebacks and rebates, periodically or when there is an event or change in circumstances that may indicate that our estimates may change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Returns:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Consistent with industry practice, we offer our Customers a limited right of return based on the product&#8217;s expiration date for product that has been purchased from us. We estimate the amount of our product sales that may be returned by our Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We consider several factors in the estimation of potential product returns including expiration dates of the product shipped, the limited product return rights, available information about Customers&#8217; inventory and other relevant factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chargebacks:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our Customers subsequently resell our product to healthcare providers, pharmacies and others. In addition to distribution agreements with Customers, we enter into arrangements with qualified healthcare providers that provide for chargebacks and discounts with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by Customers, and we issue credits for such amounts generally within a few weeks of the Customer&#8217;s notification to us of the resale. Reserves for chargebacks consists of credits that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect will be sold to the qualified healthcare providers, and chargebacks for units that our Customers have sold to the qualified healthcare providers, but for which credits have not been issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trade Discounts and Allowances:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We provide our Customers with discounts which include early payment incentives that are explicitly stated in our contracts, and are recorded as a reduction of revenue in the period the related product revenue is recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distribution Fees: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Distribution fees include fees paid to certain Customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rebates: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under certain contracts, Customers may obtain rebates for purchasing minimum volumes of our product. We estimate these rebates based upon the expected purchases and the contractual rebate rate and record this estimate as a reduction in revenue in the period the related revenue is recognized.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Revenue, Net &#8211; CpG 1018 Adjuvant</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also sell our innovative adjuvant, CpG 1018 adjuvant, to our collaboration partners for use in their development and/or commercialization of COVID-19 vaccine. We have determined that our collaboration partners meet the definition of Customers under ASC 606. Therefore, we accounted for our CpG 1018 adjuvant sales under ASC 606. Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product to the customer. Because the timing between the recognition of revenue for product sales and the receipt of payment is less than one year, there is no significant financing component on the related receivables. Since our performance obligation is part of a contract that has an original expected duration of one year or less, we elect not to disclose the information about our remaining performance obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overall, product revenue, net - CpG 1018 adjuvant, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. Our CpG 1018 adjuvant customers have purchased a significant quantity of CpG 1018 adjuvant as part of their initial COVID-19 vaccine development inventory. Accordingly, we did not recognize CpG 1018 adjuvant net product revenue during the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other revenue includes revenue from our agreement with the DoD, collaboration and manufacturing service revenue. We have entered into grant agreements, collaborative arrangements and arrangements to provide manufacturing services to other companies. Such arrangements may include promises to customers which, if capable of being distinct, are accounted for as separate performance obligations. For agreements with multiple performance obligations, we allocate estimated revenue to each performance obligation at contract inception based on the estimated transaction price of each performance obligation. Revenue allocated to each performance obligation is then recognized when we satisfy the performance obligation by transferring control of the promised good or service to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_caa5adee-7514-44e8-aeef-e2d5dc493058" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Expenses and Accruals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. Our accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties. We estimate research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to us at that time. There have been no material adjustments to the prior period accrued estimates for clinical trial activities during the years presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7d191ec-a5df-4fe8-9877-89e0b2188648" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense for restricted stock units ("RSUs"), market-based performance stock units ("PSUs") and stock options is estimated at the grant date based on the award&#8217;s estimated fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For awards that vest based on service conditions and market conditions, we use a straight-line method to recognize compensation expense over the award&#8217;s requisite service period, assuming estimated forfeiture rates. For awards that contain performance conditions, we determine the appropriate amount to expense at each reporting date based on the anticipated achievement of performance targets, which requires judgement, including forecasting the achievement of future specified targets. At the date performance conditions are determined to be probable of achievement, we record a cumulative expense catch-up, with remaining expense amortized over the remaining service period. Throughout the performance period, we re-assesses the estimated performance and updates the number of performance-based awards that we believe will ultimately vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value of RSUs is determined at the date of grant using our closing stock price, with the exception of PSUs, which are measured using the Monte Carlo simulation method on the date of grant. Our determination of the fair value of stock options on the date of grant using an option-pricing model is affected by our stock price, as well as assumptions regarding a number of subjective variables. We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value-based measurement of our stock options. The Black-Scholes model requires the use of subjective assumptions, which determine the fair value-based measurement of stock options. These assumptions include, but are not limited to, our expected stock price volatility over the term of the awards, and projected employee stock option exercise behaviors. In the future, as additional empirical evidence regarding these input estimates becomes available, we may change or refine our approach of deriving these input estimates. These changes could impact our fair value of stock options granted in the future. Changes in the fair value of stock awards could materially impact our operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby increasing stock-based compensation expense recognized in future periods. We derive the expected term assumption primarily based on our historical settlement experience, while considering options that have not yet completed a full life cycle. Stock-based compensation expense is recognized only for awards ultimately expected to vest. Our estimate of the forfeiture rate is based primarily on our historical experience. To the extent we revise this estimate in the future, our share-based compensation expense could be materially impacted in the period of revision. There have been no material adjustments to these estimates during the years presented.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c514c4e2-ba57-443e-8214-5efdfc19cfad" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Tax law and rate changes are reflected in income in the period such changes are enacted. We include interest and penalties related to income taxes, including unrecognized tax benefits, within income tax expense.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. We continually assess the likelihood and amount of potential adjustments and adjust the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and the valuation allowance recorded against our net deferred tax assets. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we believe that recognition of the deferred tax assets arising from future tax benefits is currently not more likely than not to be realized and, accordingly, we have determined a need for a full valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3535d33b-9f16-4ddf-a2c9-c35918433e9e" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Standards Update 2016-13</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which was codified in Accounting Standards Codification ASC 326, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8212; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. Because we were a smaller reporting company based on the most recent determination as of November 15, 2019, ASC 326 became effective for us for fiscal years beginning after December 15, 2022. As such, we adopted ASC 326 effective January 1, 2023, utilizing the modified retrospective transition method. Upon adoption, we updated our impairment model to utilize a forward-looking current expected credit losses (&#8220;CECL&#8221;) model in place of the incurred loss methodology for financial instruments measured at amortized cost, primarily including our accounts receivable and contract asset. In relation to AFS debt securities, the guidance eliminates the concept of &#8220;other-than-temporary&#8221; impairment, and instead focuses on determining whether any impairment is a result of a credit loss or other factors. The adoption of ASC 326 did not have a material impact on our consolidated financial statements as of the adoption date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9983625-3c54-4c92-8b4e-8c78c52d6ad9" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Observable inputs, such as quoted prices in active markets for identical assets or liabilities; </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. There wer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9d3c176-1d6a-47df-ab87-1f727d3bb84c" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7e87ff1b-9bf1-4605-a521-eb01e334528d" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ransfers between Level 1, 2 and 3 during the years ended December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash equivalents, accounts and other receivables, accounts payable and accrued liabilities are considered reasonable estimates of their respective fair value because of their short-term nature.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recurring Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8c56202-efdd-49e6-9470-6d4dce7da0ed" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.95%;"/>
        <td style="width:1%;"/>
        <td style="width:9.158000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:8.778%;"/>
        <td style="width:1%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:8.778%;"/>
        <td style="width:1%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:8.778%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">&#160;Assets</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b83b7f68-a7e5-4dc5-9a59-c51dcb4e7a8b" contextRef="C_53c34584-541c-4321-ab58-9d0fe2f1fd0b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebb88ffa-cd21-4179-bf9e-62abd8fcdc90" contextRef="C_5cff3f8b-5d8e-4085-91dc-8a1a4395f4c3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee8d18d4-04f3-4abc-8a1c-9f0fcc7211d3" contextRef="C_b40fc463-936b-4ff9-a706-0dc8d375ef2e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5449900e-81e7-4182-a074-f63222ba9636" contextRef="C_41d532a7-2bee-4d4a-a774-19c130efe064" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6789f89-c77d-4e6d-a531-a86dcf3f4540" contextRef="C_c48f9ef2-11f3-4b36-9b5a-e093eb35a836" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ed50efc-d91b-4df4-9966-d21f071be9c9" contextRef="C_d33fabd0-98d3-439e-b8a4-3bba01fe695a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,237</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21bd8c26-d2ba-4d71-86de-1d2bbaccf200" contextRef="C_4272aeb3-6074-4246-8638-d6db1157f771" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04da058d-dc04-4591-8abe-fe1ed3579a97" contextRef="C_3e7a4e28-ee23-4846-846a-acac7d54f31f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,237</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5818d790-cab7-4a09-8eec-d3c01245db83" contextRef="C_29ad1ccd-24bd-4275-9420-8e03c7809a91" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00eec5ac-02d1-43f4-b209-152b2ca14cd2" contextRef="C_5136ab72-32fb-4b8a-a285-f65c7aae72f7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216,688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a27f7e97-900d-4ab4-895e-a4c96fb728f3" contextRef="C_faa950c0-0245-4bdf-aa7b-50e9c38ec395" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c29eba1c-4ff4-40a8-bc80-e82390c7fe41" contextRef="C_56114482-df3d-4e07-a8de-d386532d7a4e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216,688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e7f139b-2669-493a-92e7-c83bfaa957eb" contextRef="C_f9937706-ff8e-4688-b5fb-817ee1b77e6f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e24a6f9-7025-4b35-9c60-7ef8f17b7f93" contextRef="C_d17521b7-e208-42c4-b34d-99bc5b411173" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,552</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f910674e-08cf-4225-a9d4-9bdd368b830f" contextRef="C_e0bdb5c9-6635-4822-a0d4-b057bdc6bf7c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_974612e8-e627-47cd-8d44-8f1a93fef723" contextRef="C_a0b842a8-48c1-4246-8a13-5bc899141fe0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,552</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_332b2455-00e0-4b5f-a9f0-8ac8058df2ed" contextRef="C_1790227d-10fa-4cab-abdb-eb0e7d848a20" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe162389-2a0b-4772-998c-9386863f15af" contextRef="C_c3753588-e357-4568-8f96-aac287465012" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">599,477</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a01dbfe4-d337-40ea-867d-ae6e486aeea4" contextRef="C_618e0bb6-70e6-4ad8-a103-f5bc6b7f8d80" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb4d3781-1505-4b55-9682-b9827a6c9f2d" contextRef="C_a02082a3-bcf6-4470-924c-b963a2bcd1c3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">731,112</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">&#160;Assets</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14ffe9e8-43b4-4a6d-8b7b-236b4791b4b9" contextRef="C_f81a00fa-c973-4197-b3a1-e0cc4a36b149" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,418</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_011aef8f-5b81-4c2d-b2f5-5ba44e8173df" contextRef="C_4324081c-f2df-428f-82a0-7b99f17493ca" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0f3d19b-79eb-4459-bf7b-7b658a4bdaf7" contextRef="C_7acdd60a-63f0-4280-9662-6e8d7e0e625f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8901376f-99df-4208-80e8-76b42b022f0c" contextRef="C_c7c94b74-9da6-4908-b131-d871909fbeb3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,418</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5622b300-69cd-4bf1-aa3c-f21c931ac3aa" contextRef="C_970dc7a0-06ce-4b4c-a6b1-53363f517586" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e532da6-20c9-41dc-9b2b-76d474ce2987" contextRef="C_08fff746-9f3a-44ee-9a05-fcd200656170" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a322d2e8-7b03-45d8-ab9c-fe51c09dcc3b" contextRef="C_ccc907f7-07b3-4485-bad7-b638c7661924" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_001db223-1463-42d8-ade4-f41e3d33d23c" contextRef="C_b671bf2b-5135-415b-beb9-c44190ad1450" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_643e67b7-1174-4d3f-b567-add073d7480c" contextRef="C_4811b6ec-afc2-4141-bee4-2808586bc8f3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36be900f-4f61-46d6-9938-7a60ce1d1792" contextRef="C_a8317906-5e1f-4330-9194-db9aef7be671" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,032</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bca8bbf-d718-4223-8223-9593dbe9ac27" contextRef="C_e83edc5d-57bf-4f45-8c00-a78bad8a160f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4550a2dc-38b1-4589-9409-6a72ce2dfecf" contextRef="C_712b1a93-fff4-4b0c-8c9b-e29381d7d61f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,032</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_162dcbc5-1f7d-4a4e-86fb-02488fc771a8" contextRef="C_0ae2c12d-5812-46ba-bc06-5eb199a307cf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebc15a47-40ec-47fa-8204-7186612f3f0a" contextRef="C_448dc083-473d-475c-ad68-1d927557d2eb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,051</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0808a2b4-22b8-4fd1-87ab-5ad184c1a0ed" contextRef="C_a7463f82-87b8-4f1d-9935-b4868bc5cd26" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be85d614-21c0-4931-82fd-8a8d78503072" contextRef="C_7b4b7402-722d-4537-a94a-f71d88ccd9c6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,051</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94b1c97e-d366-41e4-9858-8113a9451266" contextRef="C_82eb336f-5756-41e1-8639-c454abdcbaaa" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,418</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f1d759c-b887-4680-bcc8-36da0c3f58ee" contextRef="C_ebe94c6f-4531-439d-ab70-697744f5951a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">422,391</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a87ceee-e9c3-4c7c-bc67-7b26f51f99f6" contextRef="C_1b3ae74c-64c3-410c-a990-9b1b3a879aef" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3152688a-076a-49a6-aaef-c0d5d0040468" contextRef="C_e101de03-ed18-4895-96b6-d6251ed99d3b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">594,809</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasuries, U.S. government agency securities and corporate debt securities are measured at fair value using Level 2 inputs. We review trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants were issued in connection with the underwritten public offering in August 2019 and are accounted for as a derivative liability at fair value (See Note 14). The fair value of the warrant liability was estimated using the Black-Scholes model, which requires assumptions such as expected term, expected volatility and risk-free interest rate. These assumptions are subjective and require judgment to develop. Expected term is estimated using the full remaining contractual term of the warrants. We determine expected volatility based on our historical common stock price volatility. The warrant liability was classified as a Level 3 instrument as its value was based on unobservable inputs that are supported by little or no market activity. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b983bcf6-17f4-41b5-8aff-fcb7c66191df" contextRef="C_4ac1d460-1347-453f-a512-bbc25081089d" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,882,600</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the outstanding warrants as of December 31, 2021 have been exercised or expired.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbdb4f96-4887-4e48-ab10-35cd4b3abe02" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of changes in the fair value warrant liability for year ended December 31, 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80%;"/>
        <td style="width:2.1%;"/>
        <td style="width:1%;"/>
        <td style="width:15.9%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4b83d90-a565-4f15-8663-adf6cdaaf585" contextRef="C_21f845e6-44c3-401e-bfcd-a9d88abc20b3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,016</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decrease in fair value of warrants exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76adfd46-87c1-442e-8c3b-39d4f3eba413" contextRef="C_25c9967d-9381-4ce1-aec3-a06102b373ce" name="dvax:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,801</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants exercised or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dea01024-8698-4407-8d9f-eec8d1c80ef6" contextRef="C_25c9967d-9381-4ce1-aec3-a06102b373ce" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,215</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d120f14e-2e13-495b-b803-cffcf063a8e1" contextRef="C_4ac1d460-1347-453f-a512-bbc25081089d" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34fd003d-2516-4024-9aa2-5e7ccb050eeb" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and Cash Equivalents, Restricted Cash and Marketable Securities </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_643bd8d9-157b-4c06-955f-d135f97d07bb" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.151%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43d8f1ef-4a67-41b2-b89c-0cccf1c3d45b" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,279</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_169673aa-da63-49a1-bb79-3f15bf8a4640" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d42e8a3b-315c-4433-a6d8-7f9c3c1b9ed0" contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436,189</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_030a5d8c-7c33-4a59-ba90-6103938eb1ce" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb64a042-6b38-4867-8734-d0eb22b365cc" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e2c2b77-11ae-45d6-a4ff-5efa14a8a961" contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents, and restricted cash shown in the<br/>&#160;&#160;&#160;consolidated statements of cash flows</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92f87019-6f49-455c-b772-766e663631f4" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,556</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d1b3949-60e7-4746-9a4c-398c200041ca" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00edcfc5-799f-43ff-a2c4-8f62af551cc6" contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436,408</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><ix:footnote id="FNT_4b6758f3-5084-45ca-8640-344a9ad1524b" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted cash is included in "Other assets" in the Consolidated Balance Sheets.</span></ix:footnote></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash balances relate to certificates of deposit issued as collateral to certain letters of credit issued as security to our lease arrangements (See Note 8).</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58d4f3ac-d5cf-48cc-a40a-c15b3de0920f" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents, and marketable securities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50%;"/>
        <td style="width:1.32%;"/>
        <td style="width:1%;"/>
        <td style="width:9.18%;"/>
        <td style="width:1%;"/>
        <td style="width:1.32%;"/>
        <td style="width:1%;"/>
        <td style="width:9.18%;"/>
        <td style="width:1%;"/>
        <td style="width:1.32%;"/>
        <td style="width:1%;"/>
        <td style="width:9.18%;"/>
        <td style="width:1%;"/>
        <td style="width:1.32%;"/>
        <td style="width:1%;"/>
        <td style="width:9.18%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f3d8255-d5e3-41a8-bd1f-285ddae17d2f" contextRef="C_affe35a2-f489-4bea-a377-a5366608b680" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,190</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f7c7554-e5f1-4e2f-8ddf-3fed0eed28c5" contextRef="C_bdafacc4-ce23-4518-be33-853c6f2b2e35" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_506ef04d-3a74-4541-9eb3-aecd0a108267" contextRef="C_bdafacc4-ce23-4518-be33-853c6f2b2e35" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c0f4179-2ad8-4a0e-ba7c-8bf6dfdc18b7" contextRef="C_affe35a2-f489-4bea-a377-a5366608b680" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,190</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0beb4886-04a5-4eab-b105-6174cb5a20d4" contextRef="C_087bb460-7784-4ea1-8991-e6e00539b1cb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_031a0a54-5a72-4099-8e35-3fa1a40eaa7a" contextRef="C_a9ce0868-3fca-4734-adae-586106f4f8d7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62b881a7-c2f7-4702-b0d9-faafb9ee554e" contextRef="C_a9ce0868-3fca-4734-adae-586106f4f8d7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbabef95-8540-4836-9b7a-9a85b5ff89b2" contextRef="C_087bb460-7784-4ea1-8991-e6e00539b1cb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af7c9cf1-574d-4549-a777-37770d024016" contextRef="C_a49cd4e9-42d6-4cad-96d6-a2965e333846" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30c654a9-3eb0-4db1-a3e0-564713cdbb2f" contextRef="C_7e9700d5-220a-480f-9422-65d949c449a0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77394937-fef4-4ded-b99f-d547d7048838" contextRef="C_7e9700d5-220a-480f-9422-65d949c449a0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92d408b6-1f9c-41bc-9ea7-456ac812f7b0" contextRef="C_a49cd4e9-42d6-4cad-96d6-a2965e333846" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,454</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f73f185d-14fc-41e7-b5d9-1cdc2910a201" contextRef="C_876b9f96-bdb9-42b7-883d-e9aed3b08eb2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,278</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12f877d1-25a1-441e-9937-3ebe162d7c0a" contextRef="C_72b2baa2-131f-4929-818e-a53fbd5d4d42" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1e540e3-ab1d-44aa-944b-06ae58080cb0" contextRef="C_72b2baa2-131f-4929-818e-a53fbd5d4d42" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b60a0462-69a9-4624-bd00-1523a9ec7573" contextRef="C_876b9f96-bdb9-42b7-883d-e9aed3b08eb2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,279</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities available-for-sale:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac866117-df69-4a78-9a43-a8cedd325d2a" contextRef="C_bc8ddedc-d903-4ea8-884d-cff004170dad" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,109</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05670f00-af66-4d60-a0bd-1dd6861ca014" contextRef="C_721a703d-dac9-4278-b357-e4756d07b6a8" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56559484-7322-4ad8-a890-5fbb3b02eaff" contextRef="C_721a703d-dac9-4278-b357-e4756d07b6a8" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_767301ac-1735-4fc4-b571-c88fab7f81fe" contextRef="C_bc8ddedc-d903-4ea8-884d-cff004170dad" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,237</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41584850-8057-45f1-8b42-976d999f034a" contextRef="C_f400d9db-46ac-46b2-b217-0a803cda715f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216,265</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a68d01ca-25f8-41bd-b96d-6e7a5b81c125" contextRef="C_e1eda147-6a7d-43bb-8a22-8d62411d3073" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ef08e25-948c-45bb-9f6a-6f4f22b8e38c" contextRef="C_e1eda147-6a7d-43bb-8a22-8d62411d3073" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c1a7223-3b96-43d2-aa7a-3bf1e5f492bc" contextRef="C_f400d9db-46ac-46b2-b217-0a803cda715f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216,688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_449e9142-1838-4023-913e-3a9df453f320" contextRef="C_a78eb8f1-5744-4979-8db7-230dc51613bc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">300,803</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed9e4491-83f8-47dd-a659-3c9d7624ac8c" contextRef="C_a1a8ccc2-b5c3-4443-91b6-3ade9ce8f4e8" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">315</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_312b5524-5559-4f20-8a4b-a86bea0e55bf" contextRef="C_a1a8ccc2-b5c3-4443-91b6-3ade9ce8f4e8" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64f17348-5234-4601-9ef0-6524dc184d5d" contextRef="C_a78eb8f1-5744-4979-8db7-230dc51613bc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">301,098</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities available-for-sale</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_feaf8e2a-8833-4419-885a-e0220e0b0ffc" contextRef="C_333f7989-91c9-45d9-a30d-059fd745363e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591,177</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d56f60d-1cad-4f35-a242-c34474beb101" contextRef="C_709c2910-32d1-45cb-9204-ef2070cb1241" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,179</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06526488-a463-48d9-9727-f29ba7f59658" contextRef="C_709c2910-32d1-45cb-9204-ef2070cb1241" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">333</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d29f871e-f7be-4bbb-aac0-ca41a01b0285" contextRef="C_333f7989-91c9-45d9-a30d-059fd745363e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">592,023</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents, and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71851e65-deee-491c-8da6-9bfe59530b90" contextRef="C_af9c3a6e-6e11-44bc-ad28-b459d2203fed" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">741,455</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ed60859-bc04-4e9a-98c2-45c0800e4c49" contextRef="C_80741f76-5a9d-474f-ac4c-18ba54f8364e" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,180</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65d50376-e011-471e-a53e-9d393ac821d9" contextRef="C_80741f76-5a9d-474f-ac4c-18ba54f8364e" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">333</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6ae52af-3f54-4b30-ac42-860ade855870" contextRef="C_af9c3a6e-6e11-44bc-ad28-b459d2203fed" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">742,302</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ec13a1a-fab3-40bf-b39e-fa1db9692fd0" contextRef="C_1aaf5950-6ea9-46e6-a2da-ed62c66484da" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,586</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da54830f-a69d-4c73-b962-7c8854b8fb0c" contextRef="C_c82b1535-2190-4e2c-8859-50ce0d536831" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80d57ebd-d8c7-4be2-ad67-02e0915186db" contextRef="C_c82b1535-2190-4e2c-8859-50ce0d536831" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba1568a1-d73a-4738-99a9-c9d08793c0e4" contextRef="C_1aaf5950-6ea9-46e6-a2da-ed62c66484da" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,586</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_269992a2-0be3-438b-abae-48d79d5ee53c" contextRef="C_9d5090c3-cf85-4395-8b36-a4feb0cf89ba" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,418</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_691a6cf8-5551-4ad5-8779-df28e0f15a40" contextRef="C_06216486-f415-476b-92e9-c173c38795fe" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd3c82f1-5d09-4a4b-88ce-d5a34a96db36" contextRef="C_06216486-f415-476b-92e9-c173c38795fe" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40b91d9a-34b5-45be-9b43-c46e3784043f" contextRef="C_9d5090c3-cf85-4395-8b36-a4feb0cf89ba" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,418</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1023a14d-063f-4b81-be98-7736c53e3b9c" contextRef="C_6081d343-1a70-4d79-938f-b5c367c4a904" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a446cc36-0317-49bc-a0a0-3972eca7c89e" contextRef="C_8a2ff8b8-7c89-4242-a4e1-a77b739e4b68" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11dbd4d2-29b1-4e07-a3f3-6f878d2f8248" contextRef="C_8a2ff8b8-7c89-4242-a4e1-a77b739e4b68" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d298c1e2-c4f4-4539-baaa-3de0b5f449b9" contextRef="C_6081d343-1a70-4d79-938f-b5c367c4a904" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities available-for-sale:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ef659c9-dfc9-49fc-8f3d-7ff5b719558d" contextRef="C_28ee40ae-f91d-4b89-9194-6b624b4ce391" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,502</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ee24111-2cf5-4f35-94c4-6849804f329d" contextRef="C_58b0bb3f-bb8e-49d1-a9e2-0615cfa1a595" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a03d677d-d544-45bb-a6c3-797281ee6e6b" contextRef="C_58b0bb3f-bb8e-49d1-a9e2-0615cfa1a595" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56908a4f-5904-4d45-89a1-1b7d1ab9f16d" contextRef="C_28ee40ae-f91d-4b89-9194-6b624b4ce391" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b70ca8f-ca7d-4b14-b107-246d2e7e8736" contextRef="C_529c356f-70af-41f9-a631-87c29cdb73e3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,429</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfb2b925-3146-4953-9deb-faaf7058c675" contextRef="C_0797703a-9cf9-4f2a-a2ab-e188c2fa6d75" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d888f67-afd3-4ac6-963c-f8febc98192e" contextRef="C_0797703a-9cf9-4f2a-a2ab-e188c2fa6d75" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_594bdbe1-9e68-4797-990c-c081ee5130df" contextRef="C_529c356f-70af-41f9-a631-87c29cdb73e3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,032</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_177956a1-dd0e-4511-aa8c-a020e5190e6a" contextRef="C_e3e9b8ea-11ad-4a81-b1a0-52ecab46df50" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,865</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c225516-86b2-49e8-9eab-d3386b9439e6" contextRef="C_7697cec1-5a5c-4cda-96a7-3a7c51da9ed4" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67824ba8-6551-42e4-99e4-50e84805ca92" contextRef="C_7697cec1-5a5c-4cda-96a7-3a7c51da9ed4" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">826</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11198afe-593c-4c14-b556-51cd512b6ca4" contextRef="C_e3e9b8ea-11ad-4a81-b1a0-52ecab46df50" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,051</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities available-for-sale</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13124dfc-f68e-4dda-af1f-175da1cc78dc" contextRef="C_68391399-2908-490f-99f6-ed291d638344" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">423,796</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a06880ec-ff3b-4984-a4d6-e60d972e0203" contextRef="C_5ca8debb-5a5e-47ec-ac9b-67db2519efb5" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f4f2b20-88bb-41c6-a64b-a67ce90b5403" contextRef="C_5ca8debb-5a5e-47ec-ac9b-67db2519efb5" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,417</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f734571b-e963-4fd9-b5a1-b1469321ab6a" contextRef="C_68391399-2908-490f-99f6-ed291d638344" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">422,391</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents, and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c4e8730-5508-47b2-b8b9-908507ec0173" contextRef="C_9a546293-5326-4ca1-b866-7d58c5fc2258" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">625,800</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_985e6a31-676d-4304-a91d-6f809115ff2c" contextRef="C_743ce050-0aa0-47d1-90ac-18e05e613453" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a892158-3db3-4373-817b-43f83d24d710" contextRef="C_743ce050-0aa0-47d1-90ac-18e05e613453" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,417</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_630d017b-7a77-45d9-af92-3ddabc9056ab" contextRef="C_9a546293-5326-4ca1-b866-7d58c5fc2258" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">624,395</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82889629-83e1-427b-bd79-a7c8dc5a2153" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The maturities of our marketable securities available-for-sale are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mature in one year or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c846722-2c02-4f92-80cc-783be538ba61" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">440,131</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef4b71a7-cd83-47ee-b693-4d54a9b98af1" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">440,104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mature after one year through two years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ff45412-a191-44bd-9cbb-73c32668db68" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,046</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdf7b02a-17d3-486f-9918-451a63534a62" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,919</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_855a865c-ee81-4072-93e7-da6b6a882aa5" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591,177</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebea6bd0-b004-4dab-8e5d-9194c8ec6db9" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">592,023</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities. Unrealized losses are included in accumulated other comprehensive loss in stockholders&#8217; equity. Commencing with our adoption of ASC 326 on January 1, 2023, we determine whether a decline in the fair value of our AFS debt securities below their amortized cost basis (i.e., an impairment) is due to credit-related factors or noncredit-related factors. Any impairment that is not credit related is recognized in other comprehensive income (loss), net of applicable taxes. Credit-related impairments (if any) are recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Both the allowance and the adjustment to net income can be reversed if conditions change.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">re </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_201dbd20-928c-4712-b152-518e2aaa27be" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cf3fb0d6-5405-4866-a135-7b3aab556e80" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> realized gains </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or losses from the sale of marketable securities for the years ended December 31, 2023 and 2022. We do not intend to sell, and are not required to sell, the investments that are in an unrealized loss position before recovery of their amortized cost basis. For the year ended December 31, 2023, we did not record an allowance for credit losses, as management believes any such losses would be immaterial based on the investment-grade credit rating for each of the investments as of December 31, 2023. As such, there have been no declines in fair value that have been identified as a credit-related impairment.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37272bac-7ffa-45da-97e3-32abac7facd6" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:InventoryDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.13%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories</span></div></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf70ef4c-2f47-4be1-965e-199dd0a9a39f" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents inventories (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.353%;"/>
        <td style="width:2.02%;"/>
        <td style="width:1%;"/>
        <td style="width:12.302000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:2.02%;"/>
        <td style="width:1%;"/>
        <td style="width:12.302000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b336e82-8c27-4438-b8d2-93e415fde571" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:InventoryRawMaterialsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,256</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e60f586d-64bc-4617-ae17-4f1567d9c950" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:InventoryRawMaterialsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,517</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6958548d-f074-4852-93a6-ca34b5fe8575" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:InventoryWorkInProcessNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,954</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cea0607-f1a8-4a53-b532-2ab1782dffaa" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:InventoryWorkInProcessNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,934</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6926160b-0ca3-491f-bf3d-958554a27a9e" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:InventoryFinishedGoodsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a17bf29-221c-4cc0-8ded-fe3a9787c555" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:InventoryFinishedGoodsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,995</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c551bc2-2d15-4f9d-8748-e9392fab1457" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,290</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c236a43-e653-44a6-a41a-252c9fee082b" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,446</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38cc9fcc-46b7-42c8-892d-c3f390fc460e" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and Equipment, net </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c17bfaa1-e3ab-4f65-96d2-a6e86a571e0e" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.65%;"/>
        <td style="width:1.56%;"/>
        <td style="width:16.103%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.282%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Life (In years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e35dde9c-1c91-4584-9739-0403ab8a4257" contextRef="C_c882f98c-09ae-4335-9956-04f9b0df4820" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_babce959-745c-4a72-941d-d91c20b87a12" contextRef="C_be62f7fb-690c-4474-bca0-b70c2e4a2fe2" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39c69625-4f04-42c3-9e20-bec454705df7" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:MachineryAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,752</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da6a3595-889d-46e9-b96c-efc7adcb8e17" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:MachineryAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,139</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_11a094e6-c89e-4e53-b663-2addffcb6574" contextRef="C_01905c0f-bf3b-4a9e-aa83-f267ccc52200" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_4f55c607-b253-42ba-a986-5fe5d5c6ddca" contextRef="C_d63e3291-43c4-4ac8-b139-8fea8704f1a5" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39b5dccf-1c2e-4f16-8e87-59995676808e" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:LaboratoryEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,827</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20dfee14-4069-49b7-ad79-46bca0fe60b0" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:LaboratoryEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,360</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a7caa2a7-41a8-4f8d-8b4a-ede8637756e2" contextRef="C_99635370-1a22-4b6f-b761-e726efa96bc4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f28e996-5dc0-49c4-ab69-29346e578c98" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:ComputerEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,060</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3500051c-6837-4e42-baaa-3efc5a9a6a35" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:ComputerEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,720</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5561cc5d-2cf6-46bc-81a7-348223154892" contextRef="C_8132c0b8-7437-4b80-a8db-085c7a1df0da" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_9b195977-02ce-48ea-93ab-9a7ca0787d6d" contextRef="C_cade9713-0ce0-4b8f-b617-650718d89561" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9987b0e4-f2fc-4115-8717-1cd97d279787" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:FurnitureAndFixturesGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,467</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35f0faff-b1d6-4523-a549-dc3ff30757de" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:FurnitureAndFixturesGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,464</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_457d94ef-5c54-4265-be09-bf610c563ac8" contextRef="C_e8c27e53-0ae1-4e32-8d68-96f7ec110ec2" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_8f6a1a85-58a0-4d3e-a497-86ef760598fa" contextRef="C_187a89d5-4a78-4080-82d7-8eeffa21fc7b" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d989b889-9e95-486c-91fd-5f98322e1fb1" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LeaseholdImprovementsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,201</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70038340-cad1-4416-9b14-a636e8846e7e" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:LeaseholdImprovementsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,822</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0b86fdc-d1fb-440e-a70e-d0ddd37506cb" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PropertyPlantAndEquipmentOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,822</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d121ae63-60cf-42ef-bea3-c36d4329255c" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:PropertyPlantAndEquipmentOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,613</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0e91f7d-02b3-4d3c-8d22-7b635c44d81e" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,129</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5604f14d-5a9d-4563-ac0e-96901aa7808e" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_716f4247-64ac-4502-be8b-26f259119481" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,832</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65c3d0f8-7e29-4070-bb76-bbb7c79484e6" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,522</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd4749a1-af80-4128-9fc7-cfa1c22238d7" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,297</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14237b7c-2d96-4301-b1c5-0b1f2641b970" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,596</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense on property and equipment was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d62963cb-8043-4443-9eba-32006b98137a" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15b76caa-8984-4ded-ae11-f831a29fac03" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3eea359a-2de7-46cb-a482-106d235713c7" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_911ef724-2e00-4ff5-b8c2-2e1348bb1a5d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current Accrued Liabilities</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3142627c-d795-4bf1-b53c-386c77325f9f" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current accrued liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd81ec4f-b4f7-41fc-ae0c-4eb9d0d16d77" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,069</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28b1fa17-c3ea-4591-95db-cd85152967ab" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,261</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue reserve accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4011b980-c9ea-4814-acbf-45a395adc080" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:RevenueReserveAccrualCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c51e66b4-adb6-4737-ba97-d144436206a4" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:RevenueReserveAccrualCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,552</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued inventory</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0fb5978-bbd1-444f-9c31-16ecec2b7be3" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:AccruedInventory" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,456</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5a3f9d2-d785-410e-a075-4680b637ec19" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:AccruedInventory" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,209</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2a3b389-f841-4cc2-8344-0e1ec7fd11d1" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,919</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8d48fce-3420-42d4-81e1-e7e145a72083" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,697</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab12cc20-c63e-411c-9c07-a50201b7e9e0" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,448</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da19ced5-ecc5-423c-9483-463ddfbeb7b2" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,719</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_623abb4f-83e2-4079-886e-a62506bdd502" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We lease our facilities in Emeryville, California and D&#252;sseldorf, Germany. We lease and sublease certain manufacturing and office space with lease terms ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90046f46-632e-4172-a3f3-c10e8b50dfc7" contextRef="C_a7cdc223-9b33-484b-b064-ffbb1dd743fc" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11376bf6-a4e0-41ac-92f8-1f6fb85772f9" contextRef="C_b9c3ac11-c1b5-431c-85fe-3a4cce93994b" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f158626f-455a-45a5-9e56-75891ced6e03" contextRef="C_02645021-8828-4251-8736-7889f9068d7f" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of these leases also include options to renew or extend the lease for two successive five-year terms.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> These optional periods have not been considered in the determination of the right-of-use assets or lease liabilities associated with these leases as we did not consider the exercise of these options to be reasonably certain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also sublease one of our leased premises to a third party. Rent is subject to scheduled annual increases and the subtenant is responsible for certain operating expenses and taxes throughout the life of the sublease. The sublease term expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26a5fbc9-46d3-4e1b-a7a2-b23620d399e2" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, unless earlier terminated, concurrent with the term of our lease. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29c5468a-ab65-4413-8cd0-99d18903b4b5" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:LesseeOperatingSubleaseOptionToExtend" continuedAt="F_29c5468a-ab65-4413-8cd0-99d18903b4b5_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subtenant has no option to </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_29c5468a-ab65-4413-8cd0-99d18903b4b5_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extend </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sublease term.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Sublease income wa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4f8a02b-d2ec-42be-98f5-5ae30a82bb65" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">illion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e167ae61-9cc8-4617-a9ab-f84f66089c6c" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec01e53e-1379-4e53-8584-a48fd723048f" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively. Sublease income is included in other income (expense) in our consolidated statements of operations. Rent received from the subtenant in excess of rent paid to the landlord shall be shared by paying the landlord </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec6f94d3-c429-42b4-a199-7150934f235e" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:PercentageOfExcessRentPaidToLandlord" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the excess rent. The excess rent is considered a variable lease payment and the total estimated payments are being recognized as additional rent expense on a straight-line basis.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1655705a-35ad-42fa-9ae3-72aa7e189a65" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lease expense comprises of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1%;"/>
        <td style="width:10.776%;"/>
        <td style="width:1%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1%;"/>
        <td style="width:10.776%;"/>
        <td style="width:1%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1%;"/>
        <td style="width:10.776%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_393596f9-e841-4cb3-8336-9f5a8af4fb21" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,563</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26a6dce2-c2f5-4b5f-8750-96e3af2ba324" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,222</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c565c625-0184-4133-aafe-fe946c4b15a8" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,265</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2023, 2022, and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_071ae2a8-bda8-4818-86e5-16cc679a26c5" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_7ac0cefc-88d3-417c-8116-a0f12ca933cf" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b54c334-55c7-41f4-9e04-45c404c14007" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively and were included in change in lease liabilities in our consolidated statement of cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5943ae73-bb79-4a5f-82ad-463863992c09" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The balance sheet classification of our operating lease liabilities was as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f58b1a95-4b8b-4052-956a-3314f3bd58e1;"><span style="-sec-ix-hidden:F_92c8237b-9eec-4d96-8dc1-a494a9120777;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of lease liabilities</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(included in other current liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_045b22c2-b7a4-4539-bdea-3e316df37913" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,496</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66088b47-da8e-4d9a-b86d-a42f2b4e036d" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,631</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term portion of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7af77ec8-5204-43c9-bb39-b706e2f15259" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,720</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff8feb48-15d8-45e1-808e-c96ea297efbf" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,801</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec142b4b-b620-46d8-80bf-435f115e7e93" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,216</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05c37b38-befd-4322-a386-27995dd962ba" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,432</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c57d61c-e9ae-42ac-a680-c4b47631223c" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the maturities of our sublease income and operating lease liabilities were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sublease Income</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Lease<br/>Liabilities</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6406e53-4ebb-48f6-83a8-78d4d53cd2e6" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,684</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b03e54cf-fd70-40d4-9f42-f37831c5b5e5" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,605</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d0dc83d-94eb-4099-80de-f1b8b8d60e44" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,854</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cd85de5-a12e-433e-b1c1-9a097f3d7a9f" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a7f29de-e779-4f74-a5af-04b2626773be" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,030</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a270535-f3e2-46a0-ad18-7e5bec7727ca" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,122</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99d94651-86a9-4b31-9914-a5d68117fc14" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d78d58c2-ffb0-4594-b129-ac6a1304fc89" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,052</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d4aaed1-2e82-4415-b571-6da9be61ddb0" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60cb9802-6917-4e3e-84db-9cde3810076c" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,215</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b27609ec-fd6a-4f70-a139-ab26740a1972" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,103</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75d23171-9e69-4ef1-9a82-db1eb98bdae9" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,062</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c24c603c-6922-41a7-b2ae-b5d9079eddae" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:LessorSubleaseRentalsPaymentsToBeReceivedDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,279</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a90247bd-5736-4934-a541-04a0707e71a6" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,036</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90236b97-ee52-4142-abf9-634a3ab641d1" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,820</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1e0237a-8797-4fd3-8ed7-5b776393df54" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,216</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30760b13-2e89-4ad7-9d6a-9fa19844c938" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.343%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.343%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5d92fd73-3c84-4fad-b69f-afb7c1c03128" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b01dd78f-acaf-4d7f-b384-0326ca9ae057" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65efd3f6-44aa-47e9-8ca1-97c064f8b2a6" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c608a141-ad95-49f9-94d7-1d63792c4153" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our material non-cancelable purchase and other commitments for the supply of HEPLISAV-B totaled</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd21c9b3-d5fb-4d4d-98e4-c7da1454b510" contextRef="C_bc9620c9-1c43-40ea-a14b-d5100d03b2e5" name="us-gaap:PurchaseObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">43.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88bfcde2-dfaf-4ba4-a4f8-a7eb09695aca" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:ScheduleOfMaterialPurchaseCommitmentsTableTextBlock" escape="true" continuedAt="F_88bfcde2-dfaf-4ba4-a4f8-a7eb09695aca_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summarizes our material purchase commitments at December 31, 2023 and the effect those obligations are expected to have on our liquidity and cash flows in future periods (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_88bfcde2-dfaf-4ba4-a4f8-a7eb09695aca_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db713321-2133-4b23-a7f7-f082ef6a49a2" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,866</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c75baef8-68bb-4bb5-90ea-dce647faf104" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PurchaseObligationDueInSecondYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,983</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd770089-1515-426e-8df8-cd0dc7184ec1" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PurchaseObligationDueInThirdYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,516</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e4d726a-d2ba-47fa-aa65-14b2b202407c" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PurchaseObligationDueInFourthYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44937cc6-2a5e-41d9-bc9a-07be4c543920" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PurchaseObligationDueInFifthYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40761d86-8b05-493b-a340-55d261b946ac" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PurchaseObligationDueAfterFifthYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_487ad6b8-7a05-4692-a896-adcdb58685e9" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:PurchaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,365</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f6acc80-269a-40b4-9cfa-7b6217d64fbd" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:DescriptionOfAveciaSupplyAgreement"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 7, 2023 (the &#8220;Effective Date&#8221;), we entered into an agreement (the &#8220;Avecia Supply Agreement&#8221;) with Nitto Denko Avecia Inc. (&#8220;Avecia&#8221;) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the &#8220;2012 Agreement&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our aggregate minimum commitment for the supply of CpG 1018 adjuvant under the Avecia Supply Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2162dae1-f825-42c6-8e10-681ac95e1b32" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:AggregateMinimumCommitment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within the next 12 months. As of December 31, 2022, w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e had no non-cancelable purchase and other commitments for the supply of CpG 1018 adjuvant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely on and have entered into agreements with research institutions, contract research organizations and clinical investigators as well as clinical material manufacturers. These agreements are terminable by us upon written notice. Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through the notice period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the aggregate principal amount of our convertible senior notes ("Convertible Notes") was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba28f787-ea96-40c4-a60b-c8fa1ffb5e95" contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">225.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, excluding debt discount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67b001e0-b62a-43aa-8191-3c31f69e97ea" contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (See Note 10).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2004, we established a letter of credit with Deutsche Bank as security for our D&#252;sseldorf lease in the amount of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ee859d6-2c5c-47cd-abd0-2cfa5808415f" contextRef="C_a1ba67ff-228c-4a77-8fbc-f341080d81e0" name="us-gaap:FinancialInstrumentsOwnedAtFairValue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (Euros). The letter of credit remained outstanding through December 30, 2023 and was collateralized by a certificate of deposit for &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6839a99-9db5-4244-a0e2-d733888aeb3b" contextRef="C_a35251a8-36c2-46bd-be47-03e6fe5c7a03" name="us-gaap:FinancialInstrumentsOwnedAtFairValue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_15c280a3-883f-4d8b-9964-a527b6b6ee0c" contextRef="C_a407ebc3-a04a-4922-9be0-f544bb630be4" name="us-gaap:FinancialInstrumentsOwnedAtFairValue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which has been included in restricted cash in the consolidated balance sheets as of December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conjunction with our agreement with Symphony Dynamo, Inc. and Symphony Dynamo Holdings LLC (&#8220;Holdings&#8221;) in November 2009, we agreed to make contingent cash payments to Holdings equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aee61a21-b111-4fcc-86b8-66a2ae3dfb07" contextRef="C_527a5bef-aec8-4da7-8ad2-8c92c7570a64" name="dvax:LicenseArrangementContingentConsiderationPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa3a09ac-48bd-4c42-ba52-b68abe0872d3" contextRef="C_6050d5e9-4d2a-42f3-8f76-80e6c68a8a88" name="dvax:LicenseArrangementContingentPaymentToAcquireLicense" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any third party with respect to the development and/or commercialization of cancer and hepatitis C therapies originally licensed to Symphony Dynamo, Inc., including our immune-oncology compound, SD-101. In July 2020, we sold assets related to SD-101 to Surefire Medical, Inc. d/b/a TriSalus Life Sciences (&#8220;TriSalus&#8221;). We paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_380f781e-4009-4429-afc3-498947cceb67" contextRef="C_61dba5ad-822d-4501-bae4-9a20bd0eed27" name="dvax:PaymentToHoldings" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Holdings in August 2020. In each of September 2021, May 2022 and September 2023, we received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a67901ad-1d82-49ec-a9f4-47f0b85d558e" contextRef="C_7951b5b5-dd53-4f52-b40f-bfff22a01db5" name="dvax:PaymentReceivedForPreCommercializationMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_69bdef77-b2d8-4325-8f8d-b3181f50684b" contextRef="C_c45b2a41-c8d9-409b-9f76-329e71219be7" name="dvax:PaymentReceivedForPreCommercializationMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b8ec34c3-5280-42fe-a3fc-4d5f83a765f0" contextRef="C_d7b73016-1aa5-4068-89fc-abd4a56ae044" name="dvax:PaymentReceivedForPreCommercializationMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from TriSalus because it met pre-commercialization milestones. We recorded the proceeds as gain on sale of assets in our consolidated statements of operations. We paid Holdings $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a713a319-b72a-4d31-8da8-225b0d081335" contextRef="C_29f44f8e-0fe5-45f6-8bba-6cd65b85e586" name="dvax:PaymentMadeForPreCommercializationMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0fd52ac9-593c-4ba7-8d5c-c644079772ad" contextRef="C_4e8bbc07-0e01-4b4f-8236-8ea97338e319" name="dvax:PaymentMadeForPreCommercializationMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_366b2cdc-6f7d-4dac-9e17-39389f8623f0" contextRef="C_25b31f57-0a7e-4cd3-b3c8-ac133125ecf3" name="dvax:PaymentMadeForPreCommercializationMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in each of September 2021, May 2022 and October 2023. We included the payments in selling, general and administrative </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses in our consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may be involved in claims, suits, and proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, commercial claims, and other matters. Such claims, suits, and proceedings are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, such legal proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. In addition, it is possible that a resolution of one or more such proceedings could result in substantial damages, fines, penalties or orders requiring a change in our business practices, which could in the future materially and adversely affect our financial position, results of operations, or cash flows in a particular period.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c048b5b-9f2f-4059-a46d-ff9fd4b55459" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborative Research, Development and License Agreements </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Coalition for Epidemic Preparedness Innovations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2021, we entered into an agreement (together with subsequent amendments, the &#8220;CEPI Agreement&#8221;) with Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) for the manufacture and reservation of a specified quantity of CpG 1018 adjuvant (&#8220;CpG 1018 Materials&#8221;). In May 2021, we entered into the first amendment to the CEPI Agreement. The CEPI Agreement enables CEPI to direct the supply of CpG 1018 Materials to CEPI partner(s). CEPI partner(s) would purchase CpG 1018 Materials under separately negotiated agreements. The CEPI Agreement also allows us to sell CpG 1018 Materials to third parties if not purchased by a CEPI partner within a two-year term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In exchange for reserving CpG 1018 Materials and agreeing to sell CpG 1018 Materials to CEPI partner(s) at pre-negotiated prices, CEPI agreed to provide payments in the form of an interest-free, unsecured, forgivable loan (the &#8220;Advance Payments&#8221;). We are obligated to repay the Advance Payments, in proportion to quantity sold, if and to the extent we receive payments from sales of CpG 1018 Materials reserved under the CEPI Agreement. If the vaccine programs pursued by CEPI partner(s) are unsuccessful and no alternative use is found for CpG 1018 Materials reserved under the CEPI Agreement, the applicable Advance Payments will be forgiven at the end of the two-year term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 27, 2023, we entered into a waiver and second amendment to the CEPI Agreement by and between us and CEPI (the &#8220;CEPI-Bio E Assignment Agreement&#8221;). Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of the outstanding Advance Payments for CpG 1018 Materials allocated to and ordered by Bio E under the CEPI Agreement and has assumed our previous rights to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db8d08a5-847a-4618-8101-7c25c310470c" contextRef="C_e3f4c696-246e-4a9c-a510-583ee8c9731e" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of Bio E accounts receivable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through Decembe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r 31, 2023, we received Advance Payments totaling approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd077e9c-466b-4112-89bc-ad3e7a645fde" contextRef="C_48680940-6818-40d2-9606-4f38488cee91" name="dvax:AdvancePaymentFromCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">175.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million pursuant to the CEPI Agreement, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d1c8b96-7f83-462e-bee1-82dd2d5e26e1" contextRef="C_48680940-6818-40d2-9606-4f38488cee91" name="dvax:RepaymentOfAdvanceFromCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">67.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million have been repaid and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edb73c7e-643e-4bfc-abdb-a986ff21b14e" contextRef="C_48680940-6818-40d2-9606-4f38488cee91" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million have been forgiven (as discussed above). As of December 31, 2023, remaining Advance Payments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_913325f2-7354-44b8-9cee-8641610cbb52" contextRef="C_48680940-6818-40d2-9606-4f38488cee91" name="dvax:AccrualLongTermBalance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million in CEPI accrual long-term were reflected in our consolidated balance sheets, representing the outstanding balance of the Advance Payments relating to the Clover Supply Agreement (as defined and discussed below). As of December 31, 2022, we recorded Advance Payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dc6df21-e13b-4d99-bc93-9fdfa87f1961" contextRef="C_eb7a44e4-c892-49a3-b202-b907c029e24f" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">107.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million included in CEPI accrual. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91c9aceb-c644-4123-8184-17aa19920e92" contextRef="C_48680940-6818-40d2-9606-4f38488cee91" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c297766f-86de-440c-9558-0f621b39e9eb" contextRef="C_eb7a44e4-c892-49a3-b202-b907c029e24f" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> deferred revenue balances related to the CEPI Agreement as of December 31, 2023 and December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, we entered into an agreement with Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited (collectively, &#8220;Clover&#8221;), for the commercial supply of CpG 1018 adjuvant, for use with Clover&#8217;s COVID-19 vaccine candidate, SCB-2019 (together with subsequent amendments, the &#8220;Clover Supply Agreement&#8221;). Under the Clover Supply Agreement, Clover committed to purchase specified quantities of CpG 1018 adjuvant, at pre-negotiated prices pursuant to the CEPI Agreement, for use in Clover&#8217;s commercialization of vaccines containing SCB-2019 and CpG 1018 adjuvant (&#8220;Clover Product&#8221;). The Clover Supply Agreement also provides terms for Clover to order additional quantities of CpG 1018 adjuvant beyond the quantities reserved by CEPI. In 2022 and 2023, we signed four amendments to the Clover Supply Agreement. The terms and conditions of the Clover Supply Agreement were operative through December 2022, and as of December 31, 2022, we had satisfied all delivery obligations thereunder.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For CpG 1018 adjuvant reserved for Clover under the CEPI Agreement, Clover is obligated to pay us the purchase price upon the earliest of (i) the true-up exercise, (ii) within a specified period after Clover delivers Clover Product to a customer, or (iii) Clover&#8217;s receipt of payment for Clover Product from a customer. When we transfer control of CpG 1018 adjuvant that is reserved under the CEPI Agreement, we recognize product revenue and a corresponding contract asset as our right to consideration is contingent on something other than the passage of time, as outlined above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The contract asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88a54740-362c-4946-962c-517c5fbdc92a" contextRef="C_ecd4b79e-9828-475d-9c9f-5c628dfa3993" name="us-gaap:ContractWithCustomerAssetNetCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">71.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million relating to Clover was included in other current assets as of December 31, 2022. The contract asset was subsequently reclassified to other assets (long term) and remains classified in other assets (long term) as of December 31, 2023. The contract asset was reclassified to other assets (long term) to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corresponding Advance Payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7194abb-9fbb-4879-b652-abdb01c692cc" contextRef="C_0a048ebc-c8de-4126-86ee-1592940450b2" name="dvax:AccrualLongTermBalance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million relating to Clover are recorded in CEPI accrual long-term in our consolidated balance sheets as of December 31, 2023. These Advance Payments may be repaid using cash collected from Clover or forgiven in accordance with the CEPI Agreement. We had no accounts receivable balance from Clover as of December 31, 2023 and December 31, 2022. We did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14034396-c4eb-4368-86ba-174e0815199b" contextRef="C_d7e1bd25-a160-4d2a-9aa1-1570a122f4cd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize CpG 1018 adjuvant net product revenue from Clover for the year ended December 31, 2023. We recognized CpG 1018 adjuvant net product revenue o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d949f351-e451-4622-8158-5b9819f5ca0c" contextRef="C_a835f5a8-e3de-4348-8afc-9aa8d3f5191d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">288.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion for the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, during the year ended December 31, 2022 and in connection with amendments to the Clover Supply Agreement, which reduced or cancelled certain orders for CpG 1018 adjuvant, we recorded an inventory write-off of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60ea3a50-205d-4c7e-9485-71c11f6d94eb" contextRef="C_ef72dbdf-e573-4481-9cf4-b43c84730269" name="dvax:InventoryWriteOffsRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">34.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of excess CpG 1018 adjuvant raw materials and finish goods inventory. This excess inventory write-off was reflected as a charge to cost of sales &#8211; product, in the consolidated statements of operations for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biological E. Limited</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, we entered into an agreement (together with subsequent amendments, the &#8220;Bio E Supply Agreement&#8221;) with Biological E. Limited (&#8220;Bio E&#8221;), for the commercial supply of CpG 1018 adjuvant, for use with Bio E&#8217;s subunit COVID-19 vaccine candidate, CORBEVAX&#153;. Under the Bio E Supply Agreement, Bio E committed to purchase specified quantities of CpG 1018 adjuvant, at pre-negotiated prices pursuant to the CEPI Agreement, for use in Bio E&#8217;s commercialization of its CORBEVAX vaccine (&#8220;Bio E Product&#8221;) with specified delivery dates in 2021 and the first quarter of 2022. The Bio E Supply Agreement also provides terms for Bio E to order additional quantities of CpG 1018 adjuvant beyond the quantities reserved by CEPI. In June 2022 and in October 2022, we entered into amendments to the Bio E Supply Agreement (the &#8220;Bio E Amendment No. 1&#8221; and the &#8220;Bio E Amendment No. 2,&#8221; together the &#8220;Bio E Amendments&#8221;). The Bio E Amendments primarily established: (i) a new payment schedule for certain outstanding invoices related to the CEPI product to be the earlier of December 31, 2022, or receipt of certain amounts from Bio E from the Government of India in connection with their advance purchase agreement for CORBEVAX, and (ii) further modified the scope of the Bio E Supply Agreement, by reducing certain quantities of CpG 1018 adjuvant to be delivered. The terms and conditions of the Bio E Supply Agreement were operative through December 2022, and as of December 31, 2022, we had satisfied all delivery obligations thereunder.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had no accounts receivable balance from Bio E. During the first quarter of 2023, we recorded an allowance for doubtful accounts of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdc3d051-663e-494a-9aed-5338b6e8e046" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was determined by assessing changes in Bio E&#8217;s credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (defined below), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 26, 2023, we entered into a third amendment to the Bio E Supply Agreement (the &#8220;Bio E Amendment No. 3&#8221;), and on April 27, 2023, we entered into the CEPI-Bio E Assignment Agreement. Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of remaining amounts outstanding relating to a liability for Advance Payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb0d6777-ebfb-4127-914c-e72c455937c7" contextRef="C_344d9e72-8b1f-4434-9db5-252aa7e877e6" name="dvax:RepaymentOfAdvanceFromCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Bio E CEPI Advance Payments&#8221;) for CpG 1018 Materials allocated to Bio E, and has assumed our previous rights to collect $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1550a324-db8f-49aa-9ec1-1201393c5276" contextRef="C_1bc231fb-46e7-4fb0-a5fd-dde6eed5fb39" name="dvax:RepaymentOfAdvanceFromCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of Bio E accounts receivable. Pursuant to the Bio E Amendment No. 3, we collected $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c5de66d-ae39-4fab-9ab1-8cce94076cc1" contextRef="C_4dc6828d-94e8-4ca1-9e05-1d3d58d0dc47" name="dvax:PrepaymentOfAdvancePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from Bio E (including $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fef69fc-0e6d-42bc-a5ce-ddc7888824b3" contextRef="C_887ba154-ef1b-44c1-92ad-b5335653b28b" name="dvax:PrepaymentOfAdvancePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in April 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89446396-ad66-419a-8aba-f5a94853f4ca" contextRef="C_260c0775-ec5e-4e9a-83f8-a1b4aa2f06c5" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in August 2023). Accordingly, as of December 31, 2023, the CEPI-Bio E Assignment Agreement resulted in: (i) no accounts receivable balance, and (ii) the derecognition of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4933636a-4c22-4c8c-a568-090e6c478aa9" contextRef="C_4720dcda-852f-4e2a-bec3-37de58fa755d" name="dvax:RepaymentOfAdvanceFromCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million CEPI accrual in connection with the Bio E CEPI Advance Payments. The Bio E Amendment No. 3 provides for additional future payment of either $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa4b6acc-64e3-4cb0-949f-390cb1f9eb00" contextRef="C_344d9e72-8b1f-4434-9db5-252aa7e877e6" name="dvax:AdditionalFuturePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the event that Bio E receives at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35ef0311-fbe6-4e23-a682-27a1979ad50a" contextRef="C_344d9e72-8b1f-4434-9db5-252aa7e877e6" name="us-gaap:AdvancesOnInventoryPurchases" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e17f6b88-87b6-4f45-9532-dcefa181f7e1" contextRef="C_260c0775-ec5e-4e9a-83f8-a1b4aa2f06c5" name="dvax:AdditionalFuturePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the event that Bio E receives at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c6cd8f1-5151-4412-8ecc-0f66a3217ccd" contextRef="C_260c0775-ec5e-4e9a-83f8-a1b4aa2f06c5" name="us-gaap:AdvancesOnInventoryPurchases" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in future payments from the Government of India associated with its CORBEVAX product on or before August 15, 2025. These additional amounts are not considered collectible until the achievement of these future milestones.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4544231-524d-49c4-ac72-a4e8369f0e3c" contextRef="C_bc46d573-296e-4a0d-aa85-c245577e3d2d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize CpG 1018 adjuvant net product revenue from Bio E for the year ended December 31, 2023. We recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CpG 1018 adjuvant net product revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1806f1de-18d8-4b5d-9a3f-2e4eba170a81" contextRef="C_fa18ccc3-e6a3-4fc5-84a7-11116a04094b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">206.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Department of Defense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, we entered into an agreement with the DoD for the development of a recombinant plague vaccine adjuvanted with CpG 1018 adjuvant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfe2af15-1424-4340-9fc3-01d27b101577" contextRef="C_17561271-4a7b-4b2f-bb36-76707b8268dc" name="dvax:ProceedsFromGrant" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">over two and a half years. Under the agreement, we are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conducting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a Phase 2 clinical trial combining our CpG 1018 adjuvant with the DoD's rF1V vaccine. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, we executed a contract modification with the DoD to support advancement into a nonhuman primate challenge study, with the agreement now totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_995b534a-cd11-4d4d-a3dd-03c9af663e42" contextRef="C_72dff176-fdce-41b0-bd7a-2057a380f269" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For the years ended December 31, 2023 and 2022, we recognized revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2a21ea3-72bc-4f07-a94a-8db8b9dec6d7" contextRef="C_07eaa0a5-29dc-4366-a233-4616595cc0e8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_996c7f8e-ae98-458f-808f-3fecd2c4f18c" contextRef="C_4f26b2cd-7c84-4953-85e9-83acbeb93d90" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which is included in other revenue in our consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4abdbcda-f13f-4ef2-9a35-2a5228302805" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DebtDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Convertible Notes </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, we issued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_590f10d6-9c05-4833-896c-deb39fcc898e" contextRef="C_bad25b6b-347d-48e5-9b97-3f8c19355518" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">225.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of Convertible Notes in a private placement. Total proceeds from the issuance of the Convertible Notes, net of debt issuance and offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5175bd4a-8143-4621-b51e-96fa9a3931ec" contextRef="C_bad25b6b-347d-48e5-9b97-3f8c19355518" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9087cf85-b15a-4c1c-ab61-c39d9e6d8e2a" contextRef="C_751580b2-fbfe-41c1-b881-e6d093f5c273" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">219.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. We used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76a37206-1aac-4295-b3c8-9af1344095b4" contextRef="C_bbd430d0-723d-4b78-8014-3bf90a7f958f" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">190.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the net proceeds to retire our previous loan agreement with CRG Servicing LLC and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c8d29ab-175d-48a4-a72f-e9c673476ca1" contextRef="C_3fabb2f0-37ad-4f85-8819-9ad5b0716fdb" name="dvax:IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the net proceeds to pay the costs of the Capped Calls described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26cbb44a-32b0-4f3c-8916-9582cb506e3a" contextRef="C_2f6d8975-50fd-4d21-a136-be743356b082" name="us-gaap:DebtInstrumentInterestRateTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Convertible Notes are general, unsecured obligations and accrue interest at a rate of 2.50% per annum payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2021.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Convertible Notes mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b808591-1a0b-4b8e-8a46-d075ced9d28d" contextRef="C_2f6d8975-50fd-4d21-a136-be743356b082" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 15, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, unless converted, redeemed or repurchased prior to such date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Convertible Notes are convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, at an initial conversion rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd8aa758-aaae-4caa-8df5-7394f0f711ab" contextRef="C_2f6d8975-50fd-4d21-a136-be743356b082" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" unitRef="U_pure" scale="0" decimals="4" format="ixt:num-dot-decimal">95.5338</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock per $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05bfa017-c1c7-4d3d-bad4-4c0b70c70028" contextRef="C_f5d40eed-ddd7-4243-9e53-3cfc906ba5a3" name="dvax:DebtInstrumentConversionOriginalDebtBasePrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ad19f9c-954a-49a3-94bc-d2622092813f" contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of our common stock. The Convertible Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding February 15, 2026, only under the following circumstances:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_162f30e3-962e-4e95-8080-c4b9dfbdb6fb" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" unitRef="U_Days" decimals="0" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> trading days (whether or not consecutive) during a period of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61a61193-0fc3-4032-a67e-4f21cc4bcd45" contextRef="C_6f5207a1-1b60-4990-be95-58289e708128" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" unitRef="U_Days" decimals="0" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_152aa301-9a3b-46ce-a5aa-0ca596c3c293" contextRef="C_fcd78d0a-af33-44bf-8d8a-2f5c1a9a376f" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the conversion price on each applicable trading day;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a19a919-0df9-4bf7-91ee-b7b7131f7e23" contextRef="C_38284c71-50a1-429d-8131-ac0563038784" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" unitRef="U_Days" decimals="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> business day period after any </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17b302a3-d4d9-4de6-884f-bc92d3bf307a" contextRef="C_38284c71-50a1-429d-8131-ac0563038784" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" unitRef="U_Days" decimals="0" format="ixt-sec:numwordsen">ten</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive trading day period (the &#8220;measurement period&#8221;), in which the &#8220;trading price&#8221; (as defined in the indenture governing the Convertible Notes) per $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fd62538-8fe4-4e04-b225-f09154646308" contextRef="C_2f6d8975-50fd-4d21-a136-be743356b082" name="dvax:DebtInstrumentConversionOriginalDebtBasePrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> principal amount of the Convertible Notes for each trading day of the measurement period was less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9365f032-787a-448e-a02d-63064f7570fb" contextRef="C_5287e9ff-4a22-4227-b33c-aef9575adc2b" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we call such Convertible Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the occurrence of specified corporate events as set forth in the indenture governing the Convertible Notes.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On or after February 15, 2026, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Convertible Notes may convert all or any portion of their Convertible Notes regardless of the foregoing circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since we have the election of repaying the Convertible Notes in cash, shares of our common stock, or a combination of both, we continued to classify the Convertible Notes as long-term debt on the consolidated balance sheets as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_197a9599-37b4-49c6-b910-c62e63e3fcdd" contextRef="C_2f6d8975-50fd-4d21-a136-be743356b082" name="us-gaap:DebtInstrumentRedemptionDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may redeem for cash all or any portion of the Convertible Notes (subject to the partial redemption limitation described in the indenture governing the Convertible Notes), at our option, on or after May 20, 2024 and prior to the 31st scheduled trading day immediately preceding the maturity date, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we undergo a fundamental change (as set forth in the indenture governing the Convertible Notes), noteholders may require us to repurchase for cash all or any portion of their Convertible Notes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events (as set forth in the indenture governing the Convertible Notes) or if we deliver a notice of redemption prior to the maturity date, we will, in certain circumstances, adjust the conversion rate for a noteholder who elects to convert its notes in connection with such a corporate event or such notice of redemption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We accounted for the Convertible Notes as a single liability in accordance with ASU 2020-06 - </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2020-06&#8221;). As of December 31, 2023, the Convertible Notes were recorded at the aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d71f3fda-0782-465f-a692-7502d002e7a1" contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">225.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million less unamortized issuance costs of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2448b63c-6194-462f-ae83-7d8deb10b3d5" contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million as a long-term liability on the consolidated balance sheets. As of December 31, 2023, the fair value of the Convertible Notes was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_907f2b64-8c6a-4513-93b3-b55cf9cf48c8" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">330.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The fair value was estimated using a reputable third-party valuation model based on observable inputs and is considered Level 2 in the fair value hierarchy. The debt issuance costs are amortized to interest expense over the contractual term of the Convertible Notes at an effective interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c30a5c4a-190c-4731-b178-c267921eb1ca" contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97e02146-ebcd-4c3b-bc88-9c40c8a0f1c3" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:ScheduleOfConvertibleNotesInterestExpenseTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the components of interest expense related to Convertible Notes (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.64%;"/>
        <td style="width:2.06%;"/>
        <td style="width:1%;"/>
        <td style="width:15.620000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:2.06%;"/>
        <td style="width:1%;"/>
        <td style="width:15.620000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stated coupon interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75bc0119-edf3-41ec-b06b-df2950a5522d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,636</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a69c7306-1e29-4163-918d-3a17be0a789a" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,638</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1017605d-aece-42df-b88c-cac90427b1a4" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,121</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_764cc329-5806-43bc-a20e-ad543ae44f30" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,094</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9718ac95-26f0-4af4-8c9b-8fb8bce75732" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,757</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e481711e-afa1-4988-96a3-f709bc405aa7" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,732</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capped Calls</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the issuance of the Convertible Notes, we entered into capped call transactions with one of the initial purchasers of the Convertible Notes and other financial institutions, totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16168ae9-7d21-443e-b19e-848822befe13" contextRef="C_6a1fce12-44dc-4910-9727-fa459734732a" name="dvax:IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Capped Calls&#8221;). The Capped Calls cover, subject to customary adjustments, the number of shares of our common stock that initially underlie the Convertible Notes (or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48fdc47d-e81f-4d10-b717-9919a7657e7d" contextRef="C_6a1fce12-44dc-4910-9727-fa459734732a" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">21,542,871</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock). The Capped Calls have an initial strike price and an initial cap price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc610ba9-f577-43cb-9bef-7289255c0ac3" contextRef="C_c0af7c37-af17-4bba-9ae6-7bbd452527b3" name="dvax:DebtInstrumentCappedCallTransactionInitialStrikePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f379057d-0511-49d2-a280-6e38951d2663" contextRef="C_c0af7c37-af17-4bba-9ae6-7bbd452527b3" name="dvax:DebtInstrumentCappedCallTransactionInitialCapPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively, subject to certain adjustments. Conditions that cause adjustments to the initial strike price of the Capped Calls mirror conditions that result in corresponding adjustments to the conversion price of the Convertible Notes. The Capped Calls are expected to offset the potential dilution to our common stock as a result of any conversion of the Convertible Notes, subject to a cap based on the cap price.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For accounting purposes, the Capped Calls are considered separate financial instruments and not part of the Convertible Notes. As the Capped Calls transactions meet certain accounting criteria, we recorded the cost of the Capped Calls, totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73009a68-97d7-48f4-8a9a-33346fac3a24" contextRef="C_6a1fce12-44dc-4910-9727-fa459734732a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, as a reduction to additional paid-in capital within the consolidated statements of stockholders&#8217; equity.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d8a6333-316d-44f9-8431-bb8efbc24ebb" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:LongTermDebtTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-Term Debt </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-Term Debt</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 20, 2018, we entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddeb8793-8cd0-44fb-9a90-800ff849d6de" contextRef="C_d50c3d18-220b-403a-97e4-cf6868d818cb" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">175.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million term Loan Agreement with CRG Servicing LLC. We borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_450c2c26-e8e7-4c4b-a154-d9009560ceb2" contextRef="C_d50c3d18-220b-403a-97e4-cf6868d818cb" name="us-gaap:SecuredLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the Loan Agreement at closing and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9cd4820-d1bc-4f9f-8ce8-14d4b473f9ca" contextRef="C_b066d0df-653b-4391-8933-b31cdb392277" name="us-gaap:SecuredLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in March 2019 (collectively, &#8220;Term Loans&#8221;). Net proceeds under the Loan Agreement were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e35ff5fb-28b8-413a-8b67-57122a6a92bc" contextRef="C_a2e2ad27-c3c5-4b53-9737-1774805c2105" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">173.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Term Loans under the Loan Agreement bore interest at a rate equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96e2a47c-d1df-4f39-8e2b-a9a3d51fc8d6" contextRef="C_d50c3d18-220b-403a-97e4-cf6868d818cb" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum. The Term Loans had a maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_551e095b-3da9-4150-823f-b844b314ded2" contextRef="C_23485235-7712-4e50-8b13-23e29659179c" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, we repaid the principal on the Term Loans, in full, using the net proceeds from the Convertible Notes issuance. In connection with the early repayment of the Term Loans, in the year ended December 31, 2021, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_004c5867-0a88-4e9c-aac5-b30e5bbbfe18" contextRef="C_ace65c5a-30fc-4278-a936-73964385612f" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million loss on debt extinguishment related to the amount we paid to terminate the Term Loans in excess of its carrying value at the time of the repayment. Our final payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f7fb40e-41f8-43d9-9ed2-21a892c37af0" contextRef="C_23485235-7712-4e50-8b13-23e29659179c" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">190.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to CRG Servicing LLC satisfied all of our obligations under the Loan Agreement. With the full repayment of the Term Loans, all security interests, covenants, liens and encumbrances under the Loan Agreement were permanently released.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63d1b09e-a6fb-4b70-bf59-335b3faad1e4" contextRef="C_9821d0e8-ecc7-4666-9acc-0bbaa41571ea" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of i</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nterest expense related to the Term Loans during the year ended December 31, 2021.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_d7f6ce15-d0e0-49ab-84e4-ca4883046196" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disaggregation of Revenues</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2642bdc-ddfd-479a-8ebc-89a63b0cbe45" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.676%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:5.879%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:6.439%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:6.439%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:5.659%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:5.659%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:5.659%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:5.659%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:4.679%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:5.659%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Product revenue, net</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">HEPLISAV-B</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_025ba77e-f0a1-4706-9e9e-e40beabb9f8a" contextRef="C_b86641c3-95a4-4d1b-8c32-20129a34a510" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,295</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2ef5b6c-22a0-4996-beaf-7311f0c3e32c" contextRef="C_13bbb079-e389-44b2-b0fe-129eed17bc18" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b953b83e-d817-4d85-ae25-75a9891662a9" contextRef="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,295</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b02d7367-4290-4d2c-a7ec-17d87a945ed3" contextRef="C_c385cf83-1634-4094-87c8-c188ad78b7ca" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,996</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e83c04d2-8b53-44a0-b8d5-1a25c62a659b" contextRef="C_3e844c02-fd3f-4039-9675-b2ca051071e0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5bf2fdd-447e-4209-b502-0fbda3607f91" contextRef="C_bb0aaad0-c346-40c7-80b3-5c0e4926bc06" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,937</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_611bf0ba-9d09-4694-97f7-0c921743373d" contextRef="C_de1bbf7b-39e6-455e-a6ad-d72e13ff09c3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,870</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33129447-8bde-4cbe-bd29-ade17294df1f" contextRef="C_4349a3de-f389-4fe9-a46d-67b78b2213f1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17f0a123-797e-40ff-addf-a287b391a83d" contextRef="C_83ebfedc-dcd6-474a-b76f-5c72dd085aac" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,870</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CpG 1018 adjuvant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10e26d23-852f-4b69-85c5-fba25180c01e" contextRef="C_1e94f899-6711-4da9-bcee-5a61cdbdcf61" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37a9d366-4027-4512-a6b5-d6a25778e930" contextRef="C_bf03e8de-4dfe-4921-8f60-87f1256383af" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec7e9813-51da-4112-8616-d6b4500f5ecf" contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c20ce4e-c191-4913-b0af-db97577306fe" contextRef="C_8cebee1a-3aa7-4377-b9dc-63b5df400e74" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaffe092-ab17-4c3d-bc8d-163b1b82b932" contextRef="C_960f69a5-6c26-4021-b7c8-8789aedcdc97" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587,708</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f73938d-745d-45a4-9c88-dd8c224dab78" contextRef="C_51decfbd-05ba-43b9-a300-132adf0402d6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587,708</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2a0c12f-99fe-4027-bf06-a8d20c10ec13" contextRef="C_98f50ec3-eed0-482b-abdc-e3f4d764dcdb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7134515-26e7-4058-93fb-3037042dcec5" contextRef="C_dc5b84ae-0185-4375-b0d0-b39df828ca23" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375,229</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc80df2b-8984-4ee1-b6e3-da8438e589bf" contextRef="C_46ea9e3a-6a19-4c11-a0b8-d28df71f9995" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375,229</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total product revenue, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba420def-fc4b-46a6-8292-4eac896cddf6" contextRef="C_518ea503-766c-4a37-b80d-037d29359c1c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,295</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d186c2ef-af74-4e45-9cba-f22e70a24db7" contextRef="C_931a84ee-4853-4900-bad8-f584f37e2aaf" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_761e7d92-f753-4e84-b8c2-b5f82a5ed83f" contextRef="C_e9ba0f50-bcbf-42ff-bb4d-52d504f7633c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,295</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_543492c5-06bb-45c1-951a-965c27398a7a" contextRef="C_501845fd-14fc-4143-a5da-15378a311c6c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,996</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abf3196c-bf08-4b3e-afce-502e129479ca" contextRef="C_86657944-51ae-463d-89b1-ae4a4ccfa124" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">588,649</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9bc2e5e-acf7-4c70-a893-6c0a48d85a4a" contextRef="C_dfe1bbb8-9cb8-4010-b417-57ad46abca6f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">713,645</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2a8dfb9-aa88-4d96-ac7c-dd808ab42fbe" contextRef="C_ad54aada-ef84-4b1b-b532-5c907b0a02c4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,870</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea63f7da-42c4-4baa-a7f5-7e3164500dcb" contextRef="C_7c9ae35d-bbf7-49a3-ab55-60aabc35c7b8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375,229</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94d0cbcc-c991-4019-9267-d2f109dd62c7" contextRef="C_6423ea24-b03e-48e6-addc-0d0d41661afc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">437,099</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9a90b65-7be8-42a0-bc30-ae6b4c75dae4" contextRef="C_c81fc228-69ab-44c3-95b9-aea5499fe2bb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,650</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99eb184e-c0e1-4b49-863c-8f28d01292b8" contextRef="C_d65d29d7-24ac-4d7b-bfef-53e5f9ec99ef" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,339</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea184078-45ab-45ba-ac69-eaa833ca2e6d" contextRef="C_ce1c0cc3-d217-4341-a89c-76cd4302ac34" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,989</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b53c61e2-426f-406e-a223-59ea8d449f31" contextRef="C_f6d1d749-5eda-4173-857c-d2e9ec42eec9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,774</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2903405-c9a2-4f80-a2c2-5344d4ab240f" contextRef="C_7128fc7b-020c-499d-ae72-19db57703cc2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fc1b3e2-4854-4b1f-a9bb-a6497fe8bded" contextRef="C_600e9b74-60a6-45e3-9267-97174756699a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,038</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad1db50a-347a-48e9-b2e3-b99869d6598b" contextRef="C_5f971b14-535c-4dd6-9f52-1e81c12d5af5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,915</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3a97168-6652-4abb-bccc-d9b576fe07db" contextRef="C_b92550c8-3f5d-45cc-9390-8d5d61858315" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">428</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_521389be-e873-4ec0-a56e-25699167dbca" contextRef="C_e638b00f-55b0-4873-beaa-4bf842f5fdd2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,343</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3991866f-f3fd-449e-8b9d-f6288bc08c6f" contextRef="C_6788e286-c14c-450b-b13d-2eea895a38ad" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230,945</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0b7c1fa-e4d5-4130-abca-00ea8904076a" contextRef="C_0d0c6594-c70c-45dd-b459-b3da8ed9a07a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,339</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcbb9693-8906-4d03-80c0-4e9bbc046777" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">232,284</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62dc3bd7-afff-4d70-b4d5-011fe41aff6d" contextRef="C_b1074222-76a7-46bd-9644-2e3690082980" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,770</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5ba6447-cca6-46f0-980b-c0b49bb28fbb" contextRef="C_b0c51341-46c1-468f-b8a4-d22a9e93bea9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">588,913</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49af9575-2beb-4d7c-8c5f-7c22c7855de9" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722,683</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1535362-34e9-4741-802b-02892beb8970" contextRef="C_21d5cf56-92b9-4489-b44b-c533985be50f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,785</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_642e09ee-a833-4ecb-8924-5efbb2611e14" contextRef="C_92e5b8ce-fc26-44df-be6c-b93ab6266391" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375,657</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5868bb8-d583-45bb-bb1c-d43475b77db4" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,442</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenues from Major Customers and Collaboration Partners</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs and retail pharmacies. All of our HEPLISAV-B sales in Germany are to one distributor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85dd2e9c-f521-4f93-91a7-d3a695d69e1d" contextRef="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:13.523%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:13.523%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:13.523%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Largest customer</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4753f321-8abf-4848-af61-02e78e7d35ea" contextRef="C_79c0f9eb-0184-4dba-a43c-01f7640ee145" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eac599a-fa8e-4731-a208-17fae2ceb2d0" contextRef="C_fdc045d5-f884-4bd3-ac9d-65b497b60faf" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c14179f7-dec9-4a39-ad03-87f68f210efb" contextRef="C_6a1e5c04-44fa-417c-a4e7-018c2ad6e933" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Second largest customer</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f9d45f6-b6d2-41a7-832d-45121993045c" contextRef="C_d9059078-1d7f-42cf-9ac7-53b904e61b2c" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88569167-4023-4414-9e7b-bd40e72ad67b" contextRef="C_70bb3c92-fdce-4bba-8d13-f7445805823e" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_991ad532-0865-485b-bd5f-e6fb4f1f8521" contextRef="C_ad16fd8d-2d92-4d26-8d96-bf058a356d05" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Third largest customer</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ca61c77-cc35-4d9a-813a-0285439c3476" contextRef="C_ef0e8934-759f-4093-bac5-8fa40486ee52" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_216934ce-b087-4141-b381-9f3aac04e673" contextRef="C_c8cf97a7-7cc0-4345-ac03-211d0a8e0250" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b640134-e18e-4334-99d5-231871e7b64a" contextRef="C_a778631e-7026-4533-acd7-c0e2a158a18d" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33c266a4-7c7d-412e-87bc-31b7ccd10c00" contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes CpG 1018 adjuvant product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant product revenue):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.261%;"/>
        <td style="width:1.24%;"/>
        <td style="width:1%;"/>
        <td style="width:13.005999999999998%;"/>
        <td style="width:1%;"/>
        <td style="width:1.24%;"/>
        <td style="width:1%;"/>
        <td style="width:13.005999999999998%;"/>
        <td style="width:1%;"/>
        <td style="width:1.24%;"/>
        <td style="width:1%;"/>
        <td style="width:13.005999999999998%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Largest collaboration partner</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eff81809-1610-4f80-8faa-5c78723d7376" contextRef="C_93b7b614-27fa-4eae-80c5-0b38da148a6c" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7b4d771-21d8-4435-8b6e-ee7090349f35" contextRef="C_4bc4c639-7c83-4569-b3d6-4d528d1abaf5" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da649172-349f-4414-96cd-aa83e8080dc7" contextRef="C_fa937874-39fc-49fc-b659-927ec58d6789" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Second largest collaboration partner</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01d1bbce-3e39-4305-bdd3-0e2c2d34177f" contextRef="C_aa260df4-3e48-4fdf-8ab8-54f380fb7620" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9e66fdb-3215-45b3-95b9-b8d58bfc2fb8" contextRef="C_87f096fc-5022-4951-928c-a55c0c09d734" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_207d0ecb-607b-43b0-a176-2204409c52ba" contextRef="C_d0d39007-043c-4130-9d47-4b28ecc8e767" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Third largest collaboration partner</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e906aff0-e408-4f64-b34e-f85719e13cb3" contextRef="C_93236fd5-e3be-44e0-a948-b795ea15d021" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_111219fe-c248-4d23-a0ba-744fa9127e9c" contextRef="C_a814d382-f3ad-4c19-84d6-7b9bde2b4316" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00455bd0-bf9d-4f86-b534-1fe1bee23272" contextRef="C_cccd4a85-7cd2-47b0-8792-edf0ca811695" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contract Balances</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65aad060-849c-4346-bafb-20e20e39d544" contextRef="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b" name="dvax:SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:25.7%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:11.32%;"/>
        <td style="width:1%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:11.32%;"/>
        <td style="width:1%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:11.32%;"/>
        <td style="width:1%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:11.32%;"/>
        <td style="width:1%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:11.32%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning of<br/>Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Provisions<br/>related to current<br/>period sales</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Credit or payments<br/>made during<br/>the period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Adjustments related to prior periods</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance<br/>at End of<br/>Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2023:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable reserves </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2c509cf-4658-4d4b-b728-8d4a0640a162" contextRef="C_bd4dc0db-3b94-4730-9f10-12f7f1a154c7" name="dvax:ReservesAccrualBalance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,179</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55014c25-30ae-4571-8d55-fc4908e71a29" contextRef="C_52588853-8260-401a-beed-26f3945ae871" name="dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,604</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3da79f1-24c7-4632-b740-8b131a9d2be9" contextRef="C_52588853-8260-401a-beed-26f3945ae871" name="dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf5112d8-1c04-421c-a1d7-be09e25b39c7" contextRef="C_52588853-8260-401a-beed-26f3945ae871" name="dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,629</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6145b6a-d040-4dd6-9cb7-4c98c35a46d0" contextRef="C_5445db9b-2a99-4cf2-a2cd-3f86b5ae5b30" name="dvax:ReservesAccrualBalance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,011</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue reserve accruals </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f05c35cd-44b9-4458-bbd6-5b766235a786" contextRef="C_f9680928-634a-4740-b0dc-8e7ca6e0523a" name="dvax:ReservesAccrualBalance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,552</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4271787-7be9-41a9-9ec1-ae5a48e736d9" contextRef="C_1bdc419f-cd33-4f84-9be9-6a7a197b6800" name="dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,062</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_573be19d-8823-4dbc-8931-9152157e5823" contextRef="C_1bdc419f-cd33-4f84-9be9-6a7a197b6800" name="dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">38,207</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50131afd-0f80-49d3-83f5-48f0a9a291ba" contextRef="C_1bdc419f-cd33-4f84-9be9-6a7a197b6800" name="dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,597</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fd1191c-48bf-416e-9986-9e4ecc313c72" contextRef="C_10088c6a-e568-4bb6-8203-26ba3572c356" name="dvax:ReservesAccrualBalance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2022:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable reserves </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55b39750-cebc-4736-b3f2-9395cfe6ff03" contextRef="C_3ca507f0-264d-4d6b-a1d7-6b4736681fa7" name="dvax:ReservesAccrualBalance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,823</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1008207a-8c71-49e0-993d-4989f909b1a5" contextRef="C_bdb2bd2a-2c3d-42e8-ad0d-04fb4a9ce3fd" name="dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,758</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5edd96ac-e2e3-4eab-ba59-1dce17251a9e" contextRef="C_bdb2bd2a-2c3d-42e8-ad0d-04fb4a9ce3fd" name="dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">30,402</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2db33005-69a9-4d8f-82a2-0a0b43266bb2" contextRef="C_bdb2bd2a-2c3d-42e8-ad0d-04fb4a9ce3fd" name="dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56283b7b-0bf3-4c03-a372-2a21083d9543" contextRef="C_bd4dc0db-3b94-4730-9f10-12f7f1a154c7" name="dvax:ReservesAccrualBalance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,179</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue reserve accruals </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f54dd4fc-9a50-4c74-866f-36bf8b38e7ae" contextRef="C_32dacd1a-2cf4-4e7d-a9cb-0223b786f81e" name="dvax:ReservesAccrualBalance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,253</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66c01725-80e8-4499-8bed-8476bf3e4e03" contextRef="C_011b6204-96fe-4257-8305-4c2c24467a75" name="dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,806</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6af692da-77b0-4aed-aaed-263dbd1e56db" contextRef="C_011b6204-96fe-4257-8305-4c2c24467a75" name="dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,507</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af7984ca-1c6a-4061-9b34-3096cb7c7363" contextRef="C_011b6204-96fe-4257-8305-4c2c24467a75" name="dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8668cc6b-7fde-4c88-a624-d220fba70b18" contextRef="C_f9680928-634a-4740-b0dc-8e7ca6e0523a" name="dvax:ReservesAccrualBalance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,552</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><ix:footnote id="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reserves are for chargebacks, discounts and other fees</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(2) </span><ix:footnote id="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accruals are for returns, rebates and other fees</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When we transfer control of CpG 1018 adjuvant that is reserved under the CEPI Agreement to Clover and perform services under our agreement with the DoD, we recognize product revenue and a corresponding contract asset as our right to consideration is conditioned on something other than the passage of time. See Note 9 for fu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rther discussion. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf30dfe8-5b5e-436c-93c8-4e3cd29c2cc4" contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true" continuedAt="F_bf30dfe8-5b5e-436c-93c8-4e3cd29c2cc4_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes balances and activities in our contract asset account (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_bf30dfe8-5b5e-436c-93c8-4e3cd29c2cc4_1" continuedAt="F_bf30dfe8-5b5e-436c-93c8-4e3cd29c2cc4_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.952%;"/>
        <td style="width:1.941%;"/>
        <td style="width:1%;"/>
        <td style="width:10.004000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.941%;"/>
        <td style="width:1%;"/>
        <td style="width:10.444%;"/>
        <td style="width:1%;"/>
        <td style="width:1.941%;"/>
        <td style="width:1%;"/>
        <td style="width:10.444%;"/>
        <td style="width:1%;"/>
        <td style="width:1.941%;"/>
        <td style="width:1%;"/>
        <td style="width:10.444%;"/>
        <td style="width:1%;"/>
        <td style="width:1.941%;"/>
        <td style="width:1%;"/>
        <td style="width:10.004000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning<br/>of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additions</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Subtractions</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Reclassification (1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance<br/>at End of<br/>Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2023:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract asset, included in other current assets</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3c36f18-2b1d-4b81-b1c8-7e990a1b8f82" contextRef="C_90d829ca-90bc-4f0f-997f-b75da4b1cbeb" name="us-gaap:ContractWithCustomerAssetNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,965</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2703284-0338-4fab-9adc-c678bfd78578" contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722" name="us-gaap:ContractWithCustomerAssetSale" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,650</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6c2e3e9-7ea7-45bb-acd3-c2f99efa17be" contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722" name="us-gaap:ContractWithCustomerAssetPurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,919</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2187e669-a5cb-494d-ae16-0757a0fc46b6" contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722" name="us-gaap:ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,307</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cd4b012-2bd4-43b0-a40d-b6cfbe828de6" contextRef="C_38abd918-f40c-4d00-8c67-0b1cee772c9a" name="us-gaap:ContractWithCustomerAssetNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract asset, included in other assets (long term)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f29e6226-f7ac-44ea-9124-1bc9c7d80f69" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,307</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2b51c62-7479-4845-a81c-0f86478c3c86" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,307</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2022:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_754805ae-a56a-4a8e-a0ae-e63b32428419" contextRef="C_e5e1933f-3515-412a-9687-dae5c9a6b824" name="us-gaap:ContractWithCustomerAssetNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,525</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55623717-770f-4e7d-94aa-437d1d5652c4" contextRef="C_51decfbd-05ba-43b9-a300-132adf0402d6" name="us-gaap:ContractWithCustomerAssetSale" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,556</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba33ceb9-bd1d-4b43-9cfe-4f8d6d09162b" contextRef="C_51decfbd-05ba-43b9-a300-132adf0402d6" name="us-gaap:ContractWithCustomerAssetPurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83bd18a4-9a9c-4336-adb2-24c4f08e340e" contextRef="C_90d829ca-90bc-4f0f-997f-b75da4b1cbeb" name="us-gaap:ContractWithCustomerAssetNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,965</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><ix:footnote id="FNT_cb54f36d-15f9-4a6b-ae57-6ba45a3be2fe" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 9 for further discussion.</span></ix:footnote></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:continuation id="F_bf30dfe8-5b5e-436c-93c8-4e3cd29c2cc4_2"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(2) </span><ix:footnote id="FNT_c5bf0a05-18a8-4de7-a66b-18eb61ca0e15" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> $1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> million of contract asset is derived from our agreement with the DoD</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0944eb02-4cfe-4b4c-b22f-c1cd33f9eff6" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net (Loss) Income Per Share </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net (loss) income per share is computed by dividing net (loss) income attributable to common stockholders by the weighted-average number of shares of our common stock outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the calculation of diluted net income per share, net income attributable to common stockholders for basic net income per share is adjusted by the effect of dilutive securities, including awards under our equity compensation plans and change in fair value of warrant liability. Diluted net income per share attributable to common stockholders is computed by dividing the resulting net income attributable to common stockholders by the weighted-average number of fully diluted common shares outstanding.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f76ef39b-5112-4d07-9698-292ad4816c6d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The numerators and denominators of the basic net (loss) income and diluted net income per share computations for our common stock are calculated as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.34%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:10.84%;"/>
        <td style="width:1%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:10.84%;"/>
        <td style="width:1%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:10.84%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Numerator</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26ff886b-e86d-4b6f-b4ad-aed4771f6fe3" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eda846db-92fd-4e55-8729-64a9fdc45dd7" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,156</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92290cb3-024f-4c99-9175-d67d39506b46" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,713</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: undistributed earnings allocated to participating securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b34aa1a1-d648-4171-ab36-76370fa822b8" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">283</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0cf964c-db55-4b96-9e91-e098008b641e" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,569</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income allocable to common stockholders, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a8ffe1e-7ac1-40b0-a328-515fd66288c0" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b905a4e-583f-43b5-b6fa-49b26bb78a52" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,873</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e67bb3f-48d8-4551-8bf4-c91070dfb548" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,144</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: undistributed earnings allocated to Series B and warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fa4b46b-3e05-4244-9f18-6f07e0ede6b1" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f691935c-5a0a-4bc3-9e89-d013c4720875" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">283</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_270cb1cf-bbed-41d3-ad3d-a4b4306316cd" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,569</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: undistributed earnings allocated to Series B and warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55ccda57-80c7-457e-8ebf-9c5df28778a3" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87480556-f13c-4ab2-a265-88d6cea87ea5" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ec70e68-f26c-4c0e-8370-144e1c15f0a8" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,190</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on convertible notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0779dc2b-092d-448c-9447-ae6763a2142d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:InterestExpenseMediumTermNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9e6ae08-21b1-4b6f-84e0-98e330d43d52" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:InterestExpenseMediumTermNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,044</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73e3350e-42df-44dc-9ba1-5a4583186cf1" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:InterestExpenseMediumTermNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,168</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: removal of change in fair value of warrant liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5f6ebf4-3787-420f-9ecb-9b31aae5ccb8" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:FairValueAdjustmentsOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b320def-7a2d-4492-81e3-6c605995e58d" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:FairValueAdjustmentsOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,801</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38d1560d-3fc0-49be-b783-ba754e7c299b" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:FairValueAdjustmentsOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income allocable to common stockholders, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3315dc9d-cba9-4d29-997b-4cf280f2c6e0" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0864cdd-f0f6-4a7a-a29e-8b818d0a31a9" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296,399</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87388cd0-b433-4e10-aac5-8dab8ea6019f" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,691</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Denominator</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used to compute net (loss) income <br/>&#160;&#160;&#160;allocable to common stockholders per share, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8170e0f3-45db-41b5-afeb-b57cf77e8d43" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">128,733</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5a51826-e2d5-431e-a84a-60a4fadf37d3" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,398</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1095f49a-8f50-45ff-ba5f-42e59160b46b" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,264</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of dilutive shares:</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8416a192-8046-4d0a-9670-57e9c88a7478" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65966d39-034f-437f-a278-09aae8c8a8a3" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,774</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee232b72-9635-40b7-9b3e-72bd34e9e3c6" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,075</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Notes (as converted to common stock)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a3ba2ab-5e42-4320-95a8-4173dcef824d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6186c460-f671-4723-8409-684ed3b0d334" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,543</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f4fbfbe-9548-4106-b8c2-4200596d64c4" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,667</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of dilutive warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4af961d0-6bff-4b17-b3b9-ff75e645e529" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19e71b0a-f7a5-4c75-9bdd-8836b2f6cef9" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_975d223d-e89f-455b-95e3-9d7d029aacba" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used to compute net (loss) income<br/>&#160;&#160;&#160;allocable to common stockholders per share, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37014f2b-8cd2-45ef-b04f-300345d0852f" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">128,733</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25b19c89-a3ca-4fa2-940e-be6d44d1a00c" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,797</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f77cf83e-c98e-40e5-9ee1-e19ca4e31b41" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,006</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a7ce9aa-08dc-4e5c-aa3f-461f94eed65a" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following were excluded from the calculation of diluted net (loss) income per share as the effect of their inclusion would have been anti-dilutive (in thousands).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.269%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:11.438%;"/>
        <td style="width:1%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:11.438%;"/>
        <td style="width:1%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:11.438%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding securities not included in diluted net (loss) income<br/>&#160;&#160;&#160;allocable to common stockholders per share calculation<br/>&#160;&#160;&#160;(in thousands):</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and stock awards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cba23195-8529-45c9-94ab-0fa8249cba51" contextRef="C_1f301073-2f8b-4fb6-92dd-c36e81bb7b9a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,158</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bf748dc-df73-452e-89dd-2f34e442980d" contextRef="C_64302cd3-066f-4f94-90bb-67102762e43f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,165</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00abc395-4b5f-43de-aa2a-351fc0984231" contextRef="C_aa7ac349-6ef6-4d33-8b91-dc174a56618b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,953</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Notes (as converted to common stock)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c0d8e85-b773-4fb6-849d-9351938d09b1" contextRef="C_9b9b2b3e-0d8a-43a5-b40a-ddc5b8ced167" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,543</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23f3440e-e47f-44d1-9d46-24d34ecd7ce9" contextRef="C_ef39c4dd-1299-4749-a67d-a06698c37b4f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3eb13cc-a031-4a84-809a-5f24e0185f95" contextRef="C_120e58b6-236e-4e1b-bac7-eb5813c1cb61" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants (as exercisable into common stock)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_900cfd98-6a8e-4498-ac3e-0d1928d0bf6b" contextRef="C_a1f0d8d2-631d-4ed4-8031-fd5a057c56bd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9626b20b-2304-4d21-83af-366fb95982a1" contextRef="C_44be1a55-42bb-4223-9a35-d53aa56a00cc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23459170-e687-4518-ac38-6a9f75571009" contextRef="C_7da260d2-2100-4998-858a-d9177d745e45" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,883</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd97c2db-41b1-40c4-a094-655c0fa0d29b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock and Warrants</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock Outstanding</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f7f13fdb-5e29-4d10-b682-68dfda518968" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">129,530,228</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ares of our common stock outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We entered into an at-the-market Sales Agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;) on August 6, 2020 and an amendment to such agreement on August 3,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 2023 (the sales agreement as amended, the &#8220;ATM Agreement&#8221;). Under the ATM Agreement, we may offer and sell from time to time, at our sole discretion, shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4cd52ed-55ad-44b0-8cff-844d28cdb16c" contextRef="C_cdaf1c5c-c380-46df-bd25-46af0336eb49" name="dvax:CommonStockSalesAgreementAggregateSalesProceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">120.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through Cowen as our sales agent. We agreed to pay Cowen a commission of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c099c575-788e-4287-ab7e-d027a8a1cf0a" contextRef="C_01f47823-0ce7-49df-83a3-cd706589f4dc" name="dvax:SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the gross sales proceeds of any common stock sold through Cowen under the ATM Agreement. As of December 31, 2023, w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e ha</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_017904c0-5aa5-47f5-8ef5-7be096a49ffd" contextRef="C_26a1416a-c87f-4567-b7f7-4e8b77e534c8" name="dvax:ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">120.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million rema</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ining under the ATM Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, all of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3add0de-e2aa-4d33-a5a6-bb873dfd9031" contextRef="C_1d98acd8-10b6-453e-b7a4-a290b0056620" name="dvax:NumberOfCommonStockWarrantExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,882,600</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding warrants as of December 31, 2021 were exercised or expired, resulting in cash proceeds totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_826f1b3d-d86a-4603-af14-21a7ec0b645b" contextRef="C_7a801bf1-6b19-4a7c-8dc9-d56926556425" name="dvax:CashSettlementOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, we recognized</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decrease in the estimated fair value of warrant liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_496b574b-af45-49a6-b051-bc36883b7cd9" contextRef="C_ef4a36fd-eaf7-46db-ac29-52ed918668e8" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as income in other income (expense) in our consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_570f4054-52a2-48cc-a7e6-1ee24e194cc5" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Plans and Stock-Based Compensation</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2021, we adopted the Dynavax Technologies Corporation 2021 Inducement Award Plan (&#8220;2021 Inducement Plan&#8221;), pursuant to which we reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e34fb42-ebd6-43df-827f-bb276109f7f7" contextRef="C_a210ba4e-63a8-4224-b689-4b3fcc4782cb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for issuance under the plan to be used exclusively for grants of awards to individuals who were not previously our employees or directors. In June 2021, we amended the 2021 Inducement Plan (&#8220;Amended 2021 Inducement Plan&#8221;) to increase the number of shares of common stock reserved under the 2021 Inducement Plan to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98c5c983-42b0-442a-858e-eb19bb2f598b" contextRef="C_4a1fceba-ab37-4367-a47b-ccd8390d5afa" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Amended 2021 Inducement Plan was terminated effective as of April 3, 2022 and, therefore, there are no shares of our common stock available for grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2022, our stockholders approved the amendment and restatement of our 2018 Equity Incentive Plan (the &#8220;Amended 2018 EIP&#8221;) to, among other things, increase the authorized number of shares of common stock by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95919680-e634-42d1-b073-e4a4b3c928b7" contextRef="C_61e4fae6-429a-477a-9549-6b5ff699fbf7" name="dvax:IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The maximum number of shares of common stock that may be issued under the Amended 2018 EIP, will not exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9753d8e-90a3-4078-af0b-d74d7d5f6f7b" contextRef="C_3a3dbbd9-f7d4-4560-b0a0-3f291802b72e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">32,600,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. As of December 31, 2023, the Amended 2018 EIP and the Amended and Restated 2014 Employee Stock Purchase Plan are our active plans (the "Plans").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Amended 2018 EIP is administered by our Board of Directors, or a designated committee of the Board of Directors, and awards granted under the Amended 2018 EIP have a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46f5a5e7-ffe1-4065-bd49-4fe0769b49cb" contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unless earlier terminated by the Board of Directors. As of December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b686388-57be-4b93-95db-d9cf2669fc53" contextRef="C_5e53f99f-a072-4fb9-b577-17596226d68f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,388,428</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock reserved for issuance under the Amended 2018 EIP.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under our Amended 2018 EIP, we may grant stock options, RSUs, performance-based awards, and other awards that are settled in shares of our common stock. Our equity awards generally vest over a three-year period contingent upon continuous service and unless exercised, expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6d4caeb9-dd64-4460-a26d-4c0009adec9d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de0fe847-c559-4eaa-be2c-4d3c841702a0" contextRef="C_0d83504a-3b1b-47be-be67-be586b5c04f8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant (or earlier upon termination of continuous service). Activity under our stock plans is set forth below:</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_286b7a5b-eec6-46fb-a173-f92717f0e4a5" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity of stock options for the year ended December 31, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.24%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:14.7%;"/>
        <td style="width:1%;"/>
        <td style="width:2.32%;"/>
        <td style="width:1%;"/>
        <td style="width:12.32%;"/>
        <td style="width:1%;"/>
        <td style="width:2.94%;"/>
        <td style="width:1%;"/>
        <td style="width:12.8%;"/>
        <td style="width:1%;"/>
        <td style="width:1.78%;"/>
        <td style="width:1%;"/>
        <td style="width:9.6%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares Underlying <br/>Outstanding Options<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise<br/>Price Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_236c1be3-0bfb-4955-8db1-7538eaab51c5" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,339</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d865c2a0-f89b-4a58-9c71-8b98bf8367e3" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.70</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f9053398-054c-431c-9914-625b18d5a788" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.61</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dacce46-3074-4906-a512-d34638f55465" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,291</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_038f6404-698d-4643-9701-ea7876d15a0c" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f5afa8c-27bb-45da-bdab-02b389c4229c" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.17</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ccd2c4a-2d38-4b6b-9443-72458a4983bb" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">850</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d176c2d7-5b25-4571-bb2e-0f481ad3fbc7" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options cancelled:</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options forfeited (unvested)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cab392c-b17d-454c-ae88-0ac22c7499af" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d97b8ec-9be7-410c-bbcf-1c98fe4f2589" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options expired (vested)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_003d1f88-560d-41f3-a77c-9f14ac87c404" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">261</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_343eefa7-36d7-441f-a431-9b6b14d6b0f8" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">21.39</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f805246-0925-47b5-afaa-b3fe69b43bf9" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,120</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bdf8d89-1f79-4ed8-9385-90ab21b88b57" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3b03defe-7a21-40ac-a3ad-8618433be67b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.18</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c81d986-8e95-48a2-ae9c-f8f9166fcafa" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,388</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcea7bdc-71bd-4e8d-a99c-5fbc348e9741" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,976</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_875dfe6c-5643-4953-a6a9-ef7f2ec4ac0d" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.77</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e2770859-2998-41fe-ab97-5963f3051464" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.15</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9a54d43-e286-4a9d-a549-978084fd78ce" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,024</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85842aa4-d84e-425b-99b5-b082be577298" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,014</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfccbbed-dba7-4d22-8c19-6f0eac1c843c" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b6c99195-228b-4857-b5fd-898171dd0c11" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.50</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95267f25-91b6-4e73-b226-09d3537ddb77" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,613</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense related to options was approximat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49edc703-9718-40b9-a4b2-e874f57fc43a" contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fd34d88-4598-46a8-a8c0-b0f604d80515" contextRef="C_98bd1202-de67-46fa-812a-b3388651d485" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ec0ab45-8bc7-40fb-a624-e0759f9a7128" contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total intrinsic value of stock options exercised during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7957a12-accb-4846-a0b5-8c78e0bd46aa" contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21c13c0a-907d-443f-a5f6-c1a88a29d5aa" contextRef="C_98bd1202-de67-46fa-812a-b3388651d485" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92fc3e99-a4b8-4733-b864-17251316aa51" contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The total intrinsic value of exercised stock options is calculated based on the difference between the exercise price and the quoted market price of our common stock as of the close of the exercise date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total fair value of stock options vested during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f12f6f65-5cf6-42fa-ae3f-1b5304e6ca38" contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad6448e1-6fda-44a0-a356-45c287f3c75b" contextRef="C_98bd1202-de67-46fa-812a-b3388651d485" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de1fedc5-70bd-40bf-8f8f-93ad80a7aa93" contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a17a6bde-25ac-4c28-b508-cc7171a17d09" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity of RSUs for the year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55%;"/>
        <td style="width:1%;"/>
        <td style="width:17.46%;"/>
        <td style="width:1%;"/>
        <td style="width:3.36%;"/>
        <td style="width:1%;"/>
        <td style="width:20.18%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares<br/>(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Grant-Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fb797b5-0179-4af2-b42d-a782fc1780a4" contextRef="C_2ccde060-5732-4dbe-854e-2ad06dd8b47e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,479</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d8dc17d-69f2-48dc-a399-012a6781153a" contextRef="C_2ccde060-5732-4dbe-854e-2ad06dd8b47e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.00</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ca34729-041f-4f3a-8e25-03a1bf7ae1db" contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,748</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c02a99f9-ea68-49b6-8170-0354cba467a9" contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2020b3e4-1f4a-4785-a846-ac2f166dc9d8" contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,515</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70c93f68-26e0-4dc6-9761-1747a7bdeee6" contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30354380-cb5a-437e-8ae4-76bfd12117d3" contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa63b418-5682-46d8-960f-f96b38bb28bf" contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.45</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b5a3faf-7420-4c2c-8ab9-7e3593db4ca6" contextRef="C_7000fe3e-8aa0-4198-8de5-4640128d667d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,445</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67512fcd-666a-417f-b42d-8cfeadab20c5" contextRef="C_7000fe3e-8aa0-4198-8de5-4640128d667d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.57</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><ix:footnote id="FNT_f71fd845-812c-43cf-97f6-a213c94f92fc" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inclusive of approximately 600,145 RSUs for the year ended December 31, 2023, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital.</span></ix:footnote></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense related to RSUs was approximat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa5fcb9e-a0e8-4c3d-9fe4-3773dbc9a577" contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77" name="us-gaap:RestrictedStockExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6f401ce-d8c3-4783-88ac-5950a3817bbd" contextRef="C_452bdfa1-ad45-4a00-a35b-9cb73b9e9295" name="us-gaap:RestrictedStockExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f9fa626-9af5-4291-b0f1-6edc52a553ec" contextRef="C_90d340bb-3e21-4b45-b920-340abe04b8ac" name="us-gaap:RestrictedStockExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The aggregate fair value of the RSUs outstanding as of December 31, 2023, 2022 and 2021, based on our stock price on that date, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7299d9a8-450d-4a76-9f81-70f50228c54f" contextRef="C_7000fe3e-8aa0-4198-8de5-4640128d667d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">llion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5790fbe1-df1c-48b7-a319-99a264b4bae4" contextRef="C_2ccde060-5732-4dbe-854e-2ad06dd8b47e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ca9bb1d-50d4-4436-8b04-5cf8f764a850" contextRef="C_d2ca19d3-f268-4784-a5f2-05a124a3d30c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total fair value of RSUs vested during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52bb1a4f-5e46-47cf-9fcd-9f52cd20a55d" contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">illion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53590135-b45b-4e98-bba0-ecd5d412da9a" contextRef="C_452bdfa1-ad45-4a00-a35b-9cb73b9e9295" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72e4e716-a758-4df5-af1e-f163bf76b1ff" contextRef="C_90d340bb-3e21-4b45-b920-340abe04b8ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market-based Performance Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We granted PSUs to certain executives. These PSUs vest upon a specified market condition. </span><span><ix:nonNumeric id="F_86ee72a1-426b-4a2d-99a8-c9d3f28f3579" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock" escape="true" continuedAt="F_86ee72a1-426b-4a2d-99a8-c9d3f28f3579_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summary of PSU activities for the year ended December 31, 2023 is as follows:</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_86ee72a1-426b-4a2d-99a8-c9d3f28f3579_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1%;"/>
        <td style="width:13.383%;"/>
        <td style="width:1%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Grant-Date Fair<br/>Value Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00b5076f-6288-4d63-86f2-4818ab14bd04" contextRef="C_1bd10d4c-3dad-4350-b83d-0c72c2905fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5369f263-5ef7-4229-a0c4-b128ea97e759" contextRef="C_1bd10d4c-3dad-4350-b83d-0c72c2905fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f4077e7-d8c5-4b98-a8df-f8dd67490059" contextRef="C_2b70264d-6f06-4292-a106-b2ff81f59d36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">364</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_457795dd-7ba8-4df2-9d20-b5b3e02e1ca1" contextRef="C_2b70264d-6f06-4292-a106-b2ff81f59d36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.25</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6c136c3-8ecc-4152-9317-fadf31e3ab94" contextRef="C_ec73c440-29fa-41e8-b4b7-62558e948364" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">557</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_451b44b6-7d6d-40e5-a0b6-7a2ca0bf7ae3" contextRef="C_ec73c440-29fa-41e8-b4b7-62558e948364" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.95</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense related to PSUs was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_963aedda-38ee-4809-89fc-f7eda704d8a8" contextRef="C_2b70264d-6f06-4292-a106-b2ff81f59d36" name="us-gaap:RestrictedStockExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4192bb13-f403-48fd-b4c8-8f9c3f674edd" contextRef="C_fd1be51a-97e7-41a8-8c3a-1b53c43091c6" name="us-gaap:RestrictedStockExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_399152d1-317f-407f-9c53-04ec74d5b9ad" contextRef="C_00cf7693-c589-4da2-bf41-f883d3c76f3a" name="us-gaap:RestrictedStockExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively. The aggregate intrinsic value of the PSUs outstanding as of December 31, 2023, 2022 and 2021, based on our stock price on that date, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82dd3e5f-d8d4-4178-8ff9-b14696279819" contextRef="C_ec73c440-29fa-41e8-b4b7-62558e948364" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_813ce2bf-9f10-488d-9daf-dced28ccfda3" contextRef="C_1bd10d4c-3dad-4350-b83d-0c72c2905fea" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d93938f-c518-458d-88cb-fa4eb7c9ec2f" contextRef="C_5fdc1062-7a2e-42a6-a0ee-956964678351" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance-based Options</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">y </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e2c73b0-69b9-4712-82ff-d6ddcff22c05" contextRef="C_fcb751e6-cdea-4a40-9300-946017e2ec1e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">36,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares underlying performance-based options were outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Assumptions in Estimating Option Fair Value</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he fair value of each time-based option is estimated on the date of grant using the Black-Scholes option valuation model. The fair value of each RSU is determined at the date of grant using our closing stock price. The fair value of each PSU is estimated using the Monte Carlo simulation method on the date of grant. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adda5ad2-bb44-497a-82a7-f23cecc7a314" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_adda5ad2-bb44-497a-82a7-f23cecc7a314_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions used in the calculations of these fair value measurements are as follows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_adda5ad2-bb44-497a-82a7-f23cecc7a314_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.712%;"/>
        <td style="width:1.823%;"/>
        <td style="width:1%;"/>
        <td style="width:4.832%;"/>
        <td style="width:1%;"/>
        <td style="width:1.823%;"/>
        <td style="width:1%;"/>
        <td style="width:4.832%;"/>
        <td style="width:1%;"/>
        <td style="width:1.823%;"/>
        <td style="width:1%;"/>
        <td style="width:4.832%;"/>
        <td style="width:1%;"/>
        <td style="width:2.004%;"/>
        <td style="width:1%;"/>
        <td style="width:4.832%;"/>
        <td style="width:1%;"/>
        <td style="width:1.182%;"/>
        <td style="width:1%;"/>
        <td style="width:4.832%;"/>
        <td style="width:1%;"/>
        <td style="width:1.182%;"/>
        <td style="width:1%;"/>
        <td style="width:10.322%;"/>
        <td style="width:1%;"/>
        <td style="width:1.823%;"/>
        <td style="width:1%;"/>
        <td style="width:4.832%;"/>
        <td style="width:1%;"/>
        <td style="width:1.823%;"/>
        <td style="width:1%;"/>
        <td style="width:4.832%;"/>
        <td style="width:1%;"/>
        <td style="width:1.823%;"/>
        <td style="width:1%;"/>
        <td style="width:4.832%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Options</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Market-Based Performance Stock Units</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Employee Stock Purchase Plan</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65474d94-9a10-4a74-902a-5d13c2928491" contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.32</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b779fab7-ad44-4718-840b-2ef9e6810bbc" contextRef="C_98bd1202-de67-46fa-812a-b3388651d485" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.95</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4085198c-c1f7-4efb-9d00-de3091f97974" contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.17</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e781c6ef-2c9f-4835-b176-08edaf62a226" contextRef="C_25a5468a-bacc-477f-bef1-e85543a6913f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.25</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79dfb1bf-3de9-44fe-b998-240d88fca2a2" contextRef="C_35f1c43c-dc20-4692-ac8b-37df12d565ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78e2bf2c-988a-42d7-b8d3-6852896480e3" contextRef="C_0c1e3d78-dd4b-4d59-b5e6-4fe90c415647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfc698e7-a1cc-4eae-bddf-3dfa661265b4" contextRef="C_3d661040-605b-43cf-b60b-b20b979ad675" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.35</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_819cdd84-011b-439e-a698-417cf23f00f5" contextRef="C_fbe06c3d-ec16-449f-bdd3-62e26d98ec74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.37</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a5f2c1c-8ef2-441a-a05e-985465530579" contextRef="C_0e30bc85-1e80-4230-b3a9-6904f8577805" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8372cca6-ae0c-48ad-8c1d-bb1a467f8e66" contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f474c50-c179-4c8b-9fa7-e3a4981cbd5e" contextRef="C_98bd1202-de67-46fa-812a-b3388651d485" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aec17192-4eea-4928-b806-adfb16c51c05" contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63fca2a5-6d9f-4bf4-ae47-655ab4ecc5c8" contextRef="C_25a5468a-bacc-477f-bef1-e85543a6913f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bc68821-8b2d-48e0-8c44-d60065617f3a" contextRef="C_35f1c43c-dc20-4692-ac8b-37df12d565ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">From </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0557c2c-50c8-4c62-928a-e9077d13396c" contextRef="C_4e3ef292-a629-4f6e-9ba6-f332258de6b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d009fdfd-7850-4bf7-9286-2e6bd3450385" contextRef="C_6cd9059e-33d1-45f0-85b0-9bedacb0a4f0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae778bbd-81d0-4fa9-9bfd-e7519c69d37d" contextRef="C_3d661040-605b-43cf-b60b-b20b979ad675" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c017bdb-fe51-435b-961e-a9138cfb8a03" contextRef="C_fbe06c3d-ec16-449f-bdd3-62e26d98ec74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13d6ef81-e2be-4794-9323-be531d7287cc" contextRef="C_0e30bc85-1e80-4230-b3a9-6904f8577805" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_610936e6-1dd6-452a-a061-1bc81766d830" contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ddececc3-db50-495d-b455-6aa1de7973d1" contextRef="C_98bd1202-de67-46fa-812a-b3388651d485" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f74605b9-1a42-4236-a0d1-a9067097e5ec" contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_32471554-009b-4395-9c96-342c48ddcfb5" contextRef="C_25a5468a-bacc-477f-bef1-e85543a6913f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5d9365dc-7b1b-4597-afeb-69c9914d4ee7" contextRef="C_35f1c43c-dc20-4692-ac8b-37df12d565ea" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_05c13f68-9403-449a-b438-dc88c9c7fc9c" contextRef="C_0c1e3d78-dd4b-4d59-b5e6-4fe90c415647" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_476630d6-1d0d-4f05-b209-ff7b64cfd5ae" contextRef="C_3d661040-605b-43cf-b60b-b20b979ad675" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a08645ce-cfe2-476b-afbb-ee02e3f025e7" contextRef="C_fbe06c3d-ec16-449f-bdd3-62e26d98ec74" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6d523e9a-3999-4e2b-93a7-f43a2b08296a" contextRef="C_0e30bc85-1e80-4230-b3a9-6904f8577805" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bac16705-8922-48ed-b73c-21e35d7d114a" contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49a826c9-3bd9-4918-aade-bc1038e26c16" contextRef="C_98bd1202-de67-46fa-812a-b3388651d485" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e383eb1c-73f9-4f08-b073-125caefad644" contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a415e00a-b342-4826-9c7d-d698b43d4c62" contextRef="C_25a5468a-bacc-477f-bef1-e85543a6913f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f37984b-f486-4aef-a558-e41b220eea12" contextRef="C_35f1c43c-dc20-4692-ac8b-37df12d565ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48250372-cabf-4141-bdb8-e7a6a769716b" contextRef="C_0c1e3d78-dd4b-4d59-b5e6-4fe90c415647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a96a3d77-4d54-45c7-8360-39d7926ad2a6" contextRef="C_3d661040-605b-43cf-b60b-b20b979ad675" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11e7b689-4319-4597-ac4f-7fef82ebf545" contextRef="C_fbe06c3d-ec16-449f-bdd3-62e26d98ec74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cd54ed0-dc7f-4135-8a12-3991c87ad675" contextRef="C_0e30bc85-1e80-4230-b3a9-6904f8577805" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility is based on historical volatility of our stock price. The expected life of options granted is estimated based on historical option exercise and employee termination data. Our senior management, who hold a majority of the options outstanding, and other employees were grouped and considered separately for valuation purposes. The risk-free rate for periods within the contractual life of the option is based on the U.S. treasury yield curve in effect at the time of grant. Forfeiture estimates are based on historical employee turnover. The dividend yield is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35b6dbc9-3573-4d9a-86cf-85b3b6455129" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> percent for all years and is based on our history and expectation of dividend payouts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity awards with time-based vesting, the fair value is amortized to expense on a straight-line basis over the vesting periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also granted performance-based equity awards to certain of our employees. For equity awards with performance-based vesting criteria, the fair value is amortized to expense when the achievement of the vesting criteria becomes probable.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5994c16d-6de7-4ca4-8cd8-a7507e8055b1" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock-based compensation expense recorded in each component of operating expenses in our consolidated statements of operations, and amounts capitalized to our inventories (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.62%;"/>
        <td style="width:2.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.22%;"/>
        <td style="width:1%;"/>
        <td style="width:2.12%;"/>
        <td style="width:1%;"/>
        <td style="width:8.4%;"/>
        <td style="width:1%;"/>
        <td style="width:2.12%;"/>
        <td style="width:1%;"/>
        <td style="width:8.4%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employees and directors stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe31b39a-5029-48fb-a706-11d5b442caf4" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,592</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abd35de5-08b6-4310-8ad8-e2a039aec188" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,915</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8f202d9-bc7a-48ea-9fce-9f56e477e01c" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,285</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a77db1cb-6415-4e11-9fb9-4ddcddf790de" contextRef="C_3226f406-b30a-4fe8-b77d-6acd3bc687cf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,285</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65d61024-4de9-44fb-bac7-bf0ac0df4393" contextRef="C_a7cd9712-92a6-43fa-a3e4-620df529380f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,954</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4af46ff-00ee-4402-971a-15bfe92d3f70" contextRef="C_b162a2fb-1421-4817-89b7-7fd0107432f6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,818</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e610e3b-85b2-4ca0-a9f4-6a9508b624c0" contextRef="C_0cd05fc1-4367-467f-b1f4-b88105492b67" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,069</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25b810e9-9be5-4c75-90df-b0a422e49f36" contextRef="C_065dab0d-65d8-4bc3-b27e-bda7f559f545" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5c04cb0-d71e-4923-8981-99b506c60674" contextRef="C_8aafc35f-0931-49c4-99f3-ba14874dc415" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,894</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales - product</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24d6135a-8047-408e-b657-6e42d4cb2c9b" contextRef="C_c265dbab-c590-4635-805d-fcfcffc40237" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,839</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_061a3e3c-3c4c-4e90-96bf-f088eec4f6e8" contextRef="C_6adf0287-276d-4c38-aa2a-2587117e5871" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_083faa5d-11da-44c1-bd84-8f645d48113d" contextRef="C_5d1752d7-1a8f-47fe-a52e-e23618ff2973" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">553</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a78e4525-b050-4af9-9878-51b3f8fa257b" contextRef="C_99afab35-99e9-4d2e-bfac-d15173962934" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,399</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc9a09c4-19a1-4de1-9d80-1bdb443543b7" contextRef="C_39e6c092-46ac-445b-8f0b-7dcdd766c1ea" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,720</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffcd49b0-6ab7-434e-ac48-91e7a5df6748" contextRef="C_c4818259-befe-457e-b5e4-83ccf0a85a8d" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,020</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ee13694-9f94-4b94-8c44-227e3e0d30f8" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,592</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1921901e-1d66-46d9-a249-6b9ca4071127" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,915</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c111b6a9-d8a5-4327-bc32-b2f07f96f9f9" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,285</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the total unrecognized compensation cost related to non-vested stock options and RSUs deemed probable of vesting, including all stock options with time-based vesting, net of estimated forfeitures, amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09ef9a11-26b9-445d-a493-814c5326bc32" contextRef="C_ab1c6ec8-3564-4d41-9ebc-32087bc08f68" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">46.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over the remaining weighted-average vesting period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aafd2fbc-2911-40f2-8dcf-0f7fa67d0190" contextRef="C_497a4353-898d-4ae9-9975-8c32c4ebb9d3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. As of December 31, 2023, the total unrecognized compensation cost related to PSUs amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4602a102-726c-423b-9a9a-965a0efe5f4d" contextRef="C_96ad4e0b-9a01-4e43-b0c5-c677a5fe8543" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Amended and Restated 2014 Employee Stock Purchase Plan (the &#8220;Employee Stock Purchase Plan&#8221;) provides for the purchase of common stock by eligible employees. In May 2021, our stockholders approved the amendment and restatement of the Employee Stock Purchase Plan to increase the authorized number of shares of common stock by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcbfe70c-53d5-4936-b8cb-d9000bcac73d" contextRef="C_19035b31-a18b-4349-93e6-45dccd60c49e" name="dvax:IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The maximum number of shares of common stock that may be issued under the Employee Stock Purchase Plan will not exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffd6c2a2-e247-4090-89ea-0538fb78e140" contextRef="C_304335a0-4bda-469c-809d-39c049a6dfae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,850,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purchase price per share is the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1fcab9a-9245-4845-818b-f1060ab17936" contextRef="C_54064a80-7e76-458d-93d5-b4613985ec73" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the common stock on the commencement of the two-year offer period (generally, the sixteenth day in February or August) or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d2e266f-4e7b-4b57-a1f3-af50773b6bab" contextRef="C_9bbfa976-1e7d-4da7-bc09-d8fb7b04dbd9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the common stock on the exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August). For the year ended December 31, 2023, employees have acquired approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6a5526f-c25b-4f9d-a42e-854604c50bb8" contextRef="C_5431114c-d857-438b-8f6d-8010eba4cc30" name="dvax:SharesPurchasedByEmployeesUnderEmployeePurchasePlan" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">161,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock under the Employee Stock Purchase Plan and approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7653a835-681a-45f1-b46e-5b350ef62053" contextRef="C_6507c936-b545-4e7c-859a-811146d183ad" name="dvax:SharesAvailableForPurchasesUnderEmployeePurchasePlan" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">722,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock remained available for future purchases under the Employee Stock Purchase Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the total unrecognized compensation cost related to shares of our common stock under the Employee Stock Purchase Plan amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f103ae16-2f01-4a35-a09e-981dcc95b0f7" contextRef="C_6507c936-b545-4e7c-859a-811146d183ad" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over the remaining weighted-average vesting period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11ac300e-c72a-4355-acb4-f7b0c558f488" contextRef="C_5431114c-d857-438b-8f6d-8010eba4cc30" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce31f4f1-a765-443b-9be7-dad813728014" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Benefit Plan </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a 401(k) Plan, which qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Under the 401(k) Plan, participating employees may defer a portion of their pretax earnings. We may, at our discretion, contribute for the benefit of eligible employees. Our contribution to the 401(k) Plan was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6a74644-5756-448e-baec-91ecc7fccdf2" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11733941-7e14-400b-91f8-7f900e6a26d4" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09bc0811-a9a3-4bf8-85ee-f8d885d60be4" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d942c1e4-90ff-40bb-8ea4-b9d85a00c641" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd3f9d00-93b0-4962-ac69-e47158e8cfa7" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated (loss) income before provision for income taxes consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.323%;"/>
        <td style="width:1.501%;"/>
        <td style="width:1%;"/>
        <td style="width:10.724%;"/>
        <td style="width:1%;"/>
        <td style="width:1.501%;"/>
        <td style="width:1%;"/>
        <td style="width:10.724%;"/>
        <td style="width:1%;"/>
        <td style="width:1.501%;"/>
        <td style="width:1%;"/>
        <td style="width:10.724%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a171a194-d5b3-4743-aaf3-1cc3b3d50c9b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,275</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21d29cff-d653-4f12-ad0c-977089317d84" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,460</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8703a832-420b-44d4-9b29-c60bfd17ae59" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,954</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_805a6993-9a59-4ddb-bdf6-face87944bbf" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,908</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b8271ba-f7a4-439e-a86f-23399466635b" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,839</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14eef812-e341-4cd9-8aa9-590894309da3" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,567</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba1038b5-05e7-490a-8132-2856816d65a1" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:IncomeLossFromContinuingOperationsBeforeIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,367</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e44239d7-0bdf-4055-8655-504f575c670a" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:IncomeLossFromContinuingOperationsBeforeIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294,299</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3b0441d-0ee2-4884-8222-c77eacf2ec6a" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IncomeLossFromContinuingOperationsBeforeIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,521</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b0caa39-80f5-44ac-ae58-0be80094fc31" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the consolidated income tax provision for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.711%;"/>
        <td style="width:1.88%;"/>
        <td style="width:1%;"/>
        <td style="width:15.217%;"/>
        <td style="width:1%;"/>
        <td style="width:1.88%;"/>
        <td style="width:1%;"/>
        <td style="width:15.217%;"/>
        <td style="width:1%;"/>
        <td style="width:1.88%;"/>
        <td style="width:1%;"/>
        <td style="width:15.217%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2021</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_458d1528-8995-4538-98ba-c5365ec79f5c" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">178</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_937f3469-481e-429f-9aa4-c92cc72d6dad" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">165</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95eb4399-ab15-4295-a701-09c2e89b7bcd" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_427dbf71-3c3c-4e00-984b-1f6cf11d0f8a" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,533</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_880cdaf5-a8ba-4af8-999e-f36d3755eac2" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">897</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9798674c-ba37-4eae-bb8d-84d28f0a633e" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">260</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-US</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfc9d070-e3f8-499d-99ac-698b7a732a15" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">667</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72e04c62-3741-4900-a349-e13fac39a5f7" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20172d5a-036f-4197-8cf6-5d4f9a753b4b" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26bfd0ad-085a-463b-b35f-12c21440740b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,022</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e0f9d56-435a-4198-9252-8ce3e91c8401" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8041646c-f6e0-4faf-9baf-5682eff93640" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">808</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11016586-9236-4553-8b61-d79e8b6f940b" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1872ab71-d0ab-41c1-9e3b-1bc81224f8d2" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_961d8508-9472-4b97-820d-f77e7e948139" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd94c477-5c98-4b47-b532-01f50f6c32d0" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31aeabf4-9f58-462f-8392-9e632de0461a" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2f97dc1-aa3e-4e9a-bf4e-59785b4f1e3c" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-US</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89aeec94-dd0d-4463-a423-c1e2f82b4447" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c62614f3-f6dd-47bd-b121-6bfc697d6bd7" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4ec45df-66c7-45e0-ace7-5a564e90b886" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_193c61a0-9555-4ca4-84d8-4b1003373ef4" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca6edb9e-8784-46a0-b324-c2cfb4930628" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0edfd4a-7fe8-4816-b60c-ad33215e58a5" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a976fb4-a5f4-493c-9607-9ecd9f315943" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,022</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67dbcebc-48d8-48fa-9f8a-97dec01062fb" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b646b319-decf-41ae-8b84-77a93b76e855" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">808</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f3036b0-8370-49c9-9ea2-769a63fbb439" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The difference between the consolidated income tax provision and the amount computed by applying the federal statutory income tax rate to the consolidated income before income taxes in the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1%;"/>
        <td style="width:10.764000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1%;"/>
        <td style="width:10.764000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1%;"/>
        <td style="width:10.764000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision (benefit) at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f862c330-089b-4d11-903d-6adbb15bccab" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">917</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edd54ae2-e83a-4b37-913c-62a673dbfc76" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,775</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6419891-b986-4149-ab64-91c725065df5" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_463a4df0-cf90-4ce0-b95d-0f724d536055" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">574</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddc97509-59b0-4e6b-adc9-e240f4dc93ee" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,942</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1930502-2312-4cd5-9569-258ffae5aaf6" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,576</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Business credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48491509-56cc-4e7e-8c40-ba30ff810d63" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:IncomeTaxReconciliationTaxCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,050</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a573ca7-fc04-4a99-a123-9a709ea3b3da" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:IncomeTaxReconciliationTaxCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,246</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_343e6170-1ae9-4180-b700-6dab0961fc8a" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IncomeTaxReconciliationTaxCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b326de6-748f-4762-87f4-b443d0df8e7e" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxReconciliationTaxContingencies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4b76d8a-601a-40c0-90ea-a52dcaf33c43" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeTaxReconciliationTaxContingencies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">586</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df37b476-c088-4f5f-a952-9edbcd3e309e" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" unitRef="U_USD" scale="3" decimals="-3">424</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred compensation charges</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_105253c6-7393-468c-9538-0f9bba147097" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:IncomeTaxReconciliationDeferredCompensationCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">830</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9897b932-1131-4d88-a838-e6a377129d95" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:IncomeTaxReconciliationDeferredCompensationCharges" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">473</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa7daa36-39b9-47a6-b891-ba1f2edc3431" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IncomeTaxReconciliationDeferredCompensationCharges" unitRef="U_USD" scale="3" decimals="-3">131</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b07d9e3e-2273-430d-ae00-d572b570456d" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,466</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a0a4d29-c136-4a1a-b33f-d9985aef4d6b" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">324</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be7d609e-87d5-44c2-af40-0cb62be4a76c" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,847</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 162(m) limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b50b6eea-5ea1-4253-aaf5-b0a45dd5b3cb" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:Section162MLimitation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,963</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d69b7361-5b47-4e88-b3d7-b1128e9638b0" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:Section162MLimitation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,779</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9db1f43d-c8b7-48eb-9cad-d570206e725f" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:Section162MLimitation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,241</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark-to-market of warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68d48fef-3d3c-4958-bcd2-43af612b262f" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:IncomeTaxRateReconciliationMarkToMarketOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b2849f4-a7e1-439f-a98f-a3c40bdb2423" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:IncomeTaxRateReconciliationMarkToMarketOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">378</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44fa2f65-d7d7-4043-a632-34756c243069" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:IncomeTaxRateReconciliationMarkToMarketOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,364</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss and tax credit limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1dbd44b-a389-4cb6-96b5-a0bd452a2129" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="dvax:NetOperatingLossAndTaxCreditLimitations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39834f1b-342c-4b6c-a2b2-3a9726576d31" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="dvax:NetOperatingLossAndTaxCreditLimitations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">56,908</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41336f18-06a9-4ec5-aa99-99b555806c5e" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="dvax:NetOperatingLossAndTaxCreditLimitations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,459</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e3f6b34-bf8f-4045-a212-7da919d109d0" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">518</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64a70d92-6b32-4349-af19-80b652fc5223" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">879</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cafa2182-cde7-40f4-af81-a312cf934c7a" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">290</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6d27ef7-a5ac-4868-b303-295695ceebb3" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">340</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7155f208-f926-44f1-9db7-10a595b4bf6d" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">395</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9b31fa0-7783-4d29-9c33-aa44716f4dc9" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">335</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b0a5bf1-45e3-4207-aedb-387c8f3eafd9" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,022</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47371339-a7e9-4cfa-8a9a-52246f7182cb" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5649f405-6b80-44b5-9aa5-e5bf13f9462c" contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">808</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) Certain prior year amounts have been reclassified to conform to the current year presentation. In 2022 and 2021, Foreign taxes were included in Other.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b850b319-48cb-42e8-9f7d-a81a953aa8e4" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax assets and liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8acd042-c8e8-47d1-a979-a2bf4641176b" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,336</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e9db7b7-309f-47a1-9d4e-40443fc17d3a" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,228</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3c2aebd-5808-474a-8238-ebe6dad0a471" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,940</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4cc22b7-cce5-43b9-9f28-523a6f2362e8" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,444</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 174 capitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5989d1eb-6969-4704-9e35-1327ebc3093b" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:Deferredtaxassetsoperatinglosscarryforwardscapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,556</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ddb1b97-f26c-4042-a509-024560099680" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:Deferredtaxassetsoperatinglosscarryforwardscapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64589f93-393c-42e5-ae24-e03003ee9c6c" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,868</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c235351d-04df-4059-94ed-330b73df5f56" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,530</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b978887-2be3-44ca-8039-a23e33c8a232" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,572</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e756a43-2d35-48ca-90e2-d4f6ffc176e6" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,780</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47a0c3aa-a755-4c9f-9df4-a037697c51ec" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,808</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a2d5894-7c16-4785-b801-4261b2794e01" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,089</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfc3a1c1-9286-4404-93e5-2e6a58b186b5" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa14ebe5-33df-4f85-9117-b6990064bae9" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">337</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_571e06aa-7060-4ef1-8e4f-591fe10c00cc" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189,428</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf3e30e3-1df4-4f5f-9137-ba05a0fe6144" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,716</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ed86575-45a2-4202-bb37-deda1519375f" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,387</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bec8789-5d94-4c65-afdf-08256e881c6c" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,920</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fbe3389-1246-4464-a6fa-3622ec5fdf40" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,041</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60857780-8c6a-4931-9cc4-47c1d10506f1" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,796</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28c86945-87df-4d9f-b524-cbb9451121ff" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,667</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51a41657-fdbf-4860-9461-f1f85de4b259" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b637e83f-85b3-4a9a-bca7-fc9590a87f7f" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="dvax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,345</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12225877-1983-423d-8e5a-c873d49d299e" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="dvax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,785</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_536de7a3-f6db-4523-a782-a10671768dff" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54d912b6-4eb1-4403-9891-a0b4374caac4" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0660b082-d283-47e3-8a15-0a3b6a67f6ae" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,041</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32c16348-813d-4884-8ee5-2832925c1f18" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,796</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44ea0b50-807c-4e46-a112-f370e47c2917" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a71dca9-6e06-4ca1-b33c-d89a17110187" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax benefit of net operating losses, temporary differences and credit carryforwards is required to be recorded as an asset to the extent that management assesses that realization is "more likely than not." Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. A high degree of judgment is required to determine if, and the extent to which, valuation allowances should be recorded against deferred tax assets. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. Based on all available evidence as of December 31, 2023, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized, and, accordingly, has provided a valuation allowance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The valuation allowance increased by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6287fc2d-f5a3-457b-a010-7663f417e36a" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during the year ended December 31, 2023 and decreased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f6e13d7-bff7-40a6-9053-95402fc0384b" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2022. The increase </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in valuation allowance during the year ended December 31, 2023 was due to an increase in our deferred tax assets, predominantly related to Section 174 capitalization and increased reserves largely offset by utilization of net operating losses. The decrease in valuation allowance during the year ended December 31, 2022 was due to a decrease in our deferred tax assets, predominantly related to utilization of net operating losses, offset by updates to the Section 382 analysis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_975007e3-a44c-46be-9b19-edf35c5237f4" contextRef="C_2d3137c5-4a24-4ea8-bd54-b337cfe3189f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million, which began to expire in the year </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8762c4ac-1fd0-4549-9320-56a60e863c87" contextRef="C_8d904b5d-a1ff-4762-bd22-3e30cec979bb" name="dvax:OperatingLossCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, federal net operating loss carryforwards of approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">y $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29c196e6-7c74-4120-a041-0aa7a9db518a" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">353.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which do not expire and federal research and development tax credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55f5bdbd-08b7-4983-a1bc-f7bbaea3e559" contextRef="C_10ed8dc0-a4c7-4909-9310-8008b51e41a3" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, whi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ch expire in the years </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ff37029-06db-43fc-b733-7ac67abee4b1" contextRef="C_4daec9bd-18e0-4c0a-8754-6c97e388d5ab" name="dvax:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8e29cad-e48a-456e-81fc-7f5cb87d0280" contextRef="C_fc1b7051-c0ab-49af-aabf-551b7383e779" name="dvax:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2043</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had net operating loss carryforwards for California and other states for income tax purposes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1d99bcc-593f-4929-ae16-8e654003b317" contextRef="C_7ef86bfc-0585-40df-9bd1-4bd0b18b364e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">283.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which expire in the years </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9ddd36d-1a32-499b-ae74-f88ab9e53e0c" contextRef="C_88dea699-9bab-4426-88ed-ff1960599278" name="dvax:OperatingLossCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_704dc8dc-8e6a-4f93-9629-b71baf4a4373" contextRef="C_0ef049fa-5c44-4e24-81ac-16efb8ddcea8" name="dvax:OperatingLossCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2040</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and California state research and development tax credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f68f316-8eec-40d7-afa9-5cff990afac2" contextRef="C_5413023b-1fa8-4b55-b7bd-90b2b2bbf2cf" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which do not expire.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ea4a058-8bb5-42c9-96a6-0ce511d80da1" contextRef="C_8ba29514-78ad-4553-a6f6-379d75c85d9b" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> remaining net operating loss carryforwards for foreign income tax purposes.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Uncertain Income Tax positions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total amount of unrecognized tax benefits was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe745213-7d19-43d5-8827-c813a93f7dc0" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f5c18db-1b15-435a-a02a-ab2811c5b804" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and 2022, respectively. If recognized, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4b04bfc-33ea-48b4-bc01-62e50dc89ab3" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the unrecognized tax benefits would affect the effective tax rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49387e29-8a23-47b5-b108-651f4f5ac624" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity related to our unrecognized tax benefits:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8da47600-58ec-42c7-9964-3b384d5a73bf" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,339</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_321bfcc4-dcda-4fa4-bfac-5bf6f9f8c556" contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,615</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax positions related to the current year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbece5ce-22bd-419a-9387-682e8e8753db" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">762</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71800f43-d80d-4da8-91cb-aa9bb958bcaa" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">670</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0482ced4-1752-495f-992e-721d0a078577" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5443c20-b4d6-4f45-9a7f-a15a47dd8d0e" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax positions related to the prior year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a7d53d6-0a10-40cb-9b57-6be194f4d5f3" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a11b9cf6-4651-44ca-8e0a-18ac0af265ec" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,054</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_951f4f15-e679-48b8-a5d6-0b6c45204602" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc94025e-c4bc-4b70-954a-26963bf11a03" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Settlements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6b2d7c7-db3a-45ee-a8e0-c259e0d2e6ff" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08966c01-549d-45b8-980b-100c00c3b0ac" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lapses in statute</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da78389a-512d-479c-988b-bc2259f95bc2" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e95acb1-09b7-4a63-8813-b81af2b0e590" contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,101</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01490815-d6e1-4643-a400-c461b2dff33c" contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,339</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to account for interest and penalties as inco</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">me tax expense. As of December 31, 2023, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d91b4e9-b33c-48b6-aa1e-cb061c049390" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdaa78c2-ca3f-4ea1-9596-cb36f597af87" contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> penalties recognized in the provision for income taxes. As of December 31, 2022, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8effb282-a715-49f5-bd23-158e5a87bbd8" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08fd3dd4-3376-4209-81fb-8220aa35823f" contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> penalties recognized in the provision for income taxes. We do not anticipate any significant change within 12 months of this reporting date of its uncertain tax positions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Tax Reform Act of 1986 limits the annual use of net operating loss and tax credit carryforwards in certain situations where changes occur in stock ownership of a company. In the event there is a change in ownership, as defined, the annual utilization of such carryforwards could be limited. For the year ended December 31, 2021, we completed a preliminary analysis under Section 382 of the Internal Revenue Code indicating we experienced ownership changes in 2008, 2010, 2012, and 2019 that limited the future use of our pre-change federal and state net operating loss carryforwards and federal research and development tax credits. We finalized the study during the year ended December 31, 2022 and concluded that we only experienced ownership changes in 2008, 2010, and 2012, resulting in a significant reduction in the federal and state net operating loss carryforwards and federal research and development tax credits that are expected to expire unused. We have revised the net operating loss carryforwards and research and development tax credits that are expected to expire unused as a result of the annual limitations in the deferred tax assets and corresponding uncertain tax positions as of December 31, 2022. There were no changes to our Section 382 analysis as of December 31, 2023.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to income tax examinations for U.S. federal and state income taxes from 2002 forward. We are subject to tax examination in Germany from 2018 forward, in India from 2019 forward and in Italy from 2021 forward.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9. CHANGES IN AND D</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9A. CON</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TROLS AND PROCEDURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (&#8220;the Exchange Act&#8221;)) that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can only provide reasonable, not absolute, assurance of achieving the desired control objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on their evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report, our management, with the participation of our Principal Executive Officer and our Principal Financial Officer, concluded that our disclosure controls and procedures are effective and were operating at the reasonable assurance level to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2023. Our independent registered public accountants, Ernst &amp; Young LLP, audited the consolidated financial statements included in this Annual Report on Form 10-K and have issued a report on our internal control over financial reporting. The report on the audit of internal control over financial reporting appears below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Dynavax Technologies Corporation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited Dynavax Technologies Corporation&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Dynavax Technologies Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, and the related consolidated statements of operations, comprehensive (loss) income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023 and the related notes of the Company and our report dated February 22, 2024 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Francisco, California</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 22, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c) Changes in Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. OTHER INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9C. DISCLOSURE REGA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 10. DIRECTORS, EXECUTIV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">E</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> OFFICERS AND CORPORATE GOVERNANCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by this Item is incorporated by reference to the sections entitled &#8220;Proposal 1&#8212;Election of Directors,&#8221; &#8220;Executive Officers,&#8221; &#8220;Corporate Governance&#8221; and &#8220;Delinquent Section 16(a) Reports&#8221; in our Definitive Proxy Statement in connection with the 2024 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) which we expect will be filed with the Securities and Exchange Commission within 120 days after the fiscal year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted the Dynavax Code of Business Conduct and Ethics (&#8220;Code of Conduct&#8221;), a code of ethics that applies to our employees, including our Chief Executive Officer, Chief Financial Officer and to our non-employee directors. The Code of Conduct is publicly available on our website under the header &#8220;Investors&#8221; and within that under the header &#8220;Corporate Governance and Compliance&#8221; at www.dynavax.com. This website address is intended to be an inactive, textual reference only; none of the material on this website is part of this report. If any substantive amendments are made to the Code of Conduct or any waiver granted, including any implicit waiver, from a provision of the Code of Conduct to our Chief Executive Officer or Chief Financial Officer, we will disclose the nature of such amendment or waiver on that website or in a report on Form 8-K. We will provide a written copy of the Dynavax Code of Conduct to anyone without charge, upon request written to Dynavax, Attention: Corporate Secretary, 2100 Powell Street, Suite 720, Emeryville, CA 94608, (510) 848-5100.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 11. EXEC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UTIVE COMPENSATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by this Item is incorporated by reference to the section entitled &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Summary Compensation Table,&#8221; &#8220;Grants of Plan Based Awards,&#8221; &#8220;Outstanding Equity Awards at Fiscal Year End,&#8221; and &#8220;Corporate Governance&#8221; in the Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information regarding security ownership of certain beneficial owners and management is incorporated by reference to the sections entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in the Proxy Statement. Information regarding our stockholder approved and non-approved equity compensation plans are incorporated by reference to the section entitled &#8220;Equity Compensation Plan Information&#8221; in the Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 13. CERTAIN RELATIONSHIPS AND</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by this Item is incorporated by reference to the sections entitled &#8220;Certain Transactions&#8221; and &#8220;Independence of the Board of Directors&#8221; in the Proxy Statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 14. PRINCIPAL ACCOUNTA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NT FEES AND SERVICES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by this Item is incorporated by reference to the section entitled &#8220;Audit Fees&#8221; in the Proxy Statement.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 15. EXHIBI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TS, FINANCIAL STATEMENT SCHEDULES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Documents filed as part of this report:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Balance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Comprehensive (Loss) Income</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Financial Statement Schedules</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None, as all required disclosures have been made in the Consolidated Financial Statements and notes thereto or are not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Exhibits</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.292%;"/>
    <td style="width:3.532%;"/>
    <td style="width:20.347%;"/>
    <td style="width:3.522%;"/>
    <td style="width:8.998%;"/>
    <td style="width:6.002%;"/>
    <td style="width:12.956%;"/>
    <td style="width:8.095%;"/>
    <td style="width:8.095%;"/>
    <td style="width:11.161%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:6.25pt;padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td colspan="3" style="padding-left:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Document</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed Herewith</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td colspan="3" style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095014904000279/f93670a4exv3w1.txt"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">Sixth Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 5, 2004</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-109965</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td colspan="3" style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000118143110000147/rrd261383_30764.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment of Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 4, 2010</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td colspan="3" style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000118143111001736/rrd296699_33863.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment of Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 5, 2011</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span></p></td>
    <td colspan="3" style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000118143113031528/rrd381720_39641.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment of Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 30, 2013</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></p></td>
    <td colspan="3" style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459014005412/dvax-ex31_2014111067.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment of the Sixth Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 10, 2014</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td>
    <td colspan="3" style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459017012062/dvax-ex31_6.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment of the Sixth Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 2, 2017</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span></p></td>
    <td colspan="3" style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000119312517242416/d435910dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment of the Sixth Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July 31, 2017</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span></p></td>
    <td colspan="3" style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459020027622/dvax-ex31_33.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment of the Sixth Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 29, 2020</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span></p></td>
    <td colspan="3" style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001029142/000156459018027411/dvax-ex38_381.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 6, 2018</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.28%;"/>
    <td style="width:27.4%;"/>
    <td style="width:9%;"/>
    <td style="width:6%;"/>
    <td style="width:12.96%;"/>
    <td style="width:16.2%;"/>
    <td style="width:11.16%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017022002289/dvax-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Capital Stock</span></a></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2022</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">Reference is made to Exhibits </span><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095014904000279/f93670a4exv3w1.txt"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">3.1</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">, </span><a href="https://www.sec.gov/Archives/edgar/data/1029142/000118143110000147/rrd261383_30764.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">3.2</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">, </span><a href="https://www.sec.gov/Archives/edgar/data/1029142/000118143111001736/rrd296699_33863.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">3.3</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">, </span><a href="https://www.sec.gov/Archives/edgar/data/1029142/000118143113031528/rrd381720_39641.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">3.4</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">, </span><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459014005412/dvax-ex31_2014111067.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">3.5</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">, </span><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459017012062/dvax-ex31_6.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">3.6</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">, </span><a href="https://www.sec.gov/Archives/edgar/data/1029142/000119312517242416/d435910dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">3.7</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">, </span><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459020027622/dvax-ex31_33.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">3.8</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><a href="https://www.sec.gov/Archives/edgar/data/0001029142/000156459018027411/dvax-ex38_381.htm"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">3.9</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">&#160;above</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095014904000149/f93670a3exv4w2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Specimen Common Stock Certificate</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 16, 2004</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-109965</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000119312521160579/d481425dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Indenture between Company and U.S. Bank National Association, as trustee, dated May 13, 2021</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 13, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000119312521160579/d481425dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Global Note, representing Dynavax Technologies Corporation&#8217;s 2.5% Convertible Senior Notes due 2026</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 13, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459014000660/dvax-ex10_20131231596.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated July 12, 2013, by and between Robert Janssen, M.D. and Company</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.85</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 10, 2014</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459020010075/dvax-ex1017_167.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Chief Executive Officer Letter, dated December 13, 2019, between Company and Ryan Spencer</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 11, 2020</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459020010075/dvax-ex1018_166.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">President and Chief Operating Officer Letter, dated December 13, 2019, between Company and David Novack</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 11, 2020</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459021008833/dvax-ex1033_133.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter, dated December 14, 2020, by and between Company and Kelly MacDonald</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.33</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 25, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017023016685/dvax-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consulting Agreement, effective January 16, 2023, between Company and Peter Paradiso</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 2, 2023</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459019041728/dvax-ex101_194.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 7, 2019</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017023038029/dvax-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Management Continuity and Severance Agreement between Company and certain of its executive officers</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 3, 2023</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459020010075/dvax-ex1023_168.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Dynavax Technologies Corporation U.S. Annual Bonus Plan</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 11, 2020</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017022002289/dvax-ex10_34.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.34</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2022</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.28%;"/>
    <td style="width:27.4%;"/>
    <td style="width:9%;"/>
    <td style="width:6%;"/>
    <td style="width:12.96%;"/>
    <td style="width:16.2%;"/>
    <td style="width:11.16%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459020037730/dvax-ex103_185.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Sales Agreement, dated August 6, 2020, between Company and Cowen and Company, LLC</span></a></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 6, 2020</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001029142/000119312521160579/d481425dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Confirmation for Capped Call Transactions</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 13, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000114036121013102/nc10020263x1_def14a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Dynavax Technologies Corporation Amended and Restated 2014 Employee Stock Purchase Plan</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Appendix A</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 16, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000114036122014584/ny20002052x1_def14a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Dynavax Technologies Corporation 2018 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Appendix A</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 14, 2022</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459018014932/dvax-ex103_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Option Grant Notice and Option Agreement under the 2018 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 1, 2018</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459018014932/dvax-ex102_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2018 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 1, 2018</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017022002289/dvax-ex10_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restricted Stock Unit Award Agreement for Directors under the 2018 Equity Incentive Plan</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2022</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459021040926/dvax-ex103_263.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Dynavax Technologies Corporation 2021 Inducement Award Plan</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 4, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459018027411/dvax-ex101_235.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Office/Laboratory Lease, dated September 17, 2018, between Company and Emery Station West, LLC</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 6, 2018</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459019041728/dvax-ex103_532.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Sublease, dated July 12, 2019, by and between Company and Zymergen Inc.</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 7, 2019</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017021003113/dvax-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Commercial Lease Agreement, dated September 13, 2021, by and between Onyx D&#252;sseldorf S.&#224; r.l. and Dynavax GmbH</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 4, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017022007838/dvax-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease Agreement, dated March 15, 2022, by and between Company and SPUS8 2100 Powell, L.P.</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 5, 2022</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459018004917/dvax-ex1033_648.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Commercial Manufacturing and Supply Agreement, dated November 22, 2013, between Company and Baxter Pharmaceutical Solutions LLC</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.33</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 8, 2018</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017021003113/dvax-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Commercial Manufacturing and</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 4, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.28%;"/>
    <td style="width:27.4%;"/>
    <td style="width:9%;"/>
    <td style="width:6%;"/>
    <td style="width:12.96%;"/>
    <td style="width:16.2%;"/>
    <td style="width:11.16%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017021003113/dvax-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Supply Agreement, dated September 10, 2021, by and between Company and Baxter Pharmaceutical Solutions LLC</span></a></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.24</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459018004917/dvax-ex1036_946.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Supply Agreement, dated July 27, 2016, between Company and West Pharmaceutical Services, Inc.</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.36</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 8, 2018</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.25&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459021008833/dvax-ex1031_356.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement, dated January 29, 2021 between Company and Coalition for Epidemic Preparedness Innovations</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.31</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 25, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.26&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459021040926/dvax-ex101_313.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Agreement, dated May 3, 2021, by and between Company and Coalition for Epidemic Preparedness Innovations</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 4, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.27&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017023038029/dvax-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Waiver and Second Amendment to Agreement, dated effective as of April 27, 2023, by and between Company and Coalition for Epidemic Preparedness Innovations</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 3, 2023</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.28&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017023004130/dvax-ex10_35.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Supply Agreement, dated effective April 1, 2021, between Company and Becton, Dickinson and Company</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.35</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 23, 2023</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.29&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017023004130/dvax-ex10_36.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment #1 to Supply Agreement, dated September 28, 2022, between Company and Becton, Dickinson and Company</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.36</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 23, 2023</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.30&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459021040926/dvax-ex106_311.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Supply Agreement, dated June 29, 2021, by and among Company, Zhejiang Clover Biopharmaceuticals, Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 4, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.31&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017022021883/dvax-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter Agreement, dated August 30, 2022, by and among Company, Zhejiang Clover Biopharmaceuticals, Inc., Clover Biopharmaceuticals (Hong Kong) Co., Limited and Sichuan Clover Biopharmaceuticals, Inc.</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 3, 2022</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.32&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017022021883/dvax-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter Agreement No. 2, dated October 31, 2022, by and among Company, Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 3, 2022</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.28%;"/>
    <td style="width:27.4%;"/>
    <td style="width:9%;"/>
    <td style="width:6%;"/>
    <td style="width:12.96%;"/>
    <td style="width:16.2%;"/>
    <td style="width:11.16%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.33&#x5E;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017023004130/dvax-ex10_37.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 3 to Supply Agreement, effective August 15, 2022, by and among Company, Zhejiang Clover Biopharmaceuticals, Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited</span></a></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.37</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 23, 2023</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.34&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017023004130/dvax-ex10_38.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 4 to Supply Agreement, effective September 23, 2022, by and among Company, Zhejiang Clover Biopharmaceuticals, Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.38</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 23, 2023</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.35&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000156459021040926/dvax-ex107_312.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Supply Agreement, dated July 1, 2021, by and between Company and Biological E. Limited</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 4, 2021</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.36&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017022021883/dvax-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to Supply Agreement, dated effective as of June 23, 2022, by and between Company and Biological E. Limited</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 3, 2022</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.37&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017022021883/dvax-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 2 to Supply Agreement, dated effective as of September 30, 2022, by and between Company and Biological E. Limited</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 3, 2022</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.38&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017023038029/dvax-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 3 to Supply Agreement, dated effective as of April 26, 2023, by and between Company and Biological E. Limited</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 3, 2023</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.39&#x5E;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1029142/000095017023058225/dvax-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Supply Agreement, effective as of September 7, 2023, by and between Company and Nitto Denko Avecia Inc.</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 2, 2023</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-34207</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dvax-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dvax-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dvax-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dvax-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.28%;"/>
    <td style="width:27.4%;"/>
    <td style="width:9%;"/>
    <td style="width:6%;"/>
    <td style="width:12.96%;"/>
    <td style="width:16.2%;"/>
    <td style="width:11.16%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1*</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dvax-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2*</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dvax-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:9pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="margin-left:9pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="dvax-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Dynavax Technologies Corporation Incentive Compensation Recoupment Policy</span></a></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;text-indent:6.25pt;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="margin-left:6.25pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.007in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.02%;"/>
    <td style="width:1.24%;"/>
    <td style="width:85.74%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">EX&#8212;101.INS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">EX&#8212;101.SCH</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">EX&#8212;104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The cover page for this Annual Report on Form 10-K has been formatted in Inline XBRL</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#134; We have been granted confidential treatment with respect to certain portions of this agreement. Omitted portions have been filed separately with the Securities and Exchange Commission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Indicates management contract, compensatory plan or arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x5E; Certain portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted information is of the type that the Registrant customarily and actually treats as private or confidential. The Registrant agrees to furnish supplementally an unredacted copy of any exhibit to the Securities and Exchange Commission upon request; provided, however, that the Registrant may request confidential treatment of omitted items.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Form 10-K), irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 16. FORM 1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0-K SUMMARY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:59.98%;"/>
    <td style="width:4.02%;"/>
    <td style="width:1%;"/>
    <td style="width:35%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">Dynavax Technologies Corporation</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ RYAN SPENCER</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ryan Spencer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer and Director</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 22, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:60%;"/>
    <td style="width:4%;"/>
    <td style="width:1%;"/>
    <td style="width:35%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ KELLY MACDONALD</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Kelly MacDonald</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 22, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:60%;"/>
    <td style="width:4%;"/>
    <td style="width:1%;"/>
    <td style="width:35%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ JUSTIN BURGESS</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Justin Burgess</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Controller, Chief Accounting Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 22, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.92%;"/>
    <td style="width:1%;"/>
    <td style="width:35.56%;"/>
    <td style="width:1.32%;"/>
    <td style="width:26.2%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ RYAN SPENCER</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ryan Spencer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ KELLY MACDONALD</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Kelly MacDonald</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ JUSTIN BURGESS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Controller, Chief Accounting Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Justin Burgess</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ SCOTT MYERS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Scott Myers</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ FRANCIS R. CANO</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Francis R. Cano, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ JULIE EASTLAND</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Julie Eastland</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ DANIEL L. KISNER</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Daniel L. Kisner, M.D.</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ BRENT MACGREGOR</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Brent MacGregor</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ PETER R. PARADISO</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Peter R. Paradiso</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ PEGGY V. PHILLIPS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Peggy V. Phillips</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ ELAINE D. SUN</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Elaine D. Sun</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>dvax-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 21.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">List of Subsidiaries</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dynavax GmbH</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dynavax India LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>dvax-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-3ASR Nos. 333-239663, 333-241678, and 333-273674) of Dynavax Technologies Corporation and in the related Prospectuses, and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statements (Form S-8 Nos. 333-211747, 333-221832, 333-225525, 333-218470, 333-204506, 333-197838, 333-190313, 333-171552, 333-233247, 333-241674, 333-258469,333-253515 and 333-265373) pertaining to the Amended and Restated 2011 Equity Incentive Plan, the Amended and Restated 2014 Employee Stock Purchase Plan, the 2017 Inducement Award Plan, the Amended and Restated 2018 Equity Incentive Plan and the 2021 Inducement Award Plan of Dynavax Technologies Corporation;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our reports dated February 22, 2024, with respect to the consolidated financial statements of Dynavax Technologies Corporation and the effectiveness of internal control over financial reporting of Dynavax Technologies Corporation included in this Annual Report (Form 10-K) of Dynavax Technologies Corporation for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Francisco, California</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 22, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>dvax-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 13a-14(a) Certification of Principal Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Ryan Spencer, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5.1%;"></td>
    <td style="width:5.1%;"></td>
    <td style="width:89.8%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">I have reviewed this annual report on Form 10-K of Dynavax Technologies Corporation (the &#x201c;registrant&#x201d;);</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">a)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">b)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">c)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">d)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">a)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">b)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.682%;"></td>
    <td style="width:2.561%;"></td>
    <td style="width:89.758%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;/s/ RYAN SPENCER</font></p></td>
   </tr>
   <tr style="height:29.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ryan Spencer</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer and Director</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 22, 2024</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>dvax-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 13a-14(a) Certification of Principal Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Kelly MacDonald, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5.56%;"></td>
    <td style="width:5.56%;"></td>
    <td style="width:88.88%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">I have reviewed this annual report on Form 10-K of Dynavax Technologies Corporation (the &#x201c;registrant&#x201d;);</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">a)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">b)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">c)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">d)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">a)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">b)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.5%;"></td>
    <td style="width:2.5%;"></td>
    <td style="width:88%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ KELLY MACDONALD</font></p></td>
   </tr>
   <tr style="height:28.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Kelly MacDonald</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 22, 2024</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>dvax-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certification Pursuant to Section 1350 of Chapter 63</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of Title 18 of the United States Code</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), I, Ryan Spencer, Chief Executive Officer of Dynavax Technologies Corporation (the &#x201c;Company&#x201d;), hereby certify that, to the best of my knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(i) The Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, to which this Certification is attached as Exhibit 32.1 (the &#x201c;Annual Report&#x201d;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ii) The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Witness Whereof</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the undersigned has set his hand hereto as of the 22</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day of February, 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.682%;"></td>
    <td style="width:2.561%;"></td>
    <td style="width:89.758%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ RYAN SPENCER</font></p></td>
   </tr>
   <tr style="height:28.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ryan Spencer</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer and Director</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Dynavax Technologies Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>dvax-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certification Pursuant to Section 1350 of Chapter 63</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of Title 18 of the United States Code</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), I, Kelly MacDonald, Chief Financial Officer of Dynavax Technologies Corporation (the &#x201c;Company&#x201d;), hereby certify that, to the best of my knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(i) The Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, to which this Certification is attached as Exhibit 32.2 (the &#x201c;Annual Report&#x201d;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ii) The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Witness Whereof</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the undersigned has set her hand hereto as of the 22</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day of February, 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.682%;"></td>
    <td style="width:2.561%;"></td>
    <td style="width:89.758%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ KELLY MACDONALD</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:28.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Kelly MacDonald</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Dynavax Technologies Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>dvax-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dynavax Technologies Corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation Recoupment Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective November 23, 2023</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Introduction</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Dynavax Technologies Corporation, a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has determined, upon the recommendation of the Compensation Committee of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) providing for the Company&#x2019;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10D-1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Nasdaq Listing Rule 5608 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Listing Standards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Incentive Compensation is deemed &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in the Company&#x2019;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font></div></div>
  <p style="text-indent:7.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Compensation Committee or, in the absence of such committee, the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each current and former Executive Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Nasdaq Stock Market.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">290542985 v4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#x2019;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TSR</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). A measure need not be presented in the Company&#x2019;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lookback Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#x2019;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recoverable Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, on a gross basis without regarding to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities and Exchange Commission.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Applicability of Policy. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">290542985 v4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">during the Lookback Period.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment Generally. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#x2019;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Impracticability of Recovery.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Recoupment may be determined to be impracticable if, and only if:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sources of Recoupment.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification of Covered Officers.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#x2019;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">290542985 v4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnification of Administrator.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No &#x201c;Good Reason&#x201d; for Covered Officers.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#x201c;good reason&#x201d; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#x2019;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Impairment of Other Remedies</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#x2019;s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SOX 304</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that are applicable to the Company&#x2019;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">290542985 v4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment; Termination</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10.	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Required Filings</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*	*	*	*	*</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">290542985 v4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dynavax Technologies Corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation Recoupment Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Form of Executive Acknowledgment</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I, the undersigned, agree and acknowledge that I am bound by, and subject to, the Dynavax Technologies Corporation Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with Dynavax Technologies Corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agreed and Acknowledged:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">___________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name: _____________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title: ______________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: ______________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">290542985 v4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img25882306_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img25882306_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 9@"<L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEU=7 5@NZ16.U1E7Z$$'C###5Z!XETV;6?"NKZ7;M&L][936\;2$A0SH5!.
M3C)]#7@'PT^*S> 3-X/\5V\BVEG</#'+"JNUJ_F'S%?:?G0,6;(R1R &!&T
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M!'4$9 .0)/&WB'2_#/A+4-0U=8);?RFC6UF/%T[*<0XP<[N0>#@9)X!KRO\
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MOB:TTJ.,W<E@9[%)1MG#%5QN+;E9AMZ#[P)( (KU#P)_R3SPU_V"K7_T4M>
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M9[XYJ3P9\5IM9\6/X0\1Z))H^O1IM"ARZ32*I9\<?("HW+RP(_BZ;NL\"?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;2IBH2$L&"LR@.3N^4J2#@\CC/H"2Z?XHT:[MWM[LV=PCVTT=U;36K.K+A@
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M6B:SHFN65U-J'FQ/+I<_EN'1$^^%(7!3DM@ $'/7'0?%[X;_ /"<Z&ESIL,
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M:9&<+DA2P1<_0<G%>V5A^%?#4/AC2Y;=;B2ZN[JX>\OKIP%-Q</C>^T<(#@
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M4 4_BGX#N?"FLZ;XCN1J7BG08T6&[&J7SO*AW-\I= I1#N&TC(#YR.0&]_\
M#DVBW/A^SG\.BT&DR(7MQ:1A(P"23A0!M.[.1@$'.><T3VVF>+/#\MM>6<D^
MGWB%)(+NWDA8@''*.%=2",@X!X!'8UXOX0'B_P"#_B"^T"ZT#4M=\.SN;B.Y
MTNS:1@Q& XQP"0H5D8\8!!Q]\ ]\KA_C!8W&H?"C7X;6/S)%B28C<!A(Y$D<
M\^BJQ]\<<UV%C>Q:A9QW4*3I&^<">!X7&"1RC@,.G<<]>E23P0W5O+;W$4<T
M$J%)(Y%#*ZD8((/!!'&* /&_V;KZWD\&ZM8+)FZAU#SI$VGY4>- ISTY,;_E
M[BO:*^?XO#?BSX/^.;[5/#VA3ZYX=OLH+6T=RR DLBE1N;<F,;RK JQY!? [
MS2OC=X'U5+=5O[N"[G?8EF]E*\NXM@#$:L"3Q@ GJ._% 'HE?/\ ^TU_S*W_
M &]_^T:]8T;4-4\5[+VXTZ^T/2XI0T4%R?+N[HKCF11_JHPP/RY)DP,X3*OA
M_%_X?S>._#4)T_R_[6T]VEM@[$"56'SQYS@%L*03W4#(!) !Z)7/^._^2>>)
M?^P5=?\ HIJX/PM\9M#T_1K;2/&!U+1]:L+>**Y%_;RNTS;?OY"ELD!6.X#[
M_!;K1KOBJY^*EO)X7\%0W:Z9<OY>HZ_+$\<$<0"LR1]"[G=M*G&1D8VL64 [
MSP)_R3SPU_V"K7_T4M<W\,X(;JW\=6]Q%'-!+XHOTDCD4,KJ0@((/!!'&*[2
MZN[+0-.@'V:=+5-L,4-C923; !P D2L54 8Z8' ]*\[^&&LRVEQXB@U'0?$&
MGOJ>NS7UL;G2I@I28J%#,JD(1M^8L0!D<GG !R'PWGA^&WQEUOP5<RQFTOW1
M+>=V&X, 9(0S':,E)"I 4Y<J!Q7?^$YX?&OCS6/%8ECGT_27;2-*4,&4, &G
MG'49;<JJZD93@BL/XV^ ]4UZ71_$/AN">36;25+=A ^U]A;,;AMPV[')Y _C
MW$@)7H&AZ79>!/!=EIL8GEM[")4=H+>25Y'8Y9Q&N]OF=BV!G&?04 >/_P#-
MWG^?^?"O0/C;_P DAUW_ +=__2B.O./,U/\ X:&_X2__ (1CQ'_8WF^7YO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5// .22V.@^(%]<:GY'@;29/+U+7(G$]QM#K9V@P))'7D_."8US@%B?F4@4
M7--^)'AG6;=KC2YM2OH%<HTEKI%W*H; ."5B(S@@X]Q1H'Q+\'^*-473-'UJ
M.>\9"ZQ-#)$7 Z[=Z@$XYP.< GH#70:5I5CH>EV^F:9;1VUG;ILBB3HH_F23
MDDGDDDG)->"?&+PQJFL?%,2^&X,:E::)'J3_ &?Y)I"D[)N0CEI -F.<X3 R
M0 0#Z'KF]?\ 'GA[PL[+K5S=VB!PGG-I]PT3,5W +(J%&.,\ GH?0UC_  S^
M)ECX_P!+*.([;6K= ;JT!X(Z>9'GDH3VZJ3@]06C^-O_ "2'7?\ MW_]*(Z
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MN*QM_BIKBZE?1[_"VC7<D5E;EBR:E.N T[8^1H5.50#.[Y\D E#Z10 5Y_\
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MM"T>P6_U%M2M;0H',TNDW2J@+E!O/E_(2PX#8)R#T()P_P#A=OP\_P"AA_\
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M6=8MR [U'0D!@LBXW<*1D!0WTO!/#=6\5Q;RQS02H'CDC8,KJ1D$$<$$<YH
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MI&Y)R2.F3@8 X H\7>%['QCX:N]'OXXR)4)AE9-Q@EP=LB\@Y!/3(R,@\$T
M;E%>'_ 3QCJES+?>#-9\]IM-BWVWG)AX41@CQ.2<_*67:"./F&<!0/<* .;U
M_P >>'O"SLNM7-W:('"><VGW#1,Q7< LBH48XSP">A]#6AH'B/2/%.EKJ6BW
MT=W:%RF]05*L.H96 *GH<$#@@]"*Y/XV_P#)(==_[=__ $HCKSCX5:C<?#OX
MH:KX"U:XS:W4NR!W8!?- S&X&_"^8A P,L6\M>QH ^AZIZKJMCH>EW&IZG<Q
MVUG;IOEE?HH_F23@ #DD@#)-7*\?^-LUYK44?A:PN?*CAT^YUK4L Y$,*GR@
M>0&5I,@CD@A6Q@<@'::)\2?"WB.X\C1KV[OG#HCF'3KEEC+'"[V\O" X/+$#
M@^E=97C_ .SC_P D\U#_ +"LG_HJ*O8* ,?Q%XGTOPK9VMUJT_DPW-W%:1L>
M@=SU8G 50 S$DC 4]3@'8KY_^,UIJ/C;7-6M;"#%KX/T\7,[D*#))-L=E!+_
M '1$I8'&<HPYW+7IGPJ\4+XL^'VG7;22/=VR"SNS([.QEC !8L0-Q92K]_O8
MR2#0!U&I:G!I5NL]Q'=NC.$ M;26X;.">5C5B!QUQCIZBN+_ .%V_#S_ *&'
M_P DKC_XW7H%?/\ \+/^3A?&O_;]_P"E:4 >F:;\6O >JW#06_B6T1U0N3=*
M]NN,@<-(J@GGIG/7T-=I7G?QC\+Z+K/@/5=1OH[2WO[*W\VWOG0!P4)(BW9!
M(<DJ%)(RX(!(%4_@'K-YJ_PU6*\?S/[/NWLX7))8QA4=022>F\J,8 55&.*
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M.:Z32M5L=<TNWU/3+F.YL[A-\4J=&'\P0<@@\@@@X(KB_P#FX7_N5/\ V[H
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M<#C&",@@G+M?!=GI7Q.?Q-IMIY*W^GSQ7Q1@$,WF0LC!>NY@),D<';DX))8
MN:_X\\/>%G9=:N;NT0.$\YM/N&B9BNX!9%0HQQG@$]#Z&C0/'GA[Q2ZKHMS=
MW:%RGG+I]PL2L%W$-(R!%.,<$CJ/45A_&W_DD.N_]N__ *41T?!+_DD.A?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3U$R+I_A.R>SM6  $TTF5[)R%AV*1NR"J-_$:W/VCO\ DGFG_P#85C_]%2T
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M5Y_\;?\ DD.N_P#;O_Z41T 'P2_Y)#H7_;Q_Z425Z!7G_P $O^20Z%_V\?\
MI1)1\2/BGI?@;3I8;>6"]UUODBL@^?*) .^4 Y5<$$#@MD8XRP /(/!O_)T-
MS_V%=2_]!FKZ?KQ_X'?#>\\*V=QK^LP^3J5_$(X;=LAX(<[CO&<;F(4[2,KM
M'()8#V"@#Y_^,OAY_!7BC3/B)H#06TC7:I/ H9?,GPS%SM(RKJK*X&W/7DN2
M/2/A_8W&I^?XYU:/R]2UR)#!;[@ZV=H,F.-&Y/S@B1L8!8CY5(-<O^T=_P D
M\T__ +"L?_HJ6O0/ G_)//#7_8*M?_12T =!7G__ #<+_P!RI_[=UZ!7G_\
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M4GK0!TE?,GQ7L%T_QCJWB/PL+N:Q#K:Z\(%:.U$K8W0L\;*6#X'F#LS#+;G
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M._)+%3C*-D$G&.3^.MWHFKV>D^(?#_B+2I=3TV78PL[R(SE&(*.&5]QV..
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M_P#12T =!7S!^SC_ ,E#U#_L%2?^C8J]#^+?Q,L;+2[GPGH8CU76M31[*2*
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MI\;?^20Z[_V[_P#I1'1\$O\ DD.A?]O'_I1)1\;?^20Z[_V[_P#I1'1\$O\
MDD.A?]O'_I1)0!Y!X-_Y.AN?^PKJ7_H,U?3]?.'Q7T:\\ _%#3_'=BFZQNKM
M)FCMP8=LB!?,C9@"/WHW'/5LR9!P2??]&US2_$.G)?Z1?P7MJV!OA?.TD [6
M'56P1E3@C/(H T**IZEJMCI%NL]_<QP([B.,-RTKD$A$4<NYP<*H)/8&I+&:
MXN+..6ZM?LLSY)A,@<H,G:&(XW8QD D Y + ;B 6*^8/V<?^2AZA_P!@J3_T
M;%7T_7S1J-F_P?\ CE:ZI*=FA:A+)(#;HT4:02,0T9500WE$JVP9R%0_*2,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>P\OS%VOP#@Y QR#CM6A10 5Q>N_"[PYK6J)JT"W>C:LKEC?Z1-]GE;.[=G
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MSDM9GG2-\9,$[PN,$'AT(8=.QYZ=*L44 </_ ,*A\$?VC_:/]DS_ &[S?/\
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MJY)PHP!G@5T&C:+9:!IR6&G+.EJF B37,DVP  !5,C,54 #"C@>E:%% '/\
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MV321DG&6V.Y7=\H&[&<#&<5T%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !115>ZO[.Q\C[9=P6_GRK!#YT@3S)&^ZBYZL
M<' ')H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#_SUC_[Z%0?VKIW_ #_VO_?Y?\: +=%5/[5T[_G_ +7_ +_+_C1_:NG?\_\
M:_\ ?Y?\: +=%5/[5T[_ )_[7_O\O^-']JZ=_P _]K_W^7_&@"W153^U=._Y
M_P"U_P"_R_XT?VKIW_/_ &O_ '^7_&@"W153^U=._P"?^U_[_+_C1_:NG?\
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M-']JZ=_S_P!K_P!_E_QH MT54_M73O\ G_M?^_R_XT?VKIW_ #_VO_?Y?\:
M+=%5/[5T[_G_ +7_ +_+_C1_:NG?\_\ :_\ ?Y?\: +=%5/[5T[_ )_[7_O\
MO^-']JZ=_P _]K_W^7_&@"W153^U=._Y_P"U_P"_R_XT?VKIW_/_ &O_ '^7
M_&@"W153^U=._P"?^U_[_+_C1_:NG?\ /_:_]_E_QH MT54_M73O^?\ M?\
MO\O^-']JZ=_S_P!K_P!_E_QH MT54_M73O\ G_M?^_R_XT?VKIW_ #_VO_?Y
M?\: +=%5/[5T[_G_ +7_ +_+_C1_:NG?\_\ :_\ ?Y?\: +=%5/[5T[_ )_[
M7_O\O^-']JZ=_P _]K_W^7_&@"W153^U=._Y_P"U_P"_R_XT?VKIW_/_ &O_
M '^7_&@"W153^U=._P"?^U_[_+_C1_:NG?\ /_:_]_E_QH MT54_M73O^?\
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M^_R_XT?VKIW_ #_VO_?Y?\: +=%5/[5T[_G_ +7_ +_+_C1_:NG?\_\ :_\
M?Y?\: +=%5/[5T[_ )_[7_O\O^-']JZ=_P _]K_W^7_&@"W153^U=._Y_P"U
M_P"_R_XT?VKIW_/_ &O_ '^7_&@"W153^U=._P"?^U_[_+_C1_:NG?\ /_:_
M]_E_QH MT54_M73O^?\ M?\ O\O^-']JZ=_S_P!K_P!_E_QH MT54_M73O\
MG_M?^_R_XT?VKIW_ #_VO_?Y?\: +=%5/[5T[_G_ +7_ +_+_C1_:NG?\_\
M:_\ ?Y?\: +=%5/[5T[_ )_[7_O\O^-']JZ=_P _]K_W^7_&@"W153^U=._Y
M_P"U_P"_R_XT?VKIW_/_ &O_ '^7_&@"W153^U=._P"?^U_[_+_C1_:NG?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!'/_P >\O\ N'^525'/_P >\O\ N'^5
M24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1S_\
M'O+_ +A_E4E1S_\ 'O+_ +A_E4E !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP!@Q3XQG < 8!('M% !1110!'/\ \>\O^X?Y5)4<_P#Q[R_[A_E4E !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>#_$WX6Z%I>HZ#J7AYI]'OM1UNWLLV[GRX6D+MYJ+P58$+@*RJ
M . .M>@?%CP=<>-O TUA8\W]O*MU:H7"+(Z@@J21W5FQT^;;D@9KR37_ (I7
MTVE^%K'Q?HFI66M:7K%MJ,[-;>4+F"/<-ZJQ4AR21C&W*D@C[H .OT_6_%?P
MT\:Z1X9\2ZE)X@T76'$%C?. )XY2P!W9)8@-( =S'Y2I4\%*[#Q?\,M%\<:S
M8ZAK-UJ3)9H$2SBG"P,-VYLC;D%N 2I!PHZ8S7G>D2Z[\8/B5I/B"73I[#PG
MHLIN+)Y%"-*P;C#8.]F>-=P'RJJD9W<MT'Q1T#7;+Q;H'C[PY9SZA=:9BWNK
M.'#.\)8_<7:3R))%8C)&Y2!P2 #L+[X<>"M0LY+6;POI21OC)@MEA<8(/#H
MPZ=CSTZ5Q_P1OKBT@\2>#IY/M$?AW4'A@N-H3>C/("-HZ?,C-R3]_'0"J<'[
M0FFZC;Q6^D^&-9OM:D0%;*-5*LV,N ZEF( #'.SG'(';J/A?X,OO"^EW^H:Y
M)'+X@UFX-W?,G1"<D)P=I(+.25 &6(&0 : .;_9Q_P"2>:A_V%9/_145=!\;
M?^20Z[_V[_\ I1'7#R^(-4^#WQ%\02ZMI]]>>%M:NS=QW,*<1RON?"9;9NSN
M1@2&(16Z  U_$'B"X^/%Y8^&O#6GSVFDVLJW=_J%Z@S"<,H 56(/!; SEC_=
M"LU !\4_^3>O!7_;C_Z2/7T!7+_$7P]<>*OA_K&CV;8NIH@\(P/G=&614Y(
MW%0N2>,Y[5YGX>^.\/A_1H-'\9:/K,6M62+%*5B!:10HVNXE=6#D$$YSG[V>
M<  U/$/_ "=#X3_[!4G_ *#=5[!7D?PNTK6M=\8ZM\2M6MH]/BU>W$%I9#)9
MHOW>V0D]ML:@''S9+ *-N?7* "D;=CY0"?0G%+10!!.9?(DRB8VG.'/I]*C\
MS4?^?6U_\"6_^(J>?_CWE_W#_*I* *GF:C_SZVO_ ($M_P#$4>9J/_/K:_\
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M4>9J/_/K:_\ @2W_ ,15NB@"IYFH_P#/K:_^!+?_ !%'F:C_ ,^MK_X$M_\
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M .!+?_$4>9J/_/K:_P#@2W_Q%6Z* *GF:C_SZVO_ ($M_P#$4>9J/_/K:_\
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M4>9J/_/K:_\ @2W_ ,15NB@"IYFH_P#/K:_^!+?_ !%'F:C_ ,^MK_X$M_\
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M .!+?_$4>9J/_/K:_P#@2W_Q%6Z* *GF:C_SZVO_ ($M_P#$4>9J/_/K:_\
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M5+ UPV[[1%%'_=\N0OGZY48J:B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q]?\-V
M?B/^R_MDDZ?V;J$6H0^2P&Z2/.T-D'*\G(&#[UL44 %%%% !1110 4444 %%
M%% !1110 4444 1S_P#'O+_N'^525'/_ ,>\O^X?Y5)0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!'/_ ,>\O^X?Y5)4<_\ Q[R_
M[A_E4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%9?B/7['PMX?O-:U)I!:6J!G\M=S,20JJ!ZEB
M!S@<\D#FO#-<\2?%'Q%9Z#KL-U!X?TW4]5AM=-M(V97=G+&.24[27C(X(/RM
MM!\O!!(!]#T5YOX(\;ZZWBBY\%^-+6"WUN"+S;6[A(6.^C  +*">6."WR@#
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M4_#?B32H],\0:<F^2.,MME7=@D Y"@!H^=S;M^1Q7HE !1110!'/_P >\O\
MN'^525'/_P >\O\ N'^524 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<9I<<9 (.P$@L<C XZD ^;^,]-TWP3\8_!MSX7:/3+G5;A+>_L[4JL;0F2-
M3$!@!@6'H3&",,":/'_ACXB:E\5(==TS1X]4TS3'B?38KBZC2)6"*S':)$;/
MF G)Z[5!RH H H:OX+FT+X&^)-?UI(Y/$FM/!=74QA*/$LEQ$_E$'&T[LLP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!'/_P >\O\ N'^525'/_P >
M\O\ N'^524 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?OR[BH^8Q$\8(KVBO'_$/_)T/A/_ +!4G_H-U7L% !112,P49.<>PS0 R?\
MX]Y?]P_RJ2H)Y5,$@P_*GJA]/I4?]HP?\\[K_P !9?\ XF@"W153^T8/^>=U
M_P" LO\ \31_:,'_ #SNO_ 67_XF@"W153^T8/\ GG=?^ LO_P 31_:,'_/.
MZ_\  67_ .)H MT54_M&#_GG=?\ @++_ /$T?VC!_P \[K_P%E_^)H MT54_
MM&#_ )YW7_@++_\ $T?VC!_SSNO_  %E_P#B: +=%5/[1@_YYW7_ ("R_P#Q
M-']HP?\ /.Z_\!9?_B: +=%5/[1@_P">=U_X"R__ !-']HP?\\[K_P !9?\
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M@"W153^T8/\ GG=?^ LO_P 31_:,'_/.Z_\  67_ .)H MT54_M&#_GG=?\
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M9?\ XF@"W153^T8/^>=U_P" LO\ \31_:,'_ #SNO_ 67_XF@"W153^T8/\
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M/[1@_P">=U_X"R__ !-']HP?\\[K_P !9?\ XF@"W153^T8/^>=U_P" LO\
M\31_:,'_ #SNO_ 67_XF@"W153^T8/\ GG=?^ LO_P 31_:,'_/.Z_\  67_
M .)H MT54_M&#_GG=?\ @++_ /$T?VC!_P \[K_P%E_^)H MT54_M&#_ )YW
M7_@++_\ $T?VC!_SSNO_  %E_P#B: +=%5/[1@_YYW7_ ("R_P#Q-']HP?\
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MC!_SSNO_  %E_P#B: +=%5/[1@_YYW7_ ("R_P#Q-']HP?\ /.Z_\!9?_B:
M+=%5/[1@_P">=U_X"R__ !-']HP?\\[K_P !9?\ XF@"W153^T8/^>=U_P"
MLO\ \31_:,'_ #SNO_ 67_XF@"W153^T8/\ GG=?^ LO_P 31_:,'_/.Z_\
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M4_M&#_GG=?\ @++_ /$T?VC!_P \[K_P%E_^)H MT54_M&#_ )YW7_@++_\
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M-']HP?\ /.Z_\!9?_B: +=%5/[1@_P">=U_X"R__ !-']HP?\\[K_P !9?\
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M@"W153^T8/\ GG=?^ LO_P 31_:,'_/.Z_\  67_ .)H MT54_M&#_GG=?\
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M9?\ XF@"W153^T8/^>=U_P" LO\ \31_:,'_ #SNO_ 67_XF@"W153^T8/\
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M/[1@_P">=U_X"R__ !-']HP?\\[K_P !9?\ XF@"W153^T8/^>=U_P" LO\
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MS9:.0 9PN]"&V_,3MSC)SC-1^&O /A?PA<3W&A:3':SSH$DD,CR-M!S@%V)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".?_CWE_P!P_P J
MDJ.?_CWE_P!P_P JDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH CG_X]Y?\ </\ *I*CG_X]Y?\ </\ *I* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=G!(%>,:_P"(O'^DZ7X6TGQ7X8N[J[T_6+:\MKQ9?,-WLW!(&9 P,IYYSN(
M)4GYB ='%!JGP=\?>']%L=3GU/PSKTHM8K.\DR]J^]0S*0-H^:7=P!NRP(R
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MNK=% %3R]1_Y^K7_ ,!F_P#BZ/+U'_GZM?\ P&;_ .+JW10!4\O4?^?JU_\
M 9O_ (NCR]1_Y^K7_P !F_\ BZMT4 5/+U'_ )^K7_P&;_XNCR]1_P"?JU_\
M!F_^+JW10!4\O4?^?JU_\!F_^+H\O4?^?JU_\!F_^+JW10!4\O4?^?JU_P#
M9O\ XNCR]1_Y^K7_ ,!F_P#BZMT4 5/+U'_GZM?_  &;_P"+H\O4?^?JU_\
M 9O_ (NK=% %3R]1_P"?JU_\!F_^+H\O4?\ GZM?_ 9O_BZMT4 5/+U'_GZM
M?_ 9O_BZ/+U'_GZM?_ 9O_BZMT4 5/+U'_GZM?\ P&;_ .+H\O4?^?JU_P#
M9O\ XNK=% %3R]1_Y^K7_P !F_\ BZ/+U'_GZM?_  &;_P"+JW10!4\O4?\
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M_ 9O_BZMT4 5/+U'_GZM?_ 9O_BZ/+U'_GZM?_ 9O_BZMT4 5/+U'_GZM?\
MP&;_ .+H\O4?^?JU_P# 9O\ XNK=% %3R]1_Y^K7_P !F_\ BZ/+U'_GZM?_
M  &;_P"+JW10!4\O4?\ GZM?_ 9O_BZ/+U'_ )^K7_P&;_XNK=% %3R]1_Y^
MK7_P&;_XNCR]1_Y^K7_P&;_XNK=% %3R]1_Y^K7_ ,!F_P#BZ/+U'_GZM?\
MP&;_ .+JW10!4\O4?^?JU_\  9O_ (NCR]1_Y^K7_P !F_\ BZMT4 5/+U'_
M )^K7_P&;_XNCR]1_P"?JU_\!F_^+JW10!4\O4?^?JU_\!F_^+H\O4?^?JU_
M\!F_^+JW10!4\O4?^?JU_P# 9O\ XNCR]1_Y^K7_ ,!F_P#BZMT4 5/+U'_G
MZM?_  &;_P"+H\O4?^?JU_\  9O_ (NK=% %3R]1_P"?JU_\!F_^+H\O4?\
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MU'_GZM?_  &;_P"+JW10!4\O4?\ GZM?_ 9O_BZ/+U'_ )^K7_P&;_XNK=%
M%3R]1_Y^K7_P&;_XNCR]1_Y^K7_P&;_XNK=% %3R]1_Y^K7_ ,!F_P#BZ/+U
M'_GZM?\ P&;_ .+JW10!4\O4?^?JU_\  9O_ (NCR]1_Y^K7_P !F_\ BZMT
M4 5/+U'_ )^K7_P&;_XNCR]1_P"?JU_\!F_^+JW10!4\O4?^?JU_\!F_^+H\
MO4?^?JU_\!F_^+JW10!4\O4?^?JU_P# 9O\ XNCR]1_Y^K7_ ,!F_P#BZMT4
M 5/+U'_GZM?_  &;_P"+H\O4?^?JU_\  9O_ (NK=% %3R]1_P"?JU_\!F_^
M+H\O4?\ GZM?_ 9O_BZMT4 5/+U'_GZM?_ 9O_BZ/+U'_GZM?_ 9O_BZMT4
M5/+U'_GZM?\ P&;_ .+H\O4?^?JU_P# 9O\ XNK=% %3R]1_Y^K7_P !F_\
MBZ/+U'_GZM?_  &;_P"+JW10!4\O4?\ GZM?_ 9O_BZ/+U'_ )^K7_P&;_XN
MK=% %3R]1_Y^K7_P&;_XNCR]1_Y^K7_P&;_XNK=% %3R]1_Y^K7_ ,!F_P#B
MZ/+U'_GZM?\ P&;_ .+JW10!4\O4?^?JU_\  9O_ (NCR]1_Y^K7_P !F_\
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MBD_N^7&4Q]<L<U-10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9^JZ)IVM_8O[1M_.
M^PW<=[;_ #LNR9,[6X(SC)X.1[5H44 %%%% !1110 4444 %%%% !1110 44
M44 1S_\ 'O+_ +A_E4E1S_\ 'O+_ +A_E4E !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $<__ ![R_P"X?Y5)4<__ ![R_P"X?Y5)
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\FT;DCV[MNY<#!(.  ?0%%<WX^\2S>$/!&IZ[;V\=Q/;(@CCD)"[G=4!..2
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M_P */[*T[_GPM?\ ORO^% %NBJG]E:=_SX6O_?E?\*/[*T[_ )\+7_ORO^%
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M=_SX6O\ WY7_  H_LK3O^?"U_P"_*_X4 6Z*J?V5IW_/A:_]^5_PH_LK3O\
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MK_WY7_"C^RM._P"?"U_[\K_A0!;HJI_96G?\^%K_ -^5_P */[*T[_GPM?\
MORO^% %NBJG]E:=_SX6O_?E?\*/[*T[_ )\+7_ORO^% %NBJG]E:=_SX6O\
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M 6Z*J?V5IW_/A:_]^5_PH_LK3O\ GPM?^_*_X4 6Z*J?V5IW_/A:_P#?E?\
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M_P */[*T[_GPM?\ ORO^% %NBJG]E:=_SX6O_?E?\*/[*T[_ )\+7_ORO^%
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M=_SX6O\ WY7_  H_LK3O^?"U_P"_*_X4 6Z*J?V5IW_/A:_]^5_PH_LK3O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% $<_P#Q[R_[A_E4E1S_ /'O+_N'^524 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ
M+=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#B
MZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_
M (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^H
MO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB
M_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P!
MVZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^H
MO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\
MT#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\
M0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T
M#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3
M_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5
M/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD
M_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@
M"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ
M/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#B
MZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[
MZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ
M +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K
M_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO
M^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_
M +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0
M-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD_
M_0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T
M#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W15
M3[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD_
M_0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=
M%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^
M+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%
M5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+
M_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO
M_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB
M_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^
M^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-N
MO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_
M +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/
M_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-N
MO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/M
MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V
M3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD
M_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+
MH^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ
M+=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#B
MZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_
M (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^H
MO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB
M_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P!
MVZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^H
MO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\
MT#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\
M0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T
M#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3
M_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5
M/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD
M_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@
M"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ
M/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#B
MZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[
MZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ
M +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K
M_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO
M^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_
M +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0
M-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD_
M_0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T
M#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W15
M3[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD_
M_0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=
M%5/MD_\ T#;K_OJ+_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^
M+H^V3_\ 0-NO^^HO_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%
M5/MD_P#T#;K_ +ZB_P#BZ/MD_P#T#;K_ +ZB_P#BZ +=%5/MD_\ T#;K_OJ+
M_P"+H^V3_P#0-NO^^HO_ (N@"W153[9/_P! VZ_[ZB_^+H^V3_\ 0-NO^^HO
M_BZ +=%5/MD__0-NO^^HO_BZ/MD__0-NO^^HO_BZ +=%5/MD_P#T#;K_ +ZB
M_P#BZE@F>7=OMI8<=/,*G/TVDT 34444 %%%% !1110 4444 %%%% !1110
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M(;D-CLRM[Q10!X/X8^-'P[\(Z'#I&D:-KD5O'RS-!"7E<]7<^9RQP/R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CG_ ./>
M7_</\JDJ.?\ X]Y?]P_RJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@".?\ X]Y?]P_RJ2HY_P#CWE_W#_*I* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4-:NY;'2+BX@($B@
M!21G&2!G]:X#^U=1_P"?^Z_[_-_C7<>)O^1>NO\ @'_H8KS>Y=H[29U.&5&(
M/OBO)Q\I>U23Z&-67*K]C0_M74?^?^Z_[_-_C1_:NH_\_P#=?]_F_P :XO\
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M%'V.?_H)77_?,7_Q%6Z* *GV.?\ Z"5U_P!\Q?\ Q%'V.?\ Z"5U_P!\Q?\
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M?_H)77_?,7_Q%'V.?_H)77_?,7_Q%6Z* *GV.?\ Z"5U_P!\Q?\ Q%'V.?\
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M1]CG_P"@E=?]\Q?_ !%6Z* *GV.?_H)77_?,7_Q%'V.?_H)77_?,7_Q%6Z*
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M_$4?8Y_^@E=?]\Q?_$5;HH J?8Y_^@E=?]\Q?_$4?8Y_^@E=?]\Q?_$5;HH
MJ?8Y_P#H)77_ 'S%_P#$4?8Y_P#H)77_ 'S%_P#$5;HH J?8Y_\ H)77_?,7
M_P 11]CG_P"@E=?]\Q?_ !%6Z:SJ@R[!1ZDXH K?8Y_^@E=?]\Q?_$4?8Y_^
M@E=?]\Q?_$4DFK:?#]^]@!]!(":IR>)])CZ7!<^BH?\ "LW5IQWDA71=^QS_
M /02NO\ OF+_ .(H^QS_ /02NO\ OF+_ .(K'D\962_ZNWG?Z@ ?SJG)XUD/
M^JLE'NTF?Z"LGC**^T+F1TGV.?\ Z"5U_P!\Q?\ Q%'V.?\ Z"5U_P!\Q?\
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M(H^QS_\ 02NO^^8O_B*MT4 5/L<__02NO^^8O_B*/L<__02NO^^8O_B*MT4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH CG_X]Y?]P_RJ2HY_^/>7_</\JDH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRH)R%#C ]N17045G.E"?Q*XFDSGO^$-T[_GM=?\ ?2__ !-'_"&Z=_SVNO\
MOI?_ (FNAHJ/JM'^4.5&-9^&-.LYEE EE=6#(9'^Z1SQC'ZULT45I"G&"M%6
M!*P44458PHHHH *:R*XPZAAZ$9IU% %.32M/E^_90$^OE@&JDGAG29/^78H?
M578?UK7HK-TJ<MXH5D<[)X.L6_U<TZ'W((_E5.3P4W_+*^!]FC_^O7745D\)
M1?V1<J.&D\'ZBGW)(''LQ!_454D\-ZM%UM"P]58'^M>B45D\!2>UQ<B/,)--
MOH?]99SJ/4QG%5B"IP00?0UZQ37CCD&'16'HPS63RY=)!R'E'3I5B._O(?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CG_X]Y?]P_RJ
M2HY_^/>7_</\JDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***YGQ-K=WI]
MS%;6K",E/,:3 )/)&,'Z?Y[YU:L:4>:0F['345YY_P )-K'_ #]_^0T_PJ,^
M+M16=8&U&,3,,K&53<1Z@8]C^5<G]H4NS_KY@FY;(]'HKSS_ (2;6/\ G[_\
MAI_A6_X9UNYU"::VNW\QPOF(P4#CH0<?4=O6M*>-IU)**OJ)23.DHHHKK*"B
MBHI+JWA_UL\2?[S@4FTMP):*SI->TN+[U[$?]WYOY53D\6Z8GW3-)_NI_CBL
MW7I1WDA71NT5R\GC2$?ZJSD;_><+_C5.3QG=G_56T*?[Q+?X5D\;1747,CM*
M*\_D\4ZK)TF2/_=C']<U4DUC4I?OWL_T5R/Y5D\PIK9,7.CTHD*,D@#U-5I-
M2L8?]9>0*?0R#->9O+)*<R.SGU8YIE9/,7TB+G/0Y/$FDQ?\O08^BH3_ $JI
M)XQL%_U<4[G_ '0!_.N,CM;B;_502R?[J$U<CT'5)?NV4H_WL+_.H^N8B7PK
M\ YF;<GC4](K'\6D_IBJ<GC#4'^Y' @]E)/ZFF1^$M3?[PAC_P!Y_P##-6X_
M!<Q_UMY&O^ZA;_"B^,GW_(/>,R3Q'JTO6[*CT50/Z53DU"]F_P!9=SO[&0UU
M<?@RT'^MN9G_ -W"_P"-7(_"VE1]87D_WI#_ $Q1]5Q,_B?XARR//R23DG)I
M0"QP 2?05Z7'H^FQ?<LH/J4!_G5M(HXQB-%0>BC%4LNEUD'(>91Z;?3?ZNSG
M8>HC.*N1^&M6E_Y=2H]6<#^M>AT5JLNAU;'R(X>/P=?M_K)8$'^\2?Y5<C\%
M#K+?'Z+'_7-=916JP5%=!\J.?C\'Z<GWY)W/NP _05;C\.:3%TM%8^K,3_6M
M6BM5AZ2VBAV16CT^RA_U=I GN(Q5D  8 P***U22V&%%%%, HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)#%*,21HX_P!I
M0:?11:X%&31M-E^]8P?\!3;_ "JI)X6TJ3[L+Q_[LA_KFMFBLW1IRWBA61S4
MG@RT/^JN9U_WL-_A523P7*/]5>HW^\A']37845D\'1?V1<J.$D\(ZFGW?)D_
MW7_Q JG)X?U6+[UFY_W2&_D:]'HK)Y?2>S8N1'ELEE=P_P"MMID_WHR*@KUF
MHY+>&;_6PQO_ +R@UD\N[2%R'E:LRG*D@^H-6H]3OX?]7>3J/3S#BN_DT33)
M?O64(_W5V_RJG)X4TI_NQR1_[LA_KFL_J-:/PL.1G+Q^)=6C_P"7K</1D4_T
MJW'XQU!?OQ0./]T@_P ZTI/!EJ?]5=3+_O -_A523P7./]5>1M_O(5_QH]GB
MX[-_>%I$D?C7M+8_BLG],5<C\8V#??BG0_[H(_G6')X2U1/NK#)_NO\ XXJI
M)H.J1?>LI3_NX;^5'M\7'=?@%Y'91^)=)D_Y>MI]&1A_2K<>J6$W^KO(&/IY
M@S7F\EI<P_ZVWE3_ 'D(J&A9A47Q1#G9ZPK*XRK CU!I:\H5W0Y1F4^H.*M1
MZKJ$7W+V<#T\PD5JLQ76(^<]-HKSV/Q-JT?_ "\AQZ,BG^E6X_&-\O\ K(8'
M'L"#_.M5CZ3WNA\Z.WHKE(_&J_\ +6Q(]UDS_2K<?C#3G^_'.A]U!'Z&M5BZ
M+^T',CH**RH_$>DR]+L*?1E(_I5R/4;&;_5WD#>PD&:U56$MFAW19HI 0PR"
M"/44M6,**\JGGENIWGG<O(YRS'O4=>8\R[1_'_@$<YZS17DU%+^TO[OX_P#
M%SGK-%9VA7,EWHMK-*<N5*D^N"1D^_%7W=(QEV51ZDXKTHR4HJ7<T'452EU?
M3H?OWL /H'!/Z53E\4Z5'TG:0_["'^M3*M3CO)"NC9HKFI?&=H/]5:S/_O$+
M_C5*7QI<'_56<:_[[%O\*QEC**ZBYD=E17 R^*]4D^[)''_N(/ZYJG+K6IS?
M>O9O^ MM_E64LPIK9,7.CTHD 9)P*JRZE8P_ZR\@4^AD&:\SDFEE.9)'<_[3
M$TRLI9B^D1<YZ'+XETF+_EZW'T1"?Z53E\8V*\1PSN?< #^=<=%:7,W^JMY9
M/]Q":N1:!JLOW;*0?[^%_G4?7,1/X5^ <S-B7QJY_P!59*/=Y,_TJG+XNU)_
MN"&/_=3/\R:(O".I/]\PQ_[SY_D*NQ>"G/\ K;U1[)'G^M'^V3[_ )![S,:7
M7]5E^]>R#_<PO\JI2W5Q-_K9Y9/]]R:[*+P=8+S)-.Y^H _E5R+PUI,7_+KN
M/J[D_P!:/J>(G\3_ !#E9YY3XX993B.-W/\ LJ37IL6G64/^KM(%/J(QFK(
M P!@5<<N?60<AYK%HFIS?=LIA_O+M_G5R+PIJDGWDBC_ -]Q_3-=]16L<OIK
M=L?(CCHO!<Y_UMY&O^XI;_"KD7@RT7_6W,S_ .Z O^-=+16T<'170?*C&B\+
MZ5'U@:0_[;G^E78M)TZ'[EE #ZE 3^M7**UC1IQVBAV0U45!A%"CT Q3J**T
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBD) &20![T +14#WUI']^Z@7_>D
MJN^MZ9'UOH3_ +K9_E4.I%;L+E^BL=_$^DITN2Q_V8V_PJN_C#3E^ZEP_P!$
M']34/$4E]I"NCH**Y=_&D ^Y9R-_O.!_C5=_&DI^Y9(O^](3_05F\917VA<R
M.PHKAW\8Z@WW8K=?^ D_UJK+XKU3&3<I&/9%_K4/'TEW#F3V/0J*\MG\7S#/
MFZRB>PE5?Y5G3^,+;GS=8D?_ (&[?RK-YC#I%G3#"XFI\%.3]$SV(L%&6( ]
MZX;Q?(DFK1%'5@( "5.?XFKA9?%^FYSYDTI]0A_K563QI:#_ %=K.W^\0/\
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MZS17DX^-:8^;0&!]KO/_ +)2_P#"ZX_^@"__ (%#_P"(I_7*'\WYB_U<S/\
MY]?C'_,]7HKRC_A=<?\ T 7_ / H?_$4H^-<.?FT)P/:Z!_]EH^N4?YOS#_5
MS,_^?7XQ_P SU:BO*_\ A=5O_P! 27_P('_Q-'_"ZK?_ * DO_@0/_B:/KE'
M^;\Q?ZNYG_SZ_&/^9ZI17E?_  NJV_Z DO\ X$#_ .)I_P#PNFR_Z UQ_P!_
MA_A1];H_S!_J[F?_ #Z_%?YGJ-%>7?\ "Z;+_H#7'_?X?X4?\+ILO^@-<?\
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M&2;=SPLZE*-./*[:A]LNO^?F;_OX:ZFT8M9P,Q))C4DGOQ7'UU]E_P >-O\
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M<([(+(****L84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ\+\1>(;?XD?&;PII?AQ?M%OH-V;FXO@28G"M&[[< _*/+"ACPS. .,,?>*
M/'_B_P#\E#^&/_85/_HVWKV"O'_B_P#\E#^&/_85/_HVWKV"@#P_2O@AK&HZ
MMKUUXKU[[/:ZK*;B:TT2=U2:0R%_G\Q<;5).T$,><Y&.:?B'P+=_!Q(/%WA3
M5]2FT^WN(1J.GSRH!-&69268  CY@@&QBI<L#QQN>!/B;<:?K&K^%_B)JT$&
MKVEV5@NIT$,<J;3D A%55^4,K-C<)!CM1\5_&&E^)?#G_"&^&+F#6]9U:6%$
MALI?,"('WERX!3@QX(+# ;<>!0!7_: OK?4_A9HU_9R>9:W6H030OM(W(T$I
M4X/(R".M>T5Y?\2_"/\ Q8TZ2B_;;C1+2"2*7/E_ZE0KR8W8_P!7YAVDGKQD
MXK4\(_%;PSX@\-6E]?ZUINGW^P)=6]S.L!64 ;MH=LE">0<G@X/(( !S?B'_
M ).A\)_]@J3_ -!NJ]@KQ?P7=?\ "?\ QMU/Q?#;SSZ%IEI]CTZ[D3R@LF%!
M '!;(>9OFR0'7(4[17M% !2,RJ,L0 .Y-+10!!/-$8) )4)*G ##TJ/^U=._
MY_[7_O\ +_C4\_\ Q[R_[A_E4E %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?
MY?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O
M\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^
M7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7
M_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?
MY?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O
M\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^
M7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7
M_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?
MY?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O
M\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^
M7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7
M_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?
MY?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O
M\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^
M7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7
M_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?
MY?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O
M\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^
M7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7
M_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?
MY?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^7_&K=% %3^U=._Y_[7_O
M\O\ C1_:NG?\_P#:_P#?Y?\ &K=% %3^U=._Y_[7_O\ +_C1_:NG?\_]K_W^
M7_&K=% %3^U=._Y_[7_O\O\ C1_:NG?\_P#:_P#?Y?\ &K=!( R>* *G]JZ=
M_P _]K_W^7_&C^U=._Y_[7_O\O\ C4CWEK']^YA7_><"J[ZUID?6^@/^Z^?Y
M5+G%;L+DG]JZ=_S_ -K_ -_E_P :/[5T[_G_ +7_ +_+_C5-_$VDI_R]%C_L
MQM_A5=_%^FK]U9W^B#^IK-XBDOM(5T:G]JZ=_P _]K_W^7_&C^U=._Y_[7_O
M\O\ C6&_C2W'W+25O]Y@/\:KOXUD/^KL5'^])G^E0\917VA<R.D_M73O^?\
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MC?[S ?XUY))XUA'^KLG;_><#^AJK)XTN#_J[2)?]YB?\*AXZL^IV0X;S6?\
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MJ[VBCV%+^5?</^UL?_S^E_X$S@O^$!\!^L7_ (''_P"*IK> / AZ.@^EZ?\
M&N_HH]A2_E7W!_:V/_Y_2^]GG_\ PK[P)_SU7_P-_P#KT?\ "OO G_/5?_ W
M_P"O7H%%+ZO2_E0_[7Q__/Z7WL\^/P^\"D8$RCW%[_\ 7IO_  KOP-_S]?\
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M_P"_D=(WPL\.9^7Q(0/=XS7K%%'U2C_*']OYE_S]?X?Y'DW_  JSP]_T,O\
MX]'_ (T?\*L\/?\ 0R_^/1_XUZS11]4H_P H_P#6#,O^?K^Y?Y'DI^%?A_''
MB8 ^YC/]:;_PJO0O^AH7_P <_P#BJ]<HI?5*/\H?ZPYE_P _7]R_R/(_^%5Z
M%_T-"_\ CG_Q5'_"J]"_Z&A?_'/_ (JO7**/JE'^4?\ K#F7_/W\%_D>0?\
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MA\'AU&&&CKU=V_EO8^YX$S3-\RE5K9C5O%648\L5OO+1)V6RUL[OLC@-=O\
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M_P _]K_W^7_&K=% BI_:NG?\_P#:_P#?Y?\ &C^U=._Y_P"U_P"_R_XU;HH
MJ?VKIW_/_:_]_E_QH_M73O\ G_M?^_R_XU;HH \FJ%K2V9BS6\1).22@YKTZ
MYT+3+N8RS6BESU*DKGODX(R?>O//B?/IN@:;!8Z?'Y6H73;BZRMNCC4]?O9!
M)P!P00&[BO%J8.=*+E=6-,)ETL=7C0BE=_AW93^QVO\ S[0_]^Q4RJ%4*H
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M_&K=% %3^U=._P"?^U_[_+_C1_:NG?\ /_:_]_E_QJW10!4_M73O^?\ M?\
MO\O^-']JZ=_S_P!K_P!_E_QJV3@9-,,T0&3(@'^\*!V;*_\ :NG?\_\ :_\
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M *S6K@CT\U@/R%49-9M9&S)=[SZMDUJL)A_M5X_>O\S&6)S%_!@JC_[=E_\
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MJ_+R/@J/#U?*\PJ1K/X&TO-='Z6_'T'4445Y9[(4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !15"_UK3=,!^V7D4;?W,Y;_OD<URNH?$:!,II]HTA[23':/R')
M_2NBEA:U7X(G'B,?AL/_ !)J_;=_<=S6=J&O:7IF1=WD2./X =S?D.:\MU#Q
M5K&I966\:.,_\LX?D'Z<G\36. SL  68G@#DFO3I90]ZLON/#Q'$:VH0^;_R
M7^9Z!J'Q&C7*Z=9ECVDG.!_WR/\ &N5U#Q-J^I9$]XZQG_EG'\B_IU_&I]/\
M'ZUJ&&%J8(S_ !SG9^G7]*ZK3_AW9Q8:_N9+AO[D?R+_ (G]*WYL#A=K-_>S
MDY,UQ^]U'[E_P?Q/.$1I'"(I9CP !DFM_3_!FM7^&-N+:,_Q3G;^G7]*]1LM
M+L--3;9VD4/8E5Y/U/4U;KFJYO)Z4XV]3MP_#D%K7E?R7^?_  QQNG_#RP@P
MU]/)<M_=7Y%_Q_45U%GIUEIZ;+2UBA'?8N"?J>IJU17FU<35J_'*Y[F'P6'P
M_P#"@E^?W[A1116!U&-JGA;2M7NEN;F%A,"NYXVV^8!V;_'KP.:OV&G6FEVH
MMK*!88@2V 2<D]R3R?QJU16DJM245!MV70QCAZ49NI&*4GUMJ%%%%9FP4444
M %%%% !1110!7FL;.X_UUK!)_OQ@_P ZH3>%]#G^_ID _P!Q=G\L5KT5<:LX
M_"VC*="E/XXI^J.:F\!Z%)]R&:+_ ')2?YYJA-\.+%O]3?7"?[X5OY8KM**W
MCC<1':;.6>5X.>]-?+3\CSR;X;7 _P!3J43_ ._$5_D35";X?ZU']PVTO^Y(
M1_,"O4J*WCFF(6[3^1RSR'!2V37H_P#.YX]-X0UZ'[VG.P_V&5OY&J$VD:E;
M_P"NT^Z0>K0L!_*O<**VCG%3[44<L^&Z+^&;7W/_ "/!""IP001V-)7O,D,4
MPQ+$CCT90:HS:!I$_P#K-,M23W$0!_,5O'.(_:A^)RSX;FO@J)^JM_F>/0ZE
M?V_^IO;F/_<E8?R-7X?%>NP?<U*8_P"_A_Y@UZ'-X)T&7I9F,^J2L/ZXJA-\
M.]*?F*XNHS_O*1_*K_M#"3^*/WI&?]CYC2_AS^Z37^1S4/C[6X_OM;R_[\6/
MY8J]#\2+M?\ 7:? _P#N.5_GFK$WPU[PZG^#P_U!JA-\.M53F*XM9![LRG^5
M'-EU3M^*#DSFEW?S3_S-:'XD6C?Z[3YD_P!QPW\\5?A\?:))]]KB+_?BS_(F
MN+F\$Z]%TLQ(/5)5/]<U1F\/ZQ!_K-,N@!W$1(_,4OJ6!G\,ON8?VGFE+XX_
M?'_*QZC#XLT*?[NI1#_?!3^8%7X=3L+C_4WUM)_N2J?ZUXA)#+"<2Q.A]&4B
MF4GE%-_#)E1XCK+2<%^*_P SWLA77D!A[\U7DTZQE_UEE;O_ +T2G^E>(Q7,
M\!S#/)'_ +CD?RJ]#XCUF#[FIW7_  *0M_.L)9-+I)/Y'73XGBMX->C_ .&/
M5I/#FAR_ZS1M.?\ WK5#_2JLG@SPU)][0[$?[L(7^5<%#XXUZ+[UTD@]'B7^
M@%7X?B-J:_ZVUM7'^R&4_P S7/+)JO9,]"EQ53_GG'[_ -&=+)\/?"DGWM&A
M'^Z[K_(U5D^%_A)_NZ:Z?[MQ)_5C5.'XDH>)M,8>Z39_0BK\/Q#TA^)(;J,^
MZ C]#7-+*JBWI_D>A2XIO\.)DOG)?F4Y/A+X8?[J7:?[L_\ B#563X.>'V^Y
M>:DA_P"NB$?^@5TL/C/09O\ E^"'T>-A_3%7H=<TF?\ U>I6K'T\U0?RS7-+
M+U'XJ=OD>A2XEQ+^#$W_ .WDS@I/@QIA_P!7JMVO^\BG_"JTGP4B/^KUYU_W
MK4'_ -G%>J)(DJ[HW5QZJ<TZL7@Z/6)VQXBS);5?P7^1X_)\%;H?ZO6H6_WH
M"/\ V8U5D^#.L#_5ZE8M_O;Q_0U[514/!4>QO'B?,EO-/Y+_ "/"Y/@_XD3[
ML^G/_NS-_515:3X4^*D^[;V[_P"[.O\ 7%>^T5+P%+S-H\69@M^5_+_@GSQ)
M\-/%T?\ S"2P_P!F>,_^S56D\!>*8_O:+<G_ '<-_(U](45+R^GW9M'C#&=8
M1_'_ #/F63PEXCB^]H6H_A;.?Y"F?V?X@M?^7/4X<?\ 3*1?Z5].T5/]GQZ2
M-5QA5?QTD_FSYA_M/Q!:_P#+]J<./^FLB_UJ6/Q?XCC^[KNHG_>N6;^9KZ9J
M.2WAE_UD,;_[R@T?49+:?]?>/_6JC+X\,G\U_P#(GSG'X^\4Q_=UJX/^]M;^
M8JU'\3/%T?\ S%=P]&MXS_[+7O$FC:5+_K-,LW_WH%/]*JR>%/#LOWM"TWZB
MU0']!1]4K+:I^8?ZP9;+X\*ONB_T/&X_BOXI3[T]L_\ O0#^F*LQ_&'Q&GWK
M?3G_ -Z)_P"C5ZE)X%\+R?>T2U'^ZI7^559/AMX1DZZ0H/\ LSR#^34?5\2M
MIA_:^22^+#6]$O\ -' Q_&;5Q_K-,L6_W2X_J:XCQ/XCN-?U6XU>^(C&T812
M2L:*.@SGW)]R3WKK/B7H7A[PX]G9:7:O'>2@S2$RNP6/D 8/!R<]^-OO7C_B
MF^\N!+)#\TGSO_N@\?F1^GO7/)5:E149RN>S2J9?A,'+,L/2Y;K2^[UTZO=_
MAJ:NF:@FI68G5=AW%67.=I^N/3!_&O7+?XSWD5K#'-I,<TR1JLDIGV^8P'+8
M"X&3SBOGOPY??9=1$3']W/A#[-_#_A^->J^"M.TG5_$<6G:P\L<5PI2)XW"X
MDZ@$GL>0.Y)6G.,Z%7EINR9GAJ^%S7+U7QD.:5.][;^;TMNM>WW'8GXTW>?E
MT6 #WG)_I3#\:-0SQI%L![RM74+\(O#(/+7S?68?_$T]?A+X8'5+MOK/_P#6
MK?V>,_F_K[CROK?#J_Y=/\?_ )(Y$_&?5,\:59@>[-_C3#\9M8SQIMCC_@?^
M-=HOPH\+#K;W+?6<TY?A7X4'6SF/UN'_ ,:/98O^;^ON#Z_P\O\ ER_N_P#M
MCAC\9==SQ8:=C_=?_P"*IG_"Y/$/_/EI?_?J3_XNN_7X7>$@.=.=OK<2?_%4
M\?#+P@!SI)/N;F7_ .*H]CB_Y_Z^X/[2R!?\P[^Y?_)'G7_"X?$?_/OIW_?I
M_P#XNF?\+>\2_P!RP_[\G_XJO2Q\-O"*C T=?QGE/_LU/'PZ\)@8&C1_C(Y_
M]FH]ABOY_P"ON#^U<B6V&?W+_P"2/+C\6_$^.MF/^V/_ ->FGXL>*2/]=:CW
M\@5ZL/A_X5 Q_8L'XLW^-/'@/PL!C^Q;7\C_ (T?5\3_ #_F']L9*ML-^$?\
MSR,_%7Q41C[5 /<6ZTP_%+Q81@7\8]Q;I_A7L0\$>& ,?V)9_P#?NG_\(;X:
M_P"@'8?]^11]6Q'\_P"8?VWDZVPOX1/%S\3_ !<1@:HH]Q;1?_$TP_$OQ>PP
M=7/X6\0_]EKV[_A$?#G_ $ M._\  9/\*?\ \(MX>'_,!TO_ , X_P#"CZK7
M_P"?GYA_;N5+;"+[H_Y'A;?$;Q:PP=8?\(HQ_P"RTQOB%XK;KK,WX(@_I7O0
M\.:$#D:+IV?^O5/\*>-!T<'(TFQ!_P"O9/\ "CZI6_Y^?F'^L&6K;"+[H_Y'
MS^WCWQ2W76KG\,#^E,;QSXG;KK=W^#XKWZ2UT"V.9;?3(B.[)&M4Y-4\*6YR
M9=.R.\<:M_(&KCEV(EM)O[S*?%664]\/%?.*_0\*;QIXF8\ZY??A*13&\7^)
M&.3KNH?A<,/ZU[;)XM\+PG,:+(?^F=MC^8%4Y/'VD1DFWTR5CZLJ+_+-;QR7
M%RZO^OF<L^.LIA_RYC]Z_2)XV?%?B)CDZ]J?X7;C^M)_PD?B"0D_VUJ;'_KZ
MD/\ 6O6I/B,X)^SZ5$GNTF?Y 52F^(6L2?<CM8A_LH2?U-;1X=Q;WE;^O4Y9
M^(^5Q^'#I_U_A1YD-8\02$D:EJ;'N?/D/]:!?>()"2+K4V/<^9(:[Z7QEKTW
M6_91Z(BK_(51FUO59_\ 6ZC=L/0S-C\LUO'AFL_BJ_F<T_$_"KX,)^*_R..\
MS7R"Q?4SZG,E0--JH/S2W@/NS5U;R/(VYW9CZL<TVMEPNNM5_=_P3FEXIR^S
MA%_X%_\ :G)[M0/.;D_]]4SR;TC_ %=P1_NFNUAL[JX_U-M-)G^XA/\ *K\7
MAK6I_N:9<C_?3;_/%3+ANA'XJWY?YE1\3L;/^'A$_FW^AYU]CNO^?:;_ +]F
ME^PW?_/M+_WP:]3A\"Z]+]ZWCB_WY5_IFKT7PYU%O]==VJ?[NYOZ"LGD>!CO
M7_(Z(^(6<3^'!KYM_K8\>^P7?_/M+_WR:7^SKS_GWD_*O;X?AM&/]=J;-[)#
MC]235Z+X>:0G,DMU(?=P!^@K)Y5EZ_Y>2?R_X!M'C?/)?\PT%ZM_HSP/^S;S
M_GW>E_LR]_Y]V_2OHJ'P9H$/_+B'/J\C'^N*O1:%I,'^KTVT!]?*4G\\5D\O
MP*V<W]QO'C#.G\4*2_\  W^J/FE=(OW;:MLY)[ BKL/A'Q#<8\K1[MQZB/C\
MZ^EHXHXEVQHJ#T48I]9/ 8;IS?>O_D3:/%V:?:5/_P !E_\ )GSK%\./%LPR
MNCN/]^6-?YM4Z_"_Q:3@Z:B^YN(__BJ^@Z*S_L^EW?\ 7R-?];L?UC#[G_\
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M_KHF_P#]"S7045HJ--;11QSS+&5/BJR?S92@T?2[7'V?3;.+'_/.!5_D*N@
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M:L0V-W<?ZFUGD_W(R?Y5LLIHQ^*3_ YGQ%B9.U."_%GH\OQ#T=/]7%=2'V0
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M8$+GDB7) ^F*ZI'61%=&#*PR&!R"/6M:=:%7X'<Q33V%HHHK484444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,\UI45YM7%UJOQR/<P^78;#_ ,."OWW84445S':%%%% !1110 4444 %%%%
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M5WM9'5#A["1W;?S_ . >?0_#:0_Z[4T7V2(G^9%7X?ASIR_ZZ\NG_P!W:O\
M0UV5%8RS#$R^U^1U0R;!1^Q^+_S.;A\"Z%']ZWDE_P!^5OZ8J_%X9T2'[FF6
MY_WTW?SS6K16$L36EO-_>=,,%AH?#37W(@ALK6W_ -3;0Q_[D8'\JGHHK)MO
M<Z5%)62"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC^\'R2?[P_QX/XUR>RDJ:J/:Y^EUJ>$KPEDL79J"L][=NUVM)>=SV=F51EB
M/<UV-KXRT&RTVVBFOXP\<**PST( !ZU\^PV5Y> O#;S3 '!94)&?K4XT;4"<
M&V*GT9@O\S5X>=2#?LU=GSLN&<'A_P#>,6H^ME^<CW.;XF>'HONSE_HR_P!"
M:SYOBUHZ9")N_%OZ+7CXT*^/WEC7ZR _RS4@\/W)ZRP#\3_A7=&&8U/AIO\
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M%?1GF:C_ ,^MK_X$M_\ $4>9J/\ SZVO_@2W_P 15K+H]9 ^,*J5J=)+YO\
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M^OV9,_GBKT5C:6_^IM8(_P#<C _E3/,U'_GUM?\ P);_ .(H\S4?^?6U_P#
MEO\ XBK48K9'-.M5G\4F_F6Z*J>9J/\ SZVO_@2W_P 11YFH_P#/K:_^!+?_
M !%49%NBJGF:C_SZVO\ X$M_\11YFH_\^MK_ .!+?_$4 6Z*J>9J/_/K:_\
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MJ>9J/_/K:_\ @2W_ ,11YFH_\^MK_P"!+?\ Q% %NBJGF:C_ ,^MK_X$M_\
M$4>9J/\ SZVO_@2W_P 10!;HJIYFH_\ /K:_^!+?_$4>9J/_ #ZVO_@2W_Q%
M %NBJGF:C_SZVO\ X$M_\11YFH_\^MK_ .!+?_$4 6Z*J>9J/_/K:_\ @2W_
M ,11YFH_\^MK_P"!+?\ Q% %NBJGF:C_ ,^MK_X$M_\ $4>9J/\ SZVO_@2W
M_P 10!;HJIYFH_\ /K:_^!+?_$4>9J/_ #ZVO_@2W_Q% %NBJGF:C_SZVO\
MX$M_\11YFH_\^MK_ .!+?_$4 6Z*J>9J/_/K:_\ @2W_ ,11YFH_\^MK_P"!
M+?\ Q% %NBJGF:C_ ,^MK_X$M_\ $4>9J/\ SZVO_@2W_P 10!;HJIYFH_\
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M\11YFH_\^MK_ .!+?_$4 6Z*J>9J/_/K:_\ @2W_ ,11YFH_\^MK_P"!+?\
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M:_\ @2W_ ,11YFH_\^MK_P"!+?\ Q% %NBJGF:C_ ,^MK_X$M_\ $4>9J/\
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MW_Q% %NBJGF:C_SZVO\ X$M_\11YFH_\^MK_ .!+?_$4 6Z*J>9J/_/K:_\
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MJ>9J/_/K:_\ @2W_ ,11YFH_\^MK_P"!+?\ Q% %NBJGF:C_ ,^MK_X$M_\
M$4>9J/\ SZVO_@2W_P 10!;HJIYFH_\ /K:_^!+?_$4>9J/_ #ZVO_@2W_Q%
M %NBJGF:C_SZVO\ X$M_\11YFH_\^MK_ .!+?_$4 6Z*J>9J/_/K:_\ @2W_
M ,11YFH_\^MK_P"!+?\ Q% %NBJGF:C_ ,^MK_X$M_\ $4>9J/\ SZVO_@2W
M_P 10!;HJIYFH_\ /K:_^!+?_$4>9J/_ #ZVO_@2W_Q% %NBJGF:C_SZVO\
MX$M_\11YFH_\^MK_ .!+?_$4 6Z*J>9J/_/K:_\ @2W_ ,11YFH_\^MK_P"!
M+?\ Q% %NBJGF:C_ ,^MK_X$M_\ $4>9J/\ SZVO_@2W_P 10!;HJIYFH_\
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M_P 10!;HJIYFH_\ /K:_^!+?_$4>9J/_ #ZVO_@2W_Q% %NBJGF:C_SZVO\
MX$M_\11YFH_\^MK_ .!+?_$4 6Z*J>9J/_/K:_\ @2W_ ,11YFH_\^MK_P"!
M+?\ Q% %NBJGF:C_ ,^MK_X$M_\ $4>9J/\ SZVO_@2W_P 10!;HJIYFH_\
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M\11YFH_\^MK_ .!+?_$4 6Z*J>9J/_/K:_\ @2W_ ,11YFH_\^MK_P"!+?\
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MP!P*[,KE7PTI3CI?^NI\SQ;2R[,<3&I#WM-=]^G;I^1YS-\.-07_ %-[;/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNFJ6GXR@5*NLZ6_W=2LV^DZG^M2Z51;Q?W&BQ%)[27WHO4576_LW^[=P-])
M:E66-_NNK?0YJ'%K=%J47LQ]%%%(H**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ^?$3M^+_K[SS/3_  !JMUAKIH[1#_>.YOR'^-=5I_@32+/#3*]W(.\IPO\
MWR/ZYKIZ*\VKF%>IULO(]K#Y/A*&O+=^>O\ P/P(X8(;>,1P1)%&.BHH4#\!
M4E%%<3=]STTDE9!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9MIVYVP#YO[RXQNYT/\ AG'P?_T$M<_[_P /_P :K/NO WC[5OBYK^LV4O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%;ZC-0M8V;_>M(&^L8-6LY76'X_\ S?#4NE3\/\ @GA=%>WMHVEO][3;-OK
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M>4MI6HI]ZPNE^L+#^E1-:7*?>MY5^J$4?V7AWM)_>O\ (/[?QD?B@ON?^9[
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MN+^0Y_6NGM+&TL8_+M+>*%?1% S]?6IGFE&FN6C&_P""+I9%BJ[Y\1.WXO\
MKYGF.G^!=8O<-,B6L9[RGYO^^1_7%=5I_@#2[7#73R7;CLQV+^0Y_6NLHKSZ
MN8UZG6R\CV</DN$HZN/,_/7\-B&VM+:SB\NV@CA3^[&H4?I4U%%<+;;NSU4E
M%604444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%'V.?_H)77_?,7_Q%6Z* *GV.?\ Z"5U_P!\Q?\ Q%'V.?\ Z"5U_P!\Q?\
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M_P!!*Z_[YB_^(JW152DY.\G=BA",%RP5EY%3['/_ -!*Z_[YB_\ B*/L<_\
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MWS%_\11]CG_Z"5U_WS%_\15NB@"I]CG_ .@E=?\ ?,7_ ,11]CG_ .@E=?\
M?,7_ ,15NB@"I]CG_P"@E=?]\Q?_ !%'V.?_ *"5U_WS%_\ $5;HH J?8Y_^
M@E=?]\Q?_$4?8Y_^@E=?]\Q?_$5;HH J?8Y_^@E=?]\Q?_$4?8Y_^@E=?]\Q
M?_$5;HH J?8Y_P#H)77_ 'S%_P#$4?8Y_P#H)77_ 'S%_P#$5;HH J?8Y_\
MH)77_?,7_P 11]CG_P"@E=?]\Q?_ !%6Z* *GV.?_H)77_?,7_Q%'V.?_H)7
M7_?,7_Q%6Z* *GV.?_H)77_?,7_Q%'V.?_H)77_?,7_Q%6Z* *GV.?\ Z"5U
M_P!\Q?\ Q%'V.?\ Z"5U_P!\Q?\ Q%6Z* *GV.?_ *"5U_WS%_\ $4?8Y_\
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M_H)77_?,7_Q%6Z* *GV.?_H)77_?,7_Q%'V.?_H)77_?,7_Q%6Z* *GV.?\
MZ"5U_P!\Q?\ Q%'V.?\ Z"5U_P!\Q?\ Q%6Z* *GV.?_ *"5U_WS%_\ $4?8
MY_\ H)77_?,7_P 15NB@"I]CG_Z"5U_WS%_\11]CG_Z"5U_WS%_\15NB@"I]
MCG_Z"5U_WS%_\11]CG_Z"5U_WS%_\15NB@"I]CG_ .@E=?\ ?,7_ ,11]CG_
M .@E=?\ ?,7_ ,15NB@"I]CG_P"@E=?]\Q?_ !%'V.?_ *"5U_WS%_\ $5;H
MH J?8Y_^@E=?]\Q?_$4?8Y_^@E=?]\Q?_$5;HH J?8Y_^@E=?]\Q?_$4?8Y_
M^@E=?]\Q?_$5;HH J?8Y_P#H)77_ 'S%_P#$4?8Y_P#H)77_ 'S%_P#$5;HH
M J?8Y_\ H)77_?,7_P 11]CG_P"@E=?]\Q?_ !%6Z* *GV.?_H)77_?,7_Q%
M'V.?_H)77_?,7_Q%6Z* *GV.?_H)77_?,7_Q%'V.?_H)77_?,7_Q%6Z* *GV
M.?\ Z"5U_P!\Q?\ Q%'V.?\ Z"5U_P!\Q?\ Q%6Z* *GV.?_ *"5U_WS%_\
M$4?8Y_\ H)77_?,7_P 15NB@"I]CG_Z"5U_WS%_\11]CG_Z"5U_WS%_\15NB
M@"I]CG_Z"5U_WS%_\11]CG_Z"5U_WS%_\15NB@"I]CG_ .@E=?\ ?,7_ ,11
M]CG_ .@E=?\ ?,7_ ,15NB@"I]CG_P"@E=?]\Q?_ !%'V.?_ *"5U_WS%_\
M$5;HH J?8Y_^@E=?]\Q?_$4?8Y_^@E=?]\Q?_$5;HH J?8Y_^@E=?]\Q?_$4
M?8Y_^@E=?]\Q?_$5;HH J?8Y_P#H)77_ 'S%_P#$4?8Y_P#H)77_ 'S%_P#$
M5;HH J?8Y_\ H)77_?,7_P 11]CG_P"@E=?]\Q?_ !%6Z* *GV.?_H)77_?,
M7_Q%'V.?_H)77_?,7_Q%6Z* *GV.?_H)77_?,7_Q%'V.?_H)77_?,7_Q%6Z*
M *GV.?\ Z"5U_P!\Q?\ Q%'V.?\ Z"5U_P!\Q?\ Q%6Z* *GV.?_ *"5U_WS
M%_\ $4?8Y_\ H)77_?,7_P 15NB@"I]CG_Z"5U_WS%_\11]CG_Z"5U_WS%_\
M15NB@"I]CG_Z"5U_WS%_\11]CG_Z"5U_WS%_\15NB@"I]CG_ .@E=?\ ?,7_
M ,11]CG_ .@E=?\ ?,7_ ,15NB@"I]CG_P"@E=?]\Q?_ !%'V.?_ *"5U_WS
M%_\ $5;HH J?8Y_^@E=?]\Q?_$4?8Y_^@E=?]\Q?_$5;HH J?8Y_^@E=?]\Q
M?_$4?8Y_^@E=?]\Q?_$5;HH J?8Y_P#H)77_ 'S%_P#$4?8Y_P#H)77_ 'S%
M_P#$5;HH J?8Y_\ H)77_?,7_P 11]CG_P"@E=?]\Q?_ !%6Z* *GV.?_H)7
M7_?,7_Q%'V.?_H)77_?,7_Q%6Z* *GV.?_H)77_?,7_Q%'V.?_H)77_?,7_Q
M%6Z* *GV.?\ Z"5U_P!\Q?\ Q%'V.?\ Z"5U_P!\Q?\ Q%6Z* *GV.?_ *"5
MU_WS%_\ $4?8Y_\ H)77_?,7_P 15NB@"I]CG_Z"5U_WS%_\11]CG_Z"5U_W
MS%_\15NB@"I]CG_Z"5U_WS%_\11]CG_Z"5U_WS%_\15NB@"I]CG_ .@E=?\
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M04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 1S_ /'O+_N'^525'/\ \>\O^X?Y5)0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH5)10!'Y\/\ SUC_ .^A1Y\/_/6/_OH41_?F_P!__P!E%24 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
MOH4>?#_SUC_[Z%244 1^?#_SUC_[Z%'GP_\ /6/_ +Z%244 1^?#_P ]8_\
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MB@"/SX?^>L?_ 'T*//A_YZQ_]]"I** (_/A_YZQ_]]"CSX?^>L?_ 'T*DHH
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M  P!7J%% '-^#/ VB^!=+>QT>*0F5]\UQ.0TLQYQN( & #@   <GJ23TE%%
M!1110 $ @@C(/4&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ****   #.!UZT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1@9SCGUHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ (!ZC-%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4   '08HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTYR<N>,9V8+*#AO,-(\&6/@7X^>#M(L9))B=,DFN)WX,TI2Y!;&<*,*  .@
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MK'\)V-QIG@W0["\C\NZM=/MX9DW [76-0PR.#@@]*V* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MX?Q/\3=+\/>+='\,11_;=3O[N&"9$DVBU21@ S'!RW((3N.21E<Z'CVU\4ZA
MX>&G^$KB"UOKJ7RIKN9RGD0[&+,I&2&)"J" 2-V1C&X>,>(? %OX&\;_  ^)
MOY]2U/4-;,M[?39!E(F@*_*2<8W,22226))Z  'T?7E>J_&ZQ_M2XTOPIH&I
M>);RW?\ >&T7]T4'#.K*'9@&(7.T YR"1C/I&K6<VHZ-?65O=R6<]Q;R11W,
M>=T+,I <8(.03GJ.G45A^ /!=OX#\+IH\$_VF0RO-/<;"GFNQP#M+-MPH5>#
M_#GJ30!Q^D_&^W_MR+2?%GAV^\,S7&TP27;$I@[AN?<J%5R  V".N2H!->L5
MY7\?X-(;X;O<7\49OTN(TT^0J=RR,P+@$= 8U<D'@[1W"UZ!X:AOK;PKI$&J
M&0ZA'90I=&23>QE" /ELG<=V><G- &'_ ,)UYWQ0_P"$+LM.^T^1:?:;Z\\_
M9]FXR%V%?GSNBY5O^6G^R:P_%?QDL=%\0'P]H6D7?B'6$?;+!:'"J0&+*" Q
M9UP,@+@<Y(*D5C_ \S>(=4\7>-;J./?J-Z(8=[F26!5RYCW$#Y-KQ 8Z^6.!
M@5W'A7P7HO@"WU6\AO;N5[Q_M-]?:E<!F(4$Y9L  #<[$D9^8Y)XP 8?ACXN
M6^J:Y#H7B+0[[PWJUSS;17H.R8'A0&95(9CN &W!VX!)(%>D5X7\6]4TCXC/
MI/A7PL\>JZQ'>J\EU;1&6*UA90K%I5!PA9XR2N0-GS8( /M&K27T.C7TNEPQ
MSZ@EO(UK%(<*\H4[%/(X+8'4?44 8?CKQUI?@/0S?WY\VXDRMK:(V'N''8>B
MC(RW;/<D [&A:G_;?A[3-6\GR?MUI%<^5NW;-Z!MN<#.,XS@5X)XX^&6I:=X
M&USQ9XOUV36->5(EA",WE6VZY7.TG&1M8X7:JKN; /!'M?@3_DGGAK_L%6O_
M **6@#8O[ZWTS3KF_O)/+M;6)YIGVD[44$L<#DX /2N'T?XIV<_PZ?QGKMC_
M &39M*\=M"MP)WN<<#9POS%@XVD#&PL2%Y%/X[ZW-H_PRN(8/,#ZC<1V9D20
MH44@NW3J"L90CC(8_0FI?"9=;\->#M&N]0CMK/1$0WUE;QL8KU\)O.0R%22)
M/GQG]XQX).0#+_X77K%__I.@?#C7-2TQ_P#4W>'7S,<-PD;KPP8<,>G;H.L\
M _$S1?']O(MF)+74($5I[*8C< 0,LA'WT#'&>#TR!D9[2O%UL;>/]J&,>'X_
M)6/3WFUI86,:L[*W+ X#9+V[';GYCN/(8T >@>.O'6E^ ]#-_?GS;B3*VMHC
M8>X<=AZ*,C+=L]R0#Q<'QMN;&XB;Q7X'UG0=/E<1+>R*[J')Z$-&G&T,>,GY
M>%/:O-!#XG_:="3Q1JGA[3%<*ZB03M@,IYQL*M< @\\Q@]^/4/$FB0^(_#6I
M:-/Y82\MWB#O&)!&Q'ROM/4JV&'(Y Y% %RPOK?4].MK^SD\RUNHDFA?:1N1
M@"IP>1D$=:CU75;'0]+N-3U.YCMK.W3?+*_11_,DG  ')) &2:\[^ .I_;_A
M?!;>3Y?]GW<UMNW9\S)$N[&./];C'/W<]\"OJ/PV\0>.?%L]]XPU?R_#T%V3
M9Z-:NV)(D9U1GP<*S##%AN8AR,I@  '6?#_QQ#X^T:\U2WL9+2""]>UC620,
MSJJJP<X&%)#_ '<G&.IK8\1Z_8^%O#]YK6I-(+2U0,_EKN9B2%50/4L0.<#G
MD@<UYG^SC_R3S4/^PK)_Z*BH^-?^G^(? .@7/[S3-0U7_2H.GF8>)!\P^8?+
M*XX(^][# !'#\<M2N4.HP?#W69=!#LQU%"S 0JQ#/@1[,@ Y&_ ((W=Z],\,
M>)]+\7:'#J^D3^;;R<,K</$XZHX[,,C\P02""=2""&UMXK>WBCA@B0)''&H5
M44#   X  XQ7E?@Z\?3/CSXU\.VHVZ;/$FI&-G9MLY6(NRY.!N,K$\?PJ!@#
M% 'K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4453U:2^AT:^ETN&.?4$MY&M8I#A7E"G8IY'!; ZC
MZB@##\=>.M+\!Z&;^_/FW$F5M;1&P]PX[#T49&6[9[D@'8T+4_[;\/:9JWD^
M3]NM(KGRMV[9O0-MS@9QG&<"O!/''PRU+3O VN>+/%^NR:QKRI$L(1F\JVW7
M*YVDXR-K'"[55=S8!X(]K\"?\D\\-?\ 8*M?_12T 8?C/XK:+X0U1-&6WN]4
MUJ5/W=E9*&(=L>6CG.06)&  QQSCD9Y>3XY:EI3PS>(_A[K.E:>[[#<L6)W;
M20%#QH"3CIN'&3SC%=AX9^'ZZ!XU\0>*+G4Y-0O-5<B+>C*;:(MN\O.\AA@1
M@' P(QC .*Z#Q)!I%SX:U)->BCETD6[O=JZE@(U&XGCG(QD$<@@$<XH L:5J
MMCKFEV^IZ9<QW-G<)OBE3HP_F"#D$'D$$'!%<WX[\=?\(=_9%M;:=_:>IZM=
MBVM;/S_)W= 6WE2HPS(,''WL]C7-_L^PWT7PR#W9D,$M[*]GNDW 1853M&?E
M'F+)QQSD]\G/O#-XH_:9M;.2.,V?ANR\XQ3.75V9 PD1<85PTT7_ 'Z!SD 4
M =AX^^)FB^ +>-;P276H3HS064)&X@ X9R?N(6&,\GK@'!QR\'QMN;&XB;Q7
MX'UG0=/E<1+>R*[J')Z$-&G&T,>,GY>%/;M/^$#TM_B!_P )G/<7T^I)%Y4$
M4LV8;<;=IV*!D9!;@DC+L<9P1S_Q,\:>%O\ A%]5\/&[@U/5KZ*2SM]/M%%Q
M)]HR%4%1G8RN5/.#E3M!(Q0!Z)!/#=6\5Q;RQS02H'CDC8,KJ1D$$<$$<YJO
MJNJV.AZ7<:GJ=S';6=NF^65^BC^9).  .22 ,DUS?PLT:\T#X9Z)IU^GEW2Q
M-*\9!!3S':0*P(!# . 1V(-<OJ/PV\0>.?%L]]XPU?R_#T%V39Z-:NV)(D9U
M1GP<*S##%AN8AR,I@  '6?#_ ,<0^/M&O-4M[&2T@@O7M8UDD#,ZJJL'.!A2
M0_W<G&.IKK*\?_9Q_P"2>:A_V%9/_145>H:[J?\ 8GA[4]6\GSOL-I+<^5NV
M[]B%MN<'&<8S@T <WHWQ!AUGQCXCTF.SCBTO04_TG59+D*HD'WE*,H( *R_-
MDC]WGN*Y>?XYKJ%Q+%X0\(:SX@2!RL\L<;(JC/R,-JN<-AC\P4\=.N,OX9^#
MKSQ'\%]6634_LM]XCNWE?454R3-&KA660Y4MN*2\;B,2$]R*]8\*^'K?PIX7
MT[0[5M\=I$$+X(\QR<N^"3C<Q8XSQG XH XOPI\9+'6O$ \/:[I%WX>UAWVQ
M079RK$A2JDD*5=LG *X/&"2P%>@:KJMCH>EW&IZG<QVUG;IOEE?HH_F23@ #
MDD@#)->1_'VQMY_^$8.G1[/%5QJ"PV$L3&.0H.V_@#$CQ$9/!8D8^:K'QW_X
MFO\ PB'A3_5?VOJJ_P"E?>\K;B/[G&[_ %^>H^[COP 1P_'+4KE#J,'P]UF7
M00[,=10LP$*L0SX$>S( .1OP""-W>O2/"GBW2/&>C#5-&FDD@#^7(LD91HY-
MJL4.>"0&'()'H36Q!!#:V\5O;Q1PP1($CCC4*J*!@  <  <8KQ_X;P0^&?C3
MXX\,6\49@G1+Z-HU$:PKD,(@@XP!<XSD?<Z<\ &YXG^,6EZ-KDWA_1]+OM?U
MN/C[/9+E-XY="PRVY5!)VJV,8)!!QCP_'1]/U&WA\6^#-5T"UN,B.XEW/D@J
M"=K(A*@-DE=Q''!S76?#SX?KX%M]3:;4Y-4U#4;CSKB]D1D9P!P""[9.YG.[
MJ=W/04?%B#2)OAEKCZQ%&\4-NSV[,I)2XQMB*XY!WLHSTP2#P30!V$$\-U;Q
M7%O+'-!*@>.2-@RNI&001P01SFO*]4^-3MKEW8>$_"E]XFM[/:L]W9NVP.<\
M#;&^5X.&XS@XR ":<-[?:#^RV9M1BDFGDTQH55YLD13R%(CGGA8Y$(7T 7CM
MV'PGT2'0_AEH<,7EL]S;K>2R+&$+M*-_S>I52J9/4*.G0 !X*^)>D>,[B;3D
M@N[#6K9&:ZT^ZB(:/:55\-C! 9MO.&X.5%=I7C?CR"'P[\=? _B***-WU)VL
M98E4(2W^J\UFYW';.O!'2,#//'LE !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1SSPVMO+<7$L<,$
M2%Y))&"JB@9))/  '.:DKR_QCX$\4^/O%$]MJ&M_V9X1@V)';6Q)DN^(W8N,
M[?O;@"V=I0$)R20#<\#_ !&L?'FJ:[!IEK(MGIKQ+%<NV#<!]_S;,9490XR2
M2",A3Q6YXG\3Z7X1T.;5]7G\JWCX55Y>5ST1!W8X/Y$D@ D>7_!&QM],\9?$
M6PLX_+M;74$AA3<3M19+@*,GDX '6NT\>_#]?'EQHBW6IR0:?87!FN+((S+=
M@E>"0Z[2%#@-R1O./< Y/_A=>L7_ /I.@?#C7-2TQ_\ 4W>'7S,<-PD;KPP8
M<,>G;H.L\ _$S1?']O(MF)+74($5I[*8C< 0,LA'WT#'&>#TR!D9[2O%UL;>
M/]J&,>'X_)6/3WFUI86,:L[*W+ X#9+V[';GYCN/(8T >P7]];Z9IUS?WDGE
MVMK$\TS[2=J*"6.!R< 'I7)^%?B##K7@.7Q?K-G'HFGH[[6>Y$P:-2%W<*#D
MON4+C)(&,Y%8_P =];FT?X97$,'F!]1N([,R)(4**07;IU!6,H1QD,?H=2;X
M<6>J?#72/"&HW,]G#:Q0_:/[,<1K-(J_-G*G<I<E^1DL >M ')Q_'+4M5>:;
MPY\/=9U73T?8+E2P.[:"0P2-P",]-QXP>,XKT#P9XYT7QUI;WVCRR Q/LFMY
MP%EA/.-P!(P0,@@D'D=00+%YJWASP3HUK;WNH6FFV=O;[+:.:;YFCB4#" DL
MY P,#).1U)KS?X;VRZY\7O%'C32K.2#P_<V_D6TLENT0N7+)OD3C# M#(6.<
MY<9&2< 'LE</)\3=+D^)EEX*L(_MEQ)YHNKE),);NB,^P<'>WRD'D;<XR3D"
M3X@:3XOU]-/TKPUJ<>E6DKL^H7X=EE159-JQ[3G)RYXQG9@LH.&\PTCP98^!
M?CYX.TBQDDF)TR2:XG?@S2E+D%L9PHPH  Z #))R2 ?0=<?X[\=?\(=_9%M;
M:=_:>IZM=BVM;/S_ "=W0%MY4J,,R#!Q][/8UV%>-WAF\4?M,VMG)'&;/PW9
M><8IG+J[,@82(N,*X::+_OT#G( H ZCQG\5M%\(:HFC+;W>J:U*G[NRLE#$.
MV/+1SG(+$C  8XYQR,\O)\<M2TIX9O$?P]UG2M/=]AN6+$[MI("AXT!)QTW#
MC)YQBNP\,_#]= \:^(/%%SJ<FH7FJN1%O1E-M$6W>7G>0PP(P#@8$8Q@'%=!
MXD@TBY\-:DFO11RZ2+=WNU=2P$:C<3QSD8R".00".<4 6-*U6QUS2[?4],N8
M[FSN$WQ2IT8?S!!R"#R""#@BO/\ Q1\7ETKQ*^@>'/#]WXEO[=&:\6S9L0$$
M#;\J.6()PW "D@9)R!C_  ;O;[P_\$=2UB[BDG@MWNKRSB:;AHD095>NP&1)
M.W4DX.>=#X :)#IWPW345\MI]4N))781A6548QJA;JP!1F'3&\\=R :GA'XK
MZ=XCUA= U+3+[1/$)S_H%W$QW?*S\-@8^0!OF"_>&,]:W/&?CG1? NEI?:Q+
M(3*^R&W@ :68\9V@D# !R22 .!U(!\_^.L$.D7'A/QFL4<D^F:G&CQ!0K3KG
MS5!DY( ,3 #!_P!83]>PU_X?KXA^(.B>)KS4Y#::2@,>G%&VF4%F$@8.-IW>
M62-ISY8!R.@!Q\_QLUY;>6_M_AIK,FEA#-'>2,Z*T.,B0D1%0-O/WB!ZGK7H
M'@SQSHOCK2WOM'ED!B?9-;S@++"><;@"1@@9!!(/(Z@@=)7B_P .;&WMOCEX
MU'A^/R= MXEAEAB8I&MSN7C8?1EN ,# &0, C(![17#^'_B;I?BCQ]?>&M(C
M^T6]G:-.VH+)\DCJZJ51<?,OSCY\\X. 1AC3^(/A7Q?XSU2#2=/UF/1_#8M\
MW<R%C+<2-YBE-H(W(%"Y!*@^83\Q  X_X=Z!8^%OV@?$&BZ:L@M+71T5/,;<
MS$BV9F)]2Q)XP.> !Q0![I1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7#R?$W2Y/B99>"K"/[
M9<2>:+JY23"6[HC/L'!WM\I!Y&W.,DY D^(&D^+]?33]*\-:G'I5I*[/J%^'
M994563:L>TYR<N>,9V8+*#AO,-(\&6/@7X^>#M(L9))B=,DFN)WX,TI2Y!;&
M<*,*  .@ R2<D@'O\\\-K;RW%Q+'#!$A>221@JHH&223P !SFO)Y_CFNH7$L
M7A#PAK/B!('*SRQQLBJ,_(PVJYPV&/S!3QTZX] \8:!-XI\)W^B0:C)I[WB*
MAN44L57<"PP&7(905(ST8]>E2>%?#UOX4\+Z=H=JV^.TB"%\$>8Y.7?!)QN8
ML<9XS@<4 <7X4^,ECK7B >'M=TB[\/:P[[8H+LY5B0I522%*NV3@%<'C!)8"
MO3*\7^/MC;S_ /",'3H]GBJXU!8;"6)C'(4';?P!B1XB,G@L2,?-7K&NZG_8
MGA[4]6\GSOL-I+<^5NV[]B%MN<'&<8S@T <_X?\ '7_"1^.=?T"ST[-CHV(Y
M=0\_[TQ./+\LJ".1*-P)'[O_ &A7+ZM\;[?^W)=)\)^';[Q--;[C/):,0F!M
M&Y-JN67)(+8 Z8+ @U'\$M#FN?AEJ%[=W4BW>OW$[M?02$707'EY,A&=X<2,
M#S@MGJ37:>&_#OA_X:>%Y+6"[^S6"RF:>ZO[A1EV(4%F.%'15& .@[DD@&7X
M,^*%CXHU1]#U#3KO0_$$:;VT^]&"XY/R$@$G;M8@JIP<C(!-=Y7A_B6]T[XB
M_%KPE_PBR?;?[%N_,U+4HX&\E%5PZH90.?\ 52;?X27&#R<>L>*?[=/AR[3P
MUY U>39';O/C9'N=59SG^ZI9NA^[T;H0#G_B)\3=+^'UG$)8_MNISX,-BDFP
ME,X+LV#M7@@<')X X8CN*^8/B9\-G\)>"(=;UC5Y]7\0WNH0Q374CL0B>2^4
M!8DORH^9L<*H 7G/T_0!C^*O$-OX4\+ZCKETN^.TB+A,D>8Y.$3(!QN8J,XX
MSD\5S=S\4=-T;P'I?B;Q#:26$NI('M].@E6>612<@J?E!&PJQ)QC< >2 >;^
M/5S>7UGX:\)63>7)KFH!#*TI5/E*JJN #E2TJM[;!P3TZC5_AQ;ZOXY\/ZZ]
M[Y>FZ)$J6^DI$5C5U+%74A@$P?+X"\B, \= #DY_C9KRV\M_;_#369-+"&:.
M\D9T5H<9$A(B*@;>?O$#U/6O0/!GCG1?'6EO?:/+(#$^R:WG 66$\XW $C!
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M!WY("YY(!9OF/+$DG' 'F'@SQ/JO@72WL='^$/B F5]\UQ.\C2S'G&XBW P
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MQ8XSQG XK8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1UT'@3_DGGAK_L%6O_HI:Q_B_87FI_"W6;.PM)[NZD\C9#!&9';$\9.%')P
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M^5$,@, <9!&?8UL?%#P9?>*-+L-0T.2.+Q!HUP+NQ9^CD8)3D[0250@L",J
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M3:S;]][.9-D6$9AG,2CD@#J.M &'XLF7Q5^T#X7T!!(]OH2&^N'AC8-%+@2
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MCNP]17L%>+Z5I7BGXH>.=.\1^(]+G\/:-H,JR6=C*A$TLP*L>64$J2JY; &
M%49W,+GQJU7Q,Z6?A[0M&UFZL+E/,U.;3[9B9(BV/)64!@I(#;LJ>"O4%@0
M\5_$#4O%MP?"WPU\RZN97\J^UB-66"R4EAQ)C )"L=XSP/DW,1M[CP-X,L?
MOAJ/1[&228ES-<3OP9I2 "V,X484  = !DDY)\K\,>.-;\(Z'#I&D?!_7(K>
M/EF9I2\KGJ[GR.6.!^0    '>>"O'>O>*-9FLM4\#ZEH4"6[2K<W1?:[!E&P
M;HU&2&)Z_P )XH [RO'_  ]_R=#XL_[!4?\ Z#:U[!7E>A:3J4/[1OB?5)=/
MNTT^;3$2*[:%A$[;;?A7Q@GY6X!['TH ]4HHHH **** "BBB@ HHHH ****
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MIU1,7+%\K A(/EC'!/RKDC@;0J\#+>@3SPVMO+<7$L<,$2%Y))&"JB@9))/
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MN&[M;N8L0B,60[GX#+D9&"..HR#7\2Z/XO\  GQ!U#QCX4TJ/5M+U1$^W:?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BLO6M:&C"R5;"[OI[VX^SPP6IC#%O+>0DF1U4 +&W?TJG_ ,)#
MJG_0F:Y_W^LO_DB@#H**Y_\ X2'5/^A,US_O]9?_ "11_P )#JG_ $)FN?\
M?ZR_^2* .@HKG_\ A(=4_P"A,US_ +_67_R11_PD.J?]"9KG_?ZR_P#DB@#H
M**Y__A(=4_Z$S7/^_P!9?_)%'_"0ZI_T)FN?]_K+_P"2* .@HKG_ /A(=4_Z
M$S7/^_UE_P#)%'_"0ZI_T)FN?]_K+_Y(H Z"BN?_ .$AU3_H3-<_[_67_P D
M4?\ "0ZI_P!"9KG_ '^LO_DB@#H**Y__ (2'5/\ H3-<_P"_UE_\D4?\)#JG
M_0F:Y_W^LO\ Y(H Z"BN?_X2'5/^A,US_O\ 67_R11_PD.J?]"9KG_?ZR_\
MDB@#H**Y_P#X2'5/^A,US_O]9?\ R11_PD.J?]"9KG_?ZR_^2* .@HKG_P#A
M(=4_Z$S7/^_UE_\ )%'_  D.J?\ 0F:Y_P!_K+_Y(H Z"BN?_P"$AU3_ *$S
M7/\ O]9?_)%'_"0ZI_T)FN?]_K+_ .2* .@HKG_^$AU3_H3-<_[_ %E_\D4?
M\)#JG_0F:Y_W^LO_ )(H Z"BN?\ ^$AU3_H3-<_[_67_ ,D4?\)#JG_0F:Y_
MW^LO_DB@#H**Y_\ X2'5/^A,US_O]9?_ "11_P )#JG_ $)FN?\ ?ZR_^2*
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M#H**Y_\ X2'5/^A,US_O]9?_ "11_P )#JG_ $)FN?\ ?ZR_^2* .@HKG_\
MA(=4_P"A,US_ +_67_R11_PD.J?]"9KG_?ZR_P#DB@#H**Y__A(=4_Z$S7/^
M_P!9?_)%'_"0ZI_T)FN?]_K+_P"2* .@HKG_ /A(=4_Z$S7/^_UE_P#)%'_"
M0ZI_T)FN?]_K+_Y(H Z"BN?_ .$AU3_H3-<_[_67_P D4?\ "0ZI_P!"9KG_
M '^LO_DB@#H**Y__ (2'5/\ H3-<_P"_UE_\D4?\)#JG_0F:Y_W^LO\ Y(H
MZ"BN?_X2'5/^A,US_O\ 67_R11_PD.J?]"9KG_?ZR_\ DB@#H**Y_P#X2'5/
M^A,US_O]9?\ R11_PD.J?]"9KG_?ZR_^2* .@HKG_P#A(=4_Z$S7/^_UE_\
M)%'_  D.J?\ 0F:Y_P!_K+_Y(H Z"BN?_P"$AU3_ *$S7/\ O]9?_)%'_"0Z
MI_T)FN?]_K+_ .2* .@HKG_^$AU3_H3-<_[_ %E_\D4?\)#JG_0F:Y_W^LO_
M )(H Z"BN?\ ^$AU3_H3-<_[_67_ ,D4?\)#JG_0F:Y_W^LO_DB@#H**Y_\
MX2'5/^A,US_O]9?_ "11_P )#JG_ $)FN?\ ?ZR_^2* .@HKG_\ A(=4_P"A
M,US_ +_67_R11_PD.J?]"9KG_?ZR_P#DB@#H**Y__A(=4_Z$S7/^_P!9?_)%
M'_"0ZI_T)FN?]_K+_P"2* .@HKG_ /A(=4_Z$S7/^_UE_P#)%'_"0ZI_T)FN
M?]_K+_Y(H Z"BN?_ .$AU3_H3-<_[_67_P D4?\ "0ZI_P!"9KG_ '^LO_DB
M@#H**Y__ (2'5/\ H3-<_P"_UE_\D4?\)#JG_0F:Y_W^LO\ Y(H Z"BN?_X2
M'5/^A,US_O\ 67_R11_PD.J?]"9KG_?ZR_\ DB@#H**Y_P#X2'5/^A,US_O]
M9?\ R11_PD.J?]"9KG_?ZR_^2* .@HKG_P#A(=4_Z$S7/^_UE_\ )%'_  D.
MJ?\ 0F:Y_P!_K+_Y(H Z"BN?_P"$AU3_ *$S7/\ O]9?_)%'_"0ZI_T)FN?]
M_K+_ .2* .@HKG_^$AU3_H3-<_[_ %E_\D4?\)#JG_0F:Y_W^LO_ )(H Z"B
MN?\ ^$AU3_H3-<_[_67_ ,D4?\)#JG_0F:Y_W^LO_DB@#H**Y_\ X2'5/^A,
MUS_O]9?_ "11_P )#JG_ $)FN?\ ?ZR_^2* .@HKG_\ A(=4_P"A,US_ +_6
M7_R11_PD.J?]"9KG_?ZR_P#DB@#H**Y__A(=4_Z$S7/^_P!9?_)%'_"0ZI_T
M)FN?]_K+_P"2* .@HKG_ /A(=4_Z$S7/^_UE_P#)%'_"0ZI_T)FN?]_K+_Y(
MH Z"BN?_ .$AU3_H3-<_[_67_P D4?\ "0ZI_P!"9KG_ '^LO_DB@#H**Y__
M (2'5/\ H3-<_P"_UE_\D4?\)#JG_0F:Y_W^LO\ Y(H Z"BN?_X2'5/^A,US
M_O\ 67_R11_PD.J?]"9KG_?ZR_\ DB@#H**Y_P#X2'5/^A,US_O]9?\ R11_
MPD.J?]"9KG_?ZR_^2* .@HKG_P#A(=4_Z$S7/^_UE_\ )%'_  D.J?\ 0F:Y
M_P!_K+_Y(H Z"BN?_P"$AU3_ *$S7/\ O]9?_)%'_"0ZI_T)FN?]_K+_ .2*
M .@HKG_^$AU3_H3-<_[_ %E_\D4?\)#JG_0F:Y_W^LO_ )(H Z"BN?\ ^$AU
M3_H3-<_[_67_ ,D4?\)#JG_0F:Y_W^LO_DB@#H**Y_\ X2'5/^A,US_O]9?_
M "11_P )#JG_ $)FN?\ ?ZR_^2* .@HKG_\ A(=4_P"A,US_ +_67_R11_PD
M.J?]"9KG_?ZR_P#DB@#H**Y__A(=4_Z$S7/^_P!9?_)%'_"0ZI_T)FN?]_K+
M_P"2* .@HKG_ /A(=4_Z$S7/^_UE_P#)%'_"0ZI_T)FN?]_K+_Y(H Z"BN?_
M .$AU3_H3-<_[_67_P D4?\ "0ZI_P!"9KG_ '^LO_DB@#H**Y__ (2'5/\
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M^_UE_P#)%'_"0ZI_T)FN?]_K+_Y(H Z"BN?_ .$AU3_H3-<_[_67_P D4?\
M"0ZI_P!"9KG_ '^LO_DB@#H**Y__ (2'5/\ H3-<_P"_UE_\D4?\)#JG_0F:
MY_W^LO\ Y(H Z"BN?_X2'5/^A,US_O\ 67_R11_PD.J?]"9KG_?ZR_\ DB@#
MH**Y_P#X2'5/^A,US_O]9?\ R11_PD.J?]"9KG_?ZR_^2* .@HKG_P#A(=4_
MZ$S7/^_UE_\ )%'_  D.J?\ 0F:Y_P!_K+_Y(H Z"BN?_P"$AU3_ *$S7/\
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M9KG_ '^LO_DB@#H**Y__ (2'5/\ H3-<_P"_UE_\D4?\)#JG_0F:Y_W^LO\
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M=V$^E7VG75K%%,R79A.Y)#(%(,4CCK$W7':MB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .?\0_\ (<\)_P#85D_](KJN@KG_ !#_ ,ASPG_V%9/_ $BNJZ"@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#G[/_DH>L_\ 8*L/_1MW705S]G_R4/6?^P58?^C;NN@H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX )7*76&7((# X(.." :Z#X9ZS>:#J-U\.?$+[+[3<G2IYB0U_:Y8@J"2/E
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M[UV%>-_%B>&Z\=?"RXMY8YH)=3WQR1L&5U,MN001P01SFO9* "BBB@ HHHH
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M_A,M1_YXVO\ WRW_ ,51_P )EJ/_ #QM?^^6_P#BJ[OKU$TYT=Q7/^-O$_\
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MG'/LE ''_#CQU_PL#P]<:M_9WV#R;MK;RO/\W.$1MV=J_P!_&,=JT/&WB?\
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MV3S(4D5TR,94[^".H-'UZD-<*Y@WJE]Y>\3?%35H_$4L6C30+86TVU3Y:O\
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MO$-OX4^"FE:Y=+OCM-$MG"9(\QS$@1,@'&YBHSCC.3Q5&9S^L?&ZWTGQ1>V
MT;SM(L-0AL+O5/M17RG<-N_=>66;;Y<O3.=G7D5ZQ7@?A[P%-J_[/VKW%U')
M/K6K.^JI)+:&2X9D.44$G<Y<*Y#>DYP#D[O3/A=XB_X2?X=:1?22^9=1Q?9K
MDM-YK^9'\I9SUW, 'P>?G'7J0#E]6^-]O_;DND^$_#M]XFFM]QGDM&(3 VC<
MFU7++DD%L =,%@0:T/!WQ<M_$?B/_A&]6T.^T/6VW&.VG!8, @?!)565BNYL
M%<8'7) KE_"*^*?@]/=Z!=^%[[7=$N;M[B#4-)B,DGW%!W1C.,X088K@A\%Q
MBN@TCQ)\-?B?XATF[\O/B&SS-:Q7*O#,FQ]P&5.R3!&\+N; +' ^:@"QXZ^*
M5YX1\6VGAZP\+SZU=75H+E!!.0Y^9P5""-B<",G/^%8<WQLU[3D%UK'PTUFP
MT]'43W+LX$:E@,_-$H)YX!89.!D9J3Q#_P G0^$_^P5)_P"@W5>P4 8_ACQ/
MI?B[0X=7TB?S;>3AE;AXG'5''9AD?F""003C^._'7_"'?V1;6VG?VGJ>K78M
MK6S\_P G=T!;>5*C#,@P<?>SV-<7\/X(?#?QU\:>&].BC33YK>.]V[0#&WR,
M$3;@!!]H< 8Z!>>#DAF7QW^T,7022:7X5MV3YXVDB:YR5/# "-PS<'DG[.".
MQ !WG@#QI;^//"Z:Q!!]FD$KPSV^\OY3J<@;BJ[LJ5;@?Q8Z@U8\6>--"\%:
M<MYK5WY7F[A!"BEY)F49(51^ R<*"1DC(KS_ , _\4?\8?%7A!_W5CJ&-2T]
M3^YC&>2D4?1N'*DKVMSQQA:][8V_CC]HFZTC78_M&FZ#IZS6MKN/ENY\IB9%
M.0<F7G&,A$!R 00 /QTUB>SFU*P^'.JW.D+O=+XRN$,:DY9B(F5<8.?F(&#S
MQ7>>#/B-X<\=(ZZ1<R+=Q)OEL[A-DJ+N(SC)##IRI.-RYP3BNLKQ?QK8V_@S
MXS>#]<T2/[/<:]=O:ZA$&(BF#-&I8J,?,?,W'L616QG)(![17E?B7XNZEHWC
M?4/#&E^#+O69[)$=FM9V+%61&R46)B "X&<^GK7JE?/FJ>)-2\+_ +1'B:]T
MOP]=Z[.]E%$UM:EMR*8[<[SM1C@%0.G\0YH Z>#XVW-C<1-XK\#ZSH.GRN(E
MO9%=U#D]"&C3C:&/&3\O"GMU'Q ^(,/@GPK9Z];V<>JP7=PD4?EW(165D9PX
M8*P(POXYZUY9X^^)&M^(O#BZ'K?@^^\,Z9?W<,5SJ5Y'+((T#ASM7RTRPVYQ
MDY"L,<Y&O\<;6SL?@WX=L].N/M%C!=VT5O-O#^9&MO(%;<.#D '(X- 'KFO^
M(](\+:6VI:U?1VEH'";V!8LQZ!54$L>IP > 3T!KR^/XY:EJKS3>'/A[K.JZ
M>C[!<J6!W;02&"1N 1GIN/&#QG%'Q&A7Q7\9?"?@O4S(=%:W>^EBBD9#*^)>
M&YQC$0 ( (#O@C/'L$$$-K;Q6]O%'#!$@2..-0JHH&  !P !QB@#A_ WQ9\.
M>.'CLX'DLM69"QLK@<MA06V..' R?1L*3M %4_%/Q'\2:#XCN],L/AYJNK6L
M.S9>P&39+E%8XQ$PX)(ZGI7-_'&P7PS?Z%\0-)$=OJUO>K!-M5A]I&PLN\JP
MR J,A[LKX)PH%>V4 >)V?QUU[4+BZM[+X;:E<SVC[+F.&X=VA;)&' ARIRI&
M#Z'TKJ#\2M2M?AOJGBS5/"5WIT]C<+$NGW4K(TJLT:[PS1@@9D/\)^Z>?3#^
M$'_)0_B=_P!A4?\ HVXKH/C;_P DAUW_ +=__2B.@#FX/C-XJNK>*XM_A7K,
MT$J!XY(WE974C(((@P01SFNH\%>.]>\4:S-9:IX'U+0H$MVE6YNB^UV#*-@W
M1J,D,3U_A/%</X:^*?BK3O"ND65O\,=9O(+>RABCN8S+MF54 #C$)&"!GJ>O
M4UZ)X%\8:QXK^W_VMX2OM ^S>7Y?VLO^_P!V[.-T:?=VCIG[PZ4 5_&/Q2T+
MPC>?V4%GU/77VK%IMFA9RS@[ QZ+D[1@9;YE(4@UR<GQRU+2GAF\1_#W6=*T
M]WV&Y8L3NVD@*'C0$G'3<.,GG&*/@)!#JUOXD\87$48U34=3D20JHVQKA92$
MSE@"TG(R<[%],UZY?V-OJ>G7-A>1^9:W43PS)N(W(P(89'(R">E '-^(?'EC
MI/P\F\8Z8L>JV:I&\2I+Y8D#2*G7!*D%CD$9!!!P:W-"U/\ MOP]IFK>3Y/V
MZTBN?*W;MF] VW.!G&<9P*\S^('A6Q\&? '5]&TZ:[EMXWB<-=2[VRUS&3CH
M%'LH ZGJ23C^&OBGXJT[PKI%E;_#'6;R"WLH8H[F,R[9E5  XQ"1@@9ZGKU-
M 'HGC#QU_P (IXA\,:3_ &=]J_MR[^S>;Y^SR/GC7=C:=W^LSC(Z>]8_CCXM
MV_@;QEIVAWFF>9:W444TU[YY'D(TC(QV!"6VA2>#STKSCQ+XPUCQ7\0_ ']K
M>$K[0/LVJIY?VLO^_P!TL.<;HT^[M'3/WATK?\?:-9^(?VA- TB_3?:W>B2Q
M/@ E<I=89<@@,#@@XX(!H ]PKC_!_CK_ (2OQ#XGTG^SOLO]AW?V;S?/W^?\
M\B[L;1M_U><9/7VKG_AGK-YH.HW7PY\0OLOM-R=*GF)#7]KEB"H)(^4#@!N%
M^7'[MC7-^!=2FT;6?C+JENL;3V5Q+<1K("5+(UTP!P0<9'J* .L\7?&70O#F
MHMH^FV\^MZV)1!]CM,A5DRHV%\'+<D84,=RE3@UCP_'1]/U&WA\6^#-5T"UN
M,B.XEW/D@J"=K(A*@-DE=Q''!S5SX%Z!8Q>#(_%#K)/K6KO,UU>3MO<@2LNT
M$\@$KN/<DY). !Z1JNE6.N:7<:9J=M'<V=PFR6)^C#^8(."".00",$4 9]SX
MHL3X*NO%&F21ZA9Q64MY%L?:)0BEMN<94Y4@Y&0<Y&1BH_!/B?\ X3'PA8Z_
M]C^Q_:O,_<>;YFW;(R?>P,YVYZ=Z\?\  TUYI_@'XI>$IKG[3:Z'%=1V\I!!
M.Y)E; )(528MP4="S<G->@?!+_DD.A?]O'_I1)0!Z!7E>N_''2+;5$TGPOIE
MWXFU N5*6F50[=V[:P5BY&W/RJ5(.=W%=)\4]9O- ^&>MZC8/Y=TL2Q)("04
M\QUC+*000P#D@]B!5?X3^&-+\.^ =+FL(-MQJ5I#=W4[\O([H&P3_=7<0!V^
MI)(!S=A\=K2VU3[!XP\.:EX:=T#Q/.KR K\W++L5P,K@%5;))SC%>J?;[/\
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MAC5-&T/4=8\00>5K>N79N[C=P^P\J'085&W-(V .-X!P1@8_[1W_ "3S3_\
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M ."Z'_XF@"OX;^(GA7Q=J,EAH>J_:[J.(S,GV>6/" @$Y=0.K#\Z\OT77O\
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M>#_^A4T/_P %T/\ \36AIFA:/HGF_P!DZ58V'G8\S[);I%OQG&=H&<9/7U-
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MLVJBDEL;1@]2#@]#[1INDZ;HUNUOI>GVEC SEVCM85B4M@#)"@#. !GV%7*
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M-Z0[LQLQECDX=@/R!XI/^$9T?_GT_P#(C_XUK45E["E_*ON%9&3_ ,(SH_\
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MD1L$$94\'! /X5)!!#:V\5O;Q1PP1($CCC4*J*!@  <  <8H \C\2?'71/\
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M/MW3.PY5"#P0>#7MD\$-U;RV]Q%'-!*A22.10RNI&""#P01QBL/_ (03P?\
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M1110 4444 %%%% !1110 4444 <_XA_Y#GA/_L*R?^D5U705S_B'_D.>$_\
ML*R?^D5U704 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV7_R/7044 <__P (]JG_ $.>N?\ ?FR_^1Z/^$>U3_H<]<_[\V7_ ,CUT%%
M'/\ _"/:I_T.>N?]^;+_ .1Z/^$>U3_H<]<_[\V7_P CUT%% '/_ /"/:I_T
M.>N?]^;+_P"1Z/\ A'M4_P"ASUS_ +\V7_R/7044 <__ ,(]JG_0YZY_WYLO
M_D>C_A'M4_Z'/7/^_-E_\CUT%% '/_\ "/:I_P!#GKG_ 'YLO_D>C_A'M4_Z
M'/7/^_-E_P#(]=!10!S_ /PCVJ?]#GKG_?FR_P#D>C_A'M4_Z'/7/^_-E_\
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M^;+_ .1Z/^$>U3_H<]<_[\V7_P CUT%% '/_ /"/:I_T.>N?]^;+_P"1Z/\
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M9?\ R/7044 <_P#\(]JG_0YZY_WYLO\ Y'H_X1[5/^ASUS_OS9?_ "/7044
M<_\ \(]JG_0YZY_WYLO_ )'H_P"$>U3_ *'/7/\ OS9?_(]=!10!S_\ PCVJ
M?]#GKG_?FR_^1Z/^$>U3_H<]<_[\V7_R/7044 <__P (]JG_ $.>N?\ ?FR_
M^1Z/^$>U3_H<]<_[\V7_ ,CUT%% '/\ _"/:I_T.>N?]^;+_ .1Z/^$>U3_H
M<]<_[\V7_P CUT%% '/_ /"/:I_T.>N?]^;+_P"1Z/\ A'M4_P"ASUS_ +\V
M7_R/7044 <__ ,(]JG_0YZY_WYLO_D>C_A'M4_Z'/7/^_-E_\CUT%% '/_\
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M>C_A'M4_Z'/7/^_-E_\ (]=!10!S_P#PCVJ?]#GKG_?FR_\ D>C_ (1[5/\
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M% '/_P#"/:I_T.>N?]^;+_Y'H_X1[5/^ASUS_OS9?_(]=!10!S__  CVJ?\
M0YZY_P!^;+_Y'H_X1[5/^ASUS_OS9?\ R/7044 <_P#\(]JG_0YZY_WYLO\
MY'H_X1[5/^ASUS_OS9?_ "/7044 <_\ \(]JG_0YZY_WYLO_ )'H_P"$>U3_
M *'/7/\ OS9?_(]=!10!S_\ PCVJ?]#GKG_?FR_^1Z/^$>U3_H<]<_[\V7_R
M/7044 <__P (]JG_ $.>N?\ ?FR_^1Z/^$>U3_H<]<_[\V7_ ,CUT%% '/\
M_"/:I_T.>N?]^;+_ .1Z/^$>U3_H<]<_[\V7_P CUT%% '/_ /"/:I_T.>N?
M]^;+_P"1Z/\ A'M4_P"ASUS_ +\V7_R/7044 <__ ,(]JG_0YZY_WYLO_D>C
M_A'M4_Z'/7/^_-E_\CUT%% '/_\ "/:I_P!#GKG_ 'YLO_D>C_A'M4_Z'/7/
M^_-E_P#(]=!10!S_ /PCVJ?]#GKG_?FR_P#D>C_A'M4_Z'/7/^_-E_\ (]=!
M10!S_P#PCVJ?]#GKG_?FR_\ D>C_ (1[5/\ H<]<_P"_-E_\CUT%% '/_P#"
M/:I_T.>N?]^;+_Y'H_X1[5/^ASUS_OS9?_(]=!10!S__  CVJ?\ 0YZY_P!^
M;+_Y'H_X1[5/^ASUS_OS9?\ R/7044 <_P#\(]JG_0YZY_WYLO\ Y'H_X1[5
M/^ASUS_OS9?_ "/7044 <_\ \(]JG_0YZY_WYLO_ )'H_P"$>U3_ *'/7/\
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M'65NN>U;%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 45Y]\9?%'_  C7P]O%A?;>:A_HD.#R P.]OP7//J15?X(>*/\
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MITO%B499PH96 '<[6)Q[5TW@OQ%'XK\'Z;K*$;[B$>:H_AD'#C_OH'\,5O4
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M8X$L9/1<_>7Z]^H!]'UX_P#M'?\ )/=/_P"PK'_Z*EKV"O'_ -H[_DGFG_\
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MTKZOT#6K;Q%H%CK%GGR+N%95!ZKGJI]P<C\* -&OF#QE_P G0VW_ &%=-_\
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M[>=>H^]&W9E/8@_YQ0 OASQ#I_BG0K;5],EWV\ZYP?O(W=6'8@\5RG_-PO\
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MI:66JV:@RB&-4^TIT$AQU;L?P/>O7J "D*AA@@$9SS2T4 (S*B,[L%51DDG
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M 'RI_ 5[M7@/Q#0W_P"TAX3@BY:$6A8#MMF>0_I7OU 'S_\ M-?\RM_V]_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWB@0R%(T"*9)&=B ,<LQ)8^Y))[U4TC1--T&S>TTNT2U@>5YF1,X+L<L>?\
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M*2^!EE02VHSYB*%R QXQTZ=17>:'X:T7PU;-;Z-IEO91M][RD^9_]YNI_$T
M:M>/?M'LH^'^G)D;CJB$#V$4O^(KV&N2UGX:>%/$5TUSK%C=7LA=G'G:C<E4
M+')VKYF%'L  * +G@)E?X=^&BI!']EVPX]1$H-3>+O#T7BKPGJ6B2L%^U1%4
M<]$<<HWX, :;X?\ !^B^%AMT>&ZMXMA00M?3RQ $@G".Y4'(Z@9Z^IK=H \L
M^#.O?9]"D\&ZNPM=;T>9XC;RG#/&26#+_> R1QVVGO6=\6KP^.-3TKP#H$RW
M%T]R+B_DB.Y;:-01\Y' ^\3CKP!W%>A^(O WAGQ6Z2:WI$%U*@PLN61\>FY2
M#CVS5O0?#&B>&+5K;1=-@LHVY?RU^9_]YCRWXF@"3^PK'_A&?^$?\O\ XE_V
M3['L[^7LV8_*O+?A'>-X*U75_A_KLJP745P;BPDD.U;F-@ =A/7[H..O+>AK
MV2L;Q!X4T'Q5;I!K>F07BI]PN"&3UPPPP_ T <+\9->6[T-?!FCL+O7=7E2(
M6T)!:.,,&+-_=' '/8D]J[CPAX>B\*>$]-T2)@WV6(*[CH[GEV_%B33/#W@O
MPYX4#_V)I,%H[C#2#+R$>A=B6Q[9K>H *YSX@2I#\.O$K2,%4Z9<*"?4QL /
MS(KHZYS7O V@>)GD.L07ETDA!:$ZC<+%D  8C60(.G8=>>M 'D'[,TB"7Q/$
M6&]EM6"YY('FY/ZC\Z]_FE2"&2:5@L<:EF8]  ,DUQ=C\(O!.F7(N=/TJXM+
M@# EM]1N8V ^HD!K8U;P;HVN6R6VI+?SVZ0K!Y1U.Y574=-X$@#MSRS9)[DT
M <W\#Y4D^$>C*K F-IU<#L?.<X_(C\Z]#(!!!&0>U<KHOPY\,>'95DT>TO++
M$@D*0ZE<A&8=-R^9M8<=""#T-=50!\Q?%SX>W7@C5)?$7A[?#I%\KPSI%TMS
M(I5D/^PP) ],X]*]]\"?\D\\-?\ 8*M?_12UKW]A:ZII\]A?0)/:W"&.6-QD
M,II-,T^#2=*L]-M0PM[2!((@QR=B*%&3WX% %JO+OCMX5_M_P*VHP1[KS26-
MPN!R8CQ(/R ;_@->HTR6*.>%X945XY%*NK#(8'@@T >&_ :#4->9=:U-O,M]
M%M?[,T_(Z;F+N?J%*+],#M7NM8_A?PSIWA'08='TM9!;1,S R,"[%F))) &>
MN/H!6Q0!SOC^1(OAUXE9V"@Z7<KDGN8V 'YD5X]^S/-$L_B:%I%$KK;,J$\L
M!YN2![9'YU[!KW@70/$TDC:Q!=W2.03"=0N%B!  &(U<(.G8=>>M87_"DOAY
M_P!"]_Y.W'_QR@#OR0!DD >IKB/$WCF!=9T_PMH%Y%-KE_.J,T6V06D0YDD;
MJ-P4'"GZGCK7_P"%)?#S_H7O_)VX_P#CE:OA[X;>$?"NI_VEHVD"VN]AC$AG
MEDPIZX#L0.G7K0!C?%[7SX7TOPYK04LMKKD+2*O5D,4P<#W*DUV^E:M8:YIL
M.H:9=1W5I,N4DC.1]#Z'U!Y%5=>\-Z9XFCLHM5@%Q!:70NE@<!DD8(Z ."#D
M?.3CU [<'G+CX3>'/M#W&DRZGH,K_?;2+UH W_ >0/P H Q/C_+IG_"NS;W6
MQM0DN(_L*=7WAAN('7&S<#]1[5U7PTT6Z\/?#G1=-O5*7,<)>1&ZH79GVGW&
M['X55T7X7>'M(U9-6G:^U;4H_P#5W6J7!G=/<< 9]\9':NUH *^6O&=U"/VF
M(KCS%\J/5;#>V>!M$(;\B#^5?3&IZ7;ZO:BWNGNEC#;O]&NY;=B<$8+1LI(Y
MZ$XZ>@KCG^"WP_ED:2306=V)9F:^N"23W)\R@#OJ*S-'T&QT*)XK%KSRV"C;
M<7LUP% SC:)';;U[8SQGH*-9T"PUZ)(K\W9C4,-EO>S0!@<9#"-UW=.^<<XZ
MF@#YM\'7=N/VF);EID$+ZK?[7+  [EF"\^Y(_.OJ6O/_ /A27P\_Z%[_ ,G;
MC_XY1_PI+X>?]"]_Y.W'_P <H V?&/CO1?!FDRW5]=1O<[3Y%FC@RS-V '4#
MU/05I:++?0>&;6XUR9?MH@\ZZ;:%6-B-Q48[+G;]!SS7,VWP;\ 6=W#=0: !
M+"ZR(6NYV 8'(R"Y!Y'0\5T&N^$])\2@KJJ7DT31^6T,=_/%$RY)Y1'"D\]2
M,]/04 ?.W[.]S!;?$&],\T<0?3)$4R.%W-YL1P,]3P?RKZ8OM5T[3+8W%_?V
MUK"!DR32JB_F37%_\*2^'G_0O?\ D[<?_'*EA^#/P^@<.GAV,D?W[F9Q^3.1
M0!Y5\2_'-W\3M2M_"/@VVGO+19 \LJ(1Y[#H>?NQKG.3C)Y[#/L'PV\#0^ _
M"R6!=9;Z9O.NYEZ,Y&,#_9 X'XGC-=%I>BZ7HEM]GTK3[6RA[I;Q*@)]3CJ?
MK5Z@ KFO'OA*+QKX0O-'=ECF8"2WE;I'*OW3].H/L372T4 ?/7P5\12>#-?U
M'P/XD4V$LLWF0><<*)L %<]/F 4@]#CW%?0M8'B;P5X>\7P+'K>FQ7#(,1S#
M*2)]&&#CVZ5S/_"GM,,/V8^)O%1LL8^R'4_W6/3&WI0!Q'QE\12>-=7T_P !
M^&!]ON%G\VZ:$Y4. 0%+=,*"Q8]!QW!KUKP/X4@\%^$[/1H6$CQ@O/*!CS)6
MY9OIV'L!4OAKP=H'A&V:#1--BMMXQ))RTC_[S')/TZ5LSPK<V\L#F0)(A1C'
M(R, 1CAE(*GW!!':@#SWQC=0Q_&+X=QO(H9?M^03TWPA5_,@BO1JXN[^$_@R
M_OA?7FFW5Q=C!$\VIW3R#'3YC)GBNGTS2[?2;4V]J]TT9;=_I-W+<,#@# :1
MF(''0''7U- '.?$7P%9^/?#K6<FV*_@R]G<D?<?T/^R>A_ ]J\B^!D.JV/Q2
MO]*U<2I<:=I$MLL4G_+)1/&VT>V6)'UXXKZ-K,&@:<OB7_A(%MPNI&U-HTJG
M&^,LK8([D%1@T :=%%1SPK<V\L#F0)(A1C'(R, 1CAE(*GW!!':@#P#]IF5#
M/X9A##S$6Y9ESR 3$ ?_ !T_E7KO@"[MIOA]X=$5Q$YCTNV5PK@[2(E!!]"*
MSK_X1^"=4NC<ZAI=Q=W!&#+<:E<R.1]3(35;_A27P\_Z%[_R=N/_ (Y0!8\:
M_%+P[X.L)2UY#>ZE@B*R@D#,6[;B/N#W/X UY)\-O &L>./%Y\:>)X72Q,_V
MH"1=OVJ3.5"J?^68X]B  ,\X]ITKX;>#-%E66Q\.V2RJ<J\J&5E/J"Y)!KJJ
M &2R)#$\LC!412S,3P .IKY?_9UFBB^(MVLDBH9-,D1 QQN;S(C@>IP"?PKZ
M(UWPGI'B4%=52[FB*>6T*7\\43#)/*(X4GGJ1GIZ"N:_X4E\//\ H7O_ "=N
M/_CE 'H%<9XV\?67AVV33]/GAN_$%ZZV]E9HP8^8QVJS@=%!/?KT'M2_X4E\
M//\ H7O_ "=N/_CE7=(^%'@G0M5M]3T[1!#>6[;HI#<S/M.,9PSD=_2@"7QQ
MX-;QAX#ET2>X$E\L:R0W+J%S.@X8@# #<@X' 8XKR#X,>,1X)UC4/!OB?.GB
M2?=&T_RB*; !5CT 8!<'IQ[U]&US?BCP'X;\8HO]LZ;'-,HPEPA*2J/3<.2/
M8Y% '1@A@"""#R".]8.OZ\]K+'H^E%)M<NQ^YBZB!.AFD]$7_P >. .O',V'
MP>TS3%$5GXF\506P_P"7:+4]D>/3"J#^M=AH?AO2?#EN\6EVBPF4[I968O)*
M?5W8EF/U- %]3]DL@;B<OY4>9)GP"V!RQQ@#UXP*^8OV=9HHOB+=K)(J&33)
M$0,<;F\R(X'J< G\*^B-=\)Z1XE!754NYHBGEM"E_/%$PR3RB.%)YZD9Z>@K
MFO\ A27P\_Z%[_R=N/\ XY0!Z!7&>-O'UEX=MDT_3YX;OQ!>NMO96:,&/F,=
MJLX'103WZ]![4O\ A27P\_Z%[_R=N/\ XY5W2/A1X)T+5;?4].T00WENVZ*0
MW,S[3C&<,Y'?TH M^-BUG\+]>6[N?-D72)XWF8!?,<Q%<X' ))Z#UJ7P!*DW
MPZ\--&P8#3+=21ZB-01^8-&O>!M \3/(=8@O+I)""T)U"X6+(  (C60(.G8=
M>>M+H7@;0?#+QG1X+RU2,DK"-1N&BR00<QM(4/7N.O/6@#P[X[^'9_#GC*P\
M8:9F(73JS.@_U=S'@@_B #]5:O8_AOH5SI'A<76I<ZQJLK7]^Q&#YDG(7VVC
M QZYKH=7T33=>M$M-4M$NH$E294?. ZG*GC_ "1D'@U;GA6YMY8',@21"C&.
M1D8 C'#*05/N"".U '@'[3,J&;PS"&'F*MRS+W )B /_ (Z?RKV#X?RI-\.O
M#31L&4:9;J2/41J"/S!K+O\ X1^"=4N3<ZAI=Q=W!&#+<:E<R,1]3(35W3_A
MSX;TFV^S:;'J=G!G/E6VL7<:Y^BR@4 >#?M%S))\1;1$8%HM,B1P.Q\R0X_(
M@_C7T[#=VUQ%YL-Q%)'C.]'!'YBN*N?@YX#O;E[FZT66>>0Y>674+EF8^I)D
MR:B_X4E\//\ H7O_ "=N/_CE ')_';Q[HQ\*3>&;&[AO+Z[D0S"%PP@1&#?,
M1P&)4#'7&?;-_P" 'A.^T#PO>ZG?Q/!)JKHT<3C!$2 [6([9+-^&#WKLM*^&
MG@S1;A)['P]9K,ARKR@RE3Z@N3@^]=//"MS;RP.9 DB%&,<C(P!&.&4@J?<$
M$=J / ?VF9$,OAB(,-ZK=,5SR ?*P?T/Y5Z_\/YHI_AUX;:*17"Z9;H2ISAA
M&H(^H((K+OOA'X)U2Y-SJ&E7%W<$8,MQJ-S(Q'U,A-5O^%)?#S_H7O\ R=N/
M_CE '<W=]:6%NUQ>74-O"@RTDT@10/<FN5\(^+6\9ZYJMYITA_X1^RQ:0/L'
M^DS?>=\D9 4;0!WW$GMBA_PI+X>?]"]_Y.W'_P <KI=.\):+I'A[^PM-MIK/
M3]Q;;;W4L;Y+;B?,#;^O^UTXZ<4 ?/'[1<J2?$6T5&!:/3(U< ]#YDIQ^1'Y
MU]/1R1W-NDB%7BE0,#U#*17$W/P<\"7MR]S=:++//(<O++J%RS,?4DR9-=!H
M7A32?#8"Z6MY%$L?EK#)?SRQ*N0?E1W*@\=0,]?4T ?/GQ&\):A\*_&EKXK\
M-YBTZ2;?%@?+!(?O1-_L,,X]LCMFO>O!?C/3/&^@Q:E82*), 7%L6R\#]U/M
MZ'N*UM7TBPU[2Y],U2V2YLYUVR1-D9'7J.0<\Y'(KE++X0^"--N!<6.DSVLX
MX$D&HW*,/Q$F: .XJEJ^KV&@Z5<:GJ=RMM96ZAI96!(4$@#@<GD@8'K5P#:H
M S@#')S4%]86FIV,UE?6\=Q:S+MDBE7<K#W% %#1/%.A>)+3[3H^J6UW$/O;
M'PR_[RG!7\0*\L\:6</Q2^)FB:3I16YTW1"TFI7L?,:[F4F(-T+83'']X^AK
ML$^#?P_CF\U?#D1;.<-<2LO_ 'R7Q^E=AI^G66E6:6>GVD%I;)]V*",(H_ 4
M 6J1V5$9V("J,DGL*6LK7/#NG>([=;?4UNGA 93'#>30*X;&0PC90W3^+..?
M4T >)_LRLH?Q.F1N(M2![#S?\17T#7%:?\)O!FDW!N--TVZLIB-IDMM2NHVQ
MZ960&NUH HVVLZ7>7LUE:ZE9SW</^M@BG5I(^WS*#D?C5ZO$-0^'>C>#O'_A
M9O#4]^=7N]3$LL4DP<1VB@F;H 0,$#))SR*]OH *\T^(/Q3TS0+U/#UKJL-K
MJ,W%Q>-&TJ6*=R54$M)CHO3H3@=?2ZX*3X+?#^:5Y9=!9Y')9G:^N"6)ZDGS
M.30!D:!\3OA=X;TI;&QUYBNXR2RR6EPTD\A^\[MY?S,3U/\ 2MGP]\3M-\8^
M*UTGPY')<VD,#SW=Y+&R*HX"J@."26/<= >O:+_A27P\_P"A>_\ )VX_^.5T
M'AGP1X=\'?:3H.FBT-SM\X^;)(6VYQR[''4]* .!^,F@WEGJ.B>/M+@::?1I
M4^UQKU:$-N!^@)8'V;/0&O1K+Q3H=_H":Y#J=L-.,?F&=Y H08Z-GH1W!K79
M0RE6 ((P0>]<;)\)_ DNH_;G\-VGG%MV 7$>?^N8.S]* .,\!:=)XT^*>K_$
M.2)UTN(FWTPNN/-POE[P#VV@_B_L:]FID,,5O"D,,:11(H5$10JJ!T  Z"GT
M ?/W[33*7\,)D;@+HD>Q\K_ U] (RNBNI!5AD$=Q7%ZA\)O!FK7 N-2TVZO9
M@-HDN=2NI&QZ9:0FN@T/P[IOARW:WTQ;I(2%41S7DTZH%S@*)&8+U_AQGCT%
M '&?''0;_7OAS*NGH\LMG<)=/$@RSHH8-@=\;MW_  &K?PE\4Z9KO@'2;:VN
M8A=V%JEM<6Y8!T*#;NQZ$#.??V-=[7'ZK\+/!&M7C7=[X>MC.YW,T3/#N/J0
MC $T >7?%^VM/'/Q'\/:%H#)<ZE&K)>S0'<(4+*1N8=-OSD^FX=S7T#61H/A
M;0O#$#0Z+I=O9*_WS&OS/_O,>3^)K7H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'TCPUI^CW,]Y'
MYUSJ%P LU[=2>9-(!T&>BK_LJ /:MBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD8892,@CTKPV?X8>&M>^-%Q:6=BD&CZ99Q2ZA;PDJCW#EBJ#'W05P3CT[9H
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MC7Z#,<8NW,3GT)SN7ZY/TH ]9HKP#P%\8-:TGQ)_PBOCK.\2_9Q=R *\,F<
M28X93_>]\Y(Y'O\ 0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGZ^8/V<?^2AZA_V"I/\ T;%0!]/UQ'Q<T>'6?ACK22("]K";N)CU5H_FR/\
M@.X?C7;UR'Q3U*+2_AEK\TK >;:-;J,]6D^0 ?\ ?7Z4 >2?LV:O*NJZUHI8
MF&2!;M5/165@C$?4,O\ WR*M?M-?\RM_V]_^T:H?LV:9*_B'6=6VD0PVJVV[
ML6=PV/RC_45?_::_YE;_ +>__:- 'HG@OQIX5M? OAZWN/$NC0SQ:9;))')?
MQ*R,(E!!!;((/&*9XC^)FB176C:;H>MV=Y?ZAJEK;D6DB3!8FE7S,D9 RN5]
M?FR.F0_P7X+\*W7@7P]<7'AK1IIY=,MGDDDL(F9V,2DDDKDDGG-1^(_AGHLM
MWHNIZ'HEG:7^GZI:W!-K&L(:)95,F0, X7+>ORX'7! /0*\^\7JK_%SX=HZA
ME8:F"",@C[.M>@UY_P"+?^2O?#K_ +B?_I.M 'DOQ#\'ZC\*O%]MXM\,;H]-
M>;<@ RL#GK$P[HPSCVR.P)]X\%>,+#QMX<AU6Q(5C\EQ 3EH9!U4_P P>X(K
M7U32[/6M+N=-U"!9[2X0I)&W0C^A[@]C7S1C6/@/\10?WMSH=Y^5Q#G\A(F?
M\AJ /8O^;A?^Y4_]NZZ#QW_R3SQ+_P!@JZ_]%-7*:9J=GK/QRMM1T^=9[2X\
M(B2*1>A!NOT/8CL:ZOQW_P D\\2_]@JZ_P#134 >/_LR_P#,T_\ ;I_[6KZ
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M!ZE\399-3ATCP=;.1-KUV$G*GE+6/#RM^0 ]\FNZBBC@A2*) D:*%55&  .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR&., C<1GE37J_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\
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MO#6@ZS<+<:IHFFWTZH$62ZM4E8+DG + G&23CW-4_P#A!/!__0J:'_X+H?\
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MGO(XW1UC52"K$'J#6Q=_$;P796[32^*-)95&2(;I)6/T5"2?RJ?_ (03P?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)\:?A_#*T4NO,DB$JRM8W *D=B/+KH/#WC'1/%0+:-/<W$6TMYS64\<1P0"
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M>6)5R1RZ(5!XZ$YZ>HK/T7XC^&/$4RQZ/=WEZ3((RT.FW)1&/3<WE[5'/4D
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MW.EAV)\K*[R@SVQN_%/<UTGC[2K[QIJ]EX/M[N2STPQ?;=5FC^\T>[;'&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA<8\ZZGNYY,=-S7,K']37;=:Q-"TJS\'^'/L37426=O+/,)'Q&D:22O( <G
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MB"#W&*H_$?P#:>/?#S6K;(M1@R]G<$?<;^Z?]D]#^![5X;X8\=7OAGPSXG\
M^)EDAQ87<-H9.L,IC;]V?]EB?E/J?0\ 'T)X$_Y)YX:_[!5K_P"BEKP#]H[_
M )*'I_\ V"H__1LM>_\ @3_DGGAK_L%6O_HI:\ _:._Y*'I__8*C_P#1LM '
MT_1139)$BC:21U1%!9F8X  ZDF@#Y!^)?_$@^-.J7%I\CP7L5VI7LY5)"?\
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MA>3_ (0/QL-HSE]*VK^)W<4WX0>()?%6D^(=;FA\E[K6I"(LYV*(8552>Y
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MLTCMT:"0@QR'Z?*3]&%>R>%_^*N^(FK>*W^?3]+W:7I?HS#F:4?4_*#W'TH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"EJ>IP:3:BXN(KN12VP+:VDMP^<$_=C5B!QU(QTYY%?,OB
M.#Q)J7QA/BZV\'^(6LXK^WG1&TV4,Z1;!TV\$A/UKZGHH S-&URWUN)WAM=1
MMF0*72^L9;<C.>!O4!NG.TG''J*TZ** /*OC#K%QJ_@S4/#NCZ'KM]=SS)&[
M1:7/Y:!) Q.\H P)7 *Y!SGI6'\%-1OO".@7VD:[X<\0VADNS<QS#2;B12"B
MJ1\J$@_)Z=Z]QHH \T^-5IJ][H&@0Z#&\FJ_VW"]LJ$ [UBF8')X&,9Y]*DL
MOBO!IMLD/C;2-1T&^48D=K5Y;>0]RCH#D>W;U->CT4 >+>-/$\_Q3TP>%?!=
MA=7-M=2H;O4YX&B@B16#  L <Y /3/& #GCU7PWH=OX:\.6&C6I+16D(C#$8
M+GJ6/U))_&M2B@#Q;XJ_">_U'6%\6^$CLU5&62:W5@K.ZXQ(AZ;N!D=\9Z];
MF@_&ZUM;=++QOIM_HVIQC;)(UJYCD/K@#<I]L$>]>NT4 <7%\0(]>3RO".FW
MFIS/PMS-;R6]K%_M.[@$@==J@D_K6UIFGIX;T>XFN)9[VZ<M<WEPD+/)/)CD
MA%!/0!549P !6U10!XK+XEU/5OB[8:OJ'A/Q)'H.FP21V;'2IF(E<8,K*%SR
M,@=2, ^M>S6\RW-M%.BR*DJ!U$D;(P!&>58 J?8@$=ZDHH Y[QI<V:>&;VTO
M;#4+Z.\@DA\BQLY)W;*G^X#M]B<#-> ?">;Q;X"\12R7GA+Q#)I=X@CN5CTZ
M4LI'*N!MYQDCZ$U]044 >2_%C7YO$/@*ZT71= \0W=S>-'N_XD]S&(U5U<Y+
M(,_= XSUKF/A+K^M> ] O-*U7P-XJF66Z-S'):Z:[=452"&V_P!P?G7T#10!
MYW-\59EC)@^'_C5W[!]**@_B&/\ *H?A[-XA\3^)M4\4^(]*N=*$48LM.LIX
MF0QQD[Y&^8 DDA/FQS@CM7I5% !1110 5Y3\8=8N-6\&7_AW1]"UV^NYYDC=
MHM+G\M D@8G>4 8$K@%<@YSG%>K44 >'?!/4+[PCH%_I&N^'?$%IYET;F*4:
M3<2*V452/E0D'Y!V[U[C110!PWQ'\0-'X7UK1K'1]:U"_N;1[95M=-F>,&1,
M9\S;L( ;G!/(QUKR7X07NN_#Z?5AJG@GQ1/%?+%M:UTUV92F_J&QP=_KVKZ3
MHH \_/Q4../ 7C@GWTC_ .SK!36_$_Q"\::9IMQX9U31?#5K*+RY:]MW0W+1
M_,BL2 ,;MOR@G.">U>O44 >7?%OQ+K!T"]\/>'=!UN\O+H>3-<P:?*8HXR/F
MVN%PQ(XXR!D\Y%==X*O[2X\.VEE:Z;J6GK96\41@OK*2 KA<8!8 -T.2I/OU
M%='10 V1Q%&TC!B%!8A5+'CT Y/T%?+WQ(TS6]1^);>(O"OAKQ" OE2^>=+F
M3,Z?Q %<XX7J!SFOJ.B@#B](^(2W6C1W&I>'/$=E?!!YMK_8UR^7QSM94((S
MTR1[UX9X;@\2Z;\8!XNNO!_B%;26_N)W1=-E+(DN\=-O.-_Z5]3T4 4M,U.#
M5K5IX(KN- VPK=6DMNV< _=D521SU QUYX-?/_Q!^'6N^#O&UMXG\#V5U+%)
M*95ALX6D-O)_$I50?W;#/MR1Z9^C:* ..\(^.;C7X[>WU3PUKFD:@XPXN-/E
M$&X#)(DVX X_BQZ<UV-%% &#XB\3QZ##(JZ;JU_=>5YD<-CI\TP8\@#>JE <
MCH3G'..17SM\*HO$?@/Q9-JE_P""_$D]O-:/;,+?3I"ZY9&! ( /W,=>]?4]
M% 'G_P#PM/\ ZD+QS_X*/_LZYK7?%/BKQW?V?AG3_">N:-I%[,J7]]>VKQMY
M/5U!QM7(!'7G..,\^RT4 <_K_B.#PY9M#!I>J7EPD&Z""PTZ:93U"KO52B].
MA((';D5Q7P>U>XTCP9I_AW5]#URQO()GC1I=+G\MP\A8'>$(49;!+8 QGI7J
MM% !7E'QE^&(\6::=:TF$?VW:)\R*.;J,?P_[P[>O3TQZO10!S/A6Y72OAKX
M?FNHKG$.EVJO'#;R2R ^6@QL0%CSUP..<]*\$^+]IK_C3QJM_I7A7Q UG;VJ
M6R2/IDR^9AF8D KD#+XY]*^H:* /.8?BK=O%F7X>>,DE_NKII9?^^B1_*N9\
M37'Q,^(]NVD:=X>?P]H\WRSRWLP621?1OX@OJ%4^YQQ7ME% '#_#GX::;\/[
M!S&_VO4[A0+B[9<<?W$'9<_B>_8#:\1>)H]!@E5--U6^N_),D45EI\TP8\@#
M>JE <CH3G'/<5O44 ?+WP@M=>\%>-'O]5\*>(5M)[1[9I(],F8QY9&!("Y(^
M3''K7T-=>*;*UTZ"]^QZQ*LX<QQ0Z3<M)\IP0R;,I[;]N>HR*VZ* /'_ (9>
M(KS2I/$2ZWX;\0V(U#5IM1A<Z3<2#$F/E.Q"01M';'->P444 <'\4?AU;^/-
M!_<A(]8M5+6DQXW>L;'^Z?T//KE_P?LKK3OA;I%G>P26]S"UPDD4BX93]HDX
M(KN:* ..^(GP_L?'^ABUF<6]];DM:W07.PGJ".ZG S] >U>9>$=<\8?"16T/
MQ-H-[?:$KDPW=DOFB')YVGH5/7:=I'/TKWZB@#SL_&[P,8<Q7]W+/C_CW2RE
M\S/IRN,_C7F=OX>\1>//C-!XQM-!O;#25OK6X,E^OE'9$(P< _>)V'@9Z]:^
MD** "HYYEMK>6=Q(4C0NPCC9V( SPJ@EC[ $GM4E% 'SM\;GU;QKJ&DPZ)X9
M\03V]BDI:=M*G0,SE> &4'C8.H[UU_A;XAW^D>%]+TJ]^'_C#SK*SBMBT.FL
MRN40+GG&,XKUJB@#Q[Q!XD^)'C"V?3/#7A.\T2WF&V6]U!Q%*%/7 .-OU&X^
MF*U?AE\(K/P,W]I7TR7NM.I7S5'[N 'J$SR2>['''&!SGTRB@#!\1>)X]!AD
M5=-U:_NO*\R.&QT^:8,>0!O52@.1T)SCG'(KYV^%47B/P'XLFU2_\%^))[>:
MT>V86^G2%URR," 0 ?N8Z]Z^IZ* //\ _A:?_4A>.?\ P4?_ &=<UKOBGQ5X
M[O[/PSI_A/7-&TB]F5+^^O;5XV\GJZ@XVKD CKSG'&>?9:* *5_I5CJ>CSZ5
M=6Z/931&%XL8&S&,#TQV]*\!MO#OC#X*^*9]0TJQFUKP]<?+,(02Q0'C> "5
M=<GYL8Y/K@?1=% 'G6G_ !N\%WT:B2XOK6Z/6UELI&D!]/D##]:TS+J'CG;
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MB@#ROP]\;;'6O%XT*YT.\T])9S;07,S9S+SA77 V$XZ9//YUZI7GVH+)X_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>dvax-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-22T13:53:09.3318+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.dynavax.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dvax="http://www.dynavax.com/20231231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" namespace="http://xbrl.sec.gov/country/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>100070 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecurities" id="Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecurities">
        <link:definition>100100 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNet" id="Role_DisclosureInventoriesNet">
        <link:definition>100110 - Disclosure - Inventories, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNet" id="Role_DisclosureIntangibleAssetsNet">
        <link:definition>100120 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100130 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilities1" id="DisclosureCurrentAccruedLiabilities1">
        <link:definition>100140 - Disclosure - Current Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100150 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements" id="Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements">
        <link:definition>100160 - Disclosure - Collaborative Research, Development and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotes" id="DisclosureConvertibleNotes">
        <link:definition>100170 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt" id="Role_DisclosureLongTermDebt">
        <link:definition>100180 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognition" id="Role_DisclosureRevenueRecognition">
        <link:definition>100190 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShare1" id="DisclosureNetLossIncomePerShare1">
        <link:definition>100200 - Disclosure - Net (Loss) Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrants" id="DisclosureCommonStockAndWarrants">
        <link:definition>100210 - Disclosure - Common Stock and Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensation" id="Role_DisclosureEquityPlansAndStockBasedCompensation">
        <link:definition>100220 - Disclosure - Equity Plans and Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan" id="Role_DisclosureEmployeeBenefitPlan">
        <link:definition>100230 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuring" id="Role_DisclosureRestructuring">
        <link:definition>100240 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100250 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>100260 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100280 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables" id="Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables">
        <link:definition>100290 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetTables" id="Role_DisclosureInventoriesNetTables">
        <link:definition>100300 - Disclosure - Inventories, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetTables" id="Role_DisclosureIntangibleAssetsNetTables">
        <link:definition>100310 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100320 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesTables" id="DisclosureCurrentAccruedLiabilitiesTables">
        <link:definition>100330 - Disclosure - Current Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100340 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesTables" id="DisclosureConvertibleNotesTables">
        <link:definition>100350 - Disclosure - Convertible Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables" id="Role_DisclosureRevenueRecognitionTables">
        <link:definition>100360 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareTables" id="DisclosureNetLossIncomePerShareTables">
        <link:definition>100370 - Disclosure - Net (Loss) Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100380 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationTables" id="Role_DisclosureEquityPlansAndStockBasedCompensationTables">
        <link:definition>100390 - Disclosure - Equity Plans and Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringTables" id="Role_DisclosureRestructuringTables">
        <link:definition>100400 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100410 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail" id="Role_DisclosureOrganizationAdditionalInformationDetail">
        <link:definition>100420 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100450 - Disclosure - Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail" id="DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail">
        <link:definition>100460 - Disclosure - Fair Value Measurements - Summary of Assumptions to Estimate the Fair Value of Warrant Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail" id="DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail">
        <link:definition>100470 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value Warrant liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" id="Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
        <link:definition>100480 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail" id="Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail">
        <link:definition>100490 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Summary of Cash, Cash Equivalents and Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail" id="Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail">
        <link:definition>100500 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Maturities of Marketable Securities Available-for-Sale (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesAdditionalInformationDetail" id="Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>100510 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail" id="Role_DisclosureInventoriesNetSummaryOfInventoriesDetail">
        <link:definition>100520 - Disclosure - Inventories, Net - Summary of Inventories (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail" id="Role_DisclosureInventoriesNetAdditionalInformationDetail">
        <link:definition>100530 - Disclosure - Inventories, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail" id="Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail">
        <link:definition>100540 - Disclosure - Intangible Assets, Net - Summary of Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail" id="Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail">
        <link:definition>100550 - Disclosure - Intangible Assets, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" id="DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail">
        <link:definition>100560 - Disclosure - Property and Equipment, Net - Component of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail" id="DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail">
        <link:definition>100580 - Disclosure - Current Accrued Liabilities - Component of Current Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100590 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseExpenseDetail" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseExpenseDetail">
        <link:definition>100600 - Disclosure - Commitments and Contingencies - Summary of Operating Lease Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail">
        <link:definition>100610 - Disclosure - Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail">
        <link:definition>100620 - Disclosure - Commitments and Contingencies - Summary of Maturities of Sublease Income and Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail2" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail2">
        <link:definition>100630 - Disclosure - Commitments and Contingencies - Summary of Maturities of Sublease Income and Operating Lease Liabilities (Detail)2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetail" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetail">
        <link:definition>100640 - Disclosure - Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails">
        <link:definition>100650 - Disclosure - Commitments and Contingencies - Schedule of Material Purchase Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100660 - Disclosure - Collaborative Research, Development and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" id="DisclosureConvertibleNotesAdditionalInformationDetails">
        <link:definition>100670 - Disclosure - Convertible Notes (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails" id="DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails">
        <link:definition>100680 - Disclosure - Convertible Notes - Summary of Interest Expenses Related to Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" id="Role_DisclosureLongTermDebtAdditionalInformationDetail">
        <link:definition>100690 - Disclosure - Long-Term Debt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails" id="DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails">
        <link:definition>100700 - Disclosure - Revenue Recognition - Summary of Disaggregation of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails" id="DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails">
        <link:definition>100710 - Disclosure - Revenue Recognition - Schedule of Revenues from Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" id="Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail">
        <link:definition>100720 - Disclosure - Revenue Recognition - Summary of Product Revenue Allowance and Reserve Categories (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails" id="DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails">
        <link:definition>100730 - Disclosure - Revenue Recognition - Summary of Balances and Activities in our Contract Asset Account (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails" id="DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails">
        <link:definition>100740 - Disclosure - Revenue Recognition - Summary of Balances and Activities Deferred Revenue Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail" id="DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail">
        <link:definition>100750 - Disclosure - Net (Loss) Income Per Share- Computation of Basic and Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail" id="DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail">
        <link:definition>100760 - Disclosure - Net (Loss) Income Per Share - Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail" id="DisclosureCommonStockAndWarrantsAdditionalInformationDetail">
        <link:definition>100770 - Disclosure - Common Stock and Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail" id="DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail">
        <link:definition>100780 - Disclosure - Common Stock and Warrants - Summary of Common Stock Warrants Outstanding (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100790 - Disclosure - Equity Plans and Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail" id="Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail">
        <link:definition>100800 - Disclosure - Equity Plans and Stock-Based Compensation - Option Activity under Stock-Based Compensation Plans (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail" id="Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail">
        <link:definition>100810 - Disclosure - Equity Plans and Stock-Based Compensation - Summary of Non-vested Restricted Stock Units Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails" id="DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails">
        <link:definition>100820 - Disclosure - Equity Plans and Stock-Based Compensation - Summary Of Performance Based Restricted Stock Unit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail" id="Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail">
        <link:definition>100830 - Disclosure - Equity Plans and Stock-Based Compensation - Fair Value-Based Measurements and Weighted-Average Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail" id="Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>100840 - Disclosure - Equity Plans and Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetail" id="Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetail">
        <link:definition>100850 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail" id="Role_DisclosureRestructuringAdditionalInformationDetail">
        <link:definition>100860 - Disclosure - Restructuring - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail" id="Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail">
        <link:definition>100870 - Disclosure - Restructuring - Schedule of Major Components of Restructuring Costs (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail" id="Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail">
        <link:definition>100880 - Disclosure - Restructuring - Schedule of Components of the Restructuring Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail" id="DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail">
        <link:definition>100890 - Disclosure - Income Taxes - Schedule of Component of Consolidated (Loss) Income Before Provision for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100900 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" id="DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails">
        <link:definition>100910 - Disclosure - Income Taxes - Schedule of Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail" id="DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail">
        <link:definition>100920 - Disclosure - Income taxes - Schedule of Difference between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail" id="DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>100930 - Disclosure - Income taxes - Schedule of Component of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail" id="DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail">
        <link:definition>100940 - Disclosure - Income taxes - Schedule of Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" id="Role_DisclosureSubsequentEventAdditionalInformationDetail">
        <link:definition>100950 - Disclosure - Subsequent Event - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="dvax-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="dvax-20231231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="dvax-20231231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="dvax-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureInventoriesNetSummaryOfInventoriesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:href="dvax-20231231.xsd#DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail" xlink:href="dvax-20231231.xsd#DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail2" xlink:href="dvax-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails" xlink:href="dvax-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails" xlink:href="dvax-20231231.xsd#DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:href="dvax-20231231.xsd#DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail" xlink:href="dvax-20231231.xsd#DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" xlink:href="dvax-20231231.xsd#DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail" xlink:href="dvax-20231231.xsd#DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="dvax-20231231.xsd#DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="dvax-20231231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables" xlink:href="dvax-20231231.xsd#Role_DisclosureRevenueRecognitionTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureOrganizationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="dvax-20231231.xsd#DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail" xlink:href="dvax-20231231.xsd#DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail" xlink:href="dvax-20231231.xsd#DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureInventoriesNetAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" xlink:href="dvax-20231231.xsd#DisclosureConvertibleNotesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureLongTermDebtAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails" xlink:href="dvax-20231231.xsd#DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails" xlink:href="dvax-20231231.xsd#DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails" xlink:href="dvax-20231231.xsd#DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails" xlink:href="dvax-20231231.xsd#DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail" xlink:href="dvax-20231231.xsd#DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#DisclosureCommonStockAndWarrantsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail" xlink:href="dvax-20231231.xsd#DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails" xlink:href="dvax-20231231.xsd#DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="dvax-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="dvax-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganization" xlink:href="dvax-20231231.xsd#Role_DisclosureOrganization" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="dvax-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="dvax-20231231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:href="dvax-20231231.xsd#Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNet" xlink:href="dvax-20231231.xsd#Role_DisclosureInventoriesNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNet" xlink:href="dvax-20231231.xsd#Role_DisclosureIntangibleAssetsNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="dvax-20231231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilities1" xlink:href="dvax-20231231.xsd#DisclosureCurrentAccruedLiabilities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="dvax-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements" xlink:href="dvax-20231231.xsd#Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotes" xlink:href="dvax-20231231.xsd#DisclosureConvertibleNotes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt" xlink:href="dvax-20231231.xsd#Role_DisclosureLongTermDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognition" xlink:href="dvax-20231231.xsd#Role_DisclosureRevenueRecognition" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShare1" xlink:href="dvax-20231231.xsd#DisclosureNetLossIncomePerShare1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrants" xlink:href="dvax-20231231.xsd#DisclosureCommonStockAndWarrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensation" xlink:href="dvax-20231231.xsd#Role_DisclosureEquityPlansAndStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan" xlink:href="dvax-20231231.xsd#Role_DisclosureEmployeeBenefitPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuring" xlink:href="dvax-20231231.xsd#Role_DisclosureRestructuring" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="dvax-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvent" xlink:href="dvax-20231231.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dvax-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="dvax-20231231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables" xlink:href="dvax-20231231.xsd#Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetTables" xlink:href="dvax-20231231.xsd#Role_DisclosureInventoriesNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetTables" xlink:href="dvax-20231231.xsd#Role_DisclosureIntangibleAssetsNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="dvax-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesTables" xlink:href="dvax-20231231.xsd#DisclosureCurrentAccruedLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="dvax-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesTables" xlink:href="dvax-20231231.xsd#DisclosureConvertibleNotesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareTables" xlink:href="dvax-20231231.xsd#DisclosureNetLossIncomePerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="dvax-20231231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationTables" xlink:href="dvax-20231231.xsd#Role_DisclosureEquityPlansAndStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringTables" xlink:href="dvax-20231231.xsd#Role_DisclosureRestructuringTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="dvax-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseExpenseDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail" xlink:href="dvax-20231231.xsd#Role_DisclosureRestructuringAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail" xlink:href="dvax-20231231.xsd#DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UpfrontPayment" xlink:label="dvax_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_StockOptionsAndShareAwardsMember" xlink:label="dvax_StockOptionsAndShareAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ContingentMilestonePaymentReceivable" xlink:label="dvax_ContingentMilestonePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" xlink:label="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="us-gaap_PurchaseObligationDueInFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember" xlink:label="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CappedCallsPolicyTextBlock" xlink:label="dvax_CappedCallsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMediumTermNotes" xlink:label="us-gaap_InterestExpenseMediumTermNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LicenseArrangementContingentConsiderationPercentage" xlink:label="dvax_LicenseArrangementContingentConsiderationPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LaboratoryEquipmentGross" xlink:label="dvax_LaboratoryEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance" xlink:label="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" xlink:label="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ComputerEquipmentGross" xlink:label="dvax_ComputerEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" xlink:label="dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:label="us-gaap_ContractWithCustomerAssetPastDueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeveranceAndOtherTerminationBenefitsMember" xlink:label="dvax_SeveranceAndOtherTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises" xlink:label="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsFairValueAssumptionsVolatility" xlink:label="dvax_WarrantsFairValueAssumptionsVolatility"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LaboratoryMember" xlink:label="dvax_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SymphonyDynamoHoldingsLlcMember" xlink:label="dvax_SymphonyDynamoHoldingsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock" xlink:label="dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock" xlink:label="dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets" xlink:label="dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DusseldorfLeaseMember" xlink:label="dvax_DusseldorfLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ThirdLargestCustomerMember" xlink:label="dvax_ThirdLargestCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount" xlink:label="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EarningsPerShareDisclosureLineItems" xlink:label="dvax_EarningsPerShareDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashEquivalentsMaturityPeriod" xlink:label="dvax_CashEquivalentsMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SublicenseAgreementMember" xlink:label="dvax_SublicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsExpirationDate" xlink:label="dvax_WarrantsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants" xlink:label="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CommonStockSalesAgreementAggregateSalesProceeds" xlink:label="dvax_CommonStockSalesAgreementAggregateSalesProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TimeBasedVestingScheduleMember" xlink:label="dvax_TimeBasedVestingScheduleMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CloverAmendmentNoTwoMember" xlink:label="dvax_CloverAmendmentNoTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoriesMember" xlink:label="us-gaap_InventoriesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ClassOfWarrantOrRightIssued" xlink:label="dvax_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AggregateMinimumCommitment" xlink:label="dvax_AggregateMinimumCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CollaborationRevenueMember" xlink:label="dvax_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal" xlink:label="us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HortonStreetMasterLeaseMember" xlink:label="dvax_HortonStreetMasterLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OtherLongTermLiabilitiesMember" xlink:label="dvax_OtherLongTermLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsFairValueAssumptionsRiskFreeRate" xlink:label="dvax_WarrantsFairValueAssumptionsRiskFreeRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan" xlink:label="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseDecreaseInPrepaidManufacturing" xlink:label="dvax_IncreaseDecreaseInPrepaidManufacturing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromCashReceived" xlink:label="dvax_ProceedsFromCashReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock" xlink:label="dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CombinedPriceOfPreferredStockAndWarrant" xlink:label="dvax_CombinedPriceOfPreferredStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BillAndMelindaGatesFoundationMember" xlink:label="dvax_BillAndMelindaGatesFoundationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock" xlink:label="dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SupplyAgreementMember" xlink:label="dvax_SupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="us-gaap_RestructuringReserveAcceleratedDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DescriptionOfAveciaSupplyAgreement" xlink:label="dvax_DescriptionOfAveciaSupplyAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CappedCallsMember" xlink:label="dvax_CappedCallsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" xlink:label="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentMadeForPreCommercializationMilestone" xlink:label="dvax_PaymentMadeForPreCommercializationMilestone"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OtherRevenueMember" xlink:label="dvax_OtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MedigenVaccineBiologicsMember" xlink:label="dvax_MedigenVaccineBiologicsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SerumInstituteOfIndiaPrivateLimitedMember" xlink:label="dvax_SerumInstituteOfIndiaPrivateLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember" xlink:label="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" xlink:label="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount" xlink:label="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock" xlink:label="dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AssetPurchaseAgreementMember" xlink:label="dvax_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived" xlink:label="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount" xlink:label="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromWarrantsSale" xlink:label="dvax_ProceedsFromWarrantsSale"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PreferredStockDeemedDividend" xlink:label="dvax_PreferredStockDeemedDividend"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UpfrontPaymentReceivable" xlink:label="dvax_UpfrontPaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AdvancePaymentFromCustomer" xlink:label="dvax_AdvancePaymentFromCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="us-gaap_PurchaseObligationDueInFourthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PriceOfCommonStock" xlink:label="dvax_PriceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PreferredStockCommonStockAndWarrantsAbstract" xlink:label="dvax_PreferredStockCommonStockAndWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_GrantAgreementMember" xlink:label="dvax_GrantAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfStockOptions" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxReconciliationDeferredCompensationCharges" xlink:label="dvax_IncomeTaxReconciliationDeferredCompensationCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LargestCollaborationPartnerMember" xlink:label="dvax_LargestCollaborationPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NumberOfCommonStockWarrantExercised" xlink:label="dvax_NumberOfCommonStockWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PrepaymentOfAdvancePayment" xlink:label="dvax_PrepaymentOfAdvancePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForNotesReceivableMember" xlink:label="us-gaap_AllowanceForNotesReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentToHoldings" xlink:label="dvax_PaymentToHoldings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm" xlink:label="dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PrepaidManufacturing" xlink:label="dvax_PrepaidManufacturing"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromGrant" xlink:label="dvax_ProceedsFromGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentAdditionalIssueAmount" xlink:label="dvax_DebtInstrumentAdditionalIssueAmount"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus" xlink:label="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfLongLivedAssets" xlink:label="dvax_PercentageOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCappedCallOptionsSeeNote10" xlink:label="dvax_IssuanceOfCappedCallOptionsSeeNote10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock" xlink:label="dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ValnevaSEMember" xlink:label="dvax_ValnevaSEMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember" xlink:label="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TermLoanMember" xlink:label="dvax_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ModifiedPurchaseOrderMember" xlink:label="dvax_ModifiedPurchaseOrderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity" xlink:label="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance" xlink:label="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CumulativeTranslationAdjustmentNetOfTax" xlink:label="dvax_CumulativeTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock" xlink:label="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NetOperatingLossAndTaxCreditLimitations" xlink:label="dvax_NetOperatingLossAndTaxCreditLimitations"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentReceivedForPreCommercializationMilestone" xlink:label="dvax_PaymentReceivedForPreCommercializationMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodStartDate" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodStartDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CaliforniaAndOtherStatesTaxAuthorityMember" xlink:label="dvax_CaliforniaAndOtherStatesTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock" xlink:label="dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan" xlink:label="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind" xlink:label="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock" xlink:label="dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AmountPaidToThirdParty" xlink:label="dvax_AmountPaidToThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SecondLargestCollaborationPartnerMember" xlink:label="dvax_SecondLargestCollaborationPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashSettlementOfWarrants" xlink:label="dvax_CashSettlementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashSettlement" xlink:label="dvax_CashSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_GlobalAccessAndStrategyCommitmentAgreementMember" xlink:label="dvax_GlobalAccessAndStrategyCommitmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsAccruals" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeriesBConvertiblePreferredStockMember" xlink:label="dvax_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxDisclosureTable" xlink:label="dvax_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwoThousandTwentyATMAgreementMember" xlink:label="dvax_TwoThousandTwentyATMAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LargestCustomerMember" xlink:label="dvax_LargestCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" xlink:label="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount" xlink:label="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_USDepartmentOfDefenseMember" xlink:label="dvax_USDepartmentOfDefenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused" xlink:label="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MerckMember" xlink:label="dvax_MerckMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:label="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BainLifeSciencesMember" xlink:label="dvax_BainLifeSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember" xlink:label="us-gaap_RestructuringChargesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PtBioFarmaPerseroMember" xlink:label="dvax_PtBioFarmaPerseroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SecondLargestCustomerMember" xlink:label="dvax_SecondLargestCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_Cpg1018AdjuvantInventoryMember" xlink:label="dvax_Cpg1018AdjuvantInventoryMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NonCashInterestExpense" xlink:label="dvax_NonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetSale" xlink:label="us-gaap_ContractWithCustomerAssetSale"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_RevenueReserveAccrualsMember" xlink:label="dvax_RevenueReserveAccrualsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NumberOfCommonStockPreferredStockConvertibleInto" xlink:label="dvax_NumberOfCommonStockPreferredStockConvertibleInto"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BainCapitalLifeSciencesFundLimitedPartnerMember" xlink:label="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BadDebtExpense" xlink:label="dvax_BadDebtExpense"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EarningsPerShareDisclosureTable" xlink:label="dvax_EarningsPerShareDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PowellStreetSubleaseMember" xlink:label="dvax_PowellStreetSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetPurchase" xlink:label="us-gaap_ContractWithCustomerAssetPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccruedInventory" xlink:label="dvax_AccruedInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UnvestedMember" xlink:label="dvax_UnvestedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LongTermDeferredRevenueMember" xlink:label="dvax_LongTermDeferredRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PerformanceBasedRestrictedStockUnitsMember" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeutscheBankSecuritiesMember" xlink:label="dvax_DeutscheBankSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember" xlink:label="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeferredRevenueSubtractions" xlink:label="dvax_DeferredRevenueSubtractions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NetOperatingLossAndTaxCreditLimitation" xlink:label="dvax_NetOperatingLossAndTaxCreditLimitation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeriesCConvertiblePreferredStocksMember" xlink:label="dvax_SeriesCConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SublicenseLiabilityMember" xlink:label="dvax_SublicenseLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OperatingLossCarryforwardExpirationYear" xlink:label="dvax_OperatingLossCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CaliforniaStateTaxAuthorityMember" xlink:label="dvax_CaliforniaStateTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TrisalusLifeSciencesMember" xlink:label="dvax_TrisalusLifeSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SuretyBondMember" xlink:label="us-gaap_SuretyBondMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_Section162MLimitation" xlink:label="dvax_Section162MLimitation"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EmployeeSeveranceAndOtherBenefitsMember" xlink:label="dvax_EmployeeSeveranceAndOtherBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_InventoryWriteOffsRecognized" xlink:label="dvax_InventoryWriteOffsRecognized"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_StockBasedCompensationExpenseMember" xlink:label="dvax_StockBasedCompensationExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException" xlink:label="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwentySeventeenAtTheMarketAgreementMember" xlink:label="dvax_TwentySeventeenAtTheMarketAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BiologicalELimitedMember" xlink:label="dvax_BiologicalELimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesCompletionDate" xlink:label="us-gaap_RestructuringAndRelatedActivitiesCompletionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LoanAgreementMember" xlink:label="dvax_LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueAdjustmentsOfWarrants" xlink:label="dvax_FairValueAdjustmentsOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReservationAgreementMember" xlink:label="dvax_ReservationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_RepaymentOfAdvanceFromCustomer" xlink:label="dvax_RepaymentOfAdvanceFromCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccrualLongTermBalance" xlink:label="dvax_AccrualLongTermBalance"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract" xlink:label="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessRemovalOfChangeInFairValueOfWarrantLiability" xlink:label="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleSeniorNotesMember" xlink:label="dvax_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCustomer" xlink:label="us-gaap_ConcentrationRiskCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_RevenueReserveAccrualCurrent" xlink:label="dvax_RevenueReserveAccrualCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleOptionalSeniorNotesMember" xlink:label="dvax_ConvertibleOptionalSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfExcessRentPaidToLandlord" xlink:label="dvax_PercentageOfExcessRentPaidToLandlord"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxDisclosureLineItems" xlink:label="dvax_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" xlink:label="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeferredTaxAssetsLeaseLiability" xlink:label="dvax_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization" xlink:label="dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" xlink:label="dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AcceleratedDepreciationMember" xlink:label="dvax_AcceleratedDepreciationMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentsForPurchaseOfCappedCallOptions" xlink:label="dvax_PaymentsForPurchaseOfCappedCallOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:label="us-gaap_PurchaseObligationDueAfterFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CRGServicingLLCMember" xlink:label="dvax_CRGServicingLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseDecreaseInCepiAccrual" xlink:label="dvax_IncreaseDecreaseInCepiAccrual"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue" xlink:label="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" xlink:label="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LicenseArrangementContingentPaymentToAcquireLicense" xlink:label="dvax_LicenseArrangementContingentPaymentToAcquireLicense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="dvax_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ServicesAndMaterialsMember" xlink:label="dvax_ServicesAndMaterialsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:label="dvax_UndistributedEarningsAllocatedToParticipatingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReservesAccrualBalance" xlink:label="dvax_ReservesAccrualBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AdditionalFuturePayment" xlink:label="dvax_AdditionalFuturePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract" xlink:label="dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseDecreaseInLeaseLiabilities" xlink:label="dvax_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PreferredStockConversionPricePerShare" xlink:label="dvax_PreferredStockConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MarketBasedPerformanceStockUnitMember" xlink:label="dvax_MarketBasedPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_VestedMember" xlink:label="dvax_VestedMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TaxCreditCarryforwardExpirationYear" xlink:label="dvax_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity" xlink:label="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsIssuanceDate" xlink:label="dvax_WarrantsIssuanceDate"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ThirdLargestCollaborationPartnerMember" xlink:label="dvax_ThirdLargestCollaborationPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentConversionPeriodOneMember" xlink:label="dvax_DebtInstrumentConversionPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MerckSharpAndDohmeCorporationMember" xlink:label="dvax_MerckSharpAndDohmeCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxReconciliationTaxCredit" xlink:label="dvax_IncomeTaxReconciliationTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PerformanceBasedVestingScheduleMember" xlink:label="dvax_PerformanceBasedVestingScheduleMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CepiAccrualLongTerm" xlink:label="dvax_CepiAccrualLongTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:label="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsFairValueAssumptionsDividendYield" xlink:label="dvax_WarrantsFairValueAssumptionsDividendYield"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" xlink:label="dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentConversionPeriodTwoMember" xlink:label="dvax_DebtInstrumentConversionPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension and Other Postretirement Benefits Cost (Reversal of Cost) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance at December 31</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_StockOptionsAndShareAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options and share awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_StockOptionsAndShareAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options And Share Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_StockOptionsAndShareAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reduction in global workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ContingentMilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent milestone payment receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ContingentMilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Milestone Payment Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ContingentMilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions related to current period sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue Allowance And Reserves Provision Related To Current Period Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product revenue allowance and reserves provision related to current period sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Cost And Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Other, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Fair Value Warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Clover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zhejiang Clover Biopharmaceuticals Inc And Clover Hong Kong Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zhejiang clover biopharmaceuticals, inc and clover hong kong inc member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Upon Exercise Of Stock Options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock Upon Exercise Of Stock Options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CappedCallsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capped Calls</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CappedCallsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capped Calls Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CappedCallsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capped Calls Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseMediumTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Add: interest expense on convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseMediumTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Medium-term Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available-for-Sale Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LicenseArrangementContingentConsiderationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License arrangement contingent consideration percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LicenseArrangementContingentConsiderationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Arrangement Contingent Consideration Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LicenseArrangementContingentConsiderationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License arrangement contingent consideration percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Lives (In years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LaboratoryEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Equipment Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LaboratoryEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LaboratoryEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to non-vested equity awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Disaggregation of Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PledgingPurposeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pledging Purpose [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in number of employee stock purchase plan shares authorized for issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in aggregate number of shares of common stock authorized for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in unrealized gain on marketable securities available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Unrealized Gain On Marketable Securities Available For Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized loss on marketable securities available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ComputerEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment, Gross.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ComputerEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ComputerEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of the convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt, Fair Value Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: undistributed earnings allocated to Series B and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deduction of Undistributed Earnings Allocated to Series B and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deduction of undistributed earnings allocated to Series B and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetPastDueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Asset Account, [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetPastDueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, Past Due [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SeveranceAndOtherTerminationBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance and other termination benefits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SeveranceAndOtherTerminationBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance And Other Termination Benefits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SeveranceAndOtherTerminationBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance and Other Termination Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor sublease rentals payments to be received due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Sublease Rentals Payments To Be Received Due [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common stock held not to exceed by holder and affiliates for warrant exercises.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Stock Held Not To Exceed By Holder And Affiliates For Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock held not to exceed for warrant exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized in the current period included in deferred revenue balance at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock redeemed during period shares conversion of convertible securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Redeemed During Period Shares Conversion Of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Redeemed During Period, Shares, Conversion of Convertible Securities (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsFairValueAssumptionsVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants fair value assumptions volatility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsFairValueAssumptionsVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Fair Value Assumptions Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsFairValueAssumptionsVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding stock awards granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SymphonyDynamoHoldingsLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Symphony Dynamo Holdings LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SymphonyDynamoHoldingsLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Symphony Dynamo Holdings Llc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SymphonyDynamoHoldingsLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Symphony Dynamo Holdings Llc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SymphonyDynamoHoldingsLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Symphony Dynamo Holdings LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor sublease rentals payments to be received due year three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Sublease Rentals Payments To Be Received Due Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Interest Expenses Related to Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Convertible Notes Interest Expense Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of convertible notes interest expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balances (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balances (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Newly reserved shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of positions reduced in global workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and financial condition disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Financial Condition Disclosure Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Financial Condition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of contract asset from other current assets to other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification of contract asset from other current assets to other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of contract asset from other current assets to other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Component of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options expired (vested)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax positions related to the prior year, Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Income Tax Provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DusseldorfLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Dusseldorf Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DusseldorfLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Dusseldorf Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DusseldorfLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Dusseldorf Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non U.S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating lease right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ThirdLargestCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Largest Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ThirdLargestCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Largest Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ThirdLargestCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third largest Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Share-Based Payments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Allowance for doubtful accounts receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivables, net of allowance for doubtful accounts of $12,313 and $0 at December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax positions related to the prior year, Settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liabilities (included in other current liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions to Estimate the Fair Value of Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fourteen employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of financial instrument transfer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Asset &amp; Liability Level 2 to Level 1 Transfer Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers from level 2 to level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance and other termination benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mature in one year or less</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EarningsPerShareDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnings per share disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EarningsPerShareDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EarningsPerShareDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashEquivalentsMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents maturity period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashEquivalentsMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashEquivalentsMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents original maturity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SublicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SublicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SublicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation And Qualifying Accounts Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest- free unsecured forgivable loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financing Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants Called for purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax rate reconciliation mark to market of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Rate Reconciliation Mark To Market Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mark-to-market of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses and current accrued liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses And Accrued Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CommonStockSalesAgreementAggregateSalesProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock sales agreement aggregate sales proceeds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CommonStockSalesAgreementAggregateSalesProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Sales Agreement Aggregate Sales Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CommonStockSalesAgreementAggregateSalesProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock sales agreement aggregate sales proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-US</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TimeBasedVestingScheduleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Time based vesting schedule.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TimeBasedVestingScheduleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Time Based Vesting Schedule [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TimeBasedVestingScheduleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time Based Vesting Schedule</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income before income taxes, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CloverAmendmentNoTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clover Amendment No Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CloverAmendmentNoTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clover Amendment No Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CloverAmendmentNoTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clover Amendment No 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventories [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoriesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock or Unit Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation expense related to restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of realized gain on available-for-sale securities recognized in interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, Allowance for Credit Loss, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AggregateMinimumCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate minimum commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AggregateMinimumCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Minimum Commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AggregateMinimumCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate minimum commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest related to unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash proceeds received from issuance or sale of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net cash proceeds received from issuance or sale of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract asset, reclassification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, Change in Method, Credit Loss Expense (Reversal)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CpG1018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product CpG 1018.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CpG1018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cp G1018 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CpG1018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CpG 1018</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_HortonStreetMasterLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Horton street master lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_HortonStreetMasterLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Horton Street Master Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_HortonStreetMasterLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Horton Street Master Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_HortonStreetMasterLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Horton Street Master Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Raw Materials, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Non-vested, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Non-vested, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock unit awards outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Sublease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax provision (benefit) at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OtherLongTermLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other Long Term Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OtherLongTermLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Long Term Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OtherLongTermLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Long Term Liabilities Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor sublease rentals payments to be received due year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Sublease Rentals Payments To Be Received Due Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash, Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsFairValueAssumptionsRiskFreeRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants fair value assumptions risk free rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsFairValueAssumptionsRiskFreeRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Fair Value Assumptions Risk Free Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsFairValueAssumptionsRiskFreeRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The commencement of the offer period (generally, the sixteenth day in February or August)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares purchased by employees under employee purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Purchased By Employees Under Employee Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued to employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions to 401 (k) plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInPrepaidManufacturing_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid manufacturing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInPrepaidManufacturing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in prepaid manufacturing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInPrepaidManufacturing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Manufacturing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInPrepaidManufacturing_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Prepaid manufacturing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromCashReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">proceeds from cash received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromCashReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Cash Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromCashReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Received Net Cash Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss) allocable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CEPI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coalition for Epidemic Preparedness Innovations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coalition For Epidemic Preparedness Innovations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Coalition for Epidemic Preparedness Innovations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reconciliation of cash, cash equivalents and restricted cash to the statement of cash flows.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Cash Cash Equivalents And Restricted Cash To Statement Of Cash Flows Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CombinedPriceOfPreferredStockAndWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined price of preferred stock and warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CombinedPriceOfPreferredStockAndWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined Price Of Preferred Stock And Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CombinedPriceOfPreferredStockAndWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined price of preferred stock and warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized foreign currency translation (loss) gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-US</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bill And Melinda Gates Foundation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bill And Melinda Gates Foundation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bill &amp; Melinda Gates Foundation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Component of Current Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued liabilities and accrued research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities And Accrued Research And Development Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuances of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options cancelled:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares remaining available for future purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock: $0.001 par value; 278,000 shares authorized at December 31, 2023, and 2022; 129,530 shares and 127,604 shares issued and outstanding at December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, conversion price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Sublease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Existence of option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Repayment of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Realized foreign currency translation (loss) gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency transaction gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2019</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2018</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Reserve, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveAcceleratedDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Accelerated Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveAcceleratedDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accelerated depreciation charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveAcceleratedDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accelerated depreciation related to certain long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities (Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">(Loss) income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DescriptionOfAveciaSupplyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Avecia Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DescriptionOfAveciaSupplyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Avecia Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DescriptionOfAveciaSupplyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of Avecia Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total deferred tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CappedCallsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capped Calls</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CappedCallsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capped Calls [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CappedCallsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capped Calls</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax positions related to the prior year, Reductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities and redemptions of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash payments or settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of product revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of stock options and restricted stock awards net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options and release of restricted stock awards, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentMadeForPreCommercializationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment made for pre commercialization milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentMadeForPreCommercializationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Made for Pre Commercialization Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentMadeForPreCommercializationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment made for pre-commercialization milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OtherRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OtherRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OtherRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MedigenVaccineBiologicsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Medigen</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MedigenVaccineBiologicsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medigen Vaccine Biologics [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MedigenVaccineBiologicsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medigen Vaccine Biologics Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance Of Common Stock Upon Release Of Restricted Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Upon Release Of Restricted Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock Upon Release Of Restricted Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash cash equivalents and marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Cash Equivalents And Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at End of Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at Beginning of Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid during the year for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SerumInstituteOfIndiaPrivateLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Serum Institute of India Private Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SerumInstituteOfIndiaPrivateLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Serum Institute Of India Private Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SerumInstituteOfIndiaPrivateLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Serum Institute of India Pvt. Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss), net of tax:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dynavax Technologies Corporation inducement award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dynavax Technologies Corporation Inducement Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dynavax Technologies Corporation 2021 Inducement Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance at December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit or payments made during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue Allowance And Reserves Credit Or Payments Made During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product revenue allowance and reserves credit or payments made during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustment , Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustment , Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax positions related to the current year, Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon release of restricted stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Upon Release Of Restricted Stock Awards Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock Upon Release Of Restricted Stock Awards Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non U.S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets (Note 9 )</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of balance sheet components of operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Balance Sheet Components Of Operating Lease Liabilities Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Balance Sheet Classification of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Asset Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid during the year for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customers expected period of payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customers Expected Period Of Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected period of payment to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended two thousand and eighteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Two Thousand And Eighteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended 2018 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Operating Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingency Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum borrowing capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum borrowing capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Stock Warrants Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of transfer of financial instruments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Asset &amp; Liability Level 1 to Level 2 Transfer Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer from level 1 to level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of stock options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromWarrantsSale_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds From Warrants Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromWarrantsSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Warrants Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromWarrantsSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">proceeds from warrants sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_HEPLISAVBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">HEPLISAV-B.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_HEPLISAVBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">H E P L I S A V B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_HEPLISAVBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HEPLISAV-B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PreferredStockDeemedDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock deemed dividend.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PreferredStockDeemedDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Deemed Dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PreferredStockDeemedDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock deemed dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PreferredStockDeemedDividend_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Preferred stock deemed dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of sales - amortization of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon release of restricted stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings(share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings(share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument interest rate, effective percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AdvancePaymentFromCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Advance payment from customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AdvancePaymentFromCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance Payments forgiven per CEPI-Bio E Assignment Agreement (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AdvancePaymentFromCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Payment From Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AdvancePaymentFromCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance payment from customer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInFourthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInFourthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net (loss) income per share allocable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Price of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Price Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory write-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Write-down</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PreferredStockCommonStockAndWarrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock common Stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PreferredStockCommonStockAndWarrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Common Stock And Warrants [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity Under Stock-Based Compensation Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_GrantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_GrantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_GrantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Upon Exercise Of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock Upon Exercise Of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxReconciliationDeferredCompensationCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation deferred compensation charges.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxReconciliationDeferredCompensationCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Deferred Compensation Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxReconciliationDeferredCompensationCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred compensation charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based Vesting Condition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of balances and activities in our contract asset account</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial cap price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Capped Call Transaction Initial Cap Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument capped call transaction initial cap price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LargestCollaborationPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Largest Collaboration Partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LargestCollaborationPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Largest Collaboration Partner [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LargestCollaborationPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Largest collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease income and operating lease liability maturity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income And Operating Lease Liability Maturity Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturities of Sublease Income and Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NumberOfCommonStockWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock warrant exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NumberOfCommonStockWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Stock Warrant Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NumberOfCommonStockWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of sales - product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Award Types</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for doubtful accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common stock to be held by holder and affiliates for exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Stock To Be Held By Holder And Affiliates For Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock to be held for exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net (loss) income per share allocable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PrepaymentOfAdvancePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment of advance payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PrepaymentOfAdvancePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment of advance payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PrepaymentOfAdvancePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment of advance payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Sales - Product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Balance at Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Balance at Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForNotesReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Allowance, Notes Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForNotesReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentToHoldings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment to holdings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentToHoldings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment To Holdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentToHoldings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to holdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of CEPI accrual to CEPI accrual long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification of CEPI accrual to CEPI accrual long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of CEPI accrual to CEPI accrual long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PrepaidManufacturing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Manufacturing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PrepaidManufacturing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Manufacturing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PrepaidManufacturing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid manufacturing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in fair value of warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair value measurement with unobservable inputs reconciliation recurring basis liability period decrease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability period decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingency, Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentAdditionalIssueAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional issue amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentAdditionalIssueAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Additional Issue Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentAdditionalIssueAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument additional issue amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments for taxes related to net share settlement of RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for taxes related to net share settlement of RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for taxes related to net share settlement of RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for taxes related to net share settlement of RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Underlying Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of long lived assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Long Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of long lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCappedCallOptionsSeeNote10_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of capped call options (see Note 10)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCappedCallOptionsSeeNote10_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of capped call options (see Note 10)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasuries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturities of marketable securities available for sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturities Of Marketable Securities Available For Sale Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of Marketable Securities Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CEPI Partners</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coalition for Epidemic Preparedness Innovations Partners [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coalition for epidemic preparedness innovations partners.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Restructuring and Related Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restructuring And Related Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mature in one year or less</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ValnevaSEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Valneva SE.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ValnevaSEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valneva S E [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ValnevaSEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valneva SE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emeryville, California and Dusseldorf, Germany [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emeryville, California and Dusseldorf, Germany [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emeryville, California and Dusseldorf, Germany</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial conversion rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, convertible, threshold consecutive trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits would affect the effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options cancelled:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Present value adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ModifiedPurchaseOrderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Modified Purchase Order [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ModifiedPurchaseOrderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Modified Purchase Order [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ModifiedPurchaseOrderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modified Purchase Order</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fee payable upon partial prepayment or maturity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Fee Payable Upon Partial Prepayment Or Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fee payable upon partial prepayment or maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, covenant daily minimum combined cash and investment balance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Covenant Daily Minimum Combined Cash And Investment Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, covenant daily minimum combined cash and investment balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from warrants exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: preferred stock deemed dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividends, Income Statement Impact</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CumulativeTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative translation adjustment net of tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CumulativeTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Translation Adjustment Net Of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CumulativeTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Long-Term Debt, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current borrowing capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Selling commission percentage from gross offering proceeds of sales of stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling Commission Percentage From Gross Offering Proceeds Of Sales Of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commission on gross sales proceeds of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers in or out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Not Found During Migration Deprecated Concept Lease Arrangement Type Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Not Found During Migration Deprecated Concept Lease Arrangement Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Not Found During Migration Deprecated Concept Lease Arrangement Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NetOperatingLossAndTaxCreditLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss and tax credit limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NetOperatingLossAndTaxCreditLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss and Tax Credit Limitations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NetOperatingLossAndTaxCreditLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss and tax credit limitations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentReceivedForPreCommercializationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment received for pre-commercialization milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentReceivedForPreCommercializationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Received For Pre Commercialization Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentReceivedForPreCommercializationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment received for pre-commercialization milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, redemption earliest date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption Period, Start Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CaliforniaAndOtherStatesTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">California and other states tax authority.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CaliforniaAndOtherStatesTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California And Other States Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CaliforniaAndOtherStatesTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California and Other States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Amount Capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Material Purchase Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of material purchase commitments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of material purchase commitments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for purchases under employee purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Purchases Under Employee Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares remaining available for future purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Security Category [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Security Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount of collateralized debt obligations, plus interest-in-kind, with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Long Term Debt Noncurrent Plus Interest In Kind</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount including interest paid in kind</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Performance Based Restricted Stock Unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Performance Based Restricted Stock Unit Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of performance based restricted stock unit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts and Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Accounts and other receivables, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor sublease rentals payments to be received due thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Sublease Rentals Payments To Be Received Due Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, weighted-average vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance (withholding) of common stock upon exercise of options vesting of restricted stock units and vesting of early exercised options net value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AmountPaidToThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount paid to third party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AmountPaidToThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Paid To Third Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AmountPaidToThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount paid to third party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SecondLargestCollaborationPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Largest Collaboration Partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SecondLargestCollaborationPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Largest Collaboration Partner [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SecondLargestCollaborationPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second largest collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Research, Development and License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashSettlementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Settlement of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashSettlementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Settlement of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashSettlementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash settlement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, convertible, threshold trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Threshold Trading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_GlobalAccessAndStrategyCommitmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Global access and strategy/commitment agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_GlobalAccessAndStrategyCommitmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Global Access And Strategy Commitment Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_GlobalAccessAndStrategyCommitmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Global Access and Strategy/Commitment Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coalition for Epidemic Preparedness Innovations Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coalition for Epidemic Preparedness Innovations accruals.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CEPI accrual (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: removal of change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability (Note 14)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work-in-process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock upon exercise of warrants (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon exercise of warrants (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options forfeited (unvested)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in the estimated fair value of warrant liability upon revaluation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (Decrease) in estimated fair value of warrant liability upon revaluation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwoThousandTwentyATMAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty ATM Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwoThousandTwentyATMAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty A T M Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwoThousandTwentyATMAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 ATM Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Inventory, Current [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LargestCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Largest Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LargestCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Largest Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LargestCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Largest Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments related to prior periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue Allowance And Reserves Adjustments Related To Prior Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product Revenue Allowance And Reserves Adjustments Related To Prior Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt conversion, original debt, principal amount converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Conversion Original Debt Base Principal Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument conversion original debt base principal amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from long-term debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from the initial term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PledgingPurposeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pledging Purpose [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_USDepartmentOfDefenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Department of Defense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_USDepartmentOfDefenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U S Department of Defense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_USDepartmentOfDefenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Department Of Defense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing basic net (loss) income per share allocable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum age approved for vaccine prevention of infection caused.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Age Approved For Vaccine Prevention Of Infection Caused</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum age approved for vaccine prevention of infection caused</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Costs [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Major Components of Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MerckMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merck.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MerckMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merck [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MerckMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merck</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of principal redeemed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Non-vested Restricted Stock Units Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on debt extinguishment (Note 11)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Loss on debt extinguishment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure computation of basic and diluted earnings per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Computation Of Basic And Diluted Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BainLifeSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bain life sciences.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BainLifeSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bain Life Sciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BainLifeSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bain Life Sciences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Cost Incurred to Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Costs Incurred for the Year Ended December 31, 2019</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value-Based Measurements and Weighted-Average Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringChargesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringChargesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PtBioFarmaPerseroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PT Bio Farma (Persero) is related to Collaboration, Development and Supply Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PtBioFarmaPerseroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PT Bio Farma (Persero) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PtBioFarmaPerseroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PT Bio Farma (Persero)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax positions related to the current year, Reductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding securities not included in diluted net (loss) income allocable to common stockholders per share calculation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Notes (as converted to common stock)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SecondLargestCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Largest Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SecondLargestCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Largest Customer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SecondLargestCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second largest Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor sublease rentals payments to be received due year two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Sublease Rentals Payments To Be Received Due Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_Cpg1018AdjuvantInventoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CpG 1018 Adjuvant Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_Cpg1018AdjuvantInventoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CpG 1018 adjuvant inventory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_Cpg1018AdjuvantInventoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CpG 1018 Adjuvant Inventory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Cash Equivalents And Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Component of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax positions related to the prior year, Lapses in statute</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash interest expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Amortization of premiums (accretion of discounts) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract asset, additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_RevenueReserveAccrualsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue reserve accruals.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_RevenueReserveAccrualsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Reserve Accruals [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_RevenueReserveAccrualsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Reserve Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NumberOfCommonStockPreferredStockConvertibleInto_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock preferred stock convertible into.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NumberOfCommonStockPreferredStockConvertibleInto_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Preferred Stock Convertible Into</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NumberOfCommonStockPreferredStockConvertibleInto_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock allowed to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantor Obligations, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantor Obligations, Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantor Obligations, Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantor Obligations, Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bain Capital Life Sciences Fund, Limited Partner.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bain Capital Life Sciences Fund Limited Partner [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bain Capital Life Sciences Fund, L.P</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BadDebtExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bad debt expense (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BadDebtExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bad debt expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BadDebtExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bad debt expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common stock to be held by holder and affiliates for conversion of preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Stock To Be Held By Holder And Affiliates For Conversion Of Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock to be held for conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EarningsPerShareDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnings per share disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EarningsPerShareDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EarningsPerShareDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PowellStreetSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Powell Street Sublease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PowellStreetSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Powell Street Sublease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PowellStreetSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Powell Street Sublease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetPurchase_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Contract asset, subtractions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, Purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract asset, Subtractions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccruedInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccruedInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccruedInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued inventory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Productive Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of assets, net of transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Productive Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UnvestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UnvestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UnvestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LongTermDeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LongTermDeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Deferred Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LongTermDeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">PSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeutscheBankSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deutsche bank securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeutscheBankSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deutsche Bank Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeutscheBankSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deutsche Bank Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BCIP Life Sciences Associates, Limited Partners.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B C I P Life Sciences Associates Limited Partners [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BCIP Life Sciences Associates, L.P</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of derivative liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, plant and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advances on Inventory Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeferredRevenueSubtractions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subtractions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeferredRevenueSubtractions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue subtractions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeferredRevenueSubtractions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Subtractions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited (unvested)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NetOperatingLossAndTaxCreditLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net operating loss and tax credit limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NetOperatingLossAndTaxCreditLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss and tax credit limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Convertible Notes, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SeriesCConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stocks.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SeriesCConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stocks [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SeriesCConvertiblePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SublicenseLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SublicenseLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SublicenseLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OperatingLossCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforward, expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OperatingLossCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_OperatingLossCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CaliforniaStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">California state tax authority.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CaliforniaStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California State Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CaliforniaStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dynavax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SubsidiariesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dynavax GmbH</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TrisalusLifeSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trisalus Life Sciences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TrisalusLifeSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TriSalus Life Sciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TrisalusLifeSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TriSalus Life Sciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock allowed to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of the Restructuring Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SuretyBondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Surety Bond [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SuretyBondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Surety Bond</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_Section162MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 162(m) limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_Section162MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">section 162 (m) Limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_Section162MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">section 162 (m) Limitation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EmployeeSeveranceAndOtherBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee severance and other benefits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EmployeeSeveranceAndOtherBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Severance And Other Benefits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_EmployeeSeveranceAndOtherBenefitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Severance And Other Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenues from Major Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_InventoryWriteOffsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory write-offs recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_InventoryWriteOffsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory write-offs recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_InventoryWriteOffsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory write-offs recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_StockBasedCompensationExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock-based compensation expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_StockBasedCompensationExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Based Compensation Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_StockBasedCompensationExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of capital stock of subsidiaries subject to certain exception.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Capital Stock Of Subsidiaries Subject To Certain Exception</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of capital stock of subsidiaries subject to certain exception</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, and restricted cash at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, and restricted cash at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwentySeventeenAtTheMarketAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty seventeen at the market agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwentySeventeenAtTheMarketAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Seventeen At The Market Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwentySeventeenAtTheMarketAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 ATM Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BiologicalELimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biological E. Limited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BiologicalELimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biological E Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_BiologicalELimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biological E Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesCompletionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities, Completion Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesCompletionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring completion date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DE_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Germany</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DE_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GERMANY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Non-vested, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Non-vested, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan Agreement Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueAdjustmentsOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Adjustments of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueAdjustmentsOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustments of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueAdjustmentsOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: removal of change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueAdjustmentsOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: removal of change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction to additional paid-in capital, capped calls cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock: $0.001 par value, 5,000 shares authorized at December 31, 2023, and 2022; zero shares outstanding at December 31, 2023 and 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReservationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reservation Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReservationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reservation Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReservationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reservation Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_RepaymentOfAdvanceFromCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of advance from customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_RepaymentOfAdvanceFromCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment of Advance from Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_RepaymentOfAdvanceFromCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayment of Advance from Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccrualLongTermBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual long-term balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccrualLongTermBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrual Long Term Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AccrualLongTermBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrual Long Term Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilutive securities excluded from computation of earning per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earning Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding securities not included in diluted net loss per share calculation (in thousands):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant-Date Fair Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Less: removal of change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Less: removal of change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: removal of change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Undistributed earnings allocated to participating securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: undistributed earnings allocated to participating securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivables, net of allowance for doubtful accounts of $12,313 and $0 at December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Other Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability warrant on issuance date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Warrant On Issuance Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrant liability at issuance date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ConvertibleSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ConvertibleSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ConvertibleSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_RevenueReserveAccrualCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue reserve accrual current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_RevenueReserveAccrualCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Reserve Accrual Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_RevenueReserveAccrualCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue reserve accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ConvertibleOptionalSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Optional Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ConvertibleOptionalSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Optional Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ConvertibleOptionalSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Optional Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfExcessRentPaidToLandlord_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of excess rent paid to landlord.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfExcessRentPaidToLandlord_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Excess Rent Paid To Landlord</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PercentageOfExcessRentPaidToLandlord_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of excess rent paid to landlord</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Asset Account [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance (withholding) of common stock upon exercise of options vesting of restricted stock units and vesting of early exercised options net shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of product revenue allowance and reserve categories.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Product Revenue Allowance And Reserve Categories Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Product Revenue Allowance and Reserve Categories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">DeferredTaxAssetsOperatingLossCarryforwardsCapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DeferredTaxAssetsOperatingLossCarryforwardsCapitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 174 capitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on sale of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Add: undistributed earnings allocated to Series B and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Addition of Undistributed Earnings Allocated to Series B and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Addition of undistributed earnings allocated to Series B and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AcceleratedDepreciationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee severance and other benefits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AcceleratedDepreciationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accelerated Depreciation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AcceleratedDepreciationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accelerated Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentsForPurchaseOfCappedCallOptions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of capped call options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentsForPurchaseOfCappedCallOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Purchase Of Capped Call Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentsForPurchaseOfCappedCallOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of cash outflow for purchase of capped call options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PaymentsForPurchaseOfCappedCallOptions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Purchases of capped call options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Inventories, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cancelable purchase and other commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueAfterFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueAfterFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Not Found During Migration Deprecated Concept Lease Arrangement Type Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Not Found During Migration Deprecated Concept Lease Arrangement Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Not Found During Migration Deprecated Concept Lease Arrangement Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes, net of debt discount of $2,802 and $3,922 at December 31, 2023 and December 31, 2022, respectively (Note 10)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Convertible Notes Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mature after one year through two years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense related to initial term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CRGServicingLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CRG Servicing LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CRGServicingLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C R G Servicing L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CRGServicingLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRG Servicing LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employees and directors stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Expensed and Capitalized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Plans and Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInCepiAccrual_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CEPI accrual (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInCepiAccrual_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Cepi Accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInCepiAccrual_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (Decrease) In Cepi Accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Proceeds to Pay the Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Convertible Notes On Purchase Of Capped Call Options Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of convertible notes on purchase of capped call options value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2.50% Convertible Senior Notes Due 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Notes Due Two Thousand Twenty Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible senior notes due two thousand twenty six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LicenseArrangementContingentPaymentToAcquireLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License arrangement contingent payment to acquire license.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LicenseArrangementContingentPaymentToAcquireLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Arrangement Contingent Payment To Acquire License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LicenseArrangementContingentPaymentToAcquireLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License arrangement upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and eighteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ServicesAndMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Services and Materials.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ServicesAndMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Services And Materials [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ServicesAndMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services and Materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UndistributedEarningsAllocatedToParticipatingSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Undistributed earnings allocated to participating securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UndistributedEarningsAllocatedToParticipatingSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undistributed earnings allocated to participating securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UndistributedEarningsAllocatedToParticipatingSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings Allocated to Participating Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_UndistributedEarningsAllocatedToParticipatingSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Undistributed earnings allocated to participating securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReservesAccrualBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReservesAccrualBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReservesAccrualBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserves Accrual Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ReservesAccrualBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reserves Accrual Balance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AdditionalFuturePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional future payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AdditionalFuturePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional future payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_AdditionalFuturePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional future payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options aggregate intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Penalties related to unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock upon exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Current [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure component of current accrued liabilities and accrued research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Component Of Current Accrued Liabilities And Accrued Research And Development [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income allocable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PreferredStockConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock conversion price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PreferredStockConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Conversion Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PreferredStockConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MarketBasedPerformanceStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Based Performance Stock Unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MarketBasedPerformanceStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Based Performance Stock Unit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MarketBasedPerformanceStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market-based performance stock unit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expired (vested)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative foreign currency translation adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Component of Consolidated (Loss) Income Before Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_VestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_VestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vested [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_VestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward, expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward amount, expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment, not yet paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability under agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock authorized, remaining capacity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Authorized Remaining Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining proceeds from common stock, under sales agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Machinery and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsIssuanceDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issuance date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsIssuanceDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issuance Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsIssuanceDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issuance Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial strike price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Capped Call Transaction Initial Strike Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument capped call transaction initial strike price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Compensation Arrangement with Individual, Share-Based Payments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ThirdLargestCollaborationPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Largest Collaboration Partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ThirdLargestCollaborationPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Largest Collaboration Partner Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_ThirdLargestCollaborationPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third largest collaboration partner member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentConversionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Conversion, Period One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentConversionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Conversion Period One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentConversionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument conversion period one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor sublease rentals payments to be received due year five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Sublease Rentals Payments To Be Received Due Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract asset balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance within raw materials and work-in-process inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process and Raw Materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Work in Process and Raw Materials, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MerckSharpAndDohmeCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merck Sharp and Dohme Corporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MerckSharpAndDohmeCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merck Sharp And Dohme Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_MerckSharpAndDohmeCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merck, Sharp &amp; Dohme Corp.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mature after one year through two years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average shares used to compute net (loss) income allocable to common stockholders per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing diluted net (loss) income per share allocable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, redemption, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Difference Between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on sale of assets (Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain on sale of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets for Financial Service Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets for Financial Service Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Gain on sale of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxReconciliationTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxReconciliationTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeTaxReconciliationTaxCredit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Business credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PerformanceBasedVestingScheduleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based vesting schedule.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PerformanceBasedVestingScheduleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Vesting Schedule [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_PerformanceBasedVestingScheduleMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based Vesting Schedule</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share as percentage of fair market value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation And Qualifying Accounts Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stated coupon interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt, Excluding Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor sublease rentals payments to be received due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Sublease Rentals Payments To Be Received Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CepiAccrualLongTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CEPI accrual long-term (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CepiAccrualLongTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CEPI accrual long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_CepiAccrualLongTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CEPI accrual long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income loss&#8203; from continuing&#8203; operations before income&#8203; taxes&#8203;.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsFairValueAssumptionsDividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants fair value assumptions dividend yield.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsFairValueAssumptionsDividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Fair Value Assumptions Dividend Yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_WarrantsFairValueAssumptionsDividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of weighted average remaining lease term and weighted average discount rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Weighted Average Remaining Lease Term And Weighted Average Discount Rate Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and preferred stock, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock and preferred stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in revenue adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentConversionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Conversion, Period Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentConversionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Conversion Period Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_DebtInstrumentConversionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument conversion period two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of dilutive warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Instruments, Owned, at Fair Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments, Owned, at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial instruments owned at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessor sublease rentals payments to be received next twelve months.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Sublease Rentals Payments To Be Received Next Twelve Months</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_UpfrontPayment" xlink:to="dvax_UpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_StockOptionsAndShareAwardsMember" xlink:to="dvax_StockOptionsAndShareAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ContingentMilestonePaymentReceivable" xlink:to="dvax_ContingentMilestonePaymentReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" xlink:to="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOther" xlink:to="us-gaap_PropertyPlantAndEquipmentOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInFifthYear" xlink:to="us-gaap_PurchaseObligationDueInFifthYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember" xlink:to="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CappedCallsPolicyTextBlock" xlink:to="dvax_CappedCallsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMediumTermNotes" xlink:to="us-gaap_InterestExpenseMediumTermNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LicenseArrangementContingentConsiderationPercentage" xlink:to="dvax_LicenseArrangementContingentConsiderationPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LaboratoryEquipmentGross" xlink:to="dvax_LaboratoryEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="dvax_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance" xlink:to="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" xlink:to="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ComputerEquipmentGross" xlink:to="dvax_ComputerEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" xlink:to="dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetPastDueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SeveranceAndOtherTerminationBenefitsMember" xlink:to="dvax_SeveranceAndOtherTerminationBenefitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises" xlink:to="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_WarrantsFairValueAssumptionsVolatility" xlink:to="dvax_WarrantsFairValueAssumptionsVolatility_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LaboratoryMember" xlink:to="dvax_LaboratoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SymphonyDynamoHoldingsLlcMember" xlink:to="dvax_SymphonyDynamoHoldingsLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock" xlink:to="dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock" xlink:to="dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets" xlink:to="dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DusseldorfLeaseMember" xlink:to="dvax_DusseldorfLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ThirdLargestCustomerMember" xlink:to="dvax_ThirdLargestCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount" xlink:to="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_EarningsPerShareDisclosureLineItems" xlink:to="dvax_EarningsPerShareDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CashEquivalentsMaturityPeriod" xlink:to="dvax_CashEquivalentsMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SublicenseAgreementMember" xlink:to="dvax_SublicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_WarrantsExpirationDate" xlink:to="dvax_WarrantsExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants" xlink:to="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" xlink:to="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CommonStockSalesAgreementAggregateSalesProceeds" xlink:to="dvax_CommonStockSalesAgreementAggregateSalesProceeds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_TimeBasedVestingScheduleMember" xlink:to="dvax_TimeBasedVestingScheduleMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CloverAmendmentNoTwoMember" xlink:to="dvax_CloverAmendmentNoTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoriesMember" xlink:to="us-gaap_InventoriesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ClassOfWarrantOrRightIssued" xlink:to="dvax_ClassOfWarrantOrRightIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AggregateMinimumCommitment" xlink:to="dvax_AggregateMinimumCommitment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CollaborationRevenueMember" xlink:to="dvax_CollaborationRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal" xlink:to="us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CpG1018Member" xlink:to="dvax_CpG1018Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_HortonStreetMasterLeaseMember" xlink:to="dvax_HortonStreetMasterLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_OtherLongTermLiabilitiesMember" xlink:to="dvax_OtherLongTermLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_WarrantsFairValueAssumptionsRiskFreeRate" xlink:to="dvax_WarrantsFairValueAssumptionsRiskFreeRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan" xlink:to="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares" xlink:to="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IncreaseDecreaseInPrepaidManufacturing" xlink:to="dvax_IncreaseDecreaseInPrepaidManufacturing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ProceedsFromCashReceived" xlink:to="dvax_ProceedsFromCashReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock" xlink:to="dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CombinedPriceOfPreferredStockAndWarrant" xlink:to="dvax_CombinedPriceOfPreferredStockAndWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_BillAndMelindaGatesFoundationMember" xlink:to="dvax_BillAndMelindaGatesFoundationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock" xlink:to="dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SupplyAgreementMember" xlink:to="dvax_SupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" xlink:to="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="us-gaap_RestructuringReserveAcceleratedDepreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DescriptionOfAveciaSupplyAgreement" xlink:to="dvax_DescriptionOfAveciaSupplyAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CappedCallsMember" xlink:to="dvax_CappedCallsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" xlink:to="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PaymentMadeForPreCommercializationMilestone" xlink:to="dvax_PaymentMadeForPreCommercializationMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_OtherRevenueMember" xlink:to="dvax_OtherRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_MedigenVaccineBiologicsMember" xlink:to="dvax_MedigenVaccineBiologicsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="dvax_CashCashEquivalentsAndMarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SerumInstituteOfIndiaPrivateLimitedMember" xlink:to="dvax_SerumInstituteOfIndiaPrivateLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember" xlink:to="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" xlink:to="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount" xlink:to="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock" xlink:to="dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AssetPurchaseAgreementMember" xlink:to="dvax_AssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived" xlink:to="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember" xlink:to="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount" xlink:to="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ProceedsFromWarrantsSale" xlink:to="dvax_ProceedsFromWarrantsSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_HEPLISAVBMember" xlink:to="dvax_HEPLISAVBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PreferredStockDeemedDividend" xlink:to="dvax_PreferredStockDeemedDividend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_UpfrontPaymentReceivable" xlink:to="dvax_UpfrontPaymentReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueArrangementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AdvancePaymentFromCustomer" xlink:to="dvax_AdvancePaymentFromCustomer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInFourthYear" xlink:to="us-gaap_PurchaseObligationDueInFourthYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PriceOfCommonStock" xlink:to="dvax_PriceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PreferredStockCommonStockAndWarrantsAbstract" xlink:to="dvax_PreferredStockCommonStockAndWarrantsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_GrantAgreementMember" xlink:to="dvax_GrantAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IncomeTaxReconciliationDeferredCompensationCharges" xlink:to="dvax_IncomeTaxReconciliationDeferredCompensationCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare" xlink:to="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LargestCollaborationPartnerMember" xlink:to="dvax_LargestCollaborationPartnerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_NumberOfCommonStockWarrantExercised" xlink:to="dvax_NumberOfCommonStockWarrantExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants" xlink:to="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PrepaymentOfAdvancePayment" xlink:to="dvax_PrepaymentOfAdvancePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForNotesReceivableMember" xlink:to="us-gaap_AllowanceForNotesReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PaymentToHoldings" xlink:to="dvax_PaymentToHoldings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm" xlink:to="dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PrepaidManufacturing" xlink:to="dvax_PrepaidManufacturing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease" xlink:to="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ProceedsFromGrant" xlink:to="dvax_ProceedsFromGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DebtInstrumentAdditionalIssueAmount" xlink:to="dvax_DebtInstrumentAdditionalIssueAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus" xlink:to="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PercentageOfLongLivedAssets" xlink:to="dvax_PercentageOfLongLivedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCappedCallOptionsSeeNote10" xlink:to="dvax_IssuanceOfCappedCallOptionsSeeNote10_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock" xlink:to="dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ValnevaSEMember" xlink:to="dvax_ValnevaSEMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember" xlink:to="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_TermLoanMember" xlink:to="dvax_TermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ModifiedPurchaseOrderMember" xlink:to="dvax_ModifiedPurchaseOrderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity" xlink:to="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance" xlink:to="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CumulativeTranslationAdjustmentNetOfTax" xlink:to="dvax_CumulativeTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredLongTermDebt" xlink:to="us-gaap_SecuredLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock" xlink:to="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" xlink:to="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_NetOperatingLossAndTaxCreditLimitations" xlink:to="dvax_NetOperatingLossAndTaxCreditLimitations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PaymentReceivedForPreCommercializationMilestone" xlink:to="dvax_PaymentReceivedForPreCommercializationMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodStartDate" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodStartDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CaliforniaAndOtherStatesTaxAuthorityMember" xlink:to="dvax_CaliforniaAndOtherStatesTaxAuthorityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock" xlink:to="dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan" xlink:to="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind" xlink:to="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock" xlink:to="dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue" xlink:to="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AmountPaidToThirdParty" xlink:to="dvax_AmountPaidToThirdParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SecondLargestCollaborationPartnerMember" xlink:to="dvax_SecondLargestCollaborationPartnerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CashSettlementOfWarrants" xlink:to="dvax_CashSettlementOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CashSettlement" xlink:to="dvax_CashSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_GlobalAccessAndStrategyCommitmentAgreementMember" xlink:to="dvax_GlobalAccessAndStrategyCommitmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SeriesBConvertiblePreferredStockMember" xlink:to="dvax_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IncomeTaxDisclosureTable" xlink:to="dvax_IncomeTaxDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_TwoThousandTwentyATMAgreementMember" xlink:to="dvax_TwoThousandTwentyATMAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LargestCustomerMember" xlink:to="dvax_LargestCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" xlink:to="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount" xlink:to="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_PledgingPurposeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_USDepartmentOfDefenseMember" xlink:to="dvax_USDepartmentOfDefenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused" xlink:to="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_MerckMember" xlink:to="dvax_MerckMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_BainLifeSciencesMember" xlink:to="dvax_BainLifeSciencesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringChargesMember" xlink:to="us-gaap_RestructuringChargesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PtBioFarmaPerseroMember" xlink:to="dvax_PtBioFarmaPerseroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SecondLargestCustomerMember" xlink:to="dvax_SecondLargestCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_Cpg1018AdjuvantInventoryMember" xlink:to="dvax_Cpg1018AdjuvantInventoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_NonCashInterestExpense" xlink:to="dvax_NonCashInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetSale" xlink:to="us-gaap_ContractWithCustomerAssetSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_RevenueReserveAccrualsMember" xlink:to="dvax_RevenueReserveAccrualsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_NumberOfCommonStockPreferredStockConvertibleInto" xlink:to="dvax_NumberOfCommonStockPreferredStockConvertibleInto_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember" xlink:to="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_BadDebtExpense" xlink:to="dvax_BadDebtExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock" xlink:to="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_EarningsPerShareDisclosureTable" xlink:to="dvax_EarningsPerShareDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PowellStreetSubleaseMember" xlink:to="dvax_PowellStreetSubleaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetPurchase" xlink:to="us-gaap_ContractWithCustomerAssetPurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AccruedInventory" xlink:to="dvax_AccruedInventory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_UnvestedMember" xlink:to="dvax_UnvestedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LongTermDeferredRevenueMember" xlink:to="dvax_LongTermDeferredRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PerformanceBasedRestrictedStockUnitsMember" xlink:to="dvax_PerformanceBasedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DeutscheBankSecuritiesMember" xlink:to="dvax_DeutscheBankSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember" xlink:to="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DeferredRevenueSubtractions" xlink:to="dvax_DeferredRevenueSubtractions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_NetOperatingLossAndTaxCreditLimitation" xlink:to="dvax_NetOperatingLossAndTaxCreditLimitation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SeriesCConvertiblePreferredStocksMember" xlink:to="dvax_SeriesCConvertiblePreferredStocksMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SublicenseLiabilityMember" xlink:to="dvax_SublicenseLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_OperatingLossCarryforwardExpirationYear" xlink:to="dvax_OperatingLossCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CaliforniaStateTaxAuthorityMember" xlink:to="dvax_CaliforniaStateTaxAuthorityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_TrisalusLifeSciencesMember" xlink:to="dvax_TrisalusLifeSciencesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SuretyBondMember" xlink:to="us-gaap_SuretyBondMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_Section162MLimitation" xlink:to="dvax_Section162MLimitation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_EmployeeSeveranceAndOtherBenefitsMember" xlink:to="dvax_EmployeeSeveranceAndOtherBenefitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_InventoryWriteOffsRecognized" xlink:to="dvax_InventoryWriteOffsRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_StockBasedCompensationExpenseMember" xlink:to="dvax_StockBasedCompensationExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException" xlink:to="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_TwentySeventeenAtTheMarketAgreementMember" xlink:to="dvax_TwentySeventeenAtTheMarketAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_BiologicalELimitedMember" xlink:to="dvax_BiologicalELimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesCompletionDate" xlink:to="us-gaap_RestructuringAndRelatedActivitiesCompletionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LoanAgreementMember" xlink:to="dvax_LoanAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_FairValueAdjustmentsOfWarrants" xlink:to="dvax_FairValueAdjustmentsOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ReservationAgreementMember" xlink:to="dvax_ReservationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_RepaymentOfAdvanceFromCustomer" xlink:to="dvax_RepaymentOfAdvanceFromCustomer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AccrualLongTermBalance" xlink:to="dvax_AccrualLongTermBalance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract" xlink:to="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondYear" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability" xlink:to="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate" xlink:to="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ConvertibleSeniorNotesMember" xlink:to="dvax_ConvertibleSeniorNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCustomer" xlink:to="us-gaap_ConcentrationRiskCustomer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_RevenueReserveAccrualCurrent" xlink:to="dvax_RevenueReserveAccrualCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ConvertibleOptionalSeniorNotesMember" xlink:to="dvax_ConvertibleOptionalSeniorNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PercentageOfExcessRentPaidToLandlord" xlink:to="dvax_PercentageOfExcessRentPaidToLandlord_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="dvax_IncomeTaxDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares" xlink:to="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" xlink:to="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DeferredTaxAssetsLeaseLiability" xlink:to="dvax_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization" xlink:to="dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" xlink:to="dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AcceleratedDepreciationMember" xlink:to="dvax_AcceleratedDepreciationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PaymentsForPurchaseOfCappedCallOptions" xlink:to="dvax_PaymentsForPurchaseOfCappedCallOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueAfterFifthYear" xlink:to="us-gaap_PurchaseObligationDueAfterFifthYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:to="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CRGServicingLLCMember" xlink:to="dvax_CRGServicingLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IncreaseDecreaseInCepiAccrual" xlink:to="dvax_IncreaseDecreaseInCepiAccrual_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue" xlink:to="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" xlink:to="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LicenseArrangementContingentPaymentToAcquireLicense" xlink:to="dvax_LicenseArrangementContingentPaymentToAcquireLicense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:to="dvax_TwoThousandAndEighteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ServicesAndMaterialsMember" xlink:to="dvax_ServicesAndMaterialsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:to="dvax_UndistributedEarningsAllocatedToParticipatingSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ReservesAccrualBalance" xlink:to="dvax_ReservesAccrualBalance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_AdditionalFuturePayment" xlink:to="dvax_AdditionalFuturePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract" xlink:to="dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IncreaseDecreaseInLeaseLiabilities" xlink:to="dvax_IncreaseDecreaseInLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PreferredStockConversionPricePerShare" xlink:to="dvax_PreferredStockConversionPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_MarketBasedPerformanceStockUnitMember" xlink:to="dvax_MarketBasedPerformanceStockUnitMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_VestedMember" xlink:to="dvax_VestedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_TaxCreditCarryforwardExpirationYear" xlink:to="dvax_TaxCreditCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity" xlink:to="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_WarrantsIssuanceDate" xlink:to="dvax_WarrantsIssuanceDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare" xlink:to="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_ThirdLargestCollaborationPartnerMember" xlink:to="dvax_ThirdLargestCollaborationPartnerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DebtInstrumentConversionPeriodOneMember" xlink:to="dvax_DebtInstrumentConversionPeriodOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_MerckSharpAndDohmeCorporationMember" xlink:to="dvax_MerckSharpAndDohmeCorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInThirdYear" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionDescription" xlink:to="us-gaap_DebtInstrumentRedemptionDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnSalesOfAssets" xlink:to="us-gaap_GainsLossesOnSalesOfAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IncomeTaxReconciliationTaxCredit" xlink:to="dvax_IncomeTaxReconciliationTaxCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_PerformanceBasedVestingScheduleMember" xlink:to="dvax_PerformanceBasedVestingScheduleMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_CepiAccrualLongTerm" xlink:to="dvax_CepiAccrualLongTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:to="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_WarrantsFairValueAssumptionsDividendYield" xlink:to="dvax_WarrantsFairValueAssumptionsDividendYield_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" xlink:to="dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_DebtInstrumentConversionPeriodTwoMember" xlink:to="dvax_DebtInstrumentConversionPeriodTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeriesBConvertiblePreferredStockMember" xlink:label="dvax_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsAccruals" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CepiAccrualLongTerm" xlink:label="dvax_CepiAccrualLongTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dvax_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="dvax_AccruedResearchAndDevelopmentExpensesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleNotesPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="dvax_CepiAccrualLongTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OtherRevenueMember" xlink:label="dvax_OtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BadDebtExpense" xlink:label="dvax_BadDebtExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:label="dvax_UndistributedEarningsAllocatedToParticipatingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_OtherRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_SubleaseIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="dvax_BadDebtExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_UndistributedEarningsAllocatedToParticipatingSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" xlink:label="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeriesBConvertiblePreferredStockMember" xlink:label="dvax_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfStockOptions" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCappedCallOptionsSeeNote10" xlink:label="dvax_IssuanceOfCappedCallOptionsSeeNote10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_25"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_26"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dvax_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfWarrants" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCappedCallOptionsSeeNote10" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseDecreaseInPrepaidManufacturing" xlink:label="dvax_IncreaseDecreaseInPrepaidManufacturing"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets" xlink:label="dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentsForPurchaseOfCappedCallOptions" xlink:label="dvax_PaymentsForPurchaseOfCappedCallOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm" xlink:label="dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AdvancePaymentFromCustomer" xlink:label="dvax_AdvancePaymentFromCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" xlink:label="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseDecreaseInCepiAccrual" xlink:label="dvax_IncreaseDecreaseInCepiAccrual"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseDecreaseInLeaseLiabilities" xlink:label="dvax_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NonCashInterestExpense" xlink:label="dvax_NonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus" xlink:label="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BadDebtExpense" xlink:label="dvax_BadDebtExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="dvax_IncreaseDecreaseInPrepaidManufacturing" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dvax_PaymentsForPurchaseOfCappedCallOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="dvax_AdvancePaymentFromCustomer" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="dvax_IncreaseDecreaseInCepiAccrual" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="dvax_IncreaseDecreaseInLeaseLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dvax_NonCashInterestExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dvax_BadDebtExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract" xlink:label="dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShare1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PreferredStockCommonStockAndWarrantsAbstract" xlink:label="dvax_PreferredStockCommonStockAndWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_PreferredStockCommonStockAndWarrantsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuring" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CappedCallsPolicyTextBlock" xlink:label="dvax_CappedCallsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock" xlink:label="dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dvax_CappedCallsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock" xlink:label="dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock" xlink:label="dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract" xlink:label="dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock" xlink:label="dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract" xlink:to="dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock" xlink:label="dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" xlink:label="dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock" xlink:label="dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock" xlink:label="dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" xlink:label="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CpG1018Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PreferredStockCommonStockAndWarrantsAbstract" xlink:label="dvax_PreferredStockCommonStockAndWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_PreferredStockCommonStockAndWarrantsAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock" xlink:label="dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused" xlink:label="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" xlink:label="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CumulativeTranslationAdjustmentNetOfTax" xlink:label="dvax_CumulativeTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashEquivalentsMaturityPeriod" xlink:label="dvax_CashEquivalentsMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfLongLivedAssets" xlink:label="dvax_PercentageOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCustomer" xlink:label="us-gaap_ConcentrationRiskCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_InventoryWriteOffsRecognized" xlink:label="dvax_InventoryWriteOffsRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived" xlink:label="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_CumulativeTranslationAdjustmentNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_CashEquivalentsMaturityPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_DebtInstrumentAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_PercentageOfLongLivedAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConcentrationRiskCustomer" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_InventoryWriteDown" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_InventoryWriteOffsRecognized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount" xlink:label="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount" xlink:label="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_5"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SublicenseLiabilityMember" xlink:label="dvax_SublicenseLiabilityMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="dvax_SublicenseLiabilityMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsFairValueAssumptionsVolatility" xlink:label="dvax_WarrantsFairValueAssumptionsVolatility"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsFairValueAssumptionsRiskFreeRate" xlink:label="dvax_WarrantsFairValueAssumptionsRiskFreeRate"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsFairValueAssumptionsDividendYield" xlink:label="dvax_WarrantsFairValueAssumptionsDividendYield"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_WarrantsFairValueAssumptionsVolatility" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_WarrantsFairValueAssumptionsRiskFreeRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_WarrantsFairValueAssumptionsDividendYield" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_Cpg1018AdjuvantInventoryMember" xlink:label="dvax_Cpg1018AdjuvantInventoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_InventoryWriteOffsRecognized" xlink:label="dvax_InventoryWriteOffsRecognized"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PrepaidManufacturing" xlink:label="dvax_PrepaidManufacturing"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="dvax_Cpg1018AdjuvantInventoryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoods" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcessAndRawMaterials" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="dvax_InventoryWriteOffsRecognized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="dvax_PrepaidManufacturing" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AssetPurchaseAgreementMember" xlink:label="dvax_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MerckMember" xlink:label="dvax_MerckMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SymphonyDynamoHoldingsLlcMember" xlink:label="dvax_SymphonyDynamoHoldingsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UpfrontPayment" xlink:label="dvax_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UpfrontPaymentReceivable" xlink:label="dvax_UpfrontPaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ContingentMilestonePaymentReceivable" xlink:label="dvax_ContingentMilestonePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AmountPaidToThirdParty" xlink:label="dvax_AmountPaidToThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_AssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_MerckMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_SymphonyDynamoHoldingsLlcMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="dvax_UpfrontPayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="dvax_UpfrontPaymentReceivable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="dvax_ContingentMilestonePaymentReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="dvax_AmountPaidToThirdParty" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LaboratoryMember" xlink:label="dvax_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LaboratoryEquipmentGross" xlink:label="dvax_LaboratoryEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ComputerEquipmentGross" xlink:label="dvax_ComputerEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_MachineryAndEquipmentGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dvax_LaboratoryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="dvax_LaboratoryEquipmentGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="dvax_ComputerEquipmentGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FurnitureAndFixturesGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="us-gaap_RestructuringReserveAcceleratedDepreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_RestructuringReserveAcceleratedDepreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_RevenueReserveAccrualCurrent" xlink:label="dvax_RevenueReserveAccrualCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccruedInventory" xlink:label="dvax_AccruedInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="dvax_RevenueReserveAccrualCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="dvax_AccruedInventory" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AssetPurchaseAgreementMember" xlink:label="dvax_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SymphonyDynamoHoldingsLlcMember" xlink:label="dvax_SymphonyDynamoHoldingsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ServicesAndMaterialsMember" xlink:label="dvax_ServicesAndMaterialsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" xlink:label="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeutscheBankSecuritiesMember" xlink:label="dvax_DeutscheBankSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SuretyBondMember" xlink:label="us-gaap_SuretyBondMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PowellStreetSubleaseMember" xlink:label="dvax_PowellStreetSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CRGServicingLLCMember" xlink:label="dvax_CRGServicingLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SymphonyDynamoHoldingsLlcMember" xlink:label="dvax_SymphonyDynamoHoldingsLlcMember_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HortonStreetMasterLeaseMember" xlink:label="dvax_HortonStreetMasterLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember" xlink:label="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TrisalusLifeSciencesMember" xlink:label="dvax_TrisalusLifeSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DusseldorfLeaseMember" xlink:label="dvax_DusseldorfLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfExcessRentPaidToLandlord" xlink:label="dvax_PercentageOfExcessRentPaidToLandlord"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LicenseArrangementContingentConsiderationPercentage" xlink:label="dvax_LicenseArrangementContingentConsiderationPercentage"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LicenseArrangementContingentPaymentToAcquireLicense" xlink:label="dvax_LicenseArrangementContingentPaymentToAcquireLicense"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentToHoldings" xlink:label="dvax_PaymentToHoldings"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentReceivedForPreCommercializationMilestone" xlink:label="dvax_PaymentReceivedForPreCommercializationMilestone"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentMadeForPreCommercializationMilestone" xlink:label="dvax_PaymentMadeForPreCommercializationMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DescriptionOfAveciaSupplyAgreement" xlink:label="dvax_DescriptionOfAveciaSupplyAgreement"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AggregateMinimumCommitment" xlink:label="dvax_AggregateMinimumCommitment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_AssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="dvax_SymphonyDynamoHoldingsLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="dvax_ServicesAndMaterialsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="dvax_DeutscheBankSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" xlink:to="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_SuretyBondMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:to="dvax_PowellStreetSubleaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_CRGServicingLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="dvax_SymphonyDynamoHoldingsLlcMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:to="dvax_HortonStreetMasterLeaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="dvax_TrisalusLifeSciencesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:to="dvax_DusseldorfLeaseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SubleaseIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_PercentageOfExcessRentPaidToLandlord" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PledgingPurposeAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_DebtInstrumentAxis" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_LicenseArrangementContingentConsiderationPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_LicenseArrangementContingentPaymentToAcquireLicense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_PaymentToHoldings" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_PaymentReceivedForPreCommercializationMilestone" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_PaymentMadeForPreCommercializationMilestone" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PurchaseObligation" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_DescriptionOfAveciaSupplyAgreement" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_AggregateMinimumCommitment" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="us-gaap_PurchaseObligationDueInFourthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="us-gaap_PurchaseObligationDueInFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:label="us-gaap_PurchaseObligationDueAfterFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInThirdYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInFourthYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInFifthYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueAfterFifthYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReservationAgreementMember" xlink:label="dvax_ReservationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CollaborationRevenueMember" xlink:label="dvax_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ModifiedPurchaseOrderMember" xlink:label="dvax_ModifiedPurchaseOrderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OtherLongTermLiabilitiesMember" xlink:label="dvax_OtherLongTermLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SupplyAgreementMember" xlink:label="dvax_SupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_InventoryWriteOffsRecognized" xlink:label="dvax_InventoryWriteOffsRecognized"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_GrantAgreementMember" xlink:label="dvax_GrantAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AdvancePaymentFromCustomer" xlink:label="dvax_AdvancePaymentFromCustomer"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember" xlink:label="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_GlobalAccessAndStrategyCommitmentAgreementMember" xlink:label="dvax_GlobalAccessAndStrategyCommitmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_RepaymentOfAdvanceFromCustomer" xlink:label="dvax_RepaymentOfAdvanceFromCustomer"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BiologicalELimitedMember" xlink:label="dvax_BiologicalELimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SublicenseAgreementMember" xlink:label="dvax_SublicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PtBioFarmaPerseroMember" xlink:label="dvax_PtBioFarmaPerseroMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CloverAmendmentNoTwoMember" xlink:label="dvax_CloverAmendmentNoTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccrualLongTermBalance" xlink:label="dvax_AccrualLongTermBalance"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MedigenVaccineBiologicsMember" xlink:label="dvax_MedigenVaccineBiologicsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ValnevaSEMember" xlink:label="dvax_ValnevaSEMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BillAndMelindaGatesFoundationMember" xlink:label="dvax_BillAndMelindaGatesFoundationMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromGrant" xlink:label="dvax_ProceedsFromGrant"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_USDepartmentOfDefenseMember" xlink:label="dvax_USDepartmentOfDefenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SerumInstituteOfIndiaPrivateLimitedMember" xlink:label="dvax_SerumInstituteOfIndiaPrivateLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MerckSharpAndDohmeCorporationMember" xlink:label="dvax_MerckSharpAndDohmeCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PrepaymentOfAdvancePayment" xlink:label="dvax_PrepaymentOfAdvancePayment"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AdditionalFuturePayment" xlink:label="dvax_AdditionalFuturePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_ReservationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="dvax_CpG1018Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="dvax_ModifiedPurchaseOrderMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="dvax_OtherLongTermLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_SupplyAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_InventoryWriteOffsRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_GrantAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_AdvancePaymentFromCustomer" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_GlobalAccessAndStrategyCommitmentAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_RepaymentOfAdvanceFromCustomer" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_BiologicalELimitedMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_SublicenseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_PtBioFarmaPerseroMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_CloverAmendmentNoTwoMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_AccrualLongTermBalance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_MedigenVaccineBiologicsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_ValnevaSEMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_BillAndMelindaGatesFoundationMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_ProceedsFromGrant" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_USDepartmentOfDefenseMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_SerumInstituteOfIndiaPrivateLimitedMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_MerckSharpAndDohmeCorporationMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_PrepaymentOfAdvancePayment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_AdditionalFuturePayment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentConversionPeriodOneMember" xlink:label="dvax_DebtInstrumentConversionPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleSeniorNotesMember" xlink:label="dvax_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentConversionPeriodTwoMember" xlink:label="dvax_DebtInstrumentConversionPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" xlink:label="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleOptionalSeniorNotesMember" xlink:label="dvax_ConvertibleOptionalSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentAdditionalIssueAmount" xlink:label="dvax_DebtInstrumentAdditionalIssueAmount"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LoanAgreementMember" xlink:label="dvax_LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CappedCallsMember" xlink:label="dvax_CappedCallsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue" xlink:label="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount" xlink:label="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodStartDate" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodStartDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="dvax_DebtInstrumentConversionPeriodOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_ConvertibleSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="dvax_DebtInstrumentConversionPeriodTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_ConvertibleOptionalSeniorNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_DebtInstrumentAdditionalIssueAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_LoanAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_CappedCallsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionDescription" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodStartDate" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LoanAgreementMember" xlink:label="dvax_LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CRGServicingLLCMember" xlink:label="dvax_CRGServicingLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TermLoanMember" xlink:label="dvax_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind" xlink:label="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity" xlink:label="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException" xlink:label="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance" xlink:label="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_LoanAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_CRGServicingLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_TermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredLongTermDebt" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OtherRevenueMember" xlink:label="dvax_OtherRevenueMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CpG1018Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_OtherRevenueMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LargestCustomerMember" xlink:label="dvax_LargestCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SecondLargestCustomerMember" xlink:label="dvax_SecondLargestCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ThirdLargestCustomerMember" xlink:label="dvax_ThirdLargestCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LargestCollaborationPartnerMember" xlink:label="dvax_LargestCollaborationPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SecondLargestCollaborationPartnerMember" xlink:label="dvax_SecondLargestCollaborationPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ThirdLargestCollaborationPartnerMember" xlink:label="dvax_ThirdLargestCollaborationPartnerMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_LargestCustomerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ProductConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_MajorCustomersAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CpG1018Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_SecondLargestCustomerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_ThirdLargestCustomerMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_LargestCollaborationPartnerMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_SecondLargestCollaborationPartnerMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_ThirdLargestCollaborationPartnerMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForNotesReceivableMember" xlink:label="us-gaap_AllowanceForNotesReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReservesAccrualBalance" xlink:label="dvax_ReservesAccrualBalance"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_RevenueReserveAccrualsMember" xlink:label="dvax_RevenueReserveAccrualsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" xlink:label="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" xlink:label="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" xlink:label="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReservesAccrualBalance" xlink:label="dvax_ReservesAccrualBalance_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForNotesReceivableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="dvax_ReservesAccrualBalance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="dvax_RevenueReserveAccrualsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="dvax_ReservesAccrualBalance_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:label="us-gaap_ContractWithCustomerAssetPastDueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetSale" xlink:label="us-gaap_ContractWithCustomerAssetSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetPurchase" xlink:label="us-gaap_ContractWithCustomerAssetPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal" xlink:label="us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CpG1018Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ContractWithCustomerAssetPastDueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetSale" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetPurchase" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LongTermDeferredRevenueMember" xlink:label="dvax_LongTermDeferredRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeferredRevenueSubtractions" xlink:label="dvax_DeferredRevenueSubtractions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CpG1018Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="dvax_LongTermDeferredRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_DeferredRevenueArrangementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="dvax_DeferredRevenueSubtractions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:label="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" xlink:label="dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" xlink:label="dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMediumTermNotes" xlink:label="us-gaap_InterestExpenseMediumTermNotes"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessRemovalOfChangeInFairValueOfWarrantLiability" xlink:label="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueAdjustmentsOfWarrants" xlink:label="dvax_FairValueAdjustmentsOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_InterestExpenseMediumTermNotes" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="dvax_FairValueAdjustmentsOfWarrants" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EarningsPerShareDisclosureLineItems" xlink:label="dvax_EarningsPerShareDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract" xlink:label="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:label="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EarningsPerShareDisclosureTable" xlink:label="dvax_EarningsPerShareDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_StockOptionsAndShareAwardsMember" xlink:label="dvax_StockOptionsAndShareAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_EarningsPerShareDisclosureLineItems" xlink:to="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="dvax_EarningsPerShareDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dvax_StockOptionsAndShareAwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_EarningsPerShareDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_EarningsPerShareDisclosureTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_EarningsPerShareDisclosureTable" xlink:to="dvax_EarningsPerShareDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeriesBConvertiblePreferredStockMember" xlink:label="dvax_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BainLifeSciencesMember" xlink:label="dvax_BainLifeSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeriesCConvertiblePreferredStocksMember" xlink:label="dvax_SeriesCConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwentySeventeenAtTheMarketAgreementMember" xlink:label="dvax_TwentySeventeenAtTheMarketAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BainCapitalLifeSciencesFundLimitedPartnerMember" xlink:label="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ClassOfWarrantOrRightIssued" xlink:label="dvax_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwoThousandTwentyATMAgreementMember" xlink:label="dvax_TwoThousandTwentyATMAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember" xlink:label="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CombinedPriceOfPreferredStockAndWarrant" xlink:label="dvax_CombinedPriceOfPreferredStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NumberOfCommonStockPreferredStockConvertibleInto" xlink:label="dvax_NumberOfCommonStockPreferredStockConvertibleInto"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PreferredStockConversionPricePerShare" xlink:label="dvax_PreferredStockConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PriceOfCommonStock" xlink:label="dvax_PriceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromCashReceived" xlink:label="dvax_ProceedsFromCashReceived"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CommonStockSalesAgreementAggregateSalesProceeds" xlink:label="dvax_CommonStockSalesAgreementAggregateSalesProceeds"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock" xlink:label="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity" xlink:label="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises" xlink:label="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PreferredStockDeemedDividend" xlink:label="dvax_PreferredStockDeemedDividend"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NumberOfCommonStockWarrantExercised" xlink:label="dvax_NumberOfCommonStockWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashSettlementOfWarrants" xlink:label="dvax_CashSettlementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashSettlement" xlink:label="dvax_CashSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromWarrantsSale" xlink:label="dvax_ProceedsFromWarrantsSale"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dvax_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_BainLifeSciencesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dvax_SeriesCConvertiblePreferredStocksMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dvax_TwentySeventeenAtTheMarketAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_ClassOfWarrantOrRightIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dvax_TwoThousandTwentyATMAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_CombinedPriceOfPreferredStockAndWarrant" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_NumberOfCommonStockPreferredStockConvertibleInto" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PreferredStockConversionPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PriceOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_ProceedsFromCashReceived" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_CommonStockSalesAgreementAggregateSalesProceeds" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PreferredStockDeemedDividend" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_NumberOfCommonStockWarrantExercised" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_CashSettlementOfWarrants" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_CashSettlement" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_ProceedsFromWarrantsSale" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsIssuanceDate" xlink:label="dvax_WarrantsIssuanceDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsExpirationDate" xlink:label="dvax_WarrantsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_WarrantsIssuanceDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_WarrantsExpirationDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="dvax_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember" xlink:label="us-gaap_RestructuringChargesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance" xlink:label="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember" xlink:label="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TimeBasedVestingScheduleMember" xlink:label="dvax_TimeBasedVestingScheduleMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PerformanceBasedVestingScheduleMember" xlink:label="dvax_PerformanceBasedVestingScheduleMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PerformanceBasedRestrictedStockUnitsMember" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MarketBasedPerformanceStockUnitMember" xlink:label="dvax_MarketBasedPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan" xlink:label="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan" xlink:label="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_TwoThousandAndEighteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_RestructuringChargesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_TimeBasedVestingScheduleMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_PerformanceBasedVestingScheduleMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_PerformanceBasedRestrictedStockUnitsMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_MarketBasedPerformanceStockUnitMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UnvestedMember" xlink:label="dvax_UnvestedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_VestedMember" xlink:label="dvax_VestedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_UnvestedMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_VestedMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PerformanceBasedRestrictedStockUnitsMember" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MarketBasedPerformanceStockUnitMember" xlink:label="dvax_MarketBasedPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_PerformanceBasedRestrictedStockUnitsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_MarketBasedPerformanceStockUnitMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MarketBasedPerformanceStockUnitMember" xlink:label="dvax_MarketBasedPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PerformanceBasedRestrictedStockUnitsMember" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_5.0"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dvax_MarketBasedPerformanceStockUnitMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dvax_PerformanceBasedRestrictedStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember_5.0" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoriesMember" xlink:label="us-gaap_InventoriesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember" xlink:label="us-gaap_RestructuringChargesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_InventoriesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_RestructuringChargesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesCompletionDate" xlink:label="us-gaap_RestructuringAndRelatedActivitiesCompletionDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesCompletionDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeveranceAndOtherTerminationBenefitsMember" xlink:label="dvax_SeveranceAndOtherTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_StockBasedCompensationExpenseMember" xlink:label="dvax_StockBasedCompensationExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AcceleratedDepreciationMember" xlink:label="dvax_AcceleratedDepreciationMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="dvax_SeveranceAndOtherTerminationBenefitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="dvax_StockBasedCompensationExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="dvax_AcceleratedDepreciationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EmployeeSeveranceAndOtherBenefitsMember" xlink:label="dvax_EmployeeSeveranceAndOtherBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="dvax_EmployeeSeveranceAndOtherBenefitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:label="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxDisclosureTable" xlink:label="dvax_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxDisclosureLineItems" xlink:label="dvax_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CaliforniaAndOtherStatesTaxAuthorityMember" xlink:label="dvax_CaliforniaAndOtherStatesTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CaliforniaStateTaxAuthorityMember" xlink:label="dvax_CaliforniaStateTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OperatingLossCarryforwardExpirationYear" xlink:label="dvax_OperatingLossCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TaxCreditCarryforwardExpirationYear" xlink:label="dvax_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dvax_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="dvax_CaliforniaAndOtherStatesTaxAuthorityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="dvax_CaliforniaStateTaxAuthorityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureTable" xlink:to="dvax_IncomeTaxDisclosureLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="dvax_OperatingLossCarryforwardExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="dvax_TaxCreditCarryforwardExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxReconciliationTaxCredit" xlink:label="dvax_IncomeTaxReconciliationTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxReconciliationDeferredCompensationCharges" xlink:label="dvax_IncomeTaxReconciliationDeferredCompensationCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_Section162MLimitation" xlink:label="dvax_Section162MLimitation"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants" xlink:label="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NetOperatingLossAndTaxCreditLimitation" xlink:label="dvax_NetOperatingLossAndTaxCreditLimitation"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NetOperatingLossAndTaxCreditLimitations" xlink:label="dvax_NetOperatingLossAndTaxCreditLimitations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount" xlink:label="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dvax_IncomeTaxReconciliationTaxCredit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dvax_IncomeTaxReconciliationDeferredCompensationCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dvax_Section162MLimitation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dvax_NetOperatingLossAndTaxCreditLimitation" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dvax_NetOperatingLossAndTaxCreditLimitations" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization" xlink:label="dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeferredTaxAssetsLeaseLiability" xlink:label="dvax_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="dvax_DeferredTaxAssetsLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReservationAgreementMember" xlink:label="dvax_ReservationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_ReservationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeriesBConvertiblePreferredStockMember" xlink:label="dvax_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsAccruals" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CepiAccrualLongTerm" xlink:label="dvax_CepiAccrualLongTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dvax_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="dvax_AccruedResearchAndDevelopmentExpensesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleNotesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="dvax_CepiAccrualLongTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OtherRevenueMember" xlink:label="dvax_OtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BadDebtExpense" xlink:label="dvax_BadDebtExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:label="dvax_UndistributedEarningsAllocatedToParticipatingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_OtherRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="dvax_BadDebtExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_UndistributedEarningsAllocatedToParticipatingSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeriesBConvertiblePreferredStockMember" xlink:label="dvax_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares" xlink:label="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfStockOptions" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" xlink:label="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" xlink:label="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="dvax_IssuanceOfCommonStockUponExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfCappedCallOptionsSeeNote10" xlink:label="dvax_IssuanceOfCappedCallOptionsSeeNote10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dvax_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCommonStockUponExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_IssuanceOfCappedCallOptionsSeeNote10" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" xlink:label="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CpG1018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused" xlink:label="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" xlink:label="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CumulativeTranslationAdjustmentNetOfTax" xlink:label="dvax_CumulativeTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashEquivalentsMaturityPeriod" xlink:label="dvax_CashEquivalentsMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfLongLivedAssets" xlink:label="dvax_PercentageOfLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCustomer" xlink:label="us-gaap_ConcentrationRiskCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_InventoryWriteOffsRecognized" xlink:label="dvax_InventoryWriteOffsRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived" xlink:label="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_CumulativeTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_CashEquivalentsMaturityPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_PercentageOfLongLivedAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConcentrationRiskCustomer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_InventoryWriteDown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_InventoryWriteOffsRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount" xlink:label="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount" xlink:label="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SublicenseLiabilityMember" xlink:label="dvax_SublicenseLiabilityMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="dvax_SublicenseLiabilityMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsFairValueAssumptionsVolatility" xlink:label="dvax_WarrantsFairValueAssumptionsVolatility"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsFairValueAssumptionsRiskFreeRate" xlink:label="dvax_WarrantsFairValueAssumptionsRiskFreeRate"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsFairValueAssumptionsDividendYield" xlink:label="dvax_WarrantsFairValueAssumptionsDividendYield"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_WarrantsFairValueAssumptionsVolatility" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_WarrantsFairValueAssumptionsRiskFreeRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_WarrantsFairValueAssumptionsDividendYield" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate" xlink:label="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:label="dvax_CashCashEquivalentsAndMarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_Cpg1018AdjuvantInventoryMember" xlink:label="dvax_Cpg1018AdjuvantInventoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_InventoryWriteOffsRecognized" xlink:label="dvax_InventoryWriteOffsRecognized"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PrepaidManufacturing" xlink:label="dvax_PrepaidManufacturing"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="dvax_Cpg1018AdjuvantInventoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoods" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcessAndRawMaterials" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="dvax_InventoryWriteOffsRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="dvax_PrepaidManufacturing" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AssetPurchaseAgreementMember" xlink:label="dvax_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MerckMember" xlink:label="dvax_MerckMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SymphonyDynamoHoldingsLlcMember" xlink:label="dvax_SymphonyDynamoHoldingsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UpfrontPayment" xlink:label="dvax_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UpfrontPaymentReceivable" xlink:label="dvax_UpfrontPaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ContingentMilestonePaymentReceivable" xlink:label="dvax_ContingentMilestonePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AmountPaidToThirdParty" xlink:label="dvax_AmountPaidToThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_AssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_MerckMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_SymphonyDynamoHoldingsLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="dvax_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="dvax_UpfrontPaymentReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="dvax_ContingentMilestonePaymentReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="dvax_AmountPaidToThirdParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LaboratoryMember" xlink:label="dvax_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LaboratoryEquipmentGross" xlink:label="dvax_LaboratoryEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ComputerEquipmentGross" xlink:label="dvax_ComputerEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_MachineryAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dvax_LaboratoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="dvax_LaboratoryEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="dvax_ComputerEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FurnitureAndFixturesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AssetPurchaseAgreementMember" xlink:label="dvax_AssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SymphonyDynamoHoldingsLlcMember" xlink:label="dvax_SymphonyDynamoHoldingsLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ServicesAndMaterialsMember" xlink:label="dvax_ServicesAndMaterialsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" xlink:label="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeutscheBankSecuritiesMember" xlink:label="dvax_DeutscheBankSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:label="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SuretyBondMember" xlink:label="us-gaap_SuretyBondMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PowellStreetSubleaseMember" xlink:label="dvax_PowellStreetSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CRGServicingLLCMember" xlink:label="dvax_CRGServicingLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HortonStreetMasterLeaseMember" xlink:label="dvax_HortonStreetMasterLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember" xlink:label="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TrisalusLifeSciencesMember" xlink:label="dvax_TrisalusLifeSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DusseldorfLeaseMember" xlink:label="dvax_DusseldorfLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfExcessRentPaidToLandlord" xlink:label="dvax_PercentageOfExcessRentPaidToLandlord"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LicenseArrangementContingentConsiderationPercentage" xlink:label="dvax_LicenseArrangementContingentConsiderationPercentage"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LicenseArrangementContingentPaymentToAcquireLicense" xlink:label="dvax_LicenseArrangementContingentPaymentToAcquireLicense"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentToHoldings" xlink:label="dvax_PaymentToHoldings"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentReceivedForPreCommercializationMilestone" xlink:label="dvax_PaymentReceivedForPreCommercializationMilestone"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentMadeForPreCommercializationMilestone" xlink:label="dvax_PaymentMadeForPreCommercializationMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DescriptionOfAveciaSupplyAgreement" xlink:label="dvax_DescriptionOfAveciaSupplyAgreement"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AggregateMinimumCommitment" xlink:label="dvax_AggregateMinimumCommitment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_AssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="dvax_SymphonyDynamoHoldingsLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="dvax_ServicesAndMaterialsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="dvax_DeutscheBankSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" xlink:to="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" xlink:to="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_SuretyBondMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:to="dvax_PowellStreetSubleaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_CRGServicingLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:to="dvax_HortonStreetMasterLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="dvax_TrisalusLifeSciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" xlink:to="dvax_DusseldorfLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_PercentageOfExcessRentPaidToLandlord" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PledgingPurposeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_LicenseArrangementContingentConsiderationPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_LicenseArrangementContingentPaymentToAcquireLicense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_PaymentToHoldings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_PaymentReceivedForPreCommercializationMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_PaymentMadeForPreCommercializationMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PurchaseObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_DescriptionOfAveciaSupplyAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="dvax_AggregateMinimumCommitment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReservationAgreementMember" xlink:label="dvax_ReservationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CollaborationRevenueMember" xlink:label="dvax_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ModifiedPurchaseOrderMember" xlink:label="dvax_ModifiedPurchaseOrderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OtherLongTermLiabilitiesMember" xlink:label="dvax_OtherLongTermLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SupplyAgreementMember" xlink:label="dvax_SupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_InventoryWriteOffsRecognized" xlink:label="dvax_InventoryWriteOffsRecognized"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_GrantAgreementMember" xlink:label="dvax_GrantAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AdvancePaymentFromCustomer" xlink:label="dvax_AdvancePaymentFromCustomer"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember" xlink:label="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_GlobalAccessAndStrategyCommitmentAgreementMember" xlink:label="dvax_GlobalAccessAndStrategyCommitmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_RepaymentOfAdvanceFromCustomer" xlink:label="dvax_RepaymentOfAdvanceFromCustomer"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BiologicalELimitedMember" xlink:label="dvax_BiologicalELimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SublicenseAgreementMember" xlink:label="dvax_SublicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PtBioFarmaPerseroMember" xlink:label="dvax_PtBioFarmaPerseroMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CloverAmendmentNoTwoMember" xlink:label="dvax_CloverAmendmentNoTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccrualLongTermBalance" xlink:label="dvax_AccrualLongTermBalance"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MedigenVaccineBiologicsMember" xlink:label="dvax_MedigenVaccineBiologicsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ValnevaSEMember" xlink:label="dvax_ValnevaSEMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BillAndMelindaGatesFoundationMember" xlink:label="dvax_BillAndMelindaGatesFoundationMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromGrant" xlink:label="dvax_ProceedsFromGrant"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_USDepartmentOfDefenseMember" xlink:label="dvax_USDepartmentOfDefenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SerumInstituteOfIndiaPrivateLimitedMember" xlink:label="dvax_SerumInstituteOfIndiaPrivateLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MerckSharpAndDohmeCorporationMember" xlink:label="dvax_MerckSharpAndDohmeCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PrepaymentOfAdvancePayment" xlink:label="dvax_PrepaymentOfAdvancePayment"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AdditionalFuturePayment" xlink:label="dvax_AdditionalFuturePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_ReservationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="dvax_CpG1018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CollaborationRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="dvax_ModifiedPurchaseOrderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="dvax_OtherLongTermLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_SupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_InventoryWriteOffsRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_GrantAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_AdvancePaymentFromCustomer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_GlobalAccessAndStrategyCommitmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_RepaymentOfAdvanceFromCustomer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_BiologicalELimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_SublicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_PtBioFarmaPerseroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_CloverAmendmentNoTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_AccrualLongTermBalance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_MedigenVaccineBiologicsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_ValnevaSEMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_BillAndMelindaGatesFoundationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_ProceedsFromGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_USDepartmentOfDefenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_SerumInstituteOfIndiaPrivateLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_MerckSharpAndDohmeCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_PrepaymentOfAdvancePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dvax_AdditionalFuturePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentConversionPeriodOneMember" xlink:label="dvax_DebtInstrumentConversionPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleSeniorNotesMember" xlink:label="dvax_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentConversionPeriodTwoMember" xlink:label="dvax_DebtInstrumentConversionPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" xlink:label="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ConvertibleOptionalSeniorNotesMember" xlink:label="dvax_ConvertibleOptionalSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentAdditionalIssueAmount" xlink:label="dvax_DebtInstrumentAdditionalIssueAmount"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LoanAgreementMember" xlink:label="dvax_LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CappedCallsMember" xlink:label="dvax_CappedCallsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue" xlink:label="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount" xlink:label="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodStartDate" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodStartDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare" xlink:label="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="dvax_DebtInstrumentConversionPeriodOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="dvax_DebtInstrumentConversionPeriodTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_ConvertibleOptionalSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_DebtInstrumentAdditionalIssueAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_LoanAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_CappedCallsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodStartDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LoanAgreementMember" xlink:label="dvax_LoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CRGServicingLLCMember" xlink:label="dvax_CRGServicingLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TermLoanMember" xlink:label="dvax_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind" xlink:label="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity" xlink:label="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException" xlink:label="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance" xlink:label="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_LoanAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_CRGServicingLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dvax_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OtherRevenueMember" xlink:label="dvax_OtherRevenueMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CpG1018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_OtherRevenueMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LargestCustomerMember" xlink:label="dvax_LargestCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SecondLargestCustomerMember" xlink:label="dvax_SecondLargestCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ThirdLargestCustomerMember" xlink:label="dvax_ThirdLargestCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LargestCollaborationPartnerMember" xlink:label="dvax_LargestCollaborationPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SecondLargestCollaborationPartnerMember" xlink:label="dvax_SecondLargestCollaborationPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ThirdLargestCollaborationPartnerMember" xlink:label="dvax_ThirdLargestCollaborationPartnerMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_LargestCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ProductConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CpG1018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_SecondLargestCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_ThirdLargestCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_LargestCollaborationPartnerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_SecondLargestCollaborationPartnerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="dvax_ThirdLargestCollaborationPartnerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_HEPLISAVBMember" xlink:label="dvax_HEPLISAVBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForNotesReceivableMember" xlink:label="us-gaap_AllowanceForNotesReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReservesAccrualBalance" xlink:label="dvax_ReservesAccrualBalance"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_RevenueReserveAccrualsMember" xlink:label="dvax_RevenueReserveAccrualsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" xlink:label="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" xlink:label="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" xlink:label="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_HEPLISAVBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForNotesReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="dvax_ReservesAccrualBalance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="dvax_RevenueReserveAccrualsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:label="us-gaap_ContractWithCustomerAssetPastDueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetSale" xlink:label="us-gaap_ContractWithCustomerAssetSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetPurchase" xlink:label="us-gaap_ContractWithCustomerAssetPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal" xlink:label="us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CpG1018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetPurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetPastDueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CpG1018Member" xlink:label="dvax_CpG1018Member"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LongTermDeferredRevenueMember" xlink:label="dvax_LongTermDeferredRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeferredRevenueSubtractions" xlink:label="dvax_DeferredRevenueSubtractions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="dvax_CpG1018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="dvax_LongTermDeferredRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="dvax_DeferredRevenueSubtractions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EarningsPerShareDisclosureLineItems" xlink:label="dvax_EarningsPerShareDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EarningsPerShareDisclosureTable" xlink:label="dvax_EarningsPerShareDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract" xlink:label="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_StockOptionsAndShareAwardsMember" xlink:label="dvax_StockOptionsAndShareAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dvax_EarningsPerShareDisclosureLineItems" xlink:to="dvax_EarningsPerShareDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_EarningsPerShareDisclosureLineItems" xlink:to="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dvax_StockOptionsAndShareAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_EarningsPerShareDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_EarningsPerShareDisclosureTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeriesBConvertiblePreferredStockMember" xlink:label="dvax_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BainLifeSciencesMember" xlink:label="dvax_BainLifeSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeriesCConvertiblePreferredStocksMember" xlink:label="dvax_SeriesCConvertiblePreferredStocksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwentySeventeenAtTheMarketAgreementMember" xlink:label="dvax_TwentySeventeenAtTheMarketAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BainCapitalLifeSciencesFundLimitedPartnerMember" xlink:label="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ClassOfWarrantOrRightIssued" xlink:label="dvax_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwoThousandTwentyATMAgreementMember" xlink:label="dvax_TwoThousandTwentyATMAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember" xlink:label="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CombinedPriceOfPreferredStockAndWarrant" xlink:label="dvax_CombinedPriceOfPreferredStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NumberOfCommonStockPreferredStockConvertibleInto" xlink:label="dvax_NumberOfCommonStockPreferredStockConvertibleInto"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PreferredStockConversionPricePerShare" xlink:label="dvax_PreferredStockConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PriceOfCommonStock" xlink:label="dvax_PriceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromCashReceived" xlink:label="dvax_ProceedsFromCashReceived"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CommonStockSalesAgreementAggregateSalesProceeds" xlink:label="dvax_CommonStockSalesAgreementAggregateSalesProceeds"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock" xlink:label="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity" xlink:label="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises" xlink:label="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PreferredStockDeemedDividend" xlink:label="dvax_PreferredStockDeemedDividend"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NumberOfCommonStockWarrantExercised" xlink:label="dvax_NumberOfCommonStockWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashSettlementOfWarrants" xlink:label="dvax_CashSettlementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CashSettlement" xlink:label="dvax_CashSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants" xlink:label="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromWarrantsSale" xlink:label="dvax_ProceedsFromWarrantsSale"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dvax_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_BainLifeSciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dvax_SeriesCConvertiblePreferredStocksMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dvax_TwentySeventeenAtTheMarketAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_ClassOfWarrantOrRightIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dvax_TwoThousandTwentyATMAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_CombinedPriceOfPreferredStockAndWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_NumberOfCommonStockPreferredStockConvertibleInto" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PreferredStockConversionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PriceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_ProceedsFromCashReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_CommonStockSalesAgreementAggregateSalesProceeds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PreferredStockDeemedDividend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_NumberOfCommonStockWarrantExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_CashSettlementOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_CashSettlement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_ProceedsFromWarrantsSale" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsIssuanceDate" xlink:label="dvax_WarrantsIssuanceDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_WarrantsExpirationDate" xlink:label="dvax_WarrantsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_WarrantsIssuanceDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="dvax_WarrantsExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="dvax_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember" xlink:label="us-gaap_RestructuringChargesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance" xlink:label="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember" xlink:label="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TimeBasedVestingScheduleMember" xlink:label="dvax_TimeBasedVestingScheduleMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PerformanceBasedRestrictedStockUnitsMember" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PerformanceBasedVestingScheduleMember" xlink:label="dvax_PerformanceBasedVestingScheduleMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MarketBasedPerformanceStockUnitMember" xlink:label="dvax_MarketBasedPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan" xlink:label="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan" xlink:label="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_TwoThousandAndEighteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_RestructuringChargesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_TimeBasedVestingScheduleMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_PerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_PerformanceBasedVestingScheduleMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_MarketBasedPerformanceStockUnitMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UnvestedMember" xlink:label="dvax_UnvestedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_VestedMember" xlink:label="dvax_VestedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_UnvestedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_VestedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PerformanceBasedRestrictedStockUnitsMember" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MarketBasedPerformanceStockUnitMember" xlink:label="dvax_MarketBasedPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_PerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dvax_MarketBasedPerformanceStockUnitMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_MarketBasedPerformanceStockUnitMember" xlink:label="dvax_MarketBasedPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PerformanceBasedRestrictedStockUnitsMember" xlink:label="dvax_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dvax_MarketBasedPerformanceStockUnitMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dvax_PerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoriesMember" xlink:label="us-gaap_InventoriesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember" xlink:label="us-gaap_RestructuringChargesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_InventoriesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_RestructuringChargesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_SeveranceAndOtherTerminationBenefitsMember" xlink:label="dvax_SeveranceAndOtherTerminationBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_StockBasedCompensationExpenseMember" xlink:label="dvax_StockBasedCompensationExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AcceleratedDepreciationMember" xlink:label="dvax_AcceleratedDepreciationMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="dvax_SeveranceAndOtherTerminationBenefitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="dvax_StockBasedCompensationExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="dvax_AcceleratedDepreciationMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EmployeeSeveranceAndOtherBenefitsMember" xlink:label="dvax_EmployeeSeveranceAndOtherBenefitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="dvax_EmployeeSeveranceAndOtherBenefitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxDisclosureLineItems" xlink:label="dvax_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxDisclosureTable" xlink:label="dvax_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CaliforniaAndOtherStatesTaxAuthorityMember" xlink:label="dvax_CaliforniaAndOtherStatesTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CaliforniaStateTaxAuthorityMember" xlink:label="dvax_CaliforniaStateTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_OperatingLossCarryforwardExpirationYear" xlink:label="dvax_OperatingLossCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_TaxCreditCarryforwardExpirationYear" xlink:label="dvax_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="dvax_IncomeTaxDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="dvax_CaliforniaAndOtherStatesTaxAuthorityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="dvax_CaliforniaStateTaxAuthorityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dvax_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="dvax_OperatingLossCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="dvax_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dvax_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ReservationAgreementMember" xlink:label="dvax_ReservationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dvax_ReservationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="dvax_AccruedResearchAndDevelopmentExpensesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleNotesPayable" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="dvax_CepiAccrualLongTerm" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CoalitionForEpidemicPreparednessInnovationsAccruals" xlink:label="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_CepiAccrualLongTerm" xlink:label="dvax_CepiAccrualLongTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="dvax_UndistributedEarningsAllocatedToParticipatingSecurities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_SubleaseIncome" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="4" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="dvax_BadDebtExpense" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RestructuringCharges" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:label="dvax_UndistributedEarningsAllocatedToParticipatingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BadDebtExpense" xlink:label="dvax_BadDebtExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" xlink:label="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dvax_PaymentsForPurchaseOfCappedCallOptions" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dvax_BadDebtExpense" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="12" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="13" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dvax_NonCashInterestExpense" order="15" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="17" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="18" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="19" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dvax_IncreaseDecreaseInPrepaidManufacturing" order="20" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dvax_IncreaseDecreaseInCepiAccrual" order="21" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="22" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="23" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="24" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dvax_IncreaseDecreaseInLeaseLiabilities" order="26" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="27" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="28" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentsForPurchaseOfCappedCallOptions" xlink:label="dvax_PaymentsForPurchaseOfCappedCallOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" xlink:label="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus" xlink:label="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_BadDebtExpense" xlink:label="dvax_BadDebtExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_NonCashInterestExpense" xlink:label="dvax_NonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseDecreaseInPrepaidManufacturing" xlink:label="dvax_IncreaseDecreaseInPrepaidManufacturing"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseDecreaseInCepiAccrual" xlink:label="dvax_IncreaseDecreaseInCepiAccrual"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncreaseDecreaseInLeaseLiabilities" xlink:label="dvax_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="dvax_LaboratoryEquipmentGross" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="dvax_ComputerEquipmentGross" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_FurnitureAndFixturesGross" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_LeaseholdImprovementsGross" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentOther" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LaboratoryEquipmentGross" xlink:label="dvax_LaboratoryEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_ComputerEquipmentGross" xlink:label="dvax_ComputerEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" xlink:to="dvax_AccruedInventory" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" xlink:to="dvax_RevenueReserveAccrualCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" xlink:label="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_AccruedInventory" xlink:label="dvax_AccruedInventory"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_RevenueReserveAccrualCurrent" xlink:label="dvax_RevenueReserveAccrualCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" xlink:to="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter" xlink:label="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInThirdYear" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInFourthYear" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInFifthYear" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueAfterFifthYear" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="us-gaap_PurchaseObligationDueInFourthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="us-gaap_PurchaseObligationDueInFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:label="us-gaap_PurchaseObligationDueAfterFifthYear"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_InterestExpenseMediumTermNotes" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="2" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMediumTermNotes" xlink:label="us-gaap_InterestExpenseMediumTermNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_LessRemovalOfChangeInFairValueOfWarrantLiability" xlink:label="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:label="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="dvax_IncomeTaxReconciliationTaxCredit" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="dvax_IncomeTaxReconciliationDeferredCompensationCharges" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="dvax_Section162MLimitation" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="9" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="11" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxReconciliationTaxCredit" xlink:label="dvax_IncomeTaxReconciliationTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxReconciliationDeferredCompensationCharges" xlink:label="dvax_IncomeTaxReconciliationDeferredCompensationCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_Section162MLimitation" xlink:label="dvax_Section162MLimitation"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants" xlink:label="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount" xlink:label="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="dvax_DeferredTaxAssetsLeaseLiability" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="dvax-20231231.xsd#dvax_DeferredTaxAssetsLeaseLiability" xlink:label="dvax_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour" name="LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" name="ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity" name="ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_StockBasedCompensationExpenseMember" name="StockBasedCompensationExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares" name="IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree" name="LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_CappedCallsPolicyTextBlock" name="CappedCallsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" name="IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock" name="ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_AccrualLongTermBalance" name="AccrualLongTermBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_ProceedsFromCashReceived" name="ProceedsFromCashReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_CashSettlement" name="CashSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind" name="SecuredLongTermDebtNoncurrentPlusInterestInKind" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_OtherLongTermLiabilitiesMember" name="OtherLongTermLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IssuanceOfCappedCallOptionsSeeNote10" name="IssuanceOfCappedCallOptionsSeeNote10" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance" name="DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_CombinedPriceOfPreferredStockAndWarrant" name="CombinedPriceOfPreferredStockAndWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_CappedCallsMember" name="CappedCallsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ReservationAgreementMember" name="ReservationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets" name="ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_LaboratoryMember" name="LaboratoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_SeriesCConvertiblePreferredStocksMember" name="SeriesCConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_EarningsPerShareDisclosureTable" name="EarningsPerShareDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IssuanceOfCommonStockUponExerciseOfWarrants" name="IssuanceOfCommonStockUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_CashEquivalentsMaturityPeriod" name="CashEquivalentsMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_NetOperatingLossAndTaxCreditLimitation" name="NetOperatingLossAndTaxCreditLimitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_InventoryWriteOffsRecognized" name="InventoryWriteOffsRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock" name="SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_SeveranceAndOtherTerminationBenefitsMember" name="SeveranceAndOtherTerminationBenefitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" name="LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths" name="LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_HEPLISAVBMember" name="HEPLISAVBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_BadDebtExpense" name="BadDebtExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_SecondLargestCollaborationPartnerMember" name="SecondLargestCollaborationPartnerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive" name="LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_LoanAgreementMember" name="LoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" name="SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived" name="ContractWithCustomersExpectedPeriodOfPaymentToBeReceived" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_LargestCustomerMember" name="LargestCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter" name="LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" name="NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_CommonStockSalesAgreementAggregateSalesProceeds" name="CommonStockSalesAgreementAggregateSalesProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember" name="DynavaxTechnologiesCorporationInducementAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities" name="StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares" name="IssuanceOfCommonStockUponExerciseOfWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_SecondLargestCustomerMember" name="SecondLargestCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo" name="LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_StockOptionsAndShareAwardsMember" name="StockOptionsAndShareAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_VestedMember" name="VestedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares" name="IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_SupplyAgreementMember" name="SupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" name="NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ReservesAccrualBalance" name="ReservesAccrualBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_CashCashEquivalentsAndMarketableSecuritiesTable" name="CashCashEquivalentsAndMarketableSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_BillAndMelindaGatesFoundationMember" name="BillAndMelindaGatesFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance" name="IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_PaymentToHoldings" name="PaymentToHoldings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_TimeBasedVestingScheduleMember" name="TimeBasedVestingScheduleMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_GlobalAccessAndStrategyCommitmentAgreementMember" name="GlobalAccessAndStrategyCommitmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_LessRemovalOfChangeInFairValueOfWarrantLiability" name="LessRemovalOfChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_AcceleratedDepreciationMember" name="AcceleratedDepreciationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_WarrantsFairValueAssumptionsVolatility" name="WarrantsFairValueAssumptionsVolatility" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan" name="SharesPurchasedByEmployeesUnderEmployeePurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_LargestCollaborationPartnerMember" name="LargestCollaborationPartnerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember" name="ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ConvertibleOptionalSeniorNotesMember" name="ConvertibleOptionalSeniorNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_RevenueReserveAccrualsMember" name="RevenueReserveAccrualsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_CaliforniaStateTaxAuthorityMember" name="CaliforniaStateTaxAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants" name="IncomeTaxRateReconciliationMarkToMarketOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" name="AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_WarrantsFairValueAssumptionsRiskFreeRate" name="WarrantsFairValueAssumptionsRiskFreeRate" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_DusseldorfLeaseMember" name="DusseldorfLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ThirdLargestCustomerMember" name="ThirdLargestCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock" name="SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock" name="LiquidityAndFinancialConditionDisclosurePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare" name="DebtInstrumentCappedCallTransactionInitialStrikePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_SerumInstituteOfIndiaPrivateLimitedMember" name="SerumInstituteOfIndiaPrivateLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity" name="PercentageOfFeePayableUponPartialPrepaymentOrMaturity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_CpG1018Member" name="CpG1018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_CRGServicingLLCMember" name="CRGServicingLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_CumulativeTranslationAdjustmentNetOfTax" name="CumulativeTranslationAdjustmentNetOfTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_UndistributedEarningsAllocatedToParticipatingSecurities" name="UndistributedEarningsAllocatedToParticipatingSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" name="ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_DebtInstrumentConversionPeriodOneMember" name="DebtInstrumentConversionPeriodOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_PreferredStockConversionPricePerShare" name="PreferredStockConversionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember" name="AmendedTwoThousandAndEighteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember" name="EmeryvilleCaliforniaAndDusseldorfGermanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_LongTermDeferredRevenueMember" name="LongTermDeferredRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_GrantAgreementMember" name="GrantAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract" name="DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_BainCapitalLifeSciencesFundLimitedPartnerMember" name="BainCapitalLifeSciencesFundLimitedPartnerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_TwoThousandTwentyATMAgreementMember" name="TwoThousandTwentyATMAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember" name="ConvertibleSeniorNotesDueTwoThousandTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IncreaseDecreaseInCepiAccrual" name="IncreaseDecreaseInCepiAccrual" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_TrisalusLifeSciencesMember" name="TrisalusLifeSciencesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_LicenseArrangementContingentConsiderationPercentage" name="LicenseArrangementContingentConsiderationPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" name="DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares" name="IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" name="AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare" name="DebtInstrumentCappedCallTransactionInitialCapPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock" name="MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_BainLifeSciencesMember" name="BainLifeSciencesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ProceedsFromWarrantsSale" name="ProceedsFromWarrantsSale" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_ServicesAndMaterialsMember" name="ServicesAndMaterialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_DeutscheBankSecuritiesMember" name="DeutscheBankSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_OperatingLossCarryforwardExpirationYear" name="OperatingLossCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_PercentageOfExcessRentPaidToLandlord" name="PercentageOfExcessRentPaidToLandlord" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_USDepartmentOfDefenseMember" name="USDepartmentOfDefenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares" name="IssuanceOfCommonStockUponExerciseOfStockOptionsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_PaymentReceivedForPreCommercializationMilestone" name="PaymentReceivedForPreCommercializationMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_AdditionalFuturePayment" name="AdditionalFuturePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_RevenueReserveAccrualCurrent" name="RevenueReserveAccrualCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" name="IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_DeferredRevenueSubtractions" name="DeferredRevenueSubtractions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_DescriptionOfAveciaSupplyAgreement" name="DescriptionOfAveciaSupplyAgreement" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" name="IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_MerckMember" name="MerckMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants" name="PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_PreferredStockDeemedDividend" name="PreferredStockDeemedDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused" name="MinimumAgeApprovedForVaccinePreventionOfInfectionCaused" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" name="ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue" name="IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_OtherRevenueMember" name="OtherRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_NumberOfCommonStockPreferredStockConvertibleInto" name="NumberOfCommonStockPreferredStockConvertibleInto" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_PaymentsForPurchaseOfCappedCallOptions" name="PaymentsForPurchaseOfCappedCallOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_DebtInstrumentAdditionalIssueAmount" name="DebtInstrumentAdditionalIssueAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization" name="Deferredtaxassetsoperatinglosscarryforwardscapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount" name="FairValueAssetLiabilityLevel1ToLevel2TransferAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_PrepaymentOfAdvancePayment" name="PrepaymentOfAdvancePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_AssetPurchaseAgreementMember" name="AssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_AdvancePaymentFromCustomer" name="AdvancePaymentFromCustomer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_FairValueAdjustmentsOfWarrants" name="FairValueAdjustmentsOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_CaliforniaAndOtherStatesTaxAuthorityMember" name="CaliforniaAndOtherStatesTaxAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException" name="PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_PercentageOfLongLivedAssets" name="PercentageOfLongLivedAssets" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_EmployeeSeveranceAndOtherBenefitsMember" name="EmployeeSeveranceAndOtherBenefitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises" name="PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_IncreaseDecreaseInPrepaidManufacturing" name="IncreaseDecreaseInPrepaidManufacturing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_Cpg1018AdjuvantInventoryMember" name="Cpg1018AdjuvantInventoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_CashSettlementOfWarrants" name="CashSettlementOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_WarrantsIssuanceDate" name="WarrantsIssuanceDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_WarrantsFairValueAssumptionsDividendYield" name="WarrantsFairValueAssumptionsDividendYield" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_TwoThousandAndEighteenEquityIncentivePlanMember" name="TwoThousandAndEighteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_WarrantsExpirationDate" name="WarrantsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock" name="ScheduleOfMaterialPurchaseCommitmentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock" name="PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_DebtInstrumentConversionPeriodTwoMember" name="DebtInstrumentConversionPeriodTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_AggregateMinimumCommitment" name="AggregateMinimumCommitment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_PriceOfCommonStock" name="PriceOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_MerckSharpAndDohmeCorporationMember" name="MerckSharpAndDohmeCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm" name="ReclassificationOfCepiAccrualToCepiAccrualLongTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" name="DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ThirdLargestCollaborationPartnerMember" name="ThirdLargestCollaborationPartnerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember" name="BCIPLifeSciencesAssociatesLimitedPartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_NonCashInterestExpense" name="NonCashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_LaboratoryEquipmentGross" name="LaboratoryEquipmentGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_RepaymentOfAdvanceFromCustomer" name="RepaymentOfAdvanceFromCustomer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_IncomeTaxReconciliationDeferredCompensationCharges" name="IncomeTaxReconciliationDeferredCompensationCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_ConvertibleSeniorNotesMember" name="ConvertibleSeniorNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_PtBioFarmaPerseroMember" name="PtBioFarmaPerseroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IncomeTaxReconciliationTaxCredit" name="IncomeTaxReconciliationTaxCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_LicenseArrangementContingentPaymentToAcquireLicense" name="LicenseArrangementContingentPaymentToAcquireLicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_CoalitionForEpidemicPreparednessInnovationsAccruals" name="CoalitionForEpidemicPreparednessInnovationsAccruals" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_PowellStreetSubleaseMember" name="PowellStreetSubleaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare" name="IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_SymphonyDynamoHoldingsLlcMember" name="SymphonyDynamoHoldingsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IssuanceOfCommonStockUponExerciseOfStockOptions" name="IssuanceOfCommonStockUponExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_ContingentMilestonePaymentReceivable" name="ContingentMilestonePaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems" name="CashCashEquivalentsAndMarketableSecuritiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_BiologicalELimitedMember" name="BiologicalELimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" name="ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount" name="DebtInstrumentConversionOriginalDebtBasePrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount" name="EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_NetOperatingLossAndTaxCreditLimitations" name="NetOperatingLossAndTaxCreditLimitations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_PerformanceBasedVestingScheduleMember" name="PerformanceBasedVestingScheduleMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_CepiAccrualLongTerm" name="CepiAccrualLongTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_ComputerEquipmentGross" name="ComputerEquipmentGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_HortonStreetMasterLeaseMember" name="HortonStreetMasterLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_AmountPaidToThirdParty" name="AmountPaidToThirdParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" name="SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount" name="FairValueAssetLiabilityLevel2ToLevel1TransferAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue" name="LessorSubleaseRentalsPaymentsToBeReceivedDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_ValnevaSEMember" name="ValnevaSEMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_CloverAmendmentNoTwoMember" name="CloverAmendmentNoTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember" name="CoalitionForEpidemicPreparednessInnovationsPartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_NumberOfCommonStockWarrantExercised" name="NumberOfCommonStockWarrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_UpfrontPaymentReceivable" name="UpfrontPaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract" name="AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock" name="ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_SublicenseAgreementMember" name="SublicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_AccruedInventory" name="AccruedInventory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan" name="SharesAvailableForPurchasesUnderEmployeePurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dvax_CoalitionForEpidemicPreparednessInnovationsMember" name="CoalitionForEpidemicPreparednessInnovationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" name="ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_PaymentMadeForPreCommercializationMilestone" name="PaymentMadeForPreCommercializationMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_MarketBasedPerformanceStockUnitMember" name="MarketBasedPerformanceStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus" name="PaymentsForTaxesRelatedToNetShareSettlementOfRsus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dvax_ModifiedPurchaseOrderMember" name="ModifiedPurchaseOrderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_PrepaidManufacturing" name="PrepaidManufacturing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_PerformanceBasedRestrictedStockUnitsMember" name="PerformanceBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_PreferredStockCommonStockAndWarrantsAbstract" name="PreferredStockCommonStockAndWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_TwentySeventeenAtTheMarketAgreementMember" name="TwentySeventeenAtTheMarketAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ProceedsFromGrant" name="ProceedsFromGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_Section162MLimitation" name="Section162MLimitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dvax_EarningsPerShareDisclosureLineItems" name="EarningsPerShareDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_MedigenVaccineBiologicsMember" name="MedigenVaccineBiologicsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock" name="ScheduleOfConvertibleNotesInterestExpenseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_SublicenseLiabilityMember" name="SublicenseLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock" name="ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dvax_UnvestedMember" name="UnvestedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue" name="IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476998677952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 20, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DVAX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Dynavax Technologies Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001029142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,614,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0728374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 Powell Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">848-5100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Definitive Proxy Statement for the registrant&#8217;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III, Items 10-14 of this Form 10-K. The Definitive Proxy Statement will be filed no later than 120 days after the close of the registrant&#8217;s fiscal year ended December 31, 2023.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993619616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 150,279<span></span>
</td>
<td class="nump">$ 202,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities available-for-sale</a></td>
<td class="nump">592,023<span></span>
</td>
<td class="nump">422,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivables, net of allowance for doubtful accounts of $12,313 and $0 at December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">40,607<span></span>
</td>
<td class="nump">145,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">3,926<span></span>
</td>
<td class="nump">2,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">53,290<span></span>
</td>
<td class="nump">59,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">18,995<span></span>
</td>
<td class="nump">85,629<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">859,120<span></span>
</td>
<td class="nump">916,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">37,297<span></span>
</td>
<td class="nump">37,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">24,287<span></span>
</td>
<td class="nump">25,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,067<span></span>
</td>
<td class="nump">2,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets (Note 9 )</a></td>
<td class="nump">74,325<span></span>
</td>
<td class="nump">3,518<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">997,096<span></span>
</td>
<td class="nump">985,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,245<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development</a></td>
<td class="nump">2,982<span></span>
</td>
<td class="nump">4,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CoalitionForEpidemicPreparednessInnovationsAccruals', window );">CEPI accrual (Note 9)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">107,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities (Note 7)</a></td>
<td class="nump">49,448<span></span>
</td>
<td class="nump">30,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">4,520<span></span>
</td>
<td class="nump">3,631<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">62,195<span></span>
</td>
<td class="nump">150,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes, net of debt discount of $2,802 and $3,922 at December 31, 2023 and December 31, 2022, respectively (Note 10)</a></td>
<td class="nump">222,698<span></span>
</td>
<td class="nump">221,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">29,720<span></span>
</td>
<td class="nump">32,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CepiAccrualLongTerm', window );">CEPI accrual long-term (Note 9)</a></td>
<td class="nump">60,337<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">375,024<span></span>
</td>
<td class="nump">404,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.001 par value, 5,000 shares authorized at December 31, 2023, and 2022; zero shares outstanding at December 31, 2023 and 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.001 par value; 278,000 shares authorized at December 31, 2023, and 2022; 129,530 shares and 127,604 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,554,634<span></span>
</td>
<td class="nump">1,510,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,108)<span></span>
</td>
<td class="num">(5,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(930,584)<span></span>
</td>
<td class="num">(924,195)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">622,072<span></span>
</td>
<td class="nump">581,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 997,096<span></span>
</td>
<td class="nump">$ 985,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_CepiAccrualLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CEPI accrual long-term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_CepiAccrualLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_CoalitionForEpidemicPreparednessInnovationsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Coalition for Epidemic Preparedness Innovations accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_CoalitionForEpidemicPreparednessInnovationsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476998277072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts receivables</a></td>
<td class="nump">$ 12,313<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, debt discount</a></td>
<td class="nump">$ 2,802<span></span>
</td>
<td class="nump">$ 3,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">278,000,000<span></span>
</td>
<td class="nump">278,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">129,530,000<span></span>
</td>
<td class="nump">127,604,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">129,530,228<span></span>
</td>
<td class="nump">127,604,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476998342496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 232,284<span></span>
</td>
<td class="nump">$ 722,683<span></span>
</td>
<td class="nump">$ 439,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of sales - product</a></td>
<td class="nump">50,167<span></span>
</td>
<td class="nump">262,153<span></span>
</td>
<td class="nump">173,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">54,886<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
<td class="nump">32,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">152,946<span></span>
</td>
<td class="nump">131,408<span></span>
</td>
<td class="nump">100,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gain on sale of assets (Note 8)</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_BadDebtExpense', window );">Bad debt expense (Note 9)</a></td>
<td class="nump">12,313<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">269,312<span></span>
</td>
<td class="nump">439,161<span></span>
</td>
<td class="nump">304,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(37,028)<span></span>
</td>
<td class="nump">283,522<span></span>
</td>
<td class="nump">134,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">31,993<span></span>
</td>
<td class="nump">7,912<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,757)<span></span>
</td>
<td class="num">(6,732)<span></span>
</td>
<td class="num">(11,176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">7,577<span></span>
</td>
<td class="nump">7,685<span></span>
</td>
<td class="nump">7,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment (Note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability (Note 14)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
<td class="num">(49,354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="num">(152)<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net (loss) income before income taxes, Total</a></td>
<td class="num">(4,367)<span></span>
</td>
<td class="nump">294,299<span></span>
</td>
<td class="nump">77,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(2,022)<span></span>
</td>
<td class="num">(1,143)<span></span>
</td>
<td class="num">(808)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(6,389)<span></span>
</td>
<td class="nump">293,156<span></span>
</td>
<td class="nump">76,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_UndistributedEarningsAllocatedToParticipatingSecurities', window );">Undistributed earnings allocated to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(283)<span></span>
</td>
<td class="num">(4,569)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income allocable to common stockholders, basic</a></td>
<td class="num">$ (6,389)<span></span>
</td>
<td class="nump">$ 292,873<span></span>
</td>
<td class="nump">$ 72,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share allocable to common stockholders</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share allocable to common stockholders</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing basic net (loss) income per share allocable to common stockholders</a></td>
<td class="nump">128,733<span></span>
</td>
<td class="nump">126,398<span></span>
</td>
<td class="nump">116,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing diluted net (loss) income per share allocable to common stockholders</a></td>
<td class="nump">128,733<span></span>
</td>
<td class="nump">150,797<span></span>
</td>
<td class="nump">133,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 213,295<span></span>
</td>
<td class="nump">$ 713,645<span></span>
</td>
<td class="nump">$ 437,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_OtherRevenueMember', window );">Other Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 18,989<span></span>
</td>
<td class="nump">$ 9,038<span></span>
</td>
<td class="nump">$ 2,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_BadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bad debt expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_BadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_UndistributedEarningsAllocatedToParticipatingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undistributed earnings allocated to participating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_UndistributedEarningsAllocatedToParticipatingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993151040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (6,389)<span></span>
</td>
<td class="nump">$ 293,156<span></span>
</td>
<td class="nump">$ 76,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale', window );">Change in unrealized loss on marketable securities available-for-sale</a></td>
<td class="nump">2,251<span></span>
</td>
<td class="num">(1,407)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative foreign currency translation adjustments</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="num">(1,765)<span></span>
</td>
<td class="num">(2,509)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">3,330<span></span>
</td>
<td class="num">(3,172)<span></span>
</td>
<td class="num">(2,539)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive (loss) income</a></td>
<td class="num">$ (3,059)<span></span>
</td>
<td class="nump">$ 289,984<span></span>
</td>
<td class="nump">$ 74,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in unrealized gain on marketable securities available-for-sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993436288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2020</a></td>
<td class="nump">$ 58,693<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,352,374<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
<td class="num">$ (1,294,064)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,190,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,140,000<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares', window );">Issuance of common stock upon release of restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards', window );">Issuance Of Common Stock Upon Release Of Restricted Stock Awards</a></td>
<td class="num">(107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponExerciseOfStockOptions', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">6,684<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares', window );">Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,879,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement', window );">Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement</a></td>
<td class="nump">28,156<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">28,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares', window );">Issuance of common stock upon exercise of warrants (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,959,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">59,888<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCappedCallOptionsSeeNote10', window );">Issuance of capped call options (see Note 10)</a></td>
<td class="num">(27,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">21,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(2,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">76,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,713<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2021</a></td>
<td class="nump">222,374<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,441,868<span></span>
</td>
<td class="num">(2,266)<span></span>
</td>
<td class="num">(1,217,351)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares', window );">Issuance of common stock upon release of restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards', window );">Issuance Of Common Stock Upon Release Of Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponExerciseOfStockOptions', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">9,640<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares', window );">Issuance of common stock upon exercise of warrants (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,879,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">24,670<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">32,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(3,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">293,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,156<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2022</a></td>
<td class="nump">581,013<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,510,518<span></span>
</td>
<td class="num">(5,438)<span></span>
</td>
<td class="num">(924,195)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,604,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponExerciseOfStockOptions', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">6,361<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare', window );">Issuance of common stock upon release of restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings', window );">Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings</a></td>
<td class="num">(6,370)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">42,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">3,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(6,389)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2023</a></td>
<td class="nump">$ 622,072<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,554,634<span></span>
</td>
<td class="num">$ (2,108)<span></span>
</td>
<td class="num">$ (930,584)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCappedCallOptionsSeeNote10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of capped call options (see Note 10)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCappedCallOptionsSeeNote10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCommonStockUponExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock Upon Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCommonStockUponExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock Upon Exercise Of Stock Options, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCommonStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCommonStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of warrants (Shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock Upon Release Of Restricted Stock Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings(share)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock Upon Release Of Restricted Stock Awards Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476991601408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (6,389)<span></span>
</td>
<td class="nump">$ 293,156<span></span>
</td>
<td class="nump">$ 76,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,342<span></span>
</td>
<td class="nump">3,812<span></span>
</td>
<td class="nump">4,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">2,934<span></span>
</td>
<td class="nump">2,856<span></span>
</td>
<td class="nump">2,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,288<span></span>
</td>
<td class="nump">2,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums (accretion of discounts) on marketable securities</a></td>
<td class="num">(16,555)<span></span>
</td>
<td class="num">(4,181)<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,801)<span></span>
</td>
<td class="nump">49,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">42,592<span></span>
</td>
<td class="nump">32,915<span></span>
</td>
<td class="nump">21,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">1,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gain on sale of assets</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_BadDebtExpense', window );">Bad debt expense (Note 9)</a></td>
<td class="nump">12,313<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts and other receivables, net</a></td>
<td class="nump">43,268<span></span>
</td>
<td class="num">(15,699)<span></span>
</td>
<td class="num">(109,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="nump">3,909<span></span>
</td>
<td class="num">(32,399)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncreaseDecreaseInPrepaidManufacturing', window );">Prepaid manufacturing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,655<span></span>
</td>
<td class="num">(130,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,673)<span></span>
</td>
<td class="num">(11,865)<span></span>
</td>
<td class="num">(64,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="num">(767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncreaseDecreaseInCepiAccrual', window );">CEPI accrual (Note 9)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,110)<span></span>
</td>
<td class="nump">128,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(3,629)<span></span>
</td>
<td class="num">(3,125)<span></span>
</td>
<td class="num">(3,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(349,864)<span></span>
</td>
<td class="nump">311,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">19,809<span></span>
</td>
<td class="num">(24,788)<span></span>
</td>
<td class="nump">39,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">100,563<span></span>
</td>
<td class="nump">62,716<span></span>
</td>
<td class="nump">335,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(636,921)<span></span>
</td>
<td class="num">(632,306)<span></span>
</td>
<td class="num">(164,928)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and redemptions of marketable securities</a></td>
<td class="nump">486,097<span></span>
</td>
<td class="nump">322,450<span></span>
</td>
<td class="nump">187,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment, net</a></td>
<td class="num">(4,104)<span></span>
</td>
<td class="num">(7,139)<span></span>
</td>
<td class="num">(9,477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of assets, net of transaction costs</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(153,928)<span></span>
</td>
<td class="num">(315,995)<span></span>
</td>
<td class="nump">14,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of Convertible Notes, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">219,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PaymentsForPurchaseOfCappedCallOptions', window );">Purchases of capped call options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(190,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,455<span></span>
</td>
<td class="nump">17,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet', window );">Proceeds from exercise of stock options and release of restricted stock awards, net</a></td>
<td class="nump">6,360<span></span>
</td>
<td class="nump">9,639<span></span>
</td>
<td class="nump">6,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus', window );">Payments for taxes related to net share settlement of RSUs</a></td>
<td class="num">(6,509)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">19,525<span></span>
</td>
<td class="nump">55,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents, and restricted cash</a></td>
<td class="nump">324<span></span>
</td>
<td class="num">(443)<span></span>
</td>
<td class="num">(1,431)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents, and restricted cash</a></td>
<td class="num">(51,655)<span></span>
</td>
<td class="num">(234,197)<span></span>
</td>
<td class="nump">404,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash at beginning of year</a></td>
<td class="nump">202,211<span></span>
</td>
<td class="nump">436,408<span></span>
</td>
<td class="nump">32,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash at end of year</a></td>
<td class="nump">150,556<span></span>
</td>
<td class="nump">202,211<span></span>
</td>
<td class="nump">436,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the year for income taxes</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the year for interest</a></td>
<td class="nump">5,638<span></span>
</td>
<td class="nump">5,638<span></span>
</td>
<td class="nump">9,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets', window );">Reclassification of contract asset from other current assets to other assets</a></td>
<td class="nump">71,307<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm', window );">Reclassification of CEPI accrual to CEPI accrual long-term</a></td>
<td class="num">(60,337)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AdvancePaymentFromCustomer', window );">Advance Payments forgiven per CEPI-Bio E Assignment Agreement (Note 9)</a></td>
<td class="num">(47,401)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment, not yet paid</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 1,332<span></span>
</td>
<td class="nump">$ 2,848<span></span>
</td>
<td class="nump">$ 2,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_AdvancePaymentFromCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance payment from customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_AdvancePaymentFromCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_BadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bad debt expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_BadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IncreaseDecreaseInCepiAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cepi Accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IncreaseDecreaseInCepiAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IncreaseDecreaseInPrepaidManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid manufacturing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IncreaseDecreaseInPrepaidManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_PaymentsForPurchaseOfCappedCallOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of capped call options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_PaymentsForPurchaseOfCappedCallOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for taxes related to net share settlement of RSUs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of stock options and restricted stock awards net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of CEPI accrual to CEPI accrual long-term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of contract asset from other current assets to other assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001234160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dynavax Technologies Corporation (&#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Dynavax&#8221; or the &#8220;Company&#8221;) is a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Our first marketed product, HEPLISAV-B&#174; [Hepatitis B Vaccine (Recombinant), Adjuvanted] is approved in the United States, the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and older. In May 2022, we commenced commercial shipments of HEPLISAV-B in Germany.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing a pipeline of differentiated product candidates that leverage our CpG 1018&#174; adjuvant, the adjuvant used in HEPLISAV-B, to develop improved vaccines in indications with unmet medical needs. These programs include vaccine candidates under development for shingles and Tdap, and a plague vaccine candidate program in collaboration with and fully funded by the U.S. Department of Defense ("DoD").</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally. we manufacture and have supplied in the past CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B, through both commercial supply agreements, and through preclinical and clinical research collaborations with third-party organizations. As of December 31, 2022, we had satisfied all delivery obligations under our commercial supply agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477000142624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and include our accounts and those of our wholly-owned subsidiaries, Dynavax GmbH located in D&#252;sseldorf, Germany, Dynavax India LLP in India and a branch of Dynavax in Italy. All intercompany accounts and transactions among the entities have been eliminated from the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management&#8217;s estimates are based on historical information available as of the date of the consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency Translation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider the local currency to be the functional currency for our international subsidiaries, Dynavax GmbH, located in D&#252;sseldorf, Germany, Dynavax India LLP, and a branch of Dynavax registered in Italy. Accordingly, assets and liabilities denominated in this foreign currency are translated into U.S. dollars using the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the year. Currency translation adjustments arising from period to period are charged or credited to accumulated other comprehensive income (loss) in stockholders&#8217; equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of Decemb</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">er 31, 2023 and 2022, the cumulative translation adjustments balance was $</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) million, respectively, primarily related to the translation of Dynavax GmbH assets, liabilities and operating results from Euros to U.S. dollars. F</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or the years ended December 31, 2023, 2022 and 2021, we reported an unrealized foreign currency translation gain (loss) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) million and $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) million, respectively. Realized gains and losses resulting from currency transactions are included in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> other (expense) income in the consolidated statements of operations. For the years ended December 31, 2023, 2022 and 2021, we reported a (loss) gain of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">llion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, resulting from currency transactions in our consolidated statements of operations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">segment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and in assessing performance. Our Chief Executive Officer is the CODM. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, management has determined that we operate in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment that is focused on the discovery, development, and commercialization of innovative vaccines. Net assets outside of the U.S. w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ere less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of total net assets as of December 31, 2023 and 2022.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and Cash Equivalents and Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider all liquid investments purchased with an original maturity of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or less and that can be liquidated without prior notice or penalty to be cash equivalents. Management determines the appropriate classification of marketable securities at the time of purchase. In accordance with our investment policy, we invest in short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We believe these types of investments are subject to minimal credit and market risk.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive loss in stockholders&#8217; equity. Commencing with our adoption of (&#8220;ASC&#8221;) 326, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8212; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(&#8220;ASC 326")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on January 1, 2023, we determine whether a decline in the fair value of our available-for-sale ("AFS") debt securities below their amortized cost basis (i.e., an impairment) is due to credit-related factors or noncredit-related factors. Any impairment that is not credit related is recognized in other comprehensive income (loss), net of applicable taxes. Credit-related impairments (if any) are recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Both the allowance and the adjustment to net income can be reversed if conditions change. To date, there have been no declines in fair value that have been identified as a credit-related impairment.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any significant losses on our cash equivalents and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts. We estimate our allowance for doubtful accounts based on</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. During the year ended December 31, 2023, we recorded an allowance for doubtful accounts of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was determined by assessing changes in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biological E. Limited's (&#8220;Bio E&#8221;) credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (See Note 9), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customers collectively represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our HEPLISAV-B trade receivable balance, respectively. As of December 31, 2023, we had no CpG 1018 adjuvant trade receivable balance. As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our CpG 1018 adjuvant trade receivable balance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates will require approval from the United States Food and Drug Administration ("FDA") and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our product candidates will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process that could affect our authorizations in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our long-lived assets located in the United States as of December 31, 2023 and 2022, represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our total assets, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respectively, and the remaining long-lived assets were located in Germany.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HEPLISAV-B Inventories</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the years ended December 31, 2023 and 2022, there w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ere </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> invento</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ry reserves or write-offs recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to the required regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory. Instead, those are expensed as research and development costs. We begin capitalization of these inventory related costs once regulatory approval is obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CpG 1018 Adjuvant Inventories</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the year ended December 31, 2023, there was no remaining CpG 1018 adjuvant inventory balance. For the year ended December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of inventory write-off to cost of sales - product, in connection with cancelled orders and the reduction in demand for CpG 1018 adjuvant reflected in the Clover Supply Agreement, as amended (See Note 9).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized, while repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluate the carrying value of long-lived assets, whenever events or changes in business circumstances or our planned use of long-lived assets indicate, based on undiscounted future operating cash flows, that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. When an indicator of impairment exists, undiscounted future operating cash flows of long-lived assets are compared to their respective carrying value. If the carrying value is greater than the undiscounted future operating cash flows of long-lived assets, the long-lived assets are written down to their respective fair values and an impairment loss is recorded. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. There have been no material adjustments to these estimates during the years presented.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determine if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset, and whether we have the right to control the identified asset. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, other current liabilities and long-term portion of lease liabilities in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. The classification of our leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of ROU assets and lease liabilities is based on the present value of future lease payments over the lease term. The ROU asset also includes the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the implicit rate in our leases is generally unknown, we use our incremental borrowing rate based on information available at the lease commencement date in determining the present value of future lease payments. We consider our credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary, when calculating our incremental borrowing rate. The lease terms may include options to extend or terminate the lease when it is reasonably certain we will exercise any such options. Rent expense for our operating leases is recognized on a straight-line basis over the lease term. Variable lease payments are recorded as an expense in the period incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have elected not to apply the recognition requirements of Accounting Standards Codification ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases ("ASC 842")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for short-term leases. We have also elected the practical expedient to not separate lease components from non-lease components.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As lessors, we determine if an arrangement includes a lease at inception. We elected the practical expedient to not separate lease components from non-lease components. Sublease income is recognized on a straight-line basis over the expected lease term and is included in other income (expense) in our consolidated statements of operations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess purchase price over the fair value of tangible and intangible assets acquired and liabilities assumed. Our goodwill balance relates to our acquisition of Dynavax GmbH in 2006. Goodwill is not amortized, but instead is reviewed for impairment test at least annually, or more frequently if events occur or circumstances change that would indicate the carrying amount may be impaired. Goodwill is assigned to, and impairment testing is performed at, the reporting unit level. We determined that we have only </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment and there are no components of that operating segment that are deemed to be separate reporting units, such that we have one reporting unit for purposes of our goodwill impairment testing. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment has been identified for the years presented.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Convertible Notes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% convertible senior notes due in 2026 (&#8220;Convertible Notes&#8221;), as a long-term liability equal to the proceeds received from issuance, including the embedded conversion feature, net of the unamortized debt issuance and offering costs on the consolidated balance sheets (See Note 10). We evaluate all conversion, repurchase and redemption features contained in a debt instrument to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is not required to be accounted for separately as an embedded derivative. We amortize debt issuance and offering costs over the contractual term of the Convertible Notes, using the effective interest method, as interest expense on the consolidated statements of operations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capped Calls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluate financial instruments under ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging ("ASC 815")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The capped calls purchased in connection with the Convertible Notes financing ("Capped Calls") cover the same number of shares of common stock that initially underlie the Convertible Notes (subject to anti-dilution and certain other adjustments). The Capped Calls meet the definition of derivative under ASC 815. In addition, the Capped Calls meet the conditions in ASC 815 to be classified in stockholders&#8217; equity and are not subsequently remeasured as long as the conditions for the equity classification continue to be met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration, which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers ("ASC 606")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we apply the following five step model:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the performance obligation(s) in the contract;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determine the transaction price;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocate the transaction price to the performance obligation(s) in the contract; and </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognize revenue when (or as) we satisfy a performance obligation. </span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Revenue, Net &#8211; HEPLISAV-B</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We sell HEPLISAV-B to a limited number of wholesalers and specialty distributors in the U.S. (collectively, our &#8220;Customers&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product upon delivery to the Customer. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Because our standard credit terms are short-term and we expect to receive payment in less than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there is no significant financing component on the related receivables. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. Since our performance obligation is part of a contract that has an original expected duration of one year or less, we elect not to disclose the information about our remaining performance obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overall, product revenue, net - HEPLISAV-B, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reserves for Variable Consideration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration such as product returns, chargebacks, discounts, rebates and other fees that are offered within contracts between us and our Customers, healthcare providers, pharmacies and others relating to our product sales. We estimate variable consideration using either the most likely amount method or the expected value method, depending on the type of variable consideration and what method better predicts the amount of consideration we expect to receive. We take into consideration relevant factors such as industry data, current contractual terms, available information about Customers&#8217; inventory, resale and chargeback data and forecasted customer buying and payment patterns, in estimating each variable consideration. The variable consideration is recorded at the time product sales is recognized, resulting in a reduction in product revenue and a reduction in accounts receivable (if the Customer offsets the amount against its accounts receivable) or as an accrued liability (if we pay the amount through our accounts payable process). Variable consideration requires significant estimates, judgment and information obtained from external sources. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. If we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of revenue that we report in a particular period. We evaluate our estimates of variable considerations including, but not limited to, product returns, chargebacks and rebates, periodically or when there is an event or change in circumstances that may indicate that our estimates may change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Returns:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Consistent with industry practice, we offer our Customers a limited right of return based on the product&#8217;s expiration date for product that has been purchased from us. We estimate the amount of our product sales that may be returned by our Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We consider several factors in the estimation of potential product returns including expiration dates of the product shipped, the limited product return rights, available information about Customers&#8217; inventory and other relevant factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chargebacks:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our Customers subsequently resell our product to healthcare providers, pharmacies and others. In addition to distribution agreements with Customers, we enter into arrangements with qualified healthcare providers that provide for chargebacks and discounts with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by Customers, and we issue credits for such amounts generally within a few weeks of the Customer&#8217;s notification to us of the resale. Reserves for chargebacks consists of credits that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect will be sold to the qualified healthcare providers, and chargebacks for units that our Customers have sold to the qualified healthcare providers, but for which credits have not been issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trade Discounts and Allowances:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We provide our Customers with discounts which include early payment incentives that are explicitly stated in our contracts, and are recorded as a reduction of revenue in the period the related product revenue is recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distribution Fees: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Distribution fees include fees paid to certain Customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rebates: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under certain contracts, Customers may obtain rebates for purchasing minimum volumes of our product. We estimate these rebates based upon the expected purchases and the contractual rebate rate and record this estimate as a reduction in revenue in the period the related revenue is recognized.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Revenue, Net &#8211; CpG 1018 Adjuvant</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also sell our innovative adjuvant, CpG 1018 adjuvant, to our collaboration partners for use in their development and/or commercialization of COVID-19 vaccine. We have determined that our collaboration partners meet the definition of Customers under ASC 606. Therefore, we accounted for our CpG 1018 adjuvant sales under ASC 606. Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product to the customer. Because the timing between the recognition of revenue for product sales and the receipt of payment is less than one year, there is no significant financing component on the related receivables. Since our performance obligation is part of a contract that has an original expected duration of one year or less, we elect not to disclose the information about our remaining performance obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overall, product revenue, net - CpG 1018 adjuvant, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. Our CpG 1018 adjuvant customers have purchased a significant quantity of CpG 1018 adjuvant as part of their initial COVID-19 vaccine development inventory. Accordingly, we did not recognize CpG 1018 adjuvant net product revenue during the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other revenue includes revenue from our agreement with the DoD, collaboration and manufacturing service revenue. We have entered into grant agreements, collaborative arrangements and arrangements to provide manufacturing services to other companies. Such arrangements may include promises to customers which, if capable of being distinct, are accounted for as separate performance obligations. For agreements with multiple performance obligations, we allocate estimated revenue to each performance obligation at contract inception based on the estimated transaction price of each performance obligation. Revenue allocated to each performance obligation is then recognized when we satisfy the performance obligation by transferring control of the promised good or service to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Expenses and Accruals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. Our accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties. We estimate research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to us at that time. There have been no material adjustments to the prior period accrued estimates for clinical trial activities during the years presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense for restricted stock units ("RSUs"), market-based performance stock units ("PSUs") and stock options is estimated at the grant date based on the award&#8217;s estimated fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For awards that vest based on service conditions and market conditions, we use a straight-line method to recognize compensation expense over the award&#8217;s requisite service period, assuming estimated forfeiture rates. For awards that contain performance conditions, we determine the appropriate amount to expense at each reporting date based on the anticipated achievement of performance targets, which requires judgement, including forecasting the achievement of future specified targets. At the date performance conditions are determined to be probable of achievement, we record a cumulative expense catch-up, with remaining expense amortized over the remaining service period. Throughout the performance period, we re-assesses the estimated performance and updates the number of performance-based awards that we believe will ultimately vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value of RSUs is determined at the date of grant using our closing stock price, with the exception of PSUs, which are measured using the Monte Carlo simulation method on the date of grant. Our determination of the fair value of stock options on the date of grant using an option-pricing model is affected by our stock price, as well as assumptions regarding a number of subjective variables. We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value-based measurement of our stock options. The Black-Scholes model requires the use of subjective assumptions, which determine the fair value-based measurement of stock options. These assumptions include, but are not limited to, our expected stock price volatility over the term of the awards, and projected employee stock option exercise behaviors. In the future, as additional empirical evidence regarding these input estimates becomes available, we may change or refine our approach of deriving these input estimates. These changes could impact our fair value of stock options granted in the future. Changes in the fair value of stock awards could materially impact our operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby increasing stock-based compensation expense recognized in future periods. We derive the expected term assumption primarily based on our historical settlement experience, while considering options that have not yet completed a full life cycle. Stock-based compensation expense is recognized only for awards ultimately expected to vest. Our estimate of the forfeiture rate is based primarily on our historical experience. To the extent we revise this estimate in the future, our share-based compensation expense could be materially impacted in the period of revision. There have been no material adjustments to these estimates during the years presented.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Tax law and rate changes are reflected in income in the period such changes are enacted. We include interest and penalties related to income taxes, including unrecognized tax benefits, within income tax expense.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. We continually assess the likelihood and amount of potential adjustments and adjust the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and the valuation allowance recorded against our net deferred tax assets. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we believe that recognition of the deferred tax assets arising from future tax benefits is currently not more likely than not to be realized and, accordingly, we have determined a need for a full valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Standards Update 2016-13</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which was codified in Accounting Standards Codification ASC 326, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8212; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. Because we were a smaller reporting company based on the most recent determination as of November 15, 2019, ASC 326 became effective for us for fiscal years beginning after December 15, 2022. As such, we adopted ASC 326 effective January 1, 2023, utilizing the modified retrospective transition method. Upon adoption, we updated our impairment model to utilize a forward-looking current expected credit losses (&#8220;CECL&#8221;) model in place of the incurred loss methodology for financial instruments measured at amortized cost, primarily including our accounts receivable and contract asset. In relation to AFS debt securities, the guidance eliminates the concept of &#8220;other-than-temporary&#8221; impairment, and instead focuses on determining whether any impairment is a result of a credit loss or other factors. The adoption of ASC 326 did not have a material impact on our consolidated financial statements as of the adoption date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001370224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Observable inputs, such as quoted prices in active markets for identical assets or liabilities; </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. There wer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ransfers between Level 1, 2 and 3 during the years ended December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of cash equivalents, accounts and other receivables, accounts payable and accrued liabilities are considered reasonable estimates of their respective fair value because of their short-term nature.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recurring Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.95%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.158000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.778%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.778%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.778%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">&#160;Assets</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">216,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">216,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">308,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">308,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">599,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">731,112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">&#160;Assets</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422,391</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">594,809</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. treasuries, U.S. government agency securities and corporate debt securities are measured at fair value using Level 2 inputs. We review trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants were issued in connection with the underwritten public offering in August 2019 and are accounted for as a derivative liability at fair value (See Note 14). The fair value of the warrant liability was estimated using the Black-Scholes model, which requires assumptions such as expected term, expected volatility and risk-free interest rate. These assumptions are subjective and require judgment to develop. Expected term is estimated using the full remaining contractual term of the warrants. We determine expected volatility based on our historical common stock price volatility. The warrant liability was classified as a Level 3 instrument as its value was based on unobservable inputs that are supported by little or no market activity. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,882,600</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the outstanding warrants as of December 31, 2021 have been exercised or expired.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of changes in the fair value warrant liability for year ended December 31, 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80%;"></td>
        <td style="width:2.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.9%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decrease in fair value of warrants exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,801</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants exercised or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001340768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Restricted Cash and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</a></td>
<td class="text"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and Cash Equivalents, Restricted Cash and Marketable Securities </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.151%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">436,189</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents, and restricted cash shown in the<br/>&#160;&#160;&#160;consolidated statements of cash flows</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,556</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">436,408</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted cash is included in "Other assets" in the Consolidated Balance Sheets.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash balances relate to certificates of deposit issued as collateral to certain letters of credit issued as security to our lease arrangements (See Note 8).</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents, and marketable securities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,278</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities available-for-sale:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">216,265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">269</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">216,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">300,803</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">301,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities available-for-sale</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591,177</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">592,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents, and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">741,455</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,180</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">742,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,586</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,586</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities available-for-sale:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,429</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,865</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">826</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities available-for-sale</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423,796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422,391</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents, and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">625,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">624,395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The maturities of our marketable securities available-for-sale are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mature in one year or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">440,131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">440,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mature after one year through two years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">151,046</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">151,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591,177</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">592,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities. Unrealized losses are included in accumulated other comprehensive loss in stockholders&#8217; equity. Commencing with our adoption of ASC 326 on January 1, 2023, we determine whether a decline in the fair value of our AFS debt securities below their amortized cost basis (i.e., an impairment) is due to credit-related factors or noncredit-related factors. Any impairment that is not credit related is recognized in other comprehensive income (loss), net of applicable taxes. Credit-related impairments (if any) are recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Both the allowance and the adjustment to net income can be reversed if conditions change.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">re </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> realized gains </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or losses from the sale of marketable securities for the years ended December 31, 2023 and 2022. We do not intend to sell, and are not required to sell, the investments that are in an unrealized loss position before recovery of their amortized cost basis. For the year ended December 31, 2023, we did not record an allowance for credit losses, as management believes any such losses would be immaterial based on the investment-grade credit rating for each of the investments as of December 31, 2023. As such, there have been no declines in fair value that have been identified as a credit-related impairment.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477093053472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories, net</a></td>
<td class="text"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.13%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents inventories (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.353%;"></td>
        <td style="width:2.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.302000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.302000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,256</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,517</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,954</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,934</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,995</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001173056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and Equipment, net </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.65%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:16.103%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Life (In years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,139</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,827</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,060</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,720</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,467</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,464</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,201</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,832</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,596</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expense on property and equipment was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001370224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract', window );"><strong>Disclosure Component Of Current Accrued Liabilities And Accrued Research And Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Current Accrued Liabilities</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current Accrued Liabilities</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current accrued liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,069</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,261</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue reserve accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued inventory</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,456</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,697</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure component of current accrued liabilities and accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001366704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We lease our facilities in Emeryville, California and D&#252;sseldorf, Germany. We lease and sublease certain manufacturing and office space with lease terms ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of these leases also include options to renew or extend the lease for two successive five-year terms.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> These optional periods have not been considered in the determination of the right-of-use assets or lease liabilities associated with these leases as we did not consider the exercise of these options to be reasonably certain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also sublease one of our leased premises to a third party. Rent is subject to scheduled annual increases and the subtenant is responsible for certain operating expenses and taxes throughout the life of the sublease. The sublease term expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, unless earlier terminated, concurrent with the term of our lease. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subtenant has no option to </span></span><span style=""></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extend </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sublease term.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Sublease income wa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">illion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively. Sublease income is included in other income (expense) in our consolidated statements of operations. Rent received from the subtenant in excess of rent paid to the landlord shall be shared by paying the landlord </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the excess rent. The excess rent is considered a variable lease payment and the total estimated payments are being recognized as additional rent expense on a straight-line basis.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lease expense comprises of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2023, 2022, and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">6.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively and were included in change in lease liabilities in our consolidated statement of cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The balance sheet classification of our operating lease liabilities was as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f58b1a95-4b8b-4052-956a-3314f3bd58e1;"><span style="-sec-ix-hidden:F_92c8237b-9eec-4d96-8dc1-a494a9120777;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of lease liabilities</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(included in other current liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,631</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term portion of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,720</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,801</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,216</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,432</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the maturities of our sublease income and operating lease liabilities were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sublease Income</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Lease<br/>Liabilities</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,605</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,854</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,030</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,122</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,216</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our material non-cancelable purchase and other commitments for the supply of HEPLISAV-B totaled</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summarizes our material purchase commitments at December 31, 2023 and the effect those obligations are expected to have on our liquidity and cash flows in future periods (in thousands):</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,866</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,983</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,516</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 7, 2023 (the &#8220;Effective Date&#8221;), we entered into an agreement (the &#8220;Avecia Supply Agreement&#8221;) with Nitto Denko Avecia Inc. (&#8220;Avecia&#8221;) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the &#8220;2012 Agreement&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our aggregate minimum commitment for the supply of CpG 1018 adjuvant under the Avecia Supply Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within the next 12 months. As of December 31, 2022, w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e had no non-cancelable purchase and other commitments for the supply of CpG 1018 adjuvant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely on and have entered into agreements with research institutions, contract research organizations and clinical investigators as well as clinical material manufacturers. These agreements are terminable by us upon written notice. Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through the notice period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the aggregate principal amount of our convertible senior notes ("Convertible Notes") was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, excluding debt discount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (See Note 10).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2004, we established a letter of credit with Deutsche Bank as security for our D&#252;sseldorf lease in the amount of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (Euros). The letter of credit remained outstanding through December 30, 2023 and was collateralized by a certificate of deposit for &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which has been included in restricted cash in the consolidated balance sheets as of December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conjunction with our agreement with Symphony Dynamo, Inc. and Symphony Dynamo Holdings LLC (&#8220;Holdings&#8221;) in November 2009, we agreed to make contingent cash payments to Holdings equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any third party with respect to the development and/or commercialization of cancer and hepatitis C therapies originally licensed to Symphony Dynamo, Inc., including our immune-oncology compound, SD-101. In July 2020, we sold assets related to SD-101 to Surefire Medical, Inc. d/b/a TriSalus Life Sciences (&#8220;TriSalus&#8221;). We paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Holdings in August 2020. In each of September 2021, May 2022 and September 2023, we received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from TriSalus because it met pre-commercialization milestones. We recorded the proceeds as gain on sale of assets in our consolidated statements of operations. We paid Holdings $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in each of September 2021, May 2022 and October 2023. We included the payments in selling, general and administrative </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses in our consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may be involved in claims, suits, and proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, commercial claims, and other matters. Such claims, suits, and proceedings are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, such legal proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. In addition, it is possible that a resolution of one or more such proceedings could result in substantial damages, fines, penalties or orders requiring a change in our business practices, which could in the future materially and adversely affect our financial position, results of operations, or cash flows in a particular period.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001136912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research, Development and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Research, Development and License Agreements</a></td>
<td class="text"><div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborative Research, Development and License Agreements </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Coalition for Epidemic Preparedness Innovations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2021, we entered into an agreement (together with subsequent amendments, the &#8220;CEPI Agreement&#8221;) with Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) for the manufacture and reservation of a specified quantity of CpG 1018 adjuvant (&#8220;CpG 1018 Materials&#8221;). In May 2021, we entered into the first amendment to the CEPI Agreement. The CEPI Agreement enables CEPI to direct the supply of CpG 1018 Materials to CEPI partner(s). CEPI partner(s) would purchase CpG 1018 Materials under separately negotiated agreements. The CEPI Agreement also allows us to sell CpG 1018 Materials to third parties if not purchased by a CEPI partner within a two-year term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In exchange for reserving CpG 1018 Materials and agreeing to sell CpG 1018 Materials to CEPI partner(s) at pre-negotiated prices, CEPI agreed to provide payments in the form of an interest-free, unsecured, forgivable loan (the &#8220;Advance Payments&#8221;). We are obligated to repay the Advance Payments, in proportion to quantity sold, if and to the extent we receive payments from sales of CpG 1018 Materials reserved under the CEPI Agreement. If the vaccine programs pursued by CEPI partner(s) are unsuccessful and no alternative use is found for CpG 1018 Materials reserved under the CEPI Agreement, the applicable Advance Payments will be forgiven at the end of the two-year term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 27, 2023, we entered into a waiver and second amendment to the CEPI Agreement by and between us and CEPI (the &#8220;CEPI-Bio E Assignment Agreement&#8221;). Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of the outstanding Advance Payments for CpG 1018 Materials allocated to and ordered by Bio E under the CEPI Agreement and has assumed our previous rights to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of Bio E accounts receivable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through Decembe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r 31, 2023, we received Advance Payments totaling approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">175.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million pursuant to the CEPI Agreement, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">67.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million have been repaid and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million have been forgiven (as discussed above). As of December 31, 2023, remaining Advance Payments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million in CEPI accrual long-term were reflected in our consolidated balance sheets, representing the outstanding balance of the Advance Payments relating to the Clover Supply Agreement (as defined and discussed below). As of December 31, 2022, we recorded Advance Payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">107.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million included in CEPI accrual. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> deferred revenue balances related to the CEPI Agreement as of December 31, 2023 and December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, we entered into an agreement with Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited (collectively, &#8220;Clover&#8221;), for the commercial supply of CpG 1018 adjuvant, for use with Clover&#8217;s COVID-19 vaccine candidate, SCB-2019 (together with subsequent amendments, the &#8220;Clover Supply Agreement&#8221;). Under the Clover Supply Agreement, Clover committed to purchase specified quantities of CpG 1018 adjuvant, at pre-negotiated prices pursuant to the CEPI Agreement, for use in Clover&#8217;s commercialization of vaccines containing SCB-2019 and CpG 1018 adjuvant (&#8220;Clover Product&#8221;). The Clover Supply Agreement also provides terms for Clover to order additional quantities of CpG 1018 adjuvant beyond the quantities reserved by CEPI. In 2022 and 2023, we signed four amendments to the Clover Supply Agreement. The terms and conditions of the Clover Supply Agreement were operative through December 2022, and as of December 31, 2022, we had satisfied all delivery obligations thereunder.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For CpG 1018 adjuvant reserved for Clover under the CEPI Agreement, Clover is obligated to pay us the purchase price upon the earliest of (i) the true-up exercise, (ii) within a specified period after Clover delivers Clover Product to a customer, or (iii) Clover&#8217;s receipt of payment for Clover Product from a customer. When we transfer control of CpG 1018 adjuvant that is reserved under the CEPI Agreement, we recognize product revenue and a corresponding contract asset as our right to consideration is contingent on something other than the passage of time, as outlined above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The contract asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million relating to Clover was included in other current assets as of December 31, 2022. The contract asset was subsequently reclassified to other assets (long term) and remains classified in other assets (long term) as of December 31, 2023. The contract asset was reclassified to other assets (long term) to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corresponding Advance Payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million relating to Clover are recorded in CEPI accrual long-term in our consolidated balance sheets as of December 31, 2023. These Advance Payments may be repaid using cash collected from Clover or forgiven in accordance with the CEPI Agreement. We had no accounts receivable balance from Clover as of December 31, 2023 and December 31, 2022. We did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize CpG 1018 adjuvant net product revenue from Clover for the year ended December 31, 2023. We recognized CpG 1018 adjuvant net product revenue o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">288.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion for the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, during the year ended December 31, 2022 and in connection with amendments to the Clover Supply Agreement, which reduced or cancelled certain orders for CpG 1018 adjuvant, we recorded an inventory write-off of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of excess CpG 1018 adjuvant raw materials and finish goods inventory. This excess inventory write-off was reflected as a charge to cost of sales &#8211; product, in the consolidated statements of operations for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biological E. Limited</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, we entered into an agreement (together with subsequent amendments, the &#8220;Bio E Supply Agreement&#8221;) with Biological E. Limited (&#8220;Bio E&#8221;), for the commercial supply of CpG 1018 adjuvant, for use with Bio E&#8217;s subunit COVID-19 vaccine candidate, CORBEVAX&#153;. Under the Bio E Supply Agreement, Bio E committed to purchase specified quantities of CpG 1018 adjuvant, at pre-negotiated prices pursuant to the CEPI Agreement, for use in Bio E&#8217;s commercialization of its CORBEVAX vaccine (&#8220;Bio E Product&#8221;) with specified delivery dates in 2021 and the first quarter of 2022. The Bio E Supply Agreement also provides terms for Bio E to order additional quantities of CpG 1018 adjuvant beyond the quantities reserved by CEPI. In June 2022 and in October 2022, we entered into amendments to the Bio E Supply Agreement (the &#8220;Bio E Amendment No. 1&#8221; and the &#8220;Bio E Amendment No. 2,&#8221; together the &#8220;Bio E Amendments&#8221;). The Bio E Amendments primarily established: (i) a new payment schedule for certain outstanding invoices related to the CEPI product to be the earlier of December 31, 2022, or receipt of certain amounts from Bio E from the Government of India in connection with their advance purchase agreement for CORBEVAX, and (ii) further modified the scope of the Bio E Supply Agreement, by reducing certain quantities of CpG 1018 adjuvant to be delivered. The terms and conditions of the Bio E Supply Agreement were operative through December 2022, and as of December 31, 2022, we had satisfied all delivery obligations thereunder.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had no accounts receivable balance from Bio E. During the first quarter of 2023, we recorded an allowance for doubtful accounts of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was determined by assessing changes in Bio E&#8217;s credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (defined below), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 26, 2023, we entered into a third amendment to the Bio E Supply Agreement (the &#8220;Bio E Amendment No. 3&#8221;), and on April 27, 2023, we entered into the CEPI-Bio E Assignment Agreement. Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of remaining amounts outstanding relating to a liability for Advance Payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Bio E CEPI Advance Payments&#8221;) for CpG 1018 Materials allocated to Bio E, and has assumed our previous rights to collect $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of Bio E accounts receivable. Pursuant to the Bio E Amendment No. 3, we collected $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from Bio E (including $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in April 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in August 2023). Accordingly, as of December 31, 2023, the CEPI-Bio E Assignment Agreement resulted in: (i) no accounts receivable balance, and (ii) the derecognition of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million CEPI accrual in connection with the Bio E CEPI Advance Payments. The Bio E Amendment No. 3 provides for additional future payment of either $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the event that Bio E receives at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the event that Bio E receives at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in future payments from the Government of India associated with its CORBEVAX product on or before August 15, 2025. These additional amounts are not considered collectible until the achievement of these future milestones.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize CpG 1018 adjuvant net product revenue from Bio E for the year ended December 31, 2023. We recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CpG 1018 adjuvant net product revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">206.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Department of Defense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, we entered into an agreement with the DoD for the development of a recombinant plague vaccine adjuvanted with CpG 1018 adjuvant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">over two and a half years. Under the agreement, we are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conducting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a Phase 2 clinical trial combining our CpG 1018 adjuvant with the DoD's rF1V vaccine. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, we executed a contract modification with the DoD to support advancement into a nonhuman primate challenge study, with the agreement now totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For the years ended December 31, 2023 and 2022, we recognized revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which is included in other revenue in our consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001263568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Convertible Notes </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, we issued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of Convertible Notes in a private placement. Total proceeds from the issuance of the Convertible Notes, net of debt issuance and offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">219.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. We used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">190.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the net proceeds to retire our previous loan agreement with CRG Servicing LLC and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the net proceeds to pay the costs of the Capped Calls described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Convertible Notes are general, unsecured obligations and accrue interest at a rate of 2.50% per annum payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2021.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Convertible Notes mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 15, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, unless converted, redeemed or repurchased prior to such date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Convertible Notes are convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, at an initial conversion rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">95.5338</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock per $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of our common stock. The Convertible Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding February 15, 2026, only under the following circumstances:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> trading days (whether or not consecutive) during a period of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the conversion price on each applicable trading day;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">five</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> business day period after any </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">ten</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive trading day period (the &#8220;measurement period&#8221;), in which the &#8220;trading price&#8221; (as defined in the indenture governing the Convertible Notes) per $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> principal amount of the Convertible Notes for each trading day of the measurement period was less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we call such Convertible Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the occurrence of specified corporate events as set forth in the indenture governing the Convertible Notes.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On or after February 15, 2026, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Convertible Notes may convert all or any portion of their Convertible Notes regardless of the foregoing circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since we have the election of repaying the Convertible Notes in cash, shares of our common stock, or a combination of both, we continued to classify the Convertible Notes as long-term debt on the consolidated balance sheets as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may redeem for cash all or any portion of the Convertible Notes (subject to the partial redemption limitation described in the indenture governing the Convertible Notes), at our option, on or after May 20, 2024 and prior to the 31st scheduled trading day immediately preceding the maturity date, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we undergo a fundamental change (as set forth in the indenture governing the Convertible Notes), noteholders may require us to repurchase for cash all or any portion of their Convertible Notes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events (as set forth in the indenture governing the Convertible Notes) or if we deliver a notice of redemption prior to the maturity date, we will, in certain circumstances, adjust the conversion rate for a noteholder who elects to convert its notes in connection with such a corporate event or such notice of redemption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We accounted for the Convertible Notes as a single liability in accordance with ASU 2020-06 - </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2020-06&#8221;). As of December 31, 2023, the Convertible Notes were recorded at the aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million less unamortized issuance costs of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million as a long-term liability on the consolidated balance sheets. As of December 31, 2023, the fair value of the Convertible Notes was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">330.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The fair value was estimated using a reputable third-party valuation model based on observable inputs and is considered Level 2 in the fair value hierarchy. The debt issuance costs are amortized to interest expense over the contractual term of the Convertible Notes at an effective interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the components of interest expense related to Convertible Notes (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.64%;"></td>
        <td style="width:2.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.620000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.620000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stated coupon interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,636</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,638</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,121</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,757</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capped Calls</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the issuance of the Convertible Notes, we entered into capped call transactions with one of the initial purchasers of the Convertible Notes and other financial institutions, totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Capped Calls&#8221;). The Capped Calls cover, subject to customary adjustments, the number of shares of our common stock that initially underlie the Convertible Notes (or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21,542,871</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock). The Capped Calls have an initial strike price and an initial cap price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively, subject to certain adjustments. Conditions that cause adjustments to the initial strike price of the Capped Calls mirror conditions that result in corresponding adjustments to the conversion price of the Convertible Notes. The Capped Calls are expected to offset the potential dilution to our common stock as a result of any conversion of the Convertible Notes, subject to a cap based on the cap price.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For accounting purposes, the Capped Calls are considered separate financial instruments and not part of the Convertible Notes. As the Capped Calls transactions meet certain accounting criteria, we recorded the cost of the Capped Calls, totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, as a reduction to additional paid-in capital within the consolidated statements of stockholders&#8217; equity.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477087192032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-Term Debt </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-Term Debt</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 20, 2018, we entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">175.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million term Loan Agreement with CRG Servicing LLC. We borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the Loan Agreement at closing and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in March 2019 (collectively, &#8220;Term Loans&#8221;). Net proceeds under the Loan Agreement were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">173.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Term Loans under the Loan Agreement bore interest at a rate equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum. The Term Loans had a maturity date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, we repaid the principal on the Term Loans, in full, using the net proceeds from the Convertible Notes issuance. In connection with the early repayment of the Term Loans, in the year ended December 31, 2021, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million loss on debt extinguishment related to the amount we paid to terminate the Term Loans in excess of its carrying value at the time of the repayment. Our final payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">190.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to CRG Servicing LLC satisfied all of our obligations under the Loan Agreement. With the full repayment of the Term Loans, all security interests, covenants, liens and encumbrances under the Loan Agreement were permanently released.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of i</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nterest expense related to the Term Loans during the year ended December 31, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477087188512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disaggregation of Revenues</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.676%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.879%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.439%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.439%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.659%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.659%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.659%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.659%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.679%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.659%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Product revenue, net</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">HEPLISAV-B</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">213,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">213,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">124,996</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">125,937</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CpG 1018 adjuvant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">587,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">587,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">375,229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">375,229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total product revenue, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">213,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">213,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">124,996</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">588,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">713,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">375,229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">437,099</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,989</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,774</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,038</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,343</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">230,945</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">232,284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">133,770</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">588,913</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">722,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">63,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">375,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">439,442</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenues from Major Customers and Collaboration Partners</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs and retail pharmacies. All of our HEPLISAV-B sales in Germany are to one distributor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.523%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.523%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.523%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Largest customer</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Second largest customer</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Third largest customer</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes CpG 1018 adjuvant product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant product revenue):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.261%;"></td>
        <td style="width:1.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.005999999999998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.005999999999998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.005999999999998%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Largest collaboration partner</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Second largest collaboration partner</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Third largest collaboration partner</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contract Balances</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:25.7%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.32%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning of<br/>Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Provisions<br/>related to current<br/>period sales</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Credit or payments<br/>made during<br/>the period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Adjustments related to prior periods</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance<br/>at End of<br/>Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2023:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable reserves </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,604</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,629</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,011</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue reserve accruals </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2022:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable reserves </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,402</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue reserve accruals </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,253</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,806</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,507</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reserves are for chargebacks, discounts and other fees</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accruals are for returns, rebates and other fees</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When we transfer control of CpG 1018 adjuvant that is reserved under the CEPI Agreement to Clover and perform services under our agreement with the DoD, we recognize product revenue and a corresponding contract asset as our right to consideration is conditioned on something other than the passage of time. See Note 9 for fu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rther discussion. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes balances and activities in our contract asset account (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.952%;"></td>
        <td style="width:1.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.004000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.444%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.444%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.444%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.004000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning<br/>of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additions</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Subtractions</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Reclassification (1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance<br/>at End of<br/>Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2023:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract asset, included in other current assets</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,307</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract asset, included in other assets (long term)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,307</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,307</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2022:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,556</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 9 for further discussion.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> $1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> million of contract asset is derived from our agreement with the DoD</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001164096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net (Loss) Income Per Share </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net (loss) income per share is computed by dividing net (loss) income attributable to common stockholders by the weighted-average number of shares of our common stock outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the calculation of diluted net income per share, net income attributable to common stockholders for basic net income per share is adjusted by the effect of dilutive securities, including awards under our equity compensation plans and change in fair value of warrant liability. Diluted net income per share attributable to common stockholders is computed by dividing the resulting net income attributable to common stockholders by the weighted-average number of fully diluted common shares outstanding.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The numerators and denominators of the basic net (loss) income and diluted net income per share computations for our common stock are calculated as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.34%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Numerator</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">293,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,713</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: undistributed earnings allocated to participating securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">283</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income allocable to common stockholders, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,873</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: undistributed earnings allocated to Series B and warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">283</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: undistributed earnings allocated to Series B and warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on convertible notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,044</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: removal of change in fair value of warrant liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,801</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income allocable to common stockholders, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">296,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,691</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Denominator</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used to compute net (loss) income <br/>&#160;&#160;&#160;allocable to common stockholders per share, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,733</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of dilutive shares:</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,774</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,075</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Notes (as converted to common stock)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,543</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of dilutive warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used to compute net (loss) income<br/>&#160;&#160;&#160;allocable to common stockholders per share, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,733</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,797</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133,006</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following were excluded from the calculation of diluted net (loss) income per share as the effect of their inclusion would have been anti-dilutive (in thousands).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.269%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.438%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding securities not included in diluted net (loss) income<br/>&#160;&#160;&#160;allocable to common stockholders per share calculation<br/>&#160;&#160;&#160;(in thousands):</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and stock awards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,953</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Notes (as converted to common stock)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,543</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants (as exercisable into common stock)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001205408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PreferredStockCommonStockAndWarrantsAbstract', window );"><strong>Preferred Stock Common Stock And Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock and Warrants</a></td>
<td class="text"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock and Warrants</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock Outstanding</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">129,530,228</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ares of our common stock outstanding.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We entered into an at-the-market Sales Agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;) on August 6, 2020 and an amendment to such agreement on August 3,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 2023 (the sales agreement as amended, the &#8220;ATM Agreement&#8221;). Under the ATM Agreement, we may offer and sell from time to time, at our sole discretion, shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">120.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through Cowen as our sales agent. We agreed to pay Cowen a commission of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the gross sales proceeds of any common stock sold through Cowen under the ATM Agreement. As of December 31, 2023, w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e ha</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">120.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million rema</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ining under the ATM Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, all of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,882,600</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding warrants as of December 31, 2021 were exercised or expired, resulting in cash proceeds totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, we recognized</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decrease in the estimated fair value of warrant liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as income in other income (expense) in our consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_PreferredStockCommonStockAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock common Stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_PreferredStockCommonStockAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001269680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans and Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Plans and Stock-Based Compensation</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Plans and Stock-Based Compensation</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2021, we adopted the Dynavax Technologies Corporation 2021 Inducement Award Plan (&#8220;2021 Inducement Plan&#8221;), pursuant to which we reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for issuance under the plan to be used exclusively for grants of awards to individuals who were not previously our employees or directors. In June 2021, we amended the 2021 Inducement Plan (&#8220;Amended 2021 Inducement Plan&#8221;) to increase the number of shares of common stock reserved under the 2021 Inducement Plan to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Amended 2021 Inducement Plan was terminated effective as of April 3, 2022 and, therefore, there are no shares of our common stock available for grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2022, our stockholders approved the amendment and restatement of our 2018 Equity Incentive Plan (the &#8220;Amended 2018 EIP&#8221;) to, among other things, increase the authorized number of shares of common stock by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The maximum number of shares of common stock that may be issued under the Amended 2018 EIP, will not exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">32,600,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. As of December 31, 2023, the Amended 2018 EIP and the Amended and Restated 2014 Employee Stock Purchase Plan are our active plans (the "Plans").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Amended 2018 EIP is administered by our Board of Directors, or a designated committee of the Board of Directors, and awards granted under the Amended 2018 EIP have a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unless earlier terminated by the Board of Directors. As of December 31, 2023, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,388,428</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock reserved for issuance under the Amended 2018 EIP.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under our Amended 2018 EIP, we may grant stock options, RSUs, performance-based awards, and other awards that are settled in shares of our common stock. Our equity awards generally vest over a three-year period contingent upon continuous service and unless exercised, expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6d4caeb9-dd64-4460-a26d-4c0009adec9d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant (or earlier upon termination of continuous service). Activity under our stock plans is set forth below:</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity of stock options for the year ended December 31, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.24%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.6%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares Underlying <br/>Outstanding Options<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise<br/>Price Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.61</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,291</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">850</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options cancelled:</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options forfeited (unvested)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options expired (vested)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,120</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.18</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.15</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.50</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense related to options was approximat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total intrinsic value of stock options exercised during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The total intrinsic value of exercised stock options is calculated based on the difference between the exercise price and the quoted market price of our common stock as of the close of the exercise date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total fair value of stock options vested during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity of RSUs for the year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares<br/>(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Grant-Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,748</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,515</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,445</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.57</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inclusive of approximately 600,145 RSUs for the year ended December 31, 2023, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense related to RSUs was approximat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The aggregate fair value of the RSUs outstanding as of December 31, 2023, 2022 and 2021, based on our stock price on that date, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">llion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total fair value of RSUs vested during the years ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">illion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market-based Performance Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We granted PSUs to certain executives. These PSUs vest upon a specified market condition. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summary of PSU activities for the year ended December 31, 2023 is as follows:</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.383%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Grant-Date Fair<br/>Value Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">364</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense related to PSUs was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively. The aggregate intrinsic value of the PSUs outstanding as of December 31, 2023, 2022 and 2021, based on our stock price on that date, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance-based Options</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">y </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares underlying performance-based options were outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Assumptions in Estimating Option Fair Value</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he fair value of each time-based option is estimated on the date of grant using the Black-Scholes option valuation model. The fair value of each RSU is determined at the date of grant using our closing stock price. The fair value of each PSU is estimated using the Monte Carlo simulation method on the date of grant. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions used in the calculations of these fair value measurements are as follows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.712%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.004%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.322%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Options</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Market-Based Performance Stock Units</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Employee Stock Purchase Plan</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.37</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">From </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.03</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.92</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility is based on historical volatility of our stock price. The expected life of options granted is estimated based on historical option exercise and employee termination data. Our senior management, who hold a majority of the options outstanding, and other employees were grouped and considered separately for valuation purposes. The risk-free rate for periods within the contractual life of the option is based on the U.S. treasury yield curve in effect at the time of grant. Forfeiture estimates are based on historical employee turnover. The dividend yield is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> percent for all years and is based on our history and expectation of dividend payouts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity awards with time-based vesting, the fair value is amortized to expense on a straight-line basis over the vesting periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also granted performance-based equity awards to certain of our employees. For equity awards with performance-based vesting criteria, the fair value is amortized to expense when the achievement of the vesting criteria becomes probable.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock-based compensation expense recorded in each component of operating expenses in our consolidated statements of operations, and amounts capitalized to our inventories (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.62%;"></td>
        <td style="width:2.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.4%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employees and directors stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,592</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,285</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,285</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,954</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,818</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,069</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,894</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales - product</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">553</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,720</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,592</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,285</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the total unrecognized compensation cost related to non-vested stock options and RSUs deemed probable of vesting, including all stock options with time-based vesting, net of estimated forfeitures, amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">46.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over the remaining weighted-average vesting period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. As of December 31, 2023, the total unrecognized compensation cost related to PSUs amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Amended and Restated 2014 Employee Stock Purchase Plan (the &#8220;Employee Stock Purchase Plan&#8221;) provides for the purchase of common stock by eligible employees. In May 2021, our stockholders approved the amendment and restatement of the Employee Stock Purchase Plan to increase the authorized number of shares of common stock by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The maximum number of shares of common stock that may be issued under the Employee Stock Purchase Plan will not exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,850,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purchase price per share is the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the common stock on the commencement of the two-year offer period (generally, the sixteenth day in February or August) or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the common stock on the exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August). For the year ended December 31, 2023, employees have acquired approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">161,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock under the Employee Stock Purchase Plan and approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">722,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock remained available for future purchases under the Employee Stock Purchase Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the total unrecognized compensation cost related to shares of our common stock under the Employee Stock Purchase Plan amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over the remaining weighted-average vesting period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001178544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract', window );"><strong>Pension and Other Postretirement Benefits Cost (Reversal of Cost) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Benefit Plan </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a 401(k) Plan, which qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Under the 401(k) Plan, participating employees may defer a portion of their pretax earnings. We may, at our discretion, contribute for the benefit of eligible employees. Our contribution to the 401(k) Plan was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023, 2022 and 2021, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001213584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated (loss) income before provision for income taxes consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.323%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.724%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.724%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.724%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,275</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,954</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,367</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">294,299</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the consolidated income tax provision for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.711%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.217%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.217%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.217%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2021</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-US</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">808</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-US</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">808</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The difference between the consolidated income tax provision and the amount computed by applying the federal statutory income tax rate to the consolidated income before income taxes in the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.764000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.764000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.764000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision (benefit) at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,775</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,942</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,576</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Business credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,050</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">586</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred compensation charges</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">473</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,466</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 162(m) limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,963</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,779</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,241</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark-to-market of warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">378</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,364</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss and tax credit limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,459</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">340</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">808</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) Certain prior year amounts have been reclassified to conform to the current year presentation. In 2022 and 2021, Foreign taxes were included in Other.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax assets and liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,228</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,940</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 174 capitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,556</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,868</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,530</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,780</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,808</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">348</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">189,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">188,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">180,387</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178,920</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax benefit of net operating losses, temporary differences and credit carryforwards is required to be recorded as an asset to the extent that management assesses that realization is "more likely than not." Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. A high degree of judgment is required to determine if, and the extent to which, valuation allowances should be recorded against deferred tax assets. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. Based on all available evidence as of December 31, 2023, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized, and, accordingly, has provided a valuation allowance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The valuation allowance increased by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during the year ended December 31, 2023 and decreased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2022. The increase </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in valuation allowance during the year ended December 31, 2023 was due to an increase in our deferred tax assets, predominantly related to Section 174 capitalization and increased reserves largely offset by utilization of net operating losses. The decrease in valuation allowance during the year ended December 31, 2022 was due to a decrease in our deferred tax assets, predominantly related to utilization of net operating losses, offset by updates to the Section 382 analysis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million, which began to expire in the year </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, federal net operating loss carryforwards of approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">y $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">353.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which do not expire and federal research and development tax credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, whi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ch expire in the years </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2043</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had net operating loss carryforwards for California and other states for income tax purposes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">283.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which expire in the years </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2040</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and California state research and development tax credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which do not expire.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> remaining net operating loss carryforwards for foreign income tax purposes.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Uncertain Income Tax positions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total amount of unrecognized tax benefits was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and 2022, respectively. If recognized, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the unrecognized tax benefits would affect the effective tax rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity related to our unrecognized tax benefits:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax positions related to the current year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">762</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax positions related to the prior year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Settlements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lapses in statute</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,101</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to account for interest and penalties as inco</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">me tax expense. As of December 31, 2023, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> penalties recognized in the provision for income taxes. As of December 31, 2022, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> penalties recognized in the provision for income taxes. We do not anticipate any significant change within 12 months of this reporting date of its uncertain tax positions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Tax Reform Act of 1986 limits the annual use of net operating loss and tax credit carryforwards in certain situations where changes occur in stock ownership of a company. In the event there is a change in ownership, as defined, the annual utilization of such carryforwards could be limited. For the year ended December 31, 2021, we completed a preliminary analysis under Section 382 of the Internal Revenue Code indicating we experienced ownership changes in 2008, 2010, 2012, and 2019 that limited the future use of our pre-change federal and state net operating loss carryforwards and federal research and development tax credits. We finalized the study during the year ended December 31, 2022 and concluded that we only experienced ownership changes in 2008, 2010, and 2012, resulting in a significant reduction in the federal and state net operating loss carryforwards and federal research and development tax credits that are expected to expire unused. We have revised the net operating loss carryforwards and research and development tax credits that are expected to expire unused as a result of the annual limitations in the deferred tax assets and corresponding uncertain tax positions as of December 31, 2022. There were no changes to our Section 382 analysis as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to income tax examinations for U.S. federal and state income taxes from 2002 forward. We are subject to tax examination in Germany from 2018 forward, in India from 2019 forward and in Italy from 2021 forward.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993677648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and include our accounts and those of our wholly-owned subsidiaries, Dynavax GmbH located in D&#252;sseldorf, Germany, Dynavax India LLP in India and a branch of Dynavax in Italy. All intercompany accounts and transactions among the entities have been eliminated from the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management&#8217;s estimates are based on historical information available as of the date of the consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency Translation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider the local currency to be the functional currency for our international subsidiaries, Dynavax GmbH, located in D&#252;sseldorf, Germany, Dynavax India LLP, and a branch of Dynavax registered in Italy. Accordingly, assets and liabilities denominated in this foreign currency are translated into U.S. dollars using the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the year. Currency translation adjustments arising from period to period are charged or credited to accumulated other comprehensive income (loss) in stockholders&#8217; equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of Decemb</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">er 31, 2023 and 2022, the cumulative translation adjustments balance was $</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) million, respectively, primarily related to the translation of Dynavax GmbH assets, liabilities and operating results from Euros to U.S. dollars. F</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or the years ended December 31, 2023, 2022 and 2021, we reported an unrealized foreign currency translation gain (loss) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) million and $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) million, respectively. Realized gains and losses resulting from currency transactions are included in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> other (expense) income in the consolidated statements of operations. For the years ended December 31, 2023, 2022 and 2021, we reported a (loss) gain of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">llion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, resulting from currency transactions in our consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">segment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and in assessing performance. Our Chief Executive Officer is the CODM. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, management has determined that we operate in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment that is focused on the discovery, development, and commercialization of innovative vaccines. Net assets outside of the U.S. w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ere less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of total net assets as of December 31, 2023 and 2022.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Cash and Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and Cash Equivalents and Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider all liquid investments purchased with an original maturity of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or less and that can be liquidated without prior notice or penalty to be cash equivalents. Management determines the appropriate classification of marketable securities at the time of purchase. In accordance with our investment policy, we invest in short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We believe these types of investments are subject to minimal credit and market risk.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive loss in stockholders&#8217; equity. Commencing with our adoption of (&#8220;ASC&#8221;) 326, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8212; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(&#8220;ASC 326")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on January 1, 2023, we determine whether a decline in the fair value of our available-for-sale ("AFS") debt securities below their amortized cost basis (i.e., an impairment) is due to credit-related factors or noncredit-related factors. Any impairment that is not credit related is recognized in other comprehensive income (loss), net of applicable taxes. Credit-related impairments (if any) are recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Both the allowance and the adjustment to net income can be reversed if conditions change. To date, there have been no declines in fair value that have been identified as a credit-related impairment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any significant losses on our cash equivalents and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts. We estimate our allowance for doubtful accounts based on</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. During the year ended December 31, 2023, we recorded an allowance for doubtful accounts of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was determined by assessing changes in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biological E. Limited's (&#8220;Bio E&#8221;) credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (See Note 9), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customers collectively represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our HEPLISAV-B trade receivable balance, respectively. As of December 31, 2023, we had no CpG 1018 adjuvant trade receivable balance. As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our CpG 1018 adjuvant trade receivable balance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates will require approval from the United States Food and Drug Administration ("FDA") and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our product candidates will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process that could affect our authorizations in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our long-lived assets located in the United States as of December 31, 2023 and 2022, represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our total assets, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respectively, and the remaining long-lived assets were located in Germany.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories, net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HEPLISAV-B Inventories</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the years ended December 31, 2023 and 2022, there w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ere </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> invento</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ry reserves or write-offs recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to the required regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory. Instead, those are expensed as research and development costs. We begin capitalization of these inventory related costs once regulatory approval is obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CpG 1018 Adjuvant Inventories</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the year ended December 31, 2023, there was no remaining CpG 1018 adjuvant inventory balance. For the year ended December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of inventory write-off to cost of sales - product, in connection with cancelled orders and the reduction in demand for CpG 1018 adjuvant reflected in the Clover Supply Agreement, as amended (See Note 9).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized, while repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluate the carrying value of long-lived assets, whenever events or changes in business circumstances or our planned use of long-lived assets indicate, based on undiscounted future operating cash flows, that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. When an indicator of impairment exists, undiscounted future operating cash flows of long-lived assets are compared to their respective carrying value. If the carrying value is greater than the undiscounted future operating cash flows of long-lived assets, the long-lived assets are written down to their respective fair values and an impairment loss is recorded. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. There have been no material adjustments to these estimates during the years presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determine if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset, and whether we have the right to control the identified asset. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, other current liabilities and long-term portion of lease liabilities in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. The classification of our leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of ROU assets and lease liabilities is based on the present value of future lease payments over the lease term. The ROU asset also includes the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the implicit rate in our leases is generally unknown, we use our incremental borrowing rate based on information available at the lease commencement date in determining the present value of future lease payments. We consider our credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary, when calculating our incremental borrowing rate. The lease terms may include options to extend or terminate the lease when it is reasonably certain we will exercise any such options. Rent expense for our operating leases is recognized on a straight-line basis over the lease term. Variable lease payments are recorded as an expense in the period incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have elected not to apply the recognition requirements of Accounting Standards Codification ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases ("ASC 842")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for short-term leases. We have also elected the practical expedient to not separate lease components from non-lease components.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As lessors, we determine if an arrangement includes a lease at inception. We elected the practical expedient to not separate lease components from non-lease components. Sublease income is recognized on a straight-line basis over the expected lease term and is included in other income (expense) in our consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess purchase price over the fair value of tangible and intangible assets acquired and liabilities assumed. Our goodwill balance relates to our acquisition of Dynavax GmbH in 2006. Goodwill is not amortized, but instead is reviewed for impairment test at least annually, or more frequently if events occur or circumstances change that would indicate the carrying amount may be impaired. Goodwill is assigned to, and impairment testing is performed at, the reporting unit level. We determined that we have only </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment and there are no components of that operating segment that are deemed to be separate reporting units, such that we have one reporting unit for purposes of our goodwill impairment testing. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment has been identified for the years presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Notes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Convertible Notes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% convertible senior notes due in 2026 (&#8220;Convertible Notes&#8221;), as a long-term liability equal to the proceeds received from issuance, including the embedded conversion feature, net of the unamortized debt issuance and offering costs on the consolidated balance sheets (See Note 10). We evaluate all conversion, repurchase and redemption features contained in a debt instrument to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is not required to be accounted for separately as an embedded derivative. We amortize debt issuance and offering costs over the contractual term of the Convertible Notes, using the effective interest method, as interest expense on the consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CappedCallsPolicyTextBlock', window );">Capped Calls</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capped Calls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluate financial instruments under ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging ("ASC 815")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The capped calls purchased in connection with the Convertible Notes financing ("Capped Calls") cover the same number of shares of common stock that initially underlie the Convertible Notes (subject to anti-dilution and certain other adjustments). The Capped Calls meet the definition of derivative under ASC 815. In addition, the Capped Calls meet the conditions in ASC 815 to be classified in stockholders&#8217; equity and are not subsequently remeasured as long as the conditions for the equity classification continue to be met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration, which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers ("ASC 606")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we apply the following five step model:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the performance obligation(s) in the contract;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determine the transaction price;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocate the transaction price to the performance obligation(s) in the contract; and </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognize revenue when (or as) we satisfy a performance obligation. </span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Revenue, Net &#8211; HEPLISAV-B</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We sell HEPLISAV-B to a limited number of wholesalers and specialty distributors in the U.S. (collectively, our &#8220;Customers&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product upon delivery to the Customer. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Because our standard credit terms are short-term and we expect to receive payment in less than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there is no significant financing component on the related receivables. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. Since our performance obligation is part of a contract that has an original expected duration of one year or less, we elect not to disclose the information about our remaining performance obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overall, product revenue, net - HEPLISAV-B, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reserves for Variable Consideration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration such as product returns, chargebacks, discounts, rebates and other fees that are offered within contracts between us and our Customers, healthcare providers, pharmacies and others relating to our product sales. We estimate variable consideration using either the most likely amount method or the expected value method, depending on the type of variable consideration and what method better predicts the amount of consideration we expect to receive. We take into consideration relevant factors such as industry data, current contractual terms, available information about Customers&#8217; inventory, resale and chargeback data and forecasted customer buying and payment patterns, in estimating each variable consideration. The variable consideration is recorded at the time product sales is recognized, resulting in a reduction in product revenue and a reduction in accounts receivable (if the Customer offsets the amount against its accounts receivable) or as an accrued liability (if we pay the amount through our accounts payable process). Variable consideration requires significant estimates, judgment and information obtained from external sources. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. If we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of revenue that we report in a particular period. We evaluate our estimates of variable considerations including, but not limited to, product returns, chargebacks and rebates, periodically or when there is an event or change in circumstances that may indicate that our estimates may change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Returns:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Consistent with industry practice, we offer our Customers a limited right of return based on the product&#8217;s expiration date for product that has been purchased from us. We estimate the amount of our product sales that may be returned by our Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We consider several factors in the estimation of potential product returns including expiration dates of the product shipped, the limited product return rights, available information about Customers&#8217; inventory and other relevant factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chargebacks:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our Customers subsequently resell our product to healthcare providers, pharmacies and others. In addition to distribution agreements with Customers, we enter into arrangements with qualified healthcare providers that provide for chargebacks and discounts with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by Customers, and we issue credits for such amounts generally within a few weeks of the Customer&#8217;s notification to us of the resale. Reserves for chargebacks consists of credits that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect will be sold to the qualified healthcare providers, and chargebacks for units that our Customers have sold to the qualified healthcare providers, but for which credits have not been issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trade Discounts and Allowances:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We provide our Customers with discounts which include early payment incentives that are explicitly stated in our contracts, and are recorded as a reduction of revenue in the period the related product revenue is recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distribution Fees: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Distribution fees include fees paid to certain Customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rebates: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under certain contracts, Customers may obtain rebates for purchasing minimum volumes of our product. We estimate these rebates based upon the expected purchases and the contractual rebate rate and record this estimate as a reduction in revenue in the period the related revenue is recognized.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product Revenue, Net &#8211; CpG 1018 Adjuvant</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also sell our innovative adjuvant, CpG 1018 adjuvant, to our collaboration partners for use in their development and/or commercialization of COVID-19 vaccine. We have determined that our collaboration partners meet the definition of Customers under ASC 606. Therefore, we accounted for our CpG 1018 adjuvant sales under ASC 606. Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product to the customer. Because the timing between the recognition of revenue for product sales and the receipt of payment is less than one year, there is no significant financing component on the related receivables. Since our performance obligation is part of a contract that has an original expected duration of one year or less, we elect not to disclose the information about our remaining performance obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overall, product revenue, net - CpG 1018 adjuvant, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. Our CpG 1018 adjuvant customers have purchased a significant quantity of CpG 1018 adjuvant as part of their initial COVID-19 vaccine development inventory. Accordingly, we did not recognize CpG 1018 adjuvant net product revenue during the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other revenue includes revenue from our agreement with the DoD, collaboration and manufacturing service revenue. We have entered into grant agreements, collaborative arrangements and arrangements to provide manufacturing services to other companies. Such arrangements may include promises to customers which, if capable of being distinct, are accounted for as separate performance obligations. For agreements with multiple performance obligations, we allocate estimated revenue to each performance obligation at contract inception based on the estimated transaction price of each performance obligation. Revenue allocated to each performance obligation is then recognized when we satisfy the performance obligation by transferring control of the promised good or service to the customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Accruals</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Expenses and Accruals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. Our accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties. We estimate research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to us at that time. There have been no material adjustments to the prior period accrued estimates for clinical trial activities during the years presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense for restricted stock units ("RSUs"), market-based performance stock units ("PSUs") and stock options is estimated at the grant date based on the award&#8217;s estimated fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For awards that vest based on service conditions and market conditions, we use a straight-line method to recognize compensation expense over the award&#8217;s requisite service period, assuming estimated forfeiture rates. For awards that contain performance conditions, we determine the appropriate amount to expense at each reporting date based on the anticipated achievement of performance targets, which requires judgement, including forecasting the achievement of future specified targets. At the date performance conditions are determined to be probable of achievement, we record a cumulative expense catch-up, with remaining expense amortized over the remaining service period. Throughout the performance period, we re-assesses the estimated performance and updates the number of performance-based awards that we believe will ultimately vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value of RSUs is determined at the date of grant using our closing stock price, with the exception of PSUs, which are measured using the Monte Carlo simulation method on the date of grant. Our determination of the fair value of stock options on the date of grant using an option-pricing model is affected by our stock price, as well as assumptions regarding a number of subjective variables. We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value-based measurement of our stock options. The Black-Scholes model requires the use of subjective assumptions, which determine the fair value-based measurement of stock options. These assumptions include, but are not limited to, our expected stock price volatility over the term of the awards, and projected employee stock option exercise behaviors. In the future, as additional empirical evidence regarding these input estimates becomes available, we may change or refine our approach of deriving these input estimates. These changes could impact our fair value of stock options granted in the future. Changes in the fair value of stock awards could materially impact our operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby increasing stock-based compensation expense recognized in future periods. We derive the expected term assumption primarily based on our historical settlement experience, while considering options that have not yet completed a full life cycle. Stock-based compensation expense is recognized only for awards ultimately expected to vest. Our estimate of the forfeiture rate is based primarily on our historical experience. To the extent we revise this estimate in the future, our share-based compensation expense could be materially impacted in the period of revision. There have been no material adjustments to these estimates during the years presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Tax law and rate changes are reflected in income in the period such changes are enacted. We include interest and penalties related to income taxes, including unrecognized tax benefits, within income tax expense.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. We continually assess the likelihood and amount of potential adjustments and adjust the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and the valuation allowance recorded against our net deferred tax assets. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we believe that recognition of the deferred tax assets arising from future tax benefits is currently not more likely than not to be realized and, accordingly, we have determined a need for a full valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Standards Update 2016-13</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which was codified in Accounting Standards Codification ASC 326, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8212; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. Because we were a smaller reporting company based on the most recent determination as of November 15, 2019, ASC 326 became effective for us for fiscal years beginning after December 15, 2022. As such, we adopted ASC 326 effective January 1, 2023, utilizing the modified retrospective transition method. Upon adoption, we updated our impairment model to utilize a forward-looking current expected credit losses (&#8220;CECL&#8221;) model in place of the incurred loss methodology for financial instruments measured at amortized cost, primarily including our accounts receivable and contract asset. In relation to AFS debt securities, the guidance eliminates the concept of &#8220;other-than-temporary&#8221; impairment, and instead focuses on determining whether any impairment is a result of a credit loss or other factors. The adoption of ASC 326 did not have a material impact on our consolidated financial statements as of the adoption date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_CappedCallsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capped Calls Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_CappedCallsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001166608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.95%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.158000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.778%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.778%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.778%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">&#160;Assets</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">216,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">216,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">308,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">308,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">599,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">731,112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">&#160;Assets</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Total assets</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422,391</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">594,809</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value Warrant liability</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of changes in the fair value warrant liability for year ended December 31, 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80%;"></td>
        <td style="width:2.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.9%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decrease in fair value of warrants exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,801</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants exercised or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477000202800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.151%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">436,189</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents, and restricted cash shown in the<br/>&#160;&#160;&#160;consolidated statements of cash flows</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,556</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">436,408</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted cash is included in "Other assets" in the Consolidated Balance Sheets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents, and marketable securities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,278</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities available-for-sale:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">216,265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">269</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">216,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">300,803</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">301,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities available-for-sale</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591,177</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">592,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents, and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">741,455</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,180</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">742,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,586</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,586</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities available-for-sale:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. treasuries</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,429</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,865</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">826</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities available-for-sale</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423,796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422,391</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents, and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">625,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,417</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">624,395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock', window );">Maturities of Marketable Securities Available-for-Sale</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The maturities of our marketable securities available-for-sale are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mature in one year or less</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">440,131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">440,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mature after one year through two years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">151,046</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">151,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591,177</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">592,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturities of marketable securities available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of cash, cash equivalents and restricted cash to the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001273120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents inventories (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.353%;"></td>
        <td style="width:2.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.302000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.302000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,256</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,517</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,954</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,934</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,995</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001263568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Component of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.65%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:16.103%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Useful</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Life (In years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,139</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,827</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,060</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,720</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,467</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,464</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,201</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,832</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,596</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001223776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract', window );"><strong>Disclosure Component Of Current Accrued Liabilities And Accrued Research And Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock', window );">Component of Current Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current accrued liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,069</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,261</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue reserve accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued inventory</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,456</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,697</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure component of current accrued liabilities and accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued liabilities and accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993720544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Operating Lease Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lease expense comprises of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock', window );">Summary of Balance Sheet Classification of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The balance sheet classification of our operating lease liabilities was as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f58b1a95-4b8b-4052-956a-3314f3bd58e1;"><span style="-sec-ix-hidden:F_92c8237b-9eec-4d96-8dc1-a494a9120777;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of lease liabilities</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(included in other current liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,631</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term portion of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,720</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,801</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,216</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,432</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Sublease Income and Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the maturities of our sublease income and operating lease liabilities were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sublease Income</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Lease<br/>Liabilities</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,605</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,854</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,030</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,122</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,103</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,216</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock', window );">Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average remaining lease term</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock', window );">Schedule of Material Purchase Commitments</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summarizes our material purchase commitments at December 31, 2023 and the effect those obligations are expected to have on our liquidity and cash flows in future periods (in thousands):</span><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,866</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,983</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,516</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of balance sheet components of operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of material purchase commitments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease income and operating lease liability maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of weighted average remaining lease term and weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477000090864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock', window );">Summary of Interest Expenses Related to Convertible Notes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the components of interest expense related to Convertible Notes (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.64%;"></td>
        <td style="width:2.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.620000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.620000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stated coupon interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,636</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,638</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,121</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,757</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of convertible notes interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993214112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Disaggregation of Revenues</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.676%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.879%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.439%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.439%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.659%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.659%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.659%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.659%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.679%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:5.659%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Product revenue, net</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">HEPLISAV-B</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">213,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">213,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">124,996</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">125,937</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CpG 1018 adjuvant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">587,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">587,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">375,229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">375,229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total product revenue, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">213,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">213,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">124,996</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">588,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">713,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">375,229</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">437,099</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,989</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,774</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,038</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,343</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenues</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">230,945</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">232,284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">133,770</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">588,913</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">722,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">63,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">375,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">439,442</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">HEPLISAV-B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Revenues from Major Customers</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.523%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.523%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.523%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Largest customer</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Second largest customer</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Third largest customer</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock', window );">Summary of Product Revenue Allowance and Reserve Categories</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:25.7%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.32%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning of<br/>Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Provisions<br/>related to current<br/>period sales</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Credit or payments<br/>made during<br/>the period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Adjustments related to prior periods</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance<br/>at End of<br/>Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2023:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable reserves </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,604</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,629</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,011</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue reserve accruals </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2022:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable reserves </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,402</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue reserve accruals </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,253</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,806</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,507</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,552</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reserves are for chargebacks, discounts and other fees</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accruals are for returns, rebates and other fees</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_CpG1018Member', window );">CpG 1018</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Revenues from Major Customers</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes CpG 1018 adjuvant product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant product revenue):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.261%;"></td>
        <td style="width:1.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.005999999999998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.005999999999998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.005999999999998%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Largest collaboration partner</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Second largest collaboration partner</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Third largest collaboration partner</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of balances and activities in our contract asset account</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes balances and activities in our contract asset account (in thousands):</span><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.952%;"></td>
        <td style="width:1.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.004000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.444%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.444%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.444%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.941%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.004000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning<br/>of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additions</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Subtractions</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Reclassification (1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance<br/>at End of<br/>Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2023:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract asset, included in other current assets</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,307</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract asset, included in other assets (long term)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,307</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,307</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ended December 31, 2022:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,556</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 9 for further discussion.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> $1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> million of contract asset is derived from our agreement with the DoD</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of product revenue allowance and reserve categories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_HEPLISAVBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_CpG1018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_CpG1018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476999557104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The numerators and denominators of the basic net (loss) income and diluted net income per share computations for our common stock are calculated as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:57.34%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Numerator</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">293,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,713</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: undistributed earnings allocated to participating securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">283</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income allocable to common stockholders, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,873</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: undistributed earnings allocated to Series B and warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">283</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: undistributed earnings allocated to Series B and warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on convertible notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,044</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: removal of change in fair value of warrant liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,801</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (loss) income allocable to common stockholders, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">296,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,691</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Denominator</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used to compute net (loss) income <br/>&#160;&#160;&#160;allocable to common stockholders per share, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,733</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of dilutive shares:</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,774</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,075</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Notes (as converted to common stock)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,543</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of dilutive warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares used to compute net (loss) income<br/>&#160;&#160;&#160;allocable to common stockholders per share, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,733</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,797</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133,006</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following were excluded from the calculation of diluted net (loss) income per share as the effect of their inclusion would have been anti-dilutive (in thousands).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.269%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.438%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.438%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding securities not included in diluted net (loss) income<br/>&#160;&#160;&#160;allocable to common stockholders per share calculation<br/>&#160;&#160;&#160;(in thousands):</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and stock awards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,953</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Notes (as converted to common stock)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,543</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants (as exercisable into common stock)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993720800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans and Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Summary of Option Activity Under Stock-Based Compensation Plans</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity of stock options for the year ended December 31, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.24%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.6%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares Underlying <br/>Outstanding Options<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise<br/>Price Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.61</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,291</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">850</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options cancelled:</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options forfeited (unvested)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options expired (vested)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,120</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.18</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.15</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.50</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,613</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Non-vested Restricted Stock Units Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity of RSUs for the year ended December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares<br/>(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Grant-Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.00</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,748</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,515</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">267</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,445</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.57</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inclusive of approximately 600,145 RSUs for the year ended December 31, 2023, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock', window );">Summary of Performance Based Restricted Stock Unit</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summary of PSU activities for the year ended December 31, 2023 is as follows:</span><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.383%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Grant-Date Fair<br/>Value Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">364</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-vested as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value-Based Measurements and Weighted-Average Assumptions</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average assumptions used in the calculations of these fair value measurements are as follows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:17.712%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.004%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.322%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.823%;"></td>
        <td style="width:1%;"></td>
        <td style="width:4.832%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock Options</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Market-Based Performance Stock Units</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Employee Stock Purchase Plan</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.17</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.25</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.37</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">From </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.03</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.92</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes stock-based compensation expense recorded in each component of operating expenses in our consolidated statements of operations, and amounts capitalized to our inventories (in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.62%;"></td>
        <td style="width:2.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.4%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employees and directors stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,592</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,285</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,285</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,954</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,818</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,069</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,894</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales - product</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">553</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,720</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,592</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,285</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of performance based restricted stock unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477000054048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Component of Consolidated (Loss) Income Before Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated (loss) income before provision for income taxes consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.323%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.724%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.724%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.501%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.724%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,275</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">292,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,954</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,367</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">294,299</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Provision</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the consolidated income tax provision for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.711%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.217%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.217%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.217%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2021</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-US</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">808</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-US</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">808</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Difference Between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The difference between the consolidated income tax provision and the amount computed by applying the federal statutory income tax rate to the consolidated income before income taxes in the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.764000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.764000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.764000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision (benefit) at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,775</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,942</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,576</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Business credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,050</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">586</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred compensation charges</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">473</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,466</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 162(m) limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,963</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,779</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,241</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark-to-market of warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">378</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,364</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss and tax credit limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,459</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">290</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">340</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">808</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(1) Certain prior year amounts have been reclassified to conform to the current year presentation. In 2022 and 2021, Foreign taxes were included in Other.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Component of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax assets and liabilities consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,228</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,940</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 174 capitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,556</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,868</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,530</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,780</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,808</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">348</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">189,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">188,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">180,387</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178,920</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity related to our unrecognized tax benefits:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at beginning of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax positions related to the current year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">762</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax positions related to the prior year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reductions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Settlements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lapses in statute</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,101</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993132464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">HEPLISAV-B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused', window );">Minimum age approved for vaccine prevention of infection caused</a></td>
<td class="text">18 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum age approved for vaccine prevention of infection caused.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_HEPLISAVBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476991722480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency translation (loss) gain</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="num">$ (1,800)<span></span>
</td>
<td class="num">$ (2,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Realized foreign currency translation (loss) gain</a></td>
<td class="num">$ (100)<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PercentageOfLongLivedAssets', window );">Percentage of long lived assets</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-off</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 34,288<span></span>
</td>
<td class="nump">$ 2,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_InventoryWriteOffsRecognized', window );">Inventory write-offs recognized</a></td>
<td class="nump">34,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember', window );">2.50% Convertible Senior Notes Due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Trade Receivable | Credit Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCustomer', window );">Concentration risk, customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Trade Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">HEPLISAV-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-off</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">HEPLISAV-B | Credit Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCustomer', window );">Concentration risk, customer</a></td>
<td class="text">three<span></span>
</td>
<td class="text">three<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">HEPLISAV-B | Trade Receivable | Credit Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashEquivalentsMaturityPeriod', window );">Cash equivalents original maturity period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PercentageOfLongLivedAssets', window );">Percentage of long lived assets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived', window );">Expected period of payment to be received</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Dynavax GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CumulativeTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="num">$ (3,000)<span></span>
</td>
<td class="num">$ (4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_CashEquivalentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_CashEquivalentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customers expected period of payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_CumulativeTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative translation adjustment net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_CumulativeTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_InventoryWriteOffsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory write-offs recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_InventoryWriteOffsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_PercentageOfLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of long lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_PercentageOfLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes "Information about Major Customers" that may be disclosed elsewhere (for instance, segment disclosures).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_HEPLISAVBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993716976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Transfers in or out of Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,882,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993575584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 731,112<span></span>
</td>
<td class="nump">$ 594,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">131,635<span></span>
</td>
<td class="nump">172,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">74,237<span></span>
</td>
<td class="nump">42,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">216,688<span></span>
</td>
<td class="nump">88,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">308,552<span></span>
</td>
<td class="nump">292,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">131,635<span></span>
</td>
<td class="nump">172,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">131,635<span></span>
</td>
<td class="nump">172,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 | U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">599,477<span></span>
</td>
<td class="nump">422,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">74,237<span></span>
</td>
<td class="nump">42,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 | U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">216,688<span></span>
</td>
<td class="nump">88,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">308,552<span></span>
</td>
<td class="nump">292,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 | U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476998491632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assumptions to Estimate the Fair Value of Warrant Liability (Detail)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="nump">1,882,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993125200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Fair Value Warrant liability (Detail) - Fair Value, Inputs, Level 3<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 18,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease', window );">Decrease in fair value of warrants exercised</a></td>
<td class="num">(1,801)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrants exercised</a></td>
<td class="num">(16,215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability period decrease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993265520">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 150,279<span></span>
</td>
<td class="nump">$ 202,004<span></span>
</td>
<td class="nump">$ 436,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">277<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 150,556<span></span>
</td>
<td class="nump">$ 202,211<span></span>
</td>
<td class="nump">$ 436,408<span></span>
</td>
<td class="nump">$ 32,310<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted cash is included in "Other assets" in the Consolidated Balance Sheets.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476997105408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Summary of Cash, Cash Equivalents and Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 150,278<span></span>
</td>
<td class="nump">$ 202,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">150,279<span></span>
</td>
<td class="nump">202,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Marketable Securities Available-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">591,177<span></span>
</td>
<td class="nump">423,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(333)<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">592,023<span></span>
</td>
<td class="nump">422,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Marketable Securities Available-for-Sale | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">741,455<span></span>
</td>
<td class="nump">625,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">1,180<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(333)<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">742,302<span></span>
</td>
<td class="nump">624,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,190<span></span>
</td>
<td class="nump">29,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">11,190<span></span>
</td>
<td class="nump">29,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">131,635<span></span>
</td>
<td class="nump">172,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">131,635<span></span>
</td>
<td class="nump">172,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">7,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Marketable Securities Available-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">300,803<span></span>
</td>
<td class="nump">292,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">301,098<span></span>
</td>
<td class="nump">292,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Marketable Securities Available-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">74,109<span></span>
</td>
<td class="nump">42,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">74,237<span></span>
</td>
<td class="nump">42,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Securities | Marketable Securities Available-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">216,265<span></span>
</td>
<td class="nump">88,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(269)<span></span>
</td>
<td class="num">(397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 216,688<span></span>
</td>
<td class="nump">$ 88,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476992929600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Maturities of Marketable Securities Available-for-Sale (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Mature in one year or less</a></td>
<td class="nump">$ 440,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Mature after one year through two years</a></td>
<td class="nump">151,046<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total amortized cost</a></td>
<td class="nump">591,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Mature in one year or less</a></td>
<td class="nump">440,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Mature after one year through two years</a></td>
<td class="nump">151,919<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total estimated fair value</a></td>
<td class="nump">$ 592,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476996881568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Debt Securities, Available-for-Sale, Realized Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993204016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, Net - Summary of Inventories (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 27,256<span></span>
</td>
<td class="nump">$ 25,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">18,954<span></span>
</td>
<td class="nump">23,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">7,080<span></span>
</td>
<td class="nump">9,995<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 53,290<span></span>
</td>
<td class="nump">$ 59,446<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993062480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 7,080<span></span>
</td>
<td class="nump">$ 9,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_InventoryWriteOffsRecognized', window );">Inventory write-offs recognized</a></td>
<td class="nump">$ 34,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_InventoryWriteOffsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory write-offs recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_InventoryWriteOffsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001402256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 152,946<span></span>
</td>
<td class="nump">$ 131,408<span></span>
</td>
<td class="nump">$ 100,156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993647056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Component of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Manufacturing equipment</a></td>
<td class="nump">$ 15,752<span></span>
</td>
<td class="nump">$ 15,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LaboratoryEquipmentGross', window );">Lab equipment</a></td>
<td class="nump">2,827<span></span>
</td>
<td class="nump">2,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ComputerEquipmentGross', window );">Computer equipment</a></td>
<td class="nump">5,060<span></span>
</td>
<td class="nump">4,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">2,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">37,201<span></span>
</td>
<td class="nump">28,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Assets in progress</a></td>
<td class="nump">5,822<span></span>
</td>
<td class="nump">11,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">69,129<span></span>
</td>
<td class="nump">65,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(31,832)<span></span>
</td>
<td class="num">(27,522)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">$ 37,297<span></span>
</td>
<td class="nump">$ 37,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Manufacturing Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives (In years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Manufacturing Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives (In years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dvax_LaboratoryMember', window );">Lab Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives (In years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dvax_LaboratoryMember', window );">Lab Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives (In years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives (In years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives (In years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives (In years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives (In years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives (In years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ComputerEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Computer equipment, Gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ComputerEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LaboratoryEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Laboratory Equipment Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LaboratoryEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dvax_LaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dvax_LaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477001166608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 4,342<span></span>
</td>
<td class="nump">$ 3,812<span></span>
</td>
<td class="nump">$ 4,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477000329488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Current Accrued Liabilities - Component of Current Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 17,069<span></span>
</td>
<td class="nump">$ 14,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_RevenueReserveAccrualCurrent', window );">Revenue reserve accruals</a></td>
<td class="nump">21,004<span></span>
</td>
<td class="nump">10,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AccruedInventory', window );">Accrued inventory</a></td>
<td class="nump">4,456<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">6,919<span></span>
</td>
<td class="nump">3,697<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 49,448<span></span>
</td>
<td class="nump">$ 30,719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_AccruedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_AccruedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses and current accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_RevenueReserveAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue reserve accrual current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_RevenueReserveAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476991187264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th">
<div>Nov. 30, 2009 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseOptionToExtend', window );">Option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The subtenant has no option to extend the sublease term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,577<span></span>
</td>
<td class="nump">$ 7,685<span></span>
</td>
<td class="nump">$ 7,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PercentageOfExcessRentPaidToLandlord', window );">Percentage of excess rent paid to landlord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Long-term debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,802<span></span>
</td>
<td class="nump">$ 3,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Non-cancelable purchase and other commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DescriptionOfAveciaSupplyAgreement', window );">Description of Avecia Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On September 7, 2023 (the &#8220;Effective Date&#8221;), we entered into an agreement (the &#8220;Avecia Supply Agreement&#8221;) with Nitto Denko Avecia Inc. (&#8220;Avecia&#8221;) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the &#8220;2012 Agreement&#8221;). As of December 31, 2023, our aggregate minimum commitment for the supply of CpG 1018 adjuvant under the Avecia Supply Agreement was $7.4 million within the next 12 months. As of December 31, 2022, we had no non-cancelable purchase and other commitments for the supply of CpG 1018 adjuvant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AggregateMinimumCommitment', window );">Aggregate minimum commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">HEPLISAV-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Non-cancelable purchase and other commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember', window );">2.50% Convertible Senior Notes Due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Long-term debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=dvax_SymphonyDynamoHoldingsLlcMember', window );">Symphony Dynamo Holdings Llc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LicenseArrangementContingentConsiderationPercentage', window );">License arrangement contingent consideration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LicenseArrangementContingentPaymentToAcquireLicense', window );">License arrangement upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=dvax_TrisalusLifeSciencesMember', window );">Trisalus Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PaymentToHoldings', window );">Payment to holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PaymentReceivedForPreCommercializationMilestone', window );">Payment received for pre-commercialization milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=dvax_TrisalusLifeSciencesMember', window );">Trisalus Life Sciences | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PaymentMadeForPreCommercializationMilestone', window );">Payment made for pre-commercialization milestone</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=dvax_DeutscheBankSecuritiesMember', window );">Deutsche Bank Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Financial instruments owned at fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.2<span></span>
</td>
<td class="nump">&#8364; 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=dvax_DeutscheBankSecuritiesMember', window );">Deutsche Bank Securities | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Financial instruments owned at fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Certain of these leases also include options to renew or extend the lease for two successive five-year terms.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend', window );">Existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis=dvax_PowellStreetSubleaseMember', window );">Powell Street Sublease | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend', window );">Existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_AggregateMinimumCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate minimum commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_AggregateMinimumCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_DescriptionOfAveciaSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of Avecia Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_DescriptionOfAveciaSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LicenseArrangementContingentConsiderationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License arrangement contingent consideration percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LicenseArrangementContingentConsiderationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LicenseArrangementContingentPaymentToAcquireLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License arrangement contingent payment to acquire license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LicenseArrangementContingentPaymentToAcquireLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_PaymentMadeForPreCommercializationMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment made for pre commercialization milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_PaymentMadeForPreCommercializationMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_PaymentReceivedForPreCommercializationMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment received for pre-commercialization milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_PaymentReceivedForPreCommercializationMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_PaymentToHoldings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_PaymentToHoldings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_PercentageOfExcessRentPaidToLandlord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of excess rent paid to landlord.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_PercentageOfExcessRentPaidToLandlord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481961/940-320-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether sublessee has option to extend operating sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend operating sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_HEPLISAVBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dvax_SymphonyDynamoHoldingsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dvax_SymphonyDynamoHoldingsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dvax_TrisalusLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dvax_TrisalusLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dvax_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dvax_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=dvax_DeutscheBankSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=dvax_DeutscheBankSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis=dvax_PowellStreetSubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis=dvax_PowellStreetSubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477086978880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Operating Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 5,563<span></span>
</td>
<td class="nump">$ 6,222<span></span>
</td>
<td class="nump">$ 6,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477002290224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities (included in other current liabilities)</a></td>
<td class="nump">$ 4,496<span></span>
</td>
<td class="nump">$ 3,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">$ 29,720<span></span>
</td>
<td class="nump">$ 32,801<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 34,216<span></span>
</td>
<td class="nump">$ 36,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993231440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Maturities of Sublease Income and Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract', window );"><strong>Sublease Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 5,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo', window );">2025</a></td>
<td class="nump">5,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree', window );">2026</a></td>
<td class="nump">6,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour', window );">2027</a></td>
<td class="nump">6,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive', window );">2028</a></td>
<td class="nump">6,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter', window );">Thereafter</a></td>
<td class="nump">15,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue', window );">Total</a></td>
<td class="nump">45,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">7,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">6,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">6,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">6,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">6,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">15,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">48,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(13,820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 34,216<span></span>
</td>
<td class="nump">$ 36,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor sublease rentals payments to be received due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor sublease rentals payments to be received due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor sublease rentals payments to be received due thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor sublease rentals payments to be received due year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor sublease rentals payments to be received due year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor sublease rentals payments to be received due year three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor sublease rentals payments to be received due year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor sublease rentals payments to be received next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476998540144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">10.10%<span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476996929776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Material Purchase Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 18,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">11,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">12,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFifthYear', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total</a></td>
<td class="nump">$ 43,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476997710416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research, Development and License Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232,284<span></span>
</td>
<td class="nump">$ 722,683<span></span>
</td>
<td class="nump">$ 439,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_InventoryWriteOffsRecognized', window );">Inventory write-offs recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AdvancePaymentFromCustomer', window );">Advance payment from customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,401)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_RepaymentOfAdvanceFromCustomer', window );">Repayment of advance from customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,448<span></span>
</td>
<td class="nump">30,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,313<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PrepaymentOfAdvancePayment', window );">Prepayment of advance payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Increase in revenue adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=dvax_CpG1018Member', window );">CpG 1018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_InventoryWriteOffsRecognized', window );">Inventory write-offs recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dvax_CoalitionForEpidemicPreparednessInnovationsMember', window );">CEPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember', window );">CEPI Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AdvancePaymentFromCustomer', window );">Advance payment from customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_RepaymentOfAdvanceFromCustomer', window );">Repayment of advance from customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,400<span></span>
</td>
<td class="nump">107,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AccrualLongTermBalance', window );">Accrual long-term balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember', window );">Clover</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AccrualLongTermBalance', window );">Accrual long-term balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dvax_BiologicalELimitedMember', window );">Biological E. Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_RepaymentOfAdvanceFromCustomer', window );">Repayment of advance from customer</a></td>
<td class="nump">$ 47,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advance payment received</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_PrepaymentOfAdvancePayment', window );">Prepayment of advance payment</a></td>
<td class="nump">14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AdditionalFuturePayment', window );">Additional future payment</a></td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dvax_USDepartmentOfDefenseMember', window );">U.S. Department of Defense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ProceedsFromGrant', window );">Proceeds from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dvax_SupplyAgreementMember', window );">Supply Agreement | Clover</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract asset balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dvax_SupplyAgreementMember', window );">Supply Agreement | Biological E. Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 206,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_AccrualLongTermBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual Long Term Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_AccrualLongTermBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_AdditionalFuturePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional future payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_AdditionalFuturePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_AdvancePaymentFromCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance payment from customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_AdvancePaymentFromCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_InventoryWriteOffsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory write-offs recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_InventoryWriteOffsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_PrepaymentOfAdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment of advance payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_PrepaymentOfAdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ProceedsFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ProceedsFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_RepaymentOfAdvanceFromCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of Advance from Customer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_RepaymentOfAdvanceFromCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=dvax_CpG1018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=dvax_CpG1018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dvax_CoalitionForEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dvax_CoalitionForEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dvax_BiologicalELimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dvax_BiologicalELimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dvax_USDepartmentOfDefenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dvax_USDepartmentOfDefenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dvax_SupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dvax_SupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476991662640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes (Additional Information) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Days </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of Convertible Notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 219,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember', window );">2.50% Convertible Senior Notes Due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 225,500<span></span>
</td>
<td class="nump">$ 225,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance and offering costs</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of Convertible Notes, net</a></td>
<td class="nump">219,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Debt instrument, interest rate terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Convertible Notes are general, unsecured obligations and accrue interest at a rate of 2.50% per annum payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 15,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.5338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount', window );">Debt conversion, original debt, principal amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Debt Instrument, redemption, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">We may redeem for cash all or any portion of the Convertible Notes (subject to the partial redemption limitation described in the indenture governing the Convertible Notes), at our option, on or after May 20, 2024 and prior to the 31st scheduled trading day immediately preceding the maturity date, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember', window );">2.50% Convertible Senior Notes Due 2026 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount', window );">Debt conversion, original debt, principal amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember', window );">2.50% Convertible Senior Notes Due 2026 | Debt Instrument, Conversion, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember', window );">2.50% Convertible Senior Notes Due 2026 | Debt Instrument, Conversion, Period One | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember', window );">2.50% Convertible Senior Notes Due 2026 | Debt Instrument, Conversion, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember', window );">2.50% Convertible Senior Notes Due 2026 | Debt Instrument, Conversion, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_LoanAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">190,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_CappedCallsMember', window );">Capped Calls</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue', window );">Net Proceeds to Pay the Costs</a></td>
<td class="nump">$ 27,200<span></span>
</td>
<td class="nump">$ 27,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,542,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare', window );">Initial strike price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare', window );">Initial cap price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Reduction to additional paid-in capital, capped calls cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument capped call transaction initial cap price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument capped call transaction initial strike price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument conversion original debt base principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible notes on purchase of capped call options value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dvax_DebtInstrumentConversionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dvax_DebtInstrumentConversionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dvax_DebtInstrumentConversionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dvax_DebtInstrumentConversionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dvax_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dvax_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dvax_CappedCallsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dvax_CappedCallsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477000154208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes - Summary of Interest Expenses Related to Convertible Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Stated coupon interest</a></td>
<td class="nump">$ 5,636<span></span>
</td>
<td class="nump">$ 5,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance cost</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 6,757<span></span>
</td>
<td class="nump">$ 6,732<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476996832032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 20, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,802<span></span>
</td>
<td class="nump">$ 3,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense related to initial term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,757<span></span>
</td>
<td class="nump">6,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment (Note 11)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (5,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">190,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dvax_LoanAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense related to initial term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dvax_CRGServicingLLCMember', window );">CRG Servicing LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from the initial term loan</a></td>
<td class="nump">$ 173,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Current borrowing capacity</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment (Note 11)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dvax_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dvax_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dvax_CRGServicingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dvax_CRGServicingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476996670592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Summary of Disaggregation of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 232,284<span></span>
</td>
<td class="nump">$ 722,683<span></span>
</td>
<td class="nump">$ 439,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">230,945<span></span>
</td>
<td class="nump">133,770<span></span>
</td>
<td class="nump">63,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">588,913<span></span>
</td>
<td class="nump">375,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">HEPLISAV-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">213,295<span></span>
</td>
<td class="nump">125,937<span></span>
</td>
<td class="nump">61,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">HEPLISAV-B | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">213,295<span></span>
</td>
<td class="nump">124,996<span></span>
</td>
<td class="nump">61,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">HEPLISAV-B | Non U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_CpG1018Member', window );">CpG 1018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">587,708<span></span>
</td>
<td class="nump">375,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_CpG1018Member', window );">CpG 1018 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_CpG1018Member', window );">CpG 1018 | Non U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">587,708<span></span>
</td>
<td class="nump">375,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">213,295<span></span>
</td>
<td class="nump">713,645<span></span>
</td>
<td class="nump">437,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">213,295<span></span>
</td>
<td class="nump">124,996<span></span>
</td>
<td class="nump">61,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Non U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">588,649<span></span>
</td>
<td class="nump">375,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_OtherRevenueMember', window );">Other Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18,989<span></span>
</td>
<td class="nump">9,038<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_OtherRevenueMember', window );">Other Revenue | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">17,650<span></span>
</td>
<td class="nump">8,774<span></span>
</td>
<td class="nump">1,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_OtherRevenueMember', window );">Other Revenue | Non U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,339<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_HEPLISAVBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_CpG1018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_CpG1018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476998654208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Revenues from Major Customers (Details) - Revenue Benchmark [Member] - Product Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Largest Customer | HEPLISAV-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of product revenue</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Second Largest Customer | HEPLISAV-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of product revenue</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Third Largest Customer | HEPLISAV-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of product revenue</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Largest Collaboration Partner | CpG 1018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of product revenue</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Second Largest Collaboration Partner | CpG 1018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of product revenue</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Third Largest Collaboration Partner | CpG 1018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of product revenue</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dvax_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dvax_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_HEPLISAVBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dvax_SecondLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dvax_SecondLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dvax_ThirdLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dvax_ThirdLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dvax_LargestCollaborationPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dvax_LargestCollaborationPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_CpG1018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_CpG1018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dvax_SecondLargestCollaborationPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dvax_SecondLargestCollaborationPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dvax_ThirdLargestCollaborationPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dvax_ThirdLargestCollaborationPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477002159744">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Summary of Product Revenue Allowance and Reserve Categories (Detail) - HEPLISAV-B - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">Accounts Receivable Reserves</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation And Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ReservesAccrualBalance', window );">Balance at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 8,179<span></span>
</td>
<td class="nump">$ 3,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales', window );">Provisions related to current period sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">55,604<span></span>
</td>
<td class="nump">34,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod', window );">Credit or payments made during the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(54,143)<span></span>
</td>
<td class="num">(30,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod', window );">Adjustments related to prior periods</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2,629)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ReservesAccrualBalance', window );">Balance at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,011<span></span>
</td>
<td class="nump">8,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember', window );">Revenue Reserve Accruals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation And Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ReservesAccrualBalance', window );">Balance at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">10,552<span></span>
</td>
<td class="nump">8,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales', window );">Provisions related to current period sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">46,062<span></span>
</td>
<td class="nump">24,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod', window );">Credit or payments made during the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(38,207)<span></span>
</td>
<td class="num">(22,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod', window );">Adjustments related to prior periods</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,597<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ReservesAccrualBalance', window );">Balance at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 21,004<span></span>
</td>
<td class="nump">$ 10,552<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reserves are for chargebacks, discounts and other fees</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accruals are for returns, rebates and other fees</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Revenue Allowance And Reserves Adjustments Related To Prior Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product revenue allowance and reserves credit or payments made during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product revenue allowance and reserves provision related to current period sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ReservesAccrualBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserves Accrual Balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ReservesAccrualBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C(1)))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C(2)))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_HEPLISAVBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_HEPLISAVBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForNotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForNotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=dvax_RevenueReserveAccrualsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=dvax_RevenueReserveAccrualsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993220768">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Summary of Balances and Activities in our Contract Asset Account (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract', window );"><strong>Contract Asset Account [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal', window );">Contract asset, reclassification</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 71,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent', window );">Balance at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dvax_CpG1018Member', window );">Cp G1018 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract', window );"><strong>Contract Asset Account [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,965<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 62,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetSale', window );">Contract asset, additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,650<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">17,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetPurchase', window );">Contract asset, subtractions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,919)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(8,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal', window );">Contract asset, reclassification</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(71,307)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 1,389<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 71,965<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 9 for further discussion.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> $1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> million of contract asset is derived from our agreement with the DoD</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, from change in methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase from purchase of right to consideration in exchange for good or service transferred to customer when right is conditioned on passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease from sale of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time and other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dvax_CpG1018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dvax_CpG1018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476997360064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share- Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract', window );"><strong>Disclosure Computation Of Basic And Diluted Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (6,389)<span></span>
</td>
<td class="nump">$ 293,156<span></span>
</td>
<td class="nump">$ 76,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: undistributed earnings allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(283)<span></span>
</td>
<td class="num">(4,569)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income allocable to common stockholders, basic</a></td>
<td class="num">(6,389)<span></span>
</td>
<td class="nump">292,873<span></span>
</td>
<td class="nump">72,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants', window );">Add: undistributed earnings allocated to Series B and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">4,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants', window );">Less: undistributed earnings allocated to Series B and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseMediumTermNotes', window );">Add: interest expense on convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,044<span></span>
</td>
<td class="nump">3,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_FairValueAdjustmentsOfWarrants', window );">Less: removal of change in fair value of warrant liability</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="num">(1,801)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) allocable to common stockholders, diluted</a></td>
<td class="num">$ (6,389)<span></span>
</td>
<td class="nump">$ 296,399<span></span>
</td>
<td class="nump">$ 75,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing basic net (loss) income per share allocable to common stockholders</a></td>
<td class="nump">128,733<span></span>
</td>
<td class="nump">126,398<span></span>
</td>
<td class="nump">116,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,774<span></span>
</td>
<td class="nump">$ 3,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Convertible Notes (as converted to common stock)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,543<span></span>
</td>
<td class="nump">13,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Effect of dilutive warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used to compute net (loss) income allocable to common stockholders per share, diluted</a></td>
<td class="nump">128,733<span></span>
</td>
<td class="nump">150,797<span></span>
</td>
<td class="nump">133,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition of undistributed earnings allocated to Series B and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deduction of undistributed earnings allocated to Series B and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure computation of basic and diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_FairValueAdjustmentsOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustments of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_FairValueAdjustmentsOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense on medium-Term notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476991062064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract', window );"><strong>Outstanding securities not included in diluted net loss per share calculation (in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities not included in diluted net (loss) income allocable to common stockholders per share calculation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,543<span></span>
</td>
<td class="nump">13,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dvax_StockOptionsAndShareAwardsMember', window );">Stock Options and Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract', window );"><strong>Outstanding securities not included in diluted net loss per share calculation (in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities not included in diluted net (loss) income allocable to common stockholders per share calculation</a></td>
<td class="nump">15,158<span></span>
</td>
<td class="nump">7,165<span></span>
</td>
<td class="nump">5,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract', window );"><strong>Outstanding securities not included in diluted net loss per share calculation (in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities not included in diluted net (loss) income allocable to common stockholders per share calculation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract', window );"><strong>Outstanding securities not included in diluted net loss per share calculation (in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities not included in diluted net (loss) income allocable to common stockholders per share calculation</a></td>
<td class="nump">21,543<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Antidilutive securities excluded from computation of earning per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dvax_StockOptionsAndShareAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dvax_StockOptionsAndShareAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476992986864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Warrants - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 06, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,530,228<span></span>
</td>
<td class="nump">127,604,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,801)<span></span>
</td>
<td class="nump">$ 49,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_NumberOfCommonStockWarrantExercised', window );">Number of common stock warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,882,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CashSettlementOfWarrants', window );">Proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Other Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dvax_TwentySeventeenAtTheMarketAgreementMember', window );">2017 ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity', window );">Remaining proceeds from common stock, under sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_CommonStockSalesAgreementAggregateSalesProceeds', window );">Common stock sales agreement aggregate sales proceeds</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2017 ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock', window );">Commission on gross sales proceeds of common stock</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_CashSettlementOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Settlement of warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_CashSettlementOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_CommonStockSalesAgreementAggregateSalesProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock sales agreement aggregate sales proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_CommonStockSalesAgreementAggregateSalesProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_NumberOfCommonStockWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_NumberOfCommonStockWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock authorized, remaining capacity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling commission percentage from gross offering proceeds of sales of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dvax_TwentySeventeenAtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dvax_TwentySeventeenAtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476997944864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans and Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 28, 2014</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance', window );">Increase in aggregate number of shares of common stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,774<span></span>
</td>
<td class="nump">$ 3,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock based compensation expense related to restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400<span></span>
</td>
<td class="nump">13,200<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,200<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">37,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock unit awards outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,445,000<span></span>
</td>
<td class="nump">3,479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="nump">$ 17,200<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dvax_MarketBasedPerformanceStockUnitMember', window );">Market Based Performance Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock based compensation expense related to restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock unit awards outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557,000<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dvax_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Newly reserved shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,388,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dvax_TimeBasedVestingScheduleMember', window );">Time Based Vesting Schedule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted-average vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dvax_TimeBasedVestingScheduleMember', window );">Time Based Vesting Schedule | Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dvax_PerformanceBasedVestingScheduleMember', window );">Performance Based Vesting Schedule | Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock unit awards outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted-average vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan', window );">Shares issued to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan', window );">Shares remaining available for future purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan | The commencement of the offer period (generally, the sixteenth day in February or August)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price per share as percentage of fair market value of common stock</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan | The exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price per share as percentage of fair market value of common stock</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for future purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in number of employee stock purchase plan shares authorized for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares available for purchases under employee purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares purchased by employees under employee purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dvax_MarketBasedPerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dvax_MarketBasedPerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dvax_TwoThousandAndEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dvax_TwoThousandAndEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dvax_TimeBasedVestingScheduleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dvax_TimeBasedVestingScheduleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dvax_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dvax_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dvax_PerformanceBasedVestingScheduleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dvax_PerformanceBasedVestingScheduleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476992989456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans and Stock-Based Compensation - Option Activity under Stock-Based Compensation Plans (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Underlying Outstanding Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance</a></td>
<td class="nump">9,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">1,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract', window );"><strong>Options cancelled:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (unvested)</a></td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired (vested)</a></td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance</a></td>
<td class="nump">10,120<span></span>
</td>
<td class="nump">9,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at December 31, 2023</a></td>
<td class="nump">9,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2023</a></td>
<td class="nump">7,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance</a></td>
<td class="nump">$ 10.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">11.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">7.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Options cancelled:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (unvested)</a></td>
<td class="nump">10.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired (vested)</a></td>
<td class="nump">21.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance</a></td>
<td class="nump">10.78<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest at December 31, 2023</a></td>
<td class="nump">10.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2023</a></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance at December 31</a></td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
<td class="text">4 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at December 31, 2023</a></td>
<td class="text">4 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at December 31, 2023</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at December 31, 2022</a></td>
<td class="nump">$ 16,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at December 31, 2023</a></td>
<td class="nump">37,388<span></span>
</td>
<td class="nump">$ 16,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at December 31, 2023</a></td>
<td class="nump">37,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at December 31, 2023</a></td>
<td class="nump">$ 29,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140477002062512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans and Stock-Based Compensation - Summary of Non-vested Restricted Stock Units Activity (Detail) - Restricted Stock Units (RSUs)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, Beginning Balance | shares</a></td>
<td class="nump">3,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(1,515)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(267)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, Ending Balance | shares</a></td>
<td class="nump">4,445<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">11.48<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">10.13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">11.45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, Ending Balance | $ / shares</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inclusive of approximately 600,145 RSUs for the year ended December 31, 2023, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476998654256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans and Stock-Based Compensation - Summary Of Performance Based Restricted Stock Unit (Details) - Market Based Performance Stock Unit<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, Beginning Balance | shares</a></td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, Ending Balance | shares</a></td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 11.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">18.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, Ending Balance | $ / shares</a></td>
<td class="nump">$ 15.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dvax_MarketBasedPerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dvax_MarketBasedPerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476998508816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans and Stock-Based Compensation - Fair Value-Based Measurements and Weighted-Average Assumptions (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value</a></td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="nump">$ 7.95<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dvax_MarketBasedPerformanceStockUnitMember', window );">Market Based Performance Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value</a></td>
<td class="nump">$ 18.25<span></span>
</td>
<td class="nump">$ 11.62<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dvax_MarketBasedPerformanceStockUnitMember', window );">Market Based Performance Stock Unit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.03%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dvax_MarketBasedPerformanceStockUnitMember', window );">Market Based Performance Stock Unit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.92%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value</a></td>
<td class="nump">$ 5.35<span></span>
</td>
<td class="nump">$ 7.37<span></span>
</td>
<td class="nump">$ 6.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dvax_MarketBasedPerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dvax_MarketBasedPerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993081968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans and Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Employees and directors stock-based compensation expense</a></td>
<td class="nump">$ 42,592<span></span>
</td>
<td class="nump">$ 32,915<span></span>
</td>
<td class="nump">$ 21,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">9,285<span></span>
</td>
<td class="nump">5,954<span></span>
</td>
<td class="nump">3,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">29,069<span></span>
</td>
<td class="nump">23,118<span></span>
</td>
<td class="nump">14,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales - Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,399<span></span>
</td>
<td class="nump">$ 2,720<span></span>
</td>
<td class="nump">$ 2,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476998433296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract', window );"><strong>Pension and Other Postretirement Benefits Cost (Reversal of Cost) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions to 401 (k) plan</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476997188368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Component of Consolidated (Loss) Income Before Provision for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (6,275)<span></span>
</td>
<td class="nump">$ 292,460<span></span>
</td>
<td class="nump">$ 75,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non U.S.</a></td>
<td class="nump">1,908<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes', window );">Total</a></td>
<td class="num">$ (4,367)<span></span>
</td>
<td class="nump">$ 294,299<span></span>
</td>
<td class="nump">$ 77,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income loss&#8203; from continuing&#8203; operations before income&#8203; taxes&#8203;.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476996830240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 2,022<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">$ 808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">353,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">12,101<span></span>
</td>
<td class="nump">11,339<span></span>
</td>
<td class="nump">$ 5,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits would affect the effective tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Interest related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Penalties related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 23,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OperatingLossCarryforwardExpirationYear', window );">Net operating loss carryforwards, expiration year</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research And Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 28,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research And Development Tax Credits | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward amount, expiration year</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research And Development Tax Credits | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward amount, expiration year</a></td>
<td class="text">2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=dvax_CaliforniaAndOtherStatesTaxAuthorityMember', window );">California and Other States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 283,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=dvax_CaliforniaAndOtherStatesTaxAuthorityMember', window );">California and Other States | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OperatingLossCarryforwardExpirationYear', window );">Net operating loss carryforwards, expiration year</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=dvax_CaliforniaAndOtherStatesTaxAuthorityMember', window );">California and Other States | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_OperatingLossCarryforwardExpirationYear', window );">Net operating loss carryforwards, expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=dvax_CaliforniaStateTaxAuthorityMember', window );">California State | Research And Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 22,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_OperatingLossCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforward, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_OperatingLossCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=dvax_CaliforniaAndOtherStatesTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=dvax_CaliforniaAndOtherStatesTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=dvax_CaliforniaStateTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=dvax_CaliforniaStateTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993082672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (178)<span></span>
</td>
<td class="num">$ (165)<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,533<span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Non-US</a></td>
<td class="nump">667<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Non-US</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 2,022<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">$ 808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476997845296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Schedule of Difference between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax provision (benefit) at federal statutory rate</a></td>
<td class="num">$ (917)<span></span>
</td>
<td class="nump">$ 61,775<span></span>
</td>
<td class="nump">$ 16,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax</a></td>
<td class="nump">574<span></span>
</td>
<td class="num">(2,942)<span></span>
</td>
<td class="nump">3,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxReconciliationTaxCredit', window );">Business credits</a></td>
<td class="num">(2,050)<span></span>
</td>
<td class="num">(3,246)<span></span>
</td>
<td class="num">(982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxReconciliationDeferredCompensationCharges', window );">Deferred compensation charges</a></td>
<td class="nump">830<span></span>
</td>
<td class="num">(473)<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="num">(324)<span></span>
</td>
<td class="num">(86,847)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_Section162MLimitation', window );">Section 162(m) limitation</a></td>
<td class="nump">1,963<span></span>
</td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">1,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants', window );">Mark-to-market of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(378)<span></span>
</td>
<td class="nump">10,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_NetOperatingLossAndTaxCreditLimitations', window );">Net operating loss and tax credit limitation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(56,908)<span></span>
</td>
<td class="nump">56,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(518)<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="num">(290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign taxes</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 2,022<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">$ 808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax rate reconciliation mark to market of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IncomeTaxReconciliationDeferredCompensationCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation deferred compensation charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IncomeTaxReconciliationDeferredCompensationCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_IncomeTaxReconciliationTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_IncomeTaxReconciliationTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_NetOperatingLossAndTaxCreditLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss and tax credit limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_NetOperatingLossAndTaxCreditLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_Section162MLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>section 162 (m) Limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_Section162MLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476997820288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Schedule of Component of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 96,336<span></span>
</td>
<td class="nump">$ 113,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research credit carryforwards</a></td>
<td class="nump">34,940<span></span>
</td>
<td class="nump">33,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization', window );">Section 174 capitalization</a></td>
<td class="nump">22,556<span></span>
</td>
<td class="nump">15,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">8,868<span></span>
</td>
<td class="nump">9,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Stock compensation</a></td>
<td class="nump">10,572<span></span>
</td>
<td class="nump">7,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">15,808<span></span>
</td>
<td class="nump">9,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">189,428<span></span>
</td>
<td class="nump">188,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(180,387)<span></span>
</td>
<td class="num">(178,920)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">9,041<span></span>
</td>
<td class="nump">9,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(2,667)<span></span>
</td>
<td class="num">(2,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(6,345)<span></span>
</td>
<td class="num">(6,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(9,041)<span></span>
</td>
<td class="num">(9,796)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>DeferredTaxAssetsOperatingLossCarryforwardsCapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140476993004528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at Beginning Balance</a></td>
<td class="num">$ (11,339)<span></span>
</td>
<td class="num">$ (5,615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Tax positions related to the current year, Additions</a></td>
<td class="num">(762)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Tax positions related to the current year, Reductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Tax positions related to the prior year, Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Tax positions related to the prior year, Reductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities', window );">Tax positions related to the prior year, Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Tax positions related to the prior year, Lapses in statute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at Ending Balance</a></td>
<td class="num">$ (12,101)<span></span>
</td>
<td class="num">$ (11,339)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZU19FV-LXC93>R*+6.4+T+&^X%0[7AT0&FTH?L5OZ(6$2\H2MHB)0$/&5SJ
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MF0:U!2]^\2P<!&^Z O]/8JTT1$T:HE/J\;7 3>T* (\'DLIR:5:EP)V6R++
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M/EA4;T]4%X+MRO<)%DP(MBV_;BB1S5D!Y/]7C(GCA?J!TSLLL_\!4$L#!!0
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M<M45%F>PRHKMW^2Y:XB] I@>*$"Z N38 K0K0-4"_H$";E? 50J0Z8$"7E?
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MOA*U$>COUU)'F\,;\P.GA^)N_P]02P,$%     @ 48%66(DP=ES'!   90H
M !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6R55MMNVS@0_96!"A0MX/J6
MM V:Q$ <MTV!+39H>GDH^D"+(XD;BM22E%WWZ_>0DARWR&:[#W'((>=ZSHQX
MMK7NUE?,@;[7VOCSK JA>369^+SB6OBQ;=C@I+"N%@%;5TY\XUC(I%3KR7PZ
M?3&IA3+9XBS)KMWBS+9!*\/7CGQ;U\+MEJSM]CR;98/@@RJK$ 63Q5DC2K[A
M\*FY=MA-]E:DJMEX90TY+LZSB]FKY7&\GRY\5KSU!VN*F:RMO8V;=_(\F\:
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M^3PCUSUJNDVP37I(H.1XEJ1EA7<@NW@!YX7%Q.PWT<'^9;GX!U!+ P04
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M8:">N\T)4P!0PDKSA.@BH&.-1$9>[GO1CX+*\>T*3/'?U/Z]=W1J20M?9\^
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M/*AN\2QT*IWFFGR+T(:9]QHKAK9#[@C7P0XYOUPLAK<$.YZEDB*D_@903W:
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M5>66A4 <-1'@_5+A-&H?2,'N&^K=_P!02P,$%     @ 48%66(D2XOZ+ @
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MNN7F5C;?<)=/XGB9Y+K]0M/Y1L2#;*N-K';!5D'%1#?2Y]U_. B8AF\$D%T
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MIM0%X]9Y? 6?)R4%6V)#A(P%8SBS" 'E#B9JJ(H<DIYDI3<2:(<&V=3@O31
MH-O(LN0XLI'D><LMA1G"R\ZV^5C\(T$CDB6:P5J#!9)UX,=2W$@+ERS5;@CK
M,.R-![:5\[IB@;L0!V; %?$!(<VZUO\A<E@O"AVC")\7U4=8A+F1"SDZ4/J@
M0DA#4^\3M+J]4'QCV16C1"M3HO"CPXXX\IC6@4'WY-G!'Q3$WNRAX(!0$$!
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M?E#&G)9&7/6%P)L%/[Z128+D2(HMK<P=@<%5 0H[>P%CX;0J@?_=HLI8VX+
MAW6+D#,KX%M#0X.5&1A_1+N0R22B3B>\*=N^!"R!H+F*&Z<*P@D[#:N:8-D6
M8-\5XA+0R<3L/%39GHPKUA+"+-L%;!B"[?Y4PA&#87/EUPIJ5 'L/.AP*QT?
MO=!&O!*7SNEEP9-W\O-87)/[Y>9R>R;&,$#TMJX(?O#(7R'5TM]@L<Y#,PK
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M&/*M2=BINX)P+0CMNB D 8@W%:+E1.8H#U7>>B Q!"P9H*.@&AU1W_-QVRG
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M;#9DVG\A^!>K&G<K7RF+=WRW+/&C"C0)X/]KA6'H7LA _YFV_ =02P,$%
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M!MXTX11>&4]G>OBLZ!*%E@UH?FV,WPXXP' M6_P#4$L#!!0    ( %&!5EA
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M K;N%;(2?8L5X*9TQY<+5-E+S,I4RBB8?>]K&HU5 H(U5.NEJ_^K#@[J8+O
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M ?!\II2M_N "]:O$E_\#4$L#!!0    ( %&!5EB8-=, $ ,  +$&   9
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MU&H5(*>$G ,]T%+7FV'M#Z;:\ZQMO0V.VA$]]FX&O'N7PF%A-;TDA4$-3@S
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MY3V"?&+@36?1E\1N55T7W-;8^^_DSMC#*'O4H_"LI[DJLV.= \^?^NVA8@O
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MA. '& !>:1,0W""NU94#G,/E@*K0^8;F&X#UMSQ'U1;#!H8$PH8]713] %,
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M_]JIB :D YT"CX_,+  E6"6K"C5&0%X<Z)8!WSJ7;=A+!+A*D&>;')"@@-=
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MURH.B9I0==T J,F4L*Y6:]WS/\#$J5B[PEB"]7(;R( %[T%#<:0)B*BN<84
M>[2I<R/X)\!U8/7T,CJ?'6N-5K2PY"#[X=^@11'5(<=#]P4,"SB#[AD8Q<15
M1<9YL?3OO&_&B E4"9Q+\+ S#JT9<4V)0"![9Z=?Z\L!$!O%2#?72&\RIO+,
M%L6P<%\)N; ZPC["15Y\@/G &NO;:D'(F"T=PA-HI10S+42I2C\L>E -PBX(
M:NJ*9SD7."A.LO-"5+7082"&*%,D8>&*[%D6F7$W>_8H<&/-[@:@W#L<"0!&
M&DD_8ND@K8'J2*H! !?1[8"/F6%O*M!]$ M(B:HYL##/GJ6.VOUNJ1L#^410
M34.$_7CG\P?1\<3NDYO4X@85+CHBBA@)>5KYVJ\H1O1\GKU"BG;E?T1]!G[/
MG@>UR/"]&2)<[S;;Z"#US<I3H,JMP!@3I9Q$#6W=9S18=@$45A*5_>CGV8/L
M^ K,OA]!E<V^OL<F/#WW'[C^+<))Q#01BX"4A@X1S.\CX<(R*'B@8(BBL(2%
MW!)02TN1Y"L">F!E!/;42+H(<3X<'0='TX$>8]\3CK;!@?!0+E^_??K\YXO_
M/+B>U.4]Y27(9F(!<](',E_=++H0T3L97#QDJ'XDNH%?'IUE?Z%AOGK$'@K$
M_[\]?_/JY=7%SR=/A1AW47_LS-VS0L+)=5ZBUG&Y_3X[.SU[1)K--3*T?8/O
M&^Y\1JX>W>2!;9V=GL;MW'WB3(2G<#DXXY(<!AV3IL1W>2Y@(?'4WC44ZKCJ
MZ>$7WC.N/&N'5791HL7;J0IP?/3BV<41IQ*HRYU]CZ .W[+T8&4<?S4N*6:Z
MI/X5;)8X\O"U025L/,4P6]H*,1A_<#>X?4=BAKE@YW2+9=ACQUY$H"1< O(1
MI 62GF1WZF,4>"6*R4/@%0!..BKIBAS6P@4M, "F#AI\37^VOZD],_2D"J!'
MI&0=%^A\V4O@,9P$K,=@K3AN ="J_P+K!6$!NT8/DO :4L%0RLDJ,;*F6AQ
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M71R!MA\W>.C1J)9O,,:Y14<M.X9&LT==?VF8J-6EC*PS9 X&5262MPQ95^H
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M! [5V1D66H$]#0\E+&D\00>VU/R=0,8V$7W8>BJIJ+ +@YZGKIJY?X^MYE;
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M[(PPLSHH9RZR#XLF=98PY:94K3)19SJSJPF@\A5O^'"XN7&$9G1/1"A[QI7
M[KC)ICWL*3>\A!5CTK35ZC!LE4+ Y!2;5L$S7-AMZJT-!>1YT8>S9G<A+G+
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M@T_W,U*KS.*VP)R23VJSXQ8N-6<9"6X9L6=;!K((?&W.*1Q3JIM%5#*7J.T
M(>Y\C$$DYZ\KBH_9 /<$QE!5]*&=,E9@G>Z85"("Q4 *3:MY\/_+G0;CM7QG
MA^_)>\DM<JCD;-(&.OCZODL;XI@<K>/^9XU-C ^\$0Z%.C<FFG_IT!E-"NG'
MI%^;Z4P3*JL5K83$\!7$>\J7+(3^@=G[%GU(,4.N2X+-.QU.U=;&X1:Y=#"9
M7@J5[&5U?L/Y%(A>RL@YRFX:%J?7U@NVD&/)ON*:G.\&>Q]B2['/0N)""+X
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M;KYWHJ6*NPC^IOMP]HEO)-K1(G84R=O'Q1[U:D!EOT!-&=QIY6H+-ZK$\C5
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M?/?==W>YRW0OU:,N  QY+KG0,Z\PIIH$@<X***F^DA4(O-E*55*#1[4+=*6
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MGL!+/[R+AN'',RDG7<K).?3T-4]Y-L]3O,\BG^9]B$#;"/RHDIG$J=:.B"F
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M<LC_!PB)6,LNV;*;)4<1KR$[9[VXRY(HZ1W!Z[75]CQ>[R#> MFUL)G4MC+
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M8Q4N[#V-[2B^-G<C,ZZ0Y4USR2C"UP+X?LYQ29J.=M!=EEW]"U!+ P04
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M1\>B'!^2N9_DN??-RK.; >K W1,?C&2D9K>TPB_FLU[8G(1E3E@8IUZ? EL
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MH\2#JS1V\SAR?@)3-)WOYEX&OUF8PV^<I,X#5[36_)$;)JGEC]P@SY$_=>/
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ME>*-OEPS"DL/$L#[%>=J=X,*^H.NR[\ 4$L#!!0    ( %&!5ECZE0NS<@(
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MI\+(%9I)XDYSEET8/:%9HD3<RV[[.?!1HY!]=T^UOM(_@5W_O+I=D5 J:XM
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M%#B-N$\<V@U&^?MWH\/DRRM4QP/5<4 ?OUTP+@MRJ4YT.>@M6>&^CB5\U[#
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M""4YR.$% Z(I!7C-<VZ-4<?[(U$2@E@H%Q!-(8 TM9#." 8==R"H2M_43K&
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M2J@4$Q61D$^="__\,C;VUN"10:-VUL1DLA#BR0C?LZGC&4+ (46#0/5O#5?
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M=Q:D,=#[N1"X%<SL[U[NY#=02P,$%     @ 48%66+=TYP^8 @  %@8  !D
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MU7-N^3+)M?LEZ]8V"DA6:R/+%HP>E$SX+WUNX[ %Z%_L <0M('X/&.X!#%K
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M@[(&>+^4TFPV]H'NKR#]"U!+ P04    " !1@5984WLAHY "  #=!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6RM55U/VS 4_2M6AB8F ?E."4LC
M02LT'C8A"N-AVH.;W#86CIW9;@/_?G82HM"&CH>])/ZXY]QSKN.;I.;B218
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MON?DGFO[)-YP\2!+1 6/=<7DR"F56IZ[KLQ*K(D\X4MD>F7!14V4#D7ARJ5
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MXY.1!ZKQSF9B9.7<9"D->9,;YO2[064#:'\EI=E-[ '=#RS^"U!+ P04
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MV!P-&V5QRV+EJ0]'9SY -XU#-8'2U!37);"M+X&?TF0JY2S;O1"_*/;W[<\
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MZ%E1XYG:3*#[^TFK9D;&R9I!TGQ06@!*"Z%H=6V=K;8.Z&Q<XJ!DAJ3YH+0
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M QH 3P/4^0UC\KR37J#X\#+['U!+ P04    " !1@598>H+M,Z $  "M$@
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MYGH."3.E15* T8.$I_D_>RH"<02@00/ +P#^*:#?  @*0/!6"]T"T#T%=!L
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MI!D#N+\6<+C4$[-!TU-;?@=02P,$%     @ 48%66!RR,6(#!0  VB$  !D
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M@!XUA**9CK2%-K97VO?DC66;K%-=T$H;E!: TD(HFNE!6VUCT'(;@];;H+0
ME!9"T4Q?VIH;VXON_;>?A^E(+^G%A"A:[]DEM$['QB=EEH6]/V=[ 4D+H6BF
M%VT1CNU5>)VG=$UXXJ,6: D.2@M :2$4S9R_:JMUWX-,7CYHG0Y*"T!I(13-
M]*6MTWUKO5DF+R;+B7+]EPBN73(SU>';Q$Z[ZFE9;W^>X,KK'20N>U_.]@&T
M+H>B53ZX>W/8&15)^?& U#IN<E5-^S9;FP\4YN6T_,'V!;X)J\\,6DSUU<,]
M$0G+)4KI4B.]JY%^0A35AP35BN+K<J;\F2O%LW)Q18E^9BX:Z/U+SM5NI3A
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MMI#$*FX[T'33G Y]0 <1^$I3L>+@LXPUK K8,E5%OM ^7U-D5+PG00^X\!-
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MYY.U8_D.7WXBZ#K;))M3(6B2':X(#@E3-\C?%Y2*_8GJH-AGG?P/4$L#!!0
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M&NJ)W6M*?UM060/ZOI#2[ :6H/XC-/D74$L#!!0    ( %&!5E@%+8?!\P(
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M1AH:'FZ9T[1&90WH^TQ*L]M8@FK^)[\!4$L#!!0    ( %&!5EBUXU7_204
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M8,6I=7$CLK4ZQ_V6"9$EZG)%24A9;B _7V29.-SD7U#^[\#X?U!+ P04
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M'%T#!WX%MF4[/0$M7N]N][B'KW>' VR<NGY.@>=<Q%MCQLX+<LL8(ALL]2G
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M6W^!)I]0\Z6,"/.+UDVL8Z&T$I*5#5@I* M:/_%+X\,6P(V. +P&X.T#@B,
MOP'XKP4$#2 PSM2I&!\2+'$\Y&R-N(Y6;'I@S#1HE7Y!];%/)5=O"X63\1U-
M60GH$;^ 0)=HJCZKK"* V!S=LG+)*%!93ZA@I,BPA R=?V5"7* &.P;U]0&:
M<+8JS->@IFB']SP!B0MRH39XFB;H_.P"G:&"HL><50+33 QMJ7+1BNRTT3VN
M=7M'=+L>NF=4Y@)]HAEDNP2V,J%UPMLX,?9.,B:0]I#O?D">X_D=@FY?#_<Z
MX,GKX>Z);/SV7'W#Y__W7%%2B)0P4:DS^GDS$Y*KN_:KR_&:,>AFU/7G6BQQ
M"B-+%1@!? 56_/Z=&SD?N]QZ2[+DC<AVG Q:)X-3[/%3;]KK<JM&]0U*%]=5
M?!EY_7!HK[9M.(SR!EX0.;MAR6%8/QR$01NUHSQLE8<GE7]3=_&8^AH9;FWH
M#IRK/?$=05?^8$]Z1U 8];N51ZWRZ*3R1R8QZ9(='9H>^%N[U;H/H[Q!X WV
ME1^&]?NAOGT[TNVMXEH"7Y@F)5#**BKKZM*NMGWPQI3_O?6QZH]U._M'4S?7
M>\P7!16(P%Q1.KV^<I/7#:N>2+8T)7S&I&H(9IBK'@]<!ZCW<\;D9J(W:/\U
MQ'\!4$L#!!0    ( %&!5EAEU2? :P8  %PS   9    >&PO=V]R:W-H965T
M<R]S:&5E=#<X+GAM;+5;;6_;-A#^*X17#"W0Q1+EURPQD)@K&F#=@J;9/@S[
MP$BT+502/8JVTV$_?M1+1-.2Z<@]?4DDF?<<[]$==8]>KG9<?$U7C$GT'$=)
M>MU;2;F^[/=3?\5BFE[P-4O4+PLN8BK5KECVT[5@-,B-XJB/'6?4CVF8]&97
M^;%[,;OB&QF%";L7*-W$,17?;EG$=]<]M_=RX'.X7,GL0']VM:9+]L#DX_I>
MJ+U^A1*$,4O2D"=(L,5U[\:]) ,G,\A'_!&R7;JWC;)0GCC_FNW<!=<])YL1
MBY@O,PBJ_FW9G$51AJ3F\4\)VJM\9H;[VR_H'_+@53!/-&5S'OT9!G)UW9OT
M4, 6=!/)SWSWD94!#3,\GT=I_A?MBK%CW$/^)I4\+HW5#.(P*?[3YY*(/0-W
M=,0 EP;XT&!PQ, K#;S7&@Q*@T'.3!%*S@.ADLZN!-\AD8U6:-E&3F9NK<(/
MD^R\/TBA?@V5G9S=)3Z/&?I"GUF*?D(W01!FYX-&Z"XILBH[.V\)DS2,WJD1
MCP\$O7WS#KU!88*^K/@FI4F07O6EFDP&V?=+Q[>%8WS$L8O1)Y[(58I^20(6
MF !]%445"GX)Y19;$0GS+Y#GOD?8P5[#A.:O-\<-YN3UYJXE&J\Z,5Z.YYT\
M,8B$J1_Q=",8^NM7-0S=21:G?S=Q7F .FC&S->0R75.?7??4(I$RL66]V8\_
MN"/GYR:^(,$($)C!Y:#B<F!#G]T+O@WSE4JEM,K;G%F9I7P3AP76.,?*ELWM
MK,B([3XW]4&N._#,0:0^:.),JC%&*,,JE*$U%)46:GE/&7H;L&+K75:(6QIM
MBE*ED5K*:>*SIM *[.'^K(>.<Q!:?9!W.(98)WGFV1Q5%(RL%/RFKH;JNB=4
MO,D2J<)(D4^%^*;.[8Z*YK5H5(]IZ-5#MSINF_% 8 9'XXJCL96CQT0PGR^3
M\%\69)F.GEC"%J%L)&=<SPKL.NX!-PVC7,^;'B3&N);RPY$[;,[Y217,Y+Q@
M5$^QB0)$%PO512"Y8HCEFZJ3R,>I%&DL@TDME,-$L$ZH;2( @1G<32ONIB?6
M"\D4JE0]6J384/QQM&F3'-.37)T<0:Q3/), U]$=CF-?_9EJ9V2H^IMS.2@=
MV$@HAXPM+-BG>2X->XV>:Z7A PO4FADUQF>U;-LV@*(1*#23-:Q9PQVT824H
M%*&0: 0*S214M[6NM=,[Z^I=0AHMF>?6KMYVSZUYZJ)C=77+ZMI[UK)<T7_H
M4YB$\29N),:*T3K/(-$(%)K)G^Z3W6$7A0O4V):$0J(1*#234-UUN]_7=K]'
M['D=BD*%?&-4-/)K]Z&$UJ"12-#&' K-)%*WYJZ]-]>5_5FA4^&OT$T2(,*V
M+.+KF"4RS]JY8,&Q?L3JH'660J(1*#237"T5W$D790_9[\]!T0@4FDFHU@^N
M74!D3/IY*AKECFC,-XEL)'-:OUI/:K<0YG:_K5GJ0F-@K3&P76.TJVG[1=WN
MJFTR@J(1*#239JUAL-M!=6-0>0.*1J#03$*UO,'6;O]$=;_JDG["P[%+NMVL
M-8U=B!JL10VVBYKVY4^?CY8_Z#U\4#0"A6;2K#41'G11_J B"12-0*&9A&J1
MA.U/$R#*W^X!.X/F9W&@T@@*S:112R-LERUS&H6*NB2DB*JR_UVNF$ /DLKF
M!TQVM-8)":J-H-!,)K4VPN,N*AQ4#X&B$2@TDU"MA[#]V<DYM]M*R(,&?EKK
MX.VN6Q/5A<[!6N=@N\ZQU/")=AU2Q\Q!T0@4FOD&@U9%GM/%.PR@^@<4C4"A
MF81J_>/9G^& W(,[X>-8PVXW:TUD%[K'T[K'LZN2$]5^O#NWX[9.3E 1!(5F
M<KKWPE(G;RS!OK($^\Y2%W+'TW+'LS\"@JEVNP_5GSN-1(+*'"@TDT@M<SR[
M"-FK]KS&O^/6N]U3ZW0%54%0:";+6@5YHR[J'U0,@:(1*#234"V&//N#HO:W
MWKWZZU<8UV^]V_VV9JD+A>-IA>/9%<X'+EBX3!KI 'VL XI&H-!,UK3<\:9=
M%"NHU@%%(U!HYAO&6NL,[$^ SA':@Y,OC<WM7MMR!(56<-3?^^P@9F*9?[ZA
MPLY6I^*U_>IH]8G(3?YAQ,'Q6_>2%!]Z:)CBNY-/5"S#)$416RA(YV*L+G&B
M^)2CV)%\G7_<\,2EY'&^N6(T8"(;H'Y?<"Y?=C('U0<UL_\!4$L#!!0    (
M %&!5EA3MF=Z9@,  )$-   9    >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM
M;*U7T6Z;,!3]%8M-TR:M!0,A:9<@M6'5]K"I6MKMV86;!!7LS':2[N]G&TI"
M<$E5Y25@<\[QN=?A<CW>,OXHE@ 2/94%%1-G*>7JTG5%NH22B'.V JJ>S!DO
MB51#OG#%B@/)#*DL7-_S(K<D.77BL9F[Y?&8K6614[CE2*S+DO!_UU"P[<3!
MSO/$KWRQE'K"C<<KLH 9R/O5+5<CMU')\A*HR!E%'.83YPI?)CC0!(/XG<-6
M[-TC'<H#8X]Z\#V;.)YV! 6D4DL0==G %(I"*RD??VM1IUE3$_?OG]5O3/ J
MF <B8,J*/WDFEQ-GY* ,YF1=R%]L^PWJ@ 9:+V6%,+]H6V,]!Z5K(5E9DY6#
M,J?5E3S5B=@CX.@%@E\3_$-"^ (AJ G!:PEA30A-9JI03!X2(DD\YFR+N$8K
M-7UCDFG8*OR<ZGV?2:Z>YHHGX^\T926@._($ IVAF?I?9>L"$)NCW2-TR]DF
M-UO],0%)\D)\4N#[68(^OO^$WJ.<HKLE6PM",S%VI?*EU=VT]G!=>?!?\(!]
M](-1N13H*\T@:PNX*J F*O\YJFN_5S&!]!P%^#/R/3^P&)J^GNY;Z,GKZ;@G
MFJ#9H\#H!2_H3=>< Y6VQ%;$T$[4->-2K$@*$T<5!0%\ T[\X1V.O"^VI)Q2
M+#F16"MA89.PL$\]OH$,."EL":N(0T/4-7$3G^'A:.QN]A-A T6#-BCI@H)P
MAVGY'C2^![V^9Y)(L+FN:(.]M? @" Y<=T&CB^&!Z2[&CSR[Z:@Q'?6:_LGH
MV?W,YCKJ+!9%!X:F74R(\8'I+L;W KOI86-ZV&OZCDE2J/IJ7BPD58F#)_4I
M%=;L#RWKZ[K0"J0+PC@\V**D"QIY(WLDHR:246]Q2& .*HK,9GQTRNIP2K'D
M1&*MC%TT&;MX:W6XZ.R/=[#-1Q%)'Z+E%WN[;[3WMKI0\_H,'X<DO9"VY;VV
M K^Q*M3$7L]'(4DOI.W9WWGV7U$4LOJ%.E85:K'>.(Y"DEY(.XY=NX![/ZYU
M''G5OAV+(NA\QBS%S8*R5#<+JEO>W+U>M02^,#V_0"E;4UDU>,UL<ZZX,MWT
MP?RU/F^8'G@G4QU6?A"^R*E !<R5I'<^5-GE5?]?#21;F8[X@4G57YO;I3HS
M =< ]7S.F'P>Z 6:4UC\'U!+ P04    " !1@5985.T00YP$  #0#P  &0
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M!@=NT_Y*8S9/HWK4-2Q$-:II?X'I^6%][->YF(CI@L:CJBNGX[+IZ(;.6GV
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 48%66-G)V6C>!0  838   \
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MP9I ZX1<)P*O$X*=",1.2'8B,#LAVHE [81L)P*W$\*=".1.2'<BL#LAWHE
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M^6S^8_SU;U!+ 0(4 Q0    ( %&!5E@'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 48%66(7'EY?N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ 48%66)E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !1@5986;AJ29H(  #,-0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 48%66.U^R7(8!P  3!T  !@              ("!W1   'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %&!5EBU\BK\/0,
M *\*   8              " @2L8  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " !1@598KP9K9R$'  #/(@  &               @(&>
M&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 48%66,>H
MHR6+ P  C0L  !@              ("!]2(  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( %&!5EAVYW=Y;0H  -!:   8
M  " @;8F  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !1
M@598J1V^?E<+   @-P  &               @(%9,0  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ 48%66(DP=ES'!   90H  !@
M         ("!YCP  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( %&!5EC_;=0ASR<  )"%   8              " @>-!  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !1@598]]#9M 4)  !*&
M&0              @('H:0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( %&!5EC-3S-$3P@  $\5   9              " @21S  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 48%66(D2XOZ+
M @  <P4  !D              ("!JGL  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " !1@598*1FPT%X#  !/!P  &0
M@(%L?@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %&!
M5EBV-SV+P0(  "H&   9              " @0&"  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ 48%66'NO5I1T#@  @B4  !D
M         ("!^80  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " !1@598NV9+V>(-   ,+@  &0              @(&DDP  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( %&!5EC8BB]H[ H  # @
M   9              " @;VA  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ 48%66$?@EV87!   ?0D  !D              ("!X*P
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !1@598?/ .
M3&P'   S$P  &0              @($NL0  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( %&!5EAD HB$(P4  +(-   9
M  " @=&X  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M48%66%,9#><F!   H@D  !D              ("!*[X  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " !1@5980%20LE$.  !6+   &0
M            @(&(P@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( %&!5EB8-=, $ ,  +$&   9              " @1#1  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 48%66*HUM8@7#
M>2(  !D              ("!5]0  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " !1@598AE3X)Q<O  "(HP  &0              @(&E
MX   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %&!5E@D
M?E7BY0,  ,H)   9              " @?,/ 0!X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ 48%66'K)]&1"!0  GPX  !D
M     ("!#Q0! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M" !1@598#%&FS),"  !S!0  &0              @(&(&0$ >&PO=V]R:W-H
M965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( %&!5EC^HX<L)@,  *0&   9
M              " @5(< 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L!
M A0#%     @ 48%66,-RX_+) @  (08  !D              ("!KQ\! 'AL
M+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !1@598R_E?:^T$
M  #/#0  &0              @(&O(@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;%!+ 0(4 Q0    ( %&!5E@2KT4NJ0(  -T%   9              "
M@=,G 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 48%6
M6 HG+)R0!@  .!,  !D              ("!LRH! 'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " !1@598G](HH\\$  #L"P  &0
M        @(%Z,0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( %&!5EC/1VX0W 8  #$2   9              " @8 V 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 48%66*IDT-4F!P  ]!(
M !D              ("!DST! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " !1@598^I4+LW("  "Y!0  &0              @('P1 $
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( %&!5EAF%78-
M @<  &(P   9              " @9E' 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ 48%66'N^)B'M @  &0D  !D
M ("!TDX! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !1
M@598!97Z>W\&  #K-0  &0              @('V40$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( %&!5EC&WLCB9 (  %(%   9
M          " @:Q8 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#
M%     @ 48%66-%:\A;, @  O08  !D              ("!1UL! 'AL+W=O
M<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !1@598RNU3AV0#  !A
M"P  &0              @(%*7@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM
M;%!+ 0(4 Q0    ( %&!5EB*2_DN  <  '0O   9              " @>5A
M 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 48%66(+1
M:'7) @  Q0<  !D              ("!'&D! 'AL+W=O<FMS:&5E=',O<VAE
M970T-2YX;6Q02P$"% ,4    " !1@598MW3G#Y@"   6!@  &0
M    @($<; $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M %&!5EA3>R&CD (  -T&   9              " @>MN 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ 48%66"GX&+>! @  : 8  !D
M             ("!LG$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " !1@598):87\Y8"  ##!@  &0              @(%J= $ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( %&!5EC0F/#X:P4
M !@E   9              " @3=W 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ 48%66'=)JBF) @  N08  !D              ("!
MV7P! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !1@598
M?%Z%CKP"  "X!P  &0              @(&9?P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( %&!5EAR[O"!VQ   +3D   9
M      " @8R" 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ 48%66/3' BZ+ @  S 8  !D              ("!GI,! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !1@598)IPZQ_("   R"
M&0              @(%@E@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( %&!5E@B1$"@I0,  %<1   9              " @8F9 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 48%66.[HY"QU
M @  8P8  !D              ("!99T! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " !1@598"(E/F(,"  #@!@  &0
M@($1H $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( %&!
M5EBR08MAN H  ."(   9              " @<NB 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ 48%66*IQWCI4"@  ($P  !D
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M=#8T+GAM;%!+ 0(4 Q0    ( %&!5EAZ@NTSH 0  *T2   9
M  " @9'+ 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
M48%66,4%I80^!   O@\  !D              ("!:- ! 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " !1@598\B $)/P$  !Z$@  &0
M            @('=U $ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( %&!5E@)E8JLO0,  %\3   9              " @1#: 0!X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ 48%66!RR,6(#!0
MVB$  !D              ("!!-X! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    " !1@598_N(U+@ -  #RGP  &0              @($^
MXP$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( %&!5E@
MT"/05@4  ',=   9              " @77P 0!X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ 48%66.Q9&'-,!   % T  !D
M     ("! O8! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %&!5EC,UY(EY (  $$(   9              "
M@7X* @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ 48%6
M6&75)\!K!@  7#,  !D              ("!F0T" 'AL+W=O<FMS:&5E=',O
M<VAE970W."YX;6Q02P$"% ,4    " !1@5984[9G>F8#  "1#0  &0
M        @($[% ( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0
M   ( %&!5EA4[1!#G 0  - /   9              " @=@7 @!X;"]W;W)K
M<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ 48%66,*NK880!   .P\
M !D              ("!JQP" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q0
M2P$"% ,4    " !1@598F$)\:$@#   ?"P  &0              @('R( (
M>&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( %&!5E@T0(;_
M80,  -(5   -              "  7$D @!X;"]S='EL97,N>&UL4$L! A0#
M%     @ 48%66)>*NQS     $P(   L              ( !_2<" %]R96QS
M+RYR96QS4$L! A0#%     @ 48%66-G)V6C>!0  838   \
M ( !YB@" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %&!5EAFS1$Z= (
M &TP   :              "  ?$N @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( %&!5E@2 6)0(0(  " O   3              "
M 9TQ @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !: %H K1@  .\S @
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>348</ContextCount>
  <ElementCount>480</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>94</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecurities</Role>
      <ShortName>Cash, Cash Equivalents, Restricted Cash and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Inventories, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNet</Role>
      <ShortName>Inventories, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Current Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilities1</Role>
      <ShortName>Current Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Collaborative Research, Development and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements</Role>
      <ShortName>Collaborative Research, Development and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net (Loss) Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShare1</Role>
      <ShortName>Net (Loss) Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Common Stock and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrants</Role>
      <ShortName>Common Stock and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Equity Plans and Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensation</Role>
      <ShortName>Equity Plans and Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables</Role>
      <ShortName>Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecurities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Inventories, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetTables</Role>
      <ShortName>Inventories, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Current Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesTables</Role>
      <ShortName>Current Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilities1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Convertible Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesTables</Role>
      <ShortName>Convertible Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognition</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net (Loss) Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareTables</Role>
      <ShortName>Net (Loss) Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShare1</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Equity Plans and Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationTables</Role>
      <ShortName>Equity Plans and Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Fair Value Measurements - Summary of Assumptions to Estimate the Fair Value of Warrant Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Assumptions to Estimate the Fair Value of Warrant Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value Warrant liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Fair Value Warrant liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail</Role>
      <ShortName>Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Summary of Cash, Cash Equivalents and Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail</Role>
      <ShortName>Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Summary of Cash, Cash Equivalents and Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Maturities of Marketable Securities Available-for-Sale (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail</Role>
      <ShortName>Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Maturities of Marketable Securities Available-for-Sale (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Inventories, Net - Summary of Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail</Role>
      <ShortName>Inventories, Net - Summary of Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Inventories, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail</Role>
      <ShortName>Inventories, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Intangible Assets, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Property and Equipment, Net - Component of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, Net - Component of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Current Accrued Liabilities - Component of Current Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail</Role>
      <ShortName>Current Accrued Liabilities - Component of Current Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Commitments and Contingencies - Summary of Operating Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseExpenseDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Operating Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Commitments and Contingencies - Summary of Maturities of Sublease Income and Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Maturities of Sublease Income and Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Commitments and Contingencies - Schedule of Material Purchase Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Material Purchase Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Collaborative Research, Development and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaborative Research, Development and License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Convertible Notes (Additional Information) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails</Role>
      <ShortName>Convertible Notes (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Convertible Notes - Summary of Interest Expenses Related to Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails</Role>
      <ShortName>Convertible Notes - Summary of Interest Expenses Related to Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Long-Term Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail</Role>
      <ShortName>Long-Term Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Revenue Recognition - Summary of Disaggregation of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails</Role>
      <ShortName>Revenue Recognition - Summary of Disaggregation of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Revenue Recognition - Schedule of Revenues from Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Revenues from Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Revenue Recognition - Summary of Product Revenue Allowance and Reserve Categories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail</Role>
      <ShortName>Revenue Recognition - Summary of Product Revenue Allowance and Reserve Categories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Revenue Recognition - Summary of Balances and Activities in our Contract Asset Account (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails</Role>
      <ShortName>Revenue Recognition - Summary of Balances and Activities in our Contract Asset Account (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Net (Loss) Income Per Share- Computation of Basic and Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Net (Loss) Income Per Share- Computation of Basic and Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Net (Loss) Income Per Share - Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail</Role>
      <ShortName>Net (Loss) Income Per Share - Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Common Stock and Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail</Role>
      <ShortName>Common Stock and Warrants - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Equity Plans and Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Equity Plans and Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Equity Plans and Stock-Based Compensation - Option Activity under Stock-Based Compensation Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail</Role>
      <ShortName>Equity Plans and Stock-Based Compensation - Option Activity under Stock-Based Compensation Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Equity Plans and Stock-Based Compensation - Summary of Non-vested Restricted Stock Units Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail</Role>
      <ShortName>Equity Plans and Stock-Based Compensation - Summary of Non-vested Restricted Stock Units Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Equity Plans and Stock-Based Compensation - Summary Of Performance Based Restricted Stock Unit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails</Role>
      <ShortName>Equity Plans and Stock-Based Compensation - Summary Of Performance Based Restricted Stock Unit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Equity Plans and Stock-Based Compensation - Fair Value-Based Measurements and Weighted-Average Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail</Role>
      <ShortName>Equity Plans and Stock-Based Compensation - Fair Value-Based Measurements and Weighted-Average Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Equity Plans and Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Equity Plans and Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100850 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100890 - Disclosure - Income Taxes - Schedule of Component of Consolidated (Loss) Income Before Provision for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Component of Consolidated (Loss) Income Before Provision for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100900 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100910 - Disclosure - Income Taxes - Schedule of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100920 - Disclosure - Income taxes - Schedule of Difference between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail</Role>
      <ShortName>Income taxes - Schedule of Difference between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100930 - Disclosure - Income taxes - Schedule of Component of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income taxes - Schedule of Component of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="dvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100940 - Disclosure - Income taxes - Schedule of Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income taxes - Schedule of Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="dvax-20231231.htm">dvax-20231231.htm</File>
    <File>dvax-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img25882306_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1032">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>101
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dvax-20231231.htm": {
   "nsprefix": "dvax",
   "nsuri": "http://www.dynavax.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "dvax-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "dvax-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 380,
   "keyCustom": 100,
   "axisStandard": 33,
   "axisCustom": 1,
   "memberStandard": 49,
   "memberCustom": 38,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2023": 7,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 348,
   "entityCount": 1,
   "segmentCount": 94,
   "elementCount": 891,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1032,
    "http://xbrl.sec.gov/dei/2023": 40
   },
   "report": {
    "R1": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss",
     "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "dvax:ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_d6a1605d-0ed8-4293-af91-e392daff1469",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d6a1605d-0ed8-4293-af91-e392daff1469",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganization",
     "longName": "100070 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "100090 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecurities",
     "longName": "100100 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
     "shortName": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNet",
     "longName": "100110 - Disclosure - Inventories, Net",
     "shortName": "Inventories, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "longName": "100130 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilities1",
     "longName": "100140 - Disclosure - Current Accrued Liabilities",
     "shortName": "Current Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "100150 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements",
     "longName": "100160 - Disclosure - Collaborative Research, Development and License Agreements",
     "shortName": "Collaborative Research, Development and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotes",
     "longName": "100170 - Disclosure - Convertible Notes",
     "shortName": "Convertible Notes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt",
     "longName": "100180 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognition",
     "longName": "100190 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShare1",
     "longName": "100200 - Disclosure - Net (Loss) Income Per Share",
     "shortName": "Net (Loss) Income Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrants",
     "longName": "100210 - Disclosure - Common Stock and Warrants",
     "shortName": "Common Stock and Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensation",
     "longName": "100220 - Disclosure - Equity Plans and Stock-Based Compensation",
     "shortName": "Equity Plans and Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan",
     "longName": "100230 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100250 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "100280 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables",
     "longName": "100290 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)",
     "shortName": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "dvax:ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "dvax:ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetTables",
     "longName": "100300 - Disclosure - Inventories, Net (Tables)",
     "shortName": "Inventories, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "longName": "100320 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesTables",
     "longName": "100330 - Disclosure - Current Accrued Liabilities (Tables)",
     "shortName": "Current Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "dvax:ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "dvax:ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "longName": "100340 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesTables",
     "longName": "100350 - Disclosure - Convertible Notes (Tables)",
     "shortName": "Convertible Notes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "dvax:ScheduleOfConvertibleNotesInterestExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "dvax:ScheduleOfConvertibleNotesInterestExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables",
     "longName": "100360 - Disclosure - Revenue Recognition (Tables)",
     "shortName": "Revenue Recognition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareTables",
     "longName": "100370 - Disclosure - Net (Loss) Income Per Share (Tables)",
     "shortName": "Net (Loss) Income Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationTables",
     "longName": "100390 - Disclosure - Equity Plans and Stock-Based Compensation (Tables)",
     "shortName": "Equity Plans and Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "100410 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail",
     "longName": "100420 - Disclosure - Organization - Additional Information (Detail)",
     "shortName": "Organization - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_48f6e833-63e7-4015-bb6e-1aafaaf8055b",
      "name": "dvax:MinimumAgeApprovedForVaccinePreventionOfInfectionCaused",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_48f6e833-63e7-4015-bb6e-1aafaaf8055b",
      "name": "dvax:MinimumAgeApprovedForVaccinePreventionOfInfectionCaused",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "100430 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "longName": "100440 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "longName": "100450 - Disclosure - Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "shortName": "Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_a02082a3-bcf6-4470-924c-b963a2bcd1c3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a02082a3-bcf6-4470-924c-b963a2bcd1c3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail",
     "longName": "100460 - Disclosure - Fair Value Measurements - Summary of Assumptions to Estimate the Fair Value of Warrant Liability (Detail)",
     "shortName": "Fair Value Measurements - Summary of Assumptions to Estimate the Fair Value of Warrant Liability (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_4ac1d460-1347-453f-a512-bbc25081089d",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail",
     "longName": "100470 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value Warrant liability (Detail)",
     "shortName": "Fair Value Measurements - Summary of Changes in Fair Value Warrant liability (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_21f845e6-44c3-401e-bfcd-a9d88abc20b3",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_21f845e6-44c3-401e-bfcd-a9d88abc20b3",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
     "longName": "100480 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "shortName": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d3b6b8e9-b6aa-434a-b512-84475ede426d",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail",
     "longName": "100490 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Summary of Cash, Cash Equivalents and Marketable Securities (Detail)",
     "shortName": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Summary of Cash, Cash Equivalents and Marketable Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_876b9f96-bdb9-42b7-883d-e9aed3b08eb2",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_876b9f96-bdb9-42b7-883d-e9aed3b08eb2",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail",
     "longName": "100500 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Maturities of Marketable Securities Available-for-Sale (Detail)",
     "shortName": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Maturities of Marketable Securities Available-for-Sale (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesAdditionalInformationDetail",
     "longName": "100510 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Additional Information (Detail)",
     "shortName": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail",
     "longName": "100520 - Disclosure - Inventories, Net - Summary of Inventories (Detail)",
     "shortName": "Inventories, Net - Summary of Inventories (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail",
     "longName": "100530 - Disclosure - Inventories, Net - Additional Information (Detail)",
     "shortName": "Inventories, Net - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail",
     "longName": "100550 - Disclosure - Intangible Assets, Net - Additional Information (Detail)",
     "shortName": "Intangible Assets, Net - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
     "longName": "100560 - Disclosure - Property and Equipment, Net - Component of Property and Equipment, Net (Detail)",
     "shortName": "Property and Equipment, Net - Component of Property and Equipment, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
     "longName": "100570 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail",
     "longName": "100580 - Disclosure - Current Accrued Liabilities - Component of Current Accrued Liabilities (Detail)",
     "shortName": "Current Accrued Liabilities - Component of Current Accrued Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "100590 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:LeaseExpirationDate1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:LeaseExpirationDate1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseExpenseDetail",
     "longName": "100600 - Disclosure - Commitments and Contingencies - Summary of Operating Lease Expense (Detail)",
     "shortName": "Commitments and Contingencies - Summary of Operating Lease Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail",
     "longName": "100610 - Disclosure - Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Detail)",
     "shortName": "Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail",
     "longName": "100620 - Disclosure - Commitments and Contingencies - Summary of Maturities of Sublease Income and Operating Lease Liabilities (Detail)",
     "shortName": "Commitments and Contingencies - Summary of Maturities of Sublease Income and Operating Lease Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "dvax:LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "dvax:LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetail",
     "longName": "100640 - Disclosure - Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate (Detail)",
     "shortName": "Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails",
     "longName": "100650 - Disclosure - Commitments and Contingencies - Schedule of Material Purchase Commitments (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Material Purchase Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
     "longName": "100660 - Disclosure - Collaborative Research, Development and License Agreements - Additional Information (Detail)",
     "shortName": "Collaborative Research, Development and License Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4720dcda-852f-4e2a-bec3-37de58fa755d",
      "name": "dvax:RepaymentOfAdvanceFromCustomer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
     "longName": "100670 - Disclosure - Convertible Notes (Additional Information) (Details)",
     "shortName": "Convertible Notes (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DebtInstrumentConvertibleThresholdTradingDays",
      "unitRef": "U_Days",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails",
     "longName": "100680 - Disclosure - Convertible Notes - Summary of Interest Expenses Related to Convertible Notes (Details)",
     "shortName": "Convertible Notes - Summary of Interest Expenses Related to Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:ScheduleOfConvertibleNotesInterestExpenseTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:ScheduleOfConvertibleNotesInterestExpenseTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail",
     "longName": "100690 - Disclosure - Long-Term Debt - Additional Information (Detail)",
     "shortName": "Long-Term Debt - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9821d0e8-ecc7-4666-9acc-0bbaa41571ea",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
     "longName": "100700 - Disclosure - Revenue Recognition - Summary of Disaggregation of Revenues (Details)",
     "shortName": "Revenue Recognition - Summary of Disaggregation of Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6788e286-c14c-450b-b13d-2eea895a38ad",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
     "longName": "100710 - Disclosure - Revenue Recognition - Schedule of Revenues from Major Customers (Details)",
     "shortName": "Revenue Recognition - Schedule of Revenues from Major Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_79c0f9eb-0184-4dba-a43c-01f7640ee145",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_79c0f9eb-0184-4dba-a43c-01f7640ee145",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail",
     "longName": "100720 - Disclosure - Revenue Recognition - Summary of Product Revenue Allowance and Reserve Categories (Detail)",
     "shortName": "Revenue Recognition - Summary of Product Revenue Allowance and Reserve Categories (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_bd4dc0db-3b94-4730-9f10-12f7f1a154c7",
      "name": "dvax:ReservesAccrualBalance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ca507f0-264d-4d6b-a1d7-6b4736681fa7",
      "name": "dvax:ReservesAccrualBalance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dvax:SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails",
     "longName": "100730 - Disclosure - Revenue Recognition - Summary of Balances and Activities in our Contract Asset Account (Details)",
     "shortName": "Revenue Recognition - Summary of Balances and Activities in our Contract Asset Account (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail",
     "longName": "100750 - Disclosure - Net (Loss) Income Per Share- Computation of Basic and Diluted Net Loss Per Share (Detail)",
     "shortName": "Net (Loss) Income Per Share- Computation of Basic and Diluted Net Loss Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_10125268-dcf7-417c-8e67-6935f116fdcc",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail",
     "longName": "100760 - Disclosure - Net (Loss) Income Per Share - Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share (Detail)",
     "shortName": "Net (Loss) Income Per Share - Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1f301073-2f8b-4fb6-92dd-c36e81bb7b9a",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
     "longName": "100770 - Disclosure - Common Stock and Warrants - Additional Information (Detail)",
     "shortName": "Common Stock and Warrants - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d98acd8-10b6-453e-b7a4-a290b0056620",
      "name": "dvax:NumberOfCommonStockWarrantExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
     "longName": "100790 - Disclosure - Equity Plans and Stock-Based Compensation - Additional Information (Detail)",
     "shortName": "Equity Plans and Stock-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_61e4fae6-429a-477a-9549-6b5ff699fbf7",
      "name": "dvax:IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61e4fae6-429a-477a-9549-6b5ff699fbf7",
      "name": "dvax:IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail",
     "longName": "100800 - Disclosure - Equity Plans and Stock-Based Compensation - Option Activity under Stock-Based Compensation Plans (Detail)",
     "shortName": "Equity Plans and Stock-Based Compensation - Option Activity under Stock-Based Compensation Plans (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail",
     "longName": "100810 - Disclosure - Equity Plans and Stock-Based Compensation - Summary of Non-vested Restricted Stock Units Activity (Detail)",
     "shortName": "Equity Plans and Stock-Based Compensation - Summary of Non-vested Restricted Stock Units Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_2ccde060-5732-4dbe-854e-2ad06dd8b47e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c8b18ed-3d15-4464-921d-cd75ad104a77",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
     "longName": "100820 - Disclosure - Equity Plans and Stock-Based Compensation - Summary Of Performance Based Restricted Stock Unit (Details)",
     "shortName": "Equity Plans and Stock-Based Compensation - Summary Of Performance Based Restricted Stock Unit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_1bd10d4c-3dad-4350-b83d-0c72c2905fea",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2b70264d-6f06-4292-a106-b2ff81f59d36",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
     "longName": "100830 - Disclosure - Equity Plans and Stock-Based Compensation - Fair Value-Based Measurements and Weighted-Average Assumptions (Detail)",
     "shortName": "Equity Plans and Stock-Based Compensation - Fair Value-Based Measurements and Weighted-Average Assumptions (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_dadabb88-1dfa-43da-9394-44029f60ca3c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dadabb88-1dfa-43da-9394-44029f60ca3c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail",
     "longName": "100840 - Disclosure - Equity Plans and Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "shortName": "Equity Plans and Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetail",
     "longName": "100850 - Disclosure - Employee Benefit Plan - Additional Information (Detail)",
     "shortName": "Employee Benefit Plan - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail",
     "longName": "100890 - Disclosure - Income Taxes - Schedule of Component of Consolidated (Loss) Income Before Provision for Income Taxes (Detail)",
     "shortName": "Income Taxes - Schedule of Component of Consolidated (Loss) Income Before Provision for Income Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "100900 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails",
     "longName": "100910 - Disclosure - Income Taxes - Schedule of Income Tax Provision (Details)",
     "shortName": "Income Taxes - Schedule of Income Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail",
     "longName": "100920 - Disclosure - Income taxes - Schedule of Difference between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate (Detail)",
     "shortName": "Income taxes - Schedule of Difference between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail",
     "longName": "100930 - Disclosure - Income taxes - Schedule of Component of Deferred Tax Assets and Liabilities (Detail)",
     "shortName": "Income taxes - Schedule of Component of Deferred Tax Assets and Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d274567-d036-45ef-8bff-f4dc34904726",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail",
     "longName": "100940 - Disclosure - Income taxes - Schedule of Unrecognized Tax Benefits (Detail)",
     "shortName": "Income taxes - Schedule of Unrecognized Tax Benefits (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "dvax_AcceleratedDepreciationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AcceleratedDepreciationMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee severance and other benefits.",
        "label": "Accelerated Depreciation [Member]",
        "terseLabel": "Accelerated Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivables, net of allowance for doubtful accounts of $12,313 and $0 at December 31, 2023 and December 31, 2022, respectively",
        "label": "Accounts and Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Accrued Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r899"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Trade Receivable",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums (accretion of discounts) on marketable securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "dvax_AccrualLongTermBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AccrualLongTermBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrual long-term balance",
        "label": "Accrual Long Term Balance",
        "documentation": "Accrual Long Term Balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail": {
       "parentTag": "dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Payroll and related expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "dvax_AccruedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AccruedInventory",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail": {
       "parentTag": "dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued inventory",
        "label": "Accrued inventory",
        "documentation": "Accrued inventory."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued Liabilities, Current, Total",
        "verboseLabel": "Accrued liabilities",
        "terseLabel": "Accrued liabilities (Note 7)",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses and current accrued liabilities.",
        "label": "Accrued Research And Development Expenses And Accrued Liabilities Current",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r197",
      "r699"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r121",
      "r206",
      "r695",
      "r720",
      "r721"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r39",
      "r594",
      "r597",
      "r637",
      "r716",
      "r717",
      "r948",
      "r949",
      "r950",
      "r966",
      "r967",
      "r968"
     ]
    },
    "dvax_AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add: undistributed earnings allocated to Series B and warrants",
        "label": "Addition of Undistributed Earnings Allocated to Series B and Warrants",
        "documentation": "Addition of undistributed earnings allocated to Series B and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_AdditionalFuturePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AdditionalFuturePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional future payment",
        "label": "Additional future payment",
        "documentation": "Additional future payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r548",
      "r549",
      "r736",
      "r966",
      "r967",
      "r968",
      "r1041",
      "r1073"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction to additional paid-in capital, capped calls cost",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r508"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_AdvancePaymentFromCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AdvancePaymentFromCustomer",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Advance payment from customer",
        "terseLabel": "Advance Payments forgiven per CEPI-Bio E Assignment Agreement (Note 9)",
        "label": "Advance Payment From Customer",
        "documentation": "Advance payment from customer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvancesOnInventoryPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances on Inventory Purchases",
        "terseLabel": "Advance payment received",
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dvax_AggregateMinimumCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AggregateMinimumCommitment",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate minimum commitment",
        "label": "Aggregate Minimum Commitment",
        "documentation": "Aggregate minimum commitment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r554"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r316",
      "r353",
      "r359",
      "r360",
      "r1065"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Allowance for doubtful accounts receivables",
        "terseLabel": "Accounts receivables, net of allowance for doubtful accounts of $12,313 and $0 at December 31, 2023 and December 31, 2022, respectively",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r316",
      "r353"
     ]
    },
    "us-gaap_AllowanceForNotesReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForNotesReceivableMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Allowance, Notes Receivable [Member]",
        "terseLabel": "Accounts Receivable Reserves",
        "documentation": "Allowance for portion expected to be uncollectible of receivable from written agreement to receive, at specified future date, money consisting of principal and accrued interest."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r962",
      "r963",
      "r964",
      "r965"
     ]
    },
    "dvax_AmendedTwoThousandAndEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AmendedTwoThousandAndEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended two thousand and eighteen equity incentive plan.",
        "label": "Amended Two Thousand And Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "Amended 2018 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance cost",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r437",
      "r623",
      "r956"
     ]
    },
    "dvax_AmountPaidToThirdParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AmountPaidToThirdParty",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount paid to third party.",
        "label": "Amount Paid To Third Party",
        "terseLabel": "Amount paid to third party"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antidilutive securities excluded from computation of earning per share.",
        "label": "Antidilutive Securities Excluded From Computation Of Earning Per Share [Abstract]",
        "terseLabel": "Outstanding securities not included in diluted net loss per share calculation (in thousands):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding securities not included in diluted net (loss) income allocable to common stockholders per share calculation",
        "verboseLabel": "Convertible Notes (as converted to common stock)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "dvax_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase agreement.",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement",
        "verboseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r201",
      "r237",
      "r290",
      "r304",
      "r308",
      "r350",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r589",
      "r591",
      "r611",
      "r690",
      "r779",
      "r899",
      "r913",
      "r998",
      "r999",
      "r1052"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r210",
      "r237",
      "r350",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r589",
      "r591",
      "r611",
      "r899",
      "r998",
      "r999",
      "r1052"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r918",
      "r919",
      "r920"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r918",
      "r919",
      "r920"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r918",
      "r919",
      "r920"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r364",
      "r689"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses",
        "terseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Mature after one year through two years",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Mature after one year through two years",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r687"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total estimated fair value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r1063"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total amortized cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r1062"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Mature in one year or less",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesMaturitiesOfMarketableSecuritiesAvailableForSaleDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Mature in one year or less",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r686"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r364",
      "r680",
      "r973"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities available-for-sale",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r364"
     ]
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableforsaleSecuritiesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-Sale Securities [Member]",
        "terseLabel": "Marketable Securities Available-for-Sale",
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ]
    },
    "dvax_BCIPLifeSciencesAssociatesLimitedPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "BCIPLifeSciencesAssociatesLimitedPartnersMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BCIP Life Sciences Associates, Limited Partners.",
        "label": "B C I P Life Sciences Associates Limited Partners [Member]",
        "terseLabel": "BCIP Life Sciences Associates, L.P"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_BadDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "BadDebtExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense (Note 9)",
        "label": "Bad debt expense",
        "documentation": "Bad debt expense"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_BainCapitalLifeSciencesFundLimitedPartnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "BainCapitalLifeSciencesFundLimitedPartnerMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bain Capital Life Sciences Fund, Limited Partner.",
        "label": "Bain Capital Life Sciences Fund Limited Partner [Member]",
        "terseLabel": "Bain Capital Life Sciences Fund, L.P"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_BainLifeSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "BainLifeSciencesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bain life sciences.",
        "label": "Bain Life Sciences [Member]",
        "terseLabel": "Bain Life Sciences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r93"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_BillAndMelindaGatesFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "BillAndMelindaGatesFoundationMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation.",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill &amp; Melinda Gates Foundation"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_BiologicalELimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "BiologicalELimitedMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biological E. Limited",
        "documentation": "Biological E Limited.",
        "label": "Biological E Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CRGServicingLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CRGServicingLLCMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CRG Servicing LLC.",
        "label": "C R G Servicing L L C [Member]",
        "terseLabel": "CRG Servicing LLC"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CaliforniaAndOtherStatesTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CaliforniaAndOtherStatesTaxAuthorityMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California and other states tax authority.",
        "label": "California And Other States Tax Authority [Member]",
        "terseLabel": "California and Other States"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CaliforniaStateTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CaliforniaStateTaxAuthorityMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California state tax authority.",
        "label": "California State Tax Authority [Member]",
        "terseLabel": "California State"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment, not yet paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "dvax_CappedCallsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CappedCallsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capped Calls",
        "label": "Capped Calls [Member]",
        "documentation": "Capped Calls"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CappedCallsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CappedCallsPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capped Calls",
        "label": "Capped Calls Policy [Text Block]",
        "documentation": "Capped Calls Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r195",
      "r858"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r692"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CashCashEquivalentsAndMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and marketable securities",
        "label": "Cash Cash Equivalents And Marketable Securities [Line Items]",
        "terseLabel": "Cash Cash Equivalents And Marketable Securities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CashCashEquivalentsAndMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and marketable securities.",
        "label": "Cash Cash Equivalents And Marketable Securities [Table]",
        "terseLabel": "Cash Cash Equivalents And Marketable Securities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows",
        "periodStartLabel": "Cash and cash equivalents, and restricted cash at beginning of year",
        "periodEndLabel": "Cash and cash equivalents, and restricted cash at end of year",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r133",
      "r233"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents, and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r133"
     ]
    },
    "dvax_CashEquivalentsMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CashEquivalentsMaturityPeriod",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents maturity period.",
        "label": "Cash Equivalents Maturity Period",
        "terseLabel": "Cash equivalents original maturity period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "terseLabel": "Cash",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "dvax_CashSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CashSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash settlement",
        "label": "Cash Settlement",
        "documentation": "Cash settlement."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CashSettlementOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CashSettlementOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Settlement of warrants",
        "label": "Cash Settlement of warrants",
        "terseLabel": "Proceeds from warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CepiAccrualLongTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CepiAccrualLongTerm",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEPI accrual long-term (Note 9)",
        "label": "CEPI accrual long-term",
        "documentation": "CEPI accrual long-term"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in unrealized gain on marketable securities available-for-sale",
        "label": "Change In Unrealized Gain On Marketable Securities Available For Sale",
        "terseLabel": "Change in unrealized loss on marketable securities available-for-sale"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r202",
      "r203",
      "r204",
      "r237",
      "r266",
      "r270",
      "r278",
      "r282",
      "r288",
      "r289",
      "r350",
      "r406",
      "r408",
      "r409",
      "r410",
      "r413",
      "r414",
      "r445",
      "r446",
      "r449",
      "r452",
      "r459",
      "r611",
      "r730",
      "r731",
      "r732",
      "r733",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r766",
      "r790",
      "r809",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r925",
      "r957",
      "r970"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r288",
      "r445",
      "r446",
      "r447",
      "r449",
      "r452",
      "r457",
      "r459",
      "r730",
      "r731",
      "r732",
      "r733",
      "r880",
      "r925",
      "r957"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price per Share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dvax_ClassOfWarrantOrRightIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ClassOfWarrantOrRightIssued",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right issued.",
        "label": "Class Of Warrant Or Right Issued",
        "terseLabel": "Warrant issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of common stock allowed to purchase",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants Called for purchase",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Shares Issuable",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Number of shares",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CloverAmendmentNoTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CloverAmendmentNoTwoMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clover Amendment No Two [Member]",
        "label": "Clover Amendment No Two [Member]",
        "terseLabel": "Clover Amendment No 2"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CoalitionForEpidemicPreparednessInnovationsAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CoalitionForEpidemicPreparednessInnovationsAccruals",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coalition for Epidemic Preparedness Innovations Accruals",
        "documentation": "Coalition for Epidemic Preparedness Innovations accruals.",
        "terseLabel": "CEPI accrual (Note 9)"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CoalitionForEpidemicPreparednessInnovationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CoalitionForEpidemicPreparednessInnovationsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "CEPI",
        "documentation": "Coalition for Epidemic Preparedness Innovations.",
        "label": "Coalition For Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CoalitionForEpidemicPreparednessInnovationsPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CoalitionForEpidemicPreparednessInnovationsPartnersMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEPI Partners",
        "label": "Coalition for Epidemic Preparedness Innovations Partners [Member]",
        "documentation": "Coalition for epidemic preparedness innovations partners."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CollaborationRevenueMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Research, Development and License Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r176",
      "r188"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "dvax_CombinedPriceOfPreferredStockAndWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CombinedPriceOfPreferredStockAndWarrant",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined price of preferred stock and warrant.",
        "label": "Combined Price Of Preferred Stock And Warrant",
        "terseLabel": "Combined price of preferred stock and warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r103",
      "r691",
      "r765"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r394",
      "r395",
      "r841",
      "r992"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Newly reserved shares of common stock",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r904",
      "r905",
      "r907",
      "r908",
      "r909",
      "r910",
      "r966",
      "r967",
      "r1041",
      "r1069",
      "r1073"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "dvax_CommonStockSalesAgreementAggregateSalesProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CommonStockSalesAgreementAggregateSalesProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock sales agreement aggregate sales proceeds.",
        "label": "Common Stock Sales Agreement Aggregate Sales Proceeds",
        "terseLabel": "Common stock sales agreement aggregate sales proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r766"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r111",
      "r766",
      "r785",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock: $0.001 par value; 278,000 shares authorized at December 31, 2023, and 2022; 129,530 shares and 127,604 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r694",
      "r899"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r215",
      "r217",
      "r224",
      "r683",
      "r705"
     ]
    },
    "dvax_ComputerEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ComputerEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment, Gross.",
        "label": "Computer Equipment Gross",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r96",
      "r97",
      "r313",
      "r840"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r96",
      "r97",
      "r313",
      "r722",
      "r840"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r96",
      "r97",
      "r313",
      "r840",
      "r930"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r178"
     ]
    },
    "us-gaap_ConcentrationRiskCustomer": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCustomer",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Customer",
        "terseLabel": "Concentration risk, customer",
        "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r55"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of product revenue",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r96",
      "r97",
      "r313"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r96",
      "r97",
      "r313",
      "r840"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r589",
      "r590",
      "r591",
      "r592",
      "r639",
      "r851",
      "r997",
      "r1000",
      "r1001"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r589",
      "r590",
      "r591",
      "r592",
      "r639",
      "r851",
      "r997",
      "r1000",
      "r1001"
     ]
    },
    "dvax_ContingentMilestonePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ContingentMilestonePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent milestone payment receivable.",
        "label": "Contingent Milestone Payment Receivable",
        "terseLabel": "Additional milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance at end of period",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r463"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of balances and activities in our contract asset account",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract asset, reclassification",
        "label": "Contract with Customer, Asset, Change in Method, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, from change in methodology."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Increase in revenue adjustment",
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Contract asset balance",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463",
      "r482"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNetCurrentAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Asset Account [Abstract]",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetPastDueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetPastDueLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Asset Account, [Line Items]",
        "label": "Contract with Customer, Asset, Past Due [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_ContractWithCustomerAssetPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetPurchase",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contract asset, subtractions",
        "label": "Contract with Customer, Asset, Purchase",
        "terseLabel": "Contract asset, Subtractions",
        "documentation": "Amount of increase from purchase of right to consideration in exchange for good or service transferred to customer when right is conditioned on passage of time."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ContractWithCustomerAssetSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetSale",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract asset, additions",
        "label": "Contract with Customer, Asset, Sale",
        "documentation": "Amount of decrease from sale of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time and other income."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "dvax_ContractWithCustomersExpectedPeriodOfPaymentToBeReceived": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ContractWithCustomersExpectedPeriodOfPaymentToBeReceived",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customers expected period of payment to be received.",
        "label": "Contract With Customers Expected Period Of Payment To Be Received",
        "terseLabel": "Expected period of payment to be received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares converted",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of the convertible notes",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes, net of debt discount of $2,802 and $3,922 at December 31, 2023 and December 31, 2022, respectively (Note 10)",
        "label": "Convertible Notes Payable",
        "totalLabel": "Convertible Notes Payable, Total",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r164",
      "r1064"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r163"
     ]
    },
    "dvax_ConvertibleOptionalSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ConvertibleOptionalSeniorNotesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Optional Notes",
        "documentation": "Convertible Optional Senior Notes [Member]",
        "label": "Convertible Optional Senior Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series B Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446",
      "r449",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "dvax_ConvertibleSeniorNotesDueTwoThousandTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ConvertibleSeniorNotesDueTwoThousandTwentySixMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.50% Convertible Senior Notes Due 2026",
        "label": "Convertible Senior Notes Due Two Thousand Twenty Six [Member]",
        "documentation": "Convertible senior notes due two thousand twenty six."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes",
        "documentation": "Convertible Senior Notes [Member]",
        "label": "Convertible Senior Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r889",
      "r891",
      "r1068"
     ]
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of sales - product",
        "totalLabel": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization, Total",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost, Amortization",
        "terseLabel": "Cost of sales - amortization of intangible assets",
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales - Product",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring",
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r142",
      "r144"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r419",
      "r447",
      "r638",
      "r863",
      "r865"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_CpG1018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CpG1018Member",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product CpG 1018.",
        "label": "Cp G1018 [Member]",
        "terseLabel": "CpG 1018"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_Cpg1018AdjuvantInventoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "Cpg1018AdjuvantInventoryMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CpG 1018 Adjuvant Inventory",
        "documentation": "CpG 1018 adjuvant inventory.",
        "label": "CpG 1018 Adjuvant Inventory [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditConcentrationRiskMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk",
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "dvax_CumulativeTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "CumulativeTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative translation adjustment net of tax.",
        "label": "Cumulative Translation Adjustment Net Of Tax",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r960",
      "r1040"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-US",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r960"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax expense",
        "terseLabel": "Total current tax expense",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r577",
      "r583",
      "r960"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r960",
      "r1040"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r313"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "DE",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Germany",
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r235",
      "r415",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r431",
      "r438",
      "r439",
      "r441"
     ]
    },
    "dvax_DebtInstrumentAdditionalIssueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DebtInstrumentAdditionalIssueAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional issue amount",
        "label": "Debt Instrument Additional Issue Amount",
        "documentation": "Debt instrument additional issue amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r108",
      "r109",
      "r163",
      "r164",
      "r242",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r624",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r958"
     ]
    },
    "dvax_DebtInstrumentCappedCallTransactionInitialCapPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DebtInstrumentCappedCallTransactionInitialCapPricePerShare",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial cap price",
        "label": "Debt Instrument Capped Call Transaction Initial Cap Price Per Share",
        "documentation": "Debt instrument capped call transaction initial cap price per share."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DebtInstrumentCappedCallTransactionInitialStrikePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DebtInstrumentCappedCallTransactionInitialStrikePricePerShare",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial strike price",
        "label": "Debt Instrument Capped Call Transaction Initial Strike Price Per Share",
        "documentation": "Debt instrument capped call transaction initial strike price per share."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DebtInstrumentConversionOriginalDebtBasePrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DebtInstrumentConversionOriginalDebtBasePrincipalAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt conversion, original debt, principal amount converted",
        "label": "Debt Instrument Conversion Original Debt Base Principal Amount",
        "documentation": "Debt instrument conversion original debt base principal amount."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DebtInstrumentConversionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DebtInstrumentConversionPeriodOneMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Conversion, Period One",
        "label": "Debt Instrument Conversion Period One [Member]",
        "documentation": "Debt instrument conversion period one."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DebtInstrumentConversionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DebtInstrumentConversionPeriodTwoMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Conversion, Period Two",
        "label": "Debt Instrument Conversion Period Two [Member]",
        "documentation": "Debt instrument conversion period two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, conversion price per share",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r418"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial conversion rate",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r74",
      "r150",
      "r151",
      "r418"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, convertible, threshold trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DebtInstrumentCovenantDailyMinimumCombinedCashAndInvestmentBalance",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, covenant daily minimum combined cash and investment balance.",
        "label": "Debt Instrument Covenant Daily Minimum Combined Cash And Investment Balance",
        "terseLabel": "Debt instrument, covenant daily minimum combined cash and investment balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate principal amount",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r101",
      "r416",
      "r624",
      "r876",
      "r877"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument interest rate, effective percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r99",
      "r442",
      "r624"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r417"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate terms",
        "label": "Debt Instrument, Interest Rate Terms",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r624",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r958"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r875",
      "r1042"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r242",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r624",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r958"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionDescription",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, redemption, description",
        "label": "Debt Instrument, Redemption, Description",
        "documentation": "Description of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodStartDate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, redemption earliest date",
        "label": "Debt Instrument, Redemption Period, Start Date",
        "documentation": "Start date of debt instrument redemption period, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of principal redeemed",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r74",
      "r77",
      "r98",
      "r99",
      "r101",
      "r104",
      "r149",
      "r151",
      "r242",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r624",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r958"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, debt discount",
        "verboseLabel": "Long-term debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r101",
      "r1003"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "dvax_DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: undistributed earnings allocated to Series B and warrants",
        "label": "Deduction of Undistributed Earnings Allocated to Series B and Warrants",
        "documentation": "Deduction of undistributed earnings allocated to Series B and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangement with Individual, Share-Based Payments [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance and offering costs",
        "label": "Debt Issuance Costs, Net",
        "totalLabel": "Debt Issuance Costs, Net, Total",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r1003"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-US",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r960",
      "r1039"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax expense",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Total deferred tax expense",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r159",
      "r184",
      "r582",
      "r583",
      "r960"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at End of Period",
        "periodStartLabel": "Balance at Beginning of Period",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_DeferredRevenueAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Deferred Revenue, Additions",
        "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueArrangementLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue Arrangement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Revenue",
        "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Noncurrent, Total",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Long-term deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueRevenueRecognized1",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized in the current period included in deferred revenue balance at the beginning of the period",
        "label": "Deferred Revenue, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DeferredRevenueSubtractions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DeferredRevenueSubtractions",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subtractions",
        "documentation": "Deferred revenue subtractions.",
        "label": "Deferred Revenue Subtractions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets Lease Liability",
        "documentation": "Deferred Tax Assets Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1038"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1038"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r1038"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1038"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1038"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Net, Total",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1037"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating lease right of use assets.",
        "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "terseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1038"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1038"
     ]
    },
    "dvax_Deferredtaxassetsoperatinglosscarryforwardscapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "Deferredtaxassetsoperatinglosscarryforwardscapitalization",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DeferredTaxAssetsOperatingLossCarryforwardsCapitalization",
        "label": "DeferredTaxAssetsOperatingLossCarryforwardsCapitalization",
        "terseLabel": "Section 174 capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Contributions to 401 (k) plan",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r488",
      "r500",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r61"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Fair value of derivative liability",
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r92",
      "r120",
      "r211",
      "r865"
     ]
    },
    "dvax_DescriptionOfAveciaSupplyAgreement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DescriptionOfAveciaSupplyAgreement",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Avecia Supply Agreement",
        "label": "Description of Avecia Supply Agreement",
        "documentation": "Description of Avecia Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DeutscheBankSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DeutscheBankSecuritiesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deutsche bank securities.",
        "label": "Deutsche Bank Securities [Member]",
        "terseLabel": "Deutsche Bank Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Disaggregation of Revenues",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure component of current accrued liabilities and accrued research and development.",
        "label": "Disclosure Component Of Current Accrued Liabilities And Accrued Research And Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DisclosureComputationOfBasicAndDilutedEarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure computation of basic and diluted earnings per share.",
        "label": "Disclosure Computation Of Basic And Diluted Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Plans and Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r510",
      "r543",
      "r544",
      "r546",
      "r894"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r919",
      "r920"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r919",
      "r920",
      "r922"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DusseldorfLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DusseldorfLeaseMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Dusseldorf Lease",
        "documentation": "New Dusseldorf Lease [Member]",
        "label": "New Dusseldorf Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_DynavaxTechnologiesCorporationInducementAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "DynavaxTechnologiesCorporationInducementAwardPlanMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dynavax Technologies Corporation inducement award plan.",
        "label": "Dynavax Technologies Corporation Inducement Award Plan [Member]",
        "terseLabel": "Dynavax Technologies Corporation 2021 Inducement Award Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net (loss) income per share allocable to common stockholders",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r263",
      "r266",
      "r278",
      "r281",
      "r282",
      "r286",
      "r602",
      "r603",
      "r684",
      "r706",
      "r868"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net (loss) income per share allocable to common stockholders",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r266",
      "r278",
      "r281",
      "r282",
      "r286",
      "r602",
      "r603",
      "r684",
      "r706",
      "r868"
     ]
    },
    "dvax_EarningsPerShareDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "EarningsPerShareDisclosureLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings per share disclosure.",
        "label": "Earnings Per Share Disclosure [Line Items]",
        "terseLabel": "Earnings Per Share Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_EarningsPerShareDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "EarningsPerShareDisclosureTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings per share disclosure.",
        "label": "Earnings Per Share Disclosure [Table]",
        "terseLabel": "Earnings Per Share Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShare1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r283",
      "r284",
      "r285"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents, and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dvax_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax adjustment",
        "label": "Effective Income Tax Rate Reconciliation, Deferred Tax Adjustment , Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Deferred Tax Adjustment , Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_EmeryvilleCaliforniaAndDusseldorfGermanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "EmeryvilleCaliforniaAndDusseldorfGermanyMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emeryville, California and Dusseldorf, Germany [Member]",
        "label": "Emeryville, California and Dusseldorf, Germany [Member]",
        "terseLabel": "Emeryville, California and Dusseldorf, Germany"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to non-vested equity awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost, weighted-average vesting period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "dvax_EmployeeSeveranceAndOtherBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "EmployeeSeveranceAndOtherBenefitsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee severance and other benefits.",
        "label": "Employee Severance And Other Benefits [Member]",
        "terseLabel": "Employee Severance And Other Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "terseLabel": "Entity",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r190",
      "r219",
      "r220",
      "r221",
      "r248",
      "r249",
      "r250",
      "r252",
      "r258",
      "r260",
      "r287",
      "r351",
      "r352",
      "r461",
      "r547",
      "r548",
      "r549",
      "r578",
      "r579",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r614",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r637",
      "r716",
      "r717",
      "r718",
      "r736",
      "r809"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: removal of change in fair value of warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "verboseLabel": "Change in fair value of warrant liability",
        "negatedLabel": "Change in fair value of warrant liability (Note 14)",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "dvax_FairValueAdjustmentsOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "FairValueAdjustmentsOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustments of Warrants",
        "label": "Fair Value Adjustments of Warrants",
        "negatedLabel": "Less: removal of change in fair value of warrant liability",
        "terseLabel": "Less: removal of change in fair value of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_FairValueAssetLiabilityLevel1ToLevel2TransferAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "FairValueAssetLiabilityLevel1ToLevel2TransferAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instruments.",
        "label": "Fair Value Asset &amp; Liability Level 1 to Level 2 Transfer Amount",
        "terseLabel": "Transfer from level 1 to level 2"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_FairValueAssetLiabilityLevel2ToLevel1TransferAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "FairValueAssetLiabilityLevel2ToLevel1TransferAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of financial instrument transfer.",
        "label": "Fair Value Asset &amp; Liability Level 2 to Level 1 Transfer Amount",
        "terseLabel": "Transfers from level 2 to level 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606",
      "r609"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606",
      "r609"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Assumptions to Estimate the Fair Value of Warrant Liability",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r606",
      "r646",
      "r647",
      "r648",
      "r876",
      "r877",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r610"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r488",
      "r493",
      "r606",
      "r646",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r488",
      "r493",
      "r606",
      "r647",
      "r876",
      "r877",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r606",
      "r648",
      "r876",
      "r877",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Fair Value Warrant liability",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r95"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in fair value of warrants exercised",
        "label": "Fair value measurement with unobservable inputs reconciliation recurring basis liability period decrease.",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability period decrease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase in the estimated fair value of warrant liability upon revaluation",
        "terseLabel": "Increase (Decrease) in estimated fair value of warrant liability upon revaluation",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "terseLabel": "Transfers in or out of Level 3",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantOnIssuanceDate",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability warrant on issuance date.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Warrant On Issuance Date",
        "terseLabel": "Fair value of warrant liability at issuance date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "terseLabel": "Balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r646",
      "r647",
      "r648",
      "r876",
      "r877",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r610"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r354",
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r440",
      "r457",
      "r599",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r704",
      "r873",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r981",
      "r982",
      "r983",
      "r984"
     ]
    },
    "us-gaap_FinancialInstrumentsOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial Instruments, Owned, at Fair Value, Total",
        "label": "Financial Instruments, Owned, at Fair Value",
        "terseLabel": "Financial instruments owned at fair value",
        "documentation": "The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r378"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r678"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetSummaryOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r677"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Realized foreign currency translation (loss) gain",
        "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax",
        "terseLabel": "Currency transaction gain (loss)",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r911",
      "r1044",
      "r1045",
      "r1071"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "terseLabel": "Unrealized foreign currency translation (loss) gain",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r788",
      "r911",
      "r1044",
      "r1045",
      "r1072"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures, Gross",
        "terseLabel": "Furniture and fixtures",
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "terseLabel": "Gain on sale of assets",
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on debt extinguishment (Note 11)",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on debt extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69",
      "r70"
     ]
    },
    "us-gaap_GainsLossesOnSalesOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnSalesOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of assets (Note 8)",
        "verboseLabel": "Gain on sale of assets",
        "label": "Gain (Loss) on Disposition of Assets for Financial Service Operations",
        "totalLabel": "Gain (Loss) on Disposition of Assets for Financial Service Operations, Total",
        "negatedTerseLabel": "Gain on sale of assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_GlobalAccessAndStrategyCommitmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "GlobalAccessAndStrategyCommitmentAgreementMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global access and strategy/commitment agreement.",
        "label": "Global Access And Strategy Commitment Agreement [Member]",
        "terseLabel": "Global Access and Strategy/Commitment Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r373",
      "r679",
      "r874",
      "r899",
      "r987",
      "r988"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r376",
      "r874"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r374",
      "r375",
      "r376",
      "r874"
     ]
    },
    "dvax_GrantAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "GrantAgreementMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Agreement.",
        "label": "Grant Agreement [Member]",
        "terseLabel": "Grant Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Axis]",
        "terseLabel": "Guarantor Obligations, Nature",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Domain]",
        "terseLabel": "Guarantor Obligations, Nature",
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "dvax_HEPLISAVBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "HEPLISAVBMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HEPLISAV-B.",
        "label": "H E P L I S A V B [Member]",
        "terseLabel": "HEPLISAV-B"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_HortonStreetMasterLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "HortonStreetMasterLeaseMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horton street master lease.",
        "label": "Horton Street Master Lease [Member]",
        "terseLabel": "Horton Street Master Lease",
        "verboseLabel": "Horton Street Master Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "Offering",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r918",
      "r919",
      "r920"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r956",
      "r989"
     ]
    },
    "dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income loss\u200b from continuing\u200b operations before income\u200b taxes\u200b.",
        "label": "Income Loss From Continuing Operations Before Income Taxes",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail": {
       "parentTag": "dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S.",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r584"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income before income taxes, Total",
        "terseLabel": "Net (loss) income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r122",
      "r166",
      "r290",
      "r303",
      "r307",
      "r309",
      "r685",
      "r701",
      "r870"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail": {
       "parentTag": "dvax_IncomeLossFromContinuingOperationsBeforeIncomeTaxes",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentOfConsolidatedLossIncomeBeforeProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Non U.S.",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r584"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r384",
      "r793"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r793"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r557",
      "r563",
      "r569",
      "r575",
      "r580",
      "r585",
      "r586",
      "r587",
      "r735"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxProvisionDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision for income taxes",
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r185",
      "r259",
      "r260",
      "r295",
      "r561",
      "r581",
      "r708"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r559",
      "r560",
      "r569",
      "r570",
      "r574",
      "r576",
      "r729"
     ]
    },
    "dvax_IncomeTaxRateReconciliationMarkToMarketOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IncomeTaxRateReconciliationMarkToMarketOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax rate reconciliation mark to market of warrants.",
        "label": "Income Tax Rate Reconciliation Mark To Market Of Warrants",
        "terseLabel": "Mark-to-market of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dvax_IncomeTaxReconciliationDeferredCompensationCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IncomeTaxReconciliationDeferredCompensationCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation deferred compensation charges.",
        "label": "Income Tax Reconciliation Deferred Compensation Charges",
        "terseLabel": "Deferred compensation charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign taxes",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at federal statutory rate",
        "verboseLabel": "Income tax provision (benefit) at federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Uncertain tax positions",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dvax_IncomeTaxReconciliationTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IncomeTaxReconciliationTaxCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Income Tax Reconciliation Tax Credit",
        "negatedLabel": "Business credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid during the year for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedTerseLabel": "Accounts and other receivables, net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dvax_IncreaseDecreaseInCepiAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IncreaseDecreaseInCepiAccrual",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEPI accrual (Note 9)",
        "label": "Increase (Decrease) In Cepi Accrual",
        "documentation": "Increase (Decrease) In Cepi Accrual"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "negatedTerseLabel": "Inventories, net",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dvax_IncreaseDecreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Lease liabilities",
        "documentation": "Increase decrease in lease liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "negatedTerseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dvax_IncreaseDecreaseInPrepaidManufacturing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IncreaseDecreaseInPrepaidManufacturing",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid manufacturing",
        "documentation": "Amount of increase (decrease) in prepaid manufacturing.",
        "label": "Increase Decrease In Prepaid Manufacturing",
        "negatedTerseLabel": "Prepaid manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in number of employee stock purchase plan shares authorized for issuance.",
        "label": "Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance",
        "terseLabel": "Increase in aggregate number of shares of common stock authorized for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Effect of dilutive warrants",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r282"
     ]
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category",
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r169",
      "r222",
      "r294",
      "r622",
      "r794",
      "r911",
      "r1070"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense related to initial term loan",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r435",
      "r443",
      "r878",
      "r879"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesSummaryOfInterestExpensesRelatedToConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated coupon interest",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r436",
      "r878",
      "r879"
     ]
    },
    "us-gaap_InterestExpenseMediumTermNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseMediumTermNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add: interest expense on convertible notes",
        "label": "Interest Expense, Medium-term Notes",
        "documentation": "Interest expense on medium-Term notes."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the year for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r231",
      "r232"
     ]
    },
    "us-gaap_InventoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoriesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories [Member]",
        "terseLabel": "Inventory",
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories, net",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods inventory",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r860"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "totalLabel": "Total",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r859",
      "r899"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, net",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r194",
      "r208",
      "r368",
      "r369",
      "r371",
      "r675",
      "r866"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r862"
     ]
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance within raw materials and work-in-process inventory",
        "label": "Inventory, Work in Process and Raw Materials",
        "totalLabel": "Inventory, Work in Process and Raw Materials, Total",
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount."
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetSummaryOfInventoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r861"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-off",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "dvax_InventoryWriteOffsRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "InventoryWriteOffsRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-offs recognized",
        "label": "Inventory write-offs recognized",
        "documentation": "Inventory write-offs recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r293"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r725",
      "r726",
      "r727",
      "r728",
      "r817",
      "r818"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r750",
      "r751",
      "r753",
      "r755",
      "r814",
      "r816",
      "r820",
      "r823",
      "r824",
      "r825",
      "r826",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r905"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r750",
      "r751",
      "r753",
      "r755",
      "r814",
      "r816",
      "r820",
      "r823",
      "r824",
      "r825",
      "r826",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r905"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCappedCallOptionsSeeNote10": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCappedCallOptionsSeeNote10",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of capped call options (see Note 10)",
        "documentation": "Issuance of capped call options (see Note 10)"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement",
        "label": "Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement",
        "documentation": "Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)",
        "label": "Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)",
        "documentation": "Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCommonStockUponExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCommonStockUponExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Issuance Of Common Stock Upon Exercise Of Stock Options",
        "documentation": "Issuance Of Common Stock Upon Exercise Of Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCommonStockUponExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCommonStockUponExerciseOfStockOptionsShares",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Issuance Of Common Stock Upon Exercise Of Stock Options, Shares",
        "documentation": "Issuance Of Common Stock Upon Exercise Of Stock Options, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCommonStockUponExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCommonStockUponExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of warrants",
        "label": "Issuance of common stock upon exercise of warrants",
        "documentation": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCommonStockUponExerciseOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCommonStockUponExerciseOfWarrantsShares",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of warrants (Shares)",
        "label": "Issuance of common stock upon exercise of warrants (Shares)",
        "documentation": "Issuance of common stock upon exercise of warrants (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance Of Common Stock Upon Release Of Restricted Stock Awards",
        "label": "Issuance Of Common Stock Upon Release Of Restricted Stock Awards",
        "documentation": "Issuance Of Common Stock Upon Release Of Restricted Stock Awards"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings",
        "label": "Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings",
        "documentation": "Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon release of restricted stock awards",
        "label": "Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings(share)",
        "documentation": "Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings(share)"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon release of restricted stock awards",
        "label": "Issuance Of Common Stock Upon Release Of Restricted Stock Awards Shares",
        "documentation": "Issuance Of Common Stock Upon Release Of Restricted Stock Awards Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Proceeds to Pay the Costs",
        "label": "Issuance Of Convertible Notes On Purchase Of Capped Call Options Value",
        "documentation": "Issuance of convertible notes on purchase of capped call options value."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetShares",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "documentation": "Issuance (withholding) of common stock upon exercise of options vesting of restricted stock units and vesting of early exercised options net shares.",
        "label": "Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance (withholding) of common stock upon exercise of options vesting of restricted stock units and vesting of early exercised options net value.",
        "label": "Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value",
        "terseLabel": "Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LaboratoryEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LaboratoryEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment Gross",
        "label": "Laboratory Equipment Gross",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LaboratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LaboratoryMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory.",
        "label": "Laboratory [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LargestCollaborationPartnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LargestCollaborationPartnerMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Largest Collaboration Partner",
        "label": "Largest Collaboration Partner [Member]",
        "documentation": "Largest collaboration partner"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LargestCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LargestCustomerMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Largest Customer",
        "label": "Largest Customer [Member]",
        "documentation": "Largest Customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Operating Lease Expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LessRemovalOfChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LessRemovalOfChangeInFairValueOfWarrantLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Less: removal of change in fair value of warrant liability",
        "label": "Less: removal of change in fair value of warrant liability",
        "terseLabel": "Less: removal of change in fair value of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingSubleaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Sublease, Existence of Option to Extend [true false]",
        "terseLabel": "Existence of option to extend",
        "documentation": "Indicates (true false) whether sublessee has option to extend operating sublease."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_LesseeOperatingSubleaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingSubleaseOptionToExtend",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Sublease, Option to Extend",
        "terseLabel": "Option to extend",
        "documentation": "Description of terms and conditions of option to extend operating sublease."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LessorSubleaseRentalsPaymentsToBeReceivedDue",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor sublease rentals payments to be received due.",
        "label": "Lessor Sublease Rentals Payments To Be Received Due",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LessorSubleaseRentalsPaymentsToBeReceivedDueAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor sublease rentals payments to be received due.",
        "label": "Lessor Sublease Rentals Payments To Be Received Due [Abstract]",
        "terseLabel": "Sublease Income"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor sublease rentals payments to be received due thereafter.",
        "label": "Lessor Sublease Rentals Payments To Be Received Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "documentation": "Lessor sublease rentals payments to be received due year five.",
        "label": "Lessor Sublease Rentals Payments To Be Received Due Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "documentation": "Lessor sublease rentals payments to be received due year four.",
        "label": "Lessor Sublease Rentals Payments To Be Received Due Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "documentation": "Lessor sublease rentals payments to be received due year three",
        "label": "Lessor Sublease Rentals Payments To Be Received Due Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "documentation": "Lessor sublease rentals payments to be received due year two.",
        "label": "Lessor Sublease Rentals Payments To Be Received Due Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail": {
       "parentTag": "dvax_LessorSubleaseRentalsPaymentsToBeReceivedDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "documentation": "Lessor sublease rentals payments to be received next twelve months.",
        "label": "Lessor Sublease Rentals Payments To Be Received Next Twelve Months"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "terseLabel": "Liability under agreement",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r237",
      "r350",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r590",
      "r591",
      "r592",
      "r611",
      "r764",
      "r869",
      "r913",
      "r998",
      "r1052",
      "r1053"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r165",
      "r697",
      "r899",
      "r959",
      "r985",
      "r1043"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "terseLabel": "Current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r193",
      "r237",
      "r350",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r590",
      "r591",
      "r592",
      "r611",
      "r899",
      "r998",
      "r1052",
      "r1053"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "terseLabel": "Warrant liability",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LicenseArrangementContingentConsiderationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LicenseArrangementContingentConsiderationPercentage",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License arrangement contingent consideration percentage.",
        "label": "License Arrangement Contingent Consideration Percentage",
        "terseLabel": "License arrangement contingent consideration percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LicenseArrangementContingentPaymentToAcquireLicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LicenseArrangementContingentPaymentToAcquireLicense",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License arrangement contingent payment to acquire license.",
        "label": "License Arrangement Contingent Payment To Acquire License",
        "terseLabel": "License arrangement upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity",
        "verboseLabel": "Maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dvax_LiquidityAndFinancialConditionDisclosurePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LiquidityAndFinancialConditionDisclosurePolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and financial condition disclosure.",
        "label": "Liquidity And Financial Condition Disclosure Policy [Text Block]",
        "terseLabel": "Liquidity and Financial Condition"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement Member.",
        "label": "Loan Agreement [Member]",
        "terseLabel": "Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Long-Term Debt",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "dvax_LongTermDeferredRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "LongTermDeferredRevenueMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Deferred Revenue",
        "label": "Long Term Deferred Revenue [Member]",
        "documentation": "Long-term deferred revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r68"
     ]
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r401",
      "r993",
      "r994"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r401",
      "r993",
      "r994"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r401",
      "r993",
      "r994"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r401",
      "r993",
      "r994"
     ]
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Manufacturing equipment",
        "totalLabel": "Machinery and Equipment, Gross, Total",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Manufacturing Equipment",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r884",
      "r1005",
      "r1066",
      "r1067"
     ]
    },
    "dvax_MarketBasedPerformanceStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "MarketBasedPerformanceStockUnitMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Based Performance Stock Unit",
        "label": "Market Based Performance Stock Unit [Member]",
        "documentation": "Market-based performance stock unit."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturities of marketable securities available for sale.",
        "label": "Maturities Of Marketable Securities Available For Sale Table [Text Block]",
        "terseLabel": "Maturities of Marketable Securities Available-for-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r504",
      "r674",
      "r715",
      "r756",
      "r757",
      "r815",
      "r819",
      "r821",
      "r822",
      "r827",
      "r852",
      "r853",
      "r872",
      "r880",
      "r893",
      "r902",
      "r1002",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "dvax_MedigenVaccineBiologicsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "MedigenVaccineBiologicsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Medigen",
        "label": "Medigen Vaccine Biologics [Member]",
        "documentation": "Medigen Vaccine Biologics Member"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_MerckMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "MerckMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck.",
        "label": "Merck [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_MerckSharpAndDohmeCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "MerckSharpAndDohmeCorporationMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Sharp and Dohme Corporation.",
        "label": "Merck Sharp And Dohme Corporation [Member]",
        "terseLabel": "Merck, Sharp &amp; Dohme Corp."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_MinimumAgeApprovedForVaccinePreventionOfInfectionCaused": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "MinimumAgeApprovedForVaccinePreventionOfInfectionCaused",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum age approved for vaccine prevention of infection caused.",
        "label": "Minimum Age Approved For Vaccine Prevention Of Infection Caused",
        "terseLabel": "Minimum age approved for vaccine prevention of infection caused"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r504",
      "r674",
      "r715",
      "r756",
      "r757",
      "r815",
      "r819",
      "r821",
      "r822",
      "r827",
      "r852",
      "r853",
      "r872",
      "r880",
      "r893",
      "r902",
      "r1002",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "dvax_ModifiedPurchaseOrderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ModifiedPurchaseOrderMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modified Purchase Order [Member]",
        "label": "Modified Purchase Order [Member]",
        "terseLabel": "Modified Purchase Order"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r884",
      "r1005",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r135"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r135",
      "r167",
      "r191",
      "r213",
      "r216",
      "r221",
      "r237",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r275",
      "r290",
      "r303",
      "r307",
      "r309",
      "r350",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r603",
      "r611",
      "r702",
      "r789",
      "r807",
      "r808",
      "r870",
      "r911",
      "r998"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income allocable to common stockholders, basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r253",
      "r254",
      "r255",
      "r256",
      "r263",
      "r264",
      "r277",
      "r282",
      "r290",
      "r303",
      "r307",
      "r309",
      "r870"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) allocable to common stockholders, diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r265",
      "r271",
      "r272",
      "r273",
      "r274",
      "r277",
      "r282"
     ]
    },
    "dvax_NetOperatingLossAndTaxCreditLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "NetOperatingLossAndTaxCreditLimitation",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss and tax credit limitation",
        "documentation": "Net operating loss and tax credit limitation"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_NetOperatingLossAndTaxCreditLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "NetOperatingLossAndTaxCreditLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss and tax credit limitation",
        "label": "Net Operating Loss and Tax Credit Limitations",
        "documentation": "Net operating loss and tax credit limitations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_NonCashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "NonCashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non U.S.",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not Found During Migration Deprecated Concept Lease Arrangement Type Axis",
        "label": "Not Found During Migration Deprecated Concept Lease Arrangement Type [Axis]",
        "terseLabel": "Not Found During Migration Deprecated Concept Lease Arrangement Type"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not Found During Migration Deprecated Concept Lease Arrangement Type Domain",
        "label": "Not Found During Migration Deprecated Concept Lease Arrangement Type [Domain]",
        "terseLabel": "Not Found During Migration Deprecated Concept Lease Arrangement Type"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Interest- free unsecured forgivable loan",
        "totalLabel": "Financing Receivable, after Allowance for Credit Loss, Current, Total",
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r681"
     ]
    },
    "dvax_NumberOfCommonStockPreferredStockConvertibleInto": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "NumberOfCommonStockPreferredStockConvertibleInto",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock preferred stock convertible into.",
        "label": "Number Of Common Stock Preferred Stock Convertible Into",
        "terseLabel": "Number of common stock allowed to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_NumberOfCommonStockWarrantExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "NumberOfCommonStockWarrantExercised",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock warrant exercised.",
        "label": "Number of Common Stock Warrant Exercised",
        "terseLabel": "Number of common stock warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r303",
      "r307",
      "r309",
      "r870"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfSubleaseIncomeAndOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liabilities (included in other current liabilities)",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r632"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r898"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r898"
     ]
    },
    "dvax_OperatingLossCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "OperatingLossCarryforwardExpirationYear",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforward, expiration year.",
        "label": "Operating Loss Carryforward Expiration Year",
        "terseLabel": "Net operating loss carryforwards, expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r160",
      "r723",
      "r724"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail": {
       "parentTag": "dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets (Note 9 )",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Cumulative foreign currency translation adjustments",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Total other comprehensive income (loss)",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r20",
      "r214",
      "r217",
      "r223",
      "r614",
      "r615",
      "r620",
      "r682",
      "r703",
      "r948",
      "r949"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax",
        "negatedLabel": "Reclassification of realized gain on available-for-sale securities recognized in interest income",
        "totalLabel": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax, Total",
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r121",
      "r212",
      "r349"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other Liabilities, Current, Total",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r899"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "dvax_OtherLongTermLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "OtherLongTermLiabilitiesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Long Term Liabilities",
        "label": "Other Long Term Liabilities [Member]",
        "documentation": "Other Long Term Liabilities Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income:",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other Income (Expense)",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r774"
     ]
    },
    "dvax_OtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "OtherRevenueMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenue.",
        "label": "Other Revenue [Member]",
        "terseLabel": "Other Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments",
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PaymentMadeForPreCommercializationMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PaymentMadeForPreCommercializationMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for pre commercialization milestone.",
        "label": "Payment Made for Pre Commercialization Milestone",
        "terseLabel": "Payment made for pre-commercialization milestone"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PaymentReceivedForPreCommercializationMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PaymentReceivedForPreCommercializationMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment received for pre-commercialization milestone",
        "label": "Payment Received For Pre Commercialization Milestone",
        "terseLabel": "Payment received for pre-commercialization milestone"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PaymentToHoldings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PaymentToHoldings",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to holdings.",
        "label": "Payment To Holdings",
        "terseLabel": "Payment to holdings"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PaymentsForPurchaseOfCappedCallOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PaymentsForPurchaseOfCappedCallOptions",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of capped call options",
        "label": "Payments For Purchase Of Capped Call Options",
        "documentation": "Amount of cash outflow for purchase of capped call options.",
        "negatedTerseLabel": "Purchases of capped call options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "negatedLabel": "Cash payments or settlements",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r954"
     ]
    },
    "dvax_PaymentsForTaxesRelatedToNetShareSettlementOfRsus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PaymentsForTaxesRelatedToNetShareSettlementOfRsus",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for taxes related to net share settlement of RSUs",
        "terseLabel": "Payments for taxes related to net share settlement of RSUs",
        "label": "Payments for taxes related to net share settlement of RSUs",
        "documentation": "Payments for taxes related to net share settlement of RSUs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payment of issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment, net",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r486",
      "r487",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r891"
     ]
    },
    "dvax_PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PercentageOfCapitalStockOfSubsidiariesSubjectToCertainException",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of capital stock of subsidiaries subject to certain exception.",
        "label": "Percentage Of Capital Stock Of Subsidiaries Subject To Certain Exception",
        "terseLabel": "Percentage of capital stock of subsidiaries subject to certain exception"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PercentageOfCommonStockHeldNotToExceedByHolderAndAffiliatesForWarrantExercises",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock held not to exceed by holder and affiliates for warrant exercises.",
        "label": "Percentage Of Common Stock Held Not To Exceed By Holder And Affiliates For Warrant Exercises",
        "terseLabel": "Percentage of common stock held not to exceed for warrant exercises"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForConversionOfPreferredStock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock to be held by holder and affiliates for conversion of preferred stock.",
        "label": "Percentage Of Common Stock To Be Held By Holder And Affiliates For Conversion Of Preferred Stock",
        "terseLabel": "Percentage of common stock to be held for conversion"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PercentageOfCommonStockToBeHeldByHolderAndAffiliatesForExerciseOfWarrants",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock to be held by holder and affiliates for exercise of warrants.",
        "label": "Percentage Of Common Stock To Be Held By Holder And Affiliates For Exercise Of Warrants",
        "terseLabel": "Percentage of common stock to be held for exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PercentageOfExcessRentPaidToLandlord": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PercentageOfExcessRentPaidToLandlord",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of excess rent paid to landlord.",
        "label": "Percentage Of Excess Rent Paid To Landlord",
        "terseLabel": "Percentage of excess rent paid to landlord"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PercentageOfFeePayableUponPartialPrepaymentOrMaturity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PercentageOfFeePayableUponPartialPrepaymentOrMaturity",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fee payable upon partial prepayment or maturity.",
        "label": "Percentage Of Fee Payable Upon Partial Prepayment Or Maturity",
        "terseLabel": "Percentage of fee payable upon partial prepayment or maturity"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PercentageOfLongLivedAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PercentageOfLongLivedAssets",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of long lived assets.",
        "label": "Percentage Of Long Lived Assets",
        "terseLabel": "Percentage of long lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Based Restricted Stock Units",
        "label": "Performance Based Restricted Stock Units [Member]",
        "documentation": "Performance based restricted stock units.",
        "verboseLabel": "PSUs"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PerformanceBasedVestingScheduleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PerformanceBasedVestingScheduleMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based vesting schedule.",
        "label": "Performance Based Vesting Schedule [Member]",
        "terseLabel": "Performance Based Vesting Schedule"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Based Vesting Condition",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_PledgingPurposeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PledgingPurposeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pledging Purpose [Axis]",
        "documentation": "Information by pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r897",
      "r900",
      "r928"
     ]
    },
    "us-gaap_PledgingPurposeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PledgingPurposeDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pledging Purpose [Domain]",
        "documentation": "Pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r897",
      "r900",
      "r928"
     ]
    },
    "dvax_PowellStreetSubleaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PowellStreetSubleaseMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Powell Street Sublease.",
        "label": "Powell Street Sublease [Member]",
        "terseLabel": "Powell Street Sublease"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PreferredStockCommonStockAndWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PreferredStockCommonStockAndWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock common Stock and warrants.",
        "label": "Preferred Stock Common Stock And Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PreferredStockConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PreferredStockConversionPricePerShare",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock conversion price per share.",
        "label": "Preferred Stock Conversion Price Per Share",
        "terseLabel": "Conversion price per share"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PreferredStockDeemedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PreferredStockDeemedDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock deemed dividend.",
        "label": "Preferred Stock Deemed Dividend",
        "terseLabel": "Preferred stock deemed dividend",
        "negatedLabel": "Preferred stock deemed dividend"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: preferred stock deemed dividend",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r904",
      "r907",
      "r908",
      "r909",
      "r910",
      "r1069",
      "r1073"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r445"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r766"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r766",
      "r785",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock: $0.001 par value, 5,000 shares authorized at December 31, 2023, and 2022; zero shares outstanding at December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r693",
      "r899"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dvax_PrepaidManufacturing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PrepaidManufacturing",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Manufacturing.",
        "label": "Prepaid Manufacturing",
        "terseLabel": "Prepaid manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PrepaymentOfAdvancePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PrepaymentOfAdvancePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment of advance payment",
        "label": "Prepayment of advance payment",
        "documentation": "Prepayment of advance payment"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PriceOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PriceOfCommonStock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of common stock.",
        "label": "Price Of Common Stock",
        "terseLabel": "Price of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ProceedsFromCashReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ProceedsFromCashReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "proceeds from cash received.",
        "label": "Proceeds From Cash Received",
        "terseLabel": "Received Net Cash Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of Convertible Notes, net",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "dvax_ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of stock options and restricted stock awards net.",
        "label": "Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net",
        "terseLabel": "Proceeds from exercise of stock options and release of restricted stock awards, net"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ProceedsFromGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ProceedsFromGrant",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from grant.",
        "label": "Proceeds From Grant",
        "terseLabel": "Proceeds from grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuances of common stock, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dvax_ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock authorized, remaining capacity.",
        "label": "Proceeds From Issuance Of Common Stock Authorized Remaining Capacity",
        "terseLabel": "Remaining proceeds from common stock, under sales agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term debt, net",
        "verboseLabel": "Net proceeds from the initial term loan",
        "totalLabel": "Proceeds from Issuance of Long-term Debt, Total",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r730"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from warrants exercises",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Net cash proceeds received from issuance or sale of equity",
        "verboseLabel": "Net cash proceeds received from issuance or sale of equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r730"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities and redemptions of marketable securities",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r974"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from sale of assets, net of transaction costs",
        "totalLabel": "Proceeds from Sale of Productive Assets, Total",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from Employee Stock Purchase Plan",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueWarrantLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants exercised",
        "terseLabel": "Warrants exercised",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "dvax_ProceedsFromWarrantsSale": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ProceedsFromWarrantsSale",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds From Warrants Sale",
        "label": "Proceeds From Warrants Sale",
        "documentation": "proceeds from warrants sale."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "Product",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r310",
      "r676",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r856",
      "r882",
      "r901",
      "r931",
      "r995",
      "r996",
      "r1005",
      "r1066"
     ]
    },
    "dvax_ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments related to prior periods",
        "label": "Product Revenue Allowance And Reserves Adjustments Related To Prior Period",
        "documentation": "Product Revenue Allowance And Reserves Adjustments Related To Prior Period"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit or payments made during the period",
        "label": "Product Revenue Allowance And Reserves Credit Or Payments Made During Period",
        "documentation": "Product revenue allowance and reserves credit or payments made during the period."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions related to current period sales",
        "label": "Product Revenue Allowance And Reserves Provision Related To Current Period Sales",
        "documentation": "Product revenue allowance and reserves provision related to current period sales."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r310",
      "r676",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r856",
      "r882",
      "r901",
      "r931",
      "r995",
      "r996",
      "r1005",
      "r1066"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r179",
      "r182",
      "r183"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "totalLabel": "Property, plant and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r196",
      "r700"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r688",
      "r700",
      "r899"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentOther",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Other, Gross",
        "terseLabel": "Assets in progress",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r179",
      "r182",
      "r698"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Component of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Lives (In years)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_PtBioFarmaPerseroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "PtBioFarmaPerseroMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PT Bio Farma (Persero) is related to Collaboration, Development and Supply Agreements.",
        "label": "PT Bio Farma (Persero) [Member]",
        "terseLabel": "PT Bio Farma (Persero)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory",
        "documentation": "Information by type of inventory held."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory",
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Purchase Obligation",
        "terseLabel": "Non-cancelable purchase and other commitments",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueAfterFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueAfterFifthYear",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Purchase Obligation, to be Paid, after Year Five",
        "documentation": "Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInFifthYear",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Purchase Obligation, to be Paid, Year Five",
        "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInFourthYear",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Purchase Obligation, to be Paid, Year Four",
        "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInThirdYear",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaterialPurchaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Purchase Obligation, to be Paid, Year Three",
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r486",
      "r504",
      "r536",
      "r537",
      "r538",
      "r649",
      "r674",
      "r715",
      "r756",
      "r757",
      "r815",
      "r819",
      "r821",
      "r822",
      "r827",
      "r852",
      "r853",
      "r872",
      "r880",
      "r893",
      "r902",
      "r905",
      "r990",
      "r1002",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r486",
      "r504",
      "r536",
      "r537",
      "r538",
      "r649",
      "r674",
      "r715",
      "r756",
      "r757",
      "r815",
      "r819",
      "r821",
      "r822",
      "r827",
      "r852",
      "r853",
      "r872",
      "r880",
      "r893",
      "r902",
      "r905",
      "r990",
      "r1002",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "dvax_ReclassificationOfCepiAccrualToCepiAccrualLongTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ReclassificationOfCepiAccrualToCepiAccrualLongTerm",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of CEPI accrual to CEPI accrual long-term",
        "label": "Reclassification of CEPI accrual to CEPI accrual long-term",
        "documentation": "Reclassification of CEPI accrual to CEPI accrual long-term"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of contract asset from other current assets to other assets",
        "label": "Reclassification of contract asset from other current assets to other assets",
        "documentation": "Reclassification of contract asset from other current assets to other assets"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of cash, cash equivalents and restricted cash to the statement of cash flows.",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash To Statement Of Cash Flows Table [Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_RepaymentOfAdvanceFromCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "RepaymentOfAdvanceFromCustomer",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of advance from customer",
        "label": "Repayment of Advance from Customer",
        "documentation": "Repayment of Advance from Customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Repayments of Long-Term Debt, Total",
        "terseLabel": "Repayment of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Repayment of long-term debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r733"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r419",
      "r447",
      "r638",
      "r864",
      "r865"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r556",
      "r1060"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses and Accruals",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research And Development Tax Credits",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "dvax_ReservationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ReservationAgreementMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reservation Agreement.",
        "label": "Reservation Agreement [Member]",
        "terseLabel": "Reservation Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ReservesAccrualBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ReservesAccrualBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "label": "Reserves Accrual Balance",
        "documentation": "Reserves Accrual Balance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r172",
      "r233"
     ]
    },
    "us-gaap_RestrictedStockExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock or Unit Expense",
        "terseLabel": "Stock based compensation expense related to restricted stock",
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesCompletionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesCompletionDate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities, Completion Date",
        "terseLabel": "Restructuring completion date",
        "documentation": "Date the exit and disposal activities were completed or are expected to be completed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r389"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r383",
      "r386",
      "r393"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring Costs Incurred for the Year Ended December 31, 2019",
        "documentation": "Amount of costs incurred to date for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r385",
      "r390",
      "r392"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of positions reduced in global workforce",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Percentage of reduction in global workforce",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Severance and other termination benefits",
        "verboseLabel": "Restructuring",
        "totalLabel": "Restructuring Charges, Total",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r387",
      "r390",
      "r991"
     ]
    },
    "us-gaap_RestructuringChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringChargesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring",
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r390",
      "r391"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost And Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r385",
      "r390",
      "r391",
      "r392"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve",
        "periodEndLabel": "Balance at December 31, 2019",
        "periodStartLabel": "Balance at December 31, 2018",
        "totalLabel": "Restructuring Reserve, Total",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r388"
     ]
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Accelerated depreciation charges",
        "verboseLabel": "Accelerated depreciation related to certain long-lived assets",
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r152",
      "r696",
      "r719",
      "r721",
      "r734",
      "r767",
      "r899"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r248",
      "r249",
      "r250",
      "r252",
      "r258",
      "r260",
      "r351",
      "r352",
      "r547",
      "r548",
      "r549",
      "r578",
      "r579",
      "r593",
      "r595",
      "r596",
      "r598",
      "r601",
      "r716",
      "r718",
      "r736",
      "r1073"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue recognized",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r302",
      "r305",
      "r306",
      "r310",
      "r311",
      "r313",
      "r480",
      "r481",
      "r676"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r929"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r855"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r483"
     ]
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_RevenueReserveAccrualCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "RevenueReserveAccrualCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail": {
       "parentTag": "dvax_AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesComponentOfCurrentAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue reserve accrual current.",
        "label": "Revenue Reserve Accrual Current",
        "terseLabel": "Revenue reserve accruals"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_RevenueReserveAccrualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "RevenueReserveAccrualsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue reserve accruals.",
        "label": "Revenue Reserve Accruals [Member]",
        "terseLabel": "Revenue Reserve Accruals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r898"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock and Warrants Exercised",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r929"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r505",
      "r969"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r505",
      "r926",
      "r969"
     ]
    },
    "dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCurrentAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Component of Current Accrued Liabilities",
        "documentation": "Schedule of accrued liabilities and accrued research and development.",
        "label": "Schedule Of Accrued Liabilities And Accrued Research And Development Table [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Marketable Securities",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of balance sheet components of operating lease liabilities.",
        "label": "Schedule Of Balance Sheet Components Of Operating Lease Liabilities Table [Text Block]",
        "terseLabel": "Summary of Balance Sheet Classification of Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Income Tax Provision",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "dvax_ScheduleOfConvertibleNotesInterestExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ScheduleOfConvertibleNotesInterestExpenseTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureConvertibleNotesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Interest Expenses Related to Convertible Notes",
        "label": "Schedule Of Convertible Notes Interest Expense Table [Text Block]",
        "documentation": "Schedule of convertible notes interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Share-Based Payments [Table]",
        "terseLabel": "Schedule Of Deferred Compensation Arrangement With Individual Share Based Payments [Table]",
        "documentation": "Schedule, table or text reflecting equity-based arrangements (such as stock or unit options and stock or unit awards) with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r78",
      "r80",
      "r153"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Component of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Difference Between Consolidated Income Tax Benefit and Amount Computed by Federal Statutory Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r677"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Intangible Assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Component of Consolidated (Loss) Income Before Provision for Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureInventoriesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r117",
      "r118",
      "r119"
     ]
    },
    "dvax_ScheduleOfMaterialPurchaseCommitmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ScheduleOfMaterialPurchaseCommitmentsTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Material Purchase Commitments",
        "label": "Schedule of material purchase commitments [Table Text Block]",
        "documentation": "Schedule of material purchase commitments [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Performance Based Restricted Stock Unit",
        "label": "Schedule Of Performance Based Restricted Stock Unit Table [Text Block]",
        "documentation": "Summary of performance based restricted stock unit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetComponentOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule Of Restructuring And Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r385",
      "r390",
      "r391",
      "r392"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Major Components of Restructuring Costs",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r65",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of the Restructuring Liabilities",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r67"
     ]
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from Major Customers",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Option Activity Under Stock-Based Compensation Plans",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r509",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Non-vested Restricted Stock Units Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value-Based Measurements and Weighted-Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r149",
      "r151",
      "r152",
      "r202",
      "r203",
      "r204",
      "r288",
      "r445",
      "r446",
      "r447",
      "r449",
      "r452",
      "r457",
      "r459",
      "r730",
      "r731",
      "r732",
      "r733",
      "r880",
      "r925",
      "r957"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Common Stock Warrants Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r1036"
     ]
    },
    "dvax_SecondLargestCollaborationPartnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SecondLargestCollaborationPartnerMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Largest Collaboration Partner",
        "label": "Second Largest Collaboration Partner [Member]",
        "documentation": "Second largest collaboration partner"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SecondLargestCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SecondLargestCustomerMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Largest Customer",
        "label": "Second Largest Customer [Member]",
        "documentation": "Second largest Customer"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_Section162MLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "Section162MLimitation",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenConsolidatedIncomeTaxBenefitAndAmountComputedByFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 162(m) limitation",
        "label": "section 162 (m) Limitation",
        "documentation": "section 162 (m) Limitation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Long-Term Debt, Noncurrent",
        "verboseLabel": "Current borrowing capacity",
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "dvax_SecuredLongTermDebtNoncurrentPlusInterestInKind": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SecuredLongTermDebtNoncurrentPlusInterestInKind",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations, plus interest-in-kind, with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion.",
        "label": "Secured Long Term Debt Noncurrent Plus Interest In Kind",
        "terseLabel": "Principal amount including interest paid in kind"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r749",
      "r752",
      "r754",
      "r816",
      "r820",
      "r824",
      "r828",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r857",
      "r883",
      "r905",
      "r1005",
      "r1066"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r311",
      "r871"
     ]
    },
    "dvax_SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling commission percentage from gross offering proceeds of sales of stock.",
        "label": "Selling Commission Percentage From Gross Offering Proceeds Of Sales Of Stock",
        "terseLabel": "Commission on gross sales proceeds of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "totalLabel": "Selling, General and Administrative Expense, Total",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock",
        "verboseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SeriesCConvertiblePreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SeriesCConvertiblePreferredStocksMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C convertible preferred stocks.",
        "label": "Series C Convertible Preferred Stocks [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SerumInstituteOfIndiaPrivateLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SerumInstituteOfIndiaPrivateLimitedMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Serum Institute of India Private Limited.",
        "label": "Serum Institute Of India Private Limited [Member]",
        "terseLabel": "Serum Institute of India Pvt. Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ServicesAndMaterialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ServicesAndMaterialsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services and Materials.",
        "label": "Services And Materials [Member]",
        "terseLabel": "Services and Materials"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SeveranceAndOtherTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SeveranceAndOtherTerminationBenefitsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance and other termination benefits.",
        "label": "Severance And Other Termination Benefits [Member]",
        "terseLabel": "Severance and Other Termination Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Options vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested, Ending Balance",
        "periodStartLabel": "Non-vested, Beginning Balance",
        "terseLabel": "Restricted stock unit awards outstanding",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested, Ending Balance",
        "periodStartLabel": "Non-vested, Beginning Balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant-Date Fair Value Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of restricted stock units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r509",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for future purchases",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options expired (vested)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options cancelled:",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options cancelled:",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options forfeited (unvested)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at December 31, 2023",
        "periodStartLabel": "Balance at December 31, 2022",
        "terseLabel": "Balance at December 31, 2021",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Outstanding stock awards granted",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Underlying Outstanding Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureEquityPlansAndStockbasedCompensationSummaryOfPerformanceBasedRestrictedStockUnitDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationSummaryOfNonVestedRestrictedStockUnitsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "Award Type",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options expired (vested)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options forfeited (unvested)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "The commencement of the offer period (generally, the sixteenth day in February or August)",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "The exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August)",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r514",
      "r533",
      "r534",
      "r535",
      "r536",
      "r539",
      "r550",
      "r551",
      "r552",
      "r553"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "verboseLabel": "Employees and directors stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount, Total",
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate intrinsic value",
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance at December 31",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of stock options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price per share as percentage of fair market value of common stock",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SharesAvailableForPurchasesUnderEmployeePurchasePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SharesAvailableForPurchasesUnderEmployeePurchasePlan",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares available for purchases under employee purchase plan.",
        "label": "Shares Available For Purchases Under Employee Purchase Plan",
        "terseLabel": "Shares remaining available for future purchases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SharesPurchasedByEmployeesUnderEmployeePurchasePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SharesPurchasedByEmployeesUnderEmployeePurchasePlan",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares purchased by employees under employee purchase plan.",
        "label": "Shares Purchased By Employees Under Employee Purchase Plan",
        "terseLabel": "Shares issued to employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r234"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r202",
      "r203",
      "r204",
      "r237",
      "r266",
      "r270",
      "r278",
      "r282",
      "r288",
      "r289",
      "r350",
      "r406",
      "r408",
      "r409",
      "r410",
      "r413",
      "r414",
      "r445",
      "r446",
      "r449",
      "r452",
      "r459",
      "r611",
      "r730",
      "r731",
      "r732",
      "r733",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r766",
      "r790",
      "r809",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r925",
      "r957",
      "r970"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r36",
      "r190",
      "r219",
      "r220",
      "r221",
      "r248",
      "r249",
      "r250",
      "r252",
      "r258",
      "r260",
      "r287",
      "r351",
      "r352",
      "r461",
      "r547",
      "r548",
      "r549",
      "r578",
      "r579",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r614",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r637",
      "r716",
      "r717",
      "r718",
      "r736",
      "r809"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r749",
      "r752",
      "r754",
      "r816",
      "r820",
      "r824",
      "r828",
      "r839",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r857",
      "r883",
      "r905",
      "r1005",
      "r1066"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r287",
      "r676",
      "r725",
      "r747",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r766",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r775",
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r786",
      "r791",
      "r792",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r809",
      "r906"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r505",
      "r926",
      "r927",
      "r969"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r287",
      "r676",
      "r725",
      "r747",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r766",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r775",
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r786",
      "r791",
      "r792",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r809",
      "r906"
     ]
    },
    "dvax_StockBasedCompensationExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "StockBasedCompensationExpenseMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense.",
        "label": "Stock Based Compensation Expense [Member]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r74",
      "r152",
      "r432"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r152"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock and preferred stock, net of issuance costs (in shares)",
        "verboseLabel": "Issuance of common stock and preferred stock (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r152",
      "r730",
      "r809",
      "r834"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r152",
      "r520"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Preferred Stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r36",
      "r152"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r152"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock and preferred stock, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r152",
      "r736",
      "r809",
      "r834",
      "r912"
     ]
    },
    "dvax_StockOptionsAndShareAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "StockOptionsAndShareAwardsMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and share awards.",
        "label": "Stock Options And Share Awards [Member]",
        "terseLabel": "Stock Options and Stock Awards"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "StockRedeemedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock redeemed during period shares conversion of convertible securities.",
        "label": "Stock Redeemed During Period Shares Conversion Of Convertible Securities",
        "negatedLabel": "Stock Redeemed During Period, Shares, Conversion of Convertible Securities (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r114",
      "r115",
      "r137",
      "r768",
      "r785",
      "r810",
      "r811",
      "r899",
      "r913",
      "r959",
      "r985",
      "r1043",
      "r1073"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock and Warrants",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r236",
      "r444",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r461",
      "r600",
      "r812",
      "r813",
      "r838"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease Income",
        "terseLabel": "Sublease income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r898"
     ]
    },
    "dvax_SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease income and operating lease liability maturity.",
        "label": "Sublease Income And Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Maturities of Sublease Income and Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SublicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SublicenseAgreementMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense agreement.",
        "label": "Sublicense Agreement [Member]",
        "terseLabel": "Sublicense Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SublicenseLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SublicenseLiabilityMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense liability.",
        "label": "Sublicense Liability [Member]",
        "terseLabel": "Sublicense Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r641"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r641"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r641"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r641"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r641"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r642"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [Member]",
        "terseLabel": "Dynavax",
        "verboseLabel": "Dynavax GmbH"
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationFairValueBasedMeasurementsAndWeightedAverageAssumptionsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of product revenue allowance and reserve categories.",
        "label": "Summary Of Product Revenue Allowance And Reserve Categories Table [Text Block]",
        "terseLabel": "Summary of Product Revenue Allowance and Reserve Categories"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of weighted average remaining lease term and weighted average discount rate.",
        "label": "Summary Of Weighted Average Remaining Lease Term And Weighted Average Discount Rate Table [Text Block]",
        "terseLabel": "Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SupplyAgreementMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply agreement.",
        "label": "Supply Agreement [Member]",
        "terseLabel": "Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SuretyBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SuretyBondMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Surety Bond [Member]",
        "terseLabel": "Surety Bond",
        "documentation": "An obligation arising from a three-party agreement that legally binds together a principal who needs the bond, an obligee who requires the bond and a surety company that sells the bond."
       }
      }
     },
     "auth_ref": []
    },
    "dvax_SymphonyDynamoHoldingsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "SymphonyDynamoHoldingsLlcMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Symphony Dynamo Holdings LLC.",
        "label": "Symphony Dynamo Holdings Llc [Member]",
        "terseLabel": "Symphony Dynamo Holdings Llc",
        "verboseLabel": "Symphony Dynamo Holdings LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "dvax_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward, expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforward amount, expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "dvax_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ThirdLargestCollaborationPartnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ThirdLargestCollaborationPartnerMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Largest Collaboration Partner",
        "label": "Third Largest Collaboration Partner Member",
        "documentation": "Third largest collaboration partner member"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_ThirdLargestCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ThirdLargestCustomerMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Largest Customer",
        "label": "Third Largest Customer [Member]",
        "documentation": "Third largest Customer"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_TimeBasedVestingScheduleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "TimeBasedVestingScheduleMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time based vesting schedule.",
        "label": "Time Based Vesting Schedule [Member]",
        "terseLabel": "Time Based Vesting Schedule"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAccountsReceivableMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable [Member]",
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "verboseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r440",
      "r457",
      "r599",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r704",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r981",
      "r982",
      "r983",
      "r984"
     ]
    },
    "dvax_TrisalusLifeSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "TrisalusLifeSciencesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trisalus Life Sciences",
        "documentation": "TriSalus Life Sciences [Member]",
        "label": "TriSalus Life Sciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_TwentySeventeenAtTheMarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "TwentySeventeenAtTheMarketAgreementMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty seventeen at the market agreement.",
        "label": "Twenty Seventeen At The Market Agreement [Member]",
        "terseLabel": "2017 ATM Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_TwoThousandAndEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "TwoThousandAndEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and eighteen equity incentive plan.",
        "label": "Two Thousand And Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen employee stock purchase plan.",
        "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_TwoThousandTwentyATMAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "TwoThousandTwentyATMAgreementMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty ATM Agreement.",
        "label": "Two Thousand Twenty A T M Agreement [Member]",
        "terseLabel": "2020 ATM Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfComponentsOfRestructuringLiabilitiesDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRestructuringScheduleOfMajorComponentsOfRestructuringCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r390",
      "r391"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_USDepartmentOfDefenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "USDepartmentOfDefenseMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Department of Defense",
        "documentation": "U S Department of Defense.",
        "label": "U S Department Of Defense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r889",
      "r1061"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCashCashEquivalentsRestrictedCashAndMarketableSecuritiesSummaryOfCashCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r889",
      "r891",
      "r1061"
     ]
    },
    "dvax_UndistributedEarningsAllocatedToParticipatingSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "UndistributedEarningsAllocatedToParticipatingSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Undistributed earnings allocated to participating securities",
        "terseLabel": "Undistributed earnings allocated to participating securities",
        "label": "Undistributed Earnings Allocated to Participating Securities",
        "documentation": "Undistributed earnings allocated to participating securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "crdr": "debit",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Undistributed earnings allocated to participating securities",
        "terseLabel": "Less: undistributed earnings allocated to participating securities",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "totalLabel": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic, Total",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r279",
      "r280"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "negatedPeriodStartLabel": "Balance at Beginning Balance",
        "negatedPeriodEndLabel": "Balance at Ending Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r564"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "terseLabel": "Tax positions related to the current year, Reductions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Tax positions related to the prior year, Reductions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense",
        "terseLabel": "Penalties related to unrecognized tax benefits",
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "negatedLabel": "Tax positions related to the current year, Additions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "negatedLabel": "Tax positions related to the prior year, Additions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax positions related to the prior year, Settlements",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Interest related to unrecognized tax benefits",
        "documentation": "Amount of interest expense for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax positions related to the prior year, Lapses in statute",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits would affect the effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "dvax_UnvestedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "UnvestedMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested.",
        "label": "Unvested [Member]",
        "terseLabel": "Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "UpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_UpfrontPaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "UpfrontPaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIntangibleAssetsNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment receivable.",
        "label": "Upfront Payment Receivable",
        "terseLabel": "Upfront payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r175",
      "r177",
      "r180",
      "r181"
     ]
    },
    "dvax_ValnevaSEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ValnevaSEMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valneva SE.",
        "label": "Valneva S E [Member]",
        "terseLabel": "Valneva SE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation And Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenuesFromMajorCustomersDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesDeferredRevenueAccountsDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfBalancesAndActivitiesInOurContractAssetAccountDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureRevenueRecognitionSummaryOfDisaggregationOfRevenuesDetails",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "Valuation And Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "dvax_VestedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "VestedMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationOptionActivityUnderStockBasedCompensationPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vested.",
        "label": "Vested [Member]",
        "terseLabel": "Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureEquityPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareOutstandingStockOptionsAndStockAwardsExcludedFromCalculationOfNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrant Liability",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r904",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "dvax_WarrantsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "WarrantsExpirationDate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expiration date.",
        "label": "Warrants Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_WarrantsFairValueAssumptionsDividendYield": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "WarrantsFairValueAssumptionsDividendYield",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants fair value assumptions dividend yield.",
        "label": "Warrants Fair Value Assumptions Dividend Yield",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_WarrantsFairValueAssumptionsRiskFreeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "WarrantsFairValueAssumptionsRiskFreeRate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants fair value assumptions risk free rate.",
        "label": "Warrants Fair Value Assumptions Risk Free Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_WarrantsFairValueAssumptionsVolatility": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "WarrantsFairValueAssumptionsVolatility",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToEstimateTheFairValueOfWarrantLiabilityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants fair value assumptions volatility.",
        "label": "Warrants Fair Value Assumptions Volatility",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "auth_ref": []
    },
    "dvax_WarrantsIssuanceDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "WarrantsIssuanceDate",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureCommonStockAndWarrantsSummaryOfCommonStockWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issuance date.",
        "label": "Warrants Issuance Date",
        "terseLabel": "Warrants Issuance Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted average shares used to compute net (loss) income allocable to common stockholders per share, diluted",
        "terseLabel": "Weighted-average shares used in computing diluted net (loss) income per share allocable to common stockholders",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r282"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.dynavax.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing basic net (loss) income per share allocable to common stockholders",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r282"
     ]
    },
    "dvax_ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20231231",
     "localname": "ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember",
     "presentation": [
      "http://www.dynavax.com/20231231/taxonomy/role/Role_DisclosureCollaborativeResearchDevelopmentAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Clover",
        "label": "Zhejiang Clover Biopharmaceuticals Inc And Clover Hong Kong Inc [Member]",
        "documentation": "Zhejiang clover biopharmaceuticals, inc and clover hong kong inc member."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "420",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482943/710-10-55-8"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a),(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "940",
   "SubTopic": "320",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481961/940-320-45-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-8B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-26"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "65",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-65"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-66"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0000950170-24-018766-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-018766-xbrl.zip
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M6DW%@%C_[LU"'D[0)9RBR!_>+1O#M/7ESU]S_=?E_'"Q_MO:2+MW\H;K[7[
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M4;,!Z:0-KU* UA?(M41;,F63ATWQ^4B2Q(>"ZR]>_G8CDWVQZ!JH)K ^R'
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MK:2\ K5NBA*;AJRP@D[\6PJ:;=GAXIC;3@>[&<AG@*R5@*TKDR*8&*0]ITV
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MOU2-U6EAUU;:B5Q)&Z0OK^:Z7]=EXQ+"H<E;R4>YD=@IJ>ATCP$\FT#@HNN
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MXLEC*-_/1Z>CL^./7T:'XNQ\^.Z=.#C^1"CQ1A/_Y)JXWVCBC=3$!\]'$S\
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MQT)S+/S0L5"4%*\]&2C004<$:78\(>AX #U]4ZV/GYB*S5D.+^0TP>&&4P@
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M^!,W3OWM[@Z>YSE]YP)]/+CWNUN#_L[^=F^PM;_[,Y_;8U.W6-E"9E>4*FA
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M>->BP'5$6= '[A=?,#9+Z]P,^0A;J*!B/V*Z\Z)J\]FR9'&UJ-U!_L?](ES
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MJW F%HV2CZ##9A'Q[EIV56+(7@DD$@4@K_2<W,]&&V_2"S8$I21K@"Z-Q ,
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M#4NR>10[5*N"^;70FA2?.R>8S_UC;HQ]0RE5>(7/!,7ZA=R.]D*W(<8(0&C
M)B#N@:96A+1LJHR"H'\8U]](^NI6*_0T6A>@84R;0EF TQF;$E5]\*;#7)0$
M@1;*7"=P&CX_XRPDFUDL(5XQ8\?WSAF\SLA%3NTIK3&NOQ-<5T3NTM:X/E/:
M5!KF9A12"PE8;M2(MGQY68/5 ,RW&BF^.!)*R^BHK+8WQ\6X RI]=*#2UW=
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M7.*MU,P9B4N_YC"5 %-;FG04Z9TIA1@;GSE-.#5O=L?#>?PD@6CGZGD,%HD
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M9)/SNF8I/70ZG*]T2CAIR[8L7&2-B @$H'K_^"QF5UN9 (XM6U-P;#HJ^!:
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MN]=[??^Y@>,GV&V(U^S =$ 3-TH8ON<.4]]@))TL3GDYMH^DLNV+O.&29+A
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M)",MGQ+R:%KC0PS@8(W=N6 ?U07[M)WQ"" @ @  222$=X&/+9E=AB,N'A%
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M-?JR5 F4>86BG(5\GZ%3C8J)Q&YMB9H4>JWUX[\ P_ [VM/NO.PPB-/U)F,
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M"MB>L)E3;$>8AM-RQH*?.S\SN?^<#M ?PG^1Y,+^=/)CF"6ZYWV:LGORQ?[
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M\ 5]5Q'\<\!_1GQZGE\4O)@8!#BF@NE9_)6X.ZUBC[5W(&4=]A1+YC**EOL
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MT=:6U25[%2,OQ1@(N< 0:Q5B\*'#:4W@?#.GNT417+=J!4J"6L_Y5H,V\N=
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M:N"2D_ISMNA<5"M47G>"6M?E_^J_(]<F4HQ+PKB?+WZ\QA'[;.2UX\)>77&
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M5HC4%(-_S6VW6F)."C3-9'_B38/?U+G0::\87+%,+V$.M!15R<A30.%X,A7
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M!0WRJ*@"\87H9H*7$6IFKKDL5A%!'/;RH( 6!TCG)3$OB4D/*_( S.W/XRJ
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MA08#%HT<L[\=*Z$H^=[T0L].(B@(/$'\1T5'C1\<NQ P!4.]09;2N(.C[7=
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MNS>+[ODF,32V%N#Q*Y:%%S31#=:5U(3_GL5LY.T9!'VYV AT?% 5S7EEE(C
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M)#\ T)RN>+->J'H"6A+Z[DT<@(Q+\SIOO-GWK>RF$/#@#XG*FJ]OPRZ UI"
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MDU\\8'Y7KGI_9?Y%R:(WF+-Z<P:@(<&;,.\5+*&^8O.[EK<.!AA;"533#/V
M%["PIYP%EG#8.&EXV-O\@&_O\6["3WCOX9F-&UCBNJ[Z;K&KRVB!/U6+O_4^
M>7SXE;Z>P*;TJC_ #7H7U/L+\_>+)B$7A-67!T+6=4^@T08Y=Z ZV/;Q/> )
M]<302W5EWH:P.KW?0 #;N(XHTJD"?NWB"8HG>2M^A)^[>LKS\:IB)]:*#XOM
M$"W-B/5)+*R*<X/="&/%_;;WC__AEV\1?L$YGU<;V01>.JTF!-M]]"C,!#Y_
M&0>1U:\J['_*O@DFM\9#@WX,SZ_X:R@$BF6]G3#$&,<6<<[!KOP[P.-A,D7:
MC?#^&J*BAF6QN_.7_ 6O2'^]@Q5\PL3T/<6]9&CITD+PK\5'O95P4.-,A,].
M,&6$5]/=BZ?W5@76\CY_4^S[/>2=L#0/]<K?!I%J2_N)[X0$;. U6U3@BG;G
MULG*C,M9+HH".;99##\1KS7"(TKE!RKNH\#*9E9!OU  UFPHMD5) XQ^DY&@
M5PU6NU<?2'(U$T5^8)BFSV9,TYTFBOP@<20LL1SRD$O'^@+:(1&I$5>E90!5
M3_&.3A!0<(#8X$7>>B+;EW#P0@JW,2Q\*'55*;!O?5" "1=.H -_;]B+ AR+
M>!EE'A:'Z@\$ ;^J0Q!XP(Q'@4X!;8J$IQ?\*/:MAY]QZ"LZX-B7B:B_2YX'
MQ:?AC+B3-C#781?P(1=G+5IR\YN23U@>/?CL$; %A&N(^XT&/?PO'LK#MM7E
MKUTUA#G4*NOV\*$&>]<$,$_V?L=%+^"E:U?^EEX@&(@1S,-1M#(("/BVT-\)
MG"84KC9NR3#S0V8TD5O_+GW0B&$VSK+PW3#OE$NPDFS95,S/!(!>;7U,SDSF
MTIZKZDNTEQ9[;PND;R>?"HO+J9SI\ZGX41^%3W6]O?ASOX3&^,98W:/ITA-7
M;=;3YJ89>NC+1/OC6U#136,EA&8V/1!ODT6]#E,B!I5$L!T*\ZBK,6WGTD23
M/L4&CP.FW4K/A0G:#"]J:'M-E(3XPU@L0#>#4]58S.:ND71^J+JV#!KVPZ9(
M GJ:7+NQX&.95'M*FF<EL1DD^=Y%W=LZDRIX2"<YS''PF@G\,0CEAF5@F8II
M60XJ!=JR.80)</^+DO!\T@)LBI;'3MMNFK!-YRR8EDH6<;B2'67,<6]4_\-7
M.-A+6/:AD!0GV:YU/4]4_4WMTQ1>IWWCDA*Z?8UFJ:4J9@=%C69Y)!FI3+@K
M01-*+P'L3TO777$XP<^..]-VDQ#RL<A=RG57RLW2P1+*11-TM$_>NEV]IL<I
M^74L]#_ITB%FX.<(ZOFWWK_L6$N93/C\3;!KSZMA'3M0E+W@X1-_5Q?U_N"8
M&DNM*&Q)3#9RC$*PP(.$/<\T'')OY0 +3I@-;7E26*6-@*XY[+ZC"ZPQ;^@C
M-K!E+;X9%8YN.*H8:9'^^BJ40.*#H;N.)6X*/_ &GK#&$I[+7_WBX-F^%]S8
MIQVH[CN>@@[2MOSJI%&C?5&R )[U10.B!R<""D*.IWXC-,1&;T%AC\YDRO\H
M\1^\W7#LEZ\O<PEEB=A,KV,BMGC^\D37ZI/B4^ECM O_A'#8RFUK'M*+@(WA
M,'7J @++"5=A=.<4]2:NA+4G!KE/8:,Y9#</R+U9 6Z*VN_R&.F1<[E"+9"B
M>^%0;"? +K($CAG8H,.]A1*UEG8V>2'!WKBD)(#<M7]:_G%IHX]#S'9PTUQV
M^M;@KF,I"CX']^?W![EJC;ZB46$_H4$-GH0(U3 :'8LO*?16PI"X6D%8BEJ5
MTD%\HAFJ#^QA*6[3AFD6(CL%/TEX]O/HF,!B2<I S@QKA(9ITRSET6?G*/I*
M*?,1K][/,KKZJ !-S[9HP\ZS*1K_#XRMLY%Q8TN N::BRL].WZ7 N579+JD!
M)JO1_"!X8C178GI@F.ZIN1A+<%JIBU^V-3M98N%:^0GUW-/KZ8=E\=HQ9X3(
M/]DNL7:BJ^MX&7QZVC=8O.3_K2,]M0$$WZI:XE03GG*TW[EEP^G)Y_95&3\I
MA OL]KA&BG@>U''[>NU*]GX= .L0H>(RY*^AH%Q\\J>+'U_]Z5/OO"BIPEOB
MWZL,CCY<<$[2HPV*F0:C3S5<:6JP94DJQE.63MK?TMD+K6M@X[A'QXX95SJL
MSBHJCI!;?,]Z3?YY8E4'M-UTK7\HO1K>I[^1ISX\VD>]]\^NV=;C @IP17J=
MJMM:EZGGGHC@U#?@>^B%^&_MD;2?P;(0#-KN[+?Y<7?VM"Z)/976=;C8K^W%
M_D/'"9XKKA_'?17E:_VC-B1FI/!%-?(-*QGRV+??:O--1U+TR,81JWVO5")!
M!IY^<B'M<*W8/WL#3"/?#94@SOP^^)+OADU(W9PX&LPV2.>X31]9'E&(F%)W
MQ!Q(,,6%7!.B(CPY0LRNW:I81[)#OHK! ]5>^_ YDSL0BHY+-(J@5RU0!SK0
M&OR!8H?:;=X8WQA0,O&-$:&C/JM[5=*_3XEB%THV3A,#C2+)VY!E)5*K NNP
M"=0 ()62:QA4BWJ6Z9%[B@,9>I2F5 9#R&LK)DMI$A3P1L"M:I\L)%*I3'($
MHLL:)9=.86]$RPNWT_!>[?W%*I*]4[^\ZYZ[E@3($OH_U+ 4K>XO+22MR[Y\
M;9J@XWZN5OZ^X,H?^\KOGCZ)D.SOO+EX#Q>VZU?"./KU@\\7S\TUO)"@Y9-7
MSU]\*MDR![H"'4MC=+KDB[S*USG7+U6"VH[X#AA$QOU(GRFT(5P*4U(64A??
ML1 5T=GUJZL=@$^9CA?0$RPFP[IAS!5J&14)6;XB7AE8$-^3WXEXV)/_'DO_
M-&G<T4^>OPB/R6@C*.)%\GT)5OPK\?FV=E_#R[%&(" (\OG)(TAKBAR#A-AS
MD-2';(G.6[?F\=]%9_8!N.\/$._Z(Z+$9[_X,)CB*+%MKK/#DQ+"1JM11(%J
MG:6B8<2R"!Y%I,V1 ,#.M0YAUC'=2 ]+U?^6U+\"&#>/C24:GV0T)V9RI(%@
MW$@$?FP(H2/K=W2;(W"O%/[2S8@"^#-!N%(13\+HR-K'"TU3>%YKF?P5N3^X
M_'PT-]QI#+(,O<"*,9PR5;+R-W1 4-ZWS+.Z!6]5L<J,!EM+3[/T$6H50N\(
MV]57(,#DX0=FX"9 8/(&3J]4/^X/]]JY0\*.6X-N?EU?57//X2[[H@\RE/Q7
MF*[V1X66H2D&R>(PDVC:2$];;)):27$HH)CL0<+(1UT-8-Y_]4OV4BH;\9C:
M!B%_(064P4R :=_%C7[(KBQIN%29J'IL8>S'MG-[TX T;*)AR)N_!-=#,U,I
M;\"&\W@9 4O\2^IZXMC?2$I;8UG_'M8%$(@M!R.A*<E%'WLTBN]"627,W8S[
M#>W=\1@SY.K6(5>?SY"KF4;J-]WR "$1V%H27Q2@'LQ<$_@AC[5T#J;F/U"2
ME8A.6I]2&3T]-<C;AHK9]G*^I:/FCPBY4XC&\"O_K1ZMCDXK!)LBJ*5HF9$F
MG]&$L<JZ][-,=O^&7I^/15U@!E15#A0\$QWFIVY#P^>?_.EI_?1/GV:!TT8(
MD'(HVM W(MT,!Q4Y,TN3.:=$23%X&;!)^4W>AYNBA"65MV1D[(0T#8T;82*?
MR]C"IA"A#'?<R.?9V7>Y^^<6*,$HB2NB0':-CM%1WT*IMH*U>$,>Q<I**,7J
M)BHKTY%\$D-P>AH#.:F-1 1/NFCR2IMK:Q3/MGT@F:!J[?@(11LO-!-ZL3RE
M%T-S8[!<3BV3A(XU3%XJ%TF]+".E:Q1NR>TA>*"3[BDSI0E& ,EHG[])ZE95
MVO_ZN<G!M4U3+]C 7IJ:\Q2YU1B887N]3 [B(&38M79?/OELN=8J)B &P(J!
MEH8-E:,-GN)N=( VL1$V)U,0XO*+'E'=G8R@CN> TY>5Z9O*[+,P[#3QK5 E
MBGPL95:0V7F#$AE16,I;43R6GH3;@<I\+57MI\8JPZN+;C+Y-G7VEL$%UWLU
MK[83 3).2N5K53UF) O%;8U/@JE,48M)6NJO?-^&J[$+-J'[&(@XM"[=%VS!
M+X$8)'QOM:6KB]7 ,:\=_ZWMZM5K+J_-Q:<Y0+M]CK5-SNZ1=B*_7B1^]ZN_
M;JDN) +$Q488?$)#Q7 9K&0B7OVE70W1^L/1Y]#H(PR-4O9)P@:&'82E)\=6
M%N46UJ0A9S R K6;KM=12)0$3)&<E(:YY0"ALSA5"OSKLQ<_/'_UY)]GW\JD
M3F2LI49)@$.>O&ZES6IR@%#^TP.111'.DM&G\L/0;&[SC1-Q48>H)5\=SQ=/
M. S"TF'N35I+9O?-F>8"]SP@21UDV$P91OCKTT^N;L(,"^OKG'A4274T ;GF
MIQX(/0OW9N4"WI!@E'(M1I)),;?T(-[L<@ 7^2L4VA&M*\WVF+"D7F)7!Z)"
MXI-!P!RO!4?M]TL?;9?YU(#T1BG"4@-"(:5HX]=P,[!BJGP#YMHY'7AA1Y@6
MQT.C">ZO)Z$V"H'V"J[H*-!8K7SZ(/I-;2<"KHA-AO2MX7['#_O$/5E[YKBI
M(-,JVM<<+76_^_TEMR>0 7M>B=GX7E.J/"!I? #%U%>GGX 2V@5\BIHQ-6MI
M!EZ0LA8-^.24"8?.(V8H<O"L1.)$6O-9DKY41\O)WE=,=[$.1RUXP6'V[PTQ
M 1$=^^@[F<3SP@D,XXR\P'%F3FF!!2 SC" _KDWX(XGQ'CU\],6C;]Y_C'?J
M[E_ZU8XL.*C*PTR0,I<EP:1+()O\UM(=[_;KOYT8[(X%7+=?@$6^6S3KH"7%
M"CDA>1;8X@:)O%,)8/#8))2QZ/9BC ;(.D'2HKP?.6/Z&_V(HAON:U,55\A&
MJ;F-5B0IH)-D8!&8V W?UM))82!C-#'1CN^U)B%I>$5L]I=N /.W@5+HD% ,
MP#,&!C "8E *MPA&QIV0I-+6G#[:1.AT'U?9'Y[IO-7I_F8(A\ S*$MF/ZNL
MGM%VPU(0XPYU5[,>F0D-.%O)A'@TJ3$)RW0,;Y=7(.?E8C&O9EG,A77]!W']
M84&"C#_<3& ])F!N*&?:U5@'E4!=[T7;]CP)+LR]:P9W$48%]5S4VE GQ3*L
MKRK7H#>2+=J5OQ1\Z=*_S;5,@A ]).(Y<2$0:0WASY1#B<F<Y;#* Q-#.#B5
MT_F4DHWP==,HK$!4^16<+[ZC$7JX&!S%_[_M/RF\-@7D1*^6)6Y-^:B& B;
M%#J<5  T<:N>?E^"@ &/\TAX0HOM#.D5Z0GD;%8RQ%X4HE;S4@4Z)T(-O_%"
MPVS;Y(<;81W(0N%6M#,,HZ8I9NN]\ ,7'+/$R()_HCJ]O%):!@$I;X0U_-E;
M=#_*.^Z-/UY,W2T[9#;UP/SM\_XEY$WJAB5'>A\HT-@"5%P0;*!YO!;9AR!
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M3[1HGFFFT0_;+IJH#?=&[!MKQVP4F0)() F+VVSC>(.E(G/8<H4KU:CE#&!
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MM21T*)48/?<G>_@;O"_2Y OZXC$'/0]DCB);1& :&W"4F$KW&AF&[/*92X<
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MVF*H,_*,7U/9X[@A>08#F@X UC9T?-EVHQSD#(KG9A))H&) %52&86EJU\@
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M98 ,?&"J7^\T*";UG*872X='&VC&V;:(3H'3OU6VICF632RJ6YN>@6)B,T'
M;T0DT94 ROKN"L0Z*)4U+>@&S,BI3\;#/AOCR*;*+)_"U8W*!77Z,#8;C030
MEX*DHC0>1JOEN%V-6Z0Z&@)AU)#_=0MQP<O0GZI:N:83"EHL?WD*IFUARVHQ
M;NE&C;A#@<2,*G(PN(AB)/?(ZZY_$/.X0S(N)B8$_*B:>I^ZLV6I.QV?NK,Y
MJ3M;*9L5B&HA2&OHY[V*4C@8Y*6':HT*)8!JF3-<:4(HL!/=OL 47+E8N:8(
M"UVF2=9/*Y']'876!:60&<Q@<I+U)J0E$2Y6"/+-QM<)G)V$*_*:PD)\_NZ+
MN5 KV/H(KXD+CD3A/EVI9E!R=]6,/PEO<$P \=.)_W,\;S,Y^83 9.]U^%J,
M"?/?[K3R?:1H!X"I%U,FA<P-X+C"\:1K>Q1]L7VZI/9?5Z.Q4C<08[^G3]-Y
MA_,3@OU%;"?[V51[,]<SC!#N5,)D^YM-,,2FZCU4>I=N'.9 \F/NDDTF@:=&
M;/YA5DRN:RY(8>K"OB@%!_6/2/40X  TPJ(+%6B;TW")(4J:^BU=W*,!&XYN
M=H351)1%M8]Q%H@-3I99D0CC[-%U-?H@>$?OK*I96ZYP;,]>4O2J$5J3/:'5
M3:$[30GEY:Y-(,I,N@W,,)&;:(CM0&C*>/P[P7YP4XU&Z"\'^KMQF,<1IQ]!
M<B#ZV'9[^#GZ#T:/62[UVG"6[,HUM>0U!3"WZZI=/5+P21F GVQFQS9?N=]\
MOW29X">-IO>;*(GHVT#"UL#>YCU\M-IB,R&T>^%N074R*.2C!+7U09['5@RI
MT+&^[=&=SQB)Y/_3.99*%DGGDI(5?!Y)Q\515@4ZBD$A* :B&_40_9$ZGU09
M8Q5UC3JC7,V"+F'J24$]$+!#,CI[1AB*QW@'-DJ0H.IT60PJ4:Q]W,M:)H;*
M9:+;2.+P4E>S,NH;OLBJ4O6\46>Q%+#1?4,*]OPZ'2*7"G/6V9P;OL_[QS-"
MO2')AD(YN(P2QL#'?3Q1BB2ACYL1V]#/:S*%_JKB@4H/=-X1(DHW*T.$+^RJ
M6]ITPQ_$0OVMKRP3FFO*6%,5%Y+U,:8Z\YE.2M-Z$;=H51$YN,&27H7H\US-
MOPL9+P^1=\1%;[YCE@.R52)+$Q^$HP A46"[ .ZM1C8+A3Z9^$WV260:$#,,
M >6^XGKJT86Q!4JAK'/0LQ/%3\A!"NQ<59<@*:'7E!*\;68+:?,5J_#&,*F3
M+P<^>1@6:6Z+89X89\9/K8)\#&C@L:)DAE>Q%ITB3JLSZ2NT,(:IP#]UQ<RL
MM]E)+J/9ZY!2(*F/5JK[.YL<2'Z]>J,-"TW)7<>+,K6?)NAE-F.88 R*I:,^
ML?IP*K\WU-V?*06+LJT8':";5V5]V]1I.AU]K)R'S1", \!+\ZQ?XS=[7[[Y
MCE;>AQH3V&KOE/N-(9JRPU#4L736V1<Z$,R6 -CEH3-D&;C4 ?XW^0@Z4NW.
MQ(:W51F!DPO&C_\;KAPNX6IT/Q+3:[12JG2S^VW@#/F>H^%4>%DK&::BK"Y1
M6H%S;!;4H^8HB6O9&.R?0/XDV:6!/RKN' M,:$H0:;.=C5ZR0%H>E>EQI,A
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M7KA%1'QMQ=@.-!'82K_6M;$?@+#)@6+N;E9O\'[+9>GZ.F)R6Q6",&[05L'
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M]LE.0@,00AGEU'M3NDC=C+,2UP%#?JPIQHWPW=.(+.@,8P3#<#IDJAC ='#
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M54DR50^AO@WD$-0I]?C79 3S);TJ)\E;94F9P'MA41(%#&EM^/7%Y?7'?\@
MO@=S!20W7#;T\BRFVZ.U7!9[\GWVY.L@*\Y2;IX-<B1-K1ND]' $-_,MTYRZ
M_/$9U"&LXE%3 DHP/N ZK^"WXR('+:2<+!H$-H-L:]C+@0C&R9CHQ9.K)]=I
M<(X@%E,4F^9W8%P6\+ V9\,@DD#(("W[1%XI/B_QVP1-5-!^T0P-B53YU[&
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MA/S7]!J["2#5YR,@$#%$LDO38CK2)=AQ RN]_H:FI,I46<ZH PCV4HT0$R3
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M8/S<GNI,Q;GK^7?W^K0-PU;3,"RR#</6W3!L#R3.IT;)^+]BI+M=&IQP-4Z
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MK#G\5ZT73]HEN[F7\OH@[*74>S_QHB$R H7EQOE:(D856;:4?ED<=0XDGT_
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M)?$LWN 6[2Z]Z5&9##/"#;HQ1/6M;1@,'NF);ZJ.5S14BL/71Y) @9/)L(U
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M &;E 3"Q#8!9=P#,3DD#G4>'QVUP0>NLQ \_=QV63=3DY[/?VIC)V@<#$&;
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M6M<;L%760=F*H&R+9!NZE1;)>D*RB*9!E@A!O$AXV S6)5&61<1//.5*D68
M2[>13&;*39(D(G$*_W#J J9Q-R1^*"0/1)**(-L<) L!R0)ND<PBV49NI46R
MGI L]*F7RB E2F'']2A5)!9)2+!C0$)37[EJ(<$XX,Q3@G&24$_!/2H@0LJ4
M4$DE=X/ %=D&Z63<PYSC>,^1;*W];/;7V->UW1M3WTJ4?C)4;0&F/2G Y(6Q
MYP>"D9"#3.$IYR028/&#/AUE">,R#L5M890J+%&7>D0R4*:YQUTBHC@E89!*
M[E$F4H]OCC!RHT$<K5 6[4R!)HN3%B<M3MZ!DW$8RT2X@@1,9:" <Y\D,LQ
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M;-\K?%N VO>MW%& 2A(FHS3SB)NHC'#F1D1D"2/4YSRD;JJ86$A6?8HQOSJ
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M/5]\<L^75&FYI,(*Q IT*+_U=!;.BQWJ8GE+\V('MEC>TKS8@2V6M_3 %WN
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M6LX6Y:H0X3?5/*M7'Z]G#>,O*;<O7<^Z6H3>"EO-5)I]%&X-7Q\8; ,1Y"C
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MA$P(2#$VKSD8K[=NZNX;9GTYVHPOQM=X!<GM1UC(AQ$R*S#['SO['\;;HI6
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M#UUOD^-\(OLW3G=8_CC,$^9B72*0GCK'6RE(DA"J\AZ3;VH8M@I@8VB?]:$
MQ>S *&K.>L((Y(I,)+++RGUJGC;-T59GE^O5&N=E-O_E=R9JM7GU\U;JZ;.?
MOF&FI/)3)\P>S-1M=LM)&:J3,2K,QMVJG_^)(=D_)%'[YG^CAA+4IGU]A*!2
M^V<6VI;B:M#]0+*;?_AZ<=Z>^NK)WR]GZ_<].?)2!:8CTW' =&3/\=!0="DJ
M%*@@1E)@7!*0C,G@* :-QJ9,=6N<1Z:<23@H/G1CDF6 I$6&Z*2/ J746/<%
MQ3I[1P7^0<O%YG2+:<@T'"P-V5=\,"S*$+QWWD((Z,&$*"!63%#0NBR"H"HM
M8Y&Q.% L'G7"]8!8O,-S& 46+37RN2I &-_"8>%+"X=C"Z:5E(JD+CZ;3[%8
M5',JR9H6,VO=4)H]I& E5&LM8A68X];PM_V%T%,K1?MO'X'T;38+,Y(9R8Q\
M6$:>=*N3HHWVKB"0#:9Q5QA(3ADH.0BAJK8U;B4Q0VF^JT0#3G3C=;QLWQ.M
M %4TD2_."8=]$OAVC4WLU.@18OB ?=V8Q\QCYO%^>5R3$]8A@JPMWC<B*,#H
M.M^XL1F%D"3+%H]K-=$6!5EAQV/1OL?ZAN=(!9T@3<8<GL=1F:F,>QP[QD1F
M(C.13X'(>V:F$$E+(7SS8;LS)ZDBQ)H$Z.Q58VFB$M2GS$2TA5SM7%[=Z%IR
M 114P)&NT6@3J*MP.E 6P08Y%5*/#Y4'J*GEEGT[Z-G3U>JR*\&=+&HWQ_'-
MHONA;?-/+B_:A_2.EGFVVKQZ]>G%1;=?><#CKOIY"IIWTNUH]VR!<L1:'0FH
MFSRV10V!? 0?/(82M5.X=;QGH\YDBX;J2E<IH1 BD@-TP18LV3J*-Q:HO,5W
M/]PHY5E]O%')C3GZ<U/()]?Z>%8WGSJ[4L:7U]6SO174!BN&U#>6;[<QRAAE
M6RBC7-.F-*&2SMV #M>PA BZ^"(,*B0*AT997X=UC"_&UW@%R<U'6,B'$3(K
M,/L?._<)01%++ F$S09,*!*0M >-R09,Q2JU=0#B=<PUF@Q%9 U&2X*H2W-"
M2BC9!-1>AL/['_NNH1S^AF?78R""' 6YM-392RTAID1@A(O0L"0A5(5.411.
MR4_)E6J)1E@'BC" Z6IP(DD!(B>;*$MG2!Y!Y.2FVG'RAQ$V8D$>A6/-T1-K
M*VLK:RL+F;5U0((<17A07/6IFWQ>I,?N"FB$%'SG[WL=O)?);U<I:8]:11&
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MQ4DWAA!6:94U@DNZ@ E>0)!!0O HL;B,>GMB4'_510<)6&[75\)-M1]4]'+
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M)L1JM'!;L4J//>H/0&LM[33&T8VB8EHSK9G6A[_1':50QA"@KQ4,Q>;XNN1
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MS&RTOD QJ=FH;#6$H!PDK*60M%&;>[4-^+3#S*N.&R^NL/%J\8S6+SMFO/R
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M,;'[HP]'WBO@O^V*O@W;_4I5:@&3?_KD5?/JR;.C1TJ4QU+6N'\@LBZ/D)_
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M@3::UH2N9Q+7'#YC\$)V,,FG3XY__?#DV:9(0W&&@:Q3!6/P,PP@_YLP%T'
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M187,@+#**HJ3NV"%K]_^>FW:^B$A[/7<\.9\:W^3?;0Y;Q1XV>Z 2 XWTZ[
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MK-/*.HX\TU&(/N>2LI-7%XT6-Z8&$0<8IF2C&',.C[J3G6G",/!H7]BD 4!
MEPUBI@JJ7@>BZSO,S%Q5O):;7')31*2W*B&BHPB9S)Y80W04%T'L)WZ<%GF0
M)-$W" <* *0O[D-"?-_9O\$KX04F#OEN\^[->@S(?ZT;W?S00%MK%#ME&(J.
MD&&>V8H*6TUVF,.<P*Y^L5/,3 3W" DN- 3W6DL#4PN#V8"&((<2&Y?%&OC?
MOADY.87M3U?1:N7@B.ZDR]DV<5NJ[F>!@3-#\7W$S8BR'3/%9TRVI6C:MJ%^
M* 9W97C(R&)J8:J[<)<HVE:Z0ELG4,_G8RR/W?<*I=)TMZ:[17<G,G?KCVU5
MRBU<HXH>39- 1BM-M%3B3U1I0$HOC<9C7W/"82;5>(Q/\04B70UM$[7OUJ 5
M*=V1"P-U&@/6P[QA1&<]WZ5_;M3B'=VB[?(P\\F/KZX?$:"F=CI_9)0A RHG
MEI"1/MRKPWTIV9</V3$3;)T@549L/#8HX782MNH0ZR_^M8:K14:*"1ANX.Q8
M@P8!K(F(W:H;0\MC_&O,D-C\4F4U?@+A-26+.ZG3QA*O6H0%P[A0[?[T=+73
MB_<5 ]]@FE<FLVN/UJ^ML2>U2TL5,A)!EK) IIS%&:9[EWG&@BH+,QF591Z+
M6W5I.4Z+/^'$7!:G58G?1^&:WS&K!_G,STAE;ZR=_-'8Y-U;M7I"0*<TMS_^
MYX\/KYYX&'B!;T=/@!^)^HS/N_]ZPN GG3OP7T]JN/.=$L\7Z[,+,+4[M;AJ
M>S*59U45E*PHJX#%J9\PGH0!4Z4?J"B*DS#?PAX)_"!,PC1G4E09BX-,L%RE
M&4N+**F"(*VD$ ]N>Q:-];':'?KKCE_LS?Y=[>_;=JM[!XW1?V=>2!P]VH;2
MN:(9)#U.F8>/M;#JXRX@$RQRQQ8FJ'$ 4U>Z%8'-%APR>9S.P<[?W>)=B^V^
M)60'1Q&";#4+7<ZU@>-5:ZQ\&^(=9$QITES[Q[I34,P8:?T+3BAT#Z3-Y^T7
MKFCNY%WAM3[4RI7;C1KE(DGA6H.XE)+%A4I9$6<^2V4LA<HD]]6MX%=]$*=*
MKN?J7=5+$ZU8'B_DFX'BS?[+=QO"XR,2_0W*K7[\6,)'UZOKZ7R^5AG\L^YJ
M-=EVCQ]R;HVF^G23?SDPW"9;T.8N/QOE3KN6F5&0S872%<Y/2>%MUAV,UST[
M% ?TH24=W%K]I4GB^$]S:-MN&;Y>-2],!@;.!Z,",'U\G,WY9;->/:?&5R]Z
MM\.1_Y-]@?KN+COUW#:LM?O0$J.CL9\,B22K/I$$81&TWO?<CN$\"$_*L;<C
M"8Z*Y"?,,[GZF>":OQ='09+[PW^N>_[:OQ\EX7<.D1]E63Y-XYNG\9]_6;6[
MR,ND&J%*4G+QZ:0%Q4HRPU<J^L\+M!-T+M-SG=&$O]C-;793YKEJ*>Y@KKF^
M^@>3P?05:4DK.5X?[!/^];^>A$^^O-8^<<OFV2U7'M5Q>)9Y[YCYCMW);VES
MOB^!SM7.KHE<?7'[OG7+-%WZT4%LVFW3U!<WY4=<\'2)KHO&39=HND33)?J^
M2Q1-EVBZ1-,E^M9+]+%9#?4NTQ6Z 45=8W&1G;-M<@G8BDK<NLEU5DLY5_LP
MN6Z3"+>"*K=SFW\ 0W1:W\->WT2KT_H>ROHF6IW6]U#6-]'J#[&^;].E[RA\
M<?BZ-#U^';B%WG&=1##=H1__#CV*]4VT.JWOH:QOHM5I?0]E?1.M_A#KNP.?
M]&Z5V<TCI5%W+N)ZQ=K-OZ-QW(']+^2FWK?>?=5Y_-8LU&4/#0&;^F5=>\>1
M+YI=>[4_<AQOQE7K_H^O7>951+$=;APB-W>Y=,K+O$5"V%V"5.91F55ISGBF
M$A9+D;"")P4322!%&:N,Y^5F^G@2B2A.\I@E<2!8'(4!XV62LT+ZE0JKH))^
MN9D^KLV\'=!#WU1 A,5#3#8K9IYX\M<@"F9IE%Q9-?10B?W[Q<B#H_$[$J>'
M?,H32[O-HM.RS/.JXDQ(X$QQD!6LK K%TI"7,J^$%(6_Q=) Q8BJO&2)S!6+
M_1S8(#! EO. QU&15+&([IBE4>H^^[=JFR=_91,?>_B$/?&QB8]]%Q]3N0QR
M&3,_KB(6\Y+8D6 %&D,B"X- 1IM\K(SA;W$:L2)*2Q9750&*G9\R7XI<1EFB
MJE!-?&SB8Q,?F_C8??&Q)(Z+PO<5RP.%B!5YR+B?Q:Q*HS ,2UZD4;K)Q^)
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M?,LM(*(LB9(<=.0H 1TY27-0CXN4<2["'/3GQ _"^V:@25',8/83 YT8Z,1
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M"TE/H)%[KN"95<NEDD?>QU/E+8$XZL4)O* M9C3VX?]6IZI3SBCPSV[5KO6
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MM^X7FG+%ZP7,I6J;,]B=MF[6'2RO;B5;\A:6#BO@\*'F'&;8=B1U:.DT:JN
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M6!JNZ8_SZ.)U8V#SW8UVEZO]U%<IW@H17NR-9JV,"^?2]&+P_0WZP$6?^NN
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M">=N\#&='1B0;PNZ7[#6^H"BCSM^F8V]^S? Q]_U\"?<N7UF'$*CCXR 92:
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M,KM3*__H614K@%8 K0#:;H.A@(:[$QR2DAR$< J<H Z89,'FE(AAOE6COT4
MM5VQV_9 1P^@=]+2GFR1]4.$NZ=>_-]Y<"[N9RAZ)O,#-P%A(Y3L.:\1'X(!
M8QFZBCQS2W(0BK1"G_?;J##A3JY^Z[O!Y/4@_O"O:>^R4$ZUQ%A$3<N419+K
M0^(L:E[GR:1%ZAA)BQ:BTC#.+>5DQNMZ%XM1J_LAE)":<Q02=Q[]$R7!JLC
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M>DN%7D?I1O_L?'6>3]QYIM01*Y*"8"PZPJFPW"C%@;D8<PY>22UN8Q^AELA
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M.8!ZW-*L(Q#F>3E+#F B8Z"]XC(($0W=B$KF07.@S<"LLEW**H5A]8;JDKX
MZ)*JL-:)"-(5YE6)/HT+)(%5EE#G]%TL6*UZ,JU"E^Q2:BIT;>"EU#.EU3S,
M\;CC0IA>3/M-;\V8\#NAYYK]4VH9W<40A_GOYH-ZY% '70==0Z<U=#J?MV];
M3NJ])R&&HB7"A 8E7$ #AC#PR7A@*C-I*;7"M)+']_I:#[Q=40/X<S^5']"F
M>;VB#>ZU=]K*^J-=PU_FN=;C.B\\JN5H=>DJ2E>4W@%**QEX)-F 3LR"()J
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MD6 ]$ER;MV\74[;5<(@EC"MO-:0D2U!7,' ^6U!<..Z\$C32K8=#_C:(O7%
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M7L?G1QQV?WAY,=?M'T?NXH8]5@C]&W@IOUP/H1EU,2C\TEZ963?XT7P^IY>
M=DK1>"GA]2A9:3P9#M)L^*/A%=HBC7TV0$";=,8(U<V#YA9&&5X/97XV[L;B
M*:\PG]=X8^2X3AGOB@/$*9G-]E(L9K/[L8SO,>L_$S04X<%P@B-S8UP&WV_&
MB:_?*]P3\>RE;OB_%ZMU/"SB>%76K2SDNNBO"'HC@Z,T3@Y1'_^*,SB9SK?-
M8J->_WTX^N@&O7\O*#D*V48?E3PJ<?SJIS+]N/F'HW'IP_DYH?F,_UU>L60%
M67%01BC*'\[3.-W8?*.95/<&#43-/(!&-#Z/T"5"\Q27'J7LK//7-,!=WN]?
M+2WYTA&T7XA!</Q%5<UQ)F7\9=(0B SBS*MHQ.SF>"9%1#N70YRD!E=PTCMQ
MMA-7@0M_&0VG'\_GP%->9<XO\F+E[EYK>P9*"VO[$N<R]"Z+ZKAH**[G[A7>
MJ(D1->P?:=##A<-YQ2=_^\V;E3_]6C[[YKO#M*V]8R9KHR$YBW8R"0*<(AZ"
MR8[F[&6R\K9M'7G*@BF"W^$)A$D.?&0!(C71<>9)YO9VS.]M\I.?<)^.IF6W
M_(AO_+J9RY:,:\;DV?V!O_V9U]W.C'VO;,:(4W!-DXXR='#"H+0GA"8"7C$'
M@CL'AEH*/'":E4U6IS7"J<V%X6_X1X0Y'')<D+RV)15GY@!EHO/M^S1#!71
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MW%*$648,<BJ;HX$1I(/5B%+A<,":,-8Y_*( ;#SIB'"*(-4BY0(M9Y'T00H
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MWQ)GL\TX5:.+9YT@6L[7'8UBD_ '/P;:8'ZQ>I&U";_Z:)WY"W;"O.0B?EZ
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M]I2]N>RWM"\*6WIU^)[]*I_?N3RQQ()V947_L>IDM2-/;_7ZFS]RNW!W_H$
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MW[*9VE0DPQT_PSO9709N0]]FVR#6NA7Z:J6*L=KNB";AHZ0!I,6T(9*;A#8
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MMO=H%'/+T-E\$2Z.U@];6VOCR9]][F]BA!.,6^0# >,D\( L"P%AYHU-N;:
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M9#B;+?I8)2(,3@0'B8S' G$-QA1L?P]:RS&3O-=&=QIW.ANH<-(AQE6 >Z)
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ME>!LR,:V$,6&4[AXH:6W19NB=[1&IHWKEPIYMR;M "&8F2?3F.ED,S-)(8T
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MTD@YUTXRCR0Q/--&@31&S9 *.D1'L&.ADYM]-VE\2-HHVB_RH*?[Z14[;5:
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M8!$G )Q:$@G Z;C .(GH.S%@$5C E'.4A/5P3Y3(D<@1,X;SJ"55E%;@?-G
M65WU"IRO&CB-I]A''I$G!MQN Q#JL$TH.*/ XF18IHZKKGUT,1*+F+5@I3*E
MD#/!(\F<"(EC'!6OP/FR@;-:G!4X7S5P1IM2Q 8<=)<K'3T+R'D=<GV/(TY3
M9QB]#)Q&XB2-%4AZ6GQ\@EPN M)*&QN##]ZH_IS-":V.%-850RN&5@RM&/H0
MX<ZDF&$ FHJ+@'AF[S%>:Q2"]I3R8)W2':^= $ E%Q 6#CQ]Y@RR#&-$&+4A
M80#5T*,4_(JAU8&O&%HQ].$P-%"+/:$)&9./?_*YD4M8(JL#>/8$1T\ZQ>A&
M)P%?,!1CP(B#L0I6+#CPD24>E.1@B3X=XT9UX*OQ68&S N=# Z=7A'%!!**R
MT X)C0Q+#C',%.8T^.A%IS3*"Z>YC0@3+7+D4R"' 4(=,R%IJKVE/2J-@M<[
MHM14#*T86C&T8NA#U-![C4,"\U$;S1&/D2 G(T/!:LYT%-JX;NF5C-9$9I&T
MQ"#N"4$6.W#ZJ0Y)D62,$15#GRV&/A:1?*^# _?8:*7;]N#\CAV0>STK3ZVU
MGEH.:FW<(4GX+*<XQ(22YPYQ:272U%!00M9K(WT(279CQSI:@1E24GK$+5/(
M@0)#8/$':I@PGO2H-JXRC5;3_#DL: 6YAPON$BT]!9"S267[F@MDO+,H41H5
MMI0'ISK!74; ^HX1<9V)^PS&R-F@41*:)Z8BM:^C'J B6T6VBFQ]138E250!
M[+6D,DI%S<$4\Q0YD32U(@;-.I&#:)S%20">>9<0IRDAYWA @@:!>5*2L6J^
MO0R0JSYJ!;GG#W(BTTQ1+Q"6#GQ4X0DR@EADI/!4,:.MZC0S$YAH+E) A*=<
ME<09LB)81 13VC)"O.P1R%6B^&K)/8<%K2#W8"!G76+$2)_3CC3BCD7P5GU$
M M.8B?F4\1V0TU(*93A'@(;@J$H6D#:.(!NYY=XG"[C2'Y 36A])_L!G0!7D
M*LA5D.LKR"7C/(V9"=FG7.VC,++:,"0]MEP'+2SO@%Q(F4C9Z1RRT[FO&3BN
MG"@DE U<6N>M?+I 7 ?D%+BKDE=WM;JK_5[0"G(/EQ%)K0XI%]18#8 5C 2X
M4SZ7XV!M':?)=6K!;1#<6O!/8\H90(XXY 2C2'B#E<,64]\C2Z[2C59#[ADL
M:,6X!RS;EBRIS!$$P 1X92VR*@FD(B,R4P4%WVEKIKRQD8F <EL,E(GCD75"
M((DM6'%,>.6>KO7VTV0L5I"K(%=!KJ\@9WC WGF/O,FD/I@89*A4*-!$L E!
M4M])&Y&<LF@I1PZSG#L29>::]P@''#B1DMC4HW,'SM01-A7DFK%5XOA'3='^
M.#^-TV5J=@TAU%JB^ZFD6DO46.;&&NPDF.(N:C#/<\-ASS"R43KNE0@V\DY7
M=4V2IU0C::Q#G'N&C,@!C&@%SP7QU#U=(7OWL%P=2?' T8>75$I4C?<*H15"
M;V/WF^B(SF2>.(+=[[A!6C*/=*(Z8$(-=1T^I2!%H"8H1'EF00[*(9=B0H)%
MD4P$#R+VZ)2*'#%6BS$K@E8$K0CZ,.%AP$^L=":CRQF;SB+KI4'16LV8MS3*
M3L<]'XG''DS/0#,3*.,DYP9XI*0/G&%J/>O1$1C11T97"*VI !5"*X0^2&&V
M8%Z22,&%EPEQ+".RE#(D3+0Z<&X2(Y<A-,E @@)S5<32OD/EUG$Y\X!&,$$Y
MC6"']@="]9%2O")H-4(K@E8$?8B,>FHPXU@@;RS :-(8$-13<,DY#]PZRG&G
M-E(1JI,'YQU3#&Z\,0'9J"@B)CBA%&;>/UTSHVYMI*SX6?&SXF?%SP<)@R9/
M',L6J!8E)S4A:YQ#5G*C4M0NQ(X3+S&.QBF>D[HD./Z1-2D31A'%E9#2&-L?
M_#1'F%52^>K#5P2M"/H@%BBXXTY@BQA7-B>#&>0H0*(S1DL3I#"ZDR4K$F"E
M(QS,5)$/DH)$)@FP0*,FGM @;.H1KR<Y,N2!BYU>,X)6&[0BZ*M&T,@LP*'4
M2$K 0'#:'7+>>Q0,N.,R1:Q"!T&=H4)@KQ%+I1T27&Z8P4@'$2310C/2(P3E
MM%J@%3\K?E;\?!#J)$J8-BZBJ%7FA_,862$CH@(\<2(!/;NL(E$R[3!.2 B7
MVQK!C2Y:L%]=TIPFD4+H4PSTB'%6$?0Y\LKWI&;J#KSR;='"K.JI@VXM>DSS
MW@J3A1O%)]143U-3=Y.Y>!5*BX%JTE(FE%@" YZ;B+0S 25)M78>:R\[!W=2
M:1VIEL@3[L'HQ^ H$!80C=%J(RS3-O1(:3%\9!Z:)>9*>7IVBJM":H74"JEW
MCJ-@ISQ)%D4>!.(D%X2!Z8\PSO"(.5:RXP?@@+T4AB.O<BZ$"&#\<6&08\'J
M&(S%JD=G>8]>TE !M0)J!=37"JC!.V>D80C04R(>,/P->XQX- Y,5"Z5ZG!#
M,&49-5BCF'+?I( #@+#,G*V21N:%DJ1'@$H9/:+Z41/,*J162*V0^EHA5=+@
MF0L*6=CUN80V$[V"M8H)29$3^+1;-.8(5IQ2BL!^58A+%Y"1G(/;SZ3!6%.C
M<7\@E3!VI!Z:.+%":H74"JD54HO;+YP%.%3(^YR.*Q-& (@.>>PXV*E4)]=-
MG\!>D%Q]RZ7/?^B$G+8<!4JMB8:Y:'M41):;"ACRJ > %5(KI%9(?:V0RHU-
M1BB!J(LN6ZD>:2\24IY2K[00(9K+D$HPH8)*C4)I>T#R/5$J) T3B1"9@N\1
M*:2B]$CJ"JD54BND5DA]!$CU1##!)$6,1X.X MM38YIK<+7)**N-PI<AE9(@
M?!(2P15P#]<&.<[!LA6,&2U<%+A'?%L2_'Y=C_LKHE9$K8CZ&*%43B,V,:),
MMY73?AT"*.5(1'#XJ20DD@X)K*%1..TC2IY*0-0 ?G_,_0@-LTY2*9DA_4'4
MW)Y!"E4AM4)JA=0*J0\/J4YHJ7,;PB TRY2&#CE'/ J<<26<4L%U(-5Z*IP(
M&M"4!\23@7N88BARP%B,16")]0=2.3-'G-,*J7>KIH"_6QC%?R[G[[<%+-?0
MP[_#\.N-]@/1\._'+7.X]#)7_7AS:7[RV^$<?M3OW4"M",\&"81X\*O]YV0Z
M6,KO;&#'8?!A,AI9$ 5;-M@G.YV/X:O-65Y-UV93"WX,WMVWEU]Z8P9EGR=P
MWW2]'XT&DS28+*:#__KQTR\_?W[_#_3]8 8[>#88C@?STSCX^_'GXX&=QL%\
M,O"PKRQ\_N?I!*Z J]HYG9W#1K:C^<4@#&?SZ= MYA/X"BZ;Q<'Y=#CVPW,[
M&OC50L G "5QD"?W/)89'L#%YWEUFT?ZT7 \]+,CN&0>3V"U8@! &0UA:U\,
MQG'^YV3Z+_CV'';OT ].(_SZZ?*F\@#XV=ED#)?D0?P0SV&AS_+/P'!_B"F.
M9W'75_^(H$/L>#9XGY(=ML.;1ACU:'!^:@'"_##.C@?73-S?(EPYOEC.VV0<
M-V?F>"EMC[_@@TU!!W#8@PQ7/7JEI5J4:964%B%S/7J4!"59X3!DB%4H,"N-
M"-)$TDFAX#K)F-T$R:+*78X$*#89$;$VP?\T%J+3_.&S/XUA,8H?4[O7O[\H
MVWRUR[^_^#V>3T !C$\^QY.\L+,O&1V_P.]^/YKX?WTSB*"DSO,&GR[B-Z]J
MPW\!B4^ @),_87H&16L,9HLS>%=X[&Q3EL^GD[#P\V6]60.HT?K3I=S/3Z<Q
M#D8PRCB;;^SM-Q9VS> \3K-!9D]BOGY>2M<VG@X[^/(O?/?V_B!,#[LF#[4*
M'<V^U./M@K1V0?.RI<F2!=Q8&C#Y?6#U\NOGR]'(7DP6<_B)OV)XU_P<P?@8
M?[N\P6>5=SZ+;V<9ZP!*E_-0C-GFV>M2RHW*S*_#V= -1\/YQ=OE,_;57):?
MY086Z-MWW_S[%=>0XVNON.Y[=BSHO1_RBE_CFD)<??M"W)T;9;>DW(:H2S\_
M3_^E#@^D('_[W[XA^)L]8VW=K!TO]H!C7WO]=U&F?S82[R:CL'=R_D>TT\&/
MH(#"'=:_1W-R0(GH$X!<&2I\R!UVCS#/X.Z2])J0Y%9$*B\":WZ(/IZY.!TP
M<G1W&;D):4@?9JXB4D6D7B$2K8!T:?8HIJP"T6%\@;I?7L5^H76_U/U2]\N-
M]PNI^^5PAFX)27<M70]3D?S!6?2NC&X=+.7BP*;N+Y=.+!ZEY<"#3L93)RT]
MP9 ?-0VM'TE&AR\G4H(E1@G2UB7$-=?()DD0IE'IJ (3L4/,I(S'R42',-$<
M\9"[JW+FX9])28YC)+Q#</UA,L[3UF1<_#Z<_>O3ZFR0;.4/G2^F<95 A.AF
M!A&]CC'D@9FLGQSB]BWMMX^2<EGAJ\)7W^!+1>N%,19>4$?$%2/(4JP14<E&
MZJ.CH5.ZDX+'7 2!DL[PY0)#UIN I'#<*"=QLIW2G4>!+U+AJ\+7LUG;"E^'
MJ#SD1)FD,@@8Q"TSR!8J-Y6D3I3@F#K\&-*2* #!$.?)-L7<ED>5C3%/;9#1
ML$Y2=X6OIX"ON[GI#T1V_RS=],\1_AXZ^8756W^&FZGJBP,PTR<3N$@2.1DH
M8+]52#.:FTP12HQA8-?ZR_HB&"P,5F 3!P4>/O4)&>L5$LP9S*,DCG;(/QY%
M7SQP\>23(UTU=RM\5?C:A"^MA<Q=GQ#'E(']2C@R43GD L=19>-5=<Q=A9UC
MWE $;CMX^,Y9I -A*"G.A<9"4Q:? KY(A:\*7\]G;2M\W1^^C"$V"$81UE+D
MKO09N41"42;'$TE:4-(IP0Z97DT'1 -@& ]4 GP9,. 20)=E0@;\)&<EY(%[
M53P_^*J'ZO?=-5].A]/JK%=U4=5%41?86TF\RN3'#-1%,&"Y$F8SK9S@S'C&
ME>ST/DTX:L,X4L* LXX-0X Y NED.>9:QB@ZO4^KM5NMW0I?%;X.#%^42  B
M\+D=UIDTF!/DF";()&:MSY%#Q2[#E]<^&6454C[W(F)<(+B4(4I(P%9'3$6G
M'<:CP)>L\%7AZ]FL;86O V0&.<DQ 4LJDIP9Q.!OQ@2!*"-:D9B_[B0V6J6T
M9"0BA3,%I6 Y,RB  8<CM03\=:([37RKL_[4SOHUQ&<')3ABS%,I+=CG7@50
MBC0BK9Q'C#A0>8%@CSOY9B*P@"GG* GKX9XHD2.1(V8,YU%+JFC'IN\-P1$Y
M,)M.+QB./IS_;4 PT0,;_KGX:L<=&J)KB8ZV^./.6_ZX*UB/KOW%2GST[(F/
M!#FF\GJN'\KO3_:#L3#K__2]^8?J.U6"I$J05 F2*D%2I2/IS7%2I2.I!$F5
M(*DB4D6D?B%2);"H!$F5\*7NETJ05/=+W2^5(*F'^Z7F<M[7U%T1).TZZ:@I
MG<_PQ+4F%=P_J2"FI(G&!A%),.))XYR9:9'P2BO*@F+=E$[#G'*2<$15KM>/
M-B*-O4#8,1TLX=K*)ZF_Q#6GH*9$/9NUK>AU@!:2RO&@%$&4E)Z03""=.VW%
MJ+#!C)O$1*<[E_/<2V:0\J7MI#3(L2 1#X+J0*RSZ4GJEWA-B:KP]7S6ML+7
M_>$K6,D-411EI&JKQZ4/R%K-HL8:!Z\Z7&_6,##-<K)=\HCG/YP4!AFJHA<Z
M2*5-A:\^P%<E2[KOKKE,EE0]]ZH\JO)8%F.20)SS$;$(QBQG6" 7 D,X4D\#
MXT2IU"D'L%3BD$!Y1 [V<@HILR1K)'AB&B>G)'V2:J;JN5?3]_FL;46O WCN
M)DJ9@D.,$@%>N&/(" >NN Y"N^1I<OHR>FF5L)%@\ I,*9B^@H#5JSVR0GCL
ML0F*\:= +R8J?%7X>C9K6^'K *7D6 4<O4,2*P?&E\/($B41I9AS;+R@KE.+
M&7!@!F.%<&XMP0G#R 2N$'=41^]U5%(]"6TEK_!5#]L?E#BI.NY5=U3=L3QR
M-UA:P H4.<Y.N.3(,1Y1TD(1$PGSKD-#8AAE8"X+%)F+B/,(^L: "^^4$=$2
M$7 FZJN.^Y.KCFKY]GAM*WK='[T(R<3L*2)/<P@Q4(8L=A:IW+S#$*JBZ1"V
M6TUX8)JBQ&Q W!.#- \2*6=<B-1Q1N23L)#0"E\5OI[-VE;X.L"I">9"N("1
M2R;D?$>)G& <D12)BY$RJFB' \[[P*T62/G<HT*!LZ^5H2B&A#U@&Y&F,A[W
M KYVDBCU ID>@F4F2WC\RX\6(6Z30HWB7R@,I['(1*9Z69R-WX7A['QD+][F
M;]^=VQ"&XY.-$HIA\\-MB ,?J_S)/Q>S^3!=+%^BW(OB.+QSD[_R:#)MS:H8
MXZ\;"LSU$_!0E2GWFW^CM\0N4W&MY.YT%2,ZAQW>A'^03?"N;^WH3WLQRSPL
MFVNT7( B?7MF_SZ3_$PENB$X^_=-P=[-@783.=-])OIJ+LU/?CN<PX_ZO;,$
MJF2>\7WPO1U9T"JSS0G;S05W'6_6-[NYX*2P-F )ZHT;G\E.03G:Y!#%$?['
M3!"<=])I=9)1,X8DB[D-"A'(Y11<8FV"_VD,ZG:I',-7^]?;SX6U[.)C^M3P
MA;5T<.\SMUD>WOMQ^#W.XO1K_&#G\60R'<:'(8*3?1:/._+ N59$!G8<!MDF
M^#J<P_P-AN/!?_WXZ9>?/[__!_J^PPUGEW-?;ILVLS_PJ^D?O('[YZ>3Q0R^
MG^TA=NL)%EU+&7=3+'HA'&Y4'*MKF<G$O9G)R#&C]R9(JZ]17Z-\_5Q870AY
M$J1KG_]O'^!F-QW^VQ'@\@P!:@_3(Y?C/ZL03ZW'WSM[K6DYL//_<--__\_O
M([S*.%L8DU0^^ 2R-;D'$=XKK-BO#!>O>D>!=Y--M<EX5C;0-([ R N#^63@
M%],I7%,^/B_[:C"SHVVWKNZNNKOJ[MJ_NSY,8QC.!Y/IX-Q>%*[XLIW.;(B#
ML)B"YBK_GH.W?%Y5U^$WUTL<<-UN>V?O?<@G 66?#38TV3GLK&F[P:KZJNJK
M[J?;N5M%1]EY9AFOCE:?J-$>J*]!7[.U"]5]S%3W@TTFZD%F@7U;0T8WP;!^
MI,L\E0WX6H9<)?I%+^\K'/)KDN@7,-8ZON<]OBJK=7S/97Q55E_$^!Z-AFPS
M^:X\]8[5NYLY5N4YFP_&5R3T]<6=?N\]3&4)E?HX_%KRQ]JDNMFJX<Z=4P=+
M7&;/+[\AW]7*GA=;]O!_U1*?&U$+42^P\0EQ*7*%(G?(*:J1#MQBR;$ELE/B
MXP(/'F<Z(F<XXBIS<R2"$:%))6*)X%YM93&W*<HSV.O3A1VU =VMRIZ_?_YA
M5=C#-NMZ$+NFL$<?$?7R:GL>M7RMXE;%K6>&6T)@PCT5B&$;$1>* &0)@9+G
M!NNHB*7F,FX)*K36@B%-)<[5%Q:Y& .B,C'#A8U:D2W<NK;H8K9*7/J].>C]
M,OG0)"PU1U.?<ZK2@7!.B".)7Q[[4 6Z"G05Z(H_<D=OYW; F5BP"LPU1,%*
M ZN/43#X.$;:$4:L"=3%QP#.)B?MX_13FY'VJPWQAY*+UB#GS4%S!FL!?[L.
M/?D1X>S%H>?-MEKU<U_NVE88?1(8=4D00H-&Q&/P@2GQR)*@ !>QB50X9KK=
M*!X 1C=R#5<6Z*><:/@P*$J/)'UYOG8%T0JB%41OTH)'$BZ<M"A@L!AY"!(9
M[\"*]$9[)BR7 7= CW,1G'&(6F/@RD21I3X@EK1T@'D E?CQ@H7J"!/RX@"L
M-ZF@]:SKREW5*O(5:81M1/RAS[EH55W/<5=7U77(L <6H*% [W#N0 UQH9%S
MH+^$4U)2T%U*=UKW)B,U-E0CR;A%/$=)' X>Z:B\E1$+RNSCJ2Z"CX1X>1R<
M-?Y;@:L"UW[@BIPJHK1"RD4 +F(-,M$3!):SY8!$3(9.O):XX#DQ"?G 6.;M
MY,CDNZ55EACE -9P?P^ZN#S"L@)=!;K>+VD%NAY':(5B+A(3D-840# X,-P,
M(\@008E04<#'CP"<CWW0Q?01Q>K%H6>-T588K3!Z$]C#^1P_!823QHB;P)!F
M22"N$[;&4D.ZS=8> /8.=C!US7F4,"\/ZZJE6"&N0MQ^B",I$&*(!TQS"5QB
M&9$Q6H)?S*/WC##?;4M!,-;:2XNBD!IQYR32%#-$I;-,*.J9D(\7RZ/D"-=<
MSN7@#E]S52E)EI0DM%*25 *'.N0JT:]A>5_AD%^31+^ L=;Q/>_Q55FMXWLN
MXZNR^B+&5],T*R7)%3&@&M[MP9!K>/>@I?V.&24P\M'Y3"\BD6.)(L.,\"G*
M3,M\.;S+O!58)8RHY 'Q(%U3CB5=OE]JDNPC4I*P(TU?7JUI/9:JN%5QZXIC
M*8PUQ<HB[15!W$2,C&& 1D:;9+!QQ(HNE9*C+E"+J,]7TJB1#3@@S)/CUOC(
M4NAOIB;C1TKH"G05Z/J^I!7H^IRI&4,PTGH4:62(1^N0L\(@$GPDB@IB37P$
MX'ST3$U\Q/'+RW.OF9H51BN,W@#V:'",82R0--: SZH3TM12A"UVG%$IG=M!
MO7EPV'N03,W2RQW][SB=?/.?Z,5!7#40*[)59+O"H)-4,Z<<PBZ!0><Q0Y8I
MB@#="-8L&,$[$;Q**MQ7W*J<^)4GI*JN_N[JJKH.R1,B> @\>62LP*"Z%$=:
MRH28=$D[IJ.RG5@$H\'Z0+)1GD!U1140F.*@_2@%+:AETB0^INJBHAX^5=SJ
M_9)6W#H@;DGI<8Z5(HVC1IP;@[0#%UQS!<C%(H_=0W-,B),4<V1DBHA3H9!F
M6 #J44\YE\HJT=_#)\J/-)85Z"K0]7U)*]#U^/!)VB0-&'!(*0<&GP7,M+:0
M,K/@ HE"!O<(P/G8AT^4'HE*$U)A],6M;871&\&>3<IH[BTBN2B>8TF0<8PC
MAHWT3GG%Y&/8B_7PJ1J(%=DJLAT0V;24VGOID$H!4,IKC:RD' 5*<7)684=T
M9?I]-L"U>?H$?\_%.#=Z=0;_?-S3G.U3EJM^N[DR/_CM< Z_Z:\J"%H=^H X
MI,ED/I[,8R/JOWWYG\8E1YDGR N6U3B.R#'FD)"6QF2T-49],_CK;/06!/3D
MOWT3Q^COG_LQM.46&MAIS/MAX$]A26(^29P=#<)PUA9AV7$83.:G<3I(,<Y6
M8K(Q&[T8SO&F />0.^9!I)->+9TI@ET(%B-BS&;?.G,TD>@1$UHP1ZP"R[&G
MTOE^>>2ZE,YIG"^F8Y#,*8CH/#Y/N6Q5RF^+,S"O/?P[#+]N2.OF.3D_%HQ]
M>\5AN7Q"@"WO<N6/[YF-/T[C>/!G',RG=CQ+L';YJ^ED-)BDP8?SOPT()GI@
MP2GY:L?SP?S4S@?#V?(</H!Z#W /+/K@PX^??AZ\/YG&F)V7P7PR^#":@*HM
M8G$>IUG!#_)=0P\OUMPW6<#7JUO^',Y/RZ-^F/QPE-]I&OWD9 S#&YPW?A-\
MTN0!Y&=:>-4IO,CY9!R&XY/FQ<$R&-C9+.8_R^.+B97?!KZ>#>%';6,9S?('
M89C_ <. 3V:3LS@_S0]J9!B&.BYO<P[/LR<Q3\@<)O5X\#G&P6]Y5YNR#]+B
MWDD(=UZ]:7G5K!H6LWS(<+PS(>(6/[2R(=L=L6KNQG!(42/A!)B03'IDF->(
M1^8#->#N>M[I<Q18P. %HR2L1YQ$B1R)X% ;PWG4DBI*ER;D8H9.K#U_^Z%=
MPS] %#Z 'PQK,GV?EQ,\Y%^&U@U'P_G%EVSR?($?^GXT\?_Z9A#!ICS/FW6Z
M:$^BAR CX?W\IF_^/\F3;+TOIQE(<PP@2UTQY :SQ1G !#QV-G"-"=W@:K9X
MOX*TPC^'XR+8E\6]*=$>O!EFJ9TL9G#7[+NWFRB\A7-K" 3$N[.@M)-MM_H
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MP//.,PBQJ\_G_!8V/@Q'S0KE5;F[A&>KGSYFD;)W[ZX%8YU$Y#BA7DA$?AO
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M)(!+"B-E8 9AQA/B3"5DJ=((&VNC]MJNZ0#WG"VFEP2N[AFM,Z5*UO4(Q+V
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MJR)[M,JXQ*(&BM9E>.U\-EFB<'X?6+'\^OER-+)7D_DB\_^V?1S!>("_6?X
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MQ4!M>PLSD$^ZPP-,XOKI1.)K576]K#Z%+4WO!5T6]_\_/\*/W73X?\YJ\+/
MX9T.TPX8%;>C%]S5C+P*AR1(3OZV.=Q^[^BO3R4LSY!<SJJF\K=:6M UB_F"
ML[/=X9!5=W&C;]KF')J\Q^@J6^^_N.GW?UWQ<JX=U_SYMTUU/<0%\%W]*'+Z
M)T]TJ]^8]6*J7XC-M.A>T;W,DI2OB0&]@QFQ'V.U/&G;J-H?#97.'^ $-SI:
M=.U$=.TE37]1QD<K8Z.#U_P=S;]^A(OS'L_<CJH/<?JIM8A-YJ^8PJ*>13U?
M4#VOJ=,:I?L5%'$XKH>^:@XO%M=T.WWL5;_P@^SH]8,=-5OJ=M9E6CC*!@![
M:_.P/_%XG38/O6K4]@)M'J0G+C*$77*(&R&0#HX@)9B.UCI!NB>-K14ARI3+
MQS,7<O"Y/2XX:C*R9#CC.FJ\LZJV1;)C)?_1ENCNKN6#.6/,O%#+AZ(<IP"!
M^VOL<1L/-HWUWX[2XNV^@ZZ6PE.+4=(&L- *C8Q7!&EGM$N:214[I9%[QL)E
MD+R(D9?YJB95=9LM!/X:P_M<BU__GMXUE0#VI[QY.&T9'J[!$S^%?);@@=I\
MDN%0M:KTCWJ*,E5WV$[*@O=YP==7 R6#!7A!&F'!/>*,>&0,X4A2X8@.PBK=
M:8E!,*&"2HV"S_1&)-,.YII#:9A(A,@4NKT-GUUS^"#TW3#[WB0%<TZ0KJU.
MS#G"W6D 'TCR0*EAT8S>:\:^]__[+ ;%S]RAG\F"]3YRB1A6X#@:+)$5A*+
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MP@#ED<&Y!2) -+("@-L3J[6E)HBN[#S'R!^0[*@>NJ99=GKI(AB:/(NFB4G
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M0VP_;WIE_PY!Z/3#A1TOTM8@YZV8[YK[@)UQ55I<'X'2E)-IY63:5ATZ@@X
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M5KJ#'X%.%0@M$+I5-S>E3+).(1LR+8@B&FF.':(QF2@UP<[YNQ!JM L$?&%
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M\ "1%4*CR(FC%,=H20<0]\X(7P"QJ$H!Q++*+Y(PU%1@IBCRUB7$"2?(!0>
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M6M^%0(()%53F+FQ)(4Z41SI3:4J3J4.(3,&O9Q3N$P0R>F:(*!!X^#I1(+!
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MV>UP-P(;X1H4[CW5"_(B +*,Y$T P&[MJ+(;N+G==@(Y<O8_,*6R.&%-,TN
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M;Z#^>!,84)A#N[S%V+QIQ7+O!F4N+DV@<R!88?K*!*D9_3"F'XS@:[C(;6<
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M#02'-&0*G',F&.)1HI (68(P 'XJ"8^QB+>UX]](Y/&,0!Y7\KBI?A3L\#(
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M&E@U-O []Z]1L+Q"F54HBNA4<YZ";9P(Q%4:(1&E(9)@)_.02DKH@D)Y<NP
M)/&L$<1?00Z/^GI2:G8:;O81@Y?F<0];![>D>P];.ZJZ+1+&,Y*"(4T!TE+
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M@='=X#/PJ'V$W5BQFRS QW=5(/S[P[B1]HRM"">!Q8U]0%\6M_!NV;LM<\N
MX"P'YZ;"));0BF%-X+0$7 5+ ;,;F^!XH.V,-+"[(S0\W1KZ16Z A_4,B1H:
MPNPIQHD=#<'N7U#+=F7@DX!WR%$S(??";#P: _WJ11U8_P<8JZ9D9F"8,!A[
MNTU(,LM6?9YJ]M+F-H!_H!00UGZI84*]P?#*K=F$22HYA^4!$?AW/:1R--:W
M@1X7]A4/T)NZ9P,GJ]Y8N_MA?D"C0;]W^S1"U20"8A7-7K&]1,[!3=%L*#<
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M-QZ3;D#V8N8@[1+[<EH<6DV",HO%@3U<K8 KWB:XXMW@Z[?3+\>G7\&.:_K
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M+K@MR6]V;P0-[AYF:" P?6=GOW04=AEK1I:\>M#VO[]9);\ O\"R7))/?VC
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MB'M8F\4]$AB>0Z0RNRG!JJ9?@B4#(=;B*JRY7@OQ,JY13FH9=W<!DDSI<U9
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MA(<K_VZ=[\GY,"%94Q/+!D5'\Z94J\AK94QS2X?=?AN%A^L#*.5 P0/&ROM
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M+CJF4%W)OFV_!,+HHQP&]3IKY'>[D+ _T#RE?<M1U<K;M-O@3J4'X ]3"*7
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M@D8L1JE//5JXC-X!LZ8O.?MN#JW38NIJV,0;RKW#"B.R(GZM926+@RG!0C-
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MR8PH'BL""72>3UVJ6_5C)GEZF(.XSM-#7O8(?#T'^WC:]*> O,'/*<,!RI=
MPUUJJYCV-\YUH?#$1"$":%P>7@9B!O+$=*I8%J5?@BCBQBO(QW,-P;T1\7S2
M/68CM31IE.0CVC,M6 Z]? 6@,RC>8UGQ\-G=R5GN;G5'5V&68C 4PG&+6C8O
M#OJ&$* IK@9:1L(U#8[[D Y/ UW5E8IIE\H2L'C!#!#FE4.A23TJ6U6<0ZX0
M8;/H,@3H:LQ75AIJSH"7BK*#M@PJ0@\,[VV:Z(QV#,7K*-X!'Y6'9JKUB.TJ
MSHUCR<,O^G(L,@*3XG)".N&8.:^HP>C+I>RINO ,W@;1&R ]X(\%NQ=ZDHEL
MG9YS,-GYWE5-6A4L?_E4#VA5N=.U&]8FG&G>G[8(M5,(:BK8]:N#E8K1%B^6
M_XH*=@B_$'CB0\J>KPX"< H^#>2O@"YNGMP'WVR+-7[!=4YUYAN;0> ^'<<E
MPH\5*O!<\#_X\EC!W4%'US&(OQ]5F\"=%0&N'<A)<SU[@COW^^$V=<J;N&WT
M?NWJ&F:Z?B8H_FK>JO2[:7NWS"!67.>2J)'6U>RCGET>2-@IR6NA4=NHR\]!
M%N, ()();YV#75';(B-(@M:)]MBC#F+XKH0+Q+O,TL]1^A=$4-*4#%_+ZO:0
M!I4Z&ED)XPJ*PE0O585?9.D6H"] 1\=]K]V]NU) @0RB-X.'7AWOV0JSKJ&Z
MM0%^<E=;/T3Q0>R3#@%=4\'P#N36E288:6DYX\ <)9R0W 52X%;O0GP. 9LG
M]G]%C6J\801G<![X\Z 0]@#(ZP[?JZ^^E^$QU/VI6YT:(XW,Q@M2&\WWHUI\
M[$['KAV=Z<VI(E)G&R\7-,V4;OW8NR<((:F &!J%X-B'+S"-[V6[FK:1;&L>
M7&V@;565K.(Z"4E>*EO]L3EFM@.!2:V%>*:3*/ ]\"8E"E1YUAQMT8E==(AO
M1@Q1CREHIQ_A]D5XOR@1^CK5'?=)+@QA1'.X")'Z@+>M.@\39QL#YABYR/ !
MRO!!P@\JX$V[05+H-2X1A4D QR85T'E_.G,)V%;ZT91+S1EE6.W\VUC3OD_3
M+U'\ZUU(!,<$7$(>W;<\O*#)QTE;U^**L1NR_&@U)+'4U;'(Z3'WYAQ_S@T>
MHH1X;S>H?5M5-6V31C&-J=Z#)U&TW2$^KUJ8K3;59B-?=(7(* 5"#0RS:M>&
MM:FJ&!)Y N]KR#*(O+;A^5VIS O&Z2XD@DWW-+-%M9F@OSXB#]&P_FN4K&)_
MKT'7:E-S!NJ4F_4:@7=!8>X#@((R(GY'(V(/DO:LT:4\."0K^&+]G%#@<A'M
M5,^:=29C%2LUH4@R%9Q3Q= T%<9*8U+=*LS\H_ 7U=>9&[)8 \NEJV/=GL=0
MX/,Y+\._-YCS&BJ;SWG$W?B(9I:E9."7E)KQ:E?1^E*(QE'^'9O1/%R7^;*K
MA9:>Q&;#=U8T<'TC^!O)S.1U4B%/D1]UZ%>=R1P?/!'G((FYJF3>93CZ.N?!
M<1JT%T8'(6(W^-K:8;9+=0@JA>RG<BH\6YLX36V5^7K#-GBA"O+;&$ZPAEJ?
MU)(!;DTN<\C\3_ST^.L#<8:F&;>;D]WUHS''-%^J$7:J.@=ID\&=<(<"$N($
M&BZJR>@J:':B-A?M/K ;-U]600:'K472MM;5+9IBAII@K&+]N0RO@(3$LSQ?
M30>NL9II6+("S0U28 .;)IMS63%[;H2P[N!J<;?;Q]$KC<70RK^Z&O8Y%.8H
MF.J"J!6%[7L3%R]=4PHC;9515#XD&B..=A18+H/4B51BP8Q))19!&37<F8P]
MQ1"U<W;3HC14LK>_,OP$@P\S"5?[0KR9=5Z<ZO+VC\CE(?_XDX\W#A;P#B2%
M>#OO>UWED3Q497C#U^"5B$+O+SX*I&F]VU>VOR2?\(. MPB\ [<QR1:S.F@C
MWMK4G$]LC](YNVV CYK \:EP&N/'%;A2GR,2,HNT >UV.F0/61#39NF)LU5*
M,*"TQT9=WC2<&4^KVZB%A'QNY3+ CX#4#M;$#@E\S;9T?/JEQFU,(_2LP4)4
MFI\G%-MG]$9^Z@6Y5E2>B26ABS';NL5:Z3-X11/6^R0%]VK[O"\BM9<1$\@_
M19Z_]E=,2N>DNGHG#FAI4N?CY5O4U_FXJ&I?T&Z-G:&K,2]47R5&5]M:-E>%
MLM%NP(Q<Y$Z[2"F$-0.O*E#YU7E=35"TJ9RG#J/B2_868I8A;4I1T:KJ#%X&
M+(6WB<_65+"E@?Z,V;/E&PI>\2T<IENICJ@_,=FH@+#S91?@3^'F3]^@\/SY
MZ9O20/&.CK*XCJB._+]=9/B<1_&M'^_NO+\%+WE&CS@*$%U2O*)O;V_?DU6%
M!?WX_OT/[^#G=X3.-__!:#A Q+F[_O=W12,FNUMH9O$[B,J< 0\"/_!9O,:R
M3V7RNHXNQ6\2NJ=#Q!OB-U_+N-BJT>;.G+Q!A[1XYN1MGCEIY+P@!Q  SAQP
M?G46(1I[&AX '(?82 EW_A#ABPJE/KVFF9*1,8+\@>TY ZPEQPT]A[3EE!MS
M.%RO _XWSK? 7<6)&SC1FGSSG?-7WH/_;^Q9$3&D\-1@N=X5LI<6 =/,1-%S
M1H1(SU?D"&V2.1+_IO.58M')*5?Z*V42CGU"Q,,_?%;&FHP2>#B,V:=9O"!M
M>\\MP,DY!3V'$CR&08C+-OU(!BLH9'IPN.M6*?)^CD#L@WL95$$]5Y<T>T[:
M=<2^E7;QR\$1R[$..J2'9P[TT2&==(1>GCF\GT[140=Z^B\XV>(NE$S+)#,R
M(,.HV@%+E6'TXY 98LB CILZUYCOA=O:^>'#:9(,GMD%/Z1"K\\<WF^'==S)
M>^X(77>@[Z/=_20+U7X=1WD&MZZSY+%KGCH>_0<CYNPIM>]GW'.VOKS'C,J,
M.RR>VLH\CWU<L:B##A1#\#8+O6%L+B'F4&H.(>?\E1(<G6TU,PYQ(>J#&74'
M$>M"H0TCEPZY97H.I7)\"7DGHO0)?YU "XY+FACW-)L>&K^_R9 870<3IC<U
MO9O'WWFC#$W<@.7QP9+1;RC]T=4%3#&R6.=V+^ F2 KCOGH!1A+D?#H43I6(
M_4<U)'&A.%. A^7S :VF&%#)F ] %$6::1X_SK$/DIO W_DA_$R-02R$I>=2
MEEHF>Y.U35;RS*'-PXSD'7"*'IPYM \.Z\17.$^E_4%) ">()R1&@)4%?*8?
M.IL@>L&LX%L4_[J.<*E1+ZLBJ>\G/\!3@A\XMG6I7ARL,@.?F:()9\?;X*P,
M'CEO9=SW9HQQYHJ\?'PY[5PH**@?W?#$[5KDR:RO82(LXJB#9)!RS/ .J7/?
MX%XEAY>&JY),%PG1: 4TJRYSH&5N&1#&/NC4<OHP9GJWI9&SHFTX>WJ!)=#*
M5S@103X'T+C#6G?RY@F[Q3O@Y#W(7X%EY+!.\*O^Z2N=J<H%R&<L9C/FYC,&
MCV3,9VR?SUC#WAKMII2^C? B%O-USR-=C# )Q-;C%MO&^2O0=T@#HXN'8XQ2
MO"PD0[VP-%2EOS QHO2_" A1S+D!6;*..>$S:I\Y<XB7_W&-K_3PD6!*8,OP
M\=S@;HPV%HA:S9'*?D2X,7>_]5<NB23HN40B&>>O0&BTK6:T^^(*B+1&WT=R
M0*I;?YUNP28_T*WA]\?6?W[2&5FGH"OQ5[@=T?A:B_,0,A&PD ]O@9]P>"[Q
M;4OP.Y[#Z 6N6N!+[\)]EE:P@KAO=\])*6QSA1L'[HW#N^,0UH=UR"$].G/$
M/CFD4TZY5\Y?B>.Y [US2/=&?QSF,*<E'1?UX">>'ULPNI#K5S"%,J] )^#.
M,Z/[/[0%)10Q9 8ZS !EIVCHS,D[<;Z.XG/H!OZ.-\A4++=^ C<].8ZL6X<I
M'6>FG*?2*UV:A]E:P<E_&+(4%2\^V+-3DG\<UALFD7W-,R?N%ZY 9SD7F71E
M]W@4?PUR@6#0/IYP81[KN-K?A,<ZPC1*W>"^U3 3<N$OH<*H&I/_VJ*_^[CB
M51"]HOC2C_;X0.[<%<I2X, !=A\+6/37GZ)P\V?\/_Q=/],6IO$2%;Y_A.C7
M,SJV?WF;#B7KU%O%G."*Z 98"6C9@:;)#Y,8+2>=F(I^+)^@%1W^2ZWU,\P!
MKHB"@179PN3\"O^!'W:D%Z.KQ8@R06"2(74O5<_UW!G4A56@>.84-(]G-*67
ME0PIP"MSCK_>Y3RZ/YZB=X0!"=>R=HU&OI!+D5,N8$#1?R'1 -ICR;N"VLG]
M^*G2JN>FY(TYW_+FO@/YB[7HL*8$1W[:VM<Q!^+*]YR(KV-/_('.1TAP#KQE
MR09&QX\H?>J%$I$)X,8*=]0=0:%_9"D=G_> M$UQ"YE#!^/T::CAD(LM=TN)
MULZ*-.DDQ%\EPXWBR:"MPJ^)Z%9U_),05,:_@( <,G[JKP/M.;Q!^+7DHW1&
M1="O8!XJ3,M,YZ-DW/+!&9Y.1NBGR>/3\R!&MJ#)API4G6\QW>2[R;PZC8ZL
M9J]3#6\R)2S1JB8$0NK#H-42]=.4Z)E#R#H?)ELK@Z,25THSM#$#IVX@5=[A
M(7L)_-5M$+E]V7Y*QZ&$'$)IUMTNZ9<F[#MQ;,HSU28/$6[R8,3$0*DZA.R1
M=#^H]]RA))V_3F L,CR:JHN@9%3%H$;7[C%4:))[XSYRB=LV0V\(-X4#'629
MY)\!.6N 8;X@Y "ED6WS7:/>269$3&B@N?O?CGT\;+%Z1>]#>^/+@"6(Z$_(
M\[,=A)"1G3S0W_./6-BEY+FH!Q;M59&JQ@FAE>,:8Z[C8"-C5,\<2I?JK#Y/
M,:Y<N[^. .< 53,M]L4'J=E&!)O"9'R?Z<&58K!(]!6Y.H6136<3HJ@R_HHH
M5PK+9>&!#=F5?8\A$!=^_@.?2-:B(R OP&'DGN<KL5&P9[)6Q_6JGV :^!W,
MAB_:MP7'^U)C3M':L8]>W/@]=\!D,IZ &V[.M\H1J$["Z(XR++GPZ@A@Q5/H
MSREFGADYA))S,+VS7 RI,>ZC+Y*I0944O?G(QF<"E'[+SPE:9\&]O^Y[7S8X
M9U/Z#C1PA&.4.[SD8X)@BF_O0N< "8%'U]RQV!*>@: *)%KD;(%4F@G)NM=;
M:*3Q(VO<5(X:X;SAQAS>&D##L/8<WB!LY:]@$L1%)Q8V'D\S@2Y]],&5'6'X
M0L=H%6U"\&O\"H8HFE8'[.0I?*#N*9A8%!_RRXJ$L0QEX7.RQ54\;GR,T=%P
M3ORX1U'BJ-T7!W%JH_:>)&=")+P,4H1 LC*P5T2D9::$2*[Z>:M4=AEKBL05
M0EODZ?>*U@K#/3/7CRLBCCERKO-@(^9M$%<ZH16NY4EX_.G1#KBDHFM8Y[&?
MC)O=/H@."#VA^!5+IG+7[CPG!@4H(5>W^#N!6XC2OR 22$+?ND%(26'Q9H*;
M1N$8#^ ;8F!M&(7GM&OD"D@/#/;F7V;:V.&11@@4&@;B[<;FB04.D$A6W#KF
MKVGT$FV?1*-D_TK[3F!HZ"R^F)O%B;S(BC2I/":]FAR<AF#=A;1;/3=9WDR!
M%G#F\): JZ.^<V#-K_G<3;6OQIZ*BHZ!#=,370M?\VG*(0+&'K4BH64Y^XVA
M:+YR6_#-XT02W"BC9'M;.2H+H9Q8E *M+]4!/_K)KY>'@8;J$D4'2$YIL#8X
MGC+(M'108SKAW*W6,</NOTA3_!*0MF\#=]-7 7MU^^CP;  "20=H'L=(2C>B
MC>'D88EY:NDJCP#Q7K6 1!$-/2")+<BE(N=$")+<)=%^CG*I$E=%620H$S5.
M<]>!UR5,V<N!Z,PM7-\/ ?(V$.&:Q?LH&7)M<TH.(S7R?<VS\;)(! Z@E[/J
ML$<YB 3,+<O\0W,E8ZX7;Q7N3SW4+9MS5IB="G/ 0<0ZPGSS]QS/8@_K3$!/
M$\?->^.L\1W$41O'U8[8F;/"AD?GZB[DX(R+M<,[P)R@<^P/<B9H)YRB%P[N
M1@[9^15.E91KQWN+LWQ(V&5L(U4#1!0;:_2+.7M)2 +<].85KMO!EV=.SZ$$
M)S7'&QM-^1DM#VE<YUDF/8**R@U@._SH^N$B+/R9"G>F:KSY4/=:TC1LVRQO
MW-G@UL&C;U?X4R6%/Y5;"S[_:B:'2S9T4O#=5S3J0*O.(G0:G,S(K3>ZD]F4
MDU(2CV3;)8B29#[;!3.)&>ZR4?,<)UJ8A!AZW=C(M";&DHOK; Q3FN;,C* L
MH%>78H*H,HFY9B"&TZ-HFA$-4M-!,ET5_MH ,"+S:AOLS/9*G-DPVY-NT?0.
MXB.,L-!]Y4,!TJ5\3 +Y40_7-8<&7ZR?0\]/:+)4Y-VX,62/X5(T -<^H1C?
MQ9="WM1!QG&4)'_$+X#0IH-8HT0_O>*F--JN<TFV^1MK^NN9%*[GS3':\4XO
MM>KP9IT+Y;3\\M5-2^7U+$U/[UTS.H8+M^EP1&B&:SXT6,8?-=C?=.?S'<T,
M<(S>F3/92 JMH9@9#I'TDBU@*,UH UD?8,.*$<4,\A>V94M<3PNJ0JL3J'!G
M_\E',; [!Z+GR--?-TZHFXH/:WUZ1P<.D@<0#H=WTL0+3HCS9'IT)28A!WJ"
M7)_L]B>9MJ=$?BH. U$%7AZN C>A>]S W4#UH"\'AU!E9WW" SYX3"65%Q]8
M#DQR.?' 9/[%Y(9X<)/T.C.#O9_[%!/*#HOP/IL4='^T@0:5,5;\IIDK#;3B
M7&?3)!J@B<\@9S=+KT$PIR!,%_(FX7OADJ7W-I.XCC<D8$^E15O."VMLY!1V
MHPV77T+Y,"]RC#&A#8<W,E%:N]&&6[J?2DNK'O-LD8IOB#/I70BY/VAF.3)7
M6S=D"%"Y)^!C% 2W40R5[*% T^XZ0G_%Q.HY:%7>:3&-&S,&_A4&XK"1C/\N
MSGIAQ*U<G:C1T3 *ADNB!.L==RT 7TK57\<U+-%IMWEL$WGA&AZBL >G3Y5
M9#W)* :JTCFVIG29IDQQ8'I\]61#XVN17M+B&GP.79X\ 08SU+.9H)C[.?4S
MQX,O/$;YZ(96CLLLI-WC'E4@K-6=L%8":>?Z6 =7P]1O&N$D$:4H2:+X*7LA
MNI%'$&6"A"-4+:-+1 '!\*BSWC=)-=J4-.DDK$TGIHT663LI9%7,&G:\;&RP
MF GF@',M=.R\+8<UYN39II<1EB0<WB 5DT=_0R:;A8J/4\"<_ #78MQLFSGH
M3 F)]R<4>)^C=!G=?%DAY%T>?HH"#\58CKQ8KTGJ*,SW1#'C53AT[N"LFZ4,
MRR6/O"WN$!BGX0@@TB>0DK:D5T3N=/-^$54VLT[E*,\C*Q;L3B,[0L+T51&.
MH2,D= V?(MH74"+2WA!51=$?XBC%F="\2U_Q[*ES?#?M0.E&&UU'"9I?IF(>
MK(\D6N1<83ZIJM7$,$KZ8S*6Q91CH4JVOMH-IL/X!?F;+82]@A9M@]^2G>N'
M)+TMU15G;@#:-$,L!NF*0Z->2\'6;EG_E CE>.)W$FW-4?*=-]9OQZ4=QVP)
MZSF!.&-=)TK>D96Z\UX 4?'G-"C^+IGBSY$H_KAFS^']=5B'G;S'CM!EHH*=
MBD.:^1*4U"NLJ?,6L_?M-'!4EVX ZO.G+4+I/8NO&A!(Q,@YA)[#"4X4_FEJ
M+.*2R0<TC=IH(,P)4X&-#&)BI,NB$$[!NJ;)#9,'\]/$CM<1',>^H 4L.>1?
M*971=_N@/HM;G!&:V!LM_X=#60S*T%F'0(-X!.)@S#82S=D)^=^"S*,_>]RA
MC2'#89:#'G8W)55?T,8/R>W,G)6GR?MI?*)R_5W5?X_/VN-DP'&"Z0*+4H1;
MIG)T0NUMP\U..73E^,8+TX.IWX)!95R)T,;__.^___CAW_XW@R,:/R/(A>?A
M,LD3YN;1(GZ(HU>_?RPI)>DPFF<.H>I@D9;3/9;Q2)*=3#^HZLW!$6BHS7KH
M=9'C[> A$8+',8Q:FLFINIVC##-(!>:#0L&^,_R<,!=++'N8$"IXLU_1\*H[
ML,!8SM,H?LN:_>[,*5IVBJ8GDS[A1GY$'L*BIG>=Q7G"<>K$06."$A)C(<0'
M]4\!756I$'U3S-IW/-(!SNNP /-5W@>J5RRBE(J(S)&U)!-/$E=[D,GA[3JT
M89:ZGGLC%6U3O74Q.47S7\?<E%-TWC=/$<\]>"9.4J2:).=;GV-CC*ZT ,,Z
M*$G 7CLTK(,8Z8G&A5A_IP0I,#*,FGM]/I;17>M@[P!01GG?$D>7S^B-_#+L
MZ%+BU5W)XFYP$[3 ^,Z=8PRT5;)8X/GW,7\&R7=G3HA2*,B!00A4Z;AW%(_Y
M$V.'LAU5G_X<!?@M"GJ(.Y6GC#?BK(L@8;=HQWG-&QKWL1IGL&Q?YX,4'-,$
M^D[1P!&.L20+83Z-Y$9]'7U$@UU]F2%@D:5)BD\</N#4%]>>FW7N2"WTB;M2
M?_732+G7FY#S*#>$%E?._8L,_REUXY3;('(]Y+_*')1D]X(8?Q4)2+.S@2ML
M?+EWZ&3\2&[:NY R#15K(_GQ&C/D^4T\@TN']A@TY)SEJIE]21$'.BZ\9/_B
M*R&U]'('A8*I&3^.<(=9QBV>'O\54<W)9Y0NU@-SL#"SG$C<^190G@"*>DQ7
MP1'&Q<Y,B2)7,GU[#V,"\8)PV22%S$5*P2E(U'X:X8,SA47U+@20N2@^%%$#
MP].P,9*E:(A),["9&U,9:Y'2);$Y6$ :TWRPC%UXC)X.NY<HZ+D0C(9#B<RV
MM^5XAFDZK;0"X!-ITI3!#K@DU\ QC$R\FF$DN2T[Q4,<UVFBDE_)2(AV06[D
MH(*!W>9*PR*IU23!U$.[7<UB=3-)%BM\3^RW47BX/D 8#3A0 ZS3?; R$]7/
MJ#N4O,/I._?W5R.;,\R.BW/PRO$$JXE"]LV.JQ16HAG<,8VI_"#JMN $[#"/
M5:!F&JJ@[L\*YP$;A=V'DCR2D50 07,E^AFW@_I'-1KA?=<MSMRB$?^"W'BY
MC=$@Z?GC^X^_._X1#0^P)"F)G10:/_[IX*Q3CUA+:--9CCD-X\.%_$RP0KCR
MB1Q:(YJF,J0N'EX:^\3P0G6E67C4Z#<F9\V<IK0E"@[MO*A'G4Y7^A"CO>M[
MS%V*8S"9B"M@E'-/K )X:>*(@Q&&6 K'9./,\]\6X&'3!"=0_E7(EY2[W7P&
MH.R[$/<6[S V_E&R1?$VBI2XCT5*5-$/Z/.8T-U33@2_) 3<P]HX:]/B4#S7
M*12I4\Y%5> 60"YKL.WXEF-SPL[+:")X$J> E9A$@>_!5B1>USY*!@7OB 0=
M3G'T4!ZS0ZD 6M;',[KHXR:0$ '^@1<2,R7P- Y2B@ M<O&2#P+5T34B8PRJ
MM$*JD8WN=0AL-[X??.HI#2;/OA%%A)13T"(&X6/H?SEQ 0P"%8/P)AA$&<;(
M%/1PQ9=5Y$\G0NLU,*X:/%A!;ZI1W$8Q\C?A%< ]#;04,%+4\D0SNZ7C&PU,
M#J0D;%)ZD\B3HA?1$%&O[$4W^ZXKO-]8'/JD;O:&QB)W9;,Q(- ](:1 N.<*
MJ&-08DXV($%IA]"9HTM10-67#UAD/IM082>HVZ_<O9^Z =VUCRA!\2O)Y7F;
MI5F,3&3T_(S>@@/HV AI10+/HQ^QU"3$FN)A4[PQFKJ#-#=Z6E<A]QKF!U8I
M"<7 K#E324 R9I[J]2%*:&*:F\ G6."]#6.EQ@B_SC4@T)X(;YVWZ12-?AU3
M(4>IWN?CC2&7$U5T;H+H!>^2MRC^%>^,\??"Q6J5[3(R:*+]DS@)#F+?+A97
M=PKWO\F8N-'&6,(2+AIAVMRR=R1UBQP9%3+/0:,8)O3!G"\KT^66ANDS)U#B
MV'J,PV3[5K:$2@?78QRGN'=GLIQ<V"+&@=5A&;MAXJYH('SHD3\#&IS^$ 4^
M+C!01\U%2]Z@([9(GBJQ38<VZOR5_3NAT^]D$R,152NS$TP"WR4X> H8,0]Q
MA-EGS)=CLBD>>.Z$9\*KM92<@+>$/T%;.23.)*EQQQJ\-'[]UO\"*)#CVN&J
MD#%7^.,B7D9O?:T-5: 8( @X,4#R"$:AP[R98BCR5'65>!X.U_Z(=PM#UC65
MEZ\6#<7;<J"Q,X<U=^S#E\4SY8"K/)F!$T^@+6=XO2QJ>1$_0F>&JP=S!&*.
M.(WW+2$]J<;0].#*+JJ%O):,FE6(^I'Y^%;WX(H)O3R?YU44TBRQ1<C/P&>^
MZEC'6R7OW#K/([KB#9/-2EL>.;I@FO%SI5P^;@!1+_*GY@V*05Z<^YO*16&B
MJ2@9\DK[0#(?HP[X$:W@(/MKGT+$$M\, D!%/))NXVA'Y2#J.T3=E):1X+,T
M#/^RW#KST: )'PE[Y*QQ#Z3^2Z#2H-]/X,\T_30%IQGJ=I\>PTR)]F;#H:23
MN;49'D,N%;ZDMJ)[E4+>T$%I!5H+Z=3-#[02O;*/0A@9F!584^4Q$_7=;-VZ
MF0=TX:23@RX,D_9Y%@+BK(.%D6]I LYI#.&6)F(\F ^A5X6/^NA3F;TDZ!\9
M[L\-1.P/BYC,:3F$V&06&2.#J&3=*HUDX@$L<9T!21]JZP#T)LKY8&@DNL4@
MP[%TQ<"1!<7U:HN6;]&PTR*[$HI;X\QA[3BXH>E.TGC#+EF(MBA/DD7\.\^<
MMZV_VCI^0H#],;^;XN])S(/K['&'M^ 4RG!TO]V@$,5N$("7"RZ]]M<IPE.V
M)57PU7F+7N*,A$S$SD6VR9)T]"?I.2Q2'2S=+PP-&3\OJQBT@> -D@6@' 1Y
MX0$/(V8A5.Z7W".@YT82FR:V!][XF<.;=_+FJ:A .L"1=Z%*WH>O:IZD3 L,
M5_25R.-G2$8),C$0YGD&.O1IYH0WY ;@K747,M^>88X2.4WB G:.3P5W&9K,
M3\+DL$J^$<JQC0^7Q+#6(4-'N")Y!W%'F&VS^!5OJ6M_O48@B?MN9Y@?F=TT
M=;^,+_I.-#YN=L,45JG@"@%'$V@[Y>;/'#X)U7)B)_"!W4V1\5@,]F)R8;)8
M*U#XS0:_$;!OWB:-!U0#\5L0PR><&JE\7IT3DN<C&5O3?)TE"0J\*%X3P]_P
M^PV0M NBU,HY_Q%4M):R04P#FV-D-(%Z*29[0#]'X;.!R#9,QGG^_FDT4YN!
M[@9Y3W&CD\VOX [#E?<#\Y:+3C^,Y 2)3\R/IW2[LG$(N:_^..[YE3HLE;TK
MJ%%^_9P@(R:6:Q&M3TSR%>6^)@PD!MJ%5R9+$#.IC&O"GF(R<DN%W'^M&F5"
M?3(@$A^WR$ FCG<.%(IMR;*?1^OS8ME''?%RZ\>X+_$&)>E5EJ28H8E-:%TP
M58>1=3C=(QE(H!O#-(R%N<%4KA\ZJ&"BA:DZABIL*+_XZ?8N]/Q7W\M83)-H
M3TGN!^:;SZ\;I=WD#?? *;IP)K.B)),FJK<U9;+\<NIY^Z4\;[(TXM-.6PD#
M:""/50$UFI"],C(*&6=%'Y31F*J\_QQ/^3:*KZ/L)5UGP<6*>(TF%-X-)/*>
M2$UE+\>\*1*/Z+'&')>UQD#UH+GQE:MCCKH2L54;7)X<RFV8$%SD?WSX>/;#
MAQ^(7\'_> \YCZ\Q(>(M^L.',^?C^X_TM^JW'\\@ G9/-6G!Z%E]1IW/H#*5
M!<$SI[RGKO -Z$,"^&1\@#,*"Y0!H-+>C=/#9W<WQ#PKDG* ULBF65/=+ZO<
M*F.8 %R./GLD_OG!C1<Q2>=+L[X]H)@\<OTA]-B;RJ*K,7VP'=(66%HPW 9]
M28]SJ!4HO7(*.[R.$R5#D:(WF?.V4^-367+!&VW 5>RJL]J0(9]\CCZ:3\PG
M-_X5T=#I\3.J%AD;\?X%OG.QKJ=E'\@0YK3A$16I_R^."SH=BWB'1;IP ZZJ
ME%DTF2F&4V8:%WL98XP/L9PXIC+.23PK.WDE/*$T#<B.2T#2PN4![(%A2?7(
MCEQ2T;1U3A Z\55/#MO^/7Q<A)Y030+MBR-T9MJ(P!R;9QASK,/\F0CIU^RX
M9"+Q/HIYJ /5P(I*^6_]<!5D'D4X*4<]",7&QQ<0DK7BBPJ_\H)V^A/N-;X3
MO47X"*\LPX/Y',$^IG]>NHF?Y-F.EFBU#?U_9"@QXC(@I+-E/2$OY%VXSU**
M15#D62J:MN R,,M)5* OBXF!\95\DZ3^#KQ0X&X6)EP(8,V/QKAZZ;=HN8VR
M!"\K1/?A<N .>;/;!]$!(2I%,!=*") PH[)^@S>)-DKC/%FS#F+M,L#[PGD3
M-SVNK6R2>>!V"#Q^WAB-]^3CY^U17M3A+9)(F8GL%%/,0QE:[\-OM..>%N;T
MDPL 7.D!H&B'1&T5%,\<3G,22%USPZF!M^[X.,9$U26[L'RSYS?A/7I%P<=E
M1/[]0$!@UBBFKGL#[R1*!.[?(NC<+\!J4];6N)?0!,.NO_&D+>=_NKO]_R[>
M'(>TY7R$MXI^_.#PAD?VE9QJ)DJB$Z.44/8_* 9//WZP%H38/U&F-LYR$LG8
MY*#**D@AC!(50QHQ5^PH0ZJBV!U3Y^MPP,W[[<RI008?WY +-.<V RXC/D\$
M/T.8J&$I-#B:#N7'QLZ=8:[_)7U :1"3PK=>;8D_CA&<6D;K&/I?DGT1H$N!
MR;7(M81_)["UH#EX84JX8QA7V4&A1/$8NB\^--*]-7+B23%A?)+"[4CC+'B"
MH]YF#4Z.Q6V<Y<F<CF4D%>L%3;KD3X++>_'J^@%HNFZC^,D-4&'0 UF/R8WX
M+]#$^^$B)+CSF-..4]"C RKU$/&X:.W,R7MROH[B<^@+"<>B#3%H;B['4E>.
M%;%LP+WRA'=Q@,H2-H.LQUW^^N90W#"$/B)Z[)"E%XUB++ DX_H7W[@Q<' )
M=R8HC'CW?5T4*[(X;P%BMBG4W62H;R,,CFW[?%"Y+TC)"GL_OD?E6 ,L08A:
M'Z4IG!>:\!-$AB_@'X>\901?"6".%YM-3#S_\<V-7]/$7PU. ,NRC!*YEC4+
M2@AX;*1.?:=)' ]21UB+&V$MX.L2IBA^DO@8G'P0XR:&)2>YFL6./8']((DJ
M-S#Q^$&"!U2N^J5"\+B7L-&1<8FVZM.5LPSC8B69'U M\:"X3E'L;WP -Z@L
MV(1.6I0C!K^U>I8 D^Y:TH0(X[MK@4?LTPJ%+I[6YQ!\I_VUC[Q!ZA9.;W1%
M"\TXF[T$_HKD6<;W%IE/(V;=@J[C<L+C7A3&1L+7H1A!3G :LZNQD53 KVK#
M&744S'4A*6?T'+BM.-%J6L]QMY:9H;!]E0]AHO2J!D=08NZG30X+4&V+M<"Y
M#8J;"/"G"'J/'PN1&R0^&,+?--M.NG5#IUQI&@P\(X,N1UL,'?F8+VGN?H7Y
MA?_,W,!?'T H8#$\@G_PD*RZ-U<.1Y<Y<SY\/'__AS/!A0VFH6C:R>.'2C[2
MHZ:J'7TB2B)F/O +ZP,O\IA<(<"D#NY"#WWY,SH,R\7"B#F$FH/)S;[_DBPL
MDPVB@&!)$?&AC-Q0B,;[C-)A/L<,O!_O,#$BSUVGX$EB+2YOM%'+5/KGSAJS
M7TZ&.;$5^*3":#>T(2>(QG=Q,S](P:(T;'TG,CU)$[/PM)J%VO[*#0+D71XX
M[\0*#C08YNP?)4_F@KNV?F4#Y^R6.AM/D<2F:)U/S,O!R>>*UQC=0#SQ#)4$
M-)J ER3;Q:=F=&<87!'B;0?I*H@K,HT\GL@K9%BW2XYCO.^C"EXEJ,LR&B4$
M4"XC&D:9;[FAYC*F^@+X*4C@!1@"0I/.#K<&BNL=:14.WAMK=UP)>O1I"/@C
MJ\/_)#&K^(UAL:N /,7;.^[1ERW!\:_G:71>7^)I<$UR;]U"=!B(T"+X)Q<T
MCV8P]82VTV30,3< @;_3+LEDGD,T3O,:T7_O0J*LR&,)>R;=$D:91X)^R]OX
M#CPKJ$ZD")ODDW'$HPYZ#/C(1EK&Y5L*IW$Q5>:OB]4JSI#WB!+D8DX?"U_7
M$$D0$>=@!F8,(ADK5X??'!K/0ND"O _I %%S>447B'\!]('\D"?^8K6$4-AQ
MF83)IXF_,VR@O&&B#!.:YI#8"?F!EQ:!+4?63]B9G<E#$NX1/HJH'!-./3"6
MT<V7%(5][?V4\%D5?Y3[=Y 87$+_^$98RI-)KO H'Q.:9$QEE"$JQ0Y/X5M#
M4F+B\83Y>PT/3(N;1'/X.M'1CDX6 M2X@E9B@$88MA@&U&+0T\0!46>C:+>+
M0CI6-\#O S?]YVYJY.N'.%HAY U5/M#66+Q^ H0+YP_\B3O&T5_VK,V1W<?&
MG0"NXJ0#IP%2A*#@,U)X!-)?>%O'/.Y*UHSNJSZZ(I?R/"S?2RUGR, T"+@W
M1S8 OE$9;\_SX$@3OHR+*>'OJ(<P^,[B:Y ;X\V B6#BS@OQY'VEY)V$T1\9
M,<3HJ-ABD=%0OV1&-G==F C_P^BH2HHP]="F3VYA,$G'_#M?D^IDD%=', Q]
M8I'QG3SPS7GGX5;S;.K42CC,606NXS)59B(]FO%(G%<F'U0Y"1UX& "@X%6$
M>Q!F^*IA\G<4)I=HC1_"W#R#$BR$QVX48_[<C0\D-@F_]BM<$P\.-['I'=LI
MG+K/*'6^#7"OOF/1G<X+Z0;_BR3HFTZK/)LI^O_9>]?>QI$D7?BO)' 6^U8#
M<I\JS^Z9VR?Y5F,<EV78JF[LVQ\&-)FR.4V1&I*R2_/K3T9$7BG)=BF9*=$U
MP,ZV2Y8C\@F2R<BX/.$,+GN#B7X@V[C9S0]7:!EDIS'+8F9=REHF&PHWE+N4
MX.W1= PIJB?@Y.%EAD0;U<Y3?[M'313,M&2!+LI\XYY1*;?\?:!Q"3?6(1W'
M:,4OVZI>7>1EW@A_\G-59<TUI-8A;EX_[4S#H26/F)+-4#ARNT"672D8($9G
M3*Q"]P!B]Y#K4\%Q.8G7LTML6V939P+T,..(W-ZA,#O/WR/4\C?("*#!4JX3
MLWPQIO!U;UED8O78)BTYT68[>J_=K0&6SV[PSA'%83<NLSNQ)^10DSN972@Z
M0T,*V4"32;/Y5UZU@5J@17_91*L3O-43"S &*F-</AQ,-/Z 0KQ5S;Z6N4X,
M#P.,4VR*,"A2EMJ]\;(2P&:,KPWZ)@9Y%JX-RF!Y=H;,1-0:C=5&6[EG=VXB
M!CN0,D;:9 \X=07QT5[I:*.8PMF@H/H82O2%0Y/:<?UEF0EO;I^V0$H&V*P\
M.O]0!@,AD3KXO!;M# 73*P_.R0]541O:]>'0><M3*)#7@9QQ]H\E45_!$7D\
M.;V4Y$=VL3R=DL4A=-<Y!5BFM;'#GT[",)_&71<S"Z-C,BP-6RU@<6Z_P4B=
MEL4*?P#;;AQ3NV8_82'AFQ9(NO60(*L42QQJ+DCGL<9T;5AC-<37\[C\90=@
MUPV!OH@W;JS.*8@?B8,)<)BIZ;)8CCE.T^5\B2Z#/=>/FKP *P2?_"/]LF0"
MZ(\X$$G.(C&:[ .W"@U)U31Z1BD?42WNB\,,C>K X:,-+5/DLWC'^&3CV+-I
M'*.YZ3F*#UPYTA\N'>4#/*;IA$UD6YMT0(<"QWXB%90\*()N]Y>'"VBUK$7Q
M 'V6'+5=[7MY+(EMLZ\1&:]Q@'X?YZ=I3WD_UEI/W',Y-RAC,\ ;=.XF,EWQ
M!]B=/_/JH4X6C\)E*;PB1+:@X(&A7@'8#Z8M;1_UXU->SR<SY2;X12?%K2HN
M!0U* W[NX>&1M];6BG^03H1Q)#].%YY7 ^1A+G%].PK;2(5\-/7J[U_O?&[Q
MKS_?!?,:=U^AO-Q?KR^GYV?L;CJ>G@>O+W4?.O0&)[.O#<W8Z6NB)(H]JF9'
M7QLY6VA0L.P[QV"C[;%6T)9 <1BAAU 54G_)RWR^G$/5=8Z! J^PHB[/GI-8
MC/J2W(' *;I(I$1V.C0DW:[-/5R;5T?U4EAO4CI%3SZYM1<'\LH@8E4ZI4RQ
MTFX1C+!QYH.5>UO:U@%2CUB34M:+%-;[2L=EYG9F6[_KMUQC4\\MG/ZZ#>I7
M\4J88QO(V;6E.<PPG1BES]16I+D@J_*6/_%RV4_GAB-8/ $H.71K6%]8=*C6
MQB E1JKAZPW+%KI0 RA\*?HM?\BA *IL(=[E5U%O9(7E>NII\2Y77%P,9F@L
MM;!2 0^'R32-YY!&#/'EJK8 MZV94 );=@KB!P+)#ECJ2@D4%F6$9E\7QCJY
M;X,2*9^HVD\A$ZM6,9')6)B1T.Y*_JH$4Q+55+68/"J)'Q[ ;IM$"E,?5%<M
M9.%Y_@018<"=6[@;B9L/%+>[,_Y(R.WG]:WW=:3G]Y:W25[R3$UZLM+A8K/*
MTYW[E)5@IF=(?;!D,RD\6*=R.'P=-UXCRDC<  $Y\R3?=-4&>W.NDYR\&7%T
MHI-0Z W7R9NQ1YY[O*U6ASHB+LLOO'VL,E.B(T,W<+RIQ;O"[\ DBW42JLZI
M.^5=[PU[T8&]N4:)E$,<A]2/[#HE0S^A%A&6?^)T\?G3QT]_ZB5H(=[&V5+
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M1Y(R#'YCC4'>*%C+'<$A?D'32XO@C8>^EBX<(\LJ390TDM/Y#AV!74?S HS
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M2%S3;(FG2>&P#P*E>\=PR0N&"_THD>?L)'QD?9Q*P/C22I&&M02?K#?4.;[
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M:S W)HX1BA\<_W?5HNS%#D[3YTO]0]O:AV2GY$55SW@.1-7-I1R=Z>?R*X*
M&0D6GL^'I217>=?&"-?*:JT*_:XHO#[Z4"BC8+ RJ.[Z6E;WX&3!3D_)#8BF
MEJDXQ<FPKQVE4^&TU69_W>\ K<\TPBC .@RT#G/DQWKML"E+R. ;0:MY#MJ8
MG??Y)A;/?UO4-]AN+8^HM^T%RNP@<Y=H1^AQE2,=E5Z]=)[_(4UN']/W9/?
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M#P7^(+7^--IR3(LXJ>8T6>3P5%AC4BZ6T#<QSUO(B]=MV1.M LY.D>HZTV!
MXXA)G4PJ#3_@)B!V>1.\@KD+.=Y8G(#0U^;EO'C-?[Z)1W\/5 =]DO@C=4)D
M"O^=,;Q$X!\!"-UX&12K]^"B"$EJ%IS<4G%FX9^#\>3UL/YB\](/>,5K&WC$
ME=NC9:U,$]"E_(T7V<GJ;\@@":[A;(9-G6('JVH[-N%FI7Q)@9UILTXVBHAE
M'L6JH'R+F"W)9]8KPU:KU EM=/*7@?F!]VU->?-;5NSF-(F:!E;#3E:,UH--
MUV9%8HNJ[>C8)%J Z#",N'TN]+;[T;WM@EJG2PEJAC7N-/ZK\_B=K\VWQ-HV
M4A#VV>D9F'P2-LRGM,9;!AYS%@*74[VV=W WU;,XX-^U->>MHL/JAQP>!3.2
MK)FV N_>O8%1V_!&$)$(WGL#XVR'&Q$%#U,E.& -=EW(,$]FTSHIFP1[Z+P2
M?R 8AZ91?W"D1%__<)RPHHTI-!3W1>OWL'2*K6*E"OJ X#PB<7-I6PMM;V3%
MUHY5\"9/Z!00-\M[_/=>:XB_&]IWU1$KZ8.#]U+A]UW$ZV8F8=K]-]14([SV
MRQ(\ZOR)WP@%#8UTZZ'71_?P6&T^>QA6%P&\.PU(@-K0[;0?F.MM7VL#4:%5
MM%T9'H5FTC[R>OJ82!LUGY'8\K*D2@@UVU6.=L5?PB!JS4ZUORXQ0F)10C0,
ML;!6@#$]9(0'.!!4_8G"Q-2\6OP*#ONVIMW^^PJ^B:(3Y?%@(T+1E\9R?Y[I
MPE>_%4MIX<M<>UE[,<1%=PZ3:XL/7JAX4U<IYQE68)*[+SY!UH\GR:>WLY=,
M@JGZ5/GZ1KBD1AL>/M>%MD$V$B1Z,F)#A?%'XI^M.32QM&H&B=DJE'CCA0U<
M)(%/WU=LH>59+X$<)2QLZ,9OR?+94D+B!&C\ENQ47DM)(;.CLNIT=?Y-'$V$
M@P"!B]W'6: HIF1AV\"A+[XS5B0B F^FA?-OBYQ*7L@CVZ/+K%<BG>%W:S.7
MHD.C7@1%36,PJO)ARNNY(DR5O:O^VPP(/A(?S T7:^#QVOWC*0P4-MT$)<[>
MWRNF[H 6?9DRA:V.,P5==1&=0I^E)QV^DD5TO\OVL<(--U90N!<H3HLCSZ#\
M-?2ZK_FS['.%7I*Z*L6/*4U&IE@3_7]?NFJAAAD]S%4T8C+JMH?H6VC\+BE
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MA'\FA"5_ /=:7K\KWC3(RB;[PX<(;.,XHK==OTB^!49%8':+)$[=N;B\D3S
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MMID&Q%ET(&+L7>D8$>(12V;02#]V*ME.:Y[EU"JL*[,BVD1OYVXE!-8B"><
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M%JJP9D@ .^7R4C@3TIF9<#1CI("!!E6<,D"4W5<A%K#216P>6;5L9T7UC(7
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MA6Z=S,638YYEM3FD3HWQVA;;I_S\)ZFG<TM3D3)*_+E +]UQB$H)KW$IP(F
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M*6KHDD+,:Q&B=$HDB3,I!Y/6\:DCCT:DH':<3)1,CE$H[>ZW2;P3X(RR@MO
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M[CQ86K';Y;L<QJ7LW C^K27_,H5?7O'5R:5J)$Q2)/!Y-M],2.S/ZRWQ\Y!
M62L@X9+ PA>QF/2V A%F#7(3IXG%8 U&8A=?Y<6J&.M>V8>5P-1/"_EQ+EL*
MEO(@L,6,4.TSLZA6=*<,/KFBCW4<!CX+8Q7.(<$N/B6N"S.K._U/A94S%+!M
MA)?(N)-A*H<F2D2)!YQ-G1B=O$J2B"X21HP[>>R8+"P@\1VY\<@;(U]!C@U^
M2PEG60X_8[C]N$2:W?(23IG5X-N5E,X$H?0S4Y=&,2'RH:;ULPZ9KMAA?(AY
M++=#IJN>=C[.M%"%.D"+4N.#VLY#02F];XLU1[=8*]_XQ'5W+M9 6>>)T2C'
MIU-L+!,@23DXJ^A]:M35 4HT2PA JJP.4&TEI[ZCBZ(>EX>+-"795>BEZ8 @
M;#;(@HTR4QCV:!149(.2C!G]]^RKJ78##J*FB.G5;+Q3I4_LMTJL A__T\)P
MC9PJJ:H2W(O>F7194<^,I0WZO(80U8% 4/<O\^PASOY*LD<O.#;:0@R_4,=?
MR \L7O,,BAO0RQ)PW(/ID9XF(C8S";3[)-X3".EF(-14CMYSDT4DB-[/0/3P
M$.$9XH!'F&P5+I\/<UCDD4^2A2<C]S'/OX'//E< O0JVITW%O,BS;9Q ZF]9
M,=O;>VO*X,$!K"HH7V#*SO2*"7Q:)$7IZ[68P]2QK?-Q1UH!)%?@FXMJP:0R
MEGE1?EBM!RX^_=WPI"H,23+WE8VSKA3:YF<^]4+(,)OKY)<6ST=QZ0/X? :X
M]_+>'Y+:*P?]Q##M,_:@% //E>4[%8T5/ IIYJ:[77Y%T'SA@N:OWGH;1"0Y
MJ%1^2>+TV->T&+"ZAH#[%4^OL8Q'3C4.,LHWWCKC\"&%H'-"Q"B/KWV!)I;+
MV?4JP0[DU7I]1(7PVD-;0/@6;RSX1*9].<<@0QR:8OK%8W@]88GST6:O!5&>
MCP0H*E3&=)?U"A7/ZEU$Y4LO?,Z2X%<R6BZ+&'61LF%Y/LOW0VEAOGC-E"2
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M0?A!+RJ,QQT^RHBSO:BC45/1ZG4D32K#/>>[G9<<EIO6) -ZV];:@'D4@I<
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MG3J@6!<I>RPWA>,8/+L OJP59&SM41!4B6JD;'\B(<1?P 1E+5I9E#Z]@;)
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M8?V)OH8[)O")*/?,2[(ZM&7/KBC(+&H=7.39-@;/CSEYV=06!2'+Y,V+Q-&
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M%"'% ':T!^R>,!3::].2W:D;BNUH+)QE#T3JT T%>?6 *:.Q7=,.!0%4]DY
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MQF("4LJ'".K!X.FI3H;!OL@6Q=_RDXQN1/\#Y.X&U&4.&4F]V8WW5B4T5[:
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MU/C35TR6OB4F\YWNZPJY=NP2Y0>+"B;G 23(FXY+?2"UGHPQ7CGP8G?!ZP&
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MV7G0+]4Y7D'H1W%>H^,F V_?H[=#E"5.Z+U]AU,XO_H_*-G2!PRCT;$YUR=
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MKND5RNZ^"YGA=E?7WKP/(599;D=%:2<2_$]4;RNIGU!Z8]/+4UP:2'9=X*=
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MWYJ6HR;RG-M%[&YCV5(%QMTI3&==&Z\5'LQCC%R<*>C-!&ZX_:EVDQ*&W1)
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MU9T4T:&%OZ\RN029_;:[!AE3GJ[Q;345J18N];^Z!^!E <ASR9%F2G.B$1A
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MET0B6 *\-^<'G<:%1E*V[*<H_))@Z0W70G:(PNGSI[]]^ID2FM!JH-*['G$
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MY53.YH'<U'2Y ^F.K5Y:\? JY[3B=%JC0[#DPF=7T-43R!\T[T/8&CR#^/4
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M3=UAONC_K-.7D(X?YYORR/&5053*?12^W&RAKL!0+;GGW@PUPB\@@!JSEX>
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MK(3=3Y<]H0I^^+:2Q;OKR G\,IW1[<GWP-%WGV. E!XO! G4L,.HD.?P4NK
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M%XX"-U=L>ZH:L6KF?O?]71>^;C'VR.,XNW! 1HF.%!?<*6#YIZZ\<2ZV.",
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M5ZQ#?")?K'C.HB\[UO6<^$0J 2AP"^[XY4"H-Y)W67O%>EJ2QTV*I13YQ,6
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M P\4FBN[EDA>!8T:I;@)B2PKHHZ&W&@O'F229>7U41?J[$6&DHC7ZDZC>[=
MXP9R1,4ESM;HHZ#S*BH(G.>%C;Y%0/ ,V$ 0ZM66!);!F?S_<W$S72-%'0RB
MKQM8&D6T?';%_"W&)!= (B% #H@QR@38(B/D,!#C),#5' #XWGI&&(H"A+S#
M3S=D7N)CH&["[(#RX(1[/TF3Q1QJC5K1A42Q>B.-#%V>*4LP8;E4>!)1V]\8
M!P+>:%T"<9W S0)G6N]LU;QMC=^T*/ ]4G>QV<V413J-G3&O-_OZDFU55_CG
M/__YWZO[FV2'W/O[;S[>#,?408)4NYAOM==S$M+*E_SGYA\9EF,#JKGE(3M^
MN",AL*@IBGP@?[=/Z4,DY6=+0-P@(0P7+<6_CP*\^X3 EYY82&C,L114P0FO
M7)<\3<F3<R*,NQII#YPY$3-A:Y.W/2"U*$Y(D!8"IW;I,%UFAXQ6K*6\GS1.
MB-&>/,7O16U*$E**E>K-]M7Y81,"I%QW]>[X ;F-6&,BK4U?D)O%16N(M[3^
M5_?PO\"'?0C_98VR$F(Q&XXSY ENM@6@\CGQ4QQA;2(]/6$9B-34)<=X)!(2
MOK\V02AAS'6T.W(25 X^/49Y/S6[3E/M<C[%1<X3'=Z6!RT 4LZ+"_FHS &L
M[;E)TZ!;VQZ@0RSF1V5/)L*,RNQ6#/HU>D=!1&]L$3+;XT\6@,[G3^V+^TS
MV&R_)8C.L E$"8/""ND[YL/$FD&]%(74;Q.$:FP)BXN'*&3P) L@E/*D+B-J
MVOZ@ Z? ?C0<!I13.8%5&.!SH:]1Y'WX)##''F@X#"<_2'3TBQ.ZC\(=:?YH
M$VB*BFJ5<?'D^-Y=N':.?NH$#09D$\Q2WG,7$N-]%)^:DOM_P =,)KEW[,L,
MD=T"(-4H]IFD X7(NW'B$(L\2</4<HVVONM;!;- J"-GFG_-.,Z_V *:X#+2
M5]'W"I&\5%'89L^_PH=7S53"=1P- W2F3"S647;SK%IC%MNJHL^'"8+:W,5
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MZRZTV=4]"O 74DO?([*3#3'D1D!^W?MQ&V+ X>%&(";:3;IO@?SOYPZRO^U
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MM;_%QX1"%T.0?B 4-NW,U8P"NKP[6Q:F1<,Q[^I4,!Y"P1EI6%%-><8+@#!
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M3,"]<A(_J0P,>7#'-<KMBB7Z)OX1,)Q1(9O:_T?FXS$GS-HK$0A+2OG#4$M
MG%I8@Z=WB0],A&JG#D95(.$5OPB)X^:Q4WY*!<78_XYH38@R>[).+AVU".-F
M0B@C@86 [$# (C^,-ML[?,P.WOH[?@II?EW7S:\Q 22_KIDJU@\0>G).9!T2
M($5L(?CTL IQS WXF[C,)ZLL^\,FP^3*Z^/7+W_^\K>.LMG^$.01KI^_8BI\
M]UT23'^_[@# _A(D((:?K$+$W82ET^RZ(?_.\UL6O9+K[$ +(K\CRL&+GBU5
MY5P:KH+US(JN5(?;X\^7*8B4I[G^D2;:]L-N!T\'0R3R'/S"V_4MQ%)@0%S2
M7S'7V(2LX(75N^/37[^-8B*45X0S:@TPN%*IW-&N-E9&71<I/&%7;U4=#I)U
MMT,!&[MGB8Z*@X&*B*L#;;W[^A&][J,L<4@@GG=#\]902()ZTM-=2.09S!O[
M*0M#9X,\]34IRE79%C<Q+29#7L!&-IMH"+@8EIL#BD_O>#ZJO0RDE%!E4_J*
MXH,3=CP2NK- GF5=$32_F\PT \D@D(!])83'"V5A?@<2C-K0T.C,7=:[TRZ]
MW*TD,=7JX%Q)5_@DU\[13YW@WM^B%]='F-TFMQEI:4[5=6:P@/8TD#34>'5>
M/_ WI]7K ^=F* T%"60KIZURZ9.\VBY(+_X/;E2 ^E202"BC3$N#[5VX1D>_
M" 3HAJ)R!H&1M>5!FK&?8%T^:5[-#CD+1H \P+: 2'K[4 &1%RK,O;PZDT$B
MXA[K!&$K^8$42, /2?ZWQ/=0$;M5&2-KR_V J3"-D]>(]#@:Z0L?N8@]_* T
MPA&#WCX/.A?D_Q;YAD7H=J_-Q[?0IQD:U?<87<&IG.X5LQ\1)^EKF3T8U:SF
M*^I:"Y8-:7-(I5?Q0O;8)-6];/B[D7ZZ_@I +3"%)XG4LMVJF W9A8G&K@+6
MO4N/J-?+K/$*7IWJ(45R#DVR+M@(KU!369@("X>T7%-'A9S]9T'JEGP1E/<M
M2*FKV?&GJH_1L.+SOP=GT\O=GRA/LDSQXKUH:=$(D*=SC;(T<??X*H7?:X;5
M]2>(QH $B]N3G!WJJSR\29(@PGV;<1,W/UR:4!:F3XZ/)>][K+0%45SWWE(:
M"U-KJ:*3.979^=\/X.USY3Q_>[E&1R>F;N[-EEC">]U$A4- 7CV%,DG-VBS:
M-998D^'I*(544I;:P8+?$S6('P@8Q%F=!];[ 5;#L-K027!6GP9&DY8K(&7\
MO!/<9BF)<LQA[8;7][Z&HF));07,5*F.RBD> P54E5+[/7[;2R<2CP$G<\]<
M6T?(\J;\63 L0Z%?7\LW_)*]T?4(YZ]E4\$0,)"J6&<2-_:/N4D5ZZV8VW>J
M&-40RT?.?K>FZJA,[P'),<Q(RP[,2AHVT+'MEB5K@R$>Z35YP,)!I\):ZR.0
M8F)3&6D<&ZE/^ L*O*L3*?&"8L+)MEL:,DNJ_,3\9D4&%S2O IF1*5O!;M=Y
M45;_W?=0V.BO+!IC$4WG7517.[0Z'N,HEX5_=5P7"Q 81M+#AS+ NW"+*+M?
M.UE2QXH-GM[$$)3"YT]Q1+QMQ1-'7&L?19N:LO(9'O'N)S2F/,B];H5(653K
M)1) P]YF9#4PM*35^2YO3=?N;=25);C#H(CG0+V6- EB6:=EL06+:)-VFF)&
M2+*^ ?F4E]7G&J?+BLNFP5!W85H5*M:?!\XC4)95)H::(@R&T2R]8]V1CK:(
M?-L^X=J&0^.R5P?2<H7M/N8,A<)BU1^5U/GAT-<B*IT(090D;L.)@/]!PST+
MZUWWN1FP !0L21^B9DT(5!>RNR=A%E]>(_K?GVG\ ,9%FUP&3;4&,8UTUNT*
M?X)G=>RAHA$6,0AZ>B6WXT0(B\> ?//:)T)\UV5-C=J>S1\!A4R5[+R=P-Z6
M4-Q(6E09:1'=UNRGRD1-^D8'V2@P "LT16[D&U'1DY;V2E2JI\EG@+S#+8M1
M_L+FSL7M"]Z.[_D.B5S%?_\#N2E6@K$HBC=-/.?'YCL^>AFHYJ8&7"1;ZYYX
M)-MMX85#8 825*'KW6Z_[*; RL/A4WBM91%[Z&.$:9$0(>*:1@LV5JK9,DOK
MX%6!TG__0:,BF>\].&&V)6&$Q+'"?_[8H\&\" IU'(X[4K&$/&U8E$FKSNG=
MNB;B42 O!NF:\(+2-/^\_Z[SOP=S?LIU_%@U2]C?M8S?^).E;Z"HLF#IU/A?
M'[.=+E@*$UJP@JA%.+ ,P'GD_Y<G5P=<LLBU^RTT@BV;-9 T@#SZM]1JZY8&
M":>Y\9"IW:,$DS@PT!G;;"C9-@6/]/**%@8J?HBKN.!;KU/TI3$<Y/6O&M 6
MCMN:YBMSBF $%'.*@M7/[X2IU-:^_C<,P@21,T5B2\A&CB1A+MH?4*-3+B,,
M1384)$$^(Y>4F_&WOEN4/&\DM!,EOOI'6<BDCO#4GVF/4-FN[I&5]>!)"3O2
MYN':#YIIP&7^G[A&B/XJ+3\@A-C15G%E:;\0U=$@;T8>U4L29:A-FZ;!9\0I
M?RQ2X),KM(TPERJC?U$G(%AS*IB[(5>8K]9W3\V\/*Q]1"X50=J57;KI?+K3
M0-+%V*3-ZH&_"\F-QIP@U^ ,YX9*?P8<;WDDT6G)'N\7Q9AA%'GI51 %YULP
MUT;ZI-SG["^*3T1II;GWM")["2'_>VODON>>*Y?E,92-L@;<NI5(J^!M&?#0
MO+CK/7T&>RDC&C/MH71V42B5PE&@.?]3>N5'MZ3I%Y;4$A1W-%/NUR"!X5!@
MU0Q(0JF-<6#H4J6O ;^\4=5S=>5B]DM2N-SF^S-HJD6H64=.0 /52*[ T??0
MP7>I9P?/#%&2W(5A])X+KV5SM/HJ#Y@*A<G+,?,4?:" M&1 *'W)WH)^ QW1
M")B7?X),HE8)G0E_H"6W@LB!?CD=COLH/%V?,/!5R^;[H-- 4CK,+E)A9ZH/
M3'"WBE5^.V[CJ.+Z)<3=3Z$P.!5IK7C'JGS[5GI^L_R$VEA[0,<:)?D_4;C>
MG8"XGFA%FWYIJU[2]Z"IX'1N++$&T8[TK[UA]NKA?P^26<ESOG*A=1.7*0H/
MCH>N:<A*[D!2SQZ3KP2&I2DDH+.=:IO8W_FA$Y#OB:'I"8-'^G$$HHP'C>E@
M,"1G^C=;FD'YC@3]0YN)=56<;!M5HY<!@S(I41%AKEEO"M^=2FNDS,1I20S*
MP^W! &8$VXCT,7!S,VV1UE>&0'24"+7!(/DN\>[=1[V(G<ZG(+<N\'#.X<*<
M4&_-78XH9EN;>=]"@4]ZN7Z)XI3H%43I?G 2# JCM:UD$$B*S#E]7JZ.>E")
M6ZQ*WN9]:P]7?,D.![PY$J DD;'6^&G<122K@!-+9F"E+@F "2T3Y07^7.0%
M?M%/*>1.M>;BWZ,DB>+2SD9*.^)U2BF<!,B55>6NZRQ]O3G6H (?<HC>G9>;
M-M?K?0R2SZV#Z)V0'PH]\L5CU(OU$XV "9*Z)9P=(C%B 9 (890^Z.3%5!JW
MTE"CQE\308)MJU_?8,;_WAHFLPI3WR.1:I@_UE:MFQ]ND'G(RR.<&L%M130;
M+R3.U&K@3&EU8/M5CMJ7/18ZJ]Y@"2G^4JJWG81A6:3\Z 7!"CDOM)PC=:RR
M4^8% T RO**%1I4=5I%][W,H]U^N2.;5AYO-'<J4C826YBQS1YL-DEIA;-IS
MP;%YC7=Y\(,.FJZ;W0O8+KQ<V6+Z=!M&]3&+V*/B%L\]<0EH5L16FV(/)G*'
M6!ZD6ALXJV)GG30*M<$P+TA=\XH&=%<U!<L64\TTV^<D8Q7+4IT(YOCE;\=#
MY/E;'Y]G60<L]KI9 L(A,,]:D!\_2S;\A)E;'2\$JT"AV&\AF@'U-%NU^"KU
ML]'*KZO%Z,T!IZL4'5EI?5B$PE7ZND<Y\^7VME6> /2,:\F#=K!FB23%%V"X
MJ]R2GM?T_?+7GQ]J#VDE>;._M >Z;EJ<H .#TE!PM_ !/YX[%!;EFLM0FPY[
ME0P">=MJRT4CRI_&]W?2=V2&#\WI8,T<FWCGA(483]KH1H'OY?E<H8>?DH3X
M(W)[UZT?XNOAD]):6 JD@B&G$Y39-0=<CKFZ1]4FH,J3Q;,1]08 OQX*LI/L
MB@Q8 NPU^89O>]*+0>Q^"O),F_'.;9ZU"04UD)FEQ(>ML=C#CK'RWS\1I)#>
MB0?G__[_4$L#!!0    ( %*!5ECQ!3/2VP$  $(+   /    9'9A>"UE>#(Q
M7S$N:'1M[59-;]0P$+WW5YA6XN;NIA((.6%/5("T0@@X<'7B23+@+SF3)N'7
MXR2;@E:TW4+Y4&FD*(H],\\S;\9Z64U&;XY85H-4\<LR0M*P.?_(SY+3)%O-
MO]%@M;/(<J<&UM"@X?FQD:%"*YALR3U"XUT@:2GU4BFTE6#/?)\>3V$57BQ.
MNUU.SHOUZ1.TJ4'+:\"JIMU"[GK>X)<Q1NZ"@L#C2HR4^25(Z2R-)B"2M:=T
M/L@<,IWV2FE0#^(#&FC8&^C8.V>D70QS1^1,M"7HB4N-E14:2AHQ1O<%IJN1
M@#=>%B!\ -X%Z=,][&OA(E:'BFI1(O$B6H(=01Z?)$_7:;8:?3?9RL<W5FBJ
MU.],,8PUWL^Q<-H%<;*>GO3JC+N9H=QI=1<E..]KS)'8W&=S(?Z!8['O2#F0
MCN3L)JS;-=W/9#Z%5%"X( F=%:V-4Z/1PEW49(L-,5>R]VW>H$(9$)K;E^F/
M#N:-E!PZF'\CN4,;X-=8?3%8>2%[]M+DKQ[8O"]LOK9Q0-EV^_:!TGL@"_:D
M4ZFAYPH#%-,E'SNK-395V'@M!S'N+MKK,I4?"ZQ/;4-8#@OTY,K!JO]:>=7A
MFT2M@.<!Y&<N2X(@I.[DT$Q:-EN-"GAS%!7QJ)V_ E!+ P04    " !2@598
M04<-'6L$  "0'0  #P   &1V87@M97@R,U\Q+FAT;>U946_;-A!^[Z_@4JQH
M@,@6+5NR)2] T"; L*((D@+;'BF)LKA2I$92L;5?OR,E)U[JI-Z6)MGB/"14
M=+R[[W3?W5&:EZ;BQZ_0O*0DA[]H;ICA]/CT%V\4#/!\V%V"P+"7F*<R;Y$V
M+:<_'%1$+9B($6F,_(Y5M52&")/4),^96,1H6J^2 Z<V9U?K3?U=S\@Z]@<3
M)I**":^D;%&:&,-E*E>>9G]8#:E4.54>_ ?TS.NUBD(*8T5HC/W:))T;G<+$
MW2M(Q7@;?V(5U>@C7:(+61&Q%DRE,;("64-7QB.<+43,:6&L#;M];699,D,]
M79.,QK6BWE*1.KEE^UYS8&O)<E/&!3->!I)46"-O7N/03^9#N_=X/JSWR/;(
M]LCVR/;(MB$;0N]P/>2909P]%,)OC4W9SGH;7":Y5/%KW_TD=T-==GTYE3Q_
MB,=[NBI9R@SJIHN_&P(\^IK9NZ.0@0-4/9,PO)-"PPK) OTH<EI3^ 67%W3!
M-'A)<W3>I)QEZ"3+9",,S$+HC*GJ<4/V3WC_57,/S(J'QK=K0OR[Y_\S15F?
M D8B4U+$1"85#-#$,"E0VB)%"T@$D=E;3J*0G,NES80N37K12T,,K4"3CI\^
M>H^:'1MGBMY-ZU(<#((@^#[)F:XY:>."T]4FY!!<^*W1AA7MVH"3\;0ARB0.
MFP<H*AVG1%/.!/TB"C=N]L:>**F"P7@<S? ,CR?8#X-9= .;">NYY]#? _?@
M^"T^7,=U(Z"=?NS[MS4^#5^V9SQZ>R95A2Z]X.3R GV4>H#@:<#)=1:&P5&W
M'N,PFAXA(O+N.@K":'QH"^_[5I KLD*?:%8*0+%@X,J[#1+:/3WW%.5@$ZJR
MDKJFF6DTU4[I=4K:(67+J+*9F.$@#.$)W<W&<$_&ET[&T7^6C/J:C=,-*F(<
MC:.>BB,\#4;K]60RFO1K/!U'?K_VQQ,_[-9X%DV#Z7KM![BG-(XP;.[E@V!T
MK=]2?=RO)]-Q.#OJEL$$3VX*0#@)HN 0U509PH1MIWT'/JGL%)8[R0NJC2/\
MR,<8G?[>,-/"I&9G2'9%T3DGXNC>36-T6M5<MI1"A&3V&>8YE960PAM[02RR
MXU^3==7L9$E4OH/NZ7:'G%RG=X2WZ]VE["7[DK;[_/3 \!Z'OY $LE'0T^S[
M6HUREU=G-%4-42T: ;4@@X!(2V9*D'(-;TT2.[5*SKH]!1-$9(QPI&^JP*Z=
MU6JC10&Z(8$%U6XGLV<T 0JMMTIR)*^HVK#3^6Q)NXL9F*EY8QGDNCC3Z$2(
M!K1<."U]O<*^]]-N\T AE?.ZI42ACIKO*7 L!1<#[*(6#)X\AQ[MQ<Q+.&+\
M;P^@0SU$ITIH@]Z0JD[0K[(!4GWX</Y2 G )W?!,V;*B,WF$WH$_P&_!R),3
M^''P?U'OO^T+R2EL?4Z%:V.Z=@-XSI3M1%+$$/ZF$K=.+'_]0+EUA(>&8!%=
MSTNENOG@N:!>JBCY[)$"^EM,^)*TVGT9G0_M]]3C5_.A^Q+[)U!+ P04
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M:ME80F$S4^:*MC40OS1(U4"\[T#\?K^ ^.(2:OET_6//5%A;52TIJE2^?N\
M[8QQ#0XZ$0H%%=D0XA@8JJ )DY(XB>4845-439]C8:),F1+;T> :7>ED"JTB
MB/&R80<(F3$@!GM</)U$*9=#8)\QC*45!^.7'(X.X- U[1S%_I/_**B\+CUV
M4_^,8MTE2/<02[IL/%!R:: $!R([5X$>):B><M^J;@W>CPK>M5T[8]<>$-%+
M/@';2CG\\-6;&(/!7I%>7-7F=NYK4$$IXJ79O E5=@; YB/Y6I$J\4TJ,<^@
M%2?*7E *I.N'5AX7><]R[J0AXXX8JV+1@MP:55Y%-P7F0*B+49F(N76*#HR(
M!=>"#!"^I.6R.4D]E8;*3"Z.,*XFY7(=90 5LIA;4:."TT27&:<4#<UR2BS*
M5=C"%[^6:W;XUP!($&<!VT-<9TT["4^U737Q;KVGML^P!P#;8-^(=^.4\ K_
M;IY,;DS#2-TC$1.[<J.DVYK"#3(S+?40Y7(=S^@/"5EPOU^$*HOKAJ5@P#&E
M]MM0JIUWZXJG/CF?5 85I2Z0A(VKA$81OMA. ;=H- 0)FF?(Q7@'"B)Y$BFE
M]7SK=O5A?EPS[D[B4FU7S;A;[ZGM,^P!P!:]?L:%$<]*EP\2'4&20$3[O268
M-:MBB_KR!@FN_[A^I<PQ+#;$Y-3X];B!*NWU*FR2@O.Y--!B8W+[Q@DVF"UC
MNJ"A<@7JTZ/.:Y+<12BI[:I)<NL]M7V&/21G>_TD6='/51JC_8;5ZJ.[LYXL
M[Y"-4I%715&IB:V6*JKKNLV5L7B#OIB$G1ET,/N[Y!K'\MNYU[5)D'@Q4UP1
MKW2/D [=;DEY>3OYH=<KY69>@*8<TQ$UQ"[Y=BZI$N,IR\0/R*JMDRORC8=[
MJ6;GK<&P>JO-KC/: ]Z9HWJKS09;;=QW=>8$TECD')0"+4/X(OT@#+Y#[?/*
MLM]"-U[&PBIMYO5&=P'[S'-A+<!-*=Y <>WRJ%B@AJZ7 T1ZS*@,96SXFY8@
M9P0%?Y<"#7!<5,K([;(\K/?4O#2"U7;MEEU;PCC=[??4JZ+2/=A30]OV:9'-
MG32!/=(.SD@ LEE5*YSO;1GC<TW%/[_(Y<I_;GG.?6MKMH7_3AQ9;4/QNU[7
M9"D\QH8&YDG*]7Q:K>IA&^1$?/4:O@1I3(.9,D=OXA0X:ZH$<>VW'>H$9F<!
MI+:KIL:M]]2KXHT]V/5"5<1$8VK60*("ETXBU;FO!5><V/ 5."%'*AL!E>$D
M'U;?;M95!@IYD:DIX-UQJGS:R2\Q+C+DXY0IF\_)7?B;-MN\R'$W=SO4Y[Z'
MWZP>ZO-8Y]Z\O_G<FP>=<O-;\\-Q]Y93;+K-HP\;G'3SV]$SGG5S^5#"=D?(
MW@I\^&=C=K9A=2Q0)?KXL-+!ID_X-=UI>!MX/H5#CK<39M?"S#I?N)?M1F?,
M3ZOT2C>/"E20=M:O=],:FYX2RNY]5-W-H4;+M-CY_SY_8]__.OUV<GI^QR"M
M^Y'<]-2O+['_,[V[+Q'.[=KK^B(NN/89V.P]?"Q_/-Z9G]<>Y+ET1N&RVW;:
MJ)-40'+UY%%75?E2+46\&F,/;CAK=6WB<\^P>#>/X?R"<6K(OL) EW044[?;
M8-UV]_TV'/SZ;"=&DX5+IVHG&4P"OR(GE*1 O<QE+Q:FP P@I+MSZ%M$)^O.
MWOY_:6C!<C:T:QJ C/?Z4.Y4+UAF"#Y,"7B"\Q_R;,RGQL4D_18=CO[IIW[+
M':O^+U!+ P04    " !2@598Y/6W>/0(  !670  #P   &1V87@M97@S,5\R
M+FAT;>U<6V_;N!)^WU_!TV(7"6#YUJ9(;6^!GB0%@G;;@VX>]CS2TLCBJ41J
M2<J7_?5GAI1LQW$2YV[7*M DEH;DS%#ZOIDAS4%BL_3#+VR0 (_P-QM885/X
M</97\*;3[ Y:_B,*M$J)P5!%,V;L+(7?7V5<CX3L,5Y8]2^1Y4I;+FT_YU$D
MY*C'CO-I_Y7K-A+CJE%Y-[ J[[6;1T+V,R&#!,0HL>6%H9H&1OQ#?0R5CD '
M> 5[&N15)[&2ED2@UVGGMN\5\5WVW;V89R*=]2Y$!H9]A0G[KC(N*\&ALE9E
M*&MA:@.>BI'LI1!;&H.:5\-,$F$A,#D/H9=K""::Y_V5L6\<#L>:B,@FO5C8
M($1)D#3(;Z\[[]K]08O:?ABT<OR/'G*>>DH3-?EXU<90I4KW7K?=O_[U%D_\
M# U5&CV&"\ZFB1@*R_QSYAVQ!6JQI4G9<#HZW=O&NGY&0AP5])9,R?<B!=9Y
MPX/.VP-^R$Y 6Q&+D%NA)%,Q^X\6,A0Y3]DG(3G^B7]]BU$"=#V#][/]8::>
MG'V_./]T?O+QXOS;US\?,@<[Y?)U2/T\AIXWV&=(TQG[@X>G2O(T:K#0O28S
M9A-N>SLU!\]*E;?.]Z94Z:(4/D2HNA2%!*14CR*1?ADSD"X40J#J)!ZD?*8*
MB]U/(>K[H=ZWF^U?*WF<IY3G!GH&<JZYA<H%CC9]URZ:P?%U-?A8&*2Q5-A9
MKVI?"J%4-'>.&^VH>?3N5_);RT;W%SD^;AX?7Y+!/_2J7F4\Y:9\[=1,T.A@
MJ('_Z+F? 5U8H_J8'N^0I^74XW/S$H'8!N_0=0]0IWDISEKV*_:*G<C?7W5?
M_33FGK.$CX%I& N80(2P) SC4A9(UAHH1&?(YI^4SEBG'7PF7C^=23[F4W8!
M82)QY)% W4^41F'/_0<V ?;;ZVFWW0G[&D;"6(V!OK\2]0_[]X2]3;#LQJ?\
M>9[L=\\-FW=(&Q[K<=X!&VN8N\EOW?V"N7]S@^"&V)3-V ^I)BE$(VAXM"MA
M+E*HFU2642LN)*+@C!72ZH)"!^3W#+LB_.,LPT^:TIF8AWA),Y5A:FJ5E[LB
M("$$8[B>D4C&?P C@)SW:?!:A,K@D"D]GC0&"81"AT6&8A*;HR88=# T.DR8
M*>C'HOT$-)2=D &9,"EPJIJPB; )&FAR")V"U&^.JBF:9IQ5=,IPMNR&&IM?
M&K=J;-YW;'Y38[/#9F#QO'"T0+L& C.*XVV]=%_(&&-4'W\*&:9%A'TBHBY!
M6P/16&C,QE$C0UA.&)^F"[ N<=*L#(V:1H(Z;I!$D:( (K1"&'7#&:=/R$W"
MXE1-3 7?B\"7<;KH]48M&TLH;"IEKFA; _%+@U0-Q/L.Q&_W"X@O+J&63]??
M]TV)M67ADJ)*Y:OX#M#.&=?@H!.A4%"=#2&.@:$BFC )B9-8AA$U1=7T.1(F
M3)4IL!T-KM&53B;7*H0(+QMV@) 9 6*PQ\6S:9AP.0+V$<-86G<P?N'AZ  .
M7=/.4>0_^8^"BNS28S?USRC678)T#[&DR\8#Q9<&BG$@LG,5Z%&"ZBGW+>S6
MX/VHX%W;M3-V[0$1O>03L*V4PP]_>A,C,-@KTHNKVMS.?0TJ*(6\,)LWH<K.
M$-A\)%\K4@6^207F&;3H1-D+2H%T_=#BXR+O6<Z=-*3<$6-9+%J06Z/,J^BF
MP!P(=3$J%1&W3M&A$9'@6I !PI>T7#8GJ:?"4)G)Q1'&U:1<KJ,,H$(6<RMJ
ME'.:Z"+EE**A64Z)1;D*6_CBUW+-#O\: @GB+&![B.JL:2?AJ;:K)MZM]]3V
M&?8 8!ON&_%NG!)>X=_-D\F-:1BI>RPB8E=NE'2[4[A!9J:E'J)<KJ.*_I"0
M!?=;1JBRN&Y8"@8<4VJ_$Z7<?[>N>.J3\VEI4%[H'$G8N$IH&.([[!1PBT8C
MD* Y;5[".Y 3R9-((:WG6[>W#_/CFG%W$I=JNVK&W7I/;9]A#P"V\.=G7!CS
MM'#Y(-$1Q#&$5HR12,R:5;%%?7F#!-=_7+]2YA@6&V)R:OQZW% 5]GH5-DG!
M^5P::+$QOGWC!!M6RY@N:"A=@?KTJ?.:)'<12FJ[:I+<>D]MGV$/R=E^?I(L
MZ><JC=%^PW+UT=U93Y9WR$:IR*O"L-#$5DL5U77=9LI8O$%?3\+.##J8_5UP
MC6/Y[=SKVL1(O)@IKHB7NH=(AVZWI+R\G?S0ZY5P,R] 4X[IB!HBEWP[EY2)
M\8REX@>DY=;)%?G&P[U4L_/68%B]U6;7&>T![\Q1O=5F@ZTV[KLZ<P)I+'(.
M2H&6(7R1?A &WZ'V>679;Z$;+R)AE3;S>J.[@'UFF; 6X*84;ZBX=GE4)%!#
MU\L!(CUF5(8R-OQ-2Y 50<'?A4 #'!<5,G2[+ _K/34OC6"U7;MEUQXP3IU#
M[>6>&MJV3XML[KP)[)%V<(8"D,W*6N%\;\L$'V$J_OE%+E?^<\MS[EM;U1;^
M.W%DN0W%[WI=DZ7P"!L:F"<IU_-IN:J';9 3\2UK^!*D,0UFB@R]B5/@K"D3
MQ+7?=J@3F)T%D-JNFAJWWE/;9UB]Z^5&:I0S%FM,S1I(5.#22:0Z][7@DA,;
MO@(GY%BE8Z RG.2C\MO-NLQ (<M3-0.\.TF43SOY)<9%AGR<,F7S.;D+?]-F
MFQ<Y\>9NY_K<]_R;U7-]'NOHF[<W'WWSH(-NWC>/;CG$IGNKQ'.><7/Y2,)V
M1\C^"FSX9Z(ZV; \$:@4?7PXZ6#3)_QZ[JQW&V@^A4..MQ->U\++.E^XE^Q&
M9\S/JJPFD;G]]*S2:ZVSUECVM$_3O0^LN\Z#+=-BG\^^?/DO^^/CR>FWKQ^_
MG-XQ0NL>-X^?_ATFZG^F%_@E8KE=>V=?Q 77/@.;O8:/Y8_'._;S.H>M'%.X
M[+F=MNLD$1!??_[HSMMW<,,AJVMSG7M&PKMY_N8IAJ8]]@F&NJ#3E[K=!NNV
MNV^WX<379SLJFBQ<.DX[3F$:^$4XH23%YD4F^Y$P.0;]/;H[![S*F/6';O^O
M,+1&60WMF@8@H[T^C3O1"VX9@8]# A[C_/=X.N$SXR*108M.1?_PRZ#ESE/_
M/U!+ P04    " !2@5981P%.6?(%  "*(   #P   &1V87@M97@S,E\Q+FAT
M;>U:66_;1A!^[Z_8)G @ R)U6;9,J@92QP&" FE@.TC[N"2'XC;D+KM<6F)_
M?6=XZ(ID*SX2.:V!V/'N[)S?#+F?/(Y,$I_]Q,81\ !_LK$1)H:SBS^L0=_N
MC3O5KRC0J27&G@H*EIDBAE]>)%Q/A'08SXWZ622ITH9+XZ8\"(2<.&R4SMP7
MI=I W#2'ZEW+J-3IVD,AW41(*P(QB4R]X*F9E8E_2(>G= #:PA74-$X;):&2
MAD3 Z753XU:.5"K=<B_DB8@+YUHDD+'W,&67*N&R$?24,2I!60,S8_%83*03
M0VC(!AUOS$PC8<#*4NZ#DVJPIIJG[IKM6\VAK:D(3.2$PE@^2H(D(Z]>]HZ[
M[KA#9\_&G13_88;*3#UEB)IRO!ZCKV*EG9?=\LO='O&TJI"GXN Q4G QBX0G
M#*MP5B5B#]QB2T79L1R]_EVVME?$1ZN@]Z0DYZ"-"(7/C5"2?<AUEF,[,Z/8
M%?CE6F\P[#(5LO.(I^@W.QX\[]+=NY/VJFY8D&N:TZPWHN*8"-A'B;8#=F6X
M017G*H#G7:B']-BFP;YKY \+=+F%J"H:_LZ%A@3($3 LQ =FQ(1DESE5;\"M
MWE'+.VR*B%V7:V$$VKJ8^1&7$V"O?4/;O=/!49OQC'%4%F"E6W3@U<M9O]OS
MW67I:BUP#U%<!K=T,ML)1JR%NQ_M*_O<9O04.W%)$RI_UV:7!9?L*@7I@VZC
M9@$A.HY!&'$#[/<01PM:0M5O"LEO^(Q=@Q])K,1$E-HUOD!4LV<EFG.5I%P6
M2X%$H,$KF%_.JP(]Y:;=Y-B#K,Q04K#/4DUC"";@/ 3\3X3U&K $3N?('@X&
M!Q5F!993TM+)T>G!N@=+'7'\'!NB)0[9-19II:2G;L9>2YGSF%T"O4,R1,!;
MI1/6ZUJ_49.4A0U%YJ-( 5RS"O-OP(?$0T@->FW6[_8')0C0=S_"$P(AM?)
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M!__I3[ CO7AN3J!ZQ[+*TCL\GO(B*]^RQAWZ2X*SG\:=\F\0_@502P,$%
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MB0S)**(I^$T.>T\;NCMWTD[A!H!<X9PFG0&"8R)&/@FP'9"/AAI0,9(!>]I
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M2AHQSN6ZI6$FH \E/,R2\1)>@(_@Q]\F$Y7B(G<8H8;3UB3PI!+ .*DR:5V
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M;5Z;N;;23;*!#7'0R0^!7,O(#T5=]%%(N0YAX-"@K04'S]Y5LD@>G9RBHYK
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M5)=[WX V=:I\14 XFP[4U6%RNY"YE]C7_H*SWX?CSW88(SH ? > [P#PO6N
M[U>J^%^NGWU+U>3KA.!Z]^I.Q!T&E7L'5>[Q/JK<4;'8O\M2&DP[WZ:^_7L$
M2>0"')H1L%U/\:@%S[W%C^D5V +6,T[Y1UCC'/VC7,F58Y=UGD=^S<W<LJ.D
M+G.$[3HL<,8U?+ !79+66VBL2U6/K4S#(U\ ]-%!>MAUA"/PK9!5R&CM3\(>
M<19V-^TZR;1D/[$K.II8G6/L&#K!O3&7M$&<?U@;1+@EA?A#&V=XL:NXYT4V
M6!#]7,9U'[#J="$0?=IQCCK/:& RCC)A?=1B;K!$0XI4/8Z+%L?U%3C,092%
M42UFDH(:3(^V<27+*2@##-3"E586EZ%.F8+M=B:BSJM1B[2M(+P>@U@+'EK'
M&YO[YANRD2N:QXS^\YDL72T;XL\UM6APY2=@>F7'@\#?:8&?[J/ ?]?LN^!F
M<:R]W*9N$PF 0BQ10D0A9L96MD0&"#W>P;K$XDR3\]OWBF-RU+I;/!V*J)T^
M>K@/V^=S*?T8)G;V[.GCQZ<G9T^>/WGVRP9[YD:/]H'Z+IS_=1Q%@3HZMA)Y
MC3):,KX X\1XTIJ,8)!<:=72(0EGA\3X:,JZ?S?#@C$5G;@G_>;\EODFJL*%
M#P@R4F,$G(UP*5]RB+OFNP+Z#TM_)EU)#CU_60S6TP0^XSGWJ$L^%OI)MD.V
M G2,8E[% R']8Q,]R0= ^8O51C'EIVEWU(J@$EWN)H)ZD31%=@:)\1TDQCZ(
MC/9]#I^]L]U^S=4G5+5345LJR45 G(5"I*:X/OJSAA6E["LC*U\%$3$X(Y=8
MQ=B%,1AC$^6TP;'1(L-R8%="Y5X$P&;)]5+*;L[;"!].X$7"ADA9N8(XH>8B
M?4 E=(+]<7)Z( X/3A]2MEW[T2D^\CITJ*G35T=GT%%W4$?-]E%'O=2U29FQ
M&[5PF\KI1SYE8!4EU]DD,YO#?(V$R,6B#S9%IRB52J/[?, 0![W$IKC]Z4!L
M :HJ57#%TPRM_YF+UK%@8M?&K5(H;,U16]/P)VYL:--["/4K^]PBC(QJSP:4
M\S"7>!I6RD]QXP[NWC73^<]E<#(T8';K%]TPV'S<N!"@!3T9M<S_B.QI%]@%
MSV#>5 X,ZWOC#R$[9BZ6]!%"$)TVV.=-\,#S4:N&_BH*_9R"ND[-Q,3"Y6?<
M!A05E[UA+!<< 4Y1H<ESE]0(0TJ%G>'04+!7RR-6[&C"-CGPI'(I0/!:7;J?
MD;7\8^J6'N)/AQ<N\AOUQ84XK:Q(?1)3H4K+@68\L] VF]05YMO=,)P+CN4"
M(T^DHI>!/IF<2(/33%OJ881KC*H+DQ[7.;*>O[K@./'5892G[C9-7#BSNT=Q
ME 0<!8WZ.+E<WR$IU[=N;[16&;-8(^(OV@(^4;JQ(P+W>YT]J :>+_MYH%4,
MF3ZU\1>TL>%X4;#90;UP'0>B4 ?11+QZCRL8 7]'W\'MRZ]N I^3Q].M(J^1
M@;&^@C @[\:ZK"W+IC0@Y1A"EZ[9T8&_@?]Z5K1/M(:4U;I2>)470UQ%(3U7
MP[9Q=M&2C@6TSE:O#S/,O4;B+0B5OTBD6LZ;$_5FP32H=#NMTLE]5.G>(V8J
MDT79*G719=YMZGC=/#8NT](>LI@:Z?PDD3R%([$V#+!B,=^JG!*^<:*6PUEK
M"Y_@17_<H>1H37PE*K0P7F)U?'].\#F&(JK4*TI,N(L.]WB5^THEG56 $697
M.'JON3C/$%T$".V7[L0-1V+D+NH&K8*L<Y9H<VK!:>74"2-5,:Z-)9T/#ZX5
M%9%RE -)P6A5=6'Y@$97TUSCDE$IGQ"GL<W!&=^:&(UM Z$V0,GN>$\]W&$T
MT@ E&Z!D Y3L&T+)!A5Q>RKB9!]5Q![]L&4?;5,Y?$6UGXIQ5&*N-;:F0I1W
M0[3>Y1M)$,3?1!K)B]4JW+>"<&KJ)(REJ\!'UX+DBO3.B=,S_1TJG;1$T]Q!
MS'\A@$[7-FQACMH7&+OEB&W8<.6(1TKA'>;.+>J\#FU?"S89_ TNF-JU3C'2
M&-\%<\L\V'0.)282*NV$JF)#+DH7CI;#(*/:7O67%ZAWO7HG1 &2>#Z#M;S3
MHG"ZCZ(0K&6?X_IWK;/D _GF0U+GA)AP=TQG$H_NOJ554>'P<TY8M6.L&WC)
MUWE1UYB[3EJZ"J'HG?>4G"(ES2HE#=WG'H1-Y3*MN.H-5UV8<% B%ZK 42.H
MLC(UAP%B6=4X7D/\EEV&48D!8Q"H0 2(1(OWXJXX?O'N*/3)D_D+W:JJQKSR
M!%55>)\*=GEO=G.!5-P+?,DQY5YK6UF&P6QB'W^!S!KR?U\^OD_YOZ]:&LMP
MA;<KQHXEMK >,]\[G)*69F6%@@.4'0Q@*JI<TBUT,FYT0!D%"]IZ;T^H@+^F
M8CV,5R\93)S[R!?CVABZ5;)F)Z+J'<YI%G#6J^XRDNEM3:QO<#?JDV&.-#1_
M]9Y%J8D#&BOVM*)4I*(O2 .*4:)$\C4*XD*>-6AN6,:YVRF)PB@ ECHA1R..
MYO2N3%(0C>R*K*M-=/#5&6.Z01->Q"&RSY#]JRBD\?+/ #VC]6&%TN?=LHP.
M:/V.VDE0>D+ EC*5U@K#'F6,:L^-HK(BUA5^J5!I=67B*%J4ZGES#5NGG\;)
MC*3#Q  ' 2;N\'S3"HEN%OX,Y*"69#'7"Q]_;.YS]'BE;HEN?XECS*8B+IO=
M8VRMQU+ .;.>;+@\N/QA[5T5(NJ7RGFO>+0/M(,<B++7< GQN%4U1957.K\*
M;NX>4AP.Q3;N^K!]<I\.VTM)NC%MTN&H)1_1A+$G[3!:L^=T"QW45-1W'H;F
M.T*!KPV8B>R/.J,87,@]**]@^AF(GIPN9V74C N%N2B@S^U!^3#RH SZ#-8O
M?$DY%ZV/60@WYHO@"EC1Y0OKD^!\#M/MXXL:"?-T5I*[BR5<\1TN#R")V(A3
M,N:"B=.AJ#8MLD==#U+NKJ7<T_LDY1 : *J ,MXI\!LQ_0=D3=5<3/!C"[[W
M&G6\*9GZ@G*B2./K2()2M_PKIE%/A*5/4?,@J>9-$A8%C;^4?!P6-"E1B"DC
MGJ(KJ1/C%J6EP7FXPX24,I!>(-"@$U9CR48)N,$5D0M<:+TVCLFRY(YI54P.
MKB4>3 !?K<=5-<=!2(/%FLY4:#@>-Q=%Y*M:(KQ&ZA-+G A;'75?IF@7@1"!
M']:4L6R7$&2=D-U"9?: ,1#D[7$OI&#<Y"AO,0D)BU.VIZH(KX&QR3@OI@O[
M]_#)AR>/O!Y^*<Q8E-(>_7:=RZ6_I^OLY.1L3^Z>N/SM7SB?[1?;.TS"E25M
MSUXOT.?U3,E)7QTGC)C0LZ8.?_S,&1[!MFM5G_);?QX".LA)X:*F1@5PVDK#
M=2.'W'6Y*.X7 O".&BD0V=@1%BIX&./=I>AN*<JPTZ;G.::,BTS/'3Z9[$C\
ME;'OOOXF[U&L:85TA/\WZ7.C9 9VYA7?P"6J/EIT[CA:]4UX;W'M%!>Z*&F#
MEAS/>='GL^^_:BVHD;M8D$0&AY1S) 0_#PA-L.-_M*MDMXF!VF48S8"!&C!0
M P;J&V*@!O/VB\S;9_?)O'V%SA4\EB^2CXW*/UBU7%VU-YR %&L,),E6(:QX
M*KO./H;AF)[(3:L>*H7'NIKDFBC"^G ;C:O=A\4R#=VH@T\E<U"G50 1CJM;
MD6!PDMVU%'E^GZ3(99TB>VDS^,-6ZC('=[8/*%,4,G)]!_=37[Z<(%G32O".
MS:4/-31P>O+FZ-1;<)WTXY72(A0E5<9!@%*^MAB,5?@;_(]OY.62:[&,Z7&U
MN6LKR2Q=?^7#3B[N'7/_Z<GQ7_K\.SNV23]XOOF5+@JU>[5D7S?UO_3=H>*B
M^GBVYIKOS66@"E'G1NA(\*1U7!>M3&C;>EKQC:S?>:-LT[?PGW]Q_P[^G.]&
M\\<[[!(8_#F#/^<>^7,H:V,''#I;.4%V3+5YLRS%E;A./LIT5L(0IA@$?MVD
MIN_"H;MC)%N3SQ 5.F5=9R#="NE^19"OCJ.CK])/I5[D,INV[I[:IF+][<+)
M'4ETWVV'=XPK)@0MIN)0Y2X,9C(>.*R\*P#Z+A%%,M8U(L@=[J6I&L5-W2:M
MUN4:K>S-411$=2BY42C?C1B_^3RGF"L'L9MR2X7..'5RU>UX@"/<"V1%6SY]
M?\8(P I"[I.#YLIAQ+@ZBZMN+TNL/2*K!=Y,C*]%^:Q45$^:POJO8J!- V'0
MDPEY7A!1?TMTG<S66SEL?U;96>T[L,P-D(3VN(./C#RJM[6,*W<8CWP=,_*P
M-RL;%>!'M,?"8"Y$I]KJ2H,(3J%[KD/AP%!*$.\&YMWNB_85<M0>7\2"[ J9
MHM-QY6K->RW3X_W:G\:1' "1,SEIT(R>:H=-44R7 [*R0)NM"U_X,9:^]B _
M]Q6(9-8!9W7 0C(< N_X[N-P74B3L,)PNE;L)RH&2)">J.ZA\R"' 5!=4VA]
M4INF5M0-IQXR\ W%G/@P1&CG>)DL!.=9+3G[G7!C_86>1AM7>I+]A9YV@[$'
M?>R;A;"1+3G5K='#97:^$S09EATG3(UDH+ZR^G%.IQO%->^ %/^W_I]]H<\=
M4.$]& #GR8].A8]X^*PAPX]$!Z[^O,-D^ 'DXFU3/+G+*=[WH-H0;QKB3=\P
MWO3BP5AGRY=_??%@5A7YR_\'4$L#!!0    ( %*!5EA%AV2X[9$" -= !  1
M    :6UG,C4X.#(S,#9?,"YJ<&?LNV=45-VZ-;B)19(HDG,!2@;)&9$L(" B
M626'(@H4L0@2A2()O&25+$D$)$K.""B9(A89)%01"PGU\9[1W]?WGM'W]NG^
MT=VCQUDUGE][UQ[[V6NN^<SYK+VQL]@5@%);74L=P,$% )S;'X"=!U0!(D)"
M$"$!$0@$(B8F(B&[>X>,E)2,@9J&XBX+(QLK"R,S,SM8B)>=4X"+F?F^U ,!
M$5%Q<7$V7AD%:3%YH8?B8G]?!(>8F)B,E(S^SAUZ,0YF#K'_RP/; 5 1$;XD
M'L;#X01PJ7#PJ'"P/0#;[7T2X/QC /_;P,'%PR<@!!$1DY#>GE!/">#BX.'A
MXN,1$.#CWQX-OCT.X%,14'.(JA#2&+P"<7K>%0M+_DC$]:BFD];P%PK\\+57
M.#')/3IZ!D9N'M[[#_C$)22EI&5D51^KJ6MH:FD;/3-^;O+"U,S&UL[>P=')
MV?N-CZ\?U#\@XFUD5'1,;%Q*ZONT](R_,K,^%106%9>4EGW^6EM7_ZVAL:FY
MJ[NGMZ]_8'!H?&)R:GIF=@Z!7%U;W]C<VM[911\=GYR>G6,N_OR=%PZ A_,_
MQ_]A7E2W>>'BX^/A@_[."P?7[^\3J/ ).$0)J54,0*\\:3C%PHCN/DK^6--)
MS/70$$7[VNL7R3VP.)(;_7=J_\CL7TLL_/]69O\KL?\]+P1 AH=S.WEX5( 2
M</[G_J=0DG_'O^/?\>_X=_P_%QM7/FN5PAT!#.WMBI">3'/SQZX*W?#N7^KJ
MYM\"4W!V^3<3S)YAPBZU.U]YS-74MER*]<J3=!1]<4@1:[I(6[1=WXI>]_P6
MJB#4-;$:'6=T:;AF48?*;2UE7-:+ZW0K,A;H\>][ @EN"6#[_!'_N76"O"Z:
M#GD>>9"W/OO[:1MGA%D<&Y^.O<VP+A$!!:\SI6]X@:\.@6+GLU.()(N#>MOX
M :-:^-F2CC^C&!Z!#Y_F )>T8E0H^#(X_\SO+!&Q<DF1MG5=\H/5.B-A_OS-
M/-Q[@G;C[$8&K=\#43\8ZTA6*7:<_AJS,5-M(S0VE+_0IRYEXXF8N]!>[].L
M4$IH2$!:1[:QHH),J#6/P1Y:]V,?#=,V"WFG:*=L\M"?<"FVA:'R'T>K8NP^
M=M.ECWF[-:0,U+P5&D_  E)EQGR9"H_@N0"AY68T6E\[QFIG2;1FQOZ=IVSP
M02;+5VW)/+R/HWMK>'P*>M*R>;B8!)NU-\WU@:;B(\Z#<VYU<_-"H9)2N,I@
MAX@./BA7DKZ3M7B0>IHBVU5(#9J@UC4*QO/'<25,A:CW4Z8R+]DH[2ATXUK=
M$>_7S7UH?Q\K,/%QJM+VYZ& 0XODZ@/732W. 7N]QX5*)!TYPM(=6_!4Y%C\
M3+\5><,40GJUQ<11:#71=S+-,\?V#9]Q<XY;GQ9AS8U@YYVI]HC] TZX(S=:
M+46+.8[!4M-#!11.M$:[Q0I*<8]48G27?^!K>S,\9?DZ7 /_<)!G\;A6P*OO
M8;S0IDU^>JCBNVHE3 V:ZH9MV_>KJ2K^G]R](G:X1R^N$&G3?/P:GVAC\-5Q
M./]/_JVQ& _5U472/BLIQP(7.7"$YC@809%5YA5EVKE.:9II_"O*Q(-+'&<9
M0V.!;HB_XH54ZP0B+^\V^5$]:GXSP?*Y5ZQ_S()E:($,#??OV-C")* )0GB'
M5\RAK:+<*UY<C2FD;Q,RAHY5I).2?,^V0/')(S[Y^.WK2=O69V@L4$1MDH\%
M1I9@^1>H#^2UYFB-7F%B<RS@[-Q,$7T*$;KKU\SX+!6<?)^9VA:\Q@N.="5P
MW?]MN14EKU^$:5&--AGG/8:L(],:H3D^&BQ_V8:\#%?!S^.?W#MQ)W9&)%R)
MZ+L0%,:C]#H-8>_#&,!4QRET]#*+\:QI:UB@5BVA)\ OIAHA;S8B0-EW&?UC
MF_E+OQ5^[,4E(W >=W2MLYIQ!NN;UR<::A&?CH44>>5DESUJ=24:Y ^/ 0U'
M<-$D??J.9S'M>J7P<6GW_/#K]#A/&DI9$![7Q'Z/%R [TJ0]+HEKI?6S0V5K
MHW_F::#Q9]H1#1E)LAKU;B+&8225::_N 9>5X+>> \ ?MR88DQ4F5>/GZ1V;
MQTWCK2U,ZHV!+O.F](.U K/)MO07&GA.ZSX VKL3\0=3THEX7E?)$%CNXQ14
M;V?\/NCK_3NC>%$L?WP4G)58L,"@/%KX.KRJ_<3H*2@7P]_73A/D7Z#[V<D#
MJD[/V>CB:U[8]%R UIS+1:2/V>^TC =3OTH!<DE'6/>P4:BXW/E1N;$;$!3_
M\Z_HX4:.!7-0BA0A2??Z*!Y;;>)5ZHCJ3==7V'9I.<59]'2%#]VO*V$;?+^L
M\07_RO6$HRX&WPIE0,]6@/RG]Y&0RE 6<![;,^+.-S_([/V>4RJ9]/,W:6X5
M_/BS@;'2:B:T>X\^*]2F'P&+M+$FMQPLO5"R;W0Q76-K]:9?:G.!=./];*!7
MT .50O7ZUIZ@W*)?^;-E^+B4S'>+N8%<*ISI;3T\5':LA-'Z-WITG=9GM[-:
MY*[,BG0^3V=\<_P[*S(^[_D.(_2EY*]^>@:YB(%K$2W7,/B"[<52\F?H\:HL
MS'6[N;XD2EYVC&\NU3G#Q 3GA= .+7R*P61;!10OTFWR 9JAFVV*JJHNFJ]S
M4=A_/XVN>QM)MOV,)E1/+/@.%-2M'S>R0B,5<67BSHDP79 7'28IKR^_B/YA
M@@AY0V;Z54R#G1 ? OP^%:8.TD'EQUPI?7*A=FI N!64=;M)Q$#B!G8GX@OB
MWVH\Z,,]&:5/ P?B'W>[N OV]M1TXVM::8%??HXCU *C .;-&F3+KR#()U7%
M_-)^/WLA]D9J<VEN*UZMM!=4:3+&0TE$H)IJJ>M/]6<35RPVGWK&^7<S" J[
MRI['"8@:ZK,?.L;TG^LKQ! ,PY@Q):N2!7X.*YH?)L1=3!][_9ZIR7#8T#^P
MX6*J:=QWO2KRL@$_C_P7R#.?^$3SC5*4&;.HO^NYY&]_@7?TC_;O+Q\'I!F6
MI4[>W_GI^QZG%T.Z*I&8,+X[M6\[(5'.:]<\X>#:#,PN$ /)>11 V0I<11H+
M4+7JK!T2S%JX/*?"A%QJQ$XJ9>*7R7/D?%[W;_00B_#HY&[;QI/8S*<JTH_&
M FP502JN\QSY@VU9TNQ/'XDZ%C\E[GX8Z9TG S/(.H4EM!]I^BQ?^F&!\9AM
M/.^.I8<UZ)FH@FD!FQ1JYFY/O*-7[P'M+?I74?A4DU1)Y,JSDP6310W&XP?[
M@B5+I I3M7I%'E"2KQP@Z2V%1&;T\5:L@(]^F)5,X@O4B?<(LE(5U]S?7#0U
MY0EW$T?H1?+ *#&;))N2RHY9);RI:'XWP.Z'GZ0?<=L#HP**32(9?%85?&8J
M96:E,!\LP 3-6GL&T7:G0'06[;J7#*5/IVI.B-OZ9YL6X:@3(305])[9Y#^^
MY6Y3+/"P^CK!;_F2.X  ,)KR,6>AT&F</)7[:[]B?R+H:[L:VX\4#X Y19F!
MIW5,&RT%#^&Q/^ZVIR"#^G/S99R+O'N7G>/.\)C+?F$/WY<=.8]O\N!2Z_>>
MF[@[N?HX_C.IB3)C1$]*<E+ ^FL+..B'[-D9%KBSG83Q[C9S2P"E&XXN<@HE
MQ_3$@WY<:CP:29?/TUK_":* .:%5NP:OR]RKS*!?E\""GB4Z+[]]_1IE&)3*
MZJ>XN*C_RR*)OQ E#*]K9W5\?=-Q84*%=*MD^7IV$,AF+"WMAME3P2NMSA+/
M-$)B@7U^A<B6UWU'AWLC=RGY0C,XK*2[MC:>^28FPVG"1A' W@U/D"JZH;L\
M0<:T5:E4)2CEKJ>=^).*2#_<-F^R5S,@Q58R[W%8[S(6*&/" CR_Q[" 4_5%
M6OO^(19PG*G21X,ZOTT?C=[P_8I3CYS5"&2J 1PB#7787A(KE.*E3ER9HG'[
M5Q43D6,T.PC&%[M6L R?5YML#X??-LTW'8EH1S2I^_=7!D1ZAY#/<*#SHP2"
ME,]J0L_I*)Q919LE3,&Q%$;11Q@PVZJKAZ<E-T"+#*CN38RI=<Z@AGIW>EEL
M5UQ\;0P6VU65M^[F43&(8A.A7Z&4Z=,OA:+KL0!&M7H%U5N8P5@_Y$_Y/LWF
M2-5CW,W!@K*I$S]W'MKGTB-P(PC% AT4A-FK";@R@EQ^<(GTF;VWG^];)K7:
M#-\O<1IXOG+:20^<8H$HQ'E<JT:!Y1*FY$GBDUPW^5)(9,X7R9\?,A1MJ%4$
MPT)%ZXZ\^YU>W-"C%3-6]\E9K#7S1QI2HYXC5SVGF'U?)5^$$^/3U"@3W#50
M9I5",_6W4X:P?J\;[T1>7BMN#*EYL^1VT;[\@.S/>I2:CL!CCN2-?]TRAN.,
MZ(^1%W:J=)XQ>]8.B;6#*\CRDE+P\OT8G?_+@PC']\NK,;/9&7$7)<IMOV:U
M/^[U+;&?@FY77H&0"DY8)XB9\@X4UOT]\!G&96TGA T*-QW-]'R@*ZD1S178
MQN73*6>3FA/6XG(Z?YP%G":R[B+ZHZ^$_2J=I,R>6;^.+4I14.?EE^(BJ:AJ
M>7$$<#2(&O2;C:%Z;KE$(H&<Z=I*ET*S,7O37'W"/NV7'!T6T+2L\+_P[V?H
M'* ]3<14*G*61&6?9]V+I;;<_=FPT-08\C)R)MQ8^5@IE@(G2KE:^0,%3?ZJ
M5 \M)E\X#+**ZLD(&X"O:@I12UKSC^"O/E*9G\]A%=.0F/X/^!L5KMX[&4/T
MZ0Q?-@H*VO1=E"2IO\NF)'R!$M-D2PA4NN(-H< "'ZM5L4!GO-*5,>!]PX &
MP2D2BU&'<2?7?/RPO;.6AN:)<<M46NADZ&A_\1$1.U7GMHIBF,5R^.E T"OD
MO!)U<+JX?]Z&X&P?7J%BX'U0:OASZ6' 0_.,=OPIB )MTR?%2HP2GSF3MU[0
M_O:MZJELWQZQ@(I"FCE+"*0)W[Z9@@03M=P;0C=1/VP\Q[*@,F2;+]C97:S)
M@.B,\AP5DZY6FGJ331&+!>Y*,)%FYTMIH@[RIJMB-U+/6D([,_6F1Z>L,/Q@
M&[R('-@<%C!MK<VP1.F57@K5S3WYTJ'E]=?KU/LOM2,IOH3*9MB,O:1P;-,9
M%%@W)UX)WUZS3>VR4UMWX&/06E/J4?#?L9)2ZG&/X4<K6N/.]R)CA?&267J2
M+,"N;299Q#UO(QH:I.5MX2[S_%M8X*)E[!@+*-[%F78)N8\I0O+#]G5-5% W
ME45=\'-5[13;%&Z\\"=O<VS7DRI#*W._NWQ!2<7O!?D@2T_?T:^_C1994+[Z
MRPZ@;NJC?Q6&[X-OBY<$1C?$O&DGP^@\G93P"3>'/2@P-TVDTQOR)!?Q;DF"
M2C/PAKH,80'[$;X_,SHS/C+[A?#1TQ4=)_.P!XD_EAN:@"\,.SGP#RMXB_<_
M-;6S_=Y'PG!^R_;H<HX1-+U@H7U16/5(?=:-B&Q(S[M#GO4]S@@F>M5XO4V0
ME0+U/)^PO)("<]&4.S97\:7;][KU&Z%*)SVW\L*<60H%V95NU!)_-";220'!
M[EN7JA&C?$ 85,N)/*/I6\'I9\?K];Q5K_:Q)(Z(T=8E<WV)CMHG?5+JI1_G
M[\R0V5K %5=^SR_>Q_MQ);>62+5X9:AX#\V24)S^<H)EBBO5:UGWNU(@C0C(
M_A<'D9@ZFR=WB 4L-I_R"H+:7=-[[DZQ2VD-CF0VU:7AY[#LJ,[IIO?I'*O&
M8_ZC7HXL]=&GP< L76*Y\C7\A]0!?KYA!G50(_L^^R45W$O>_2P+"V2:WRQA
M@;,$(- ^EK4U_;+^]W=)ISG*O2_?H.F2_3^DY.,M'.BEK7)EUH3[9MK OTX4
M5%_\$GI3+=3WJXH5<3:M+N8Z+ DV)50TZ$#XLRC+^]".80YOM+9B87NTMP7T
M4U:HV)64]QKD[SI5J5B"O#3YWJ 31N+DK4UEX6;0N""D-_ZP'\255Q*!&NM+
M<-./5>UJXZD;+XA?''SI4*.E/M=-:^$FV&0:M11QB*L)Q)U2X,(&Y5$SU^&5
ML!/#F5!H=6?[O!4=.C'&%;D87 2MP@*CLTU.@H.Z<UTIOLQ28 (CC@\4)=M5
M2LC$=^U(<91$>A&_6]N[:\;S^) +8#CXI^)+8Q0AX9YOZ0V/LY$&\B/R6L$F
MXSF:-%=R6HH@O#Q>AQ_PPW\LH /XIC31?Z!0&K]YB(GNS:>FZVYCB5!_IY^'
M'%_:/6#(C=<LBG]+:*5=QN$A&ZIO9!D-/QUC@C[L\I,],6EC:]-Q4!$0+-$E
M1OR@X0LZ&UP8[NQGV(IG$_]YXJ)$$3)YSTPMW+6^+O;UDU#2U]WIK@ I38J>
M##CK! O\)WV$JQ_U!PO$M5HC+Y4HG5,=?]ZJV# (!,)]3%+V()5+)U+N/;J^
M$2])GR6JB+5(L+DJP\\)HH@R/:C,\N&/Z#!.)I+IE]F#;L&%5S*N4EA(;Y:4
M3CYIGY  QS!"ER5YM,;9&**J5<;N.K-4JR2?K\^_=9#K<BLSE71HY51^G<Q[
M#-.PRILH+[JVK]154QTMM#X9E%]K(5&!3ER2B7>WEOB&#-LVCV<MP2O]CYK(
M'POT*EU(6Q/ YA-OTKX#@<79K$6T+4)E?D[>BD?&^Y L M*PSN?)@S)C,@?2
M:]GO#90)/+# /7D;SY5\/%V83>]U3[F+\P9>A5M'2@_-G''-S.9\DKI+8S7O
MO\A^213*J.H8R)4),EC.HMXR>;&'N5CK:(%9UC8LMX+>@7F-*RZUI_D]0BK2
M)]APT<9IKZ*X,<$6O\SV40<SI6?R+O\ %G"XMC\:M?3KE"W8:YZP$^O&X1YZ
M%??D8QC?7<4N8-<R4>'[IYN^9:.)*E=AKF-!MT]0>]T>-W5\D8%U6YKQ4/EE
MU:DV(1<$2WHE;4,$!-D::P^7N9EHM_$JW+=GCF?]?M$Y4 53QB2BV7I"Q*;D
MA1T@R,=M$T'+LEHI*^I+%N&2"%5J?RX&O+ASD@LL@'2XRA%.@.U?8@'M\5#9
M$9U>-NI6J0I,B*#71#?USI_BDCOQ*;/$P^J6T6QRY-H'["N)&7ESJ:O1\4&O
M5N[(LIA-ZY(?]076NG&FC]JF"$39KFNKHBJ(NX[CR:$G[^:9@A\11.TJB4FD
MRX0NJ+-*F5*BMX=*EIG15OJ7&K<K< (+[/&SW<2EA\KI$RU!R\U04\6594N.
MO[Y?)^4102J*>IZLB-ME%E]T&(I]$.;%:1P\;J<*TL;$(I?9S#"&YDKD\C-?
M>]+]>!C"-5,4>WQQ#4V25)C70 STO)/RQ%@ ?-QM?49R*[Q^Z5C!T)?_6.2)
M/9(>!VWC[3.N%G7IZU?_<8&_J-$9V%LSOUC)VW8(2GKT6GU]C<0T9HVM)QBZ
M\R)$JGVF+O&.U2[B;K-C()._$'?4'Y G7^G"HZ^R^QRJ/B!>O(WU*5C4TGUW
M.@R%[I1#BF3K[*L6Q*Y^5K23 ("C ["Y$>+!9R4RT$HWO+#9$)!UZ@TU4^W6
M$'3.W3W6%N'?$TU"QZ=AL1:A#(J2H(C)8T>]E_TQ ?7J6]T5EIV>JBA.$J/]
M8;>@?W3PN\,55VY#@VW%.N96^MRP![=?\LQW)5U'#Q\K3F>0YE[6)%0L+RAX
M(KYWM7E<YTDLLCW& F]3+\V-:[X<MXUL7%<A.9<3I:07U#V3)R:?@DIN5];_
M$C2JR.48>975.[R&BKP3*U\F]WQ =5 .]:< 7!*4[KH5H@+"?YEH9-UK?5=>
MZA/4VF#RS;ZW=GM;%-=9H*/06EK>(]^J9[=VG_V;#.*.;W(GF?##WKN.QXH7
MIL]P]^N$S"?WC1D40EE*<;6/Y<;N0B\-,='5T,!NR3RV2];W20\MG#F?>H.=
M.T/4!\&'?73T5GJ>^4\^GYU)GJ4NCN '@EO>Z\HLZ)T3U42,Z:?=]=SYG06@
M82Q!&IA$U"V8V!#32W>S]Y<<,LX>-[JZSN<<V-U@=O).I_5Y^^Y#-M(X4,\.
M8DQ?QR]$>8$6F6(8%&38 Y(MV/8EL(!8P_7W6WO"^ <W5$8)!UKE3G4E_Q7-
M\P4B:/4X<\MV2(VQ$-YT$=N!: +GFZWO7WFOYL<@$A;SPS@CGORJM*,:KK;J
ML\Q/4VJ*CW?K6ZNO/4H;C$\VA;'5WP]26GFG1/%"("G![,P\5ADG[;U2-CMW
M+'NFK3K]"5=8YX$BS7;2-HRL3OKUT=P!9/K(])Y(),*@??.4K\B(M]1@X@,P
MW/KSYL&. >FB7)^D[-XO-U[][Q-<W[34)SK>R"SFO+33*.L'&7584U4$N64\
MKW;AR:PTE1.<SI:S^TG8MZ*)'X^"$NCC>Q'O\V\FQHR7=&.!Q&E%]F^0I+'U
M95UFROL<]'5&]_&1F5U-8\SMI2- @.56G'QP69#J3*L",EN?XCI16Y.A2H+J
MODR*Q,MV+ML4OS72>&%>Z3&IM>I_()#M.N+2;+XK-;CEQ]'-0,:=A&SOW!_M
MRRP/E[Y_6NI;&@]L^I!HF^$56R(7NX2\)^*_<_0)KJ#@;45QJ0O[48D%W&&7
MZJ%R@^N8WCNM7PL527)_D0H89">-*E\6>.+QEH I#/F]D<NQPO*6*[I2%NUP
MHH.JUL4=W*0(UZH(("7@_J&EFDEM3</$BB/$YFC-R?:OA)Z-==_D,<6*'\&U
M_7=Q7K>V(_UZA3%Z]2,A7<B@;W C[Y*/NB5[K3S3>.PB<EK<\"?1]*1F^?<D
MGD=T.7V86^@G+UMEBCD9MKS4[(F_I_[2RQ?"K0-H"K5]F/D+FJ$;O7+>FW_'
M.<M%R_W3PGRON]<1I>IG"/RUH0BQ7%"3#$B,^3@>H/CT>_A?Z@\G/JUFNRYH
M7\]SNA51M(E80$U'F:4_W#U(J\(Q(*2F<F''RO+TTP)W?5I%G,URE,7 ./-5
M27*=5T"2S"Y_/HKW*G7L#FR6;^;VCX)O[@+&"MH*VN8^ED('XXC@E=I%<_%=
M$U!H.2>E-]Q[%CU&=_\#!<5/1:XK#31;?+T^Z=P\U$"X;EEJ-,6VD:HA@SWA
M6U)/GF:?\FK][:I@N5)'<4I^7%4B=T2DIU ^:!RW3Q&]&S_+-'S [IG8%/_U
M:F[E&$:JM(X,<KF=QN4_S].VV1CD58NV\\GK^5U.PP,3U'D:ZNN3C@X\C\,B
M;JHYCG?OVE+?QZM ;;;;K.93S/TV<]&$""5]]7]7_S[<^'WBTPZXF/1*\H@_
MK&<L)D02X^-9PB\5?4HDG/((+E <FY94M6(R^BI>=F5K)@S^1LGAFN_R"<;K
M,!@"QCT[/:@\1UEQ,3NSL2ASZSV<? DGXDV]+F[??(X%&MJO"Y19P[  '>RF
MT/TJN^+RD#+HZ4\?"*7S'UBTD/CP_B,FG=B3]=R$1G]:K_F_;.1B0/@.P"EP
MQH;*Q2C=1'V_M7&$(E@ ;:S_&&V5O7I(_3O+\F-=V\1)7:U/KN10RI/>]:$O
M8,H6KLX.CH@ $J ?K1$G;YM/5=G*CS37953^\[(M'?)8*Z;_KVT]@["^1P!N
M:OK)(/.M-@MR04MU!(C+%I>!WMJ'FT<V&-?KI+_L-?WJ)Q;_B@*F?=I3TY!H
MD'5MTSOY2X,LL?%J('(H_LW*K9K(_U+-^\_08<S2*T([F/ZJ\-'Q01EV!KJS
M]+BP-Y/13HJ \.-7_F2E=MYPH?O?R2N4_5B>#0BI+G&FNR=F/NPBD%S[B0//
M:^3HJC?L54O\2\\Q@Q7]"]X\1BSPQ;CZ)LYLMJ&FH2[OP)%KCGOAD]/HJE^C
M6CQK0%!I0:*^Q4]0\M6MI%USCVE@C"N'PO3#>[F$-H><3#.'(3A!&_1=DGK!
MTC)KL[PT$JWE[F#/T:<Q2X^%/L^NI.%3/YSG4OS42G%F=^LD2FX6E<[J@W&4
M6=VOOZ^-84RM4;'7Y=UY^F>PL^AYQ6[%0V'?'_XA?DO+?5(V[C)CP\]NP)CN
MOF6*.A== S=YI5(5B?ZY1=VW/[^*&@YI',Y21;H>B?9;H,NP@!0I%O"ZO?Z,
MTC^)#W$!"?=W6?G1E?79<NZ$@RQ3GRQ507\TDR/8[:S,'6V29%P=VF3*Y!G0
M9A"'WD0D!=5VBN.?$Z>Z^UX[XG%%^<Q!H:4+K5^X,,UNO_]9=3!46JFNY2.$
M=;*[GR<OJKSR='43JOSRW"Y*>?S)2*@(#A&YWOZ[<*]/H0J'/0]6U6OO(,M.
M"INM:G:?#@SR<F&2PY[<6>Z:6_&<;KT5:UN]Y2.!O70A=]%J;^^9+7@-,EO;
MXO>-T,NM*3U\%34M5UL7JH%_9ZG&6M*9C6(337"KTG0_!5= W^F@U9"1D+\.
MLB3>N JS1QN:OJ_F30[77L';D3T.=K=";Z:NZ5,X4EE"O:"G^5*0X=G1*.'[
M;JD/MIBO"FTV&>19"K(4*:\T;S7$EFH@1-N1L,6A9R#_09ZBJ(C%2]L<RB;@
M^"C*X+F\.1;@#D3.7/=@@9-<1[S&_T9//?]_>Z_U_\]Q$:%^:^]@9Q]3+XVN
MV4:FW'QAK"$_J]>O%ZX/)10SM^BE_X2T)JZ>=S,=4EF88A*[?O6S?G==&Z%J
M3P6O4-5TIP!O^HW"-6!I*L#I$/_@B7O"V?-+@5;/PF6HNR$5\4.)NB@9#3RO
MJL7?Z<NA*H#P$D^SCCLK&[6%N3E&1[?E>SB2-/=6*&NZ?GQJJD40ZF0A@C=L
MX<"[94$-R-_R5/J$?8;Z3PDUQZMW@;&012VY=YJ?AS3H^SA=CQ=\]G?RR84K
M3RFBVIBSIO7%)":0;W,+7ZT9,,&#&5X$KL'Y-LN1YBS>77ZL+).;+4W?&I_H
M/!R^G Z>/]_ZP/'E45C=2^"C.N(("Y N_[8FI-Y20RLD+&Y%WORT&C.M,^)4
M9DAB$Q5[XJCCP.+G/M\N [#.68L%>20$:: 3G_QRY4G<MU]"]%YU#-4,@^.'
MB/MUOW(,C%D;Q)W*C27DT4+?6K%=^K:7#3:JO+)SN._'H6.;;A"YEH)'E;.R
M,@WK'HMF++2ZWX*>B8=+7,;:.@IR9028$Q)H@47'AGP_KT=:^$@C<&K0^C>V
MU9>,>["S@$TLX&A-HEJ*T1.F?LRE\UUPBMLFU#9*G12>R6U1!B0!#@<NJJLA
MM8*+_=$O)^K8*)TIBEV^+%MD0_A>?^00H.<7"UT_N-!.(:?@BO^#JU."*5!O
M:0@,K'7P2(2(^SV?,*LM%Z('=BO#F9BBV\C5 /]%+-#3OK\<^>=9L_$/2FAT
M#W5Q&C6QY'4>,D;+FF3CUS.6(77-92JNK!JTAGHMZKQ#5U7SBV[ZMV3SQYG
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M:$"51)ZR>.WX]3M1>61R_?#RB$TBEQ(UR/',R>./'C\]I(0NKPH6/G0TJTI
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M BG^R.I+ C,LL%U4.;@2M;MD'AA3D$7\M#!YX&/:9#RERDJX=*\7[%^3/9%
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M/VUM6D1WNU2Z=UHI3H$3.Y>X(KIE<RK"'Q8/C;F%#4;.;]A#/O=0,F%B+V*
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M9>-'MWZ6)'.83]!A.^)$]?DT"JXR\_>(PR?U_RES4"J+7,$1\H&.+^AENX?
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M,ZW=3&@73TCCFH/1@%U&__4Q^<KUAL.L5>/)J=N[W[J_JA>V,-S6BK7%:F'
M#=[\RY,&S!<_V[;0:<2Q7NH?FR__;S\ @<'_@S ,16D@3=[9^\:'%H)]\K]M
M5[,XS_;=V?*O,[Z[N9*#T \F#BHI N;)JM?8Z&18W. N.!I/K/K/8,5>#F%M
M_/'9(7E),X\KOJ],)5]Q[+D83*,-O]L'TE7L!$85/G8T-J]P*ACH=UHF?L4Q
M+5Y4\8@Y6?EV+:\JQU806;/6&,H0\;VK027<7[U0;9&4WL@-+VXOB#O^40O+
M#ZY(4G9\#[:7A;JM#W[)6"#ZE':Z*JT*',6-4[C>X*I+Y!/CD$YE<#@K.F/Q
M*K;%O^KWF4T2;-P)731(623T7/\EPYW3Z\P/52(8_NA\:T+Z!U1L&K^W*,\6
M)##DKS,D-B5$M\8JAUC./ D;>QWC5RSA.H!(DW?S3OF2K/146'F9W545^"74
MQ SFTZY,'G,A7E=C@M\@MOEM[ 7\Q=BK&T795%<5V@$E@VI5J2S,*"Z$P.TT
MU@;9.>S6]SC$.<]0GMB%K:=W[1OB8 8G6N%B&9L.]_&>Y^KS]L?6D;U_%83#
M_&N5.7BJ &DQW[=-O XZ":_G=$>&/JX3!WU]2Y&9F,F2%S*@IGW%*#@1*YO,
MY=#MLJMJ 63"0.N,EM:3[6\Z,)$+18IIA<Y1^BL*EN;/F8--C!O%W:;;,E7X
MMOQOF#S[M:6,&WZ-M@$@A5" 0^#PSN6$<)A8_J!]WF1O+>@D;(.DS;47T']*
MCO=1)$U^AJA? ;]3_EB\_'<3D639 "S3Y@X+<E-P\<)Y1>Z/&L$/D3(<.*N>
M-DFZR<"TGJ :7'+3W'9A.QZ!A"B'JNRD)91TECZ^WGG3*-B>AF=RB\O+<HE"
MTR/K,]05$).Y=]DD<D'^%$\-#63/&'XT3$()#E>7@KJD:CM*C2=EY03,IQ7M
MK84?YYS-_B"4K>G*9O;_P8\=5W_0"]QD\I;3)MSGIJG2QJ5^[1\E'!67+^&Q
MOE^ ZE<Y#W""(+B:D=%0"/(H_:P=5?0 *%QQD-_[Z8@&@@700(?.W^SI-_!@
MY[\N0 .#I>7GN+5H@%+E;_8,UK*)H,]RT8!<33.2:@ZEQ/K7.R8Y0;P^;Q)0
M)Y-H8%X=LD/SUSNTSM$8:8PT1AHCC9'&2&.D,=(8:8PT1AHCC9'&2&.D_]NE
M]3Z*M3N?WM=1.9L3O'M\LJS,Z\ #Y$3_8R@)@+1[!W*<]YU:I^0?.K^C>T>>
MW.*<++-)FN@.RPP.W3:AT<92^H^!ZX$&NF'-6VS+C_3^V/R[;\< @_\3P(0A
M!G\:;) )%A6(VHAML5*U/+JT D94]?17-:(B_,*G^!+,NPHK,!'3'>Y.-LK'
M:U*_Q+7!$(V1 R,GSRG5'ZDSF17Q:IK#YL(2[*C2*C8A7"JL?5G:E7."G::&
M69YZA$6<@&7MV'Q,?W7CB[#XDUL ?S;4:+ZV%VAQU2>B"+@>1,37?2Z,TJ]#
MI"?E@'TWL(I[3OM>NW(ZZLT73"J:#4*/VV+A*X]D.=I EUTL/:7_TL52;M8^
MRX[I;>ZC?^EB.9$#<^EHNKZSTKACJXW("CTPT1 0_<GY1JOZNE2O9A<_852D
M_&?];JV7F7O1*>>4V_&0?<DUR-$RY)@U2#8DNF^'M=EJP85\UM$X155 0%OD
MV+'^53*M'OFC#C)7R:7@?A^Y#(^=]*Z:S?)UX[2,[/5T9^/AW@TQ_NLMDRVO
MC!)]EY*@JE@/AO!K=,Q!B+U%UO>+LK:ZB+DHT8+]00K[GB95N$"-_DR(@B01
M8'<\/56[Y&8>]?NF-^8)"PS^-##/)<#$Q&-0E(5K!D>44X/ND5;)"@^V5 P!
M>"*AJ6VFK81$)SC\';RPZDRH%4JW8Y $RG.X>J7"5O13U?U.KA*FE*_F:E;C
M6^$&DZHRFZQS<(NKZTTXW]Z-BJD*KH28A-7J5RL](]'/X/;@Z:(XVB]S6<R:
M.-"0;K78$.)WAJE;K7-Z*+>>OWL9NL\^A*_VS@%*L1/7X7N8>.+\SL<Y@V[I
M?K-=L-J3T#I\A4!_G-@0MT2'Y@XVY@DD?;NNA1;_LW,]ZX^U'&YO3-T2":2Q
MV"N^M, +@>/FV/T9\59Y!A23QX)WPL/Z46>JV?.!D:*NH=<<"@\5+*_@1;R[
M'7*KY8T,9"$A\DUZIZK7C(A*@MYWT>ZH_8DRP5S5U!"^VY.<RH.O"'M^5BOV
M!O%@AY?/UU<)!3=QCA_DQ6M1.6KAC8YT4250];A1']]G=I+^]!4PUY0D(O5C
M"Y9?@H(=SUL-FD]N.G;)77>4IRU#$18J+EJ0K!L8W_.QL(,2TC0\U>,+NN%<
M6N4I"[FZ+_^"OHFO'E$*,V?_+B @BGQ>:O@@C0XO/^;)<1;9A/1]VYP#&5_
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M%0U8__'4!NX.3\B]] 4M0[DLXX13*?+C=:^+.N71Q1OTL)RC"\_>XJ/V&]!
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M3%2<;)TSKD=)\9Q;IR2K+26K]8BY!Q'QY 1Q9)W++J,!5S3 FYS[5]N_7\0
M@S\+F$#$X)\"F$#$X$\#!Q3LY+1<5Y<F81E%W,,92ZNCT,,)!7 RQV-^9K$*
M&B_^@-U<R/A\3TN\V&&\LF.CECSE]%5(/$NZ_2.?U5<_ZY"5[RT<+4C$BDGO
M3*H7UZK.7$M(LTS.K<'WJ-;"21FRWC&W=5J$D&^<7T':?UC7;6593H\416X]
M;])+,KN'GV*Y4=+?"-XPR<I@!WPC0N2NVP>*G6J4N [F;QSZFZV/6SU/2@KJ
M@/C<L_$(4NRZN_1L-1;ED8.D5U???/J8,/7PG@M RM\=NXD;'$2FQHG5LJ'
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M$4:<\=+&S9CK&J?30]D7350A<(FPO :&(GZ58&D,8! <GF( O&,,H'"9,$V
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M"%O9LPCEZ1\$R]0@'6?D[@-YPXB$>KJ+B257>J6F"7-3F"^2>;9Q<R*NM11
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M-@;(@6LV$X9[,B0&\UZ#A #(#6%<@QI%/W.Y\ #-6[Q-Z!(')UK7TYW)I??
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M#U>T[$(=J4=324@,>F%,"11Q<(2^#?2WT$^_@YMQ;Z,M?UMG2]S-&-[I UE
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M0OMT [9*>DO1&1D.B>O7*L%C70M [PLN_=,O+_#4A)E3IFF>UB3J0!NY5-L
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MUPCR=I"?AQI H]W830?:F?"RQ-ZEH7>41E[HN%K .DGCE1H!TWPT8*$0QLU
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MS!F#I'5<[<,8[)PMN^FRY\EE%M">T+@4>Q&J**1)F@T6($+TU^7G@QH[\:]
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MK P71KW_@9P>4I@O\(WTV^,-9<)N0@V':M'YUL&O5[+I7@2J9<(]CQ_K)&+
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MY=;)/;Y&7Y._#CA/O,'CKX5R'1(_>Y8LO<G@NM.G:)]I9FLR.=J*#-E5$1B
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MBO,S)6PI$9\PM2Z^R$D.<-N!D,9VN*Z>Y'BU'DGUCJX+GTW$[PT?"^S!F;&
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MY<>Z_@-Y]CTG9V&/@3*N*1\,!+O6A/[1PZ9QU[5*?I["+NTX^;L[\QY0O$
M'T,_4QIP],&'\8>OZ''N.;GE/-):YNM8>U[!8%_KBPT( @ .:P'+R>>_^J!B
M /YW>L0D_W$O.?]G O!7G'?_68G 9; =H[P__/.@]RV,'=Y_8J)S *#'_J>]
M5&P9LA\N^=_T[:^'1?FKCQ9T%>F>O0Q<BY.YF__-)$X%P!BR5+B!T%2(>YWB
MXO"79W-!-==?(53\+"Y3'5^?(B)G:H>6?]7>FIU3)4Z-DQ 0)8+3='<G?V_
M_FKU8':[C+3383_ CA$\6$']^K-@+XL_#QE<)YT5+IX$H2>T-M#*Z*N)#M18
M7W<<)78U#K@@E0-BU]$ UD?KDV%J+^D?%=']5543I%1O[$5>F]3>Y7$7!)Q+
MQ[N;B::[DV@>+%HZ2.;-Z%*7<OCS<LX\=&,1WK\OY;L0VPA=P(Q' X'3Q09H
M(&>+D9!O4/$5^%3 S?F8N]TNMA[6&HSOX;(E/ P@7XUZ@6T?S(9R.M\A>>?Y
M)&0! Y/CD_<)OGTZT2N_V/2Q1KV/UM#K?&,&QNA>[9/SE'?:VEW%>R7]F+ZS
M7#;=-C[&M4=4(S@_#)9UMI.=!Z_7TO5*BE6>#U>FY7]+%*1+!3RT6"$&(<]V
M]3&3.B\'4ST>I4==O3UXV9JM1NEZEU#Q0+6VE\E8B#P:OJR3(HLPM<=G>.\M
MLRK"^T!.-2M&K][YMO%C66I\GV UVV *C[QV/>8VFLB!,[NY3J(Y4 6=3(5<
MT;$YF^L3!X/8N!:&2HS>;GB_VJ2^1:,0[/SMI-.)M_^Z(F;#!Y9G<@NW>,?M
MH3@1J[\P6].%1KV<<W^=17/X=EP]JDF]G7AO2 "0:\5D\I=<<\;"HTRN"1:]
ME_UN?FF'(MDZ[5=3_X>-E(T/JZK/?..&)%I:>H7HY<L$$+8?ZS<[#\G<QA4J
MXHB(%N8O*,9Z;4;QDCA2UI2?M53R4 @-Z9J8I *>#^V.O)3&UA!?35>*[J!F
M[5F3GY:JO7K8D,6[1T>_?Q3C3NL8$1_#@O#+030;*($48%-Y# D6[!4[E)!9
M4VE-I2*&\=34.BCUK'\?(>W \VAL;00E=#.@,IR:Y4L:CWPIJP_^V.>ZV^6I
MC]M\@2V@EY7%UQM'%QR%=$8#=US/I*NJTZ[S"G:FC>:FAH>/7)UNUR2P/1L(
MP&'T%(MT(8>Z!MF2^8SS5SO(4E? %I-2C;[V%U4P&3YX^JR4YD/SX8A0SRU?
MX6AJI.:HU_W"1Q'5YQ[?J]A\#OIZI8CWHSGI-IG*F0%LP4VZB*,C+X>)RKP@
M6Q*DV)13B=BR89U1Q\&<W%V&YUBI3@N"O9M4I>WM(*)I"7A9B.AKQX+>?'W+
MTI<ZHY_G7^JX)J6M/6N)P/3SH^K"Z'1B8 F0JX--Y22?O.[/"7?UK'+FP+(4
MN-<M1-7#'"/!G*IZ.Y)=HWSZ>8.WRJNZJ(TAB$ GFY,ALA6'*:"'*<"??1CY
M&N[N5$;:Y <9)EI$)*(6J<LH!E.(B27FC[(3F5(%@"=,)JE^T3";LZL;T(GE
MS&ET\(35?_&@C&/5HO9#++:&QQ[VR_@:-65"]Q$$1I94GI> DK17=89Z;9R6
M(96FA@QW(<5."YD9/7<C?,'7TDUVM2EM5<S0B4#Q5=.HZ M'E)_K/?IE=A"!
M7W0,]H7_-23BM$RBC!:QBR4LW?T):58NRW)IED<C*OFB<C>#3S(^#N!^AHES
M;0@R> 57.=N&K<^Y6?70-*8PU[C#?XH-%0XY7D]R+!(M;BW>P0'![ZW:),$N
MA^YS@*TG-EN#.EEF%,QOS_YP*<,B)%0![#I<R8]Q.H:#AB%<6%(ENS2-E\TA
MMLYWC))W9(U(1)/Z;G4DK<L.S$#4@<;-[4M@%>EYH[9:<:TL$W]:>DSN%LYM
M_^"G;_UHPW)+8AC37QN&@Q4%5D",%!7JS" :VBZ3@F[/[U77-A"L<S-ZVIN\
M^$8:P$0L8+*/R1?LZ6P.(9I[L:L-?]@\6WFM.6HT?I@K82PO6AM3?;C2-?W"
MPW<EE=VLU,L,[AKDG(%%3Z3TJW+*V>HJ)+&/'5LG,;*]5&>=U8)- =_!=>66
MP'O,V<?%8-R9!8MT@I$]+N:C@Q*G*S<SI99]YT@I_"C".V+L1O_Y[1&"5($+
M*,+.PYW ^-*,\\XB5[7OOY(J94VRO,?D;NUWN*,,C9/1$F80JX(K9T(@>0B%
M53R=W0*O@M(-A_27(E053ZCOA][]YBNW&!MAP\"]R@CH(&B[T !1:'.&VL0I
MP<=^3V]^R<^AW]B/XNPC!^19XK3C/ ",$V]W_2)X??>5&E01]MVOP"WQ:!$-
MN%E3GDOCX._TT7_!ON]8B9GJ+\.[35.5.A<5Z6UJZ_HP]9SB2)I^P'T1CR>&
M[GU C+)'5)JT(0*SU06%":O_ %,Y^XI?]OR<]JY[:3>PSS%OEZD5@!3:40+L
M+U6ZKL#[/949%&XN5^V\NM;/Y%TZOA-"ZL[9R'5],=]'U;%A\.V2KX,95\9H
M(0T+!IW4S8HAXRHQ!0L_>6^MD(Q03?;B!%2ZXNG[0?)M2QK9<R0+J0DSZ3\_
M<3*)]Z1^ 5Q\3.MV<>\=! S10)OSII<J&OCTM%_Y2B76XBQE=QAD/EO;HQ?H
MXW40GF![88'J+0:1(TW*1[TDO,0R+2A][D^1G/7?SFPKP A_S,1MKHOO6TNW
MYI^C"6HY%@AQ5J%TF]H1/-\1R*)RK8O3)G?8$.L@BK?JP!:^,/;ST^L.]*+,
M0MQ:UF@,.CO0:@17+AM8:F%\"<1:3P$  1%2&1_C.+<6;,8@\:<Z.\EKPI0A
ME2*'!#O3HO/2'H2]?A ),XW[7PX Z]9Y7WDFK1RM0*3.Y//HD.$<A%;;,$-1
ML:Q'V</)2AGM$D/3NYVYJG:!Z3P*:P09_'> *YF2AR?"?"?UNMS#^0\;(ZW(
M@N\>!8J0'0ER^DUX2P.&B-WN=P:^)[Q@'Z_Y4)[JZI 9SV#ZX*R(B)J/YRR8
MY9F6X'D?AG$^6];>*^<<+7'-_7F!;]9U+4.\$2M:_FY02&)NGANM+MP\_'26
M+])=[>$G9H$$Z_IUQ\I4$VOCP+G"AA0 )EN%^/NW_/Q<AR4G@\(;J".5IU-3
MK,GF<\H3JHITA,J &'OP*.K)[#!L&VE>.H,&3&8KR^@KV>U8/5/M^.V:N=]#
M+3!I\4@I8U6@337\T;"^52K1ELO(#A>SES&9TDP-3CMWNU2C>*BN<0N\'NG9
MMNL3CI:>WMDO/GDI=3-!::G*#' ;UWC(64+%O<S/(]Q8UC"Y4)3ZY6!4_#<O
MP6D^3FXT,+$(F1[H)FB3V6W'IN/>GO^V*XH)YY6&7S>&F[%433!)6^Q]9[;#
MPO])<C["W>4FQH,MXZD =RZOB3[+C'#S 3TT'E^RMC TIJGX6<-!B&GRJX&^
M[B(*VF,LP> '+:.W\,$<&;R^.+9AZ9N;8S8\H'-A"./A6:Q8B"&BQ.F:3Z$-
M2>GTP9ERHA?7(N'<"SO([-V2DDFUQG?KO7![,]<X(K4*GG-B@<L40/:Y==GS
M8Y1G\/-2/[)- P'#W '+T:KP1Z%$(4B^@@_C%X9<G$M,AU0Q,AU>996G;#.&
M/6N$TH#NCZ::B9-=JRLAT7Z=_+@/!A:TL;YL=N[46,[YIWJ:W5)C!WQBRALB
M5B).RQQEH[+'+*D #DL,MGR9" *SX+H9XD6QI))TG>'*5[T_>\SSLJ$\"C0%
MI;M>.&\IRT?RPW&BO'3$SB/XP%SM(WKQYMGO&HSD8M->9^#<'7C6&;1QOZ?O
M/8 QY06"=XB+CY;Q*7I2<S+YG^X;OV7!'RHL;!W")HM! ZZL5#M6QAT>U]&!
MC2#W$DLEILHJB>'UT@TC.0U5,45BH9;-.!R^#7!%-#)^4 K5]A.\E9^/F$9E
MW.BW+4I0XS@?@=8U&V&Z&0,+X[.+X'[VJ#M72^T 2?N-[54GE=]Z8WHE21(.
M.)-QM+PHEA+'\N0!A&AA=YA=/4Z&\=TR%.$NP81E.2H;\[WM['9PP9THD6<]
MR%8L?]P)_SO6UJLU-6&"[T-OR=)9DK^6: $( <P(K02$,/QD.%J<#[:?/_]]
MF-12AM_%NB(AI.&I,C:4_5XW+)\*DPQC]S\?,U/]U((K<[0L=PP2Y2W)N6:E
MG2.H]?G)3%YLZT?"[)W'F$3=^L)C2)S,E*OCC07YA*I*F?8%P3TQ,A/3!O,Z
M)OI(O#>H>=C9UR)W<97YD@=U1S4VL[\PK8>P[5/-;S7>ZV;$K^(4:9G;#!<U
M*.TMMNJ+Y;A/W5AD/<V>E@-EMJ)[.JFQ,(/C+U;6DG&D(LJ'!MX7&5R356($
M0T%A<UR?^%Z.)BX=JD_EJBS.OGUL1%^^GIVZ1L'R'NBF@\:FZZM$O4O\#!M<
M!077#R7D->P)<&BGS<MC2'7YQD>E!%.+0LEGW,PAEUL,?'"<L*?.0GQX@QH]
MX1X\*1_";8Z.&X.H2'SMGC%3M0B6!G3$6%"*TTS$ZX<).<7:'+J4YOI&RJRZ
M;3)38SG<P7(, \IS+:N%-Y)L"[:3N!=F%QXA<I4C0%^8UHC=L8CMI!U]1.#3
MR/O+LQ13<ZYGZ7E%>N%6.B!0[^((Q9)Z?CL//IWWWAG?(&KXQ[(TK$=L-J:5
M<Z_,O%ZI13KP3:7Y.H-1;S?=VGGO<".O6_;9UZJ*.,'!C*"]1BC9D)[>5TQ<
M$OM NW%I-.#C-R1!AC'C=K5J%KZ"YS8%DW?.5XX8>?M"9A40-&<]N&\8<>2Q
M0D?G /.RKBNO#6W46O$VEQQ?MR==ZBG=H4O_]-RB:Z0[(B,I4*Q!!2%Q4H/P
M0P.XJ>>4XSORE E8:H-?K+L6\XS\8F-T_.7ZR[OL9$%PWJYTBIM=S4 #!F\(
M>#-9EA4WM*Q2^=J>=8Z'7/)U6D2I^G% @H@D,QG&5HP*P62C%L51]W/2;VYK
MD0'L!=18)*U8CLEEA3O5P@Q)]@4[KMSS;^>_7YCZA(&^LJP 0BR^/$J.8+SG
M5H.8D/30/(.\)*?RYV746&3']#EW6WRE@!62F0#=IFS8? >#$/SC^=*S260S
MD:2+4GJDY7[H QEG&2\Z]F?M%+1?@IF?^ (X;V%HH)L8<273.,FY9U+ICS==
M%6D2PRM<6(0C2*4F=;V0:EQ0^K,1?&:/!N+<\\$SFBK7Y.0>00T%:,#(S?/-
M9&.&R!Y_W,*%3O7A3&#U)@YU%V^ !-U2)!R;WKQ+G'G,N"**DTM2Y21-4S&F
MD(7178'''V#G&HP#N::OUKFCA$HS[3GTB6%!%:M8?GW#'/8_V2*0$?Q%J?Q4
MR%85>F$H%R0CH$Q4%F:@^98/]'/9+6I_W5M:O9=7II0\42J!LS:GT8:9]-Y"
MV&GT783'<ELZY7BEB.8R?8XDWDHT=V]_$Z[@0F<4;Y>=X#="KK8,:@[G,F(B
M(JMZZ>7@JF#O<DD7AV(YM4+YNQKSK$ I$17+#_(MFM(BX\QM5YKT/$?ZJK1Z
MVT2MK>R+.&4 ,TX.DV4Z%NE=7I.!(@G(DZWHU*+Q;S?D>&4<\VV_V9>;N4-&
MY78HU45A=S<8D7QCX-R'J)P:S%T6HH%<[T-V&^:K5!LT8)">?0!M_@\IP>B[
M;C5R\/0(/B4:"Q9?4-*#7FJ9**7"3D(W%FPZ?]E,OG(LXKGY3EM;,KM64JPH
MP0FV+#]?@ [ H2IC1-ABB5,CQJ'1^#J=U/Y.BEMS?"3%[#%M3 $1&(X1:]Y#
MJ3",NE5PQ#O]R%(ER#6C8M/T:2WB2BQN72!*#P^_>EU5?JXDXGV,9)<HB)Y1
M9<(: K<-X-.[-05](!+J*B['ACO7\RF?($[+GL[.4<^\?3AX=T7'6^G[Q-KO
MZ/K0H=I?L=34+72W\*J5-QP;"A:')64[0YZ'-E%;11=+TW82-(@U\,2I06F-
MV*,DE_IXQ[$"6I]CS$B*"FC"=77ZZ484_*!Q_/BE.?_B6-%WJA*I/+>^&/P)
M^<1[U<I3K$AL,:6Z95.4H+Q)*R (*BC8 R3;+2U_ /V<37D=)I\7_^J#AO['
M6+(CLI#-= HAXL 3#+?]&2_6T?LC*.H/=IWK%0OS)6L_.0SQ*K/!@SL:"M]5
M5+/S)  W]E7]6*A(:.6:_T'[NVH9JQ+QG0<T8KD:L)E6C!1;01M"=2T+?0%H
MSWW88;<!)B+L<;;K1%JQ::CZ?4Y4T:#9IOV\,$Q6KF58U//?CJ3\;Q$YW7&[
ME2UG9T=Y.Y:<OCS+^\(P;'D6&$"WD5/&!8_V$WT#/213L<ZW L^FDP08R5I_
ME(\[#%D,C]B_FO?E3,O%P.UEP71L00,DQ5[NA58_+!)_<J8GPSFTGLX(8)PC
MY[D3J*4BXN28[ZN0W\R!>]L^)",;DZ?NR"(WA(:^OI88"8Z+("B6Q1>7P0 F
MT[7\"I[4H8,GB&S0T9.\'RAPKXI"T3>;-=X7Y]V^J"?LVLO=/HMS*H^%QCNP
M-7FUAYEGT5_+7ZITC$R0H)=V2*Q%"(30\^A$ Y?*?C"H[D1E-QIXXQILP$LG
M@$M;AD]EUYUG$U ,(^H8I.P^.^+\$C>MZD>>]_-+9 LQ3X_LLD0W]<I)#S7U
M/GOG5-<2:"Z(&X) )D2KN%?E!D98#O4M_! DB#O;<]G<$(F^'PEXWKX^;?J:
MI[N\)+\^-]=Q_.I*?BX,U]BOMP4GU\&''!% 6+4BY&50/-N=9;%U6)6^]HJ&
M[[ZKW;>UIG6\B#ALWEAM-$!_6E<)#M(B;MW F;!AKN!A";S[Y/9\GJHFSR?[
MF.XMYT<(>_-"+[XQT?OY"\/F!,6JU]E7W!U6S\.:^1WR')(>7E!S8.Q*T*6"
MZ:HX-392VC.(G-.T5&1GGJK_$*GVE\**;&$6$V!XYC;$/B)*#4VC['ZGL_SA
MJ =?Y:>5>\M;0U&H'58$,<\=%@9958ER]R(WQU9AOI)?!YD6WV?G;^!TE$63
M6=1#S#NX'&OX^/CQL1/)Q^"@L_Y2+WVX;.3S(B$FV/5@<ZPU1^(^<9U#;]-+
M*#Z>U'WCU/4N&?D6G)]:1*P=BT]50A/U[_Z(WD\B=<_:66=ITZEG%F]M75I^
M@A-;(]@K=$LEA$8E_/1D_*2,P-)^6S.N03S3ASY17<-DKGQ?J+<_G3OM"\<W
M2&.[',PTVL]'W$U$KCQ./G2<)7G5=67PB6*,#G5;Q&. T!<_SD$.9\2Y&W&S
M6&#!8!,='8OE.8_T$A?.DH](-,#J*J'CKI:-W_/,_KQB9MI07\#-#"Z[SVME
MSF*? B*8=>]ZDEK?P(--^@!Z%_(]''6-F>K[&#,?GM%I3=E&D_6AW]:UT$HM
M[V"O^#,WX<S1Z) #'NDSP#C*OF>8B[6;4U'AICO&]D5SA?'%,]I$#N7]'-],
MJ(1\MU)[1+I]V)XH+^S:B8@&$=!)*9R:'+A1N";]BUJI4KK&W7U)"O].BR 5
M2<1[.BW)5;GGX1D$EO)ETG3U<C6N#5IJ+3+9]J*.L1'^0EBWA#H![;$J'7I'
MQ1N3OO_+P<>#>UYJ>3*, \0.=T3][P@^:$0#G8R420IP]BT&.MCU<JCM_F@R
M_.-L.08603.;D!%NN]VM.&SY'BHT@'UHVPB"R:I-/5V-<^-<VCD:>I02%$IL
MJE7:8B(OXLRRLIE&Y$O#(NS:[C2AU6]QJACZT(4DT%3=F";3IAA#QG"<=IB^
M!SOODP_[]A+S%*7$1&7__KT.5M 6I3WWXE$%;(;J K#]PK5$-?QN 9X1Y61P
M:]O"NUCQ/D]3C_4*1NX7>-JWF&<8O2R^@O1R.,,HX5;"6'L(B+KX=:_XUX*N
M:&+5$N'-0563-5_\5T K&M!6F?XQC6(L"_%AVDI_U#BQQI^L@,F0^KKZJZ09
M*38A?]K26V:+X42,GBV,[F%XA;Z.N^T^BL:*Q\(0?W1);BAL!/K@Q4MIB?GA
M)2:/]*HMAG\O")]3PBH:(/QHO=\DY#9Q _-8)6I"#1.ION18.=:YS7A3VP M
M+=280(2OI[0=BA&1DHO([IY>HAECOI+^E9:M/.??>R2WLY/[VOZ8:TC<ZSC
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MS1!!"8?<5R)-YUXFQBR8QAJ(1>/K OM<Q!N)B49%=QLTT,@??I45$.1L2CB
M25PWAS$DR4P=+8]8MKVNHXA?'29<=C.SBOR.^W3F<^N"@/CZBZ(8X"/)]$.)
M1PU$@-O3Y18?2B4&7-3X_82-=*BA"M_,"GUNB@T9&PP<+"9?J@)%TDAY"7B&
M([(%MNUI+([(11)EWNO>$L:DJ6."N41!/F".\?V;=R:LT=#$W,+&<3='R$%%
MX?;6U>V^1!R7$;GWL;58YM^A7434G2Z4Z7BV%$BAT1-&DJ4=S>/<7PWZ*9Z!
MRQP%5/BE'<_L&S8.X[YMALTT3C8*K:313"V=JU:.?]S?/].1?;[,*TOJ]PDK
MT0$;^P;%[2@!6O\!@X+V/^H6\I\X1W)# VU$%X_!]YKWV$ GUIV>M]T-V@99
MU<:1SG#2U7.5AFK_PS=$UBPC/SGZ-X8</D4\:\>,W1&SDEI%U:Q:"[2KSB#>
MJ$SD-3>[R#_E*'GWQI:8D?_N490B0"B,S8R%*4&.M(8_-:G-:&? \5<RZ+P]
MH.;.31G5G7![,61.C@.'U3+UD)E6N;L] X/+_WE#4GU#W-6["5VE_,6*"AP?
M.;QTN=LI&Z+E+*EV.%_<>#LNR_R<:LI'4<0(WZ\&7M/W&B-_1Q!\L( /V $
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MLZ=("Q>]ZOEMA?Q0J<74P3;K1KQ\PG.?AY,'UYFM-LT0(Y/-'G#";/L?G/7
MG$!*HNTT^QSX8!4-7#DJ(_ZEY*8^&1;2<V( MRB?_V&NZ^_+D_J%CD-4[BEH
MN"?I$< #K9C [I:H"@M2</>D2IF@R7Z1IG$[P_X)13B>?#@IW7MB8A.CFF^G
MK8FZ!LU)"^/+4J/\IWJ(81X 8Y@3(\UE\.Q.?55BSLAN"ZAU*@@;,SKGLH!W
M(=:88W-HT\T@[+MG<X?K9Q%%3AM0>E^>3.;"17<'QW2;V*?1AH7Q!7K!R0TU
M-O&D==; _-Q;=_U25/0M%)A8:>2-7-RIVSM[B)_1W59.':3+,*(B H ( &.
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MTGW#]80^Q:_HH'"Z(Z]_?XO+H[)(RSA[7E<A+D7E$$\<M+-A51R5I\.H<9-
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M\&!MRZ.@$05$=D)(?W,N[.Q(H6WT>]+[L*2.FZ136868.LOL<HZPB%E&D9+
M\WLGX5L:;NT:YIM('*?5>5;"7T7V>3+U^/9MJ=QT X_Z^>XJZL<DR.[X>8?S
MDVY@HX#8-D_HR;TI07FY$N>YG*W#T2'[1F>*6=Y-MH"):M%;*Q81=1X5BU65
MIJ:+NSF^]9&Y(585Y5I$=YK>?7Z/32^?"\A^PY9J_AZDX5[R<S_ .2B,8?;W
M"F/H&)WMR-#5H\>Y=W^!%#.VD<)P[?5VTIZ6I/KUR-9O9ZZ2*]I-;@=NVP+W
M.&A4F^%$S?1T'$D%;',PH>0-%' K2&5:'HU8^!0LM&?(%9>+N\K+RPEP;..\
MQ@<]2:AK.AY6>=L8S2ER!#V</!0G5NJA +E-^LP'!)3HW&8N3B$[,(BHSP@U
M&?(@^>:EK$"Y/A?C)F\$10$:L\*TM ;W]>U23UK$U">Z #<^"\ SUZ^,1>[&
MU&_87&%;@7]^*LMC^B80)+A^I4"K8X9=5$JM*](H1J$M1KEGFCZ *P](ER+%
MPUVJ;L&C5E;N<.=9B6YQ)$D(C ]PH\$-9YZ(,M-JM_ EIRSM=1MX]W[&&,(I
M.TAEPP8/1(Z51K@XW=)FRF$GX&G_WE>:/_&3%TCZ!W[7_FP06W7;E"+-SUG_
M\_0%*XV=HRC05[?FO'NBQ:DI*@@74M5)7T$PI+)V0T=;MS5"=U*P/S-GSJ..
MZ\V6&:2K+Q;9MIG>%SNH\YZEQ)(U*81K >2\^;WN9M=:_Z=\HN0*3TJE8</.
M@BPV8T-$4[@L9I-3D/KL605A]QPEW%^WM7WFDV_XDH5Y-N*CU\.$@NK''A[J
M&\U8E-8R:XGN%E"3!;<"N-F&@JI)V_:17JNSN19^MZV2YW')BP91+>GA%T1
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M$^SJ'1'",(?MDF*=]0FRXODVG8*GA&^XO"9UZ AH7N0>C@>P5?,0IS"K>:.
M?VDXC_D>=M&W"E?UC5?@GM!$SG3D3+K,/[W23=U29:AU&[['R,XEC:O$\TC-
MEX4:1MP9AQ N=LDL^R+7%/%Z6-$B(OIABEA]!!$DU][3VF:-W!U&NA$=UV;E
MB;O@$_.4P37.LL<^\7L4W0</R2W#M#>['BI[_I;P._(+@H.Q080O!1(5DP,G
M7DR)J*?12(_<#S <B1[B#($';H;ZLMR"G8#&(18U+=\W)\^(6=94//&;S+(X
MJ]>[Z-E3NR',>#SRO@P-122)!3;/LP@Y5!S<N?KBZ;#C/F:RV8?EDNI9FY2#
M^UFO[N\&UB(:%+GKKJC21D^>/JF_]][:Y'4CO:W&^!(*\-L9='U@MRY'2F1:
M[K7'</W+#W:O*WRDO"+C1:1!YPBKR,_!/4!V @!]@0RLT.IX!?-?2<H4^80I
M?N,^(7]$N(F1_.9N-VMOWBL3UO(@M\;)(+V7MN+N<IK5T^S5K3.*TR8C_L2M
M%]9FSQ:W1J=DYN=2K2+/!K*@$^O3:?VTOTE2G6C$.9RSX01TI=#Q38>:F5B%
M_1&$PMJ=>O#\E4E32Y+66879JI$65YVHI1C[""_GH=>Z9=1I[AK3NRX6F$RV
MZY8+")+F\6H@34;MV2!0C166!Y<^E>B'4V[P@7KU9D[?CDE=\9M,;HF,.<UI
M2Z[A&_,ITR]T182%96P>;@SV')&#>W2A^YH=:3:B>](=8U[F[A*((:3^>."A
M+>;:R4E2NRXK+&1\M2=P(!;&T-6-4^3L5VVI5AW5J:XO>=B+;1NNTI3<$KAE
M2$:2WF=#OJ@#VWZWMLRJE6PX(Y0>U'IDC-5()WC"7.Y%;3;4);V8N%ACM14
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M\8AC_&+!ARDAN!7):N:0@^=*]0'Y32=!8ZWV]E<_Z,>73H^LL -0P+^O<_X
MTS5K^X8>^<#$B$M_;8J^M%LJNB*SHNA[WR715(BAPAC;[V3RB7?5$\\GW,T*
MX9XFS+CCG*':Z'=03AV?VJC$E\&VXT]MW0NI+VHH.2>E WGK0Z=:<&-W3%*H
M+YL=?E3BF "E#5HR _R%<-WU1.'>#HS)[>H(UX$B9^+EZ:/1H<.P:MT+$T_
M[W?:HYWX-F$[""NQU<\+V,#]SP]%O[C=U8YH4-MD"@^TM[=GP7]/K-LXCP(<
MP4[7E:35E];@A:#NK4O0<J>_3M..@HBU"1BV,+EC>(4;@9 I 65\)QR!\@_<
M0K25_G+D$ PW,\$B<I38R8=FN[!"Q_(=3CJW^:]3MP_!8K^0-F\;Y3K7Z'9K
MMP8#?Y/V*-+60/VC*L1?XD%N<>(X&TEF;W4M<W@]TF(6];B+"SS&95T_2C#.
M:OG*P!,KSJS=FU,T5;K0Z\OX9:PYG)MDQE:;AJER]35BN<Q[0RFI<]T&'KAJ
MC!R_ K_S:U@QR=^RXSUHE;.X>C,@-T<+46((8H?-9F;*#C2SB2C"W=AJWSF\
M@KTK[%/'HV,+)\7]C*5QI6QCL7=#R?$7ET_%/?P/P85NZN'ZQ;BI*1KFP+XB
M1Y#ZVRY_!HGVCDCN"L7/QYR>@S*)$7>4 0RZ&BY8LMMEI?N_UAV7('S;WCZ"
MF?1>+;[4$N9I;,\T/2@8W\VVOD5F2YFF+LO23FSY'P\PD$!Z%/G;YMH4_,M<
M<IB03%?BE174)QG7"Q]K4K(,>X[5/9-?GUC*KS*S/IYV8X=F14A8A<RNWM*.
M:>3&%\!8^+QYAS#%PED>*F+57]B8)P/W]<CZ[?.;>;;$V?/%^4F)8^-RQ]T^
MLD)8U "NS4#;44\(!XRU9XP,[MVW0CI=Z7.MP)TCJ*NEJT#D,.KP&YLU^,N#
M%,DM7'/@ESPV[-[@P%RCN6&.[TI6A5F!0G\NQ.-Q5=UZ-8D*?\I((4W7.'[E
M,?J6O[-Z.YE!-?+:!>7N&]HNOHXKG'&&QOK17IN<KW 63-T&1\02ZW^^QAB&
M3VQ(1<L3Q+2T?TWTYW./&U^6&MEO(H*P\>Z/DK^K2$B-6__[)J^L)&O1?:P,
M00$;A#\*I')\N[XT$!0\K[061&Q&+^+18P5?0' QYWDQ67M9>"815A]ZRW8I
M+QN./4:6Y!_)%B1]%56ZJ\(6#E+PAR2ENI9RIZ\'BQ[U+81Y%0F*?O8[7*X/
MK_&2W-G2+V0ZW$@F_RF93Z!(#?\$Z:58[KL0HK\_1]*S^M4W_@+$X6ST(FKK
M"ZWG"PR+?'R$2!'<OTO6<I;,M6FZ@KVUY=UE /,W27SDWB$;R:J^%K#]2U'.
MW.)YOBTL.EI"F%CN/2C/-P##YFVF5=R:@P=!F7UZ[M/69%IX"RL1Z/9^WSET
M\',WQ7U8N7>DF;&&$98TD4CTN(>WL;S5^DM6.OCS(XW.)%&N>T\RTCW#+9F_
M"+-M4DYQ<+!!=4 .4;4!9<B1WTLFR=M@Q^5!1\(T;;J^:MEP+06I#+HN@E*1
M?L#7(^@9S.B&P@8%$)QEO\_ '.1TY_^+Q08'CR-W=C!24=1TWYJ-A67.)[Z3
MU(7DZFGXKRW3E"+#-*JRAD<8EBQWM6SYLZ!S@ZL$/U>H)]$65LG,^5?YA\;4
M@JC;1:FWTL38I(=.J:TDWAXE@"F#I%X6[9KXY3%_JR3N[L@3,IL>^%6NZHJ5
MD7@O7)/(=-,#D--E#M)O@R;'N\HK/%D/."LK*U/Q"L<?\CZ1YB-3[UM3?P3N
MJ?[[3\, =MA8#/(^CX7.5I19!N<-$-]I&_83.U@^SV#BY3Q67C-1J0QRAQ(X
M^7?HK)[7)5*R54M^X6V:8#1M<27P'O<> /&$8RPYY?%,GAT1=F_(F2':)4US
M#+@&#Q'O"Z-7\W FR_''I8<XO:W]_Y%-A$E#LWZA3:N\TCK;#'C1#+M5 QZ,
M GB6J, ABM'0P2CQ3KR?'KL,]UF,VH)JI?XZ&=SZ;X<' 1+2>W!(H>5><B&\
MX&$K=/P]$Z]VVQ?B1;_#IZ6/W\U?ON;%E&NN3/\;2SBC%+]"6X.&RP>/7&(@
M%NV2*]JC%N'93B/$7PM2>_D.%%J8*#ZVU0[FC&UW7DG##?0ZP:*[]=BQFYQI
M2/,E=?I8SDQV#)YF[E!9%/"O_<!^RA/#[+1A405"B=Z.BJF5_4T*B</C&X51
MAB]NF2D/ZY=J2&/=X<A' 5%)4/ UIN_$%8P4!3"7HP!<W=(@37@O;I)2+<_4
MJ:#D]_4OF:8H ++)*@(LY]*,#@VZW3L@")"+P2T'E?5)(JF@'0655D+P@]M"
ME)P!28_(13$&MOG$DL32^[V0&/"W*  _LR:@<,69==[DVX+J2RH;YQ/$#WLC
MUWF\6VOR&E@[.[O=E6"(SLE^3G)T"*OIL*S5\T;/,1]HF506P*5B3T?2O+23
M)Y^;UZ<!<6*'"O?GXX'R)GD/?%KK&(PV^CZNX$T'E4Y*7VH2=$6R>;K)0+:
M WE?"+%=3[XM<AB:<=YYGB_V]8H=O.2ZF'"0B#R'S+'ZG%62Z":UG,H6REIV
M$M=S3G/KP,PE>F.M K8,AH=9^;UP[7:MY_]C-\=065ULT)$U3+U6(K-D+5C[
M7IC@@E%SBW#]#]'$")_GHJJ4<W!=:N_U0?2<VX("(3=SCION-XN>\^T=O,16
M.9,K^("<R1,;:1 I.@)1<F2EWI,DW5H6>O^=,S3%X*L%:/0.%EF7#-LYVV-<
M_TJ$YZ1@_?W)(.%/5O"WCX4,BSX9D2PO-E0;"ZDO(4H-(]XM&;TD39K-7"C^
M(?]D?4R[]]%/%IYWULHFVUM93YOH+6^5SG/NT%6FKRNA/V02.*YV3@]Q(T-&
MH92_0:<P1PM.M]*R51_&XIZ67)X0M#TY(4C"OV!UD)[BP]V1X:9N(9)YVA0O
M_-W4U!00=R@_O+/_&]RNF]::IS%*01TOC2?1+I=OY(OL9_:N)PF*WA$YR5TL
MXHVPG<@ITW#26DTND&/CBLV(KPRFI]%R!M\2Z<;@8Y<! 8FW8S;G)K,;;6"Q
M*\5#.6G+--,!KK!I"JW=ML\#@)%>$K^N=KA[E%T/4N)+G 846?/);'$_M325
MN8P.0JA(F:8U/&PP[)D[=!=C-^\?A/U6D:#5_MCU%MA<SVA\@%T.OJ\";)@1
MQ\1 L/G?",'.'_S#;?J2YW,5Q<[IR[=Q[3&!TV$VL+E^6IQ7,-"JYH$"H-G/
ME4X&YI"7[C<[CP_K62\A+B@@J!$%4%OF6W_4E96+^U!A-6I7:&FIK)RJ3* Y
M+JH\L6_9B. V3T; ZE% AP4*B"N]6.%JFQ;8K,_DI6:EYRUDP5/LF*$6F5YB
MB)]^I%EP7?89!4Q<SUTCW6$%5R9Z*"#_JNH*L0HQNQ#ZOO!PSV,D0>6BWQN\
M<+%ZLHH"F&R@5;*YSW6LQ,;[GU%!*]2=]Q>13 =*];ZLERB@!8T'QY 2/QD4
M%E>=)2\H2-]E$1^JL.4/TE<)-_BE3=+:9=KKZW;P!P[V->8$Y_K5J&'>=L2>
M3A_FF5MIZ-E0>+TJ]^VP6'PRR_L;;R4KDE)0 PE:0 &K@BB@_R;EDEF MJJN
MX*-,%+!1UKH_K2/S?<E$">).B0)ZF-<)#\"_P"^NA+.NDJ5&EUO4=-LC$MPF
M'LTD_X<K2Z,'"%,#H 8FS00&7[6?+:A +F"_48#B687 ?;Z&CQ*<8R@  $VN
M#N;1ZCS%4QQCRUC/6PT WYG>).XW\3,L\U"*9U8I_4?XT+&H6ZI79!W,,*_&
M 0>;3@D<G W-:";-)'A&YN,/<VYNEFPVC=O3_8#7R$M9R\+-/-T%O%6$BCMD
M.&Q']AP:_ZU5ND7"V>C5?K#8H^;.MO31^OK8[>SS]'HJBD',]%#2!R=@+(0M
M"GA5U2<IJW,8>9UU7>#,-9;0Z7*"N$X:,<' 63WSRJUA]5[2@TWT"1>#!,7Y
MN?)T=*U>6Z@P84>\QM:&.,G59N@TTY_(K<7M(#G@_D@R9M)N%O;)C1-.Z%*-
MA>5;TZ!T3_KN9_Z6OXQMUR)2=+KWM)8P?N7\M\1KZ7_/V-TZP>BD!'T7I-0Q
M6;?_@_8 IL'5/N _\,,A-8"U9U%Y22S4.^(;-)"U+]BFJX,A7AN6%7[VUG[2
M=;V1=E8$_[TOP)?IU4T%L5U_*Z"[O*O,7-R+ F)R;/J890/*G^0M[$W9MC2^
M<7QBJ\G7&V49!4!#K)6'*A7W(8]J;K)W-86[BA@=,^!:H<V&- NM9>3^ERCV
MIW+>=;F4/\[Z?5D(T6.*:SDGH40%,AA*U\^ZD/HRN*T>XEJ13FE+W*^R1)O&
MF.9O(@R-0#Y@[3NZ(DB^9O14QOI[\C7K9BSHLD7_7S-]L\'S0[0E-46%B4Q#
MIC1P.]%Q@YGD0K-3Y[S14UPW%-_RU&&([:XT&R0<HTH,3E]5;H/GQC/-(/WB
M]&5\I"A?S6VVC\^>87*FV+M%O&=R_(P]P1AT\RT8]$DMZ&1&7I=<OW-F'COM
M=#F63SPLI<4F.3I+92I1 O^8*S1%HZ! W_KKW#R'BFDM<>&ZQ*$N:FGYA'#9
MN7B$-/0(P;/ FHA0+57;&M[0<FAHD'I\.; BDE:>]&.EM!_ !!@]OX4U%L*9
M*\8^@TBON*^^ZJBJ-;V4^9AWS\%H?'.I^#4F]UU2Q(GT;BC&!TA^O"(35&[8
M46[X91D?#HTQ)&,DK74)&KH6V$#'7,BPM0G?*G'6)5KA@+\LWS5_V='KU1^[
M7)=")>^$+[W;Y)D^+J*'(*MIA(G_GDNN-T5<^P7?T]2;C^=J>:$:TSW,I+BB
MU?-9+RSWBO._VO4/%3LE)=]EN3,YI__=O:"U3L@@,+S(U)>H',/@VUI8-^X'
MZA)K*>@V-;1XP(8&)/Q0E)C:=?(W;U%J;A\\/G*'KJ^00H7SMGVN]Z_7&(,(
M:?3*%R EM7R^.K]J>^RVL#AR@EA:)V]T?(X"P'2#S[_!&F_:[)- (]%!@E)#
M<-;H]>#;K</EV\4KW0-2CL7/3U# _"!2:_O#OV6Z#(V^!?U+_U!EYJC($A3@
M"G_Y<*8MG^=@-M7RTJ+QQ4I8PPZF]+A8F!%"=R-8N$>6::&C2BG#G96@;'1D
MYR/;X2#N,6<*QNW.?^D^2KJQ$R'<YKY6\.23%EU;0Y-%T\<0K'ZCK&>_UK5(
M/'3I 2;,%(SA_*2<OG/OY\:L)+X6[]C]6VSH+=D3M49%R$4K[WJ?D-T-V&CG
MZ%X1F41XHI5V<58,[/E2)ZHAZPI:LEU;2P'Q@7BJ*I4WUN#]DHGN%*#5GL#Q
M1.DFFB]6@V[V=8))EC)L$/;QF=7CA/"92="MP6XEN_;9(&JF6ZN/LVB)"35Q
M3@7\+EV158S#!+>@O9AH?-SS_RA!R=]7!!^MS,[M?5+,J9;4[^-G*W=+E2@_
MB+3(SKCMCL7;DI];E\8\K&._*"Y<7[:ZHP"BEZ[4ZV@7VRROBK;\@3;7O]-1
M0'P!DI8G!KPSH8WV8_I@F&_RW.>\K-]E;\YM @ZI3*+17F831HJXW 5?[.DB
MA3ZVP%LW&,MD#A#Q>$$_YN6']-5\A@8,C]:2WG\_VU.UY'\C56H3\+)OE5K"
M":$F8"[^33"R;M'P$OV5.&'2+WF%Z*MT6Q7CSA67P,&6]3":>/?/"RVIM\,X
MG\^+:(4UDV*FGF[:GM[N,,_9X^6*DF'"R6YXS^D[ /Z]JL]?"NU,/+/![_4D
MCNL6,/A2HQWZM51=W1"'CB?A]UJ@"1>398'<]'R^2K;'&<$/7UV\M!)"H;FS
MD[U@5C40&"&D2X9V^GE9*""D$.T0?Z* R&%T3'HRB0*.IO,15K[7@;$GJWN5
M=O/!.TUZUJPH@#"]3^EDIPCMBTN4X"U*ZUZ@:&30:>?5&0\*H-68^QS]?XT2
M]38*( X17$3<FW8O9WR('&]IC'V6*'\BE9/=R_3K<:N6;N61G97C*]]MF'!4
M1?T=MN-GP<.W(VU;7Z]E<'J16HLEJ6OA=("@I)%'E4@F](!;K?_<="=W,N]+
MZZ72&ENRMI3;>$'69^=)0,K^3ID+OI?P.BUM#T1=\BA12S^G-K[VDE4%OMB'
MGMEHT+TKFRO61<71+21D[/C"+=7@R!;"6#M5[^1DGG^^&ETW9C%\'++L3#V1
MT>HW]I/1S4,L 2)-O1VB!%-+3@ [CFF;5J>)<FD_$7]PE4!Q^=TML0F7+:^)
MGHXCG+]PJDW5?5TW/,?X+^:D[X*YW)HG3'UAE&Q,;D\+I"$R\D;TN<@:6,NJ
M%DSM(/1[V\'MWL=1/4>&5WHV=Y8DCY8#'-ZZ9PD_W'&T5@OL![%&MV%+5ETI
M/;^@U1M6K"^3VROA;(C2CK*74<-Z-V[)G[*2GHN9WCJE2 N*1U* H\W53M,N
ML_3ZSUW2I@*JMC6.,[WGO %6W/Q<WSUEF6 +2'#G^6:+[BN$7/"&<\4%_6;=
M4TI,IZ6W1J-"6MC5N ]IL!B^0?W[1\'D\&0D>;N%:L>WLX8ENX9<&J);N-U<
M1AEQAR^H!W M4]!H/PY>O'9Z$8B]&GE4OTRQ?7#(-BW^)B$MN!_7QTYZG.Q)
MW%ITMV?<3_%DBB )>/X&,_?1Z$3,BQ.)<A,^Z->WK![T!E\>DK<);7<)>"@^
M!VH@57$F>>0PU^+H<GEAQ7I?7R>AQRHR)"&.V/?P?N3B#4_ C9E6&24.9+!G
M:Z!39M53WZ=UO7ZMJ1>%3HQ1A >LT=!+T].7W*Q:'M5UI2ML+13P?MFD^C&.
MTG]+ @3Y9XR&M% D7I 4;&X@CW'J8Z+X906D?;$.DS$H@5QR#8O5R0-'%GLG
M(HT^:Q!<)^)#H54$-UY.WTDLC*WT,H1VX2V)>03P_%I+Z@/\\P!846>RO%!.
M'UEPC@I_KT+',=*@9(@QKO)7B?$:F$8VPEC>#*)#V&WNM>)B$F+RMDF%X$X
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M>YM:2,(C2,TAR5@E+>7I:9\[K>+ISMYNBV<+*G^ZK$D<!R&"?_#178%&^'%
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M3G@"BV*;,G/V=^XB/<'2R F+$IJ1!L,54ER4"@RN_>'DX?CQY174N"%!\HM
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M26ICA[;;L$'+\G("WH?5S$<T!(?I-SCZQ 61C!B@<X&^LGXDDW=A*VJ?:_)
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MEVMQ04<:PRCJ=?K<%FV*_MZ&4>:!S/P7%6/2\TZ .U3T12XR]WGU^'&O^^Q
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ME?)B\=F29U4X$U8--K_=;N!L7651MQRTNGSY]0")2'T1S' _,;B+,<E&%B"
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M8)'I(%?+G %[B04UXJ]N45"J^[8$M45&3<B761OZC!GY;M7C>IN,A@;4--3
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M7@'JDYB3]AWQ3CD>4TY47(^['05(=G:YO(([!K^((%C-<L:#!&G[KWWOP<J
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MEK)AB:\JQM7MC+ZTG>^<16B=\09L'#NWI![65IX95#%%*TL$UM=%2N1^N'W
M3<<E.!*],]#\#4F(G=@^Q934A[^])\36QR+E]2>\TLGW@BG370M'M52JZ9F/
ML2F'5+"IB 4[[(6.[*D,2+3(L*:YS@7*DO^3Z<9U&;P&_^%,#;\(O9[C0\_T
ME;"E&G#V"?G#P,OGG?:?+S[? 8>?1J[%%:FJGG;0X[1)ODUDGCM> ?&*95?
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M"MPZR\KT>65O\ZE>@S7M7A^OBP8=E,_;0K7RJXL'29=8R_PC0Y)^W3K^K_4
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MO]>O:L!FDI=J.B[=7*%62O"?O-B+I&0PU[#'6@Q7E4T3PCHP1S3[,\+&NF\
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M&G^X$6M*6BSEQBXMK>@J^\]EH'G.0C7'*U]S8$\O<.?QOCD_YI_:R[/!YC>
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M<@O3?W__,$6_G.^9WQ;P+0DL/!8UPC4D0X=6&VM1A%\UM[X>F-^?#R0U')D
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M8+F6B5ISH-<7JY2=Q?X'%>F'TU0J]^MN ,[^[F?$E%C;KE"]- LV<!A&V/.
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MO^Q?]B_[E_W'!KN9^Q]02P$"% ,4    " !2@598G:0-77"0! !6&S@ $0
M            @ $     9'9A>"TR,#(S,3(S,2YH=&U02P$"% ,4    " !2
M@598)]+;/I)* @#6="( $0              @ &?D 0 9'9A>"TR,#(S,3(S
M,2YX<V102P$"% ,4    " !2@598\04STML!  !""P  #P
M@ %@VP8 9'9A>"UE>#(Q7S$N:'1M4$L! A0#%     @ 4H%66$%'#1UK!
MD!T   \              ( !:-T& &1V87@M97@R,U\Q+FAT;5!+ 0(4 Q0
M   ( %*!5E@:?;D* PD  %U=   /              "  0#B!@!D=F%X+65X
M,S%?,2YH=&U02P$"% ,4    " !2@598Y/6W>/0(  !670  #P
M    @ $PZP8 9'9A>"UE>#,Q7S(N:'1M4$L! A0#%     @ 4H%66$<!3EGR
M!0  BB    \              ( !4?0& &1V87@M97@S,E\Q+FAT;5!+ 0(4
M Q0    ( %*!5EA*P#9!\04  %@@   /              "  7#Z!@!D=F%X
M+65X,S)?,BYH=&U02P$"% ,4    " !2@598@GY-$5,:  "FU@  #P
M        @ &.  < 9'9A>"UE>#DW7S$N:'1M4$L! A0#%     @ 4H%66$6'
M9+CMD0( UT $ !$              ( !#AL' &EM9S(U.#@R,S V7S N:G!G
64$L%!@     *  H : (  "JM"0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>dvax-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:dvax="http://www.dynavax.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dvax-20231231.xsd" xlink:type="simple"/>
    <context id="C_92e5b8ce-fc26-44df-be6c-b93ab6266391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a7cd9712-92a6-43fa-a3e4-620df529380f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_99635370-1a22-4b6f-b761-e726efa96bc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bad25b6b-347d-48e5-9b97-3f8c19355518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_aa260df4-3e48-4fdf-8ab8-54f380fb7620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCollaborationPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1bdc419f-cd33-4f84-9be9-6a7a197b6800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">dvax:RevenueReserveAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e3f4c696-246e-4a9c-a510-583ee8c9731e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="C_99afab35-99e9-4d2e-bfac-d15173962934">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_70bb3c92-fdce-4bba-8d13-f7445805823e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cbf226fd-6dcc-47b4-b352-348770773ff2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dvax:NotFoundDuringMigrationDeprecatedConceptLeaseArrangementTypeAxis">dvax:PowellStreetSubleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a78eb8f1-5744-4979-8db7-230dc51613bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b9c3ac11-c1b5-431c-85fe-3a4cce93994b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_38284c71-50a1-429d-8131-ac0563038784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dvax:DebtInstrumentConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bc8ddedc-d903-4ea8-884d-cff004170dad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_527a5bef-aec8-4da7-8ad2-8c92c7570a64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:SymphonyDynamoHoldingsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-11-30</instant>
        </period>
    </context>
    <context id="C_7697cec1-5a5c-4cda-96a7-3a7c51da9ed4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b0c51341-46c1-468f-b8a4-d22a9e93bea9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d26b0e54-e633-48c7-b851-f555aaf0ac91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a0b842a8-48c1-4246-8a13-5bc899141fe0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a9bb4111-0938-4d2d-bd83-eeb18b9ba154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f9680928-634a-4740-b0dc-8e7ca6e0523a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">dvax:RevenueReserveAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1bd10d4c-3dad-4350-b83d-0c72c2905fea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8d904b5d-a1ff-4762-bd22-3e30cec979bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f2119199-7038-4bb0-8c9c-d8181ef231e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b066d0df-653b-4391-8933-b31cdb392277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CRGServicingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="C_1b272903-9c51-40dd-8f58-0e6dd1d903ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_751580b2-fbfe-41c1-b881-e6d093f5c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_9822878d-e9c6-42eb-aba9-e6d1be0c6c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6f5207a1-1b60-4990-be95-58289e708128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dvax:DebtInstrumentConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4bc4c639-7c83-4569-b3d6-4d528d1abaf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCollaborationPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a1ba67ff-228c-4a77-8fbc-f341080d81e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">dvax:DeutscheBankSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b86641c3-95a4-4d1b-8c32-20129a34a510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4e8bbc07-0e01-4b4f-8236-8ea97338e319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_7b4b7402-722d-4537-a94a-f71d88ccd9c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_06216486-f415-476b-92e9-c173c38795fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_25c9967d-9381-4ce1-aec3-a06102b373ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bc46d573-296e-4a0d-aa85-c245577e3d2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_46ea9e3a-6a19-4c11-a0b8-d28df71f9995">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a7463f82-87b8-4f1d-9935-b4868bc5cd26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_52588853-8260-401a-beed-26f3945ae871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_087bb460-7784-4ea1-8991-e6e00539b1cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8a2ff8b8-7c89-4242-a4e1-a77b739e4b68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8aafc35f-0931-49c4-99f3-ba14874dc415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b4c83557-99eb-4dae-a4b6-8f5fe7a1fff4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_58b0bb3f-bb8e-49d1-a9e2-0615cfa1a595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_39e6c092-46ac-445b-8f0b-7dcdd766c1ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_25a5468a-bacc-477f-bef1-e85543a6913f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_90d829ca-90bc-4f0f-997f-b75da4b1cbeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_98bd1202-de67-46fa-812a-b3388651d485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_55e18a2b-9266-46ed-bd0b-26af19bac2fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="C_60a06249-5799-4cae-8123-c33c744ecedc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d3b6b8e9-b6aa-434a-b512-84475ede426d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1aaf5950-6ea9-46e6-a2da-ed62c66484da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a9ce0868-3fca-4734-adae-586106f4f8d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e83edc5d-57bf-4f45-8c00-a78bad8a160f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2d3137c5-4a24-4ea8-bd54-b337cfe3189f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_501845fd-14fc-4143-a5da-15378a311c6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ebe94c6f-4531-439d-ab70-697744f5951a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_01f47823-0ce7-49df-83a3-cd706589f4dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:TwentySeventeenAtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-06</instant>
        </period>
    </context>
    <context id="C_c3753588-e357-4568-8f96-aac287465012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6788e286-c14c-450b-b13d-2eea895a38ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c45b2a41-c8d9-409b-9f76-329e71219be7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_79c0f9eb-0184-4dba-a43c-01f7640ee145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b671bf2b-5135-415b-beb9-c44190ad1450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_48680940-6818-40d2-9606-4f38488cee91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CoalitionForEpidemicPreparednessInnovationsPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a35251a8-36c2-46bd-be47-03e6fe5c7a03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">dvax:DeutscheBankSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ef72dbdf-e573-4481-9cf4-b43c84730269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">dvax:CpG1018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a02082a3-bcf6-4470-924c-b963a2bcd1c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7cdc223-9b33-484b-b064-ffbb1dd743fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ef0e8934-759f-4093-bac5-8fa40486ee52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a8317906-5e1f-4330-9194-db9aef7be671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5cff3f8b-5d8e-4085-91dc-8a1a4395f4c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c4818259-befe-457e-b5e4-83ccf0a85a8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d2ca19d3-f268-4784-a5f2-05a124a3d30c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_16e235b1-3b2d-4e5d-8443-14ad46e6d0bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_64302cd3-066f-4f94-90bb-67102762e43f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dvax:StockOptionsAndShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1bc231fb-46e7-4fb0-a5fd-dde6eed5fb39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="C_d65d29d7-24ac-4d7b-bfef-53e5f9ec99ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fd1be51a-97e7-41a8-8c3a-1b53c43091c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c265dbab-c590-4635-805d-fcfcffc40237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_10ed8dc0-a4c7-4909-9310-8008b51e41a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0cd05fc1-4367-467f-b1f4-b88105492b67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a210ba4e-63a8-4224-b689-4b3fcc4782cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_344d9e72-8b1f-4434-9db5-252aa7e877e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-26</instant>
        </period>
    </context>
    <context id="C_a1f0d8d2-631d-4ed4-8031-fd5a057c56bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_887ba154-ef1b-44c1-92ad-b5335653b28b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="C_3679aead-0bf6-46ad-8149-c7043f490baf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_518ea503-766c-4a37-b80d-037d29359c1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c385cf83-1634-4094-87c8-c188ad78b7ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bc9620c9-1c43-40ea-a14b-d5100d03b2e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b1074222-76a7-46bd-9644-2e3690082980">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_56114482-df3d-4e07-a8de-d386532d7a4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_876b9f96-bdb9-42b7-883d-e9aed3b08eb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_98f50ec3-eed0-482b-abdc-e3f4d764dcdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5ca8debb-5a5e-47ec-ac9b-67db2519efb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c8cf97a7-7cc0-4345-ac03-211d0a8e0250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8cebee1a-3aa7-4377-b9dc-63b5df400e74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_01905c0f-bf3b-4a9e-aa83-f267ccc52200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dvax:LaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_44be1a55-42bb-4223-9a35-d53aa56a00cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_960f69a5-6c26-4021-b7c8-8789aedcdc97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8ba29514-78ad-4553-a6f6-379d75c85d9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c882f98c-09ae-4335-9956-04f9b0df4820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ef4a36fd-eaf7-46db-ac29-52ed918668e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_00cf7693-c589-4da2-bf41-f883d3c76f3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_affe35a2-f489-4bea-a377-a5366608b680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_90d340bb-3e21-4b45-b920-340abe04b8ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e381175a-06e1-46c3-b77b-df4ad235482a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_61dba5ad-822d-4501-bae4-9a20bd0eed27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_bd4dc0db-3b94-4730-9f10-12f7f1a154c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c0af7c37-af17-4bba-9ae6-7bbd452527b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:CappedCallsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9d5090c3-cf85-4395-8b36-a4feb0cf89ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b2def0eb-ee73-4354-805a-b882be4a3888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_10125268-dcf7-417c-8e67-6935f116fdcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d7b73016-1aa5-4068-89fc-abd4a56ae044">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_b40fc463-936b-4ff9-a706-0dc8d375ef2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6a1e5c04-44fa-417c-a4e7-018c2ad6e933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a1a8ccc2-b5c3-4443-91b6-3ade9ce8f4e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8004c05b-80cb-4d34-b5be-e0a034b69331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7951b5b5-dd53-4f52-b40f-bfff22a01db5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_5431114c-d857-438b-8f6d-8010eba4cc30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_448dc083-473d-475c-ad68-1d927557d2eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_709c2910-32d1-45cb-9204-ef2070cb1241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_29f44f8e-0fe5-45f6-8bba-6cd65b85e586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_4daec9bd-18e0-4c0a-8754-6c97e388d5ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_21d5cf56-92b9-4489-b44b-c533985be50f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c81fc228-69ab-44c3-95b9-aea5499fe2bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_23872491-571b-4186-b6ac-a7b968b913ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b3aa89f6-f4c8-4a9f-8753-f6b4ba518016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fdc045d5-f884-4bd3-ac9d-65b497b60faf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e1eda147-6a7d-43bb-8a22-8d62411d3073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3727f25c-7b34-4d8b-ad87-5a284d913f8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4cecce06-d788-4a18-b30c-961790a113af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a407ebc3-a04a-4922-9be0-f544bb630be4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">dvax:DeutscheBankSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_35f1c43c-dc20-4692-ac8b-37df12d565ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_187a89d5-4a78-4080-82d7-8eeffa21fc7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fbe06c3d-ec16-449f-bdd3-62e26d98ec74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_28ee40ae-f91d-4b89-9194-6b624b4ce391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_aa7ac349-6ef6-4d33-8b91-dc174a56618b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dvax:StockOptionsAndShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a2e2ad27-c3c5-4b53-9737-1774805c2105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CRGServicingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-19</startDate>
            <endDate>2018-02-20</endDate>
        </period>
    </context>
    <context id="C_be62f7fb-690c-4474-bca0-b70c2e4a2fe2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e638b00f-55b0-4873-beaa-4bf842f5fdd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5cce5446-2af2-4a9a-b1c4-38be430937ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fcd78d0a-af33-44bf-8d8a-2f5c1a9a376f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dvax:DebtInstrumentConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4a1fceba-ab37-4367-a47b-ccd8390d5afa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_c4bb7def-af41-4d15-8eda-59023addc137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9b9b2b3e-0d8a-43a5-b40a-ddc5b8ced167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_54064a80-7e76-458d-93d5-b4613985ec73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-05-27</startDate>
            <endDate>2014-05-28</endDate>
        </period>
    </context>
    <context id="C_4349a3de-f389-4fe9-a46d-67b78b2213f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e101de03-ed18-4895-96b6-d6251ed99d3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7fc345ed-b272-49ff-b9eb-c47bc4c9266b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a49cd4e9-42d6-4cad-96d6-a2965e333846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bb0aaad0-c346-40c7-80b3-5c0e4926bc06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c7c94b74-9da6-4908-b131-d871909fbeb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e9ba0f50-bcbf-42ff-bb4d-52d504f7633c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3e7a4e28-ee23-4846-846a-acac7d54f31f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1d98acd8-10b6-453e-b7a4-a290b0056620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_86657944-51ae-463d-89b1-ae4a4ccfa124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7ef86bfc-0585-40df-9bd1-4bd0b18b364e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">dvax:CaliforniaAndOtherStatesTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1e94f899-6711-4da9-bcee-5a61cdbdcf61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4720dcda-852f-4e2a-bec3-37de58fa755d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="C_ec73c440-29fa-41e8-b4b7-62558e948364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0e30bc85-1e80-4230-b3a9-6904f8577805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dadabb88-1dfa-43da-9394-44029f60ca3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_96ad4e0b-9a01-4e43-b0c5-c677a5fe8543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TimeBasedVestingScheduleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2f6d8975-50fd-4d21-a136-be743356b082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8ff495d2-c2ab-4702-a574-69eda60e3e44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cdaf1c5c-c380-46df-bd25-46af0336eb49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <context id="C_cade9713-0ce0-4b8f-b617-650718d89561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_120e58b6-236e-4e1b-bac7-eb5813c1cb61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_93b7b614-27fa-4eae-80c5-0b38da148a6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCollaborationPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4811b6ec-afc2-4141-bee4-2808586bc8f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e889c2ed-7138-45fb-adce-a5dc91946a89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f6d1d749-5eda-4173-857c-d2e9ec42eec9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_739cf94c-d0c3-431e-93da-9d8dc48a3718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1b3ae74c-64c3-410c-a990-9b1b3a879aef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_08fff746-9f3a-44ee-9a05-fcd200656170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dc5b84ae-0185-4375-b0d0-b39df828ca23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3fabb2f0-37ad-4f85-8819-9ad5b0716fdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:CappedCallsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_452bdfa1-ad45-4a00-a35b-9cb73b9e9295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ab1c6ec8-3564-4d41-9ebc-32087bc08f68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TimeBasedVestingScheduleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e3e9b8ea-11ad-4a81-b1a0-52ecab46df50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_721a703d-dac9-4278-b357-e4756d07b6a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2ccde060-5732-4dbe-854e-2ad06dd8b47e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7128fc7b-020c-499d-ae72-19db57703cc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_48cfc4ff-27e8-4913-84be-fd420b811781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_41d532a7-2bee-4d4a-a774-19c130efe064">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_011b6204-96fe-4257-8305-4c2c24467a75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">dvax:RevenueReserveAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0c75ba6c-c9fa-4cf1-982e-13bb8407020d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_618e0bb6-70e6-4ad8-a103-f5bc6b7f8d80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ad16fd8d-2d92-4d26-8d96-bf058a356d05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3a3dbbd9-f7d4-4560-b0a0-3f291802b72e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_5413023b-1fa8-4b55-b7bd-90b2b2bbf2cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">dvax:CaliforniaStateTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_83ebfedc-dcd6-474a-b76f-5c72dd085aac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6a1fce12-44dc-4910-9727-fa459734732a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:CappedCallsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6507c936-b545-4e7c-859a-811146d183ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b162a2fb-1421-4817-89b7-7fd0107432f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bbd430d0-723d-4b78-8014-3bf90a7f958f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_3ca507f0-264d-4d6b-a1d7-6b4736681fa7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f81a00fa-c973-4197-b3a1-e0cc4a36b149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a835f5a8-e3de-4348-8afc-9aa8d3f5191d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5fdc1062-7a2e-42a6-a0ee-956964678351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4dc5908b-5edd-428d-affa-04a86844ffaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6050d5e9-4d2a-42f3-8f76-80e6c68a8a88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:SymphonyDynamoHoldingsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2009-11-30</endDate>
        </period>
    </context>
    <context id="C_29ad1ccd-24bd-4275-9420-8e03c7809a91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c82b1535-2190-4e2c-8859-50ce0d536831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7e9700d5-220a-480f-9422-65d949c449a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bdb2bd2a-2c3d-42e8-ad0d-04fb4a9ce3fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_497a4353-898d-4ae9-9975-8c32c4ebb9d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TimeBasedVestingScheduleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6cd9059e-33d1-45f0-85b0-9bedacb0a4f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_dfe1bbb8-9cb8-4010-b417-57ad46abca6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_931a84ee-4853-4900-bad8-f584f37e2aaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fa937874-39fc-49fc-b659-927ec58d6789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:LargestCollaborationPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6423ea24-b03e-48e6-addc-0d0d41661afc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d63e3291-43c4-4ac8-b139-8fea8704f1a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dvax:LaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ef39c4dd-1299-4749-a67d-a06698c37b4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4272aeb3-6074-4246-8638-d6db1157f771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5445db9b-2a99-4cf2-a2cd-3f86b5ae5b30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForNotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0d83504a-3b1b-47be-be67-be586b5c04f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1f301073-2f8b-4fb6-92dd-c36e81bb7b9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dvax:StockOptionsAndShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_413555f4-1d4a-4bf8-8c72-64ae359a9907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7d274567-d036-45ef-8bff-f4dc34904726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4e3ef292-a629-4f6e-9ba6-f332258de6b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fc1b7051-c0ab-49af-aabf-551b7383e779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b92550c8-3f5d-45cc-9390-8d5d61858315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a814d382-f3ad-4c19-84d6-7b9bde2b4316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCollaborationPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5d1752d7-1a8f-47fe-a52e-e23618ff2973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_30de9d80-f061-4903-9ccb-6711842fb3d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0d0c6594-c70c-45dd-b459-b3da8ed9a07a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8c5e6277-2512-4769-b1e2-9247324bb9ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_82eb336f-5756-41e1-8639-c454abdcbaaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7000fe3e-8aa0-4198-8de5-4640128d667d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5f971b14-535c-4dd6-9f52-1e81c12d5af5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3712e127-94e3-4474-a4e8-4efc91f83f9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8cba3a01-4eef-41de-8eac-974320f6f0aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_93236fd5-e3be-44e0-a948-b795ea15d021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCollaborationPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3d661040-605b-43cf-b60b-b20b979ad675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e8c27e53-0ae1-4e32-8d68-96f7ec110ec2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4cda2680-5634-444f-82ba-0702b3f55696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_93f06617-1210-471c-aa60-542728a9d90e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9821d0e8-ecc7-4666-9acc-0bbaa41571ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e60f6c41-5373-4982-bda4-495d22ef947a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ce1c0cc3-d217-4341-a89c-76cd4302ac34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7acdd60a-63f0-4280-9662-6e8d7e0e625f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7da260d2-2100-4998-858a-d9177d745e45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_10088c6a-e568-4bb6-8203-26ba3572c356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">dvax:RevenueReserveAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6081d343-1a70-4d79-938f-b5c367c4a904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1790227d-10fa-4cab-abdb-eb0e7d848a20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_065dab0d-65d8-4bc3-b27e-bda7f559f545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_32dacd1a-2cf4-4e7d-a9cb-0223b786f81e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">dvax:RevenueReserveAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e5e1933f-3515-412a-9687-dae5c9a6b824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f5d40eed-ddd7-4243-9e53-3cfc906ba5a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eab3cba9-923b-419c-bdef-b0654a1ab2b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_97e9955d-8f3c-4e73-96cc-3ff1b69da22b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cccd4a85-7cd2-47b0-8792-edf0ca811695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCollaborationPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6451506c-a0f7-4a87-ac9f-42b2634d9a77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_970dc7a0-06ce-4b4c-a6b1-53363f517586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_72dff176-fdce-41b0-bd7a-2057a380f269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_53c34584-541c-4321-ab58-9d0fe2f1fd0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_26a1416a-c87f-4567-b7f7-4e8b77e534c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:TwentySeventeenAtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0a048ebc-c8de-4126-86ee-1592940450b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_68391399-2908-490f-99f6-ed291d638344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fcb751e6-cdea-4a40-9300-946017e2ec1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:PerformanceBasedVestingScheduleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_304335a0-4bda-469c-809d-39c049a6dfae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_ccc907f7-07b3-4485-bad7-b638c7661924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_743ce050-0aa0-47d1-90ac-18e05e613453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6adf0287-276d-4c38-aa2a-2587117e5871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4324081c-f2df-428f-82a0-7b99f17493ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_17561271-4a7b-4b2f-bb36-76707b8268dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:USDepartmentOfDefenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_faa950c0-0245-4bdf-aa7b-50e9c38ec395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5287e9ff-4a22-4227-b33c-aef9575adc2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dvax:ConvertibleSeniorNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dvax:DebtInstrumentConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_02645021-8828-4251-8736-7889f9068d7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ad54aada-ef84-4b1b-b532-5c907b0a02c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f400d9db-46ac-46b2-b217-0a803cda715f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d0d39007-043c-4130-9d47-4b28ecc8e767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCollaborationPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_260c0775-ec5e-4e9a-83f8-a1b4aa2f06c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="C_529c356f-70af-41f9-a631-87c29cdb73e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9bbfa976-1e7d-4da7-bc09-d8fb7b04dbd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-05-27</startDate>
            <endDate>2014-05-28</endDate>
        </period>
    </context>
    <context id="C_eb7a44e4-c892-49a3-b202-b907c029e24f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CoalitionForEpidemicPreparednessInnovationsPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_23485235-7712-4e50-8b13-23e29659179c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CRGServicingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6d7cb580-217f-495d-9dc8-c7a31af8234f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_61e4fae6-429a-477a-9549-6b5ff699fbf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_bfd94056-2ea8-4584-9e10-0cb5bec164e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4f26b2cd-7c84-4953-85e9-83acbeb93d90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:USDepartmentOfDefenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_58733421-ee84-4c5d-9a12-53149c7e8b38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0797703a-9cf9-4f2a-a2ab-e188c2fa6d75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2b70264d-6f06-4292-a106-b2ff81f59d36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5e53f99f-a072-4fb9-b577-17596226d68f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dvax:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7a801bf1-6b19-4a7c-8dc9-d56926556425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a778631e-7026-4533-acd7-c0e2a158a18d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:ThirdLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c48f9ef2-11f3-4b36-9b5a-e093eb35a836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_af9c3a6e-6e11-44bc-ad28-b459d2203fed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d33fabd0-98d3-439e-b8a4-3bba01fe695a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_10486a1b-be2f-40a5-b01f-0bcd65255d81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_07eaa0a5-29dc-4366-a233-4616595cc0e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:USDepartmentOfDefenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2c8b18ed-3d15-4464-921d-cd75ad104a77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_712b1a93-fff4-4b0c-8c9b-e29381d7d61f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8d9fa1a4-607b-4714-b950-2d3ee7d6606a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7c9ae35d-bbf7-49a3-ab55-60aabc35c7b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_333f7989-91c9-45d9-a30d-059fd745363e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_87f096fc-5022-4951-928c-a55c0c09d734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCollaborationPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5d3d0244-f5ac-41e6-b1e4-39944e862722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bdafacc4-ce23-4518-be33-853c6f2b2e35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_de1bbf7b-39e6-455e-a6ad-d72e13ff09c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bf03e8de-4dfe-4921-8f60-87f1256383af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_25b31f57-0a7e-4cd3-b3c8-ac133125ecf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dvax:TrisalusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_19035b31-a18b-4349-93e6-45dccd60c49e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_d9059078-1d7f-42cf-9ac7-53b904e61b2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dvax:SecondLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d50c3d18-220b-403a-97e4-cf6868d818cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CRGServicingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-20</instant>
        </period>
    </context>
    <context id="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3226f406-b30a-4fe8-b77d-6acd3bc687cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f9937706-ff8e-4688-b5fb-817ee1b77e6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_22fa84c0-ee5b-418a-bab8-0db6e2ecbd21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_13bbb079-e389-44b2-b0fe-129eed17bc18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d7e1bd25-a160-4d2a-9aa1-1570a122f4cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fa18ccc3-e6a3-4fc5-84a7-11116a04094b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_74aa1aa7-40d9-43b4-9261-d413646b1f6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9a546293-5326-4ca1-b866-7d58c5fc2258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4ac1d460-1347-453f-a512-bbc25081089d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5136ab72-32fb-4b8a-a285-f65c7aae72f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1b2ac57c-b971-472c-8ad3-2eb87f03dd71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0ae2c12d-5812-46ba-bc06-5eb199a307cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8132c0b8-7437-4b80-a8db-085c7a1df0da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ecd4b79e-9828-475d-9c9f-5c628dfa3993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:ZhejiangCloverBiopharmaceuticalsIncAndCloverHongKongIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dvax:SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_df4c54ad-6b4c-4547-9c0b-6d82cd6c4cde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4dc6828d-94e8-4ca1-9e05-1d3d58d0dc47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:BiologicalELimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-26</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <context id="C_72b2baa2-131f-4929-818e-a53fbd5d4d42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0ef049fa-5c44-4e24-81ac-16efb8ddcea8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">dvax:CaliforniaAndOtherStatesTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_38abd918-f40c-4d00-8c67-0b1cee772c9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_21f845e6-44c3-401e-bfcd-a9d88abc20b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_88dea699-9bab-4426-88ed-ff1960599278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">dvax:CaliforniaAndOtherStatesTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_51decfbd-05ba-43b9-a300-132adf0402d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:CpG1018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d6a1605d-0ed8-4293-af91-e392daff1469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3e844c02-fd3f-4039-9675-b2ca051071e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:HEPLISAVBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ace65c5a-30fc-4278-a936-73964385612f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dvax:CRGServicingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_47db32ab-ff21-4bf4-92e5-39d73f0bf345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_80741f76-5a9d-474f-ac4c-18ba54f8364e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e0bdb5c9-6635-4822-a0d4-b057bdc6bf7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_600e9b74-60a6-45e3-9267-97174756699a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dvax:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d17521b7-e208-42c4-b34d-99bc5b411173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0c1e3d78-dd4b-4d59-b5e6-4fe90c415647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dvax:MarketBasedPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3eff1578-c6f0-49d6-9432-a944eed0709e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="U_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Days">
        <measure>dvax:Days</measure>
    </unit>
    <unit id="U_Segment">
        <measure>dvax:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend
      contextRef="C_cbf226fd-6dcc-47b4-b352-348770773ff2"
      id="F_a3342d5e-59ac-45d1-9d04-2069f075ab1c">false</us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend
      contextRef="C_eab3cba9-923b-419c-bdef-b0654a1ab2b1"
      id="F_8a51f06c-f78d-454c-a591-a149eb677053">false</us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend>
    <dei:AmendmentFlag
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_49781d38-8281-4017-b0c0-310f8c7fa3af">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_9b89cf33-a247-457c-a842-47ee488137e6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_1a94fa36-f1e2-4e14-9333-16743c2d50d4">0001029142</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_628f4796-66d9-4e33-90c9-c2fdc02facf2">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      id="F_3031d482-7693-42b9-bd85-bcbc62b2bbaa"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      id="F_f9326331-0510-474c-8729-f02e4262a88e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      id="F_f58b1a95-4b8b-4052-956a-3314f3bd58e1">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      id="F_92c8237b-9eec-4d96-8dc1-a494a9120777">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_8cba3a01-4eef-41de-8eac-974320f6f0aa"
      id="F_6d4caeb9-dd64-4460-a26d-4c0009adec9d">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dei:DocumentType
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_f1ce2261-86b5-4702-a828-fa42bc8b89bd">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_79bd63e4-5340-4727-a1a8-d54dfe6e3000">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_9c4ea41a-ee19-456e-bad2-be365d85d680">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_050edb6f-8be3-4c8f-b6bc-39c8477a6fc2">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_3fff9108-4dd2-4197-b46d-c75372f6c42a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_63ea247d-4f20-464b-bfe0-a2342c182a84">001-34207</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_641d0dab-2bd1-420f-b5a9-9f2d380351c3">Dynavax Technologies Corp</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_13d7fbae-3863-466b-be28-0c0c73c5a35d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_2cb5fb24-62e0-416b-9514-af332f9344c7">33-0728374</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_edc5d1fe-2ecb-4d10-8687-c257a35222a3">2100 Powell Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_cea424ba-fbc8-47a3-816d-1396fb26228b">Suite 720</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_c2126771-0e76-49ea-891c-398afc130916">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_73b35706-9056-458b-9e7d-b4df9a851ec2">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_2f9f370e-bee5-4e78-989b-e91b75b8ae71">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_c9f4bf92-927c-4eb1-82e5-465bb6b50adb">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_6dda5e74-202e-47a4-815f-f07f1912266a">848-5100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_9b8c38a8-4e6f-489b-a73d-aabbaa2f6f39">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_565314b4-090c-4505-b1e3-799bba90b2c9">DVAX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_228400fb-4252-4ea7-80fd-18006ecae4bc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_62acd4b9-1f8e-4179-8563-543a9a66b9aa">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_1db291cd-5900-481e-8c9d-d6fd46b64bef">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_12218843-c603-476b-abde-311784a66041">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_e7b964f8-1d32-4dff-88af-f7c824168698">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_02475e4f-48d1-4a52-82c3-b754301621e5">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_f13b9f9b-ca50-42c1-a961-2c0c151e9d5a">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_db0d0094-bff9-4fee-8788-97a775ab5920">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_73e0818e-f40d-48b5-9bd9-5d81b42d604e">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_59de8064-775e-481a-8660-f7ddc36eaa69">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_5d2beddc-bdc5-487c-8530-cd76f1da8365">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_1b272903-9c51-40dd-8f58-0e6dd1d903ad"
      decimals="-8"
      id="F_1c24ffdc-14aa-4ba4-be98-5e2da3c6ee82"
      unitRef="U_USD">900000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_55e18a2b-9266-46ed-bd0b-26af19bac2fd"
      decimals="0"
      id="F_6e1c148b-7477-4fcf-9730-00ef12a4e7a5"
      unitRef="U_shares">130614772</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_b303d141-6b7c-4455-8019-6e6e6820c0ab">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the Definitive Proxy Statement for the registrant&#x2019;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III, Items 10-14 of this Form 10-K. The Definitive Proxy Statement will be filed no later than 120 days after the close of the registrant&#x2019;s fiscal year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_c7a8b951-26d7-46ad-a456-3549f1dd9eb1">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_6febfd91-7891-422b-a722-b619ec01c6bb">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_815973ca-4209-4a64-9fda-189e7024c65f">San Francisco, California</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_a9fe1da1-fb1d-4652-b165-59a7244ac624">42</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_db113578-e79e-4d32-945a-c537f1823e6a"
      unitRef="U_USD">150279000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_fa9aec73-0234-4ed3-8a9f-aa2fcf90cc6e"
      unitRef="U_USD">202004000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_8840f5b8-bbbb-422f-91c5-3f28bf76016e"
      unitRef="U_USD">592023000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_b1f560a7-2481-4f3e-8e22-9de77f676a73"
      unitRef="U_USD">422391000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_d380b0a3-4f46-4631-8380-46b26e843b0d"
      unitRef="U_USD">12313000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_1e4a26bd-ae1b-4909-963b-8344f4a5cc05"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_69474df5-3821-4c48-96ed-2c0f86553899"
      unitRef="U_USD">40607000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_e4ea4ad1-f214-4083-bda0-af080c1edc02"
      unitRef="U_USD">145130000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:OtherReceivables
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_5f01176c-0c5b-4dd2-adc4-d8da2a6159f1"
      unitRef="U_USD">3926000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_7a077a45-e15c-4ee9-97ad-9d221fdbfcc3"
      unitRef="U_USD">2385000</us-gaap:OtherReceivables>
    <us-gaap:InventoryNet
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_dfbff718-5a0c-4e0f-9bf4-1cc27cb4498f"
      unitRef="U_USD">53290000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_9ae03704-a2fc-4e1d-9c5c-f3dd616aefbd"
      unitRef="U_USD">59446000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_bb984053-f9b6-446e-8644-3d357c3f4bd0"
      unitRef="U_USD">18995000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_738178f7-bc10-4a5d-839f-7a196b603372"
      unitRef="U_USD">85629000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_ef593e6a-a5e7-4fbc-8437-8f80ee5bc9db"
      unitRef="U_USD">859120000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_6677ec1a-d7eb-4d85-b983-fb6787cace11"
      unitRef="U_USD">916985000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_238bf37c-9f28-4209-92c4-a89aaa7e3f07"
      unitRef="U_USD">37297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_643a2275-b65f-49d8-a67b-3b081f27e6ad"
      unitRef="U_USD">37596000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_ef6e9759-c148-4d5e-ad97-10001c7cf170"
      unitRef="U_USD">24287000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_ed812de2-31a9-46a1-9c6e-02d6f3373c34"
      unitRef="U_USD">25745000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_c1be834c-9184-4602-9073-6b83b789e205"
      unitRef="U_USD">2067000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_1f52306a-0432-4cf8-bc44-8146bce60fe6"
      unitRef="U_USD">2006000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_4a1d4bee-61a8-464e-9bc3-ec272d2fd8dc"
      unitRef="U_USD">74325000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_164a8eb9-c3f3-4034-afa7-27ccea71eafa"
      unitRef="U_USD">3518000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_90da2919-3c3e-41fb-9009-7e3cf4087150"
      unitRef="U_USD">997096000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_45ff681f-7933-49a4-9a21-6f325ce734de"
      unitRef="U_USD">985850000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_b4d5dbb1-49b7-412b-8ee2-7cba8e493627"
      unitRef="U_USD">5245000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_7b2db2ad-86de-4286-9b0e-9ed9cd1f2771"
      unitRef="U_USD">3211000</us-gaap:AccountsPayableCurrent>
    <dvax:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_03d7afcf-a032-4112-be4a-3c646e0ce110"
      unitRef="U_USD">2982000</dvax:AccruedResearchAndDevelopmentExpensesCurrent>
    <dvax:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_f8eba079-2fde-4889-8a87-281b74f50042"
      unitRef="U_USD">4775000</dvax:AccruedResearchAndDevelopmentExpensesCurrent>
    <dvax:CoalitionForEpidemicPreparednessInnovationsAccruals
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_0fc5b422-1df1-4116-8246-79a38c10c676"
      unitRef="U_USD">0</dvax:CoalitionForEpidemicPreparednessInnovationsAccruals>
    <dvax:CoalitionForEpidemicPreparednessInnovationsAccruals
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_dd2c8fee-d695-4d73-a176-c5c961a88aed"
      unitRef="U_USD">107738000</dvax:CoalitionForEpidemicPreparednessInnovationsAccruals>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_2198aa33-e0c7-4958-a7de-956ee2ed3c40"
      unitRef="U_USD">49448000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_652d5904-a2ca-4265-92c7-c24fee09f9c3"
      unitRef="U_USD">30719000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_0e2ee94f-8b21-4082-9fe3-af10b3d72ffe"
      unitRef="U_USD">4520000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_8c47801f-8623-4067-8b1e-f86fa765b08f"
      unitRef="U_USD">3631000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_3a4f2a2d-cfb4-431f-8230-8cefb3f34c5a"
      unitRef="U_USD">62195000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_8361bbe1-ee95-4990-bd31-c05aef7ba6b0"
      unitRef="U_USD">150074000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_d9d38e49-a2a4-4da4-b395-76e763c1fe1b"
      unitRef="U_USD">2802000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_520471a4-3919-44dd-88f2-3e6495a3d385"
      unitRef="U_USD">3922000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleNotesPayable
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_a39dc4db-f800-4ff7-96c4-be061605bced"
      unitRef="U_USD">222698000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_f362f45b-5f1c-4c8c-8147-ef5f8236a51e"
      unitRef="U_USD">221578000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_5abf1700-252b-419f-b185-d8ab27344c1f"
      unitRef="U_USD">29720000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_050b775e-4c45-4fac-8d80-0f1d6cc2268f"
      unitRef="U_USD">32801000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <dvax:CepiAccrualLongTerm
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_1ab04638-2233-4383-b4e3-2810482102b8"
      unitRef="U_USD">60337000</dvax:CepiAccrualLongTerm>
    <dvax:CepiAccrualLongTerm
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_adc9ad9c-fe12-4821-a978-ce6b28350905"
      unitRef="U_USD">0</dvax:CepiAccrualLongTerm>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_f52f9a0c-280a-4fa7-b35f-43bec244fd60"
      unitRef="U_USD">74000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_959e3550-9cb4-46d8-8485-5f74793a1a3d"
      unitRef="U_USD">384000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_6d65289d-eb1e-457b-b954-a835ae95e59e"
      unitRef="U_USD">375024000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_b5bdaef5-234c-4fd0-8a53-d3c3fc0abd21"
      unitRef="U_USD">404837000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="INF"
      id="F_8e697531-46b5-45b1-b024-0abd5f1fa986"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="INF"
      id="F_3ae02837-4c01-4659-8aca-c9d46ab83776"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_e47e4693-2d5c-42ad-962b-1e9cac61a971"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_3bac5ac5-bf96-4777-8269-837d6f259847"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_ea8697c0-fab9-415d-b808-3fe0f53f9cba"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_7381862f-f1eb-444a-8069-fd48f875fb8e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_de58c35d-d303-4e0b-9a1a-ef38eedb686e"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_ed3124e9-62dc-4a2f-8d48-fd2bd75748c9"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="INF"
      id="F_252820cb-61d6-4273-94bb-9a75adafb4bd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="INF"
      id="F_ffb9293f-6b9c-4562-99a0-5e996923ce50"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_163250c2-9d3d-410d-91bb-81bb833accf6"
      unitRef="U_shares">278000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_a181e8fa-a549-43a4-ae50-a38fce3ea046"
      unitRef="U_shares">278000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_94c4a4c3-196d-4bae-b656-4da791af67b8"
      unitRef="U_shares">129530000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_5b0dffdf-e292-409f-8ec5-70a6ea4caa77"
      unitRef="U_shares">129530000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_08d4118d-9640-494f-9ee0-d235eaf599b4"
      unitRef="U_shares">127604000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_ea8283c3-7037-48a0-b7b5-c8cd6180d959"
      unitRef="U_shares">127604000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_2aab72ba-4970-4949-9194-5943eaae0630"
      unitRef="U_USD">130000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_f5cdf9a6-07e5-4336-a22f-5d4731bf1730"
      unitRef="U_USD">128000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_812cefbd-1c49-48f3-b5a1-6e1a91443b10"
      unitRef="U_USD">1554634000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_d557c4d6-c69f-4c96-b444-b98541aa1623"
      unitRef="U_USD">1510518000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_d60096f0-2770-4792-8ad2-8fdc39c53a09"
      unitRef="U_USD">-2108000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_4389851a-de0b-4218-a7ac-8a91337328d4"
      unitRef="U_USD">-5438000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_47232dd1-5bae-4435-9da2-0d72464a8fe5"
      unitRef="U_USD">-930584000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_a1f97a25-4c97-4eaf-bb4e-1fa40ad4e83f"
      unitRef="U_USD">-924195000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_d0c04f05-7f32-46dc-8f0a-5d961c0c9859"
      unitRef="U_USD">622072000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_1d29a54a-458c-4915-bc5e-348029d12f52"
      unitRef="U_USD">581013000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_621043b9-d1eb-44a0-9fea-43aa83c76118"
      unitRef="U_USD">997096000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_6670c5cd-70ce-4f04-a8e5-36c8557c9977"
      unitRef="U_USD">985850000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e9ba0f50-bcbf-42ff-bb4d-52d504f7633c"
      decimals="-3"
      id="F_380e2d8d-40f3-464a-880f-be29ce93008d"
      unitRef="U_USD">213295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_dfe1bbb8-9cb8-4010-b417-57ad46abca6f"
      decimals="-3"
      id="F_80c6fbaa-38a3-48a1-8ff8-5b3e1dacf633"
      unitRef="U_USD">713645000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6423ea24-b03e-48e6-addc-0d0d41661afc"
      decimals="-3"
      id="F_7503cd6c-ee92-48ce-9ab7-096fb0c5e1e8"
      unitRef="U_USD">437099000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ce1c0cc3-d217-4341-a89c-76cd4302ac34"
      decimals="-3"
      id="F_379356a2-74e6-4c44-8aff-cf68fb24d97a"
      unitRef="U_USD">18989000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_600e9b74-60a6-45e3-9267-97174756699a"
      decimals="-3"
      id="F_979dba1a-62ef-4845-bd7f-ee467f5cb310"
      unitRef="U_USD">9038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e638b00f-55b0-4873-beaa-4bf842f5fdd2"
      decimals="-3"
      id="F_97f60a4b-4d0c-4aab-bb2c-d67d5ead95ff"
      unitRef="U_USD">2343000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_9e61904c-f7a1-42cb-9d8b-e3e80fe53f4b"
      unitRef="U_USD">232284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_ebc5a7c2-38ec-44c1-9604-9042d58b3bf9"
      unitRef="U_USD">722683000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_2027afd0-9935-4dd0-9b7c-00b4759f316b"
      unitRef="U_USD">439442000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_39bf8c4c-03a3-4c30-9491-a7cb181c5b6a"
      unitRef="U_USD">50167000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_2b9e0622-1277-49dc-a990-dbd954b03709"
      unitRef="U_USD">262153000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_a254a02b-a5cb-4204-96d9-83bbf2c270d0"
      unitRef="U_USD">173572000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_2d2aa332-fce4-43d8-bcbe-f717886e481b"
      unitRef="U_USD">54886000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_c7a6f405-bde1-4d5d-a6fb-7a120566e049"
      unitRef="U_USD">46600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_00f16f20-0204-4e40-a4d4-e3d3b11039fc"
      unitRef="U_USD">32228000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_ca2d88bb-8b5c-4ef5-9dfa-3eaf4af310ef"
      unitRef="U_USD">152946000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_0f009e8a-36f4-4adb-99df-2b62b6a2687d"
      unitRef="U_USD">131408000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_aa1cc8ba-bdfe-4ab7-bfdb-40636ca63489"
      unitRef="U_USD">100156000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_d1bdf656-01e3-443b-9a09-0ac069f16324"
      unitRef="U_USD">1000000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_3e9a5f25-718a-4b5d-ad99-ed22d5f46cd1"
      unitRef="U_USD">1000000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_7d4c56da-d8ec-473e-b2aa-b18e0c03f362"
      unitRef="U_USD">1000000</us-gaap:GainsLossesOnSalesOfAssets>
    <dvax:BadDebtExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_bfdad6e4-1ba7-4403-8520-451dcc7cc9be"
      unitRef="U_USD">12313000</dvax:BadDebtExpense>
    <dvax:BadDebtExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_a8abeee8-ef91-4f2b-95e6-cca7a505698d"
      unitRef="U_USD">0</dvax:BadDebtExpense>
    <dvax:BadDebtExpense
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_8c4ff06c-f07a-45df-9afc-073c2f6d038e"
      unitRef="U_USD">0</dvax:BadDebtExpense>
    <us-gaap:CostsAndExpenses
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_4e3098ee-d195-4bd9-adfc-09ad1f4dc73d"
      unitRef="U_USD">269312000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_0107e57a-4f1d-4925-a00e-959aa1e8bf0f"
      unitRef="U_USD">439161000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_70cfebfc-ebd4-4855-980d-5d597ad481d7"
      unitRef="U_USD">304956000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_8867a762-739c-4bb1-b777-74e9ccccb9dd"
      unitRef="U_USD">-37028000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_0e8734d9-e55b-4998-b053-59fe6f2fc0ba"
      unitRef="U_USD">283522000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_bb2d8cf3-1bef-4218-afb2-0544701ce2a4"
      unitRef="U_USD">134486000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_0392e7c8-11a9-45b0-88f1-2f47b4d7d476"
      unitRef="U_USD">31993000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_6956b99e-3bb7-4b10-b994-389c9bb42310"
      unitRef="U_USD">7912000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_8b5c1fbf-af85-444d-8abe-e4a125423cf3"
      unitRef="U_USD">140000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_15d8df44-d3d0-4aab-86bd-0a7e90f966e6"
      unitRef="U_USD">6757000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_28c26f63-e3cc-457c-bd38-5bd7bd42f899"
      unitRef="U_USD">6732000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b85fcf9c-ed41-4ea7-8e06-aada4abf2563"
      unitRef="U_USD">11176000</us-gaap:InterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_f4801a38-fd43-4612-a074-36c634e7b752"
      unitRef="U_USD">7577000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_213fc923-cc90-46cc-9932-8b70efa111be"
      unitRef="U_USD">7685000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_3e6526e0-de8d-48ca-ae07-7b30bc481d9b"
      unitRef="U_USD">7735000</us-gaap:SubleaseIncome>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_035ed737-b2e6-4d62-ab36-5fdf36426b4b"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_cb0c7af1-52f3-48b3-8601-c6fad479de8f"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_a820a77b-78d4-445e-9eb0-b1cd124bb8e5"
      unitRef="U_USD">-5232000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_483c1ea8-dca8-4cba-9438-00833d74cb73"
      unitRef="U_USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_567e1c02-20a5-4916-a3dc-553706e375bd"
      unitRef="U_USD">-1801000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_3017db99-b49e-4491-9b19-6658f13e1f82"
      unitRef="U_USD">49354000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_40221923-6d7c-41d7-a1e7-55e8f4268ecb"
      unitRef="U_USD">-152000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_79cf62f0-a678-4be7-a090-7d2fe284fda8"
      unitRef="U_USD">111000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_06fbbbe6-a843-4090-8701-4f0d982eff76"
      unitRef="U_USD">922000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_fb9919e6-3f14-4ef7-97e5-f54c865c89e0"
      unitRef="U_USD">-4367000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_1a509523-a4ef-4297-8241-0919de3a554d"
      unitRef="U_USD">294299000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_f05afaaa-c8f0-4a5a-a492-e6a684bd6498"
      unitRef="U_USD">77521000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_c9ef3492-778b-42cd-ad33-b2b32071b082"
      unitRef="U_USD">2022000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_db6f43e5-4fde-4344-be8e-e144654d3152"
      unitRef="U_USD">1143000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_57aca8a7-679f-4e79-8c86-55c05f966b82"
      unitRef="U_USD">808000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_0f1c5274-3bea-4e05-9e3f-f7d14c99247c"
      unitRef="U_USD">-6389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_a779a901-9c76-4685-9198-cfc471130949"
      unitRef="U_USD">293156000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_0cc8c878-1ada-4689-a2b0-93e1a18a374a"
      unitRef="U_USD">76713000</us-gaap:NetIncomeLoss>
    <dvax:UndistributedEarningsAllocatedToParticipatingSecurities
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_1026a715-b2fe-4da0-9654-462ba7469f3a"
      unitRef="U_USD">0</dvax:UndistributedEarningsAllocatedToParticipatingSecurities>
    <dvax:UndistributedEarningsAllocatedToParticipatingSecurities
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_d991df7d-fe32-4381-94cd-93b0a06a4bf9"
      unitRef="U_USD">283000</dvax:UndistributedEarningsAllocatedToParticipatingSecurities>
    <dvax:UndistributedEarningsAllocatedToParticipatingSecurities
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b503a36f-1c16-4977-a166-0378fdc753d5"
      unitRef="U_USD">4569000</dvax:UndistributedEarningsAllocatedToParticipatingSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_953a39b9-d5b7-41d9-8a8c-601ec50e4459"
      unitRef="U_USD">-6389000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_30273a2a-a901-4ad7-a642-506503d279fa"
      unitRef="U_USD">292873000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_1c8152c2-9276-42ac-afce-428569c78688"
      unitRef="U_USD">72144000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="2"
      id="F_b05230f8-ef42-4d99-b132-1d69b3771dd2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="2"
      id="F_ae3b7fd4-f33c-4ae4-93ea-bb764a683e9a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="2"
      id="F_0ed45e57-67be-4a42-a486-9b0f6b3c2faf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="2"
      id="F_1c6a9e67-0aab-4969-887a-e5aa3195e71e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="2"
      id="F_9ba2c86d-c20f-45c1-b553-28f406e95110"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="2"
      id="F_7c35a32d-2249-4dc3-8ec9-e32b0667a99a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_76f43863-8542-4d7c-8df3-9da12ab32924"
      unitRef="U_shares">128733000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_c4e77704-71cc-4bb0-be44-285f02b7993a"
      unitRef="U_shares">126398000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_529729b9-23a9-460a-bf03-e52a18e3d1d1"
      unitRef="U_shares">116264000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_5fc5a8e5-0ce1-46c4-989b-d712e0f60bb6"
      unitRef="U_shares">128733000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_ddf99fed-2c97-47a7-9275-67b2f340ffaf"
      unitRef="U_shares">150797000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_97931827-3c15-45c6-8b6d-ea64d2ddc630"
      unitRef="U_shares">133006000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_ffa0c4a3-bfb9-4097-9874-20253c08f35b"
      unitRef="U_USD">-6389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_b8c9a9f8-57db-4a45-b289-55d692f81b88"
      unitRef="U_USD">293156000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_6e0f5dee-97a0-4e4b-bf2f-86200c326209"
      unitRef="U_USD">76713000</us-gaap:NetIncomeLoss>
    <dvax:ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_c2189e9d-df45-4018-8b61-2232e0d90c40"
      unitRef="U_USD">2251000</dvax:ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale>
    <dvax:ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_4b3e9ad8-3852-4e99-a71a-984bb589ea95"
      unitRef="U_USD">-1407000</dvax:ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale>
    <dvax:ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_185dee78-c80a-405e-9b3e-a9a0f4d8eada"
      unitRef="U_USD">-30000</dvax:ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_8a572116-ec24-4e62-b686-b6455d78ba71"
      unitRef="U_USD">1079000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_a0d38dce-defd-4aad-85bb-5a4854842d8a"
      unitRef="U_USD">-1765000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b1db3968-3cd9-4b32-ba08-9bfd750b95a5"
      unitRef="U_USD">-2509000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_e8603efc-4e7a-45a9-bd8d-44eaf1547995"
      unitRef="U_USD">3330000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_67270217-e213-4e69-96d2-7caf870b8c12"
      unitRef="U_USD">-3172000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_c21373c7-adaf-40b8-8dcb-f72eecc46df7"
      unitRef="U_USD">-2539000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_412d9564-f1f8-44a3-bbb2-cff66ae30fbd"
      unitRef="U_USD">-3059000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_77901f21-98c7-4758-927d-673d86ed9e94"
      unitRef="U_USD">289984000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_5b4f6712-f7dd-41f1-b0cb-0ca6046b560c"
      unitRef="U_USD">74174000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_60a06249-5799-4cae-8123-c33c744ecedc"
      decimals="INF"
      id="F_f2339adf-5230-4911-a7a3-c7a3d8c08185"
      unitRef="U_shares">110190000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_60a06249-5799-4cae-8123-c33c744ecedc"
      decimals="-3"
      id="F_ca0e8d9e-f1c2-41bc-b9a5-79f08d293717"
      unitRef="U_USD">110000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_1b2ac57c-b971-472c-8ad3-2eb87f03dd71"
      decimals="-3"
      id="F_a28bf2b3-8575-46e2-b29a-64de51b4273c"
      unitRef="U_shares">4000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1b2ac57c-b971-472c-8ad3-2eb87f03dd71"
      decimals="-3"
      id="F_bd1e2bd2-d4b2-47bb-971b-5eb889739799"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e60f6c41-5373-4982-bda4-495d22ef947a"
      decimals="-3"
      id="F_5fa31524-c0a0-4fbf-b0e7-39601c799bfd"
      unitRef="U_USD">1352374000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e889c2ed-7138-45fb-adce-a5dc91946a89"
      decimals="-3"
      id="F_9a8ecb5c-151f-41b2-93e6-8909914397a6"
      unitRef="U_USD">273000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8c5e6277-2512-4769-b1e2-9247324bb9ea"
      decimals="-3"
      id="F_4b540deb-aa61-4ebb-9cd4-deea762fda8a"
      unitRef="U_USD">-1294064000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d6a1605d-0ed8-4293-af91-e392daff1469"
      decimals="-3"
      id="F_ebdc760a-1cda-4d8b-b116-6a4cc35175ab"
      unitRef="U_USD">58693000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"
      decimals="INF"
      id="F_64f5fba6-9cf9-44f0-80a0-164ac5a672a7"
      unitRef="U_shares">4140000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"
      decimals="-3"
      id="F_bce71dcd-9edb-4a3f-a3d5-94871f58d246"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_22fa84c0-ee5b-418a-bab8-0db6e2ecbd21"
      decimals="INF"
      id="F_c055d85e-6436-4022-b7b0-68d5d4584ae6"
      unitRef="U_shares">-4000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_22fa84c0-ee5b-418a-bab8-0db6e2ecbd21"
      decimals="-3"
      id="F_ce462c6a-7607-4f45-87bd-bff5ab5e7448"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff"
      decimals="-3"
      id="F_6b55096c-3106-4235-a3d0-8be54922b231"
      unitRef="U_USD">-4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptionsShares
      contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"
      decimals="INF"
      id="F_30d54d71-9eda-44b4-9c54-36a05fc2217e"
      unitRef="U_shares">1035000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptionsShares>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"
      decimals="-3"
      id="F_8245ee0d-b08d-44f4-aa71-c57dd29f5297"
      unitRef="U_USD">2000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff"
      decimals="-3"
      id="F_b17499d2-ca68-4bb1-86cd-ce8105ac18a3"
      unitRef="U_USD">6682000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_49dced53-1c2a-4a3f-861c-7cdb87c3cc18"
      unitRef="U_USD">6684000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares
      contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"
      decimals="-3"
      id="F_6f812493-2bcf-4d17-9db3-c3ac174abf46"
      unitRef="U_shares">525000</dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares>
    <dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards
      contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff"
      decimals="-3"
      id="F_8b60c51a-4463-4796-bcc2-f20357afed01"
      unitRef="U_USD">-107000</dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards>
    <dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_9f253975-74c1-4260-900f-c1ab1fb17e49"
      unitRef="U_USD">-107000</dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"
      decimals="INF"
      id="F_4c95ecc5-1904-4890-8a5a-ff6ed664a220"
      unitRef="U_shares">217000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff"
      decimals="-3"
      id="F_571e1718-6752-424b-9889-9bfde13e7db1"
      unitRef="U_USD">841000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_e2cec085-2ace-4ba7-9278-002a70d50b42"
      unitRef="U_USD">841000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <dvax:IssuanceOfCommonStockUponExerciseOfWarrantsShares
      contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"
      decimals="INF"
      id="F_dc07fcbb-1e5b-4695-a8ae-6fc8b9a1e252"
      unitRef="U_shares">3959000</dvax:IssuanceOfCommonStockUponExerciseOfWarrantsShares>
    <dvax:IssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"
      decimals="-3"
      id="F_57edcb99-df05-4201-a94f-4296f67c7adf"
      unitRef="U_USD">4000</dvax:IssuanceOfCommonStockUponExerciseOfWarrants>
    <dvax:IssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_22fa84c0-ee5b-418a-bab8-0db6e2ecbd21"
      decimals="-3"
      id="F_d1dafc69-4303-4138-8560-a96470df8594"
      unitRef="U_USD">0</dvax:IssuanceOfCommonStockUponExerciseOfWarrants>
    <dvax:IssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff"
      decimals="-3"
      id="F_d3692b57-763d-49de-b69c-11cd1965caf7"
      unitRef="U_USD">59884000</dvax:IssuanceOfCommonStockUponExerciseOfWarrants>
    <dvax:IssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_0fca0ad8-9966-4fc1-82a2-73257cdba45a"
      unitRef="U_USD">59888000</dvax:IssuanceOfCommonStockUponExerciseOfWarrants>
    <dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares
      contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"
      decimals="INF"
      id="F_664f165e-2092-406f-881d-94fb409a847f"
      unitRef="U_shares">2879000</dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreementShares>
    <dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement
      contextRef="C_ff4f3645-688b-4e8e-bf76-c5287f89d89a"
      decimals="-3"
      id="F_2a65085d-7f1d-40bd-bc56-a4453f001912"
      unitRef="U_USD">3000</dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement>
    <dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement
      contextRef="C_22fa84c0-ee5b-418a-bab8-0db6e2ecbd21"
      decimals="-3"
      id="F_56b21f12-9418-4d52-b8ba-ce18ac531cbc"
      unitRef="U_USD">0</dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement>
    <dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement
      contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff"
      decimals="-3"
      id="F_eb7b3e59-ccb1-4503-8da8-47bd1977d7a4"
      unitRef="U_USD">28153000</dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement>
    <dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b98c2ad1-4af6-4df9-b3e3-a7d4b565ad2b"
      unitRef="U_USD">28156000</dvax:IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement>
    <dvax:IssuanceOfCappedCallOptionsSeeNote10
      contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff"
      decimals="-3"
      id="F_9c94cfa5-f192-4e29-aec7-88471059661c"
      unitRef="U_USD">-27240000</dvax:IssuanceOfCappedCallOptionsSeeNote10>
    <dvax:IssuanceOfCappedCallOptionsSeeNote10
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b8a7ab97-0aa1-46c9-8a1d-add7be162cfa"
      unitRef="U_USD">-27240000</dvax:IssuanceOfCappedCallOptionsSeeNote10>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cfc8bf99-570a-4c5a-9351-1d7fe566d7ff"
      decimals="-3"
      id="F_81daa921-0e51-40a4-9d2d-89a29ee41bfe"
      unitRef="U_USD">21285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_eda36706-dd9c-41a2-aacf-895a2579aea3"
      unitRef="U_USD">21285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6d7cb580-217f-495d-9dc8-c7a31af8234f"
      decimals="-3"
      id="F_dc832f2c-62e1-4ea0-8822-1ebafa21dae8"
      unitRef="U_USD">-2539000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_1342c3e2-8dbd-4373-8df0-170fe0fb7116"
      unitRef="U_USD">-2539000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_4dc5908b-5edd-428d-affa-04a86844ffaf"
      decimals="-3"
      id="F_7a681ed6-176a-43a8-a5d0-97e23a4e28c4"
      unitRef="U_USD">76713000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_5ccbd483-2379-409a-bd21-f4c7e873cbca"
      unitRef="U_USD">76713000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_97e9955d-8f3c-4e73-96cc-3ff1b69da22b"
      decimals="INF"
      id="F_bdcc2eaa-b2f3-4720-8dcb-2382d439f5b3"
      unitRef="U_shares">122945000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_97e9955d-8f3c-4e73-96cc-3ff1b69da22b"
      decimals="-3"
      id="F_8d7466c1-c789-4aa9-bc49-e1ca0163469a"
      unitRef="U_USD">123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4cda2680-5634-444f-82ba-0702b3f55696"
      decimals="-3"
      id="F_6265748f-9fe2-48d6-99db-80f2ea48d67c"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4cda2680-5634-444f-82ba-0702b3f55696"
      decimals="-3"
      id="F_5ac7a37b-437e-4db9-8510-00ce2cd1ac3f"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3eff1578-c6f0-49d6-9432-a944eed0709e"
      decimals="-3"
      id="F_63ec0575-1ee7-48ea-b330-c84f2eb378af"
      unitRef="U_USD">1441868000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_10486a1b-be2f-40a5-b01f-0bcd65255d81"
      decimals="-3"
      id="F_59449e4a-1561-47ef-a222-976352a549bb"
      unitRef="U_USD">-2266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e381175a-06e1-46c3-b77b-df4ad235482a"
      decimals="-3"
      id="F_c27e1c1d-0c30-4b85-9e90-2133a6ff30b5"
      unitRef="U_USD">-1217351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d"
      decimals="-3"
      id="F_35d3dba0-4a7d-41e0-86b6-63b01553e08f"
      unitRef="U_USD">222374000</us-gaap:StockholdersEquity>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptionsShares
      contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38"
      decimals="INF"
      id="F_46d1c619-48b3-48b9-878e-b23c199afc02"
      unitRef="U_shares">1194000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptionsShares>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38"
      decimals="-3"
      id="F_ad07cf57-b2b5-48c7-8cea-ae993b684734"
      unitRef="U_USD">2000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_b3aa89f6-f4c8-4a9f-8753-f6b4ba518016"
      decimals="-3"
      id="F_a475d320-d1c4-43dd-8fda-83a422bdbf2e"
      unitRef="U_USD">0</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_48cfc4ff-27e8-4913-84be-fd420b811781"
      decimals="-3"
      id="F_53aa9f00-14a3-4986-8b83-c1418859c544"
      unitRef="U_USD">9638000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_3fcf0b11-683c-4cde-a332-45315e25d1f7"
      unitRef="U_USD">9640000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares
      contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38"
      decimals="-3"
      id="F_1d78d1b0-7477-42eb-bb25-aea6174fb2d2"
      unitRef="U_shares">1432000</dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsShares>
    <dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards
      contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38"
      decimals="-3"
      id="F_642bd897-26db-41aa-b04f-e3f912756604"
      unitRef="U_USD">1000</dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards>
    <dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards
      contextRef="C_48cfc4ff-27e8-4913-84be-fd420b811781"
      decimals="-3"
      id="F_ce96dbe3-ae52-474f-b242-43a6ad9e8abd"
      unitRef="U_USD">-1000</dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38"
      decimals="INF"
      id="F_88baf44b-44de-4fc2-b49e-00bc5b24fdb1"
      unitRef="U_shares">154000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_48cfc4ff-27e8-4913-84be-fd420b811781"
      decimals="-3"
      id="F_0419457c-9d49-45a3-9e65-8a7f4fcc027d"
      unitRef="U_USD">1430000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_008c1798-b357-4b09-b6ca-fefd125e4108"
      unitRef="U_USD">1430000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <dvax:IssuanceOfCommonStockUponExerciseOfWarrantsShares
      contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38"
      decimals="INF"
      id="F_24226978-c1da-4f94-95fb-3f9df7c06021"
      unitRef="U_shares">1879000</dvax:IssuanceOfCommonStockUponExerciseOfWarrantsShares>
    <dvax:IssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_58733421-ee84-4c5d-9a12-53149c7e8b38"
      decimals="-3"
      id="F_bd97963d-5e55-49d4-bef6-43539c737aa3"
      unitRef="U_USD">2000</dvax:IssuanceOfCommonStockUponExerciseOfWarrants>
    <dvax:IssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_b3aa89f6-f4c8-4a9f-8753-f6b4ba518016"
      decimals="-3"
      id="F_d3c398eb-7b20-4ba9-8bef-da5f553a069d"
      unitRef="U_USD">0</dvax:IssuanceOfCommonStockUponExerciseOfWarrants>
    <dvax:IssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_48cfc4ff-27e8-4913-84be-fd420b811781"
      decimals="-3"
      id="F_359e7514-d28a-4998-9470-94d83cf5bd9c"
      unitRef="U_USD">24668000</dvax:IssuanceOfCommonStockUponExerciseOfWarrants>
    <dvax:IssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_f9c31498-4ae5-43b5-bf29-868f3923edf7"
      unitRef="U_USD">24670000</dvax:IssuanceOfCommonStockUponExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_48cfc4ff-27e8-4913-84be-fd420b811781"
      decimals="-3"
      id="F_eaee08de-49bc-452f-a17d-8f0d7ada9c70"
      unitRef="U_USD">32915000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_5c8460d1-527b-4665-8783-93e194be2e39"
      unitRef="U_USD">32915000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f2119199-7038-4bb0-8c9c-d8181ef231e3"
      decimals="-3"
      id="F_b0e126c7-5158-41ae-b3ec-c7970819d80a"
      unitRef="U_USD">-3172000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_fa604e68-8b25-4b8a-94f4-98ef7eb77e50"
      unitRef="U_USD">-3172000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_3727f25c-7b34-4d8b-ad87-5a284d913f8c"
      decimals="-3"
      id="F_7f3e7328-f7ad-47b9-aa47-732f1deac93c"
      unitRef="U_USD">293156000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_4fadb692-70f3-4b9e-a0fc-84ed18bfca2b"
      unitRef="U_USD">293156000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_9822878d-e9c6-42eb-aba9-e6d1be0c6c26"
      decimals="INF"
      id="F_4acd56be-17e4-4d22-b1ea-f277ab702280"
      unitRef="U_shares">127604000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_9822878d-e9c6-42eb-aba9-e6d1be0c6c26"
      decimals="-3"
      id="F_a378e6a3-d82e-49b9-82b3-dc035dd6f830"
      unitRef="U_USD">128000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4cecce06-d788-4a18-b30c-961790a113af"
      decimals="-3"
      id="F_6b92a0a2-99e2-46b0-b44c-6e983a45bcef"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4cecce06-d788-4a18-b30c-961790a113af"
      decimals="-3"
      id="F_18877675-88a7-4890-9fab-da56c080ef15"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d26b0e54-e633-48c7-b851-f555aaf0ac91"
      decimals="-3"
      id="F_5e0ef6f0-0476-407d-ab9e-42112e13d7c4"
      unitRef="U_USD">1510518000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8d9fa1a4-607b-4714-b950-2d3ee7d6606a"
      decimals="-3"
      id="F_d34376da-e584-4204-b624-dc8002f35f90"
      unitRef="U_USD">-5438000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8ff495d2-c2ab-4702-a574-69eda60e3e44"
      decimals="-3"
      id="F_fb6056aa-1f18-4082-a966-40420a001e1d"
      unitRef="U_USD">-924195000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_00b31007-e5e2-4129-9fb0-3c7256abed82"
      unitRef="U_USD">581013000</us-gaap:StockholdersEquity>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptionsShares
      contextRef="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9"
      decimals="INF"
      id="F_c9aff6e0-f476-45a3-8e79-787a8d9362a5"
      unitRef="U_shares">850000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptionsShares>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9"
      decimals="-3"
      id="F_ecfb9fab-fe3c-4bb6-9aaa-3d7d04a2aee8"
      unitRef="U_USD">1000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_739cf94c-d0c3-431e-93da-9d8dc48a3718"
      decimals="-3"
      id="F_7a09d9db-05c4-48d1-ae37-3ab58abd522d"
      unitRef="U_USD">0</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_bfd94056-2ea8-4584-9e10-0cb5bec164e1"
      decimals="-3"
      id="F_313c7131-9bbe-4069-9cf1-8f2a62e90621"
      unitRef="U_USD">6360000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_d6f7b199-d17a-4899-b874-9e738771b782"
      unitRef="U_USD">6361000</dvax:IssuanceOfCommonStockUponExerciseOfStockOptions>
    <dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare
      contextRef="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9"
      decimals="-3"
      id="F_668ee53e-3955-4965-9ab4-34ed78b7bf04"
      unitRef="U_shares">915000</dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdingsShare>
    <dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
      contextRef="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9"
      decimals="-3"
      id="F_c8476a8f-4466-45ab-9c75-4a7d743180fb"
      unitRef="U_USD">1000</dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings>
    <dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
      contextRef="C_bfd94056-2ea8-4584-9e10-0cb5bec164e1"
      decimals="-3"
      id="F_05232c3a-6b3d-4870-8181-87a1ad6ca32b"
      unitRef="U_USD">-6371000</dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings>
    <dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_d8edac67-cda3-42a8-9eae-2eceeea2a007"
      unitRef="U_USD">-6370000</dvax:IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_593ce5d3-f6d2-462a-9ae6-a685dadc56e9"
      decimals="INF"
      id="F_67c9beac-46de-4e5d-83b2-7b85388fdd0b"
      unitRef="U_shares">161000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_bfd94056-2ea8-4584-9e10-0cb5bec164e1"
      decimals="-3"
      id="F_b9f0352e-f1d6-44e2-b85a-bb7d205854e3"
      unitRef="U_USD">1535000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_418bc2f4-db6d-4e5f-ae5f-065d2c4edfa4"
      unitRef="U_USD">1535000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_bfd94056-2ea8-4584-9e10-0cb5bec164e1"
      decimals="-3"
      id="F_8ef4bdbd-9341-4a66-bda2-9cc47dbad512"
      unitRef="U_USD">42592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_0d953b69-4bd1-48a7-b470-ddced47d0ec4"
      unitRef="U_USD">42592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0c75ba6c-c9fa-4cf1-982e-13bb8407020d"
      decimals="-3"
      id="F_a2425a38-f71e-45a1-b4fd-33c2417e20a1"
      unitRef="U_USD">3330000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_697d25d3-88a9-4768-92d2-b0d026bdc8c0"
      unitRef="U_USD">3330000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_74aa1aa7-40d9-43b4-9261-d413646b1f6d"
      decimals="-3"
      id="F_ecd2040c-bda9-44a0-a9b3-68d80f886e45"
      unitRef="U_USD">-6389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_57969e1d-53e5-4c57-8fe4-ae552e5dd426"
      unitRef="U_USD">-6389000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_7fc345ed-b272-49ff-b9eb-c47bc4c9266b"
      decimals="-3"
      id="F_f53e8f6a-a855-436e-afcb-bb094b7b98a5"
      unitRef="U_shares">129530000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7fc345ed-b272-49ff-b9eb-c47bc4c9266b"
      decimals="-3"
      id="F_91a630b1-6cd2-49ae-9976-bd5499e25ba7"
      unitRef="U_USD">130000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6451506c-a0f7-4a87-ac9f-42b2634d9a77"
      decimals="-3"
      id="F_291d9064-c6e6-4831-a6b5-33e1b8c8d4ef"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6451506c-a0f7-4a87-ac9f-42b2634d9a77"
      decimals="-3"
      id="F_14f1ae22-acc3-4d5c-b0bb-7fa7ebba47ca"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_413555f4-1d4a-4bf8-8c72-64ae359a9907"
      decimals="-3"
      id="F_bc62f34d-b51e-485f-acf2-915c7cc5619b"
      unitRef="U_USD">1554634000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_30de9d80-f061-4903-9ccb-6711842fb3d0"
      decimals="-3"
      id="F_4c1b6b1a-a809-4df6-8888-1967e58e0d73"
      unitRef="U_USD">-2108000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a9bb4111-0938-4d2d-bd83-eeb18b9ba154"
      decimals="-3"
      id="F_e3017e58-642d-4dc9-b0d5-a75f13853c44"
      unitRef="U_USD">-930584000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_ea289423-b99e-427d-8cbe-4684d7a8431c"
      unitRef="U_USD">622072000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_d79aedb6-fd98-4435-a6cb-9758273b2f47"
      unitRef="U_USD">-6389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_d0a903b1-d495-4caf-91ff-de594ee2f538"
      unitRef="U_USD">293156000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_df798bbf-0c28-4c29-af0d-92a46ceb25cb"
      unitRef="U_USD">76713000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_1febd96d-0324-432f-92fb-ff697ad369aa"
      unitRef="U_USD">4342000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_b9e5610c-63df-41b8-b6ed-7bceb14b1e3a"
      unitRef="U_USD">3812000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b30dec5f-2854-4186-abd0-448f9f0d04ce"
      unitRef="U_USD">4296000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_7c9709fd-cbbb-474b-b68f-1161381f0a21"
      unitRef="U_USD">2934000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_a4b33e65-ffea-424d-a262-d20e6893f75c"
      unitRef="U_USD">2856000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_f0f1ba85-d7a7-4c62-a902-761c9968eaa8"
      unitRef="U_USD">2762000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:InventoryWriteDown
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_d75d7be7-c599-4edb-a70e-fd9fab28d836"
      unitRef="U_USD">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_039bf0c0-41a7-49c3-8c31-d713e68be3d1"
      unitRef="U_USD">34288000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_8956c563-f7b8-4b88-9beb-6d74f5df27e1"
      unitRef="U_USD">2588000</us-gaap:InventoryWriteDown>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_b2414f8e-a895-4407-a857-6989abbc9487"
      unitRef="U_USD">16555000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_f3b6b591-2ab0-4fbb-932a-84e7268634df"
      unitRef="U_USD">4181000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_5f88d0a2-6aae-416a-9525-8686457a08f2"
      unitRef="U_USD">-470000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_a953bc3c-368f-42e6-9dd6-01e7eb670c11"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_6dcf0ede-8805-43bb-a19f-4828bfd08f96"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_9a9376c8-5b44-417c-ba55-4e8c7908194c"
      unitRef="U_USD">-5232000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_968cceb4-8e50-4836-8a1a-b13034727523"
      unitRef="U_USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_dc3f033c-88aa-47d1-94f3-e71769bffeb3"
      unitRef="U_USD">-1801000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_93e2a9ad-3569-4076-8931-738cfd42c775"
      unitRef="U_USD">49354000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_d5931f42-112a-438c-b21b-3d5b1e751243"
      unitRef="U_USD">42592000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_5ea51d90-e864-42f8-a33a-2ac4867004ca"
      unitRef="U_USD">32915000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_d1fe343a-658a-48bf-8d14-d0cd7ed026b3"
      unitRef="U_USD">21285000</us-gaap:ShareBasedCompensation>
    <dvax:NonCashInterestExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_a58682a4-86e7-4df7-aedf-77e3499898b2"
      unitRef="U_USD">1120000</dvax:NonCashInterestExpense>
    <dvax:NonCashInterestExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_d256a157-d454-4fee-9cd0-45a891f4af8a"
      unitRef="U_USD">1088000</dvax:NonCashInterestExpense>
    <dvax:NonCashInterestExpense
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b5d89a18-8b5c-4a10-bb45-e231ea08ce9e"
      unitRef="U_USD">1608000</dvax:NonCashInterestExpense>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_c038c4cd-6425-42dd-8f64-cfdb6f70a87d"
      unitRef="U_USD">1000000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_f437d391-9200-4927-bd01-b05425291d58"
      unitRef="U_USD">1000000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_d7d1540d-73e1-4c84-9da3-e6313aa7f68b"
      unitRef="U_USD">1000000</us-gaap:GainsLossesOnSalesOfAssets>
    <dvax:BadDebtExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_5d2957e3-0a26-4436-abaf-cfda92b0d7eb"
      unitRef="U_USD">12313000</dvax:BadDebtExpense>
    <dvax:BadDebtExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_53aad0d4-1b45-4c70-bb87-9484cfc4c9ed"
      unitRef="U_USD">0</dvax:BadDebtExpense>
    <dvax:BadDebtExpense
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_5a6e2883-b6e6-4f7b-8ca6-02ba53933930"
      unitRef="U_USD">0</dvax:BadDebtExpense>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_3e473ef2-00d8-49c4-9736-d4738f567fba"
      unitRef="U_USD">-43268000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_efe3d2a7-05f8-416f-9092-bfe081ef8a68"
      unitRef="U_USD">15699000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_e5c52643-67f6-48b2-a63f-65b86551edfc"
      unitRef="U_USD">109155000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_f1ea17d0-f603-4820-afe5-b6c38e2c810d"
      unitRef="U_USD">-3909000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_f73a02c4-da56-46b1-a531-c8619e136226"
      unitRef="U_USD">32399000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_bbe7d298-cc9d-4ef3-a766-beaa0482dfaf"
      unitRef="U_USD">234000</us-gaap:IncreaseDecreaseInInventories>
    <dvax:IncreaseDecreaseInPrepaidManufacturing
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_43c5bfea-917e-40ab-b4a2-a204f0558dae"
      unitRef="U_USD">-0</dvax:IncreaseDecreaseInPrepaidManufacturing>
    <dvax:IncreaseDecreaseInPrepaidManufacturing
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_8190f012-4a1d-481f-86de-daee28654876"
      unitRef="U_USD">-159655000</dvax:IncreaseDecreaseInPrepaidManufacturing>
    <dvax:IncreaseDecreaseInPrepaidManufacturing
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_91184e0d-28dd-4387-93db-36b206687774"
      unitRef="U_USD">130232000</dvax:IncreaseDecreaseInPrepaidManufacturing>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_711c5005-a6c5-4d5a-b00e-bebab2595f89"
      unitRef="U_USD">4673000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_68506c07-bf5c-4f2b-a9ae-94aed5c0c7b7"
      unitRef="U_USD">11865000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_f01c23be-18fe-4ff4-8257-3e41e7d36ddf"
      unitRef="U_USD">64558000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_2409ba3c-8a86-4cf5-8bc0-cb7f4fcce258"
      unitRef="U_USD">-570000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_e65200a8-47ee-48b0-ab99-a7daa34145d8"
      unitRef="U_USD">-87000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_51929c58-3727-4603-a688-a24568d940b9"
      unitRef="U_USD">-175000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_316ce678-7d76-47a9-97ce-8cd5638eb961"
      unitRef="U_USD">1952000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_a205327a-ac5e-4a00-b51b-1ae548057cf8"
      unitRef="U_USD">691000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_52f53cd9-b4be-450d-a260-0c80bf122521"
      unitRef="U_USD">-767000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <dvax:IncreaseDecreaseInCepiAccrual
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_e354b852-e386-4d58-97de-b1467be4bb83"
      unitRef="U_USD">0</dvax:IncreaseDecreaseInCepiAccrual>
    <dvax:IncreaseDecreaseInCepiAccrual
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_21e1421c-2404-4d14-a80a-9164994e8995"
      unitRef="U_USD">-21110000</dvax:IncreaseDecreaseInCepiAccrual>
    <dvax:IncreaseDecreaseInCepiAccrual
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_9642b3c0-f403-4b3e-935c-8f71aafcef6b"
      unitRef="U_USD">128848000</dvax:IncreaseDecreaseInCepiAccrual>
    <dvax:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_e4743adb-2c4c-46e0-8b12-4fe05549d680"
      unitRef="U_USD">3629000</dvax:IncreaseDecreaseInLeaseLiabilities>
    <dvax:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_ec59d8e5-295b-4b11-9d28-f387640f3f57"
      unitRef="U_USD">3125000</dvax:IncreaseDecreaseInLeaseLiabilities>
    <dvax:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_751d9898-c8ae-46d7-9b23-e7b5bf05e9bd"
      unitRef="U_USD">3234000</dvax:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_f858004d-1058-4bf4-be86-51da8324d8c1"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_49e82067-61a9-4186-9f34-ea581fc2992a"
      unitRef="U_USD">-349864000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_98e2fa73-503b-4dd2-9042-13dad0c301dd"
      unitRef="U_USD">311652000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_85f9a322-4934-4363-8a8b-fd7eae70e272"
      unitRef="U_USD">19809000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_c54787b6-7125-4827-a54b-ce078a5f9e05"
      unitRef="U_USD">-24788000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_21f742f3-4c55-41c5-a72c-6e9fc56201bf"
      unitRef="U_USD">39725000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_b7303085-d6f2-4400-90f3-d8d132c8dd44"
      unitRef="U_USD">100563000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_e34a8e1e-733b-4e2c-9c14-8c490202c363"
      unitRef="U_USD">62716000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_87b9edea-1cc1-40b2-be4d-4159f63638d3"
      unitRef="U_USD">335528000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_f2188547-18e5-43ce-8c67-0cee0361bcca"
      unitRef="U_USD">636921000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_97965cc7-b48b-4d63-bb1b-6e23328b1b95"
      unitRef="U_USD">632306000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_8d582069-2e76-43b5-ad55-a2ff0175eadc"
      unitRef="U_USD">164928000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_18a0fead-bdfa-46c0-983a-59692f939e08"
      unitRef="U_USD">486097000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_0903d6db-a77a-4a70-98a4-d3413211cc31"
      unitRef="U_USD">322450000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_acab4632-beb5-418c-99e1-2e799eae447d"
      unitRef="U_USD">187630000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_c0885f98-c501-4154-9912-76c03f9e5f35"
      unitRef="U_USD">4104000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_2a5e2f16-0ffa-4c7b-9a5e-1e596ac6830a"
      unitRef="U_USD">7139000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_f90c6fcb-e11d-484b-a255-6a03e9763d01"
      unitRef="U_USD">9477000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_7af4ff79-8f34-41da-943b-3680220d7ce6"
      unitRef="U_USD">1000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_09def43b-596b-4084-955b-bdf793d15c96"
      unitRef="U_USD">1000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b1b6f0d7-d7a9-43d2-923a-209d532ec472"
      unitRef="U_USD">1000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_a52e8579-e090-41f8-b8a6-a88745f69780"
      unitRef="U_USD">-153928000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_a3454253-859e-421b-950d-d3f489f43062"
      unitRef="U_USD">-315995000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_1910244e-a7ff-4e96-a6b6-077a0bca69ec"
      unitRef="U_USD">14225000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_626a55f2-9a8f-430d-a9de-1549d86e9b67"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_9b125b2e-91cc-48f1-9ec6-9c7af828be9f"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_c5d58a69-29e9-45aa-ade0-e43c648bf811"
      unitRef="U_USD">28156000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_9d57a117-e043-4aa9-b255-ea0bb320c813"
      unitRef="U_USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_5ec3e12f-d554-4bb5-800a-848204466536"
      unitRef="U_USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_4d55e5e6-201a-4a19-94e8-93facec96bb9"
      unitRef="U_USD">219822000</us-gaap:ProceedsFromConvertibleDebt>
    <dvax:PaymentsForPurchaseOfCappedCallOptions
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_7ae70e22-4f78-46dc-b8df-afa8ae52d3b4"
      unitRef="U_USD">0</dvax:PaymentsForPurchaseOfCappedCallOptions>
    <dvax:PaymentsForPurchaseOfCappedCallOptions
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_027e7655-757a-476a-ae4c-0d1d8d383180"
      unitRef="U_USD">0</dvax:PaymentsForPurchaseOfCappedCallOptions>
    <dvax:PaymentsForPurchaseOfCappedCallOptions
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_f848b6f5-fa64-4bc8-a66a-b22d8966bda1"
      unitRef="U_USD">27240000</dvax:PaymentsForPurchaseOfCappedCallOptions>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_873b25b8-de4b-47fb-83b5-f8cb6d076b18"
      unitRef="U_USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_25a2f240-3f66-4345-ae8b-88cc37eb1dc3"
      unitRef="U_USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_cc9df6fe-c1e5-4c17-acc8-46b4d80eaed1"
      unitRef="U_USD">190194000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_52dfe52b-f12f-4f1f-b07a-946f3a98a001"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_579e04c0-f5f6-4db9-a521-fff393a5863e"
      unitRef="U_USD">8455000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_c0de04b7-7a91-4d7c-a236-6151996814fd"
      unitRef="U_USD">17814000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <dvax:ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_d895abeb-f714-40d1-b8fb-0d1e8a9084b1"
      unitRef="U_USD">6360000</dvax:ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet>
    <dvax:ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_bb724bd4-2ff2-4a11-89dd-bb34dc52620b"
      unitRef="U_USD">9639000</dvax:ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet>
    <dvax:ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_45e4602f-70a9-48f7-bf76-5b098bc22a31"
      unitRef="U_USD">6577000</dvax:ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_0e862ac5-e30d-4849-8f34-993c27d12c7e"
      unitRef="U_USD">1535000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_1991cd14-7a09-4ad1-9bbe-2f0a08f988ce"
      unitRef="U_USD">1431000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_da0bc9e1-3ea7-42d0-843b-4a699bb95059"
      unitRef="U_USD">841000</us-gaap:ProceedsFromStockPlans>
    <dvax:PaymentsForTaxesRelatedToNetShareSettlementOfRsus
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_1605957d-d4b8-4c53-8826-bafdde159348"
      unitRef="U_USD">6509000</dvax:PaymentsForTaxesRelatedToNetShareSettlementOfRsus>
    <dvax:PaymentsForTaxesRelatedToNetShareSettlementOfRsus
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_ce0b80ae-9773-4fdf-b931-1c5a865c5774"
      unitRef="U_USD">0</dvax:PaymentsForTaxesRelatedToNetShareSettlementOfRsus>
    <dvax:PaymentsForTaxesRelatedToNetShareSettlementOfRsus
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_5444af80-7d72-4457-b6f0-9d73e5d9887f"
      unitRef="U_USD">0</dvax:PaymentsForTaxesRelatedToNetShareSettlementOfRsus>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_aa4278f1-4b49-4dc4-910e-ef2c8c50fc0b"
      unitRef="U_USD">1386000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_829c16d5-eed7-4cb0-a082-01f32b676f16"
      unitRef="U_USD">19525000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_981822e7-62f5-419a-bc5d-751b35c6ce38"
      unitRef="U_USD">55776000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_226fd49d-5950-490b-8595-7882e1b07908"
      unitRef="U_USD">324000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_03fa2dd1-cc39-499a-8347-270d31400a55"
      unitRef="U_USD">-443000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_1042fbbc-7428-42f9-abe5-57d01486e1e2"
      unitRef="U_USD">-1431000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_1aaa2cb1-834e-4b97-96cd-ebefb942e19c"
      unitRef="U_USD">-51655000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_63040909-b156-44db-941c-af71bcf8b8ae"
      unitRef="U_USD">-234197000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_edea9a5a-f632-4f7a-8814-014a25914e64"
      unitRef="U_USD">404098000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_aa37acca-36bd-49ef-b7f4-d9bbf92ddbc9"
      unitRef="U_USD">202211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d"
      decimals="-3"
      id="F_ffa6aa42-ac09-45ef-9f3e-ee3f7780d60e"
      unitRef="U_USD">436408000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d6a1605d-0ed8-4293-af91-e392daff1469"
      decimals="-3"
      id="F_8379b787-28d1-4322-af7c-f1446d79bf0e"
      unitRef="U_USD">32310000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_37eb5675-0bf4-48e5-b8a4-55c290db9bd7"
      unitRef="U_USD">150556000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_5abd9abd-7ba2-495f-8c34-d7d97abfd8d4"
      unitRef="U_USD">202211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d"
      decimals="-3"
      id="F_a232c518-ab24-49de-8faf-ef71eeb67c22"
      unitRef="U_USD">436408000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_81f1ff16-69a7-4934-ade9-f0a134a70858"
      unitRef="U_USD">2014000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_5c9e7a6c-5f0e-4140-bf71-0ec2dbed4fce"
      unitRef="U_USD">2208000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_0158da6d-2e41-49d3-807d-891a70b88953"
      unitRef="U_USD">1312000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_ee7be46e-41cf-49ab-8fdd-a83da9e9566f"
      unitRef="U_USD">5638000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_89c6c203-98e7-4d43-9e72-703a8b7edf29"
      unitRef="U_USD">5638000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_379e5afa-f737-4e99-a9c3-44ec87d0f200"
      unitRef="U_USD">9815000</us-gaap:InterestPaidNet>
    <dvax:ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_01276704-f5bc-4d90-ae0f-d4f91c934c2f"
      unitRef="U_USD">71307000</dvax:ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets>
    <dvax:ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_7fb99a91-cd83-4a3d-b10d-9f4694dadc6c"
      unitRef="U_USD">0</dvax:ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets>
    <dvax:ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_14c5115e-06cf-46c7-b1ba-af20444229f7"
      unitRef="U_USD">0</dvax:ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets>
    <dvax:ReclassificationOfCepiAccrualToCepiAccrualLongTerm
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_418ceca0-ed04-45e9-a31a-7de6fc1fb378"
      unitRef="U_USD">-60337000</dvax:ReclassificationOfCepiAccrualToCepiAccrualLongTerm>
    <dvax:ReclassificationOfCepiAccrualToCepiAccrualLongTerm
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_10d53c41-797c-4dca-95bb-5db092569684"
      unitRef="U_USD">0</dvax:ReclassificationOfCepiAccrualToCepiAccrualLongTerm>
    <dvax:ReclassificationOfCepiAccrualToCepiAccrualLongTerm
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_7950b6ee-b38d-4e34-bcce-883825975f26"
      unitRef="U_USD">0</dvax:ReclassificationOfCepiAccrualToCepiAccrualLongTerm>
    <dvax:AdvancePaymentFromCustomer
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_028e9706-dc0e-4208-a1c3-d275f4475fb8"
      unitRef="U_USD">-47401000</dvax:AdvancePaymentFromCustomer>
    <dvax:AdvancePaymentFromCustomer
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_ac410721-a41a-49f8-919a-7ba8c535406d"
      unitRef="U_USD">0</dvax:AdvancePaymentFromCustomer>
    <dvax:AdvancePaymentFromCustomer
      contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d"
      decimals="-3"
      id="F_601f2200-80c4-49d2-ac0e-60d7919907e7"
      unitRef="U_USD">0</dvax:AdvancePaymentFromCustomer>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_476959f0-b745-4982-b939-4da7c64843f5"
      unitRef="U_USD">299000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_29f7a100-f9f9-4f41-b41c-8bf4229c1234"
      unitRef="U_USD">1015000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_e9528520-8844-4753-a282-56517ddc30b6"
      unitRef="U_USD">591000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_3765356a-9dcc-498c-88c7-776ecce38918"
      unitRef="U_USD">1332000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_47ead126-cf4d-492a-87fa-a5def4e25d76"
      unitRef="U_USD">2848000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_05c1e17c-53dd-49df-90d9-e313a50fe7c4"
      unitRef="U_USD">2468000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_5ead21dd-e683-429b-a372-389444bfa309">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Dynavax Technologies Corporation (&#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us,&#x201d; &#x201c;Dynavax&#x201d; or the &#x201c;Company&#x201d;) is a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Our first marketed product, HEPLISAV-B&#xae; [Hepatitis B Vaccine (Recombinant), Adjuvanted] is approved in the United States, the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and older. In May 2022, we commenced commercial shipments of HEPLISAV-B in Germany.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are advancing a pipeline of differentiated product candidates that leverage our CpG 1018&#xae; adjuvant, the adjuvant used in HEPLISAV-B, to develop improved vaccines in indications with unmet medical needs. These programs include vaccine candidates under development for shingles and Tdap, and a plague vaccine candidate program in collaboration with and fully funded by the U.S. Department of Defense ("DoD").&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additionally. we manufacture and have supplied in the past CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B, through both commercial supply agreements, and through preclinical and clinical research collaborations with third-party organizations. As of December 31, 2022, we had satisfied all delivery obligations under our commercial supply agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dvax:MinimumAgeApprovedForVaccinePreventionOfInfectionCaused
      contextRef="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b"
      id="F_47e3ae98-6178-45a1-8e9a-08c3ef7dfaf5">P18Y</dvax:MinimumAgeApprovedForVaccinePreventionOfInfectionCaused>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_c3638845-2ba8-4a78-9ce5-fa0502b76d92">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include our accounts and those of our wholly-owned subsidiaries, Dynavax GmbH located in D&#xfc;sseldorf, Germany, Dynavax India LLP in India and a branch of Dynavax in Italy. All intercompany accounts and transactions among the entities have been eliminated from the consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management&#x2019;s estimates are based on historical information available as of the date of the consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consider the local currency to be the functional currency for our international subsidiaries, Dynavax GmbH, located in D&#xfc;sseldorf, Germany, Dynavax India LLP, and a branch of Dynavax registered in Italy. Accordingly, assets and liabilities denominated in this foreign currency are translated into U.S. dollars using the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the year. Currency translation adjustments arising from period to period are charged or credited to accumulated other comprehensive income (loss) in stockholders&#x2019; equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of Decemb&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;er 31, 2023 and 2022, the cumulative translation adjustments balance was $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) million, respectively, primarily related to the translation of Dynavax GmbH assets, liabilities and operating results from Euros to U.S. dollars. F&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or the years ended December 31, 2023, 2022 and 2021, we reported an unrealized foreign currency translation gain (loss) of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) million and $(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) million, respectively. Realized gains and losses resulting from currency transactions are included in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; other (expense) income in the consolidated statements of operations. For the years ended December 31, 2023, 2022 and 2021, we reported a (loss) gain of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) mi&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;llion, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, resulting from currency transactions in our consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;segment &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and in assessing performance. Our Chief Executive Officer is the CODM. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, management has determined that we operate in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment that is focused on the discovery, development, and commercialization of innovative vaccines. Net assets outside of the U.S. w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ere less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of total net assets as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consider all liquid investments purchased with an original maturity of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or less and that can be liquidated without prior notice or penalty to be cash equivalents. Management determines the appropriate classification of marketable securities at the time of purchase. In accordance with our investment policy, we invest in short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We believe these types of investments are subject to minimal credit and market risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive loss in stockholders&#x2019; equity. Commencing with our adoption of (&#x201c;ASC&#x201d;) 326, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments &#x2014; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(&#x201c;ASC 326")&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on January 1, 2023, we determine whether a decline in the fair value of our available-for-sale ("AFS") debt securities below their amortized cost basis (i.e., an impairment) is due to credit-related factors or noncredit-related factors. Any impairment that is not credit related is recognized in other comprehensive income (loss), net of applicable taxes. Credit-related impairments (if any) are recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Both the allowance and the adjustment to net income can be reversed if conditions change. To date, there have been no declines in fair value that have been identified as a credit-related impairment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any significant losses on our cash equivalents and marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts. We estimate our allowance for doubtful accounts based on&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. During the year ended December 31, 2023, we recorded an allowance for doubtful accounts of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which was determined by assessing changes in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Biological E. Limited's (&#x201c;Bio E&#x201d;) credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (See Note 9), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India. As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;customers collectively represented approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of our HEPLISAV-B trade receivable balance, respectively. As of December 31, 2023, we had no CpG 1018 adjuvant trade receivable balance. As of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; customer represented approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of our CpG 1018 adjuvant trade receivable balance&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our product candidates will require approval from the United States Food and Drug Administration ("FDA") and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our product candidates will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process that could affect our authorizations in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our long-lived assets located in the United States as of December 31, 2023 and 2022, represented &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of our total assets, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;respectively, and the remaining long-lived assets were located in Germany.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;HEPLISAV-B Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the years ended December 31, 2023 and 2022, there w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ere &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; invento&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ry reserves or write-offs recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to the required regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory. Instead, those are expensed as research and development costs. We begin capitalization of these inventory related costs once regulatory approval is obtained.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;CpG 1018 Adjuvant Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the year ended December 31, 2023, there was no remaining CpG 1018 adjuvant inventory balance. For the year ended December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of inventory write-off to cost of sales - product, in connection with cancelled orders and the reduction in demand for CpG 1018 adjuvant reflected in the Clover Supply Agreement, as amended (See Note 9).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized, while repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We evaluate the carrying value of long-lived assets, whenever events or changes in business circumstances or our planned use of long-lived assets indicate, based on undiscounted future operating cash flows, that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. When an indicator of impairment exists, undiscounted future operating cash flows of long-lived assets are compared to their respective carrying value. If the carrying value is greater than the undiscounted future operating cash flows of long-lived assets, the long-lived assets are written down to their respective fair values and an impairment loss is recorded. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. There have been no material adjustments to these estimates during the years presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We determine if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset, and whether we have the right to control the identified asset. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, other current liabilities and long-term portion of lease liabilities in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. The classification of our leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of ROU assets and lease liabilities is based on the present value of future lease payments over the lease term. The ROU asset also includes the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As the implicit rate in our leases is generally unknown, we use our incremental borrowing rate based on information available at the lease commencement date in determining the present value of future lease payments. We consider our credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary, when calculating our incremental borrowing rate. The lease terms may include options to extend or terminate the lease when it is reasonably certain we will exercise any such options. Rent expense for our operating leases is recognized on a straight-line basis over the lease term. Variable lease payments are recorded as an expense in the period incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have elected not to apply the recognition requirements of Accounting Standards Codification ASC 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases ("ASC 842")&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, for short-term leases. We have also elected the practical expedient to not separate lease components from non-lease components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As lessors, we determine if an arrangement includes a lease at inception. We elected the practical expedient to not separate lease components from non-lease components. Sublease income is recognized on a straight-line basis over the expected lease term and is included in other income (expense) in our consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill represents the excess purchase price over the fair value of tangible and intangible assets acquired and liabilities assumed. Our goodwill balance relates to our acquisition of Dynavax GmbH in 2006. Goodwill is not amortized, but instead is reviewed for impairment test at least annually, or more frequently if events occur or circumstances change that would indicate the carrying amount may be impaired. Goodwill is assigned to, and impairment testing is performed at, the reporting unit level. We determined that we have only &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment and there are no components of that operating segment that are deemed to be separate reporting units, such that we have one reporting unit for purposes of our goodwill impairment testing. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment has been identified for the years presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Convertible Notes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We account for our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% convertible senior notes due in 2026 (&#x201c;Convertible Notes&#x201d;), as a long-term liability equal to the proceeds received from issuance, including the embedded conversion feature, net of the unamortized debt issuance and offering costs on the consolidated balance sheets (See Note 10). We evaluate all conversion, repurchase and redemption features contained in a debt instrument to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is not required to be accounted for separately as an embedded derivative. We amortize debt issuance and offering costs over the contractual term of the Convertible Notes, using the effective interest method, as interest expense on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Capped Calls&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We evaluate financial instruments under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging ("ASC 815")&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The capped calls purchased in connection with the Convertible Notes financing ("Capped Calls") cover the same number of shares of common stock that initially underlie the Convertible Notes (subject to anti-dilution and certain other adjustments). The Capped Calls meet the definition of derivative under ASC 815. In addition, the Capped Calls meet the conditions in ASC 815 to be classified in stockholders&#x2019; equity and are not subsequently remeasured as long as the conditions for the equity classification continue to be met.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration, which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers ("ASC 606")&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, we apply the following five step model:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;identify the performance obligation(s) in the contract;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;allocate the transaction price to the performance obligation(s) in the contract; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;recognize revenue when (or as) we satisfy a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Product Revenue, Net &#x2013; HEPLISAV-B&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We sell HEPLISAV-B to a limited number of wholesalers and specialty distributors in the U.S. (collectively, our &#x201c;Customers&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product upon delivery to the Customer. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Because our standard credit terms are short-term and we expect to receive payment in less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there is no significant financing component on the related receivables. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. Since our performance obligation is part of a contract that has an original expected duration of one year or less, we elect not to disclose the information about our remaining performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Overall, product revenue, net - HEPLISAV-B, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration such as product returns, chargebacks, discounts, rebates and other fees that are offered within contracts between us and our Customers, healthcare providers, pharmacies and others relating to our product sales. We estimate variable consideration using either the most likely amount method or the expected value method, depending on the type of variable consideration and what method better predicts the amount of consideration we expect to receive. We take into consideration relevant factors such as industry data, current contractual terms, available information about Customers&#x2019; inventory, resale and chargeback data and forecasted customer buying and payment patterns, in estimating each variable consideration. The variable consideration is recorded at the time product sales is recognized, resulting in a reduction in product revenue and a reduction in accounts receivable (if the Customer offsets the amount against its accounts receivable) or as an accrued liability (if we pay the amount through our accounts payable process). Variable consideration requires significant estimates, judgment and information obtained from external sources. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. If we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of revenue that we report in a particular period. We evaluate our estimates of variable considerations including, but not limited to, product returns, chargebacks and rebates, periodically or when there is an event or change in circumstances that may indicate that our estimates may change.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Product Returns:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Consistent with industry practice, we offer our Customers a limited right of return based on the product&#x2019;s expiration date for product that has been purchased from us. We estimate the amount of our product sales that may be returned by our Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We consider several factors in the estimation of potential product returns including expiration dates of the product shipped, the limited product return rights, available information about Customers&#x2019; inventory and other relevant factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Our Customers subsequently resell our product to healthcare providers, pharmacies and others. In addition to distribution agreements with Customers, we enter into arrangements with qualified healthcare providers that provide for chargebacks and discounts with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by Customers, and we issue credits for such amounts generally within a few weeks of the Customer&#x2019;s notification to us of the resale. Reserves for chargebacks consists of credits that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect will be sold to the qualified healthcare providers, and chargebacks for units that our Customers have sold to the qualified healthcare providers, but for which credits have not been issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Trade Discounts and Allowances:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; We provide our Customers with discounts which include early payment incentives that are explicitly stated in our contracts, and are recorded as a reduction of revenue in the period the related product revenue is recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Distribution Fees: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Distribution fees include fees paid to certain Customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Rebates: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under certain contracts, Customers may obtain rebates for purchasing minimum volumes of our product. We estimate these rebates based upon the expected purchases and the contractual rebate rate and record this estimate as a reduction in revenue in the period the related revenue is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Product Revenue, Net &#x2013; CpG 1018 Adjuvant&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We also sell our innovative adjuvant, CpG 1018 adjuvant, to our collaboration partners for use in their development and/or commercialization of COVID-19 vaccine. We have determined that our collaboration partners meet the definition of Customers under ASC 606. Therefore, we accounted for our CpG 1018 adjuvant sales under ASC 606. Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product to the customer. Because the timing between the recognition of revenue for product sales and the receipt of payment is less than one year, there is no significant financing component on the related receivables. Since our performance obligation is part of a contract that has an original expected duration of one year or less, we elect not to disclose the information about our remaining performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Overall, product revenue, net - CpG 1018 adjuvant, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. Our CpG 1018 adjuvant customers have purchased a significant quantity of CpG 1018 adjuvant as part of their initial COVID-19 vaccine development inventory. Accordingly, we did not recognize CpG 1018 adjuvant net product revenue during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other revenue includes revenue from our agreement with the DoD, collaboration and manufacturing service revenue. We have entered into grant agreements, collaborative arrangements and arrangements to provide manufacturing services to other companies. Such arrangements may include promises to customers which, if capable of being distinct, are accounted for as separate performance obligations. For agreements with multiple performance obligations, we allocate estimated revenue to each performance obligation at contract inception based on the estimated transaction price of each performance obligation. Revenue allocated to each performance obligation is then recognized when we satisfy the performance obligation by transferring control of the promised good or service to the customer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and Development Expenses and Accruals&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. Our accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties. We estimate research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to us at that time. There have been no material adjustments to the prior period accrued estimates for clinical trial activities during the years presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense for restricted stock units ("RSUs"), market-based performance stock units ("PSUs") and stock options is estimated at the grant date based on the award&#x2019;s estimated fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For awards that vest based on service conditions and market conditions, we use a straight-line method to recognize compensation expense over the award&#x2019;s requisite service period, assuming estimated forfeiture rates. For awards that contain performance conditions, we determine the appropriate amount to expense at each reporting date based on the anticipated achievement of performance targets, which requires judgement, including forecasting the achievement of future specified targets. At the date performance conditions are determined to be probable of achievement, we record a cumulative expense catch-up, with remaining expense amortized over the remaining service period. Throughout the performance period, we re-assesses the estimated performance and updates the number of performance-based awards that we believe will ultimately vest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value of RSUs is determined at the date of grant using our closing stock price, with the exception of PSUs, which are measured using the Monte Carlo simulation method on the date of grant. Our determination of the fair value of stock options on the date of grant using an option-pricing model is affected by our stock price, as well as assumptions regarding a number of subjective variables. We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value-based measurement of our stock options. The Black-Scholes model requires the use of subjective assumptions, which determine the fair value-based measurement of stock options. These assumptions include, but are not limited to, our expected stock price volatility over the term of the awards, and projected employee stock option exercise behaviors. In the future, as additional empirical evidence regarding these input estimates becomes available, we may change or refine our approach of deriving these input estimates. These changes could impact our fair value of stock options granted in the future. Changes in the fair value of stock awards could materially impact our operating results.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby increasing stock-based compensation expense recognized in future periods. We derive the expected term assumption primarily based on our historical settlement experience, while considering options that have not yet completed a full life cycle. Stock-based compensation expense is recognized only for awards ultimately expected to vest. Our estimate of the forfeiture rate is based primarily on our historical experience. To the extent we revise this estimate in the future, our share-based compensation expense could be materially impacted in the period of revision. There have been no material adjustments to these estimates during the years presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Tax law and rate changes are reflected in income in the period such changes are enacted. We include interest and penalties related to income taxes, including unrecognized tax benefits, within income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. We continually assess the likelihood and amount of potential adjustments and adjust the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and the valuation allowance recorded against our net deferred tax assets. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we believe that recognition of the deferred tax assets arising from future tax benefits is currently not more likely than not to be realized and, accordingly, we have determined a need for a full valuation allowance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Standards Update 2016-13&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which was codified in Accounting Standards Codification ASC 326, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments &#x2014; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. Because we were a smaller reporting company based on the most recent determination as of November 15, 2019, ASC 326 became effective for us for fiscal years beginning after December 15, 2022. As such, we adopted ASC 326 effective January 1, 2023, utilizing the modified retrospective transition method. Upon adoption, we updated our impairment model to utilize a forward-looking current expected credit losses (&#x201c;CECL&#x201d;) model in place of the incurred loss methodology for financial instruments measured at amortized cost, primarily including our accounts receivable and contract asset. In relation to AFS debt securities, the guidance eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment, and instead focuses on determining whether any impairment is a result of a credit loss or other factors. The adoption of ASC 326 did not have a material impact on our consolidated financial statements as of the adoption date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_e785bc37-ffd5-4bfc-a17a-e18fc7f51d5b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include our accounts and those of our wholly-owned subsidiaries, Dynavax GmbH located in D&#xfc;sseldorf, Germany, Dynavax India LLP in India and a branch of Dynavax in Italy. All intercompany accounts and transactions among the entities have been eliminated from the consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_ae72bd5a-d9a8-47af-9fc9-f3540b46fa53">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management&#x2019;s estimates are based on historical information available as of the date of the consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_082065dd-a252-43a8-827e-eeb05449db59">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consider the local currency to be the functional currency for our international subsidiaries, Dynavax GmbH, located in D&#xfc;sseldorf, Germany, Dynavax India LLP, and a branch of Dynavax registered in Italy. Accordingly, assets and liabilities denominated in this foreign currency are translated into U.S. dollars using the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the year. Currency translation adjustments arising from period to period are charged or credited to accumulated other comprehensive income (loss) in stockholders&#x2019; equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of Decemb&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;er 31, 2023 and 2022, the cumulative translation adjustments balance was $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) million, respectively, primarily related to the translation of Dynavax GmbH assets, liabilities and operating results from Euros to U.S. dollars. F&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or the years ended December 31, 2023, 2022 and 2021, we reported an unrealized foreign currency translation gain (loss) of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) million and $(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) million, respectively. Realized gains and losses resulting from currency transactions are included in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; other (expense) income in the consolidated statements of operations. For the years ended December 31, 2023, 2022 and 2021, we reported a (loss) gain of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) mi&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;llion, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, resulting from currency transactions in our consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <dvax:CumulativeTranslationAdjustmentNetOfTax
      contextRef="C_df4c54ad-6b4c-4547-9c0b-6d82cd6c4cde"
      decimals="-5"
      id="F_c5816ded-2e6c-491a-ace2-c51dc12f6ce9"
      unitRef="U_USD">-3000000</dvax:CumulativeTranslationAdjustmentNetOfTax>
    <dvax:CumulativeTranslationAdjustmentNetOfTax
      contextRef="C_8004c05b-80cb-4d34-b5be-e0a034b69331"
      decimals="-5"
      id="F_6b1c1892-718b-4a34-a724-8bdd9abaf22d"
      unitRef="U_USD">-4000000</dvax:CumulativeTranslationAdjustmentNetOfTax>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-5"
      id="F_d4897a9a-ae86-4b98-afaa-f9e76fe2cc23"
      unitRef="U_USD">1100000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-5"
      id="F_9bc36523-42e2-4d8b-a710-0329cc9f44d0"
      unitRef="U_USD">-1800000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-5"
      id="F_f4c72ed0-b689-4248-87b0-d72ec09bdc93"
      unitRef="U_USD">-2500000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-5"
      id="F_ee05be14-02b4-4dd0-932b-750705468301"
      unitRef="U_USD">-100000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-5"
      id="F_3b5792bb-a2a7-441e-bdae-66fd81cd4579"
      unitRef="U_USD">100000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-5"
      id="F_47f7d39d-33a1-474b-8188-d911e0b298b8"
      unitRef="U_USD">900000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_24954831-31e8-4b69-b721-54402632b9ce">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;segment &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and in assessing performance. Our Chief Executive Officer is the CODM. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, management has determined that we operate in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment that is focused on the discovery, development, and commercialization of innovative vaccines. Net assets outside of the U.S. w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ere less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of total net assets as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="0"
      id="F_90d57e20-4d45-4b03-b576-5373ea1ed4ff"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <dvax:PercentageOfLongLivedAssets
      contextRef="C_b4c83557-99eb-4dae-a4b6-8f5fe7a1fff4"
      decimals="2"
      id="F_eb327e6e-06af-444b-98ab-305202d381c7"
      unitRef="U_pure">0.10</dvax:PercentageOfLongLivedAssets>
    <dvax:PercentageOfLongLivedAssets
      contextRef="C_16e235b1-3b2d-4e5d-8443-14ad46e6d0bb"
      decimals="2"
      id="F_598cb243-ba03-4f9e-9dfb-7beaa447c4dc"
      unitRef="U_pure">0.10</dvax:PercentageOfLongLivedAssets>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_8f819a9e-88cb-4c94-90df-a2538f216c4f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consider all liquid investments purchased with an original maturity of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or less and that can be liquidated without prior notice or penalty to be cash equivalents. Management determines the appropriate classification of marketable securities at the time of purchase. In accordance with our investment policy, we invest in short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We believe these types of investments are subject to minimal credit and market risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive loss in stockholders&#x2019; equity. Commencing with our adoption of (&#x201c;ASC&#x201d;) 326, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments &#x2014; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(&#x201c;ASC 326")&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on January 1, 2023, we determine whether a decline in the fair value of our available-for-sale ("AFS") debt securities below their amortized cost basis (i.e., an impairment) is due to credit-related factors or noncredit-related factors. Any impairment that is not credit related is recognized in other comprehensive income (loss), net of applicable taxes. Credit-related impairments (if any) are recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Both the allowance and the adjustment to net income can be reversed if conditions change. To date, there have been no declines in fair value that have been identified as a credit-related impairment.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <dvax:CashEquivalentsMaturityPeriod
      contextRef="C_c4bb7def-af41-4d15-8eda-59023addc137"
      id="F_57702625-d3d0-4c79-a093-6defa3adb4de">P3M</dvax:CashEquivalentsMaturityPeriod>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_c9070f18-487e-4e0c-9455-67e04e48d0e9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any significant losses on our cash equivalents and marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts. We estimate our allowance for doubtful accounts based on&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. During the year ended December 31, 2023, we recorded an allowance for doubtful accounts of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which was determined by assessing changes in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Biological E. Limited's (&#x201c;Bio E&#x201d;) credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (See Note 9), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India. As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;customers collectively represented approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of our HEPLISAV-B trade receivable balance, respectively. As of December 31, 2023, we had no CpG 1018 adjuvant trade receivable balance. As of December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; customer represented approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of our CpG 1018 adjuvant trade receivable balance&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our product candidates will require approval from the United States Food and Drug Administration ("FDA") and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our product candidates will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process that could affect our authorizations in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our long-lived assets located in the United States as of December 31, 2023 and 2022, represented &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of our total assets, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;respectively, and the remaining long-lived assets were located in Germany.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-5"
      id="F_661f5b31-e854-41dc-b0f6-ef8d890204f4"
      unitRef="U_USD">12300000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ConcentrationRiskCustomer
      contextRef="C_23872491-571b-4186-b6ac-a7b968b913ea"
      id="F_f8576c74-baa3-4ac3-a96b-9bc015095c4c">three</us-gaap:ConcentrationRiskCustomer>
    <us-gaap:ConcentrationRiskCustomer
      contextRef="C_3712e127-94e3-4474-a4e8-4efc91f83f9a"
      id="F_b6f3312c-d390-4489-ab28-eb588ef4515c">three</us-gaap:ConcentrationRiskCustomer>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_5cce5446-2af2-4a9a-b1c4-38be430937ac"
      decimals="2"
      id="F_80b923c3-1a94-4e8e-beae-989bb193a749"
      unitRef="U_pure">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_b2def0eb-ee73-4354-805a-b882be4a3888"
      decimals="2"
      id="F_61786731-da1e-47a3-ad72-c8756aa200fe"
      unitRef="U_pure">0.78</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskCustomer
      contextRef="C_93f06617-1210-471c-aa60-542728a9d90e"
      id="F_363e8caf-1c6a-4fd5-b6ef-4cd3686d8698">one</us-gaap:ConcentrationRiskCustomer>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_47db32ab-ff21-4bf4-92e5-39d73f0bf345"
      decimals="INF"
      id="F_35025d4e-9dd5-4f54-84be-9db99e08bf71"
      unitRef="U_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <dvax:PercentageOfLongLivedAssets
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="2"
      id="F_79b1553a-6790-4121-a81c-3281a250207d"
      unitRef="U_pure">0.31</dvax:PercentageOfLongLivedAssets>
    <dvax:PercentageOfLongLivedAssets
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="2"
      id="F_af761efc-88e7-445b-aaf9-1e054e755e97"
      unitRef="U_pure">0.34</dvax:PercentageOfLongLivedAssets>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_ad8a0650-c436-48f9-87e8-44de1f1dec37">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;HEPLISAV-B Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the years ended December 31, 2023 and 2022, there w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ere &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; invento&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ry reserves or write-offs recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to the required regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory. Instead, those are expensed as research and development costs. We begin capitalization of these inventory related costs once regulatory approval is obtained.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;CpG 1018 Adjuvant Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the year ended December 31, 2023, there was no remaining CpG 1018 adjuvant inventory balance. For the year ended December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of inventory write-off to cost of sales - product, in connection with cancelled orders and the reduction in demand for CpG 1018 adjuvant reflected in the Clover Supply Agreement, as amended (See Note 9).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b"
      decimals="-6"
      id="F_85a913c6-0868-4105-94cb-38f84d20f02f"
      unitRef="U_USD">0</us-gaap:InventoryWriteDown>
    <dvax:InventoryWriteOffsRecognized
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-5"
      id="F_1aa11362-c345-4a82-8c4d-5766e25659bc"
      unitRef="U_USD">34300000</dvax:InventoryWriteOffsRecognized>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_ad7e97a3-dc76-4701-adbf-b287c09f6ded">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized, while repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We evaluate the carrying value of long-lived assets, whenever events or changes in business circumstances or our planned use of long-lived assets indicate, based on undiscounted future operating cash flows, that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. When an indicator of impairment exists, undiscounted future operating cash flows of long-lived assets are compared to their respective carrying value. If the carrying value is greater than the undiscounted future operating cash flows of long-lived assets, the long-lived assets are written down to their respective fair values and an impairment loss is recorded. Fair value is determined primarily using the discounted cash flows expected to be generated from the use of assets. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. There have been no material adjustments to these estimates during the years presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_9cfd5e2f-5437-45c7-8749-275c4d352e7d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We determine if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset, and whether we have the right to control the identified asset. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, other current liabilities and long-term portion of lease liabilities in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. The classification of our leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of ROU assets and lease liabilities is based on the present value of future lease payments over the lease term. The ROU asset also includes the effect of any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As the implicit rate in our leases is generally unknown, we use our incremental borrowing rate based on information available at the lease commencement date in determining the present value of future lease payments. We consider our credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary, when calculating our incremental borrowing rate. The lease terms may include options to extend or terminate the lease when it is reasonably certain we will exercise any such options. Rent expense for our operating leases is recognized on a straight-line basis over the lease term. Variable lease payments are recorded as an expense in the period incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have elected not to apply the recognition requirements of Accounting Standards Codification ASC 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases ("ASC 842")&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, for short-term leases. We have also elected the practical expedient to not separate lease components from non-lease components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As lessors, we determine if an arrangement includes a lease at inception. We elected the practical expedient to not separate lease components from non-lease components. Sublease income is recognized on a straight-line basis over the expected lease term and is included in other income (expense) in our consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_6cfc3206-3a92-4f90-9093-65804495faa8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill represents the excess purchase price over the fair value of tangible and intangible assets acquired and liabilities assumed. Our goodwill balance relates to our acquisition of Dynavax GmbH in 2006. Goodwill is not amortized, but instead is reviewed for impairment test at least annually, or more frequently if events occur or circumstances change that would indicate the carrying amount may be impaired. Goodwill is assigned to, and impairment testing is performed at, the reporting unit level. We determined that we have only &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment and there are no components of that operating segment that are deemed to be separate reporting units, such that we have one reporting unit for purposes of our goodwill impairment testing. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment has been identified for the years presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="0"
      id="F_3e902699-e288-4acf-aa4b-20d6a7b9d9b1"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_f766ce33-050e-4f92-9d7f-82b4e7f64b1c"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DebtPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_35a0265e-3a5b-4c7a-98db-fbe8114d21a4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Convertible Notes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We account for our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% convertible senior notes due in 2026 (&#x201c;Convertible Notes&#x201d;), as a long-term liability equal to the proceeds received from issuance, including the embedded conversion feature, net of the unamortized debt issuance and offering costs on the consolidated balance sheets (See Note 10). We evaluate all conversion, repurchase and redemption features contained in a debt instrument to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is not required to be accounted for separately as an embedded derivative. We amortize debt issuance and offering costs over the contractual term of the Convertible Notes, using the effective interest method, as interest expense on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39"
      decimals="4"
      id="F_6e699c69-5606-481d-9f77-e0f3217c5659"
      unitRef="U_pure">0.025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <dvax:CappedCallsPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_3c815413-5855-4836-9898-cac4c412b46e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Capped Calls&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We evaluate financial instruments under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging ("ASC 815")&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The capped calls purchased in connection with the Convertible Notes financing ("Capped Calls") cover the same number of shares of common stock that initially underlie the Convertible Notes (subject to anti-dilution and certain other adjustments). The Capped Calls meet the definition of derivative under ASC 815. In addition, the Capped Calls meet the conditions in ASC 815 to be classified in stockholders&#x2019; equity and are not subsequently remeasured as long as the conditions for the equity classification continue to be met.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dvax:CappedCallsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_6a4c47d3-1ddd-4197-b72d-17310a1cc9c8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration, which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers ("ASC 606")&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, we apply the following five step model:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;identify the performance obligation(s) in the contract;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;allocate the transaction price to the performance obligation(s) in the contract; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;recognize revenue when (or as) we satisfy a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Product Revenue, Net &#x2013; HEPLISAV-B&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We sell HEPLISAV-B to a limited number of wholesalers and specialty distributors in the U.S. (collectively, our &#x201c;Customers&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product upon delivery to the Customer. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Because our standard credit terms are short-term and we expect to receive payment in less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there is no significant financing component on the related receivables. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. Since our performance obligation is part of a contract that has an original expected duration of one year or less, we elect not to disclose the information about our remaining performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Overall, product revenue, net - HEPLISAV-B, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration such as product returns, chargebacks, discounts, rebates and other fees that are offered within contracts between us and our Customers, healthcare providers, pharmacies and others relating to our product sales. We estimate variable consideration using either the most likely amount method or the expected value method, depending on the type of variable consideration and what method better predicts the amount of consideration we expect to receive. We take into consideration relevant factors such as industry data, current contractual terms, available information about Customers&#x2019; inventory, resale and chargeback data and forecasted customer buying and payment patterns, in estimating each variable consideration. The variable consideration is recorded at the time product sales is recognized, resulting in a reduction in product revenue and a reduction in accounts receivable (if the Customer offsets the amount against its accounts receivable) or as an accrued liability (if we pay the amount through our accounts payable process). Variable consideration requires significant estimates, judgment and information obtained from external sources. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. If we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of revenue that we report in a particular period. We evaluate our estimates of variable considerations including, but not limited to, product returns, chargebacks and rebates, periodically or when there is an event or change in circumstances that may indicate that our estimates may change.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Product Returns:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Consistent with industry practice, we offer our Customers a limited right of return based on the product&#x2019;s expiration date for product that has been purchased from us. We estimate the amount of our product sales that may be returned by our Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We consider several factors in the estimation of potential product returns including expiration dates of the product shipped, the limited product return rights, available information about Customers&#x2019; inventory and other relevant factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Our Customers subsequently resell our product to healthcare providers, pharmacies and others. In addition to distribution agreements with Customers, we enter into arrangements with qualified healthcare providers that provide for chargebacks and discounts with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by Customers, and we issue credits for such amounts generally within a few weeks of the Customer&#x2019;s notification to us of the resale. Reserves for chargebacks consists of credits that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect will be sold to the qualified healthcare providers, and chargebacks for units that our Customers have sold to the qualified healthcare providers, but for which credits have not been issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Trade Discounts and Allowances:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; We provide our Customers with discounts which include early payment incentives that are explicitly stated in our contracts, and are recorded as a reduction of revenue in the period the related product revenue is recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Distribution Fees: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Distribution fees include fees paid to certain Customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Rebates: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under certain contracts, Customers may obtain rebates for purchasing minimum volumes of our product. We estimate these rebates based upon the expected purchases and the contractual rebate rate and record this estimate as a reduction in revenue in the period the related revenue is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Product Revenue, Net &#x2013; CpG 1018 Adjuvant&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We also sell our innovative adjuvant, CpG 1018 adjuvant, to our collaboration partners for use in their development and/or commercialization of COVID-19 vaccine. We have determined that our collaboration partners meet the definition of Customers under ASC 606. Therefore, we accounted for our CpG 1018 adjuvant sales under ASC 606. Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product to the customer. Because the timing between the recognition of revenue for product sales and the receipt of payment is less than one year, there is no significant financing component on the related receivables. Since our performance obligation is part of a contract that has an original expected duration of one year or less, we elect not to disclose the information about our remaining performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Overall, product revenue, net - CpG 1018 adjuvant, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. Our CpG 1018 adjuvant customers have purchased a significant quantity of CpG 1018 adjuvant as part of their initial COVID-19 vaccine development inventory. Accordingly, we did not recognize CpG 1018 adjuvant net product revenue during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other revenue includes revenue from our agreement with the DoD, collaboration and manufacturing service revenue. We have entered into grant agreements, collaborative arrangements and arrangements to provide manufacturing services to other companies. Such arrangements may include promises to customers which, if capable of being distinct, are accounted for as separate performance obligations. For agreements with multiple performance obligations, we allocate estimated revenue to each performance obligation at contract inception based on the estimated transaction price of each performance obligation. Revenue allocated to each performance obligation is then recognized when we satisfy the performance obligation by transferring control of the promised good or service to the customer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <dvax:ContractWithCustomersExpectedPeriodOfPaymentToBeReceived
      contextRef="C_c4bb7def-af41-4d15-8eda-59023addc137"
      id="F_896ef656-0b9b-4bce-9e3d-9128f06d7d5c">P1Y</dvax:ContractWithCustomersExpectedPeriodOfPaymentToBeReceived>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_caa5adee-7514-44e8-aeef-e2d5dc493058">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and Development Expenses and Accruals&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We contract with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. Our accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. We may terminate these contracts upon written notice and we are generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances we may be further responsible for termination fees and penalties. We estimate research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to us at that time. There have been no material adjustments to the prior period accrued estimates for clinical trial activities during the years presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_a7d191ec-a5df-4fe8-9877-89e0b2188648">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense for restricted stock units ("RSUs"), market-based performance stock units ("PSUs") and stock options is estimated at the grant date based on the award&#x2019;s estimated fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For awards that vest based on service conditions and market conditions, we use a straight-line method to recognize compensation expense over the award&#x2019;s requisite service period, assuming estimated forfeiture rates. For awards that contain performance conditions, we determine the appropriate amount to expense at each reporting date based on the anticipated achievement of performance targets, which requires judgement, including forecasting the achievement of future specified targets. At the date performance conditions are determined to be probable of achievement, we record a cumulative expense catch-up, with remaining expense amortized over the remaining service period. Throughout the performance period, we re-assesses the estimated performance and updates the number of performance-based awards that we believe will ultimately vest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value of RSUs is determined at the date of grant using our closing stock price, with the exception of PSUs, which are measured using the Monte Carlo simulation method on the date of grant. Our determination of the fair value of stock options on the date of grant using an option-pricing model is affected by our stock price, as well as assumptions regarding a number of subjective variables. We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value-based measurement of our stock options. The Black-Scholes model requires the use of subjective assumptions, which determine the fair value-based measurement of stock options. These assumptions include, but are not limited to, our expected stock price volatility over the term of the awards, and projected employee stock option exercise behaviors. In the future, as additional empirical evidence regarding these input estimates becomes available, we may change or refine our approach of deriving these input estimates. These changes could impact our fair value of stock options granted in the future. Changes in the fair value of stock awards could materially impact our operating results.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby increasing stock-based compensation expense recognized in future periods. We derive the expected term assumption primarily based on our historical settlement experience, while considering options that have not yet completed a full life cycle. Stock-based compensation expense is recognized only for awards ultimately expected to vest. Our estimate of the forfeiture rate is based primarily on our historical experience. To the extent we revise this estimate in the future, our share-based compensation expense could be materially impacted in the period of revision. There have been no material adjustments to these estimates during the years presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_c514c4e2-ba57-443e-8214-5efdfc19cfad">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Tax law and rate changes are reflected in income in the period such changes are enacted. We include interest and penalties related to income taxes, including unrecognized tax benefits, within income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. We continually assess the likelihood and amount of potential adjustments and adjust the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and the valuation allowance recorded against our net deferred tax assets. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on all available evidence, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, we believe that recognition of the deferred tax assets arising from future tax benefits is currently not more likely than not to be realized and, accordingly, we have determined a need for a full valuation allowance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_3535d33b-9f16-4ddf-a2c9-c35918433e9e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Standards Update 2016-13&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which was codified in Accounting Standards Codification ASC 326, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments &#x2014; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. Because we were a smaller reporting company based on the most recent determination as of November 15, 2019, ASC 326 became effective for us for fiscal years beginning after December 15, 2022. As such, we adopted ASC 326 effective January 1, 2023, utilizing the modified retrospective transition method. Upon adoption, we updated our impairment model to utilize a forward-looking current expected credit losses (&#x201c;CECL&#x201d;) model in place of the incurred loss methodology for financial instruments measured at amortized cost, primarily including our accounts receivable and contract asset. In relation to AFS debt securities, the guidance eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment, and instead focuses on determining whether any impairment is a result of a credit loss or other factors. The adoption of ASC 326 did not have a material impact on our consolidated financial statements as of the adoption date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_b9983625-3c54-4c92-8b4e-8c78c52d6ad9">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We measure fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs, such as quoted prices in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. There wer&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ransfers between Level 1, 2 and 3 during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of cash equivalents, accounts and other receivables, accounts payable and accrued liabilities are considered reasonable estimates of their respective fair value because of their short-term nature.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.95%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.158000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.778%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.778%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.778%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;&#160;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;599,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;731,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;&#160;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;422,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;594,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;U.S. treasuries, U.S. government agency securities and corporate debt securities are measured at fair value using Level 2 inputs. We review trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants were issued in connection with the underwritten public offering in August 2019 and are accounted for as a derivative liability at fair value (See Note 14). The fair value of the warrant liability was estimated using the Black-Scholes model, which requires assumptions such as expected term, expected volatility and risk-free interest rate. These assumptions are subjective and require judgment to develop. Expected term is estimated using the full remaining contractual term of the warrants. We determine expected volatility based on our historical common stock price volatility. The warrant liability was classified as a Level 3 instrument as its value was based on unobservable inputs that are supported by little or no market activity. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, all &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,882,600&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the outstanding warrants as of December 31, 2021 have been exercised or expired.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a summary of changes in the fair value warrant liability for year ended December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Decrease in fair value of warrants exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants exercised or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_e9d3c176-1d6a-47df-ab87-1f727d3bb84c"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_7e87ff1b-9bf1-4605-a521-eb01e334528d"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_b8c56202-efdd-49e6-9470-6d4dce7da0ed">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.95%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.158000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.778%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.778%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.778%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;&#160;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;308,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;599,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;731,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;&#160;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;422,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;594,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_53c34584-541c-4321-ab58-9d0fe2f1fd0b"
      decimals="-3"
      id="F_b83b7f68-a7e5-4dc5-9a59-c51dcb4e7a8b"
      unitRef="U_USD">131635000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5cff3f8b-5d8e-4085-91dc-8a1a4395f4c3"
      decimals="-3"
      id="F_ebb88ffa-cd21-4179-bf9e-62abd8fcdc90"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b40fc463-936b-4ff9-a706-0dc8d375ef2e"
      decimals="-3"
      id="F_ee8d18d4-04f3-4abc-8a1c-9f0fcc7211d3"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_41d532a7-2bee-4d4a-a774-19c130efe064"
      decimals="-3"
      id="F_5449900e-81e7-4182-a074-f63222ba9636"
      unitRef="U_USD">131635000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c48f9ef2-11f3-4b36-9b5a-e093eb35a836"
      decimals="-3"
      id="F_b6789f89-c77d-4e6d-a531-a86dcf3f4540"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d33fabd0-98d3-439e-b8a4-3bba01fe695a"
      decimals="-3"
      id="F_2ed50efc-d91b-4df4-9966-d21f071be9c9"
      unitRef="U_USD">74237000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4272aeb3-6074-4246-8638-d6db1157f771"
      decimals="-3"
      id="F_21bd8c26-d2ba-4d71-86de-1d2bbaccf200"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3e7a4e28-ee23-4846-846a-acac7d54f31f"
      decimals="-3"
      id="F_04da058d-dc04-4591-8abe-fe1ed3579a97"
      unitRef="U_USD">74237000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_29ad1ccd-24bd-4275-9420-8e03c7809a91"
      decimals="-3"
      id="F_5818d790-cab7-4a09-8eec-d3c01245db83"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5136ab72-32fb-4b8a-a285-f65c7aae72f7"
      decimals="-3"
      id="F_00eec5ac-02d1-43f4-b209-152b2ca14cd2"
      unitRef="U_USD">216688000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_faa950c0-0245-4bdf-aa7b-50e9c38ec395"
      decimals="-3"
      id="F_a27f7e97-900d-4ab4-895e-a4c96fb728f3"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_56114482-df3d-4e07-a8de-d386532d7a4e"
      decimals="-3"
      id="F_c29eba1c-4ff4-40a8-bc80-e82390c7fe41"
      unitRef="U_USD">216688000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f9937706-ff8e-4688-b5fb-817ee1b77e6f"
      decimals="-3"
      id="F_7e7f139b-2669-493a-92e7-c83bfaa957eb"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d17521b7-e208-42c4-b34d-99bc5b411173"
      decimals="-3"
      id="F_4e24a6f9-7025-4b35-9c60-7ef8f17b7f93"
      unitRef="U_USD">308552000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e0bdb5c9-6635-4822-a0d4-b057bdc6bf7c"
      decimals="-3"
      id="F_f910674e-08cf-4225-a9d4-9bdd368b830f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a0b842a8-48c1-4246-8a13-5bc899141fe0"
      decimals="-3"
      id="F_974612e8-e627-47cd-8d44-8f1a93fef723"
      unitRef="U_USD">308552000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1790227d-10fa-4cab-abdb-eb0e7d848a20"
      decimals="-3"
      id="F_332b2455-00e0-4b5f-a9f0-8ac8058df2ed"
      unitRef="U_USD">131635000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c3753588-e357-4568-8f96-aac287465012"
      decimals="-3"
      id="F_fe162389-2a0b-4772-998c-9386863f15af"
      unitRef="U_USD">599477000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_618e0bb6-70e6-4ad8-a103-f5bc6b7f8d80"
      decimals="-3"
      id="F_a01dbfe4-d337-40ea-867d-ae6e486aeea4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a02082a3-bcf6-4470-924c-b963a2bcd1c3"
      decimals="-3"
      id="F_eb4d3781-1505-4b55-9682-b9827a6c9f2d"
      unitRef="U_USD">731112000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f81a00fa-c973-4197-b3a1-e0cc4a36b149"
      decimals="-3"
      id="F_14ffe9e8-43b4-4a6d-8b7b-236b4791b4b9"
      unitRef="U_USD">172418000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4324081c-f2df-428f-82a0-7b99f17493ca"
      decimals="-3"
      id="F_011aef8f-5b81-4c2d-b2f5-5ba44e8173df"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7acdd60a-63f0-4280-9662-6e8d7e0e625f"
      decimals="-3"
      id="F_b0f3d19b-79eb-4459-bf7b-7b658a4bdaf7"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c7c94b74-9da6-4908-b131-d871909fbeb3"
      decimals="-3"
      id="F_8901376f-99df-4208-80e8-76b42b022f0c"
      unitRef="U_USD">172418000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_970dc7a0-06ce-4b4c-a6b1-53363f517586"
      decimals="-3"
      id="F_5622b300-69cd-4bf1-aa3c-f21c931ac3aa"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_08fff746-9f3a-44ee-9a05-fcd200656170"
      decimals="-3"
      id="F_9e532da6-20c9-41dc-9b2b-76d474ce2987"
      unitRef="U_USD">42308000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ccc907f7-07b3-4485-bad7-b638c7661924"
      decimals="-3"
      id="F_a322d2e8-7b03-45d8-ab9c-fe51c09dcc3b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b671bf2b-5135-415b-beb9-c44190ad1450"
      decimals="-3"
      id="F_001db223-1463-42d8-ade4-f41e3d33d23c"
      unitRef="U_USD">42308000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4811b6ec-afc2-4141-bee4-2808586bc8f3"
      decimals="-3"
      id="F_643e67b7-1174-4d3f-b567-add073d7480c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a8317906-5e1f-4330-9194-db9aef7be671"
      decimals="-3"
      id="F_36be900f-4f61-46d6-9938-7a60ce1d1792"
      unitRef="U_USD">88032000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e83edc5d-57bf-4f45-8c00-a78bad8a160f"
      decimals="-3"
      id="F_9bca8bbf-d718-4223-8223-9593dbe9ac27"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_712b1a93-fff4-4b0c-8c9b-e29381d7d61f"
      decimals="-3"
      id="F_4550a2dc-38b1-4589-9409-6a72ce2dfecf"
      unitRef="U_USD">88032000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0ae2c12d-5812-46ba-bc06-5eb199a307cf"
      decimals="-3"
      id="F_162dcbc5-1f7d-4a4e-86fb-02488fc771a8"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_448dc083-473d-475c-ad68-1d927557d2eb"
      decimals="-3"
      id="F_ebc15a47-40ec-47fa-8204-7186612f3f0a"
      unitRef="U_USD">292051000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a7463f82-87b8-4f1d-9935-b4868bc5cd26"
      decimals="-3"
      id="F_0808a2b4-22b8-4fd1-87ab-5ad184c1a0ed"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7b4b7402-722d-4537-a94a-f71d88ccd9c6"
      decimals="-3"
      id="F_be85d614-21c0-4931-82fd-8a8d78503072"
      unitRef="U_USD">292051000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_82eb336f-5756-41e1-8639-c454abdcbaaa"
      decimals="-3"
      id="F_94b1c97e-d366-41e4-9858-8113a9451266"
      unitRef="U_USD">172418000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ebe94c6f-4531-439d-ab70-697744f5951a"
      decimals="-3"
      id="F_0f1d759c-b887-4680-bcc8-36da0c3f58ee"
      unitRef="U_USD">422391000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1b3ae74c-64c3-410c-a990-9b1b3a879aef"
      decimals="-3"
      id="F_6a87ceee-e9c3-4c7c-bc67-7b26f51f99f6"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e101de03-ed18-4895-96b6-d6251ed99d3b"
      decimals="-3"
      id="F_3152688a-076a-49a6-aaef-c0d5d0040468"
      unitRef="U_USD">594809000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_4ac1d460-1347-453f-a512-bbc25081089d"
      decimals="-3"
      id="F_b983bcf6-17f4-41b5-8aff-fcb7c66191df"
      unitRef="U_shares">1882600000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_bbdb4f96-4887-4e48-ab10-35cd4b3abe02">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a summary of changes in the fair value warrant liability for year ended December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Decrease in fair value of warrants exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants exercised or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_21f845e6-44c3-401e-bfcd-a9d88abc20b3"
      decimals="-3"
      id="F_e4b83d90-a565-4f15-8663-adf6cdaaf585"
      unitRef="U_USD">18016000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <dvax:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease
      contextRef="C_25c9967d-9381-4ce1-aec3-a06102b373ce"
      decimals="-3"
      id="F_76adfd46-87c1-442e-8c3b-39d4f3eba413"
      unitRef="U_USD">-1801000</dvax:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodDecrease>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_25c9967d-9381-4ce1-aec3-a06102b373ce"
      decimals="-3"
      id="F_dea01024-8698-4407-8d9f-eec8d1c80ef6"
      unitRef="U_USD">16215000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_4ac1d460-1347-453f-a512-bbc25081089d"
      decimals="-3"
      id="F_d120f14e-2e13-495b-b803-cffcf063a8e1"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_34fd003d-2516-4024-9aa2-5e7ccb050eeb">&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and Cash Equivalents, Restricted Cash and Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.151%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;436,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents, and restricted cash shown in the&lt;br/&gt;&#160;&#160;&#160;consolidated statements of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;436,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted cash is included in "Other assets" in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash balances relate to certificates of deposit issued as collateral to certain letters of credit issued as security to our lease arrangements (See Note 8).&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents, and marketable securities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities available-for-sale:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;301,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities available-for-sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;592,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents, and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;741,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;742,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities available-for-sale:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities available-for-sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;422,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents, and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;625,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;624,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The maturities of our marketable securities available-for-sale are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Mature in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;440,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;440,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Mature after one year through two years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;151,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;151,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;592,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities. Unrealized losses are included in accumulated other comprehensive loss in stockholders&#x2019; equity. Commencing with our adoption of ASC 326 on January 1, 2023, we determine whether a decline in the fair value of our AFS debt securities below their amortized cost basis (i.e., an impairment) is due to credit-related factors or noncredit-related factors. Any impairment that is not credit related is recognized in other comprehensive income (loss), net of applicable taxes. Credit-related impairments (if any) are recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Both the allowance and the adjustment to net income can be reversed if conditions change.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There we&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;re &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; realized gains &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or losses from the sale of marketable securities for the years ended December 31, 2023 and 2022. We do not intend to sell, and are not required to sell, the investments that are in an unrealized loss position before recovery of their amortized cost basis. For the year ended December 31, 2023, we did not record an allowance for credit losses, as management believes any such losses would be immaterial based on the investment-grade credit rating for each of the investments as of December 31, 2023. As such, there have been no declines in fair value that have been identified as a credit-related impairment.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <dvax:ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_643bd8d9-157b-4c06-955f-d135f97d07bb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.151%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;436,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents, and restricted cash shown in the&lt;br/&gt;&#160;&#160;&#160;consolidated statements of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;436,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted cash is included in "Other assets" in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;</dvax:ReconciliationOfCashCashEquivalentsAndRestrictedCashToStatementOfCashFlowsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_43d8f1ef-4a67-41b2-b89c-0cccf1c3d45b"
      unitRef="U_USD">150279000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_169673aa-da63-49a1-bb79-3f15bf8a4640"
      unitRef="U_USD">202004000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d"
      decimals="-3"
      id="F_d42e8a3b-315c-4433-a6d8-7f9c3c1b9ed0"
      unitRef="U_USD">436189000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_030a5d8c-7c33-4a59-ba90-6103938eb1ce"
      unitRef="U_USD">277000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_cb64a042-6b38-4867-8734-d0eb22b365cc"
      unitRef="U_USD">207000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d"
      decimals="-3"
      id="F_3e2c2b77-11ae-45d6-a4ff-5efa14a8a961"
      unitRef="U_USD">219000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_92f87019-6f49-455c-b772-766e663631f4"
      unitRef="U_USD">150556000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_7d1b3949-60e7-4746-9a4c-398c200041ca"
      unitRef="U_USD">202211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d"
      decimals="-3"
      id="F_00edcfc5-799f-43ff-a2c4-8f62af551cc6"
      unitRef="U_USD">436408000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_58d4f3ac-d5cf-48cc-a40a-c15b3de0920f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents, and marketable securities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities available-for-sale:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;301,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities available-for-sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;592,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents, and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;741,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;742,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities available-for-sale:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities available-for-sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;422,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents, and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;625,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;624,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_affe35a2-f489-4bea-a377-a5366608b680"
      decimals="-3"
      id="F_7f3d8255-d5e3-41a8-bd1f-285ddae17d2f"
      unitRef="U_USD">11190000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_bdafacc4-ce23-4518-be33-853c6f2b2e35"
      decimals="-3"
      id="F_5f7c7554-e5f1-4e2f-8ddf-3fed0eed28c5"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_bdafacc4-ce23-4518-be33-853c6f2b2e35"
      decimals="-3"
      id="F_506ef04d-3a74-4541-9eb3-aecd0a108267"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_affe35a2-f489-4bea-a377-a5366608b680"
      decimals="-3"
      id="F_6c0f4179-2ad8-4a0e-ba7c-8bf6dfdc18b7"
      unitRef="U_USD">11190000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_087bb460-7784-4ea1-8991-e6e00539b1cb"
      decimals="-3"
      id="F_0beb4886-04a5-4eab-b105-6174cb5a20d4"
      unitRef="U_USD">131635000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_a9ce0868-3fca-4734-adae-586106f4f8d7"
      decimals="-3"
      id="F_031a0a54-5a72-4099-8e35-3fa1a40eaa7a"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_a9ce0868-3fca-4734-adae-586106f4f8d7"
      decimals="-3"
      id="F_62b881a7-c2f7-4702-b0d9-faafb9ee554e"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_087bb460-7784-4ea1-8991-e6e00539b1cb"
      decimals="-3"
      id="F_fbabef95-8540-4836-9b7a-9a85b5ff89b2"
      unitRef="U_USD">131635000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a49cd4e9-42d6-4cad-96d6-a2965e333846"
      decimals="-3"
      id="F_af7c9cf1-574d-4549-a777-37770d024016"
      unitRef="U_USD">7453000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_7e9700d5-220a-480f-9422-65d949c449a0"
      decimals="-3"
      id="F_30c654a9-3eb0-4db1-a3e0-564713cdbb2f"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_7e9700d5-220a-480f-9422-65d949c449a0"
      decimals="-3"
      id="F_77394937-fef4-4ded-b99f-d547d7048838"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a49cd4e9-42d6-4cad-96d6-a2965e333846"
      decimals="-3"
      id="F_92d408b6-1f9c-41bc-9ea7-456ac812f7b0"
      unitRef="U_USD">7454000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_876b9f96-bdb9-42b7-883d-e9aed3b08eb2"
      decimals="-3"
      id="F_f73f185d-14fc-41e7-b5d9-1cdc2910a201"
      unitRef="U_USD">150278000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_72b2baa2-131f-4929-818e-a53fbd5d4d42"
      decimals="-3"
      id="F_12f877d1-25a1-441e-9937-3ebe162d7c0a"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_72b2baa2-131f-4929-818e-a53fbd5d4d42"
      decimals="-3"
      id="F_f1e540e3-ab1d-44aa-944b-06ae58080cb0"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_876b9f96-bdb9-42b7-883d-e9aed3b08eb2"
      decimals="-3"
      id="F_b60a0462-69a9-4624-bd00-1523a9ec7573"
      unitRef="U_USD">150279000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_bc8ddedc-d903-4ea8-884d-cff004170dad"
      decimals="-3"
      id="F_ac866117-df69-4a78-9a43-a8cedd325d2a"
      unitRef="U_USD">74109000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_721a703d-dac9-4278-b357-e4756d07b6a8"
      decimals="-3"
      id="F_05670f00-af66-4d60-a0bd-1dd6861ca014"
      unitRef="U_USD">172000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_721a703d-dac9-4278-b357-e4756d07b6a8"
      decimals="-3"
      id="F_56559484-7322-4ad8-a890-5fbb3b02eaff"
      unitRef="U_USD">44000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bc8ddedc-d903-4ea8-884d-cff004170dad"
      decimals="-3"
      id="F_767301ac-1735-4fc4-b571-c88fab7f81fe"
      unitRef="U_USD">74237000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f400d9db-46ac-46b2-b217-0a803cda715f"
      decimals="-3"
      id="F_41584850-8057-45f1-8b42-976d999f034a"
      unitRef="U_USD">216265000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_e1eda147-6a7d-43bb-8a22-8d62411d3073"
      decimals="-3"
      id="F_a68d01ca-25f8-41bd-b96d-6e7a5b81c125"
      unitRef="U_USD">692000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_e1eda147-6a7d-43bb-8a22-8d62411d3073"
      decimals="-3"
      id="F_6ef08e25-948c-45bb-9f6a-6f4f22b8e38c"
      unitRef="U_USD">269000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f400d9db-46ac-46b2-b217-0a803cda715f"
      decimals="-3"
      id="F_2c1a7223-3b96-43d2-aa7a-3bf1e5f492bc"
      unitRef="U_USD">216688000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a78eb8f1-5744-4979-8db7-230dc51613bc"
      decimals="-3"
      id="F_449e9142-1838-4023-913e-3a9df453f320"
      unitRef="U_USD">300803000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_a1a8ccc2-b5c3-4443-91b6-3ade9ce8f4e8"
      decimals="-3"
      id="F_ed9e4491-83f8-47dd-a659-3c9d7624ac8c"
      unitRef="U_USD">315000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_a1a8ccc2-b5c3-4443-91b6-3ade9ce8f4e8"
      decimals="-3"
      id="F_312b5524-5559-4f20-8a4b-a86bea0e55bf"
      unitRef="U_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a78eb8f1-5744-4979-8db7-230dc51613bc"
      decimals="-3"
      id="F_64f17348-5234-4601-9ef0-6524dc184d5d"
      unitRef="U_USD">301098000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_333f7989-91c9-45d9-a30d-059fd745363e"
      decimals="-3"
      id="F_feaf8e2a-8833-4419-885a-e0220e0b0ffc"
      unitRef="U_USD">591177000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_709c2910-32d1-45cb-9204-ef2070cb1241"
      decimals="-3"
      id="F_6d56f60d-1cad-4f35-a242-c34474beb101"
      unitRef="U_USD">1179000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_709c2910-32d1-45cb-9204-ef2070cb1241"
      decimals="-3"
      id="F_06526488-a463-48d9-9727-f29ba7f59658"
      unitRef="U_USD">333000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_333f7989-91c9-45d9-a30d-059fd745363e"
      decimals="-3"
      id="F_d29f871e-f7be-4bbb-aac0-ca41a01b0285"
      unitRef="U_USD">592023000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_af9c3a6e-6e11-44bc-ad28-b459d2203fed"
      decimals="-3"
      id="F_71851e65-deee-491c-8da6-9bfe59530b90"
      unitRef="U_USD">741455000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_80741f76-5a9d-474f-ac4c-18ba54f8364e"
      decimals="-3"
      id="F_6ed60859-bc04-4e9a-98c2-45c0800e4c49"
      unitRef="U_USD">1180000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_80741f76-5a9d-474f-ac4c-18ba54f8364e"
      decimals="-3"
      id="F_65d50376-e011-471e-a53e-9d393ac821d9"
      unitRef="U_USD">333000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_af9c3a6e-6e11-44bc-ad28-b459d2203fed"
      decimals="-3"
      id="F_e6ae52af-3f54-4b30-ac42-860ade855870"
      unitRef="U_USD">742302000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1aaf5950-6ea9-46e6-a2da-ed62c66484da"
      decimals="-3"
      id="F_3ec13a1a-fab3-40bf-b39e-fa1db9692fd0"
      unitRef="U_USD">29586000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_c82b1535-2190-4e2c-8859-50ce0d536831"
      decimals="-3"
      id="F_da54830f-a69d-4c73-b962-7c8854b8fb0c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_c82b1535-2190-4e2c-8859-50ce0d536831"
      decimals="-3"
      id="F_80d57ebd-d8c7-4be2-ad67-02e0915186db"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1aaf5950-6ea9-46e6-a2da-ed62c66484da"
      decimals="-3"
      id="F_ba1568a1-d73a-4738-99a9-c9d08793c0e4"
      unitRef="U_USD">29586000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9d5090c3-cf85-4395-8b36-a4feb0cf89ba"
      decimals="-3"
      id="F_269992a2-0be3-438b-abae-48d79d5ee53c"
      unitRef="U_USD">172418000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_06216486-f415-476b-92e9-c173c38795fe"
      decimals="-3"
      id="F_691a6cf8-5551-4ad5-8779-df28e0f15a40"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_06216486-f415-476b-92e9-c173c38795fe"
      decimals="-3"
      id="F_fd3c82f1-5d09-4a4b-88ce-d5a34a96db36"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9d5090c3-cf85-4395-8b36-a4feb0cf89ba"
      decimals="-3"
      id="F_40b91d9a-34b5-45be-9b43-c46e3784043f"
      unitRef="U_USD">172418000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6081d343-1a70-4d79-938f-b5c367c4a904"
      decimals="-3"
      id="F_1023a14d-063f-4b81-be98-7736c53e3b9c"
      unitRef="U_USD">202004000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_8a2ff8b8-7c89-4242-a4e1-a77b739e4b68"
      decimals="-3"
      id="F_a446cc36-0317-49bc-a0a0-3972eca7c89e"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_8a2ff8b8-7c89-4242-a4e1-a77b739e4b68"
      decimals="-3"
      id="F_11dbd4d2-29b1-4e07-a3f3-6f878d2f8248"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6081d343-1a70-4d79-938f-b5c367c4a904"
      decimals="-3"
      id="F_d298c1e2-c4f4-4539-baaa-3de0b5f449b9"
      unitRef="U_USD">202004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_28ee40ae-f91d-4b89-9194-6b624b4ce391"
      decimals="-3"
      id="F_6ef659c9-dfc9-49fc-8f3d-7ff5b719558d"
      unitRef="U_USD">42502000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_58b0bb3f-bb8e-49d1-a9e2-0615cfa1a595"
      decimals="-3"
      id="F_2ee24111-2cf5-4f35-94c4-6849804f329d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_58b0bb3f-bb8e-49d1-a9e2-0615cfa1a595"
      decimals="-3"
      id="F_a03d677d-d544-45bb-a6c3-797281ee6e6b"
      unitRef="U_USD">194000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_28ee40ae-f91d-4b89-9194-6b624b4ce391"
      decimals="-3"
      id="F_56908a4f-5904-4d45-89a1-1b7d1ab9f16d"
      unitRef="U_USD">42308000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_529c356f-70af-41f9-a631-87c29cdb73e3"
      decimals="-3"
      id="F_3b70ca8f-ca7d-4b14-b107-246d2e7e8736"
      unitRef="U_USD">88429000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_0797703a-9cf9-4f2a-a2ab-e188c2fa6d75"
      decimals="-3"
      id="F_bfb2b925-3146-4953-9deb-faaf7058c675"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_0797703a-9cf9-4f2a-a2ab-e188c2fa6d75"
      decimals="-3"
      id="F_2d888f67-afd3-4ac6-963c-f8febc98192e"
      unitRef="U_USD">397000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_529c356f-70af-41f9-a631-87c29cdb73e3"
      decimals="-3"
      id="F_594bdbe1-9e68-4797-990c-c081ee5130df"
      unitRef="U_USD">88032000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e3e9b8ea-11ad-4a81-b1a0-52ecab46df50"
      decimals="-3"
      id="F_177956a1-dd0e-4511-aa8c-a020e5190e6a"
      unitRef="U_USD">292865000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_7697cec1-5a5c-4cda-96a7-3a7c51da9ed4"
      decimals="-3"
      id="F_5c225516-86b2-49e8-9eab-d3386b9439e6"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_7697cec1-5a5c-4cda-96a7-3a7c51da9ed4"
      decimals="-3"
      id="F_67824ba8-6551-42e4-99e4-50e84805ca92"
      unitRef="U_USD">826000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e3e9b8ea-11ad-4a81-b1a0-52ecab46df50"
      decimals="-3"
      id="F_11198afe-593c-4c14-b556-51cd512b6ca4"
      unitRef="U_USD">292051000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_68391399-2908-490f-99f6-ed291d638344"
      decimals="-3"
      id="F_13124dfc-f68e-4dda-af1f-175da1cc78dc"
      unitRef="U_USD">423796000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_5ca8debb-5a5e-47ec-ac9b-67db2519efb5"
      decimals="-3"
      id="F_a06880ec-ff3b-4984-a4d6-e60d972e0203"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_5ca8debb-5a5e-47ec-ac9b-67db2519efb5"
      decimals="-3"
      id="F_6f4f2b20-88bb-41c6-a64b-a67ce90b5403"
      unitRef="U_USD">1417000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_68391399-2908-490f-99f6-ed291d638344"
      decimals="-3"
      id="F_f734571b-e963-4fd9-b5a1-b1469321ab6a"
      unitRef="U_USD">422391000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9a546293-5326-4ca1-b866-7d58c5fc2258"
      decimals="-3"
      id="F_3c4e8730-5508-47b2-b8b9-908507ec0173"
      unitRef="U_USD">625800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_743ce050-0aa0-47d1-90ac-18e05e613453"
      decimals="-3"
      id="F_985e6a31-676d-4304-a91d-6f809115ff2c"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_743ce050-0aa0-47d1-90ac-18e05e613453"
      decimals="-3"
      id="F_2a892158-3db3-4373-817b-43f83d24d710"
      unitRef="U_USD">1417000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9a546293-5326-4ca1-b866-7d58c5fc2258"
      decimals="-3"
      id="F_630d017b-7a77-45d9-af92-3ddabc9056ab"
      unitRef="U_USD">624395000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <dvax:MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_82889629-83e1-427b-bd79-a7c8dc5a2153">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The maturities of our marketable securities available-for-sale are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Mature in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;440,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;440,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Mature after one year through two years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;151,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;151,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;592,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</dvax:MaturitiesOfMarketableSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_6c846722-2c02-4f92-80cc-783be538ba61"
      unitRef="U_USD">440131000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_ef4b71a7-cd83-47ee-b693-4d54a9b98af1"
      unitRef="U_USD">440104000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_3ff45412-a191-44bd-9cbb-73c32668db68"
      unitRef="U_USD">151046000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_fdf7b02a-17d3-486f-9918-451a63534a62"
      unitRef="U_USD">151919000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_855a865c-ee81-4072-93e7-da6b6a882aa5"
      unitRef="U_USD">591177000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_ebea6bd0-b004-4dab-8e5d-9194c8ec6db9"
      unitRef="U_USD">592023000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_201dbd20-928c-4712-b152-518e2aaa27be"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_cf3fb0d6-5405-4866-a135-7b3aab556e80"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_37272bac-7ffa-45da-97e3-32abac7facd6">&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.13%;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents inventories (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.353%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.302000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.302000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_bf70ef4c-2f47-4be1-965e-199dd0a9a39f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents inventories (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.353%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.302000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.302000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_6b336e82-8c27-4438-b8d2-93e415fde571"
      unitRef="U_USD">27256000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_e60f586d-64bc-4617-ae17-4f1567d9c950"
      unitRef="U_USD">25517000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_6958548d-f074-4852-93a6-ca34b5fe8575"
      unitRef="U_USD">18954000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_9cea0607-f1a8-4a53-b532-2ab1782dffaa"
      unitRef="U_USD">23934000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_6926160b-0ca3-491f-bf3d-958554a27a9e"
      unitRef="U_USD">7080000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_0a17bf29-221c-4cc0-8ded-fe3a9787c555"
      unitRef="U_USD">9995000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_4c551bc2-2d15-4f9d-8748-e9392fab1457"
      unitRef="U_USD">53290000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_3c236a43-e653-44a6-a41a-252c9fee082b"
      unitRef="U_USD">59446000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_38cc9fcc-46b7-42c8-892d-c3f390fc460e">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and Equipment, net &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.65%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.103%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Useful&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Life (In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Manufacturing equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation and amortization expense on property and equipment was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; mil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;lion, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_c17bfaa1-e3ab-4f65-96d2-a6e86a571e0e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.65%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.103%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Useful&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Life (In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Manufacturing equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c882f98c-09ae-4335-9956-04f9b0df4820"
      id="F_e35dde9c-1c91-4584-9739-0403ab8a4257">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_be62f7fb-690c-4474-bca0-b70c2e4a2fe2"
      id="F_babce959-745c-4a72-941d-d91c20b87a12">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_39c69625-4f04-42c3-9e20-bec454705df7"
      unitRef="U_USD">15752000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_da6a3595-889d-46e9-b96c-efc7adcb8e17"
      unitRef="U_USD">15139000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_01905c0f-bf3b-4a9e-aa83-f267ccc52200"
      id="F_11a094e6-c89e-4e53-b663-2addffcb6574">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d63e3291-43c4-4ac8-b139-8fea8704f1a5"
      id="F_4f55c607-b253-42ba-a986-5fe5d5c6ddca">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dvax:LaboratoryEquipmentGross
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_39b5dccf-1c2e-4f16-8e87-59995676808e"
      unitRef="U_USD">2827000</dvax:LaboratoryEquipmentGross>
    <dvax:LaboratoryEquipmentGross
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_20dfee14-4069-49b7-ad79-46bca0fe60b0"
      unitRef="U_USD">2360000</dvax:LaboratoryEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_99635370-1a22-4b6f-b761-e726efa96bc4"
      id="F_a7caa2a7-41a8-4f8d-8b4a-ede8637756e2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dvax:ComputerEquipmentGross
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_0f28e996-5dc0-49c4-ab69-29346e578c98"
      unitRef="U_USD">5060000</dvax:ComputerEquipmentGross>
    <dvax:ComputerEquipmentGross
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_3500051c-6837-4e42-baaa-3efc5a9a6a35"
      unitRef="U_USD">4720000</dvax:ComputerEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_8132c0b8-7437-4b80-a8db-085c7a1df0da"
      id="F_5561cc5d-2cf6-46bc-81a7-348223154892">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_cade9713-0ce0-4b8f-b617-650718d89561"
      id="F_9b195977-02ce-48ea-93ab-9a7ca0787d6d">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_9987b0e4-f2fc-4115-8717-1cd97d279787"
      unitRef="U_USD">2467000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_35f0faff-b1d6-4523-a549-dc3ff30757de"
      unitRef="U_USD">2464000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e8c27e53-0ae1-4e32-8d68-96f7ec110ec2"
      id="F_457d94ef-5c54-4265-be09-bf610c563ac8">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_187a89d5-4a78-4080-82d7-8eeffa21fc7b"
      id="F_8f6a1a85-58a0-4d3e-a497-86ef760598fa">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_d989b889-9e95-486c-91fd-5f98322e1fb1"
      unitRef="U_USD">37201000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_70038340-cad1-4416-9b14-a636e8846e7e"
      unitRef="U_USD">28822000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_c0b86fdc-d1fb-440e-a70e-d0ddd37506cb"
      unitRef="U_USD">5822000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_d121ae63-60cf-42ef-bea3-c36d4329255c"
      unitRef="U_USD">11613000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_a0e91f7d-02b3-4d3c-8d22-7b635c44d81e"
      unitRef="U_USD">69129000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_5604f14d-5a9d-4563-ac0e-96901aa7808e"
      unitRef="U_USD">65118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_716f4247-64ac-4502-be8b-26f259119481"
      unitRef="U_USD">31832000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_65c3d0f8-7e29-4070-bb76-bbb7c79484e6"
      unitRef="U_USD">27522000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_cd4749a1-af80-4128-9fc7-cfa1c22238d7"
      unitRef="U_USD">37297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_14237b7c-2d96-4301-b1c5-0b1f2641b970"
      unitRef="U_USD">37596000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-5"
      id="F_d62963cb-8043-4443-9eba-32006b98137a"
      unitRef="U_USD">4300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-5"
      id="F_15b76caa-8984-4ded-ae11-f831a29fac03"
      unitRef="U_USD">3800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-5"
      id="F_3eea359a-2de7-46cb-a482-106d235713c7"
      unitRef="U_USD">4300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_911ef724-2e00-4ff5-b8c2-2e1348bb1a5d">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Current Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Current accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue reserve accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <dvax:ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_3142627c-d795-4bf1-b53c-386c77325f9f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Current accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue reserve accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</dvax:ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_fd81ec4f-b4f7-41fc-ae0c-4eb9d0d16d77"
      unitRef="U_USD">17069000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_28b1fa17-c3ea-4591-95db-cd85152967ab"
      unitRef="U_USD">14261000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <dvax:RevenueReserveAccrualCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_4011b980-c9ea-4814-acbf-45a395adc080"
      unitRef="U_USD">21004000</dvax:RevenueReserveAccrualCurrent>
    <dvax:RevenueReserveAccrualCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_c51e66b4-adb6-4737-ba97-d144436206a4"
      unitRef="U_USD">10552000</dvax:RevenueReserveAccrualCurrent>
    <dvax:AccruedInventory
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_f0fb5978-bbd1-444f-9c31-16ecec2b7be3"
      unitRef="U_USD">4456000</dvax:AccruedInventory>
    <dvax:AccruedInventory
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_b5a3f9d2-d785-410e-a075-4680b637ec19"
      unitRef="U_USD">2209000</dvax:AccruedInventory>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_f2a3b389-f841-4cc2-8344-0e1ec7fd11d1"
      unitRef="U_USD">6919000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_f8d48fce-3420-42d4-81e1-e7e145a72083"
      unitRef="U_USD">3697000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <dvax:AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_ab12cc20-c63e-411c-9c07-a50201b7e9e0"
      unitRef="U_USD">49448000</dvax:AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent>
    <dvax:AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_da19ced5-ecc5-423c-9483-463ddfbeb7b2"
      unitRef="U_USD">30719000</dvax:AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_623abb4f-83e2-4079-886e-a62506bdd502">&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We lease our facilities in Emeryville, California and D&#xfc;sseldorf, Germany. We lease and sublease certain manufacturing and office space with lease terms ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain of these leases also include options to renew or extend the lease for two successive five-year terms.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; These optional periods have not been considered in the determination of the right-of-use assets or lease liabilities associated with these leases as we did not consider the exercise of these options to be reasonably certain.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We also sublease one of our leased premises to a third party. Rent is subject to scheduled annual increases and the subtenant is responsible for certain operating expenses and taxes throughout the life of the sublease. The sublease term expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, unless earlier terminated, concurrent with the term of our lease. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;subtenant has no option to &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;extend &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the sublease term.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Sublease income wa&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;s $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;illion, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023, 2022 and 2021, respectively. Sublease income is included in other income (expense) in our consolidated statements of operations. Rent received from the subtenant in excess of rent paid to the landlord shall be shared by paying the landlord &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the excess rent. The excess rent is considered a variable lease payment and the total estimated payments are being recognized as additional rent expense on a straight-line basis.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our lease expense comprises of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2023, 2022, and 2021 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively and were included in change in lease liabilities in our consolidated statement of cash flows.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The balance sheet classification of our operating lease liabilities was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_f58b1a95-4b8b-4052-956a-3314f3bd58e1;"&gt;&lt;span style="-sec-ix-hidden:F_92c8237b-9eec-4d96-8dc1-a494a9120777;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;(included in other current liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the maturities of our sublease income and operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Sublease Income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Operating Lease&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, our material non-cancelable purchase and other commitments for the supply of HEPLISAV-B totaled&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;million. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following summarizes our material purchase commitments at December 31, 2023 and the effect those obligations are expected to have on our liquidity and cash flows in future periods (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 7, 2023 (the &#x201c;Effective Date&#x201d;), we entered into an agreement (the &#x201c;Avecia Supply Agreement&#x201d;) with Nitto Denko Avecia Inc. (&#x201c;Avecia&#x201d;) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the &#x201c;2012 Agreement&#x201d;). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, our aggregate minimum commitment for the supply of CpG 1018 adjuvant under the Avecia Supply Agreement was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million within the next 12 months. As of December 31, 2022, w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e had no non-cancelable purchase and other commitments for the supply of CpG 1018 adjuvant&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We also rely on and have entered into agreements with research institutions, contract research organizations and clinical investigators as well as clinical material manufacturers. These agreements are terminable by us upon written notice. Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through the notice period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the aggregate principal amount of our convertible senior notes ("Convertible Notes") was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, excluding debt discount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (See Note 10).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During 2004, we established a letter of credit with Deutsche Bank as security for our D&#xfc;sseldorf lease in the amount of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (Euros). The letter of credit remained outstanding through December 30, 2023 and was collateralized by a certificate of deposit for &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which has been included in restricted cash in the consolidated balance sheets as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;conjunction with our agreement with Symphony Dynamo, Inc. and Symphony Dynamo Holdings LLC (&#x201c;Holdings&#x201d;) in November 2009, we agreed to make contingent cash payments to Holdings equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the first $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any third party with respect to the development and/or commercialization of cancer and hepatitis C therapies originally licensed to Symphony Dynamo, Inc., including our immune-oncology compound, SD-101. In July 2020, we sold assets related to SD-101 to Surefire Medical, Inc. d/b/a TriSalus Life Sciences (&#x201c;TriSalus&#x201d;). We paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to Holdings in August 2020. In each of September 2021, May 2022 and September 2023, we received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from TriSalus because it met pre-commercialization milestones. We recorded the proceeds as gain on sale of assets in our consolidated statements of operations. We paid Holdings $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in each of September 2021, May 2022 and October 2023. We included the payments in selling, general and administrative &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;expenses in our consolidated statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, we may be involved in claims, suits, and proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, commercial claims, and other matters. Such claims, suits, and proceedings are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, such legal proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. In addition, it is possible that a resolution of one or more such proceedings could result in substantial damages, fines, penalties or orders requiring a change in our business practices, which could in the future materially and adversely affect our financial position, results of operations, or cash flows in a particular period.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_a7cdc223-9b33-484b-b064-ffbb1dd743fc"
      id="F_90046f46-632e-4172-a3f3-c10e8b50dfc7">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_b9c3ac11-c1b5-431c-85fe-3a4cce93994b"
      id="F_11376bf6-a4e0-41ac-92f8-1f6fb85772f9">P12Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_02645021-8828-4251-8736-7889f9068d7f"
      id="F_f158626f-455a-45a5-9e56-75891ced6e03">Certain of these leases also include options to renew or extend the lease for two successive five-year terms.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_26a5fbc9-46d3-4e1b-a7a2-b23620d399e2">2031-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingSubleaseOptionToExtend
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_29c5468a-ab65-4413-8cd0-99d18903b4b5">The subtenant has no option to extend the sublease term.</us-gaap:LesseeOperatingSubleaseOptionToExtend>
    <us-gaap:SubleaseIncome
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-5"
      id="F_a4f8a02b-d2ec-42be-98f5-5ae30a82bb65"
      unitRef="U_USD">7600000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-5"
      id="F_e167ae61-9cc8-4617-a9ab-f84f66089c6c"
      unitRef="U_USD">7700000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-5"
      id="F_ec01e53e-1379-4e53-8584-a48fd723048f"
      unitRef="U_USD">7700000</us-gaap:SubleaseIncome>
    <dvax:PercentageOfExcessRentPaidToLandlord
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="2"
      id="F_ec6f94d3-c429-42b4-a199-7150934f235e"
      unitRef="U_pure">0.50</dvax:PercentageOfExcessRentPaidToLandlord>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_1655705a-35ad-42fa-9ae3-72aa7e189a65">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our lease expense comprises of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_393596f9-e841-4cb3-8336-9f5a8af4fb21"
      unitRef="U_USD">5563000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_26a6dce2-c2f5-4b5f-8750-96e3af2ba324"
      unitRef="U_USD">6222000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_c565c625-0184-4133-aafe-fe946c4b15a8"
      unitRef="U_USD">6265000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-5"
      id="F_071ae2a8-bda8-4818-86e5-16cc679a26c5"
      unitRef="U_USD">7200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-5"
      id="F_7ac0cefc-88d3-417c-8116-a0f12ca933cf"
      unitRef="U_USD">6800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-5"
      id="F_9b54c334-55c7-41f4-9e04-45c404c14007"
      unitRef="U_USD">7000000</us-gaap:OperatingLeasePayments>
    <dvax:ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_5943ae73-bb79-4a5f-82ad-463863992c09">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The balance sheet classification of our operating lease liabilities was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_f58b1a95-4b8b-4052-956a-3314f3bd58e1;"&gt;&lt;span style="-sec-ix-hidden:F_92c8237b-9eec-4d96-8dc1-a494a9120777;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;(included in other current liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</dvax:ScheduleOfBalanceSheetComponentsOfOperatingLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_045b22c2-b7a4-4539-bdea-3e316df37913"
      unitRef="U_USD">4496000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_66088b47-da8e-4d9a-b86d-a42f2b4e036d"
      unitRef="U_USD">3631000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_7af77ec8-5204-43c9-bb39-b706e2f15259"
      unitRef="U_USD">29720000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_ff8feb48-15d8-45e1-808e-c96ea297efbf"
      unitRef="U_USD">32801000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_ec142b4b-b620-46d8-80bf-435f115e7e93"
      unitRef="U_USD">34216000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_05c37b38-befd-4322-a386-27995dd962ba"
      unitRef="U_USD">36432000</us-gaap:OperatingLeaseLiability>
    <dvax:SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_7c57d61c-e9ae-42ac-a680-c4b47631223c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the maturities of our sublease income and operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Sublease Income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Operating Lease&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</dvax:SubleaseIncomeAndOperatingLeaseLiabilityMaturityTableTextBlock>
    <dvax:LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_c6406e53-4ebb-48f6-83a8-78d4d53cd2e6"
      unitRef="U_USD">5684000</dvax:LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_b03e54cf-fd70-40d4-9f42-f37831c5b5e5"
      unitRef="U_USD">7605000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_1d0dc83d-94eb-4099-80de-f1b8b8d60e44"
      unitRef="U_USD">5854000</dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_9cd85de5-a12e-433e-b1c1-9a097f3d7a9f"
      unitRef="U_USD">6980000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_1a7f29de-e779-4f74-a5af-04b2626773be"
      unitRef="U_USD">6030000</dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_1a270535-f3e2-46a0-ad18-7e5bec7727ca"
      unitRef="U_USD">6122000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_99d94651-86a9-4b31-9914-a5d68117fc14"
      unitRef="U_USD">6211000</dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_d78d58c2-ffb0-4594-b129-ac6a1304fc89"
      unitRef="U_USD">6052000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_1d4aaed1-2e82-4415-b571-6da9be61ddb0"
      unitRef="U_USD">6397000</dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_60cb9802-6917-4e3e-84db-9cde3810076c"
      unitRef="U_USD">6215000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_b27609ec-fd6a-4f70-a139-ab26740a1972"
      unitRef="U_USD">15103000</dvax:LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_75d23171-9e69-4ef1-9a82-db1eb98bdae9"
      unitRef="U_USD">15062000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <dvax:LessorSubleaseRentalsPaymentsToBeReceivedDue
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_c24c603c-6922-41a7-b2ae-b5d9079eddae"
      unitRef="U_USD">45279000</dvax:LessorSubleaseRentalsPaymentsToBeReceivedDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_a90247bd-5736-4934-a541-04a0707e71a6"
      unitRef="U_USD">48036000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_90236b97-ee52-4142-abf9-634a3ab641d1"
      unitRef="U_USD">13820000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_a1e0237a-8797-4fd3-8ed7-5b776393df54"
      unitRef="U_USD">34216000</us-gaap:OperatingLeaseLiability>
    <dvax:SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_30760b13-2e89-4ad7-9d6a-9fa19844c938">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.7 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</dvax:SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      id="F_5d92fd73-3c84-4fad-b69f-afb7c1c03128">P6Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      id="F_b01dd78f-acaf-4d7f-b384-0326ca9ae057">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="3"
      id="F_65efd3f6-44aa-47e9-8ca1-97c064f8b2a6"
      unitRef="U_pure">0.101</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="3"
      id="F_c608a141-ad95-49f9-94d7-1d63792c4153"
      unitRef="U_pure">0.101</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:PurchaseObligation
      contextRef="C_bc9620c9-1c43-40ea-a14b-d5100d03b2e5"
      decimals="-5"
      id="F_fd21c9b3-d5fb-4d4d-98e4-c7da1454b510"
      unitRef="U_USD">43400000</us-gaap:PurchaseObligation>
    <dvax:ScheduleOfMaterialPurchaseCommitmentsTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_88bfcde2-dfaf-4ba4-a4f8-a7eb09695aca">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following summarizes our material purchase commitments at December 31, 2023 and the effect those obligations are expected to have on our liquidity and cash flows in future periods (in thousands):&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</dvax:ScheduleOfMaterialPurchaseCommitmentsTableTextBlock>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_db713321-2133-4b23-a7f7-f082ef6a49a2"
      unitRef="U_USD">18866000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_c75baef8-68bb-4bb5-90ea-dce647faf104"
      unitRef="U_USD">11983000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_cd770089-1515-426e-8df8-cd0dc7184ec1"
      unitRef="U_USD">12516000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_3e4d726a-d2ba-47fa-aa65-14b2b202407c"
      unitRef="U_USD">0</us-gaap:PurchaseObligationDueInFourthYear>
    <us-gaap:PurchaseObligationDueInFifthYear
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_44937cc6-2a5e-41d9-bc9a-07be4c543920"
      unitRef="U_USD">0</us-gaap:PurchaseObligationDueInFifthYear>
    <us-gaap:PurchaseObligationDueAfterFifthYear
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_40761d86-8b05-493b-a340-55d261b946ac"
      unitRef="U_USD">0</us-gaap:PurchaseObligationDueAfterFifthYear>
    <us-gaap:PurchaseObligation
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_487ad6b8-7a05-4692-a896-adcdb58685e9"
      unitRef="U_USD">43365000</us-gaap:PurchaseObligation>
    <dvax:DescriptionOfAveciaSupplyAgreement
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_6f6acc80-269a-40b4-9cfa-7b6217d64fbd">On September 7, 2023 (the &#x201c;Effective Date&#x201d;), we entered into an agreement (the &#x201c;Avecia Supply Agreement&#x201d;) with Nitto Denko Avecia Inc. (&#x201c;Avecia&#x201d;) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the &#x201c;2012 Agreement&#x201d;). As of December 31, 2023, our aggregate minimum commitment for the supply of CpG 1018 adjuvant under the Avecia Supply Agreement was $7.4 million within the next 12 months. As of December 31, 2022, we had no non-cancelable purchase and other commitments for the supply of CpG 1018 adjuvant.</dvax:DescriptionOfAveciaSupplyAgreement>
    <dvax:AggregateMinimumCommitment
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-5"
      id="F_2162dae1-f825-42c6-8e10-681ac95e1b32"
      unitRef="U_USD">7400000</dvax:AggregateMinimumCommitment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39"
      decimals="-5"
      id="F_ba28f787-ea96-40c4-a60b-c8fa1ffb5e95"
      unitRef="U_USD">225500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39"
      decimals="-5"
      id="F_67b001e0-b62a-43aa-8191-3c31f69e97ea"
      unitRef="U_USD">2800000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="C_a1ba67ff-228c-4a77-8fbc-f341080d81e0"
      decimals="-5"
      id="F_7ee859d6-2c5c-47cd-abd0-2cfa5808415f"
      unitRef="U_EUR">200000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="C_a35251a8-36c2-46bd-be47-03e6fe5c7a03"
      decimals="-5"
      id="F_a6839a99-9db5-4244-a0e2-d733888aeb3b"
      unitRef="U_EUR">200000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="C_a407ebc3-a04a-4922-9be0-f544bb630be4"
      decimals="-5"
      id="F_15c280a3-883f-4d8b-9964-a527b6b6ee0c"
      unitRef="U_EUR">200000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <dvax:LicenseArrangementContingentConsiderationPercentage
      contextRef="C_527a5bef-aec8-4da7-8ad2-8c92c7570a64"
      decimals="2"
      id="F_aee61a21-b111-4fcc-86b8-66a2ae3dfb07"
      unitRef="U_pure">0.50</dvax:LicenseArrangementContingentConsiderationPercentage>
    <dvax:LicenseArrangementContingentPaymentToAcquireLicense
      contextRef="C_6050d5e9-4d2a-42f3-8f76-80e6c68a8a88"
      decimals="-6"
      id="F_fa3a09ac-48bd-4c42-ba52-b68abe0872d3"
      unitRef="U_USD">50000000</dvax:LicenseArrangementContingentPaymentToAcquireLicense>
    <dvax:PaymentToHoldings
      contextRef="C_61dba5ad-822d-4501-bae4-9a20bd0eed27"
      decimals="-5"
      id="F_380f781e-4009-4429-afc3-498947cceb67"
      unitRef="U_USD">2500000</dvax:PaymentToHoldings>
    <dvax:PaymentReceivedForPreCommercializationMilestone
      contextRef="C_7951b5b5-dd53-4f52-b40f-bfff22a01db5"
      decimals="-5"
      id="F_a67901ad-1d82-49ec-a9f4-47f0b85d558e"
      unitRef="U_USD">1000000</dvax:PaymentReceivedForPreCommercializationMilestone>
    <dvax:PaymentReceivedForPreCommercializationMilestone
      contextRef="C_c45b2a41-c8d9-409b-9f76-329e71219be7"
      decimals="-5"
      id="F_69bdef77-b2d8-4325-8f8d-b3181f50684b"
      unitRef="U_USD">1000000</dvax:PaymentReceivedForPreCommercializationMilestone>
    <dvax:PaymentReceivedForPreCommercializationMilestone
      contextRef="C_d7b73016-1aa5-4068-89fc-abd4a56ae044"
      decimals="-5"
      id="F_b8ec34c3-5280-42fe-a3fc-4d5f83a765f0"
      unitRef="U_USD">1000000</dvax:PaymentReceivedForPreCommercializationMilestone>
    <dvax:PaymentMadeForPreCommercializationMilestone
      contextRef="C_29f44f8e-0fe5-45f6-8bba-6cd65b85e586"
      decimals="-5"
      id="F_a713a319-b72a-4d31-8da8-225b0d081335"
      unitRef="U_USD">500000</dvax:PaymentMadeForPreCommercializationMilestone>
    <dvax:PaymentMadeForPreCommercializationMilestone
      contextRef="C_4e8bbc07-0e01-4b4f-8236-8ea97338e319"
      decimals="-5"
      id="F_0fd52ac9-593c-4ba7-8d5c-c644079772ad"
      unitRef="U_USD">500000</dvax:PaymentMadeForPreCommercializationMilestone>
    <dvax:PaymentMadeForPreCommercializationMilestone
      contextRef="C_25b31f57-0a7e-4cd3-b3c8-ac133125ecf3"
      decimals="-5"
      id="F_366b2cdc-6f7d-4dac-9e17-39389f8623f0"
      unitRef="U_USD">500000</dvax:PaymentMadeForPreCommercializationMilestone>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_8c048b5b-9f2f-4059-a46d-ff9fd4b55459">&lt;div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Collaborative Research, Development and License Agreements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Coalition for Epidemic Preparedness Innovations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2021, we entered into an agreement (together with subsequent amendments, the &#x201c;CEPI Agreement&#x201d;) with Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;) for the manufacture and reservation of a specified quantity of CpG 1018 adjuvant (&#x201c;CpG 1018 Materials&#x201d;). In May 2021, we entered into the first amendment to the CEPI Agreement. The CEPI Agreement enables CEPI to direct the supply of CpG 1018 Materials to CEPI partner(s). CEPI partner(s) would purchase CpG 1018 Materials under separately negotiated agreements. The CEPI Agreement also allows us to sell CpG 1018 Materials to third parties if not purchased by a CEPI partner within a two-year term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In exchange for reserving CpG 1018 Materials and agreeing to sell CpG 1018 Materials to CEPI partner(s) at pre-negotiated prices, CEPI agreed to provide payments in the form of an interest-free, unsecured, forgivable loan (the &#x201c;Advance Payments&#x201d;). We are obligated to repay the Advance Payments, in proportion to quantity sold, if and to the extent we receive payments from sales of CpG 1018 Materials reserved under the CEPI Agreement. If the vaccine programs pursued by CEPI partner(s) are unsuccessful and no alternative use is found for CpG 1018 Materials reserved under the CEPI Agreement, the applicable Advance Payments will be forgiven at the end of the two-year term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 27, 2023, we entered into a waiver and second amendment to the CEPI Agreement by and between us and CEPI (the &#x201c;CEPI-Bio E Assignment Agreement&#x201d;). Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of the outstanding Advance Payments for CpG 1018 Materials allocated to and ordered by Bio E under the CEPI Agreement and has assumed our previous rights to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of Bio E accounts receivable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Through Decembe&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;r 31, 2023, we received Advance Payments totaling approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million pursuant to the CEPI Agreement, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million have been repaid and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million have been forgiven (as discussed above). As of December 31, 2023, remaining Advance Payments totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;million in CEPI accrual long-term were reflected in our consolidated balance sheets, representing the outstanding balance of the Advance Payments relating to the Clover Supply Agreement (as defined and discussed below). As of December 31, 2022, we recorded Advance Payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;107.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million included in CEPI accrual. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; deferred revenue balances related to the CEPI Agreement as of December 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2021, we entered into an agreement with Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited (collectively, &#x201c;Clover&#x201d;), for the commercial supply of CpG 1018 adjuvant, for use with Clover&#x2019;s COVID-19 vaccine candidate, SCB-2019 (together with subsequent amendments, the &#x201c;Clover Supply Agreement&#x201d;). Under the Clover Supply Agreement, Clover committed to purchase specified quantities of CpG 1018 adjuvant, at pre-negotiated prices pursuant to the CEPI Agreement, for use in Clover&#x2019;s commercialization of vaccines containing SCB-2019 and CpG 1018 adjuvant (&#x201c;Clover Product&#x201d;). The Clover Supply Agreement also provides terms for Clover to order additional quantities of CpG 1018 adjuvant beyond the quantities reserved by CEPI. In 2022 and 2023, we signed four amendments to the Clover Supply Agreement. The terms and conditions of the Clover Supply Agreement were operative through December 2022, and as of December 31, 2022, we had satisfied all delivery obligations thereunder.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For CpG 1018 adjuvant reserved for Clover under the CEPI Agreement, Clover is obligated to pay us the purchase price upon the earliest of (i) the true-up exercise, (ii) within a specified period after Clover delivers Clover Product to a customer, or (iii) Clover&#x2019;s receipt of payment for Clover Product from a customer. When we transfer control of CpG 1018 adjuvant that is reserved under the CEPI Agreement, we recognize product revenue and a corresponding contract asset as our right to consideration is contingent on something other than the passage of time, as outlined above.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The contract asset of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million relating to Clover was included in other current assets as of December 31, 2022. The contract asset was subsequently reclassified to other assets (long term) and remains classified in other assets (long term) as of December 31, 2023. The contract asset was reclassified to other assets (long term) to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Corresponding Advance Payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million relating to Clover are recorded in CEPI accrual long-term in our consolidated balance sheets as of December 31, 2023. These Advance Payments may be repaid using cash collected from Clover or forgiven in accordance with the CEPI Agreement. We had no accounts receivable balance from Clover as of December 31, 2023 and December 31, 2022. We did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize CpG 1018 adjuvant net product revenue from Clover for the year ended December 31, 2023. We recognized CpG 1018 adjuvant net product revenue o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;f $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;288.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; mill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ion for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additionally, during the year ended December 31, 2022 and in connection with amendments to the Clover Supply Agreement, which reduced or cancelled certain orders for CpG 1018 adjuvant, we recorded an inventory write-off of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of excess CpG 1018 adjuvant raw materials and finish goods inventory. This excess inventory write-off was reflected as a charge to cost of sales &#x2013; product, in the consolidated statements of operations for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Biological E. Limited&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2021, we entered into an agreement (together with subsequent amendments, the &#x201c;Bio E Supply Agreement&#x201d;) with Biological E. Limited (&#x201c;Bio E&#x201d;), for the commercial supply of CpG 1018 adjuvant, for use with Bio E&#x2019;s subunit COVID-19 vaccine candidate, CORBEVAX&#x99;. Under the Bio E Supply Agreement, Bio E committed to purchase specified quantities of CpG 1018 adjuvant, at pre-negotiated prices pursuant to the CEPI Agreement, for use in Bio E&#x2019;s commercialization of its CORBEVAX vaccine (&#x201c;Bio E Product&#x201d;) with specified delivery dates in 2021 and the first quarter of 2022. The Bio E Supply Agreement also provides terms for Bio E to order additional quantities of CpG 1018 adjuvant beyond the quantities reserved by CEPI. In June 2022 and in October 2022, we entered into amendments to the Bio E Supply Agreement (the &#x201c;Bio E Amendment No. 1&#x201d; and the &#x201c;Bio E Amendment No. 2,&#x201d; together the &#x201c;Bio E Amendments&#x201d;). The Bio E Amendments primarily established: (i) a new payment schedule for certain outstanding invoices related to the CEPI product to be the earlier of December 31, 2022, or receipt of certain amounts from Bio E from the Government of India in connection with their advance purchase agreement for CORBEVAX, and (ii) further modified the scope of the Bio E Supply Agreement, by reducing certain quantities of CpG 1018 adjuvant to be delivered. The terms and conditions of the Bio E Supply Agreement were operative through December 2022, and as of December 31, 2022, we had satisfied all delivery obligations thereunder.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we had no accounts receivable balance from Bio E. During the first quarter of 2023, we recorded an allowance for doubtful accounts of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which was determined by assessing changes in Bio E&#x2019;s credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (defined below), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 26, 2023, we entered into a third amendment to the Bio E Supply Agreement (the &#x201c;Bio E Amendment No. 3&#x201d;), and on April 27, 2023, we entered into the CEPI-Bio E Assignment Agreement. Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of remaining amounts outstanding relating to a liability for Advance Payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the &#x201c;Bio E CEPI Advance Payments&#x201d;) for CpG 1018 Materials allocated to Bio E, and has assumed our previous rights to collect $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of Bio E accounts receivable. Pursuant to the Bio E Amendment No. 3, we collected $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from Bio E (including $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in April 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in August 2023). Accordingly, as of December 31, 2023, the CEPI-Bio E Assignment Agreement resulted in: (i) no accounts receivable balance, and (ii) the derecognition of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million CEPI accrual in connection with the Bio E CEPI Advance Payments. The Bio E Amendment No. 3 provides for additional future payment of either $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the event that Bio E receives at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the event that Bio E receives at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in future payments from the Government of India associated with its CORBEVAX product on or before August 15, 2025. These additional amounts are not considered collectible until the achievement of these future milestones.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize CpG 1018 adjuvant net product revenue from Bio E for the year ended December 31, 2023. We recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;CpG 1018 adjuvant net product revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;U.S. Department of Defense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2021, we entered into an agreement with the DoD for the development of a recombinant plague vaccine adjuvanted with CpG 1018 adjuvant &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;over two and a half years. Under the agreement, we are&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;conducting &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;a Phase 2 clinical trial combining our CpG 1018 adjuvant with the DoD's rF1V vaccine. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2023, we executed a contract modification with the DoD to support advancement into a nonhuman primate challenge study, with the agreement now totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million through 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; For the years ended December 31, 2023 and 2022, we recognized revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;which is included in other revenue in our consolidated statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_e3f4c696-246e-4a9c-a510-583ee8c9731e"
      decimals="-5"
      id="F_db8d08a5-847a-4618-8101-7c25c310470c"
      unitRef="U_USD">47400000</us-gaap:AccountsReceivableNetCurrent>
    <dvax:AdvancePaymentFromCustomer
      contextRef="C_48680940-6818-40d2-9606-4f38488cee91"
      decimals="-5"
      id="F_dd077e9c-466b-4112-89bc-ad3e7a645fde"
      unitRef="U_USD">175000000</dvax:AdvancePaymentFromCustomer>
    <dvax:RepaymentOfAdvanceFromCustomer
      contextRef="C_48680940-6818-40d2-9606-4f38488cee91"
      decimals="-5"
      id="F_0d1c8b96-7f83-462e-bee1-82dd2d5e26e1"
      unitRef="U_USD">67300000</dvax:RepaymentOfAdvanceFromCustomer>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_48680940-6818-40d2-9606-4f38488cee91"
      decimals="-5"
      id="F_edb73c7e-643e-4bfc-abdb-a986ff21b14e"
      unitRef="U_USD">47400000</us-gaap:AccruedLiabilitiesCurrent>
    <dvax:AccrualLongTermBalance
      contextRef="C_48680940-6818-40d2-9606-4f38488cee91"
      decimals="-5"
      id="F_913325f2-7354-44b8-9cee-8641610cbb52"
      unitRef="U_USD">60300000</dvax:AccrualLongTermBalance>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_eb7a44e4-c892-49a3-b202-b907c029e24f"
      decimals="-5"
      id="F_4dc6df21-e13b-4d99-bc93-9fdfa87f1961"
      unitRef="U_USD">107700000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_48680940-6818-40d2-9606-4f38488cee91"
      decimals="-6"
      id="F_91c9aceb-c644-4123-8184-17aa19920e92"
      unitRef="U_USD">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_eb7a44e4-c892-49a3-b202-b907c029e24f"
      decimals="-6"
      id="F_c297766f-86de-440c-9558-0f621b39e9eb"
      unitRef="U_USD">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_ecd4b79e-9828-475d-9c9f-5c628dfa3993"
      decimals="-5"
      id="F_88a54740-362c-4946-962c-517c5fbdc92a"
      unitRef="U_USD">71300000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <dvax:AccrualLongTermBalance
      contextRef="C_0a048ebc-c8de-4126-86ee-1592940450b2"
      decimals="-5"
      id="F_b7194abb-9fbb-4879-b652-abdb01c692cc"
      unitRef="U_USD">60300000</dvax:AccrualLongTermBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d7e1bd25-a160-4d2a-9aa1-1570a122f4cd"
      decimals="-6"
      id="F_14034396-c4eb-4368-86ba-174e0815199b"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a835f5a8-e3de-4348-8afc-9aa8d3f5191d"
      decimals="-5"
      id="F_d949f351-e451-4622-8158-5b9819f5ca0c"
      unitRef="U_USD">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dvax:InventoryWriteOffsRecognized
      contextRef="C_ef72dbdf-e573-4481-9cf4-b43c84730269"
      decimals="-5"
      id="F_60ea3a50-205d-4c7e-9485-71c11f6d94eb"
      unitRef="U_USD">34300000</dvax:InventoryWriteOffsRecognized>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-5"
      id="F_cdc3d051-663e-494a-9aed-5338b6e8e046"
      unitRef="U_USD">12300000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <dvax:RepaymentOfAdvanceFromCustomer
      contextRef="C_344d9e72-8b1f-4434-9db5-252aa7e877e6"
      decimals="-5"
      id="F_fb0d6777-ebfb-4127-914c-e72c455937c7"
      unitRef="U_USD">47400000</dvax:RepaymentOfAdvanceFromCustomer>
    <dvax:RepaymentOfAdvanceFromCustomer
      contextRef="C_1bc231fb-46e7-4fb0-a5fd-dde6eed5fb39"
      decimals="-5"
      id="F_1550a324-db8f-49aa-9ec1-1201393c5276"
      unitRef="U_USD">47400000</dvax:RepaymentOfAdvanceFromCustomer>
    <dvax:PrepaymentOfAdvancePayment
      contextRef="C_4dc6828d-94e8-4ca1-9e05-1d3d58d0dc47"
      decimals="-5"
      id="F_6c5de66d-ae39-4fab-9ab1-8cce94076cc1"
      unitRef="U_USD">14500000</dvax:PrepaymentOfAdvancePayment>
    <dvax:PrepaymentOfAdvancePayment
      contextRef="C_887ba154-ef1b-44c1-92ad-b5335653b28b"
      decimals="-5"
      id="F_4fef69fc-0e6d-42bc-a5ce-ddc7888824b3"
      unitRef="U_USD">13500000</dvax:PrepaymentOfAdvancePayment>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_260c0775-ec5e-4e9a-83f8-a1b4aa2f06c5"
      decimals="-5"
      id="F_89446396-ad66-419a-8aba-f5a94853f4ca"
      unitRef="U_USD">1000000</us-gaap:AccountsReceivableNetCurrent>
    <dvax:RepaymentOfAdvanceFromCustomer
      contextRef="C_4720dcda-852f-4e2a-bec3-37de58fa755d"
      decimals="-5"
      id="F_4933636a-4c22-4c8c-a568-090e6c478aa9"
      unitRef="U_USD">47400000</dvax:RepaymentOfAdvanceFromCustomer>
    <dvax:AdditionalFuturePayment
      contextRef="C_344d9e72-8b1f-4434-9db5-252aa7e877e6"
      decimals="-5"
      id="F_aa4b6acc-64e3-4cb0-949f-390cb1f9eb00"
      unitRef="U_USD">5500000</dvax:AdditionalFuturePayment>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="C_344d9e72-8b1f-4434-9db5-252aa7e877e6"
      decimals="-5"
      id="F_35ef0311-fbe6-4e23-a682-27a1979ad50a"
      unitRef="U_USD">125000000</us-gaap:AdvancesOnInventoryPurchases>
    <dvax:AdditionalFuturePayment
      contextRef="C_260c0775-ec5e-4e9a-83f8-a1b4aa2f06c5"
      decimals="-5"
      id="F_e17f6b88-87b6-4f45-9532-dcefa181f7e1"
      unitRef="U_USD">12300000</dvax:AdditionalFuturePayment>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="C_260c0775-ec5e-4e9a-83f8-a1b4aa2f06c5"
      decimals="-5"
      id="F_4c6cd8f1-5151-4412-8ecc-0f66a3217ccd"
      unitRef="U_USD">250000000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_bc46d573-296e-4a0d-aa85-c245577e3d2d"
      decimals="-6"
      id="F_b4544231-524d-49c4-ac72-a4e8369f0e3c"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_fa18ccc3-e6a3-4fc5-84a7-11116a04094b"
      decimals="-5"
      id="F_1806f1de-18d8-4b5d-9a3f-2e4eba170a81"
      unitRef="U_USD">206200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dvax:ProceedsFromGrant
      contextRef="C_17561271-4a7b-4b2f-bb36-76707b8268dc"
      decimals="-5"
      id="F_dfe2af15-1424-4340-9fc3-01d27b101577"
      unitRef="U_USD">22000000</dvax:ProceedsFromGrant>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="C_72dff176-fdce-41b0-bd7a-2057a380f269"
      decimals="-5"
      id="F_995b534a-cd11-4d4d-a3dd-03c9af663e42"
      unitRef="U_USD">33700000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_07eaa0a5-29dc-4366-a233-4616595cc0e8"
      decimals="-5"
      id="F_f2a21ea3-72bc-4f07-a94a-8db8b9dec6d7"
      unitRef="U_USD">17600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4f26b2cd-7c84-4953-85e9-83acbeb93d90"
      decimals="-5"
      id="F_996c7f8e-ae98-458f-808f-3fecd2c4f18c"
      unitRef="U_USD">8800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_4abdbcda-f13f-4ef2-9a35-2a5228302805">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Convertible Notes &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2021, we issued $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of Convertible Notes in a private placement. Total proceeds from the issuance of the Convertible Notes, net of debt issuance and offering costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;219.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. We used $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the net proceeds to retire our previous loan agreement with CRG Servicing LLC and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the net proceeds to pay the costs of the Capped Calls described below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Convertible Notes are general, unsecured obligations and accrue interest at a rate of 2.50% per annum payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2021.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Convertible Notes mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;May 15, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, unless converted, redeemed or repurchased prior to such date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Convertible Notes are convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, at an initial conversion rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95.5338&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock per $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share of our common stock. The Convertible Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding February 15, 2026, only under the following circumstances:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; trading days (whether or not consecutive) during a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the conversion price on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; business day period after any &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ten&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; consecutive trading day period (the &#x201c;measurement period&#x201d;), in which the &#x201c;trading price&#x201d; (as defined in the indenture governing the Convertible Notes) per $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; principal amount of the Convertible Notes for each trading day of the measurement period was less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If we call such Convertible Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon the occurrence of specified corporate events as set forth in the indenture governing the Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On or after February 15, 2026, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Convertible Notes may convert all or any portion of their Convertible Notes regardless of the foregoing circumstances.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since we have the election of repaying the Convertible Notes in cash, shares of our common stock, or a combination of both, we continued to classify the Convertible Notes as long-term debt on the consolidated balance sheets as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We may redeem for cash all or any portion of the Convertible Notes (subject to the partial redemption limitation described in the indenture governing the Convertible Notes), at our option, on or after May 20, 2024 and prior to the 31st scheduled trading day immediately preceding the maturity date, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If we undergo a fundamental change (as set forth in the indenture governing the Convertible Notes), noteholders may require us to repurchase for cash all or any portion of their Convertible Notes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events (as set forth in the indenture governing the Convertible Notes) or if we deliver a notice of redemption prior to the maturity date, we will, in certain circumstances, adjust the conversion rate for a noteholder who elects to convert its notes in connection with such a corporate event or such notice of redemption.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We accounted for the Convertible Notes as a single liability in accordance with ASU 2020-06 - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASU 2020-06&#x201d;). As of December 31, 2023, the Convertible Notes were recorded at the aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million less unamortized issuance costs of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;million as a long-term liability on the consolidated balance sheets. As of December 31, 2023, the fair value of the Convertible Notes was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;330.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The fair value was estimated using a reputable third-party valuation model based on observable inputs and is considered Level 2 in the fair value hierarchy. The debt issuance costs are amortized to interest expense over the contractual term of the Convertible Notes at an effective interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the components of interest expense related to Convertible Notes (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.620000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.620000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stated coupon interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization of debt issuance cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Capped Calls&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the issuance of the Convertible Notes, we entered into capped call transactions with one of the initial purchasers of the Convertible Notes and other financial institutions, totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the &#x201c;Capped Calls&#x201d;). The Capped Calls cover, subject to customary adjustments, the number of shares of our common stock that initially underlie the Convertible Notes (or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,542,871&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock). The Capped Calls have an initial strike price and an initial cap price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively, subject to certain adjustments. Conditions that cause adjustments to the initial strike price of the Capped Calls mirror conditions that result in corresponding adjustments to the conversion price of the Convertible Notes. The Capped Calls are expected to offset the potential dilution to our common stock as a result of any conversion of the Convertible Notes, subject to a cap based on the cap price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For accounting purposes, the Capped Calls are considered separate financial instruments and not part of the Convertible Notes. As the Capped Calls transactions meet certain accounting criteria, we recorded the cost of the Capped Calls, totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, as a reduction to additional paid-in capital within the consolidated statements of stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_bad25b6b-347d-48e5-9b97-3f8c19355518"
      decimals="-5"
      id="F_590f10d6-9c05-4833-896c-deb39fcc898e"
      unitRef="U_USD">225500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_bad25b6b-347d-48e5-9b97-3f8c19355518"
      decimals="-5"
      id="F_5175bd4a-8143-4621-b51e-96fa9a3931ec"
      unitRef="U_USD">5700000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_751580b2-fbfe-41c1-b881-e6d093f5c273"
      decimals="-5"
      id="F_9087cf85-b15a-4c1c-ab61-c39d9e6d8e2a"
      unitRef="U_USD">219800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_bbd430d0-723d-4b78-8014-3bf90a7f958f"
      decimals="-5"
      id="F_76a37206-1aac-4295-b3c8-9af1344095b4"
      unitRef="U_USD">190200000</us-gaap:RepaymentsOfDebt>
    <dvax:IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue
      contextRef="C_3fabb2f0-37ad-4f85-8819-9ad5b0716fdb"
      decimals="-5"
      id="F_3c8d29ab-175d-48a4-a72f-e9c673476ca1"
      unitRef="U_USD">27200000</dvax:IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="C_2f6d8975-50fd-4d21-a136-be743356b082"
      id="F_26cbb44a-32b0-4f3c-8916-9582cb506e3a">The Convertible Notes are general, unsecured obligations and accrue interest at a rate of 2.50% per annum payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2021.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_2f6d8975-50fd-4d21-a136-be743356b082"
      id="F_2b808591-1a0b-4b8e-8a46-d075ced9d28d">2026-05-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="C_2f6d8975-50fd-4d21-a136-be743356b082"
      decimals="4"
      id="F_fd8aa758-aaae-4caa-8df5-7394f0f711ab"
      unitRef="U_pure">95.5338</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dvax:DebtInstrumentConversionOriginalDebtBasePrincipalAmount
      contextRef="C_f5d40eed-ddd7-4243-9e53-3cfc906ba5a3"
      decimals="-3"
      id="F_05bfa017-c1c7-4d3d-bad4-4c0b70c70028"
      unitRef="U_USD">1000000</dvax:DebtInstrumentConversionOriginalDebtBasePrincipalAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39"
      decimals="2"
      id="F_0ad19f9c-954a-49a3-94bc-d2622092813f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.47</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="0"
      id="F_162f30e3-962e-4e95-8080-c4b9dfbdb6fb"
      unitRef="U_Days">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="C_6f5207a1-1b60-4990-be95-58289e708128"
      decimals="0"
      id="F_61a61193-0fc3-4032-a67e-4f21cc4bcd45"
      unitRef="U_Days">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="C_fcd78d0a-af33-44bf-8d8a-2f5c1a9a376f"
      decimals="2"
      id="F_152aa301-9a3b-46ce-a5aa-0ca596c3c293"
      unitRef="U_pure">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="C_38284c71-50a1-429d-8131-ac0563038784"
      decimals="0"
      id="F_5a19a919-0df9-4bf7-91ee-b7b7131f7e23"
      unitRef="U_Days">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="C_38284c71-50a1-429d-8131-ac0563038784"
      decimals="0"
      id="F_17b302a3-d4d9-4de6-884f-bc92d3bf307a"
      unitRef="U_Days">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <dvax:DebtInstrumentConversionOriginalDebtBasePrincipalAmount
      contextRef="C_2f6d8975-50fd-4d21-a136-be743356b082"
      decimals="-3"
      id="F_6fd62538-8fe4-4e04-b225-f09154646308"
      unitRef="U_USD">1000000</dvax:DebtInstrumentConversionOriginalDebtBasePrincipalAmount>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="C_5287e9ff-4a22-4227-b33c-aef9575adc2b"
      decimals="2"
      id="F_9365f032-787a-448e-a02d-63064f7570fb"
      unitRef="U_pure">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentRedemptionDescription
      contextRef="C_2f6d8975-50fd-4d21-a136-be743356b082"
      id="F_197a9599-37b4-49c6-b910-c62e63e3fcdd">We may redeem for cash all or any portion of the Convertible Notes (subject to the partial redemption limitation described in the indenture governing the Convertible Notes), at our option, on or after May 20, 2024 and prior to the 31st scheduled trading day immediately preceding the maturity date, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39"
      decimals="-5"
      id="F_d71f3fda-0782-465f-a692-7502d002e7a1"
      unitRef="U_USD">225500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39"
      decimals="-5"
      id="F_2448b63c-6194-462f-ae83-7d8deb10b3d5"
      unitRef="U_USD">2800000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-5"
      id="F_907f2b64-8c6a-4513-93b3-b55cf9cf48c8"
      unitRef="U_USD">330100000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_d3ef4260-ea3e-48ea-bd2c-d18da32b0f39"
      decimals="3"
      id="F_c30a5c4a-190c-4731-b178-c267921eb1ca"
      unitRef="U_pure">0.031</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <dvax:ScheduleOfConvertibleNotesInterestExpenseTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_97e02146-ebcd-4c3b-bc88-9c40c8a0f1c3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the components of interest expense related to Convertible Notes (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.620000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.620000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stated coupon interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization of debt issuance cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</dvax:ScheduleOfConvertibleNotesInterestExpenseTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_75bc0119-edf3-41ec-b06b-df2950a5522d"
      unitRef="U_USD">5636000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_a69c7306-1e29-4163-918d-3a17be0a789a"
      unitRef="U_USD">5638000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_1017605d-aece-42df-b88c-cac90427b1a4"
      unitRef="U_USD">1121000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_764cc329-5806-43bc-a20e-ad543ae44f30"
      unitRef="U_USD">1094000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_9718ac95-26f0-4af4-8c9b-8fb8bce75732"
      unitRef="U_USD">6757000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_e481711e-afa1-4988-96a3-f709bc405aa7"
      unitRef="U_USD">6732000</us-gaap:InterestExpenseDebt>
    <dvax:IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue
      contextRef="C_6a1fce12-44dc-4910-9727-fa459734732a"
      decimals="-5"
      id="F_16168ae9-7d21-443e-b19e-848822befe13"
      unitRef="U_USD">27200000</dvax:IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_6a1fce12-44dc-4910-9727-fa459734732a"
      decimals="0"
      id="F_48fdc47d-e81f-4d10-b717-9919a7657e7d"
      unitRef="U_shares">21542871</us-gaap:ConversionOfStockSharesConverted1>
    <dvax:DebtInstrumentCappedCallTransactionInitialStrikePricePerShare
      contextRef="C_c0af7c37-af17-4bba-9ae6-7bbd452527b3"
      decimals="2"
      id="F_fc610ba9-f577-43cb-9bef-7289255c0ac3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.47</dvax:DebtInstrumentCappedCallTransactionInitialStrikePricePerShare>
    <dvax:DebtInstrumentCappedCallTransactionInitialCapPricePerShare
      contextRef="C_c0af7c37-af17-4bba-9ae6-7bbd452527b3"
      decimals="2"
      id="F_f379057d-0511-49d2-a280-6e38951d2663"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.8</dvax:DebtInstrumentCappedCallTransactionInitialCapPricePerShare>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="C_6a1fce12-44dc-4910-9727-fa459734732a"
      decimals="-5"
      id="F_73009a68-97d7-48f4-8a9a-33346fac3a24"
      unitRef="U_USD">27200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:LongTermDebtTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_1d8a6333-316d-44f9-8431-bb8efbc24ebb">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-Term Debt &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-Term Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 20, 2018, we entered into a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million term Loan Agreement with CRG Servicing LLC. We borrowed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the Loan Agreement at closing and the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in March 2019 (collectively, &#x201c;Term Loans&#x201d;). Net proceeds under the Loan Agreement were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Term Loans under the Loan Agreement bore interest at a rate equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum. The Term Loans had a maturity date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2021, we repaid the principal on the Term Loans, in full, using the net proceeds from the Convertible Notes issuance. In connection with the early repayment of the Term Loans, in the year ended December 31, 2021, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million loss on debt extinguishment related to the amount we paid to terminate the Term Loans in excess of its carrying value at the time of the repayment. Our final payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to CRG Servicing LLC satisfied all of our obligations under the Loan Agreement. With the full repayment of the Term Loans, all security interests, covenants, liens and encumbrances under the Loan Agreement were permanently released.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recorded &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of i&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;nterest expense related to the Term Loans during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_d50c3d18-220b-403a-97e4-cf6868d818cb"
      decimals="-5"
      id="F_ddeb8793-8cd0-44fb-9a90-800ff849d6de"
      unitRef="U_USD">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:SecuredLongTermDebt
      contextRef="C_d50c3d18-220b-403a-97e4-cf6868d818cb"
      decimals="-5"
      id="F_450c2c26-e8e7-4c4b-a154-d9009560ceb2"
      unitRef="U_USD">100000000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="C_b066d0df-653b-4391-8933-b31cdb392277"
      decimals="-5"
      id="F_c9cd4820-d1bc-4f9f-8ce8-14d4b473f9ca"
      unitRef="U_USD">75000000</us-gaap:SecuredLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_a2e2ad27-c3c5-4b53-9737-1774805c2105"
      decimals="-5"
      id="F_e35ff5fb-28b8-413a-8b67-57122a6a92bc"
      unitRef="U_USD">173300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_d50c3d18-220b-403a-97e4-cf6868d818cb"
      decimals="3"
      id="F_96e2a47c-d1df-4f39-8e2b-a9a3d51fc8d6"
      unitRef="U_pure">0.095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_23485235-7712-4e50-8b13-23e29659179c"
      id="F_551e095b-3da9-4150-823f-b844b314ded2">2023-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_ace65c5a-30fc-4278-a936-73964385612f"
      decimals="-5"
      id="F_004c5867-0a88-4e9c-aac5-b30e5bbbfe18"
      unitRef="U_USD">5200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_23485235-7712-4e50-8b13-23e29659179c"
      decimals="-5"
      id="F_6f7fb40e-41f8-43d9-9ed2-21a892c37af0"
      unitRef="U_USD">190200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_9821d0e8-ecc7-4666-9acc-0bbaa41571ea"
      decimals="-5"
      id="F_63d1b09e-a6fb-4b70-bf59-335b3faad1e4"
      unitRef="U_USD">7000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_d7f6ce15-d0e0-49ab-84e4-ca4883046196">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:17.676%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.879%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.439%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.439%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.659%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.659%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.659%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.659%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.679%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.659%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Non U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Non U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Non U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;HEPLISAV-B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CpG 1018 adjuvant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;587,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;587,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;588,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;713,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;437,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;230,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;232,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;588,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;439,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenues from Major Customers and Collaboration Partners&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs and retail pharmacies. All of our HEPLISAV-B sales in Germany are to one distributor.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.53%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Largest customer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Second largest customer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Third largest customer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes CpG 1018 adjuvant product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant product revenue):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.261%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.005999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.005999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.005999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Largest collaboration partner&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Second largest collaboration partner&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Third largest collaboration partner&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contract Balances&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:25.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;Beginning of&lt;br/&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Provisions&lt;br/&gt;related to current&lt;br/&gt;period sales&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Credit or payments&lt;br/&gt;made during&lt;br/&gt;the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Adjustments related to prior periods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance&lt;br/&gt;at End of&lt;br/&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts receivable reserves &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue reserve accruals &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts receivable reserves &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue reserve accruals &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reserves are for chargebacks, discounts and other fees&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accruals are for returns, rebates and other fees&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;When we transfer control of CpG 1018 adjuvant that is reserved under the CEPI Agreement to Clover and perform services under our agreement with the DoD, we recognize product revenue and a corresponding contract asset as our right to consideration is conditioned on something other than the passage of time. See Note 9 for fu&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;rther discussion. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes balances and activities in our contract asset account (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.952%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.004000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.004000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;Beginning&lt;br/&gt;of Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Subtractions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Reclassification (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance&lt;br/&gt;at End of&lt;br/&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract asset, included in other current assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract asset, included in other assets (long term)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 9 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; $1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; million of contract asset is derived from our agreement with the DoD&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_d2642bdc-ddfd-479a-8ebc-89a63b0cbe45">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:17.676%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.879%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.439%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.439%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.659%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.659%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.659%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.659%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.679%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.659%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Non U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Non U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Non U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;HEPLISAV-B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CpG 1018 adjuvant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;587,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;587,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;588,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;713,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;437,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;230,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;232,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;588,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;439,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b86641c3-95a4-4d1b-8c32-20129a34a510"
      decimals="-3"
      id="F_025ba77e-f0a1-4706-9e9e-e40beabb9f8a"
      unitRef="U_USD">213295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_13bbb079-e389-44b2-b0fe-129eed17bc18"
      decimals="-3"
      id="F_e2ef5b6c-22a0-4996-beaf-7311f0c3e32c"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b"
      decimals="-3"
      id="F_b953b83e-d817-4d85-ae25-75a9891662a9"
      unitRef="U_USD">213295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c385cf83-1634-4094-87c8-c188ad78b7ca"
      decimals="-3"
      id="F_b02d7367-4290-4d2c-a7ec-17d87a945ed3"
      unitRef="U_USD">124996000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3e844c02-fd3f-4039-9675-b2ca051071e0"
      decimals="-3"
      id="F_e83c04d2-8b53-44a0-b8d5-1a25c62a659b"
      unitRef="U_USD">941000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_bb0aaad0-c346-40c7-80b3-5c0e4926bc06"
      decimals="-3"
      id="F_f5bf2fdd-447e-4209-b502-0fbda3607f91"
      unitRef="U_USD">125937000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_de1bbf7b-39e6-455e-a6ad-d72e13ff09c3"
      decimals="-3"
      id="F_611bf0ba-9d09-4694-97f7-0c921743373d"
      unitRef="U_USD">61870000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4349a3de-f389-4fe9-a46d-67b78b2213f1"
      decimals="-3"
      id="F_33129447-8bde-4cbe-bd29-ade17294df1f"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_83ebfedc-dcd6-474a-b76f-5c72dd085aac"
      decimals="-3"
      id="F_17f0a123-797e-40ff-addf-a287b391a83d"
      unitRef="U_USD">61870000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1e94f899-6711-4da9-bcee-5a61cdbdcf61"
      decimals="-3"
      id="F_10e26d23-852f-4b69-85c5-fba25180c01e"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_bf03e8de-4dfe-4921-8f60-87f1256383af"
      decimals="-3"
      id="F_37a9d366-4027-4512-a6b5-d6a25778e930"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722"
      decimals="-3"
      id="F_ec7e9813-51da-4112-8616-d6b4500f5ecf"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8cebee1a-3aa7-4377-b9dc-63b5df400e74"
      decimals="-3"
      id="F_9c20ce4e-c191-4913-b0af-db97577306fe"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_960f69a5-6c26-4021-b7c8-8789aedcdc97"
      decimals="-3"
      id="F_eaffe092-ab17-4c3d-bc8d-163b1b82b932"
      unitRef="U_USD">587708000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_51decfbd-05ba-43b9-a300-132adf0402d6"
      decimals="-3"
      id="F_3f73938d-745d-45a4-9c88-dd8c224dab78"
      unitRef="U_USD">587708000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_98f50ec3-eed0-482b-abdc-e3f4d764dcdb"
      decimals="-3"
      id="F_d2a0c12f-99fe-4027-bf06-a8d20c10ec13"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_dc5b84ae-0185-4375-b0d0-b39df828ca23"
      decimals="-3"
      id="F_c7134515-26e7-4058-93fb-3037042dcec5"
      unitRef="U_USD">375229000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_46ea9e3a-6a19-4c11-a0b8-d28df71f9995"
      decimals="-3"
      id="F_fc80df2b-8984-4ee1-b6e3-da8438e589bf"
      unitRef="U_USD">375229000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_518ea503-766c-4a37-b80d-037d29359c1c"
      decimals="-3"
      id="F_ba420def-fc4b-46a6-8292-4eac896cddf6"
      unitRef="U_USD">213295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_931a84ee-4853-4900-bad8-f584f37e2aaf"
      decimals="-3"
      id="F_d186c2ef-af74-4e45-9cba-f22e70a24db7"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e9ba0f50-bcbf-42ff-bb4d-52d504f7633c"
      decimals="-3"
      id="F_761e7d92-f753-4e84-b8c2-b5f82a5ed83f"
      unitRef="U_USD">213295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_501845fd-14fc-4143-a5da-15378a311c6c"
      decimals="-3"
      id="F_543492c5-06bb-45c1-951a-965c27398a7a"
      unitRef="U_USD">124996000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_86657944-51ae-463d-89b1-ae4a4ccfa124"
      decimals="-3"
      id="F_abf3196c-bf08-4b3e-afce-502e129479ca"
      unitRef="U_USD">588649000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_dfe1bbb8-9cb8-4010-b417-57ad46abca6f"
      decimals="-3"
      id="F_f9bc2e5e-acf7-4c70-a893-6c0a48d85a4a"
      unitRef="U_USD">713645000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ad54aada-ef84-4b1b-b532-5c907b0a02c4"
      decimals="-3"
      id="F_c2a8dfb9-aa88-4d96-ac7c-dd808ab42fbe"
      unitRef="U_USD">61870000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7c9ae35d-bbf7-49a3-ab55-60aabc35c7b8"
      decimals="-3"
      id="F_ea63f7da-42c4-4baa-a7f5-7e3164500dcb"
      unitRef="U_USD">375229000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6423ea24-b03e-48e6-addc-0d0d41661afc"
      decimals="-3"
      id="F_94d0cbcc-c991-4019-9267-d2f109dd62c7"
      unitRef="U_USD">437099000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c81fc228-69ab-44c3-95b9-aea5499fe2bb"
      decimals="-3"
      id="F_e9a90b65-7be8-42a0-bc30-ae6b4c75dae4"
      unitRef="U_USD">17650000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d65d29d7-24ac-4d7b-bfef-53e5f9ec99ef"
      decimals="-3"
      id="F_99eb184e-c0e1-4b49-863c-8f28d01292b8"
      unitRef="U_USD">1339000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ce1c0cc3-d217-4341-a89c-76cd4302ac34"
      decimals="-3"
      id="F_ea184078-45ab-45ba-ac69-eaa833ca2e6d"
      unitRef="U_USD">18989000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f6d1d749-5eda-4173-857c-d2e9ec42eec9"
      decimals="-3"
      id="F_b53c61e2-426f-406e-a223-59ea8d449f31"
      unitRef="U_USD">8774000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7128fc7b-020c-499d-ae72-19db57703cc2"
      decimals="-3"
      id="F_a2903405-c9a2-4f80-a2c2-5344d4ab240f"
      unitRef="U_USD">264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_600e9b74-60a6-45e3-9267-97174756699a"
      decimals="-3"
      id="F_9fc1b3e2-4854-4b1f-a9bb-a6497fe8bded"
      unitRef="U_USD">9038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5f971b14-535c-4dd6-9f52-1e81c12d5af5"
      decimals="-3"
      id="F_ad1db50a-347a-48e9-b2e3-b99869d6598b"
      unitRef="U_USD">1915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b92550c8-3f5d-45cc-9390-8d5d61858315"
      decimals="-3"
      id="F_e3a97168-6652-4abb-bccc-d9b576fe07db"
      unitRef="U_USD">428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e638b00f-55b0-4873-beaa-4bf842f5fdd2"
      decimals="-3"
      id="F_521389be-e873-4ec0-a56e-25699167dbca"
      unitRef="U_USD">2343000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6788e286-c14c-450b-b13d-2eea895a38ad"
      decimals="-3"
      id="F_3991866f-f3fd-449e-8b9d-f6288bc08c6f"
      unitRef="U_USD">230945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0d0c6594-c70c-45dd-b459-b3da8ed9a07a"
      decimals="-3"
      id="F_e0b7c1fa-e4d5-4130-abca-00ea8904076a"
      unitRef="U_USD">1339000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_dcbb9693-8906-4d03-80c0-4e9bbc046777"
      unitRef="U_USD">232284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b1074222-76a7-46bd-9644-2e3690082980"
      decimals="-3"
      id="F_62dc3bd7-afff-4d70-b4d5-011fe41aff6d"
      unitRef="U_USD">133770000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b0c51341-46c1-468f-b8a4-d22a9e93bea9"
      decimals="-3"
      id="F_e5ba6447-cca6-46f0-980b-c0b49bb28fbb"
      unitRef="U_USD">588913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_49af9575-2beb-4d7c-8c5f-7c22c7855de9"
      unitRef="U_USD">722683000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_21d5cf56-92b9-4489-b44b-c533985be50f"
      decimals="-3"
      id="F_c1535362-34e9-4741-802b-02892beb8970"
      unitRef="U_USD">63785000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_92e5b8ce-fc26-44df-be6c-b93ab6266391"
      decimals="-3"
      id="F_642e09ee-a833-4ecb-8924-5efbb2611e14"
      unitRef="U_USD">375657000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b5868bb8-d583-45bb-bb1c-d43475b77db4"
      unitRef="U_USD">439442000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b"
      id="F_85dd2e9c-f521-4f93-91a7-d3a695d69e1d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.53%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Largest customer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Second largest customer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Third largest customer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_79c0f9eb-0184-4dba-a43c-01f7640ee145"
      decimals="2"
      id="F_4753f321-8abf-4848-af61-02e78e7d35ea"
      unitRef="U_pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_fdc045d5-f884-4bd3-ac9d-65b497b60faf"
      decimals="2"
      id="F_7eac599a-fa8e-4731-a208-17fae2ceb2d0"
      unitRef="U_pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_6a1e5c04-44fa-417c-a4e7-018c2ad6e933"
      decimals="2"
      id="F_c14179f7-dec9-4a39-ad03-87f68f210efb"
      unitRef="U_pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_d9059078-1d7f-42cf-9ac7-53b904e61b2c"
      decimals="2"
      id="F_3f9d45f6-b6d2-41a7-832d-45121993045c"
      unitRef="U_pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_70bb3c92-fdce-4bba-8d13-f7445805823e"
      decimals="2"
      id="F_88569167-4023-4414-9e7b-bd40e72ad67b"
      unitRef="U_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_ad16fd8d-2d92-4d26-8d96-bf058a356d05"
      decimals="2"
      id="F_991ad532-0865-485b-bd5f-e6fb4f1f8521"
      unitRef="U_pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_ef0e8934-759f-4093-bac5-8fa40486ee52"
      decimals="2"
      id="F_0ca61c77-cc35-4d9a-813a-0285439c3476"
      unitRef="U_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_c8cf97a7-7cc0-4345-ac03-211d0a8e0250"
      decimals="2"
      id="F_216934ce-b087-4141-b381-9f3aac04e673"
      unitRef="U_pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_a778631e-7026-4533-acd7-c0e2a158a18d"
      decimals="2"
      id="F_7b640134-e18e-4334-99d5-231871e7b64a"
      unitRef="U_pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722"
      id="F_33c266a4-7c7d-412e-87bc-31b7ccd10c00">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes CpG 1018 adjuvant product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant product revenue):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.261%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.005999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.005999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.005999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Largest collaboration partner&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Second largest collaboration partner&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Third largest collaboration partner&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_93b7b614-27fa-4eae-80c5-0b38da148a6c"
      decimals="2"
      id="F_eff81809-1610-4f80-8faa-5c78723d7376"
      unitRef="U_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_4bc4c639-7c83-4569-b3d6-4d528d1abaf5"
      decimals="2"
      id="F_b7b4d771-21d8-4435-8b6e-ee7090349f35"
      unitRef="U_pure">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_fa937874-39fc-49fc-b659-927ec58d6789"
      decimals="2"
      id="F_da649172-349f-4414-96cd-aa83e8080dc7"
      unitRef="U_pure">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_aa260df4-3e48-4fdf-8ab8-54f380fb7620"
      decimals="2"
      id="F_01d1bbce-3e39-4305-bdd3-0e2c2d34177f"
      unitRef="U_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_87f096fc-5022-4951-928c-a55c0c09d734"
      decimals="2"
      id="F_b9e66fdb-3215-45b3-95b9-b8d58bfc2fb8"
      unitRef="U_pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_d0d39007-043c-4130-9d47-4b28ecc8e767"
      decimals="2"
      id="F_207d0ecb-607b-43b0-a176-2204409c52ba"
      unitRef="U_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_93236fd5-e3be-44e0-a948-b795ea15d021"
      decimals="2"
      id="F_e906aff0-e408-4f64-b34e-f85719e13cb3"
      unitRef="U_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_a814d382-f3ad-4c19-84d6-7b9bde2b4316"
      decimals="2"
      id="F_111219fe-c248-4d23-a0ba-744fa9127e9c"
      unitRef="U_pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_cccd4a85-7cd2-47b0-8792-edf0ca811695"
      decimals="2"
      id="F_00455bd0-bf9d-4f86-b534-1fe1bee23272"
      unitRef="U_pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <dvax:SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock
      contextRef="C_48f6e833-63e7-4015-bb6e-1aafaaf8055b"
      id="F_65aad060-849c-4346-bafb-20e20e39d544">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:25.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;Beginning of&lt;br/&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Provisions&lt;br/&gt;related to current&lt;br/&gt;period sales&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Credit or payments&lt;br/&gt;made during&lt;br/&gt;the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Adjustments related to prior periods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance&lt;br/&gt;at End of&lt;br/&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts receivable reserves &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue reserve accruals &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts receivable reserves &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue reserve accruals &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reserves are for chargebacks, discounts and other fees&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accruals are for returns, rebates and other fees&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</dvax:SummaryOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock>
    <dvax:ReservesAccrualBalance
      contextRef="C_bd4dc0db-3b94-4730-9f10-12f7f1a154c7"
      decimals="-3"
      id="F_b2c509cf-4658-4d4b-b728-8d4a0640a162"
      unitRef="U_USD">8179000</dvax:ReservesAccrualBalance>
    <dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales
      contextRef="C_52588853-8260-401a-beed-26f3945ae871"
      decimals="-3"
      id="F_55014c25-30ae-4571-8d55-fc4908e71a29"
      unitRef="U_USD">55604000</dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales>
    <dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod
      contextRef="C_52588853-8260-401a-beed-26f3945ae871"
      decimals="-3"
      id="F_f3da79f1-24c7-4632-b740-8b131a9d2be9"
      unitRef="U_USD">-54143000</dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod>
    <dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod
      contextRef="C_52588853-8260-401a-beed-26f3945ae871"
      decimals="-3"
      id="F_bf5112d8-1c04-421c-a1d7-be09e25b39c7"
      unitRef="U_USD">-2629000</dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod>
    <dvax:ReservesAccrualBalance
      contextRef="C_5445db9b-2a99-4cf2-a2cd-3f86b5ae5b30"
      decimals="-3"
      id="F_d6145b6a-d040-4dd6-9cb7-4c98c35a46d0"
      unitRef="U_USD">7011000</dvax:ReservesAccrualBalance>
    <dvax:ReservesAccrualBalance
      contextRef="C_f9680928-634a-4740-b0dc-8e7ca6e0523a"
      decimals="-3"
      id="F_f05c35cd-44b9-4458-bbd6-5b766235a786"
      unitRef="U_USD">10552000</dvax:ReservesAccrualBalance>
    <dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales
      contextRef="C_1bdc419f-cd33-4f84-9be9-6a7a197b6800"
      decimals="-3"
      id="F_e4271787-7be9-41a9-9ec1-ae5a48e736d9"
      unitRef="U_USD">46062000</dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales>
    <dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod
      contextRef="C_1bdc419f-cd33-4f84-9be9-6a7a197b6800"
      decimals="-3"
      id="F_573be19d-8823-4dbc-8931-9152157e5823"
      unitRef="U_USD">-38207000</dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod>
    <dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod
      contextRef="C_1bdc419f-cd33-4f84-9be9-6a7a197b6800"
      decimals="-3"
      id="F_50131afd-0f80-49d3-83f5-48f0a9a291ba"
      unitRef="U_USD">2597000</dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod>
    <dvax:ReservesAccrualBalance
      contextRef="C_10088c6a-e568-4bb6-8203-26ba3572c356"
      decimals="-3"
      id="F_1fd1191c-48bf-416e-9986-9e4ecc313c72"
      unitRef="U_USD">21004000</dvax:ReservesAccrualBalance>
    <dvax:ReservesAccrualBalance
      contextRef="C_3ca507f0-264d-4d6b-a1d7-6b4736681fa7"
      decimals="-3"
      id="F_55b39750-cebc-4736-b3f2-9395cfe6ff03"
      unitRef="U_USD">3823000</dvax:ReservesAccrualBalance>
    <dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales
      contextRef="C_bdb2bd2a-2c3d-42e8-ad0d-04fb4a9ce3fd"
      decimals="-3"
      id="F_1008207a-8c71-49e0-993d-4989f909b1a5"
      unitRef="U_USD">34758000</dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales>
    <dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod
      contextRef="C_bdb2bd2a-2c3d-42e8-ad0d-04fb4a9ce3fd"
      decimals="-3"
      id="F_5edd96ac-e2e3-4eab-ba59-1dce17251a9e"
      unitRef="U_USD">-30402000</dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod>
    <dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod
      contextRef="C_bdb2bd2a-2c3d-42e8-ad0d-04fb4a9ce3fd"
      decimals="-3"
      id="F_2db33005-69a9-4d8f-82a2-0a0b43266bb2"
      unitRef="U_USD">0</dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod>
    <dvax:ReservesAccrualBalance
      contextRef="C_bd4dc0db-3b94-4730-9f10-12f7f1a154c7"
      decimals="-3"
      id="F_56283b7b-0bf3-4c03-a372-2a21083d9543"
      unitRef="U_USD">8179000</dvax:ReservesAccrualBalance>
    <dvax:ReservesAccrualBalance
      contextRef="C_32dacd1a-2cf4-4e7d-a9cb-0223b786f81e"
      decimals="-3"
      id="F_f54dd4fc-9a50-4c74-866f-36bf8b38e7ae"
      unitRef="U_USD">8253000</dvax:ReservesAccrualBalance>
    <dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales
      contextRef="C_011b6204-96fe-4257-8305-4c2c24467a75"
      decimals="-3"
      id="F_66c01725-80e8-4499-8bed-8476bf3e4e03"
      unitRef="U_USD">24806000</dvax:ProductRevenueAllowanceAndReservesProvisionRelatedToCurrentPeriodSales>
    <dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod
      contextRef="C_011b6204-96fe-4257-8305-4c2c24467a75"
      decimals="-3"
      id="F_6af692da-77b0-4aed-aaed-263dbd1e56db"
      unitRef="U_USD">-22507000</dvax:ProductRevenueAllowanceAndReservesCreditOrPaymentsMadeDuringPeriod>
    <dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod
      contextRef="C_011b6204-96fe-4257-8305-4c2c24467a75"
      decimals="-3"
      id="F_af7984ca-1c6a-4061-9b34-3096cb7c7363"
      unitRef="U_USD">0</dvax:ProductRevenueAllowanceAndReservesAdjustmentsRelatedToPriorPeriod>
    <dvax:ReservesAccrualBalance
      contextRef="C_f9680928-634a-4740-b0dc-8e7ca6e0523a"
      decimals="-3"
      id="F_8668cc6b-7fde-4c88-a624-d220fba70b18"
      unitRef="U_USD">10552000</dvax:ReservesAccrualBalance>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722"
      id="F_bf30dfe8-5b5e-436c-93c8-4e3cd29c2cc4">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes balances and activities in our contract asset account (in thousands):&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.952%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.004000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.941%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.004000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;Beginning&lt;br/&gt;of Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Subtractions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Reclassification (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance&lt;br/&gt;at End of&lt;br/&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract asset, included in other current assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;&#160;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract asset, included in other assets (long term)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 9 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; $1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; million of contract asset is derived from our agreement with the DoD&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_90d829ca-90bc-4f0f-997f-b75da4b1cbeb"
      decimals="-3"
      id="F_f3c36f18-2b1d-4b81-b1c8-7e990a1b8f82"
      unitRef="U_USD">71965000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetSale
      contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722"
      decimals="-3"
      id="F_b2703284-0338-4fab-9adc-c678bfd78578"
      unitRef="U_USD">17650000</us-gaap:ContractWithCustomerAssetSale>
    <us-gaap:ContractWithCustomerAssetPurchase
      contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722"
      decimals="-3"
      id="F_e6c2e3e9-7ea7-45bb-acd3-c2f99efa17be"
      unitRef="U_USD">16919000</us-gaap:ContractWithCustomerAssetPurchase>
    <us-gaap:ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal
      contextRef="C_5d3d0244-f5ac-41e6-b1e4-39944e862722"
      decimals="-3"
      id="F_2187e669-a5cb-494d-ae16-0757a0fc46b6"
      unitRef="U_USD">-71307000</us-gaap:ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_38abd918-f40c-4d00-8c67-0b1cee772c9a"
      decimals="-3"
      id="F_2cd4b012-2bd4-43b0-a40d-b6cfbe828de6"
      unitRef="U_USD">1389000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_f29e6226-f7ac-44ea-9124-1bc9c7d80f69"
      unitRef="U_USD">71307000</us-gaap:ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_b2b51c62-7479-4845-a81c-0f86478c3c86"
      unitRef="U_USD">71307000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_e5e1933f-3515-412a-9687-dae5c9a6b824"
      decimals="-3"
      id="F_754805ae-a56a-4a8e-a0ae-e63b32428419"
      unitRef="U_USD">62525000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetSale
      contextRef="C_51decfbd-05ba-43b9-a300-132adf0402d6"
      decimals="-3"
      id="F_55623717-770f-4e7d-94aa-437d1d5652c4"
      unitRef="U_USD">17556000</us-gaap:ContractWithCustomerAssetSale>
    <us-gaap:ContractWithCustomerAssetPurchase
      contextRef="C_51decfbd-05ba-43b9-a300-132adf0402d6"
      decimals="-3"
      id="F_ba33ceb9-bd1d-4b43-9cfe-4f8d6d09162b"
      unitRef="U_USD">8116000</us-gaap:ContractWithCustomerAssetPurchase>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_90d829ca-90bc-4f0f-997f-b75da4b1cbeb"
      decimals="-3"
      id="F_83bd18a4-9a9c-4336-adb2-24c4f08e340e"
      unitRef="U_USD">71965000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_0944eb02-4cfe-4b4c-b22f-c1cd33f9eff6">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net (Loss) Income Per Share &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net (loss) income per share is computed by dividing net (loss) income attributable to common stockholders by the weighted-average number of shares of our common stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the calculation of diluted net income per share, net income attributable to common stockholders for basic net income per share is adjusted by the effect of dilutive securities, including awards under our equity compensation plans and change in fair value of warrant liability. Diluted net income per share attributable to common stockholders is computed by dividing the resulting net income attributable to common stockholders by the weighted-average number of fully diluted common shares outstanding.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The numerators and denominators of the basic net (loss) income and diluted net income per share computations for our common stock are calculated as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;293,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: undistributed earnings allocated to participating securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income allocable to common stockholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Add: undistributed earnings allocated to Series B and warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: undistributed earnings allocated to Series B and warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Add: interest expense on convertible notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: removal of change in fair value of warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income allocable to common stockholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;296,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average shares used to compute net (loss) income &lt;br/&gt;&#160;&#160;&#160;allocable to common stockholders per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effect of dilutive shares:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Notes (as converted to common stock)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effect of dilutive warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average shares used to compute net (loss) income&lt;br/&gt;&#160;&#160;&#160;allocable to common stockholders per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following were excluded from the calculation of diluted net (loss) income per share as the effect of their inclusion would have been anti-dilutive (in thousands).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.269%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding securities not included in diluted net (loss) income&lt;br/&gt;&#160;&#160;&#160;allocable to common stockholders per share calculation&lt;br/&gt;&#160;&#160;&#160;(in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options and stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Notes (as converted to common stock)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants (as exercisable into common stock)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_f76ef39b-5112-4d07-9698-292ad4816c6d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The numerators and denominators of the basic net (loss) income and diluted net income per share computations for our common stock are calculated as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;293,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: undistributed earnings allocated to participating securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income allocable to common stockholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Add: undistributed earnings allocated to Series B and warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: undistributed earnings allocated to Series B and warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Add: interest expense on convertible notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: removal of change in fair value of warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net (loss) income allocable to common stockholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;296,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average shares used to compute net (loss) income &lt;br/&gt;&#160;&#160;&#160;allocable to common stockholders per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effect of dilutive shares:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Notes (as converted to common stock)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effect of dilutive warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average shares used to compute net (loss) income&lt;br/&gt;&#160;&#160;&#160;allocable to common stockholders per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_26ff886b-e86d-4b6f-b4ad-aed4771f6fe3"
      unitRef="U_USD">-6389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_eda846db-92fd-4e55-8729-64a9fdc45dd7"
      unitRef="U_USD">293156000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_92290cb3-024f-4c99-9175-d67d39506b46"
      unitRef="U_USD">76713000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_b34aa1a1-d648-4171-ab36-76370fa822b8"
      unitRef="U_USD">-283000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b0cf964c-db55-4b96-9e91-e098008b641e"
      unitRef="U_USD">-4569000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_8a8ffe1e-7ac1-40b0-a328-515fd66288c0"
      unitRef="U_USD">-6389000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_3b905a4e-583f-43b5-b6fa-49b26bb78a52"
      unitRef="U_USD">292873000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_2e67bb3f-48d8-4551-8bf4-c91070dfb548"
      unitRef="U_USD">72144000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <dvax:AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_5fa4b46b-3e05-4244-9f18-6f07e0ede6b1"
      unitRef="U_USD">0</dvax:AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants>
    <dvax:AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_f691935c-5a0a-4bc3-9e89-d013c4720875"
      unitRef="U_USD">283000</dvax:AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants>
    <dvax:AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_270cb1cf-bbed-41d3-ad3d-a4b4306316cd"
      unitRef="U_USD">4569000</dvax:AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants>
    <dvax:DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_55ccda57-80c7-457e-8ebf-9c5df28778a3"
      unitRef="U_USD">0</dvax:DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants>
    <dvax:DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_87480556-f13c-4ab2-a265-88d6cea87ea5"
      unitRef="U_USD">0</dvax:DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants>
    <dvax:DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_9ec70e68-f26c-4c0e-8370-144e1c15f0a8"
      unitRef="U_USD">-4190000</dvax:DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants>
    <us-gaap:InterestExpenseMediumTermNotes
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_0779dc2b-092d-448c-9447-ae6763a2142d"
      unitRef="U_USD">0</us-gaap:InterestExpenseMediumTermNotes>
    <us-gaap:InterestExpenseMediumTermNotes
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_e9e6ae08-21b1-4b6f-84e0-98e330d43d52"
      unitRef="U_USD">5044000</us-gaap:InterestExpenseMediumTermNotes>
    <us-gaap:InterestExpenseMediumTermNotes
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_73e3350e-42df-44dc-9ba1-5a4583186cf1"
      unitRef="U_USD">3168000</us-gaap:InterestExpenseMediumTermNotes>
    <dvax:FairValueAdjustmentsOfWarrants
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_b5f6ebf4-3787-420f-9ecb-9b31aae5ccb8"
      unitRef="U_USD">-0</dvax:FairValueAdjustmentsOfWarrants>
    <dvax:FairValueAdjustmentsOfWarrants
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_4b320def-7a2d-4492-81e3-6c605995e58d"
      unitRef="U_USD">-1801000</dvax:FairValueAdjustmentsOfWarrants>
    <dvax:FairValueAdjustmentsOfWarrants
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_38d1560d-3fc0-49be-b783-ba754e7c299b"
      unitRef="U_USD">0</dvax:FairValueAdjustmentsOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_3315dc9d-cba9-4d29-997b-4cf280f2c6e0"
      unitRef="U_USD">-6389000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_a0864cdd-f0f6-4a7a-a29e-8b818d0a31a9"
      unitRef="U_USD">296399000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_87388cd0-b433-4e10-aac5-8dab8ea6019f"
      unitRef="U_USD">75691000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_8170e0f3-45db-41b5-afeb-b57cf77e8d43"
      unitRef="U_shares">128733000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_c5a51826-e2d5-431e-a84a-60a4fadf37d3"
      unitRef="U_shares">126398000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_1095f49a-8f50-45ff-ba5f-42e59160b46b"
      unitRef="U_shares">116264000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_8416a192-8046-4d0a-9670-57e9c88a7478"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_65966d39-034f-437f-a278-09aae8c8a8a3"
      unitRef="U_USD">2774000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_ee232b72-9635-40b7-9b3e-72bd34e9e3c6"
      unitRef="U_USD">3075000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_3a3ba2ab-5e42-4320-95a8-4173dcef824d"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_6186c460-f671-4723-8409-684ed3b0d334"
      unitRef="U_shares">21543000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_7f4fbfbe-9548-4106-b8c2-4200596d64c4"
      unitRef="U_shares">13667000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_4af961d0-6bff-4b17-b3b9-ff75e645e529"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_19e71b0a-f7a5-4c75-9bdd-8836b2f6cef9"
      unitRef="U_shares">82000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_975d223d-e89f-455b-95e3-9d7d029aacba"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_37014f2b-8cd2-45ef-b04f-300345d0852f"
      unitRef="U_shares">128733000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_25b19c89-a3ca-4fa2-940e-be6d44d1a00c"
      unitRef="U_shares">150797000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_f77cf83e-c98e-40e5-9ee1-e19ca4e31b41"
      unitRef="U_shares">133006000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_8a7ce9aa-08dc-4e5c-aa3f-461f94eed65a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following were excluded from the calculation of diluted net (loss) income per share as the effect of their inclusion would have been anti-dilutive (in thousands).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.269%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.438%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding securities not included in diluted net (loss) income&lt;br/&gt;&#160;&#160;&#160;allocable to common stockholders per share calculation&lt;br/&gt;&#160;&#160;&#160;(in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options and stock awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Notes (as converted to common stock)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants (as exercisable into common stock)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1f301073-2f8b-4fb6-92dd-c36e81bb7b9a"
      decimals="-3"
      id="F_cba23195-8529-45c9-94ab-0fa8249cba51"
      unitRef="U_shares">15158000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_64302cd3-066f-4f94-90bb-67102762e43f"
      decimals="-3"
      id="F_7bf748dc-df73-452e-89dd-2f34e442980d"
      unitRef="U_shares">7165000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_aa7ac349-6ef6-4d33-8b91-dc174a56618b"
      decimals="-3"
      id="F_00abc395-4b5f-43de-aa2a-351fc0984231"
      unitRef="U_shares">5953000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9b9b2b3e-0d8a-43a5-b40a-ddc5b8ced167"
      decimals="-3"
      id="F_1c0d8e85-b773-4fb6-849d-9351938d09b1"
      unitRef="U_shares">21543000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ef39c4dd-1299-4749-a67d-a06698c37b4f"
      decimals="-3"
      id="F_23f3440e-e47f-44d1-9d46-24d34ecd7ce9"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_120e58b6-236e-4e1b-bac7-eb5813c1cb61"
      decimals="-3"
      id="F_d3eb13cc-a031-4a84-809a-5f24e0185f95"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a1f0d8d2-631d-4ed4-8031-fd5a057c56bd"
      decimals="-3"
      id="F_900cfd98-6a8e-4498-ac3e-0d1928d0bf6b"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_44be1a55-42bb-4223-9a35-d53aa56a00cc"
      decimals="-3"
      id="F_9626b20b-2304-4d21-83af-366fb95982a1"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7da260d2-2100-4998-858a-d9177d745e45"
      decimals="-3"
      id="F_23459170-e687-4518-ac38-6a9f75571009"
      unitRef="U_shares">1883000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_dd97c2db-41b1-40c4-a094-655c0fa0d29b">&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;14.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common Stock and Warrants&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common Stock Outstanding&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;129,530,228&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; sh&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ares of our common stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We entered into an at-the-market Sales Agreement with Cowen and Company, LLC (&#x201c;Cowen&#x201d;) on August 6, 2020 and an amendment to such agreement on August 3,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; 2023 (the sales agreement as amended, the &#x201c;ATM Agreement&#x201d;). Under the ATM Agreement, we may offer and sell from time to time, at our sole discretion, shares of our common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million through Cowen as our sales agent. We agreed to pay Cowen a commission of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the gross sales proceeds of any common stock sold through Cowen under the ATM Agreement. As of December 31, 2023, w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e ha&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;d approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million rema&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ining under the ATM Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2022, all of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,882,600&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; outstanding warrants as of December 31, 2021 were exercised or expired, resulting in cash proceeds totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the year ended December 31, 2022, we recognized&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;decrease in the estimated fair value of warrant liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as income in other income (expense) in our consolidated statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="0"
      id="F_f7f13fdb-5e29-4d10-b682-68dfda518968"
      unitRef="U_shares">129530228</us-gaap:CommonStockSharesOutstanding>
    <dvax:CommonStockSalesAgreementAggregateSalesProceeds
      contextRef="C_cdaf1c5c-c380-46df-bd25-46af0336eb49"
      decimals="-5"
      id="F_c4cd52ed-55ad-44b0-8cff-844d28cdb16c"
      unitRef="U_USD">120000000</dvax:CommonStockSalesAgreementAggregateSalesProceeds>
    <dvax:SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock
      contextRef="C_01f47823-0ce7-49df-83a3-cd706589f4dc"
      decimals="2"
      id="F_c099c575-788e-4287-ab7e-d027a8a1cf0a"
      unitRef="U_pure">0.03</dvax:SellingCommissionPercentageFromGrossOfferingProceedsOfSalesOfStock>
    <dvax:ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity
      contextRef="C_26a1416a-c87f-4567-b7f7-4e8b77e534c8"
      decimals="-5"
      id="F_017904c0-5aa5-47f5-8ef5-7be096a49ffd"
      unitRef="U_USD">120000000</dvax:ProceedsFromIssuanceOfCommonStockAuthorizedRemainingCapacity>
    <dvax:NumberOfCommonStockWarrantExercised
      contextRef="C_1d98acd8-10b6-453e-b7a4-a290b0056620"
      decimals="INF"
      id="F_c3add0de-e2aa-4d33-a5a6-bb873dfd9031"
      unitRef="U_shares">1882600</dvax:NumberOfCommonStockWarrantExercised>
    <dvax:CashSettlementOfWarrants
      contextRef="C_7a801bf1-6b19-4a7c-8dc9-d56926556425"
      decimals="-5"
      id="F_826f1b3d-d86a-4603-af14-21a7ec0b645b"
      unitRef="U_USD">8500000</dvax:CashSettlementOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_ef4a36fd-eaf7-46db-ac29-52ed918668e8"
      decimals="-5"
      id="F_496b574b-af45-49a6-b051-bc36883b7cd9"
      unitRef="U_USD">1800000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_570f4054-52a2-48cc-a7e6-1ee24e194cc5">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;15.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equity Plans and Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equity Plans&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2021, we adopted the Dynavax Technologies Corporation 2021 Inducement Award Plan (&#x201c;2021 Inducement Plan&#x201d;), pursuant to which we reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock for issuance under the plan to be used exclusively for grants of awards to individuals who were not previously our employees or directors. In June 2021, we amended the 2021 Inducement Plan (&#x201c;Amended 2021 Inducement Plan&#x201d;) to increase the number of shares of common stock reserved under the 2021 Inducement Plan to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Amended 2021 Inducement Plan was terminated effective as of April 3, 2022 and, therefore, there are no shares of our common stock available for grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2022, our stockholders approved the amendment and restatement of our 2018 Equity Incentive Plan (the &#x201c;Amended 2018 EIP&#x201d;) to, among other things, increase the authorized number of shares of common stock by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The maximum number of shares of common stock that may be issued under the Amended 2018 EIP, will not exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,600,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. As of December 31, 2023, the Amended 2018 EIP and the Amended and Restated 2014 Employee Stock Purchase Plan are our active plans (the "Plans").&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Amended 2018 EIP is administered by our Board of Directors, or a designated committee of the Board of Directors, and awards granted under the Amended 2018 EIP have a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unless earlier terminated by the Board of Directors. As of December 31, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,388,428&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock reserved for issuance under the Amended 2018 EIP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under our Amended 2018 EIP, we may grant stock options, RSUs, performance-based awards, and other awards that are settled in shares of our common stock. Our equity awards generally vest over a three-year period contingent upon continuous service and unless exercised, expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6d4caeb9-dd64-4460-a26d-4c0009adec9d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant (or earlier upon termination of continuous service). Activity under our stock plans is set forth below:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the activity of stock options for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares Underlying &lt;br/&gt;Outstanding Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.61&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options cancelled:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options forfeited (unvested)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options expired (vested)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.18&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.15&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense related to options was approximat&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ely $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; milli&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;on, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023, 2022 and 2021, respectively&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total intrinsic value of stock options exercised during the years ended December 31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The total intrinsic value of exercised stock options is calculated based on the difference between the exercise price and the quoted market price of our common stock as of the close of the exercise date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total fair value of stock options vested during the years ended December 31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the activity of RSUs for the year ended December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;br/&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Grant-Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-vested as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-vested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inclusive of approximately 600,145 RSUs for the year ended December 31, 2023, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense related to RSUs was approximat&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ely $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; milli&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;on, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023, 2022 and 2021, respectively&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The aggregate fair value of the RSUs outstanding as of December 31, 2023, 2022 and 2021, based on our stock price on that date, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; mi&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;llion, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total fair value of RSUs vested during the years ended December 31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;illion, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Market-based Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We granted PSUs to certain executives. These PSUs vest upon a specified market condition. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The summary of PSU activities for the year ended December 31, 2023 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Grant-Date Fair&lt;br/&gt;Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-vested as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-vested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense related to PSUs was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023, 2022 and 2021, respectively. The aggregate intrinsic value of the PSUs outstanding as of December 31, 2023, 2022 and 2021, based on our stock price on that date, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Performance-based Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, approximatel&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;y &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;shares underlying performance-based options were outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Significant Assumptions in Estimating Option Fair Value&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;he fair value of each time-based option is estimated on the date of grant using the Black-Scholes option valuation model. The fair value of each RSU is determined at the date of grant using our closing stock price. The fair value of each PSU is estimated using the Monte Carlo simulation method on the date of grant. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average assumptions used in the calculations of these fair value measurements are as follows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:17.712%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.004%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.322%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Market-Based Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;From &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expected volatility is based on historical volatility of our stock price. The expected life of options granted is estimated based on historical option exercise and employee termination data. Our senior management, who hold a majority of the options outstanding, and other employees were grouped and considered separately for valuation purposes. The risk-free rate for periods within the contractual life of the option is based on the U.S. treasury yield curve in effect at the time of grant. Forfeiture estimates are based on historical employee turnover. The dividend yield is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; percent for all years and is based on our history and expectation of dividend payouts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity awards with time-based vesting, the fair value is amortized to expense on a straight-line basis over the vesting periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have also granted performance-based equity awards to certain of our employees. For equity awards with performance-based vesting criteria, the fair value is amortized to expense when the achievement of the vesting criteria becomes probable.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes stock-based compensation expense recorded in each component of operating expenses in our consolidated statements of operations, and amounts capitalized to our inventories (in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employees and directors stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of sales - product&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the total unrecognized compensation cost related to non-vested stock options and RSUs deemed probable of vesting, including all stock options with time-based vesting, net of estimated forfeitures, amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over the remaining weighted-average vesting period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. As of December 31, 2023, the total unrecognized compensation cost related to PSUs amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Amended and Restated 2014 Employee Stock Purchase Plan (the &#x201c;Employee Stock Purchase Plan&#x201d;) provides for the purchase of common stock by eligible employees. In May 2021, our stockholders approved the amendment and restatement of the Employee Stock Purchase Plan to increase the authorized number of shares of common stock by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The maximum number of shares of common stock that may be issued under the Employee Stock Purchase Plan will not exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,850,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The purchase price per share is the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the fair market value of the common stock on the commencement of the two-year offer period (generally, the sixteenth day in February or August) or (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the fair market value of the common stock on the exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August). For the year ended December 31, 2023, employees have acquired approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock under the Employee Stock Purchase Plan and approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock remained available for future purchases under the Employee Stock Purchase Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the total unrecognized compensation cost related to shares of our common stock under the Employee Stock Purchase Plan amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over the remaining weighted-average vesting period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a210ba4e-63a8-4224-b689-4b3fcc4782cb"
      decimals="INF"
      id="F_7e34fb42-ebd6-43df-827f-bb276109f7f7"
      unitRef="U_shares">1500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4a1fceba-ab37-4367-a47b-ccd8390d5afa"
      decimals="INF"
      id="F_98c5c983-42b0-442a-858e-eb19bb2f598b"
      unitRef="U_shares">3250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <dvax:IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
      contextRef="C_61e4fae6-429a-477a-9549-6b5ff699fbf7"
      decimals="INF"
      id="F_95919680-e634-42d1-b073-e4a4b3c928b7"
      unitRef="U_shares">15000000</dvax:IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_3a3dbbd9-f7d4-4560-b0a0-3f291802b72e"
      decimals="INF"
      id="F_a9753d8e-90a3-4078-af0b-d74d7d5f6f7b"
      unitRef="U_shares">32600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c"
      id="F_46f5a5e7-ffe1-4065-bd49-4fe0769b49cb">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5e53f99f-a072-4fb9-b577-17596226d68f"
      decimals="INF"
      id="F_7b686388-57be-4b93-95db-d9cf2669fc53"
      unitRef="U_shares">9388428</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0d83504a-3b1b-47be-be67-be586b5c04f8"
      id="F_de0fe847-c559-4eaa-be2c-4d3c841702a0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_286b7a5b-eec6-46fb-a173-f92717f0e4a5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the activity of stock options for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares Underlying &lt;br/&gt;Outstanding Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.61&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options cancelled:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options forfeited (unvested)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options expired (vested)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.18&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.15&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_236c1be3-0bfb-4955-8db1-7538eaab51c5"
      unitRef="U_shares">9339000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="2"
      id="F_d865c2a0-f89b-4a58-9c71-8b98bf8367e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      id="F_f9053398-054c-431c-9914-625b18d5a788">P4Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_3dacce46-3074-4906-a512-d34638f55465"
      unitRef="U_USD">16291000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_038f6404-698d-4643-9701-ea7876d15a0c"
      unitRef="U_shares">1982000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="2"
      id="F_7f5afa8c-27bb-45da-bdab-02b389c4229c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_6ccd2c4a-2d38-4b6b-9443-72458a4983bb"
      unitRef="U_shares">850000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="2"
      id="F_d176c2d7-5b25-4571-bb2e-0f481ad3fbc7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_3cab392c-b17d-454c-ae88-0ac22c7499af"
      unitRef="U_shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="2"
      id="F_5d97b8ec-9be7-410c-bbcf-1c98fe4f2589"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_003d1f88-560d-41f3-a77c-9f14ac87c404"
      unitRef="U_shares">261000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="2"
      id="F_343eefa7-36d7-441f-a431-9b6b14d6b0f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_5f805246-0925-47b5-afaa-b3fe69b43bf9"
      unitRef="U_shares">10120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="2"
      id="F_7bdf8d89-1f79-4ed8-9385-90ab21b88b57"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_3b03defe-7a21-40ac-a3ad-8618433be67b">P4Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_3c81d986-8e95-48a2-ae9c-f8f9166fcafa"
      unitRef="U_USD">37388000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_dcea7bdc-71bd-4e8d-a99c-5fbc348e9741"
      unitRef="U_shares">9976000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="2"
      id="F_875dfe6c-5643-4953-a6a9-ef7f2ec4ac0d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_e2770859-2998-41fe-ab97-5963f3051464">P4Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_a9a54d43-e286-4a9d-a549-978084fd78ce"
      unitRef="U_USD">37024000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_85842aa4-d84e-425b-99b5-b082be577298"
      unitRef="U_shares">7014000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="2"
      id="F_bfccbbed-dba7-4d22-8c19-6f0eac1c843c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_b6c99195-228b-4857-b5fd-898171dd0c11">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_95267f25-91b6-4e73-b226-09d3537ddb77"
      unitRef="U_USD">29613000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c"
      decimals="-5"
      id="F_49edc703-9718-40b9-a4b2-e874f57fc43a"
      unitRef="U_USD">18700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_98bd1202-de67-46fa-812a-b3388651d485"
      decimals="-5"
      id="F_2fd34d88-4598-46a8-a8c0-b0f604d80515"
      unitRef="U_USD">17200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf"
      decimals="-5"
      id="F_6ec0ab45-8bc7-40fb-a624-e0759f9a7128"
      unitRef="U_USD">11100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c"
      decimals="-5"
      id="F_b7957a12-accb-4846-a0b5-8c78e0bd46aa"
      unitRef="U_USD">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_98bd1202-de67-46fa-812a-b3388651d485"
      decimals="-5"
      id="F_21c13c0a-907d-443f-a5f6-c1a88a29d5aa"
      unitRef="U_USD">7700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf"
      decimals="-5"
      id="F_92fc3e99-a4b8-4733-b864-17251316aa51"
      unitRef="U_USD">7900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c"
      decimals="-5"
      id="F_f12f6f65-5cf6-42fa-ae3f-1b5304e6ca38"
      unitRef="U_USD">19500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_98bd1202-de67-46fa-812a-b3388651d485"
      decimals="-5"
      id="F_ad6448e1-6fda-44a0-a356-45c287f3c75b"
      unitRef="U_USD">17500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf"
      decimals="-5"
      id="F_de1fedc5-70bd-40bf-8f8f-93ad80a7aa93"
      unitRef="U_USD">9000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_a17a6bde-25ac-4c28-b508-cc7171a17d09">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the activity of RSUs for the year ended December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;br/&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Grant-Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-vested as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-vested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inclusive of approximately 600,145 RSUs for the year ended December 31, 2023, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_2ccde060-5732-4dbe-854e-2ad06dd8b47e"
      decimals="-3"
      id="F_8fb797b5-0179-4af2-b42d-a782fc1780a4"
      unitRef="U_shares">3479000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_2ccde060-5732-4dbe-854e-2ad06dd8b47e"
      decimals="2"
      id="F_3d8dc17d-69f2-48dc-a399-012a6781153a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77"
      decimals="-3"
      id="F_5ca34729-041f-4f3a-8e25-03a1bf7ae1db"
      unitRef="U_shares">2748000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77"
      decimals="2"
      id="F_c02a99f9-ea68-49b6-8170-0354cba467a9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77"
      decimals="-3"
      id="F_2020b3e4-1f4a-4785-a846-ac2f166dc9d8"
      unitRef="U_shares">1515000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77"
      decimals="2"
      id="F_70c93f68-26e0-4dc6-9761-1747a7bdeee6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77"
      decimals="-3"
      id="F_30354380-cb5a-437e-8ae4-76bfd12117d3"
      unitRef="U_shares">267000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77"
      decimals="2"
      id="F_fa63b418-5682-46d8-960f-f96b38bb28bf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_7000fe3e-8aa0-4198-8de5-4640128d667d"
      decimals="-3"
      id="F_9b5a3faf-7420-4c2c-8ab9-7e3593db4ca6"
      unitRef="U_shares">4445000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_7000fe3e-8aa0-4198-8de5-4640128d667d"
      decimals="2"
      id="F_67512fcd-666a-417f-b42d-8cfeadab20c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockExpense
      contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77"
      decimals="-5"
      id="F_fa5fcb9e-a0e8-4c3d-9fe4-3773dbc9a577"
      unitRef="U_USD">20400000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="C_452bdfa1-ad45-4a00-a35b-9cb73b9e9295"
      decimals="-5"
      id="F_c6f401ce-d8c3-4783-88ac-5950a3817bbd"
      unitRef="U_USD">13200000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="C_90d340bb-3e21-4b45-b920-340abe04b8ac"
      decimals="-5"
      id="F_4f9fa626-9af5-4291-b0f1-6edc52a553ec"
      unitRef="U_USD">7900000</us-gaap:RestrictedStockExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="C_7000fe3e-8aa0-4198-8de5-4640128d667d"
      decimals="-5"
      id="F_7299d9a8-450d-4a76-9f81-70f50228c54f"
      unitRef="U_USD">62200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="C_2ccde060-5732-4dbe-854e-2ad06dd8b47e"
      decimals="-5"
      id="F_5790fbe1-df1c-48b7-a319-99a264b4bae4"
      unitRef="U_USD">37000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="C_d2ca19d3-f268-4784-a5f2-05a124a3d30c"
      decimals="-5"
      id="F_0ca9bb1d-50d4-4436-8b04-5cf8f764a850"
      unitRef="U_USD">37300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_2c8b18ed-3d15-4464-921d-cd75ad104a77"
      decimals="-5"
      id="F_52bb1a4f-5e46-47cf-9fcd-9f52cd20a55d"
      unitRef="U_USD">16100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_452bdfa1-ad45-4a00-a35b-9cb73b9e9295"
      decimals="-5"
      id="F_53590135-b45b-4e98-bba0-ecd5d412da9a"
      unitRef="U_USD">15700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_90d340bb-3e21-4b45-b920-340abe04b8ac"
      decimals="-5"
      id="F_72e4e716-a758-4df5-af1e-f163bf76b1ff"
      unitRef="U_USD">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <dvax:ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_86ee72a1-426b-4a2d-99a8-c9d3f28f3579">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The summary of PSU activities for the year ended December 31, 2023 is as follows:&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.383%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Grant-Date Fair&lt;br/&gt;Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-vested as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-vested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</dvax:ScheduleOfPerformanceBasedRestrictedStockUnitTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_1bd10d4c-3dad-4350-b83d-0c72c2905fea"
      decimals="-3"
      id="F_00b5076f-6288-4d63-86f2-4818ab14bd04"
      unitRef="U_shares">193000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_1bd10d4c-3dad-4350-b83d-0c72c2905fea"
      decimals="2"
      id="F_5369f263-5ef7-4229-a0c4-b128ea97e759"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_2b70264d-6f06-4292-a106-b2ff81f59d36"
      decimals="-3"
      id="F_1f4077e7-d8c5-4b98-a8df-f8dd67490059"
      unitRef="U_shares">364000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2b70264d-6f06-4292-a106-b2ff81f59d36"
      decimals="2"
      id="F_457795dd-7ba8-4df2-9d20-b5b3e02e1ca1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_ec73c440-29fa-41e8-b4b7-62558e948364"
      decimals="-3"
      id="F_b6c136c3-8ecc-4152-9317-fadf31e3ab94"
      unitRef="U_shares">557000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_ec73c440-29fa-41e8-b4b7-62558e948364"
      decimals="2"
      id="F_451b44b6-7d6d-40e5-a0b6-7a2ca0bf7ae3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockExpense
      contextRef="C_2b70264d-6f06-4292-a106-b2ff81f59d36"
      decimals="-5"
      id="F_963aedda-38ee-4809-89fc-f7eda704d8a8"
      unitRef="U_USD">2500000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="C_fd1be51a-97e7-41a8-8c3a-1b53c43091c6"
      decimals="-5"
      id="F_4192bb13-f403-48fd-b4c8-8f9c3f674edd"
      unitRef="U_USD">800000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="C_00cf7693-c589-4da2-bf41-f883d3c76f3a"
      decimals="-5"
      id="F_399152d1-317f-407f-9c53-04ec74d5b9ad"
      unitRef="U_USD">1800000</us-gaap:RestrictedStockExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="C_ec73c440-29fa-41e8-b4b7-62558e948364"
      decimals="-5"
      id="F_82dd3e5f-d8d4-4178-8ff9-b14696279819"
      unitRef="U_USD">7800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="C_1bd10d4c-3dad-4350-b83d-0c72c2905fea"
      decimals="-5"
      id="F_813ce2bf-9f10-488d-9daf-dced28ccfda3"
      unitRef="U_USD">2100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="C_5fdc1062-7a2e-42a6-a0ee-956964678351"
      decimals="-5"
      id="F_6d93938f-c518-458d-88cb-fa4eb7c9ec2f"
      unitRef="U_USD">3300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_fcb751e6-cdea-4a40-9300-946017e2ec1e"
      decimals="0"
      id="F_1e2c73b0-69b9-4712-82ff-d6ddcff22c05"
      unitRef="U_shares">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_adda5ad2-bb44-497a-82a7-f23cecc7a314">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average assumptions used in the calculations of these fair value measurements are as follows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:17.712%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.004%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.322%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.832%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Market-Based Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;From &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c"
      decimals="2"
      id="F_65474d94-9a10-4a74-902a-5d13c2928491"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_98bd1202-de67-46fa-812a-b3388651d485"
      decimals="2"
      id="F_b779fab7-ad44-4718-840b-2ef9e6810bbc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf"
      decimals="2"
      id="F_4085198c-c1f7-4efb-9d00-de3091f97974"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_25a5468a-bacc-477f-bef1-e85543a6913f"
      decimals="2"
      id="F_e781c6ef-2c9f-4835-b176-08edaf62a226"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_35f1c43c-dc20-4692-ac8b-37df12d565ea"
      decimals="2"
      id="F_79dfb1bf-3de9-44fe-b998-240d88fca2a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0c1e3d78-dd4b-4d59-b5e6-4fe90c415647"
      decimals="2"
      id="F_78e2bf2c-988a-42d7-b8d3-6852896480e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3d661040-605b-43cf-b60b-b20b979ad675"
      decimals="2"
      id="F_cfc698e7-a1cc-4eae-bddf-3dfa661265b4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_fbe06c3d-ec16-449f-bdd3-62e26d98ec74"
      decimals="2"
      id="F_819cdd84-011b-439e-a698-417cf23f00f5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0e30bc85-1e80-4230-b3a9-6904f8577805"
      decimals="2"
      id="F_6a5f2c1c-8ef2-441a-a05e-985465530579"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c"
      decimals="3"
      id="F_8372cca6-ae0c-48ad-8c1d-bb1a467f8e66"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_98bd1202-de67-46fa-812a-b3388651d485"
      decimals="3"
      id="F_0f474c50-c179-4c8b-9fa7-e3a4981cbd5e"
      unitRef="U_pure">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf"
      decimals="3"
      id="F_aec17192-4eea-4928-b806-adfb16c51c05"
      unitRef="U_pure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_25a5468a-bacc-477f-bef1-e85543a6913f"
      decimals="3"
      id="F_63fca2a5-6d9f-4bf4-ae47-655ab4ecc5c8"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_35f1c43c-dc20-4692-ac8b-37df12d565ea"
      decimals="3"
      id="F_9bc68821-8b2d-48e0-8c44-d60065617f3a"
      unitRef="U_pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_4e3ef292-a629-4f6e-9ba6-f332258de6b4"
      decimals="4"
      id="F_f0557c2c-50c8-4c62-928a-e9077d13396c"
      unitRef="U_pure">0.0003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_6cd9059e-33d1-45f0-85b0-9bedacb0a4f0"
      decimals="4"
      id="F_d009fdfd-7850-4bf7-9286-2e6bd3450385"
      unitRef="U_pure">0.0192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_3d661040-605b-43cf-b60b-b20b979ad675"
      decimals="3"
      id="F_ae778bbd-81d0-4fa9-9bfd-e7519c69d37d"
      unitRef="U_pure">0.049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_fbe06c3d-ec16-449f-bdd3-62e26d98ec74"
      decimals="3"
      id="F_8c017bdb-fe51-435b-961e-a9138cfb8a03"
      unitRef="U_pure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0e30bc85-1e80-4230-b3a9-6904f8577805"
      decimals="3"
      id="F_13d6ef81-e2be-4794-9323-be531d7287cc"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c"
      id="F_610936e6-1dd6-452a-a061-1bc81766d830">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_98bd1202-de67-46fa-812a-b3388651d485"
      id="F_ddececc3-db50-495d-b455-6aa1de7973d1">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf"
      id="F_f74605b9-1a42-4236-a0d1-a9067097e5ec">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_25a5468a-bacc-477f-bef1-e85543a6913f"
      id="F_32471554-009b-4395-9c96-342c48ddcfb5">P2Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_35f1c43c-dc20-4692-ac8b-37df12d565ea"
      id="F_5d9365dc-7b1b-4597-afeb-69c9914d4ee7">P2Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0c1e3d78-dd4b-4d59-b5e6-4fe90c415647"
      id="F_05c13f68-9403-449a-b438-dc88c9c7fc9c">P2Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3d661040-605b-43cf-b60b-b20b979ad675"
      id="F_476630d6-1d0d-4f05-b209-ff7b64cfd5ae">P1Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fbe06c3d-ec16-449f-bdd3-62e26d98ec74"
      id="F_a08645ce-cfe2-476b-afbb-ee02e3f025e7">P1Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0e30bc85-1e80-4230-b3a9-6904f8577805"
      id="F_6d523e9a-3999-4e2b-93a7-f43a2b08296a">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_dadabb88-1dfa-43da-9394-44029f60ca3c"
      decimals="3"
      id="F_bac16705-8922-48ed-b73c-21e35d7d114a"
      unitRef="U_pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_98bd1202-de67-46fa-812a-b3388651d485"
      decimals="3"
      id="F_49a826c9-3bd9-4918-aade-bc1038e26c16"
      unitRef="U_pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_3679aead-0bf6-46ad-8149-c7043f490baf"
      decimals="3"
      id="F_e383eb1c-73f9-4f08-b073-125caefad644"
      unitRef="U_pure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_25a5468a-bacc-477f-bef1-e85543a6913f"
      decimals="3"
      id="F_a415e00a-b342-4826-9c7d-d698b43d4c62"
      unitRef="U_pure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_35f1c43c-dc20-4692-ac8b-37df12d565ea"
      decimals="3"
      id="F_5f37984b-f486-4aef-a558-e41b220eea12"
      unitRef="U_pure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0c1e3d78-dd4b-4d59-b5e6-4fe90c415647"
      decimals="3"
      id="F_48250372-cabf-4141-bdb8-e7a6a769716b"
      unitRef="U_pure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_3d661040-605b-43cf-b60b-b20b979ad675"
      decimals="3"
      id="F_a96a3d77-4d54-45c7-8360-39d7926ad2a6"
      unitRef="U_pure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_fbe06c3d-ec16-449f-bdd3-62e26d98ec74"
      decimals="3"
      id="F_11e7b689-4319-4597-ac4f-7fef82ebf545"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0e30bc85-1e80-4230-b3a9-6904f8577805"
      decimals="3"
      id="F_7cd54ed0-dc7f-4135-8a12-3991c87ad675"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="2"
      id="F_35b6dbc9-3573-4d9a-86cf-85b3b6455129"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_5994c16d-6de7-4ca4-8cd8-a7507e8055b1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes stock-based compensation expense recorded in each component of operating expenses in our consolidated statements of operations, and amounts capitalized to our inventories (in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employees and directors stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of sales - product&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_fe31b39a-5029-48fb-a706-11d5b442caf4"
      unitRef="U_USD">42592000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_abd35de5-08b6-4310-8ad8-e2a039aec188"
      unitRef="U_USD">32915000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_e8f202d9-bc7a-48ea-9fce-9f56e477e01c"
      unitRef="U_USD">21285000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3226f406-b30a-4fe8-b77d-6acd3bc687cf"
      decimals="-3"
      id="F_a77db1cb-6415-4e11-9fb9-4ddcddf790de"
      unitRef="U_USD">9285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a7cd9712-92a6-43fa-a3e4-620df529380f"
      decimals="-3"
      id="F_65d61024-4de9-44fb-bac7-bf0ac0df4393"
      unitRef="U_USD">5954000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b162a2fb-1421-4817-89b7-7fd0107432f6"
      decimals="-3"
      id="F_e4af46ff-00ee-4402-971a-15bfe92d3f70"
      unitRef="U_USD">3818000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0cd05fc1-4367-467f-b1f4-b88105492b67"
      decimals="-3"
      id="F_3e610e3b-85b2-4ca0-a9f4-6a9508b624c0"
      unitRef="U_USD">29069000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_065dab0d-65d8-4bc3-b27e-bda7f559f545"
      decimals="-3"
      id="F_25b810e9-9be5-4c75-90df-b0a422e49f36"
      unitRef="U_USD">23118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8aafc35f-0931-49c4-99f3-ba14874dc415"
      decimals="-3"
      id="F_b5c04cb0-d71e-4923-8981-99b506c60674"
      unitRef="U_USD">14894000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c265dbab-c590-4635-805d-fcfcffc40237"
      decimals="-3"
      id="F_24d6135a-8047-408e-b657-6e42d4cb2c9b"
      unitRef="U_USD">1839000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6adf0287-276d-4c38-aa2a-2587117e5871"
      decimals="-3"
      id="F_061a3e3c-3c4c-4e90-96bf-f088eec4f6e8"
      unitRef="U_USD">1123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5d1752d7-1a8f-47fe-a52e-e23618ff2973"
      decimals="-3"
      id="F_083faa5d-11da-44c1-bd84-8f645d48113d"
      unitRef="U_USD">553000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="C_99afab35-99e9-4d2e-bfac-d15173962934"
      decimals="-3"
      id="F_a78e4525-b050-4af9-9878-51b3f8fa257b"
      unitRef="U_USD">2399000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="C_39e6c092-46ac-445b-8f0b-7dcdd766c1ea"
      decimals="-3"
      id="F_dc9a09c4-19a1-4de1-9d80-1bdb443543b7"
      unitRef="U_USD">2720000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="C_c4818259-befe-457e-b5e4-83ccf0a85a8d"
      decimals="-3"
      id="F_ffcd49b0-6ab7-434e-ac48-91e7a5df6748"
      unitRef="U_USD">2020000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_6ee13694-9f94-4b94-8c44-227e3e0d30f8"
      unitRef="U_USD">42592000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_1921901e-1d66-46d9-a249-6b9ca4071127"
      unitRef="U_USD">32915000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_c111b6a9-d8a5-4327-bc32-b2f07f96f9f9"
      unitRef="U_USD">21285000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_ab1c6ec8-3564-4d41-9ebc-32087bc08f68"
      decimals="-5"
      id="F_09ef9a11-26b9-445d-a493-814c5326bc32"
      unitRef="U_USD">46100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_497a4353-898d-4ae9-9975-8c32c4ebb9d3"
      id="F_aafd2fbc-2911-40f2-8dcf-0f7fa67d0190">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_96ad4e0b-9a01-4e43-b0c5-c677a5fe8543"
      decimals="-5"
      id="F_4602a102-726c-423b-9a9a-965a0efe5f4d"
      unitRef="U_USD">5500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <dvax:IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
      contextRef="C_19035b31-a18b-4349-93e6-45dccd60c49e"
      decimals="INF"
      id="F_dcbfe70c-53d5-4936-b8cb-d9000bcac73d"
      unitRef="U_shares">1000000</dvax:IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_304335a0-4bda-469c-809d-39c049a6dfae"
      decimals="INF"
      id="F_ffd6c2a2-e247-4090-89ea-0538fb78e140"
      unitRef="U_shares">1850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_54064a80-7e76-458d-93d5-b4613985ec73"
      decimals="2"
      id="F_c1fcab9a-9245-4845-818b-f1060ab17936"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_9bbfa976-1e7d-4da7-bc09-d8fb7b04dbd9"
      decimals="2"
      id="F_5d2e266f-4e7b-4b57-a1f3-af50773b6bab"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <dvax:SharesPurchasedByEmployeesUnderEmployeePurchasePlan
      contextRef="C_5431114c-d857-438b-8f6d-8010eba4cc30"
      decimals="0"
      id="F_c6a5526f-c25b-4f9d-a42e-854604c50bb8"
      unitRef="U_shares">161000</dvax:SharesPurchasedByEmployeesUnderEmployeePurchasePlan>
    <dvax:SharesAvailableForPurchasesUnderEmployeePurchasePlan
      contextRef="C_6507c936-b545-4e7c-859a-811146d183ad"
      decimals="0"
      id="F_7653a835-681a-45f1-b46e-5b350ef62053"
      unitRef="U_shares">722000</dvax:SharesAvailableForPurchasesUnderEmployeePurchasePlan>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_6507c936-b545-4e7c-859a-811146d183ad"
      decimals="-5"
      id="F_f103ae16-2f01-4a35-a09e-981dcc95b0f7"
      unitRef="U_USD">1000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_5431114c-d857-438b-8f6d-8010eba4cc30"
      id="F_11ac300e-c72a-4355-acb4-f7b0c558f488">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_ce31f4f1-a765-443b-9be7-dad813728014">&lt;div style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;16.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Employee Benefit Plan &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We maintain a 401(k) Plan, which qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Under the 401(k) Plan, participating employees may defer a portion of their pretax earnings. We may, at our discretion, contribute for the benefit of eligible employees. Our contribution to the 401(k) Plan was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-5"
      id="F_b6a74644-5756-448e-baec-91ecc7fccdf2"
      unitRef="U_USD">1300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-5"
      id="F_11733941-7e14-400b-91f8-7f900e6a26d4"
      unitRef="U_USD">900000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-5"
      id="F_09bc0811-a9a3-4bf8-85ee-f8d885d60be4"
      unitRef="U_USD">300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_d942c1e4-90ff-40bb-8ea4-b9d85a00c641">&lt;div style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;17.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Consolidated (loss) income before provision for income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.323%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.501%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.724%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.501%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.724%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.501%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.724%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;294,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of the consolidated income tax provision for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.711%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.217%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.217%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.217%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-US&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-US&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The difference between the consolidated income tax provision and the amount computed by applying the federal statutory income tax rate to the consolidated income before income taxes in the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax provision (benefit) at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Business credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred compensation charges&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Mark-to-market of warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss and tax credit limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(1) Certain prior year amounts have been reclassified to conform to the current year presentation. In 2022 and 2021, Foreign taxes were included in Other.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred tax assets and liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Section 174 capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;189,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;180,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The tax benefit of net operating losses, temporary differences and credit carryforwards is required to be recorded as an asset to the extent that management assesses that realization is "more likely than not." Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. A high degree of judgment is required to determine if, and the extent to which, valuation allowances should be recorded against deferred tax assets. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. Based on all available evidence as of December 31, 2023, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized, and, accordingly, has provided a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The valuation allowance increased by &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; during the year ended December 31, 2023 and decreased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the year ended December 31, 2022. The increase &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in valuation allowance during the year ended December 31, 2023 was due to an increase in our deferred tax assets, predominantly related to Section 174 capitalization and increased reserves largely offset by utilization of net operating losses. The decrease in valuation allowance during the year ended December 31, 2022 was due to a decrease in our deferred tax assets, predominantly related to utilization of net operating losses, offset by updates to the Section 382 analysis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we had federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;million, which began to expire in the year &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, federal net operating loss carryforwards of approximatel&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;y $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;353.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which do not expire and federal research and development tax credits of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, whi&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ch expire in the years &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2043&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we had net operating loss carryforwards for California and other states for income tax purposes of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;283.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which expire in the years &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and California state research and development tax credits of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which do not expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; remaining net operating loss carryforwards for foreign income tax purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Uncertain Income Tax positions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total amount of unrecognized tax benefits was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023 and 2022, respectively. If recognized, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the unrecognized tax benefits would affect the effective tax rate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the activity related to our unrecognized tax benefits:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax positions related to the prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Settlements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lapses in statute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our policy is to account for interest and penalties as inco&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;me tax expense. As of December 31, 2023, there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; interest and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; penalties recognized in the provision for income taxes. As of December 31, 2022, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; interest and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; penalties recognized in the provision for income taxes. We do not anticipate any significant change within 12 months of this reporting date of its uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Tax Reform Act of 1986 limits the annual use of net operating loss and tax credit carryforwards in certain situations where changes occur in stock ownership of a company. In the event there is a change in ownership, as defined, the annual utilization of such carryforwards could be limited. For the year ended December 31, 2021, we completed a preliminary analysis under Section 382 of the Internal Revenue Code indicating we experienced ownership changes in 2008, 2010, 2012, and 2019 that limited the future use of our pre-change federal and state net operating loss carryforwards and federal research and development tax credits. We finalized the study during the year ended December 31, 2022 and concluded that we only experienced ownership changes in 2008, 2010, and 2012, resulting in a significant reduction in the federal and state net operating loss carryforwards and federal research and development tax credits that are expected to expire unused. We have revised the net operating loss carryforwards and research and development tax credits that are expected to expire unused as a result of the annual limitations in the deferred tax assets and corresponding uncertain tax positions as of December 31, 2022. There were no changes to our Section 382 analysis as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are subject to income tax examinations for U.S. federal and state income taxes from 2002 forward. We are subject to tax examination in Germany from 2018 forward, in India from 2019 forward and in Italy from 2021 forward.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_cd3f9d00-93b0-4962-ac69-e47158e8cfa7">&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Consolidated (loss) income before provision for income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.323%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.501%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.724%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.501%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.724%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.501%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.724%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;294,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_a171a194-d5b3-4743-aaf3-1cc3b3d50c9b"
      unitRef="U_USD">-6275000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_21d29cff-d653-4f12-ad0c-977089317d84"
      unitRef="U_USD">292460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_8703a832-420b-44d4-9b29-c60bfd17ae59"
      unitRef="U_USD">75954000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_805a6993-9a59-4ddb-bdf6-face87944bbf"
      unitRef="U_USD">1908000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_5b8271ba-f7a4-439e-a86f-23399466635b"
      unitRef="U_USD">1839000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_14eef812-e341-4cd9-8aa9-590894309da3"
      unitRef="U_USD">1567000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <dvax:IncomeLossFromContinuingOperationsBeforeIncomeTaxes
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_ba1038b5-05e7-490a-8132-2856816d65a1"
      unitRef="U_USD">-4367000</dvax:IncomeLossFromContinuingOperationsBeforeIncomeTaxes>
    <dvax:IncomeLossFromContinuingOperationsBeforeIncomeTaxes
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_e44239d7-0bdf-4055-8655-504f575c670a"
      unitRef="U_USD">294299000</dvax:IncomeLossFromContinuingOperationsBeforeIncomeTaxes>
    <dvax:IncomeLossFromContinuingOperationsBeforeIncomeTaxes
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_f3b0441d-0ee2-4884-8222-c77eacf2ec6a"
      unitRef="U_USD">77521000</dvax:IncomeLossFromContinuingOperationsBeforeIncomeTaxes>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_3b0caa39-80f5-44ac-ae58-0be80094fc31">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of the consolidated income tax provision for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.711%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.217%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.217%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.217%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-US&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-US&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_458d1528-8995-4538-98ba-c5365ec79f5c"
      unitRef="U_USD">-178000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_937f3469-481e-429f-9aa4-c92cc72d6dad"
      unitRef="U_USD">-165000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_95eb4399-ab15-4295-a701-09c2e89b7bcd"
      unitRef="U_USD">345000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_427dbf71-3c3c-4e00-984b-1f6cf11d0f8a"
      unitRef="U_USD">1533000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_880cdaf5-a8ba-4af8-999e-f36d3755eac2"
      unitRef="U_USD">897000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_9798674c-ba37-4eae-bb8d-84d28f0a633e"
      unitRef="U_USD">260000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_dfc9d070-e3f8-499d-99ac-698b7a732a15"
      unitRef="U_USD">667000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_72e04c62-3741-4900-a349-e13fac39a5f7"
      unitRef="U_USD">411000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_20172d5a-036f-4197-8cf6-5d4f9a753b4b"
      unitRef="U_USD">203000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_26bfd0ad-085a-463b-b35f-12c21440740b"
      unitRef="U_USD">2022000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_0e0f9d56-435a-4198-9252-8ce3e91c8401"
      unitRef="U_USD">1143000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_8041646c-f6e0-4faf-9baf-5682eff93640"
      unitRef="U_USD">808000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_11016586-9236-4553-8b61-d79e8b6f940b"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_1872ab71-d0ab-41c1-9e3b-1bc81224f8d2"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_961d8508-9472-4b97-820d-f77e7e948139"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_dd94c477-5c98-4b47-b532-01f50f6c32d0"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_31aeabf4-9f58-462f-8392-9e632de0461a"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_d2f97dc1-aa3e-4e9a-bf4e-59785b4f1e3c"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_89aeec94-dd0d-4463-a423-c1e2f82b4447"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_c62614f3-f6dd-47bd-b121-6bfc697d6bd7"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_e4ec45df-66c7-45e0-ace7-5a564e90b886"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_193c61a0-9555-4ca4-84d8-4b1003373ef4"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_ca6edb9e-8784-46a0-b324-c2cfb4930628"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_d0edfd4a-7fe8-4816-b60c-ad33215e58a5"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_7a976fb4-a5f4-493c-9607-9ecd9f315943"
      unitRef="U_USD">2022000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_67dbcebc-48d8-48fa-9f8a-97dec01062fb"
      unitRef="U_USD">1143000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_b646b319-decf-41ae-8b84-77a93b76e855"
      unitRef="U_USD">808000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_3f3036b0-8370-49c9-9ea2-769a63fbb439">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The difference between the consolidated income tax provision and the amount computed by applying the federal statutory income tax rate to the consolidated income before income taxes in the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax provision (benefit) at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Business credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred compensation charges&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Mark-to-market of warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss and tax credit limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(1) Certain prior year amounts have been reclassified to conform to the current year presentation. In 2022 and 2021, Foreign taxes were included in Other.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_f862c330-089b-4d11-903d-6adbb15bccab"
      unitRef="U_USD">-917000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_edd54ae2-e83a-4b37-913c-62a673dbfc76"
      unitRef="U_USD">61775000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_d6419891-b986-4149-ab64-91c725065df5"
      unitRef="U_USD">16397000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_463a4df0-cf90-4ce0-b95d-0f724d536055"
      unitRef="U_USD">574000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_ddc97509-59b0-4e6b-adc9-e240f4dc93ee"
      unitRef="U_USD">-2942000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_f1930502-2312-4cd5-9569-258ffae5aaf6"
      unitRef="U_USD">3576000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <dvax:IncomeTaxReconciliationTaxCredit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_48491509-56cc-4e7e-8c40-ba30ff810d63"
      unitRef="U_USD">2050000</dvax:IncomeTaxReconciliationTaxCredit>
    <dvax:IncomeTaxReconciliationTaxCredit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_4a573ca7-fc04-4a99-a123-9a709ea3b3da"
      unitRef="U_USD">3246000</dvax:IncomeTaxReconciliationTaxCredit>
    <dvax:IncomeTaxReconciliationTaxCredit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_343e6170-1ae9-4180-b700-6dab0961fc8a"
      unitRef="U_USD">982000</dvax:IncomeTaxReconciliationTaxCredit>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_8b326de6-748f-4762-87f4-b443d0df8e7e"
      unitRef="U_USD">334000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_e4b76d8a-601a-40c0-90ea-a52dcaf33c43"
      unitRef="U_USD">586000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_df37b476-c088-4f5f-a952-9edbcd3e309e"
      unitRef="U_USD">424000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <dvax:IncomeTaxReconciliationDeferredCompensationCharges
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_105253c6-7393-468c-9538-0f9bba147097"
      unitRef="U_USD">830000</dvax:IncomeTaxReconciliationDeferredCompensationCharges>
    <dvax:IncomeTaxReconciliationDeferredCompensationCharges
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_9897b932-1131-4d88-a838-e6a377129d95"
      unitRef="U_USD">-473000</dvax:IncomeTaxReconciliationDeferredCompensationCharges>
    <dvax:IncomeTaxReconciliationDeferredCompensationCharges
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_aa7daa36-39b9-47a6-b891-ba1f2edc3431"
      unitRef="U_USD">131000</dvax:IncomeTaxReconciliationDeferredCompensationCharges>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_b07d9e3e-2273-430d-ae00-d572b570456d"
      unitRef="U_USD">1466000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_6a0a4d29-c136-4a1a-b33f-d9985aef4d6b"
      unitRef="U_USD">-324000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_be7d609e-87d5-44c2-af40-0cb62be4a76c"
      unitRef="U_USD">-86847000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <dvax:Section162MLimitation
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_b50b6eea-5ea1-4253-aaf5-b0a45dd5b3cb"
      unitRef="U_USD">1963000</dvax:Section162MLimitation>
    <dvax:Section162MLimitation
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_d69b7361-5b47-4e88-b3d7-b1128e9638b0"
      unitRef="U_USD">1779000</dvax:Section162MLimitation>
    <dvax:Section162MLimitation
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_9db1f43d-c8b7-48eb-9cad-d570206e725f"
      unitRef="U_USD">1241000</dvax:Section162MLimitation>
    <dvax:IncomeTaxRateReconciliationMarkToMarketOfWarrants
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_68d48fef-3d3c-4958-bcd2-43af612b262f"
      unitRef="U_USD">0</dvax:IncomeTaxRateReconciliationMarkToMarketOfWarrants>
    <dvax:IncomeTaxRateReconciliationMarkToMarketOfWarrants
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_5b2849f4-a7e1-439f-a98f-a3c40bdb2423"
      unitRef="U_USD">-378000</dvax:IncomeTaxRateReconciliationMarkToMarketOfWarrants>
    <dvax:IncomeTaxRateReconciliationMarkToMarketOfWarrants
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_44fa2f65-d7d7-4043-a632-34756c243069"
      unitRef="U_USD">10364000</dvax:IncomeTaxRateReconciliationMarkToMarketOfWarrants>
    <dvax:NetOperatingLossAndTaxCreditLimitations
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_c1dbd44b-a389-4cb6-96b5-a0bd452a2129"
      unitRef="U_USD">0</dvax:NetOperatingLossAndTaxCreditLimitations>
    <dvax:NetOperatingLossAndTaxCreditLimitations
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_39834f1b-342c-4b6c-a2b2-3a9726576d31"
      unitRef="U_USD">-56908000</dvax:NetOperatingLossAndTaxCreditLimitations>
    <dvax:NetOperatingLossAndTaxCreditLimitations
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_41336f18-06a9-4ec5-aa99-99b555806c5e"
      unitRef="U_USD">56459000</dvax:NetOperatingLossAndTaxCreditLimitations>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_6e3f6b34-bf8f-4045-a212-7da919d109d0"
      unitRef="U_USD">-518000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_64a70d92-6b32-4349-af19-80b652fc5223"
      unitRef="U_USD">879000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_cafa2182-cde7-40f4-af81-a312cf934c7a"
      unitRef="U_USD">-290000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_a6d27ef7-a5ac-4868-b303-295695ceebb3"
      unitRef="U_USD">340000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_7155f208-f926-44f1-9db7-10a595b4bf6d"
      unitRef="U_USD">395000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_c9b31fa0-7783-4d29-9c33-aa44716f4dc9"
      unitRef="U_USD">335000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_2b0a5bf1-45e3-4207-aedb-387c8f3eafd9"
      unitRef="U_USD">2022000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_47371339-a7e9-4cfa-8a9a-52246f7182cb"
      unitRef="U_USD">1143000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ac25b5d8-444d-4f9b-b373-e4fc2005d3f3"
      decimals="-3"
      id="F_5649f405-6b80-44b5-9aa5-e5bf13f9462c"
      unitRef="U_USD">808000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_b850b319-48cb-42e8-9f7d-a81a953aa8e4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred tax assets and liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Section 174 capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;189,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;180,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_d8acd042-c8e8-47d1-a979-a2bf4641176b"
      unitRef="U_USD">96336000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_2e9db7b7-309f-47a1-9d4e-40443fc17d3a"
      unitRef="U_USD">113228000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_a3c2aebd-5808-474a-8238-ebe6dad0a471"
      unitRef="U_USD">34940000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_e4cc22b7-cce5-43b9-9f28-523a6f2362e8"
      unitRef="U_USD">33444000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <dvax:Deferredtaxassetsoperatinglosscarryforwardscapitalization
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_5989d1eb-6969-4704-9e35-1327ebc3093b"
      unitRef="U_USD">22556000</dvax:Deferredtaxassetsoperatinglosscarryforwardscapitalization>
    <dvax:Deferredtaxassetsoperatinglosscarryforwardscapitalization
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_3ddb1b97-f26c-4042-a509-024560099680"
      unitRef="U_USD">15308000</dvax:Deferredtaxassetsoperatinglosscarryforwardscapitalization>
    <dvax:DeferredTaxAssetsLeaseLiability
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_64589f93-393c-42e5-ae24-e03003ee9c6c"
      unitRef="U_USD">8868000</dvax:DeferredTaxAssetsLeaseLiability>
    <dvax:DeferredTaxAssetsLeaseLiability
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_c235351d-04df-4059-94ed-330b73df5f56"
      unitRef="U_USD">9530000</dvax:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_0b978887-2be3-44ca-8039-a23e33c8a232"
      unitRef="U_USD">10572000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_9e756a43-2d35-48ca-90e2-d4f6ffc176e6"
      unitRef="U_USD">7780000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_47a0c3aa-a755-4c9f-9df4-a037697c51ec"
      unitRef="U_USD">15808000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_4a2d5894-7c16-4785-b801-4261b2794e01"
      unitRef="U_USD">9089000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_bfc3a1c1-9286-4404-93e5-2e6a58b186b5"
      unitRef="U_USD">348000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_fa14ebe5-33df-4f85-9117-b6990064bae9"
      unitRef="U_USD">337000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_571e06aa-7060-4ef1-8e4f-591fe10c00cc"
      unitRef="U_USD">189428000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_bf3e30e3-1df4-4f5f-9137-ba05a0fe6144"
      unitRef="U_USD">188716000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_7ed86575-45a2-4202-bb37-deda1519375f"
      unitRef="U_USD">180387000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_7bec8789-5d94-4c65-afdf-08256e881c6c"
      unitRef="U_USD">178920000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_9fbe3389-1246-4464-a6fa-3622ec5fdf40"
      unitRef="U_USD">9041000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_60857780-8c6a-4931-9cc4-47c1d10506f1"
      unitRef="U_USD">9796000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_28c86945-87df-4d9f-b524-cbb9451121ff"
      unitRef="U_USD">2667000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_51a41657-fdbf-4860-9461-f1f85de4b259"
      unitRef="U_USD">2916000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <dvax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_b637e83f-85b3-4a9a-bca7-fc9590a87f7f"
      unitRef="U_USD">6345000</dvax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <dvax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_12225877-1983-423d-8e5a-c873d49d299e"
      unitRef="U_USD">6785000</dvax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_536de7a3-f6db-4523-a782-a10671768dff"
      unitRef="U_USD">29000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_54d912b6-4eb1-4403-9891-a0b4374caac4"
      unitRef="U_USD">95000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_0660b082-d283-47e3-8a15-0a3b6a67f6ae"
      unitRef="U_USD">9041000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_32c16348-813d-4884-8ee5-2832925c1f18"
      unitRef="U_USD">9796000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_44ea0b50-807c-4e46-a112-f370e47c2917"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_9a71dca9-6e06-4ca1-b33c-d89a17110187"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-5"
      id="F_6287fc2d-f5a3-457b-a010-7663f417e36a"
      unitRef="U_USD">1500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-5"
      id="F_9f6e13d7-bff7-40a6-9053-95402fc0384b"
      unitRef="U_USD">300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_2d3137c5-4a24-4ea8-bd54-b337cfe3189f"
      decimals="-5"
      id="F_975007e3-a44c-46be-9b19-edf35c5237f4"
      unitRef="U_USD">23100000</us-gaap:OperatingLossCarryforwards>
    <dvax:OperatingLossCarryforwardExpirationYear
      contextRef="C_8d904b5d-a1ff-4762-bd22-3e30cec979bb"
      id="F_8762c4ac-1fd0-4549-9320-56a60e863c87">2024</dvax:OperatingLossCarryforwardExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-5"
      id="F_29c196e6-7c74-4120-a041-0aa7a9db518a"
      unitRef="U_USD">353500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_10ed8dc0-a4c7-4909-9310-8008b51e41a3"
      decimals="-5"
      id="F_55f5bdbd-08b7-4983-a1bc-f7bbaea3e559"
      unitRef="U_USD">28300000</us-gaap:TaxCreditCarryforwardAmount>
    <dvax:TaxCreditCarryforwardExpirationYear
      contextRef="C_4daec9bd-18e0-4c0a-8754-6c97e388d5ab"
      id="F_4ff37029-06db-43fc-b733-7ac67abee4b1">2024</dvax:TaxCreditCarryforwardExpirationYear>
    <dvax:TaxCreditCarryforwardExpirationYear
      contextRef="C_fc1b7051-c0ab-49af-aabf-551b7383e779"
      id="F_c8e29cad-e48a-456e-81fc-7f5cb87d0280">2043</dvax:TaxCreditCarryforwardExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_7ef86bfc-0585-40df-9bd1-4bd0b18b364e"
      decimals="-5"
      id="F_c1d99bcc-593f-4929-ae16-8e654003b317"
      unitRef="U_USD">283900000</us-gaap:OperatingLossCarryforwards>
    <dvax:OperatingLossCarryforwardExpirationYear
      contextRef="C_88dea699-9bab-4426-88ed-ff1960599278"
      id="F_f9ddd36d-1a32-499b-ae74-f88ab9e53e0c">2024</dvax:OperatingLossCarryforwardExpirationYear>
    <dvax:OperatingLossCarryforwardExpirationYear
      contextRef="C_0ef049fa-5c44-4e24-81ac-16efb8ddcea8"
      id="F_704dc8dc-8e6a-4f93-9629-b71baf4a4373">2040</dvax:OperatingLossCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_5413023b-1fa8-4b55-b7bd-90b2b2bbf2cf"
      decimals="-5"
      id="F_1f68f316-8eec-40d7-afa9-5cff990afac2"
      unitRef="U_USD">22300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_8ba29514-78ad-4553-a6f6-379d75c85d9b"
      decimals="-6"
      id="F_6ea4a058-8bb5-42c9-96a6-0ce511d80da1"
      unitRef="U_USD">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-5"
      id="F_fe745213-7d19-43d5-8827-c813a93f7dc0"
      unitRef="U_USD">12100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-5"
      id="F_0f5c18db-1b15-435a-a02a-ab2811c5b804"
      unitRef="U_USD">11300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-6"
      id="F_a4b04bfc-33ea-48b4-bc01-62e50dc89ab3"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      id="F_49387e29-8a23-47b5-b108-651f4f5ac624">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the activity related to our unrecognized tax benefits:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax positions related to the prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Settlements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lapses in statute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_8da47600-58ec-42c7-9964-3b384d5a73bf"
      unitRef="U_USD">11339000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_d3b6b8e9-b6aa-434a-b512-84475ede426d"
      decimals="-3"
      id="F_321bfcc4-dcda-4fa4-bfac-5bf6f9f8c556"
      unitRef="U_USD">5615000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_fbece5ce-22bd-419a-9387-682e8e8753db"
      unitRef="U_USD">762000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_71800f43-d80d-4da8-91cb-aa9bb958bcaa"
      unitRef="U_USD">670000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_0482ced4-1752-495f-992e-721d0a078577"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_d5443c20-b4d6-4f45-9a7f-a15a47dd8d0e"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_8a7d53d6-0a10-40cb-9b57-6be194f4d5f3"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_a11b9cf6-4651-44ca-8e0a-18ac0af265ec"
      unitRef="U_USD">5054000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_951f4f15-e679-48b8-a5d6-0b6c45204602"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_fc94025e-c4bc-4b70-954a-26963bf11a03"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-3"
      id="F_c6b2d7c7-db3a-45ee-a8e0-c259e0d2e6ff"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_08966c01-549d-45b8-980b-100c00c3b0ac"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-3"
      id="F_da78389a-512d-479c-988b-bc2259f95bc2"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_7d274567-d036-45ef-8bff-f4dc34904726"
      decimals="-3"
      id="F_8e95acb1-09b7-4a63-8813-b81af2b0e590"
      unitRef="U_USD">12101000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_aa5de6f4-4236-4dcd-a0ed-6e3f94348e80"
      decimals="-3"
      id="F_01490815-d6e1-4643-a400-c461b2dff33c"
      unitRef="U_USD">11339000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-6"
      id="F_5d91b4e9-b33c-48b6-aa1e-cb061c049390"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="C_37a32908-ef6c-4d0d-ab6d-8962e3c5761a"
      decimals="-6"
      id="F_fdaa78c2-ca3f-4ea1-9596-cb36f597af87"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-6"
      id="F_8effb282-a715-49f5-bd23-158e5a87bbd8"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="C_10125268-dcf7-417c-8e67-6935f116fdcc"
      decimals="-6"
      id="F_08fd3dd4-3376-4209-81fb-8220aa35823f"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_030a5d8c-7c33-4a59-ba90-6103938eb1ce"
          xlink:label="F_030a5d8c-7c33-4a59-ba90-6103938eb1ce"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_cb64a042-6b38-4867-8734-d0eb22b365cc"
          xlink:label="F_cb64a042-6b38-4867-8734-d0eb22b365cc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3e2c2b77-11ae-45d6-a4ff-5efa14a8a961"
          xlink:label="F_3e2c2b77-11ae-45d6-a4ff-5efa14a8a961"
          xlink:type="locator"/>
        <link:footnote id="FNT_4b6758f3-5084-45ca-8640-344a9ad1524b" xlink:label="FNT_4b6758f3-5084-45ca-8640-344a9ad1524b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted cash is included in "Other assets" in the Consolidated Balance Sheets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_030a5d8c-7c33-4a59-ba90-6103938eb1ce"
          xlink:to="FNT_4b6758f3-5084-45ca-8640-344a9ad1524b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cb64a042-6b38-4867-8734-d0eb22b365cc"
          xlink:to="FNT_4b6758f3-5084-45ca-8640-344a9ad1524b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3e2c2b77-11ae-45d6-a4ff-5efa14a8a961"
          xlink:to="FNT_4b6758f3-5084-45ca-8640-344a9ad1524b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_b2c509cf-4658-4d4b-b728-8d4a0640a162"
          xlink:label="F_b2c509cf-4658-4d4b-b728-8d4a0640a162"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_55b39750-cebc-4736-b3f2-9395cfe6ff03"
          xlink:label="F_55b39750-cebc-4736-b3f2-9395cfe6ff03"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d6145b6a-d040-4dd6-9cb7-4c98c35a46d0"
          xlink:label="F_d6145b6a-d040-4dd6-9cb7-4c98c35a46d0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f3da79f1-24c7-4632-b740-8b131a9d2be9"
          xlink:label="F_f3da79f1-24c7-4632-b740-8b131a9d2be9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_2db33005-69a9-4d8f-82a2-0a0b43266bb2"
          xlink:label="F_2db33005-69a9-4d8f-82a2-0a0b43266bb2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bf5112d8-1c04-421c-a1d7-be09e25b39c7"
          xlink:label="F_bf5112d8-1c04-421c-a1d7-be09e25b39c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_55014c25-30ae-4571-8d55-fc4908e71a29"
          xlink:label="F_55014c25-30ae-4571-8d55-fc4908e71a29"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_56283b7b-0bf3-4c03-a372-2a21083d9543"
          xlink:label="F_56283b7b-0bf3-4c03-a372-2a21083d9543"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_1008207a-8c71-49e0-993d-4989f909b1a5"
          xlink:label="F_1008207a-8c71-49e0-993d-4989f909b1a5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5edd96ac-e2e3-4eab-ba59-1dce17251a9e"
          xlink:label="F_5edd96ac-e2e3-4eab-ba59-1dce17251a9e"
          xlink:type="locator"/>
        <link:footnote id="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997" xlink:label="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reserves are for chargebacks, discounts and other fees</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b2c509cf-4658-4d4b-b728-8d4a0640a162"
          xlink:to="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_55b39750-cebc-4736-b3f2-9395cfe6ff03"
          xlink:to="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d6145b6a-d040-4dd6-9cb7-4c98c35a46d0"
          xlink:to="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f3da79f1-24c7-4632-b740-8b131a9d2be9"
          xlink:to="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2db33005-69a9-4d8f-82a2-0a0b43266bb2"
          xlink:to="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bf5112d8-1c04-421c-a1d7-be09e25b39c7"
          xlink:to="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_55014c25-30ae-4571-8d55-fc4908e71a29"
          xlink:to="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_56283b7b-0bf3-4c03-a372-2a21083d9543"
          xlink:to="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1008207a-8c71-49e0-993d-4989f909b1a5"
          xlink:to="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5edd96ac-e2e3-4eab-ba59-1dce17251a9e"
          xlink:to="FNT_9bfb23c1-c53a-400e-b33b-56a2ef98a997"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_66c01725-80e8-4499-8bed-8476bf3e4e03"
          xlink:label="F_66c01725-80e8-4499-8bed-8476bf3e4e03"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_50131afd-0f80-49d3-83f5-48f0a9a291ba"
          xlink:label="F_50131afd-0f80-49d3-83f5-48f0a9a291ba"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f05c35cd-44b9-4458-bbd6-5b766235a786"
          xlink:label="F_f05c35cd-44b9-4458-bbd6-5b766235a786"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f54dd4fc-9a50-4c74-866f-36bf8b38e7ae"
          xlink:label="F_f54dd4fc-9a50-4c74-866f-36bf8b38e7ae"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_1fd1191c-48bf-416e-9986-9e4ecc313c72"
          xlink:label="F_1fd1191c-48bf-416e-9986-9e4ecc313c72"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_af7984ca-1c6a-4061-9b34-3096cb7c7363"
          xlink:label="F_af7984ca-1c6a-4061-9b34-3096cb7c7363"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e4271787-7be9-41a9-9ec1-ae5a48e736d9"
          xlink:label="F_e4271787-7be9-41a9-9ec1-ae5a48e736d9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6af692da-77b0-4aed-aaed-263dbd1e56db"
          xlink:label="F_6af692da-77b0-4aed-aaed-263dbd1e56db"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8668cc6b-7fde-4c88-a624-d220fba70b18"
          xlink:label="F_8668cc6b-7fde-4c88-a624-d220fba70b18"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_573be19d-8823-4dbc-8931-9152157e5823"
          xlink:label="F_573be19d-8823-4dbc-8931-9152157e5823"
          xlink:type="locator"/>
        <link:footnote id="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2" xlink:label="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accruals are for returns, rebates and other fees</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_66c01725-80e8-4499-8bed-8476bf3e4e03"
          xlink:to="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_50131afd-0f80-49d3-83f5-48f0a9a291ba"
          xlink:to="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f05c35cd-44b9-4458-bbd6-5b766235a786"
          xlink:to="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f54dd4fc-9a50-4c74-866f-36bf8b38e7ae"
          xlink:to="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1fd1191c-48bf-416e-9986-9e4ecc313c72"
          xlink:to="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_af7984ca-1c6a-4061-9b34-3096cb7c7363"
          xlink:to="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e4271787-7be9-41a9-9ec1-ae5a48e736d9"
          xlink:to="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6af692da-77b0-4aed-aaed-263dbd1e56db"
          xlink:to="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8668cc6b-7fde-4c88-a624-d220fba70b18"
          xlink:to="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_573be19d-8823-4dbc-8931-9152157e5823"
          xlink:to="FNT_fec24620-33a0-4a86-91ec-35853b1a74c2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_2187e669-a5cb-494d-ae16-0757a0fc46b6"
          xlink:label="F_2187e669-a5cb-494d-ae16-0757a0fc46b6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f29e6226-f7ac-44ea-9124-1bc9c7d80f69"
          xlink:label="F_f29e6226-f7ac-44ea-9124-1bc9c7d80f69"
          xlink:type="locator"/>
        <link:footnote id="FNT_cb54f36d-15f9-4a6b-ae57-6ba45a3be2fe" xlink:label="FNT_cb54f36d-15f9-4a6b-ae57-6ba45a3be2fe" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 9 for further discussion.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2187e669-a5cb-494d-ae16-0757a0fc46b6"
          xlink:to="FNT_cb54f36d-15f9-4a6b-ae57-6ba45a3be2fe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f29e6226-f7ac-44ea-9124-1bc9c7d80f69"
          xlink:to="FNT_cb54f36d-15f9-4a6b-ae57-6ba45a3be2fe"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_f3c36f18-2b1d-4b81-b1c8-7e990a1b8f82"
          xlink:label="F_f3c36f18-2b1d-4b81-b1c8-7e990a1b8f82"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_2cd4b012-2bd4-43b0-a40d-b6cfbe828de6"
          xlink:label="F_2cd4b012-2bd4-43b0-a40d-b6cfbe828de6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b2703284-0338-4fab-9adc-c678bfd78578"
          xlink:label="F_b2703284-0338-4fab-9adc-c678bfd78578"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e6c2e3e9-7ea7-45bb-acd3-c2f99efa17be"
          xlink:label="F_e6c2e3e9-7ea7-45bb-acd3-c2f99efa17be"
          xlink:type="locator"/>
        <link:footnote id="FNT_c5bf0a05-18a8-4de7-a66b-18eb61ca0e15" xlink:label="FNT_c5bf0a05-18a8-4de7-a66b-18eb61ca0e15" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> $1.4</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> million of contract asset is derived from our agreement with the DoD</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f3c36f18-2b1d-4b81-b1c8-7e990a1b8f82"
          xlink:to="FNT_c5bf0a05-18a8-4de7-a66b-18eb61ca0e15"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2187e669-a5cb-494d-ae16-0757a0fc46b6"
          xlink:to="FNT_c5bf0a05-18a8-4de7-a66b-18eb61ca0e15"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2cd4b012-2bd4-43b0-a40d-b6cfbe828de6"
          xlink:to="FNT_c5bf0a05-18a8-4de7-a66b-18eb61ca0e15"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b2703284-0338-4fab-9adc-c678bfd78578"
          xlink:to="FNT_c5bf0a05-18a8-4de7-a66b-18eb61ca0e15"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e6c2e3e9-7ea7-45bb-acd3-c2f99efa17be"
          xlink:to="FNT_c5bf0a05-18a8-4de7-a66b-18eb61ca0e15"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_2020b3e4-1f4a-4785-a846-ac2f166dc9d8"
          xlink:label="F_2020b3e4-1f4a-4785-a846-ac2f166dc9d8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_70c93f68-26e0-4dc6-9761-1747a7bdeee6"
          xlink:label="F_70c93f68-26e0-4dc6-9761-1747a7bdeee6"
          xlink:type="locator"/>
        <link:footnote id="FNT_f71fd845-812c-43cf-97f6-a213c94f92fc" xlink:label="FNT_f71fd845-812c-43cf-97f6-a213c94f92fc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inclusive of approximately 600,145 RSUs for the year ended December 31, 2023, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2020b3e4-1f4a-4785-a846-ac2f166dc9d8"
          xlink:to="FNT_f71fd845-812c-43cf-97f6-a213c94f92fc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_70c93f68-26e0-4dc6-9761-1747a7bdeee6"
          xlink:to="FNT_f71fd845-812c-43cf-97f6-a213c94f92fc"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
